patient_id,visit_num,note_tone_label,clinical_note
P00001,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.62. AE: no. CRP 4.1 mg/L; ALT 17 U/L.
P00001,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.68. AE: no. CRP 3.4 mg/L; ALT 20 U/L.
P00001,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.55. AE: no. CRP 3.4 mg/L; ALT 18 U/L.
P00001,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.63. AE: no. CRP 3.1 mg/L; ALT 15 U/L.
P00001,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P00001,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.72. AE: no. CRP 2.3 mg/L; ALT 20 U/L.
P00001,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.53. AE: yes. CRP 2.1 mg/L; ALT 19 U/L.
P00002,0,neutral,Visit 0: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00002,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P00002,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.79. AE: no.
P00002,3,positive,Visit 3: Patient on RX-17A at S005. tolerating medication well. Notes: joint pain. Adherence ~0.89. AE: no. CRP 5.7 mg/L; ALT 47 U/L.
P00002,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no.
P00002,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.91. AE: no. CRP 5.6 mg/L; ALT 49 U/L.
P00002,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.71. AE: no. CRP 4.8 mg/L; ALT 53 U/L.
P00002,7,neutral,Visit 7: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P00003,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P00003,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.81. AE: no.
P00003,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.79. AE: no.
P00003,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00003,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P00003,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no.
P00003,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.85. AE: no.
P00004,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.66. AE: no.
P00004,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00004,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00004,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.84. AE: no.
P00004,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no.
P00004,5,positive,Visit 5: Patient on RX-17A at S015. feels better overall. Notes: brain fog. Adherence ~0.79. AE: no.
P00005,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00005,1,neutral,Visit 1: Patient on RX-17A at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: no. CRP 9.7 mg/L; ALT 26 U/L.
P00005,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no.
P00005,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P00005,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.89. AE: no.
P00006,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 4.7 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00006,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: insomnia. Adherence ~0.88. AE: no.
P00006,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: headache. Adherence ~0.88. AE: no.
P00006,3,negative,Visit 3: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 3.5 mg/L; ALT 38 U/L.
P00006,4,positive,Visit 4: Patient on RX-17A at S019. tolerating medication well. Notes: insomnia. Adherence ~0.90. AE: no.
P00006,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: yes.
P00007,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00007,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.66. AE: no.
P00007,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.88. AE: no.
P00007,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.64. AE: no.
P00007,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: yes.
P00008,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.76. AE: no. CRP 4.6 mg/L; ALT 33 U/L.
P00008,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 4.1 mg/L; ALT 28 U/L.
P00008,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P00008,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00008,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.85. AE: no.
P00008,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.65. AE: no.
P00008,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P00009,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: nausea. Adherence ~0.60. AE: yes.
P00009,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00009,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P00009,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: yes. CRP 11.8 mg/L; ALT 23 U/L.
P00009,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no.
P00009,5,neutral,Visit 5: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00009,6,neutral,Visit 6: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no.
P00009,7,neutral,Visit 7: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no.
P00010,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.68. AE: yes.
P00010,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 7.1 mg/L; ALT 34 U/L.
P00010,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.51. AE: no.
P00010,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P00010,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no. CRP 6.0 mg/L; ALT 35 U/L.
P00010,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no. CRP 5.3 mg/L; ALT 33 U/L.
P00011,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00011,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.97. AE: yes. CRP 4.8 mg/L; ALT 19 U/L.
P00011,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.95. AE: no. CRP 4.6 mg/L; ALT 16 U/L.
P00011,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: yes.
P00011,4,positive,Visit 4: Patient on RX-17B at S015. feels better overall. Notes: joint pain. Adherence ~0.87. AE: no.
P00011,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: yes.
P00011,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~1.00. AE: no.
P00012,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P00012,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.95. AE: yes.
P00012,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.76. AE: no. CRP 3.1 mg/L; ALT 47 U/L.
P00013,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~0.86. AE: yes.
P00013,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 7.5 mg/L; ALT 30 U/L.
P00013,2,positive,Visit 2: Patient on RX-17A at S004. symptoms improving. Notes: fatigue. Adherence ~0.77. AE: no. CRP 8.7 mg/L; ALT 33 U/L.
P00013,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no.
P00013,4,negative,Visit 4: Patient on RX-17A at S004. feels frustrated. Notes: fatigue. Adherence ~0.87. AE: no.
P00013,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P00014,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00014,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 12.0 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P00014,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.78. AE: no.
P00014,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.96. AE: no.
P00014,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: yes.
P00014,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.85. AE: no.
P00014,6,neutral,Visit 6: Patient on RX-17A at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: yes. CRP 10.8 mg/L; ALT 41 U/L.
P00014,7,positive,Visit 7: Patient on RX-17A at S013. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no.
P00015,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: joint pain. Adherence ~0.86. AE: no.
P00015,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: headache. Adherence ~0.86. AE: no. CRP 4.4 mg/L; ALT 11 U/L.
P00015,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.81. AE: no. CRP 4.1 mg/L; ALT 13 U/L.
P00015,3,neutral,Visit 3: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00015,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no. CRP 3.9 mg/L; ALT 11 U/L.
P00015,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.78. AE: no.
P00016,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.92. AE: no.
P00016,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.79. AE: no.
P00016,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.86. AE: no. CRP 5.0 mg/L; ALT 22 U/L.
P00016,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no.
P00016,4,negative,Visit 4: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.73. AE: no.
P00016,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00016,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.92. AE: no.
P00016,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: dizziness. Adherence ~0.97. AE: no.
P00017,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.99. AE: no.
P00017,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.94. AE: yes. CRP 4.4 mg/L; ALT 26 U/L.
P00017,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.86. AE: no.
P00017,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 26 U/L.
P00017,4,negative,Visit 4: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.98. AE: no. CRP 3.8 mg/L; ALT 27 U/L.
P00017,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 26 U/L.
P00017,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00018,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.84. AE: no. CRP 19.8 mg/L; ALT 42 U/L.
P00018,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no. CRP 15.6 mg/L; ALT 45 U/L.
P00018,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: yes.
P00018,3,positive,Visit 3: Patient on RX-17B at S004. tolerating medication well. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00018,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no.
P00018,5,positive,Visit 5: Patient on RX-17B at S004. feels better overall. Notes: fatigue. Adherence ~0.91. AE: no.
P00018,6,positive,Visit 6: Patient on RX-17B at S004. symptoms improving. Notes: nausea. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00019,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00019,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.97. AE: no.
P00019,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no. CRP 1.8 mg/L; ALT 24 U/L.
P00019,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 1.9 mg/L; ALT 22 U/L.
P00019,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.70. AE: no.
P00019,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 1.5 mg/L; ALT 23 U/L.
P00019,6,positive,Visit 6: Patient on RX-17B at S004. reports improvement. Notes: insomnia. Adherence ~0.78. AE: no.
P00019,7,positive,Visit 7: Patient on RX-17B at S004. symptoms improving. Notes: headache. Adherence ~0.92. AE: no.
P00020,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. CRP 14.1 mg/L; ALT 75 U/L.
P00020,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00020,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.86. AE: no.
P00020,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: yes.
P00020,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: yes.
P00021,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.81. AE: no.
P00021,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.92. AE: no. CRP 5.8 mg/L; ALT 27 U/L.
P00021,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 5.1 mg/L; ALT 28 U/L.
P00021,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: joint pain. Adherence ~0.94. AE: no. CRP 5.4 mg/L; ALT 27 U/L.
P00021,4,negative,Visit 4: Patient on RX-17A at S005. increased discomfort. Notes: nausea. Adherence ~0.86. AE: yes.
P00021,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no.
P00021,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.99. AE: no.
P00022,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00022,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.78. AE: no. CRP 6.1 mg/L; ALT 20 U/L.
P00022,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00022,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P00022,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.71. AE: no.
P00022,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00022,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no. CRP 4.5 mg/L; ALT 20 U/L.
P00023,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.81. AE: no.
P00023,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.61. AE: no.
P00023,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.71. AE: no.
P00023,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00023,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no.
P00023,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no.
P00024,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.95. AE: no.
P00024,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.81. AE: no. CRP 7.5 mg/L; ALT 23 U/L.
P00024,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 7.0 mg/L; ALT 23 U/L.
P00024,3,positive,Visit 3: Patient on RX-17B at S012. tolerating medication well. Notes: insomnia. Adherence ~0.92. AE: no.
P00025,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00025,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00025,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.94. AE: no.
P00025,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P00025,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P00025,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P00026,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: joint pain. Adherence ~0.71. AE: no. CRP 13.8 mg/L; ALT 42 U/L.
P00026,1,negative,Visit 1: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.67. AE: yes.
P00026,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 11.3 mg/L; ALT 44 U/L.
P00026,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P00026,4,positive,Visit 4: Patient on RX-17B at S002. feels better overall. Notes: joint pain. Adherence ~0.77. AE: no.
P00027,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: no.
P00027,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.77. AE: no.
P00027,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.68. AE: no. CRP 11.2 mg/L; ALT 41 U/L.
P00027,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.79. AE: yes.
P00027,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.72. AE: no. CRP 9.4 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00028,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.95. AE: yes. CRP 4.9 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P00028,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.61. AE: yes.
P00028,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 3.5 mg/L; ALT 36 U/L.
P00028,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00028,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~1.00. AE: yes.
P00029,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P00029,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no. CRP 9.4 mg/L; ALT 46 U/L.
P00029,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00029,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.8 mg/L; ALT 47 U/L.
P00029,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P00029,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.7 mg/L; ALT 47 U/L.
P00030,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.41. AE: yes. Plan: consider dose adjustment; counsel patient.
P00030,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P00030,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.45. AE: no. CRP 5.2 mg/L; ALT 34 U/L.
P00030,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no.
P00030,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.53. AE: yes.
P00031,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00031,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.62. AE: no. CRP 6.7 mg/L; ALT 21 U/L.
P00031,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.80. AE: no.
P00031,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P00031,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: brain fog. Adherence ~0.77. AE: no. CRP 5.9 mg/L; ALT 19 U/L.
P00031,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.2 mg/L; ALT 24 U/L.
P00031,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 3.8 mg/L; ALT 24 U/L.
P00032,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.66. AE: no. CRP 15.6 mg/L; ALT 38 U/L.
P00032,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.52. AE: no.
P00032,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00032,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.50. AE: no. CRP 13.9 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00032,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P00032,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P00032,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P00032,7,neutral,Visit 7: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: yes. CRP 9.0 mg/L; ALT 42 U/L.
P00033,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 5.2 mg/L; ALT 20 U/L.
P00033,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.71. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P00033,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.87. AE: no.
P00033,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P00033,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.72. AE: no.
P00033,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P00034,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.45. AE: no. CRP 13.4 mg/L; ALT 24 U/L.
P00034,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P00034,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.40. AE: yes.
P00035,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.82. AE: yes.
P00035,1,positive,Visit 1: Patient on RX-17A at S014. tolerating medication well. Notes: headache. Adherence ~0.83. AE: no.
P00035,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.91. AE: no. CRP 8.0 mg/L; ALT 27 U/L.
P00035,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 8.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00035,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 7.4 mg/L; ALT 32 U/L.
P00036,0,neutral,Visit 0: Patient on RX-17B at S009. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00036,1,neutral,Visit 1: Patient on RX-17B at S009. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no.
P00036,2,neutral,Visit 2: Patient on RX-17B at S009. continues regimen. Notes: fatigue. Adherence ~0.95. AE: no.
P00036,3,neutral,Visit 3: Patient on RX-17B at S009. no major change. Notes: brain fog. Adherence ~0.91. AE: no.
P00036,4,neutral,Visit 4: Patient on RX-17B at S009. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: no. CRP 4.5 mg/L; ALT 31 U/L.
P00036,5,neutral,Visit 5: Patient on RX-17B at S009. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: no.
P00036,6,positive,Visit 6: Patient on RX-17B at S009. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00037,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: brain fog. Adherence ~0.86. AE: no.
P00037,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: fatigue. Adherence ~0.87. AE: yes. CRP 8.9 mg/L; ALT 18 U/L.
P00037,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no.
P00037,3,negative,Visit 3: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: no.
P00037,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.97. AE: no.
P00037,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00037,6,positive,Visit 6: Patient on RX-17B at S012. energy increasing. Notes: headache. Adherence ~0.80. AE: no.
P00037,7,neutral,Visit 7: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no.
P00038,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00038,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.78. AE: yes.
P00038,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.79. AE: yes.
P00038,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.82. AE: yes.
P00038,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.76. AE: no.
P00038,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no. CRP 4.9 mg/L; ALT 24 U/L.
P00038,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00039,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.39. AE: no.
P00039,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00039,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P00039,3,negative,Visit 3: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.28. AE: no. CRP 2.8 mg/L; ALT 29 U/L.
P00039,4,negative,Visit 4: Patient on RX-17A at S013. symptoms persist. Notes: insomnia. Adherence ~0.49. AE: no. CRP 2.8 mg/L; ALT 30 U/L.
P00039,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no. CRP 2.8 mg/L; ALT 30 U/L.
P00040,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00040,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00040,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: headache. Adherence ~0.59. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P00040,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 4.2 mg/L; ALT 28 U/L.
P00040,4,neutral,Visit 4: Patient on RX-17B at S002. stable symptoms. Notes: brain fog. Adherence ~0.38. AE: no. CRP 3.3 mg/L; ALT 27 U/L.
P00040,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no. CRP 3.3 mg/L; ALT 29 U/L.
P00040,6,neutral,Visit 6: Patient on RX-17B at S002. continues regimen. Notes: dizziness. Adherence ~0.36. AE: no. CRP 3.0 mg/L; ALT 26 U/L.
P00041,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: joint pain. Adherence ~0.15. AE: no.
P00041,1,neutral,Visit 1: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.09. AE: no.
P00041,2,neutral,Visit 2: Patient on RX-17A at S018. follow-up as scheduled. Notes: nausea. Adherence ~0.46. AE: no.
P00041,3,negative,Visit 3: Patient on RX-17A at S018. symptoms persist. Notes: headache. Adherence ~0.16. AE: no.
P00041,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: fatigue. Adherence ~0.16. AE: no.
P00041,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.25. AE: no. CRP 2.5 mg/L; ALT 51 U/L.
P00041,6,neutral,Visit 6: Patient on RX-17A at S018. stable symptoms. Notes: brain fog. Adherence ~0.28. AE: no.
P00041,7,neutral,Visit 7: Patient on RX-17A at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.23. AE: no.
P00042,0,negative,Visit 0: Patient on RX-17A at S021. reports worsening. Notes: dizziness. Adherence ~0.90. AE: no. CRP 5.8 mg/L; ALT 51 U/L.
P00042,1,negative,Visit 1: Patient on RX-17A at S021. poor tolerance. Notes: nausea. Adherence ~0.97. AE: no.
P00042,2,negative,Visit 2: Patient on RX-17A at S021. symptoms persist. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00042,3,neutral,Visit 3: Patient on RX-17A at S021. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no.
P00043,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00043,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.91. AE: no.
P00043,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 12.6 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00044,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.58. AE: no. CRP 9.1 mg/L; ALT 32 U/L.
P00044,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.61. AE: no.
P00044,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.43. AE: no. CRP 7.5 mg/L; ALT 30 U/L.
P00044,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.80. AE: yes.
P00045,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.99. AE: no. CRP 3.0 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P00045,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.85. AE: no. CRP 3.1 mg/L; ALT 57 U/L.
P00045,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00045,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no.
P00045,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00046,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: insomnia. Adherence ~0.60. AE: no. CRP 6.4 mg/L; ALT 27 U/L.
P00046,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.93. AE: yes.
P00046,2,neutral,Visit 2: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P00047,0,negative,Visit 0: Patient on RX-17B at S011. feels frustrated. Notes: insomnia. Adherence ~0.82. AE: no.
P00047,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. CRP 7.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00047,2,negative,Visit 2: Patient on RX-17B at S011. reports worsening. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00047,3,positive,Visit 3: Patient on RX-17B at S011. tolerating medication well. Notes: dizziness. Adherence ~0.78. AE: no.
P00047,4,neutral,Visit 4: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no.
P00048,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.69. AE: no.
P00048,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.64. AE: no. CRP 10.5 mg/L; ALT 42 U/L.
P00048,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.63. AE: no.
P00048,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00048,4,negative,Visit 4: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.58. AE: yes.
P00048,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: no.
P00048,6,positive,Visit 6: Patient on RX-17A at S015. reports improvement. Notes: insomnia. Adherence ~0.80. AE: no.
P00049,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~0.51. AE: yes.
P00049,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: fatigue. Adherence ~0.46. AE: no.
P00049,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: brain fog. Adherence ~0.78. AE: no.
P00049,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.41. AE: no. CRP 4.2 mg/L; ALT 27 U/L.
P00049,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.52. AE: yes. Plan: consider dose adjustment; counsel patient.
P00049,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.47. AE: no. CRP 3.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00049,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.68. AE: no.
P00049,7,neutral,Visit 7: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00050,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: dizziness. Adherence ~0.42. AE: yes.
P00050,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.54. AE: no. CRP 3.3 mg/L; ALT 42 U/L.
P00050,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.51. AE: no.
P00050,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no.
P00050,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.47. AE: no.
P00050,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.49. AE: yes.
P00051,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.98. AE: yes.
P00051,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: yes. CRP 7.5 mg/L; ALT 27 U/L.
P00051,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.94. AE: yes.
P00051,3,negative,Visit 3: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: no. CRP 5.6 mg/L; ALT 24 U/L.
P00051,4,negative,Visit 4: Patient on RX-17A at S004. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.9 mg/L; ALT 25 U/L.
P00051,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 5.8 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00052,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.67. AE: no.
P00052,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.71. AE: no.
P00052,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 8.2 mg/L; ALT 27 U/L.
P00052,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no.
P00053,0,negative,Visit 0: Patient on RX-17A at S007. symptoms persist. Notes: insomnia. Adherence ~0.89. AE: no.
P00053,1,neutral,Visit 1: Patient on RX-17A at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no. CRP 7.5 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P00053,2,neutral,Visit 2: Patient on RX-17A at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.90. AE: yes.
P00053,3,neutral,Visit 3: Patient on RX-17A at S007. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no. CRP 6.5 mg/L; ALT 35 U/L.
P00053,4,neutral,Visit 4: Patient on RX-17A at S007. no major change. Notes: joint pain. Adherence ~0.76. AE: no.
P00053,5,neutral,Visit 5: Patient on RX-17A at S007. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no. CRP 5.5 mg/L; ALT 41 U/L.
P00054,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00054,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00054,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.89. AE: yes. CRP 3.7 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00054,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00054,4,neutral,Visit 4: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.90. AE: yes.
P00054,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.5 mg/L; ALT 33 U/L.
P00054,6,positive,Visit 6: Patient on RX-17B at S002. tolerating medication well. Notes: fatigue. Adherence ~0.87. AE: no. CRP 2.6 mg/L; ALT 37 U/L.
P00055,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.55. AE: no.
P00055,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.68. AE: no.
P00055,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.59. AE: no.
P00055,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.42. AE: no.
P00055,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.60. AE: no. CRP 13.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00055,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P00056,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no.
P00056,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.74. AE: no. CRP 5.9 mg/L; ALT 17 U/L.
P00056,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: no. CRP 5.6 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P00056,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.77. AE: no. CRP 4.8 mg/L; ALT 17 U/L.
P00056,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.66. AE: no. CRP 4.9 mg/L; ALT 18 U/L.
P00056,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.59. AE: no. CRP 4.2 mg/L; ALT 16 U/L.
P00057,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: headache. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P00057,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P00057,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: no.
P00057,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P00057,4,neutral,Visit 4: Patient on RX-17B at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no.
P00058,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.97. AE: no. CRP 5.0 mg/L; ALT 44 U/L.
P00058,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no. CRP 5.2 mg/L; ALT 40 U/L.
P00058,2,neutral,Visit 2: Patient on RX-17A at S018. no major change. Notes: nausea. Adherence ~0.82. AE: no.
P00058,3,negative,Visit 3: Patient on RX-17A at S018. reports worsening. Notes: headache. Adherence ~0.95. AE: no. CRP 4.5 mg/L; ALT 39 U/L.
P00058,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: brain fog. Adherence ~0.89. AE: no.
P00058,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no.
P00058,6,neutral,Visit 6: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00059,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.79. AE: no. CRP 14.6 mg/L; ALT 21 U/L.
P00059,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.70. AE: no.
P00059,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no.
P00059,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.83. AE: no.
P00059,4,negative,Visit 4: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.59. AE: no. CRP 9.3 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P00060,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no.
P00060,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: yes.
P00060,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.99. AE: no. CRP 8.4 mg/L; ALT 36 U/L.
P00060,3,negative,Visit 3: Patient on RX-17B at S022. feels frustrated. Notes: fatigue. Adherence ~0.95. AE: yes.
P00060,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~1.00. AE: yes.
P00060,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00060,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.98. AE: no.
P00061,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: nausea. Adherence ~0.74. AE: no.
P00061,1,neutral,Visit 1: Patient on RX-17A at S011. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no.
P00061,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: nausea. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00061,3,neutral,Visit 3: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00061,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.72. AE: no.
P00062,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.56. AE: yes. CRP 4.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00062,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no. CRP 3.7 mg/L; ALT 25 U/L.
P00062,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no.
P00062,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00062,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.47. AE: no.
P00062,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.59. AE: yes. CRP 2.8 mg/L; ALT 29 U/L.
P00062,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.68. AE: no.
P00062,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.49. AE: no.
P00063,0,negative,Visit 0: Patient on RX-17A at S008. poor tolerance. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00063,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: headache. Adherence ~0.87. AE: no.
P00063,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.85. AE: no. CRP 12.9 mg/L; ALT 47 U/L.
P00063,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: joint pain. Adherence ~0.65. AE: no.
P00063,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no.
P00063,5,neutral,Visit 5: Patient on RX-17A at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no. CRP 9.1 mg/L; ALT 54 U/L.
P00063,6,neutral,Visit 6: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P00063,7,neutral,Visit 7: Patient on RX-17A at S008. continues regimen. Notes: fatigue. Adherence ~0.77. AE: yes.
P00064,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: dizziness. Adherence ~0.52. AE: no.
P00064,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.39. AE: no. CRP 9.4 mg/L; ALT 28 U/L.
P00064,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P00064,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.44. AE: no.
P00064,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.59. AE: no.
P00064,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.47. AE: no.
P00064,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.60. AE: no.
P00064,7,neutral,Visit 7: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.61. AE: no.
P00065,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P00065,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.68. AE: no.
P00065,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: headache. Adherence ~0.73. AE: yes.
P00065,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00065,4,negative,Visit 4: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.66. AE: yes.
P00065,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.54. AE: yes.
P00066,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: dizziness. Adherence ~0.89. AE: no. CRP 7.2 mg/L; ALT 28 U/L.
P00066,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.87. AE: no. CRP 6.7 mg/L; ALT 28 U/L.
P00066,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.78. AE: no.
P00066,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: no. CRP 6.6 mg/L; ALT 29 U/L.
P00066,4,negative,Visit 4: Patient on RX-17A at S002. symptoms persist. Notes: headache. Adherence ~0.88. AE: no.
P00066,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.88. AE: no. CRP 4.7 mg/L; ALT 28 U/L.
P00066,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.72. AE: no. CRP 5.1 mg/L; ALT 29 U/L.
P00066,7,neutral,Visit 7: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: yes.
P00067,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.71. AE: no.
P00067,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: joint pain. Adherence ~0.66. AE: no. CRP 6.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00067,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no. CRP 5.3 mg/L; ALT 34 U/L.
P00067,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: no.
P00067,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.61. AE: no.
P00067,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 4.9 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00068,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P00068,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~0.62. AE: no.
P00068,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.80. AE: no.
P00068,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no.
P00068,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: yes.
P00068,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P00069,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: nausea. Adherence ~0.79. AE: no.
P00069,1,negative,Visit 1: Patient on RX-17A at S020. increased discomfort. Notes: brain fog. Adherence ~0.85. AE: yes. CRP 24.2 mg/L; ALT 21 U/L.
P00069,2,neutral,Visit 2: Patient on RX-17A at S020. stable symptoms. Notes: headache. Adherence ~0.87. AE: no. CRP 20.1 mg/L; ALT 20 U/L.
P00069,3,neutral,Visit 3: Patient on RX-17A at S020. no major change. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00069,4,neutral,Visit 4: Patient on RX-17A at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no.
P00070,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.78. AE: no.
P00070,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.74. AE: no.
P00070,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no.
P00070,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.77. AE: no.
P00070,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00070,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.72. AE: no. CRP 3.0 mg/L; ALT 38 U/L.
P00070,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: no. CRP 3.9 mg/L; ALT 41 U/L.
P00071,0,neutral,Visit 0: Patient on RX-17B at S020. reviewed dosing instructions. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00071,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: brain fog. Adherence ~0.95. AE: no.
P00071,2,neutral,Visit 2: Patient on RX-17B at S020. stable symptoms. Notes: nausea. Adherence ~0.99. AE: no.
P00071,3,neutral,Visit 3: Patient on RX-17B at S020. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: yes.
P00072,0,neutral,Visit 0: Patient on RX-17B at S020. no major change. Notes: nausea. Adherence ~0.81. AE: no. CRP 6.2 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00072,1,positive,Visit 1: Patient on RX-17B at S020. reports improvement. Notes: dizziness. Adherence ~0.78. AE: no. CRP 5.5 mg/L; ALT 34 U/L.
P00072,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 5.3 mg/L; ALT 35 U/L.
P00072,3,neutral,Visit 3: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.97. AE: no.
P00072,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.58. AE: yes.
P00072,5,neutral,Visit 5: Patient on RX-17B at S020. continues regimen. Notes: brain fog. Adherence ~0.60. AE: no.
P00073,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no.
P00073,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00073,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: no.
P00073,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 76 U/L.
P00073,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.82. AE: no. CRP 3.8 mg/L; ALT 70 U/L.
P00074,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.59. AE: no. CRP 13.5 mg/L; ALT 25 U/L.
P00074,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no. CRP 12.2 mg/L; ALT 27 U/L.
P00074,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00074,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.54. AE: no.
P00074,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.56. AE: no. CRP 10.8 mg/L; ALT 26 U/L.
P00074,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.52. AE: no. CRP 9.8 mg/L; ALT 26 U/L.
P00075,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.78. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P00075,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.46. AE: no. CRP 3.4 mg/L; ALT 22 U/L.
P00075,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.67. AE: no.
P00075,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00075,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.74. AE: no. CRP 2.4 mg/L; ALT 20 U/L.
P00076,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.85. AE: no.
P00076,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.96. AE: no. CRP 4.9 mg/L; ALT 34 U/L.
P00076,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no. CRP 5.5 mg/L; ALT 33 U/L.
P00076,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P00076,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no.
P00076,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no.
P00077,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.92. AE: no.
P00077,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no.
P00077,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P00077,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 6.5 mg/L; ALT 34 U/L.
P00077,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no. CRP 4.8 mg/L; ALT 36 U/L.
P00077,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.82. AE: no. CRP 4.5 mg/L; ALT 37 U/L.
P00077,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00077,7,positive,Visit 7: Patient on RX-17B at S012. energy increasing. Notes: insomnia. Adherence ~0.83. AE: no. CRP 3.8 mg/L; ALT 37 U/L.
P00078,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: headache. Adherence ~0.78. AE: no.
P00078,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.57. AE: no.
P00078,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~0.77. AE: no.
P00078,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.72. AE: no. CRP 11.6 mg/L; ALT 39 U/L.
P00078,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P00078,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no. CRP 9.7 mg/L; ALT 42 U/L.
P00079,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.81. AE: no.
P00079,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no.
P00079,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.86. AE: yes.
P00079,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no.
P00079,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00079,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 8.5 mg/L; ALT 25 U/L.
P00080,0,negative,Visit 0: Patient on RX-17B at S009. symptoms persist. Notes: insomnia. Adherence ~0.92. AE: no.
P00080,1,neutral,Visit 1: Patient on RX-17B at S009. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no.
P00080,2,neutral,Visit 2: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.38. AE: no. CRP 13.8 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00080,3,positive,Visit 3: Patient on RX-17B at S009. symptoms improving. Notes: headache. Adherence ~0.83. AE: no.
P00080,4,neutral,Visit 4: Patient on RX-17B at S009. no major change. Notes: nausea. Adherence ~0.68. AE: no. CRP 12.1 mg/L; ALT 25 U/L.
P00080,5,neutral,Visit 5: Patient on RX-17B at S009. follow-up as scheduled. Notes: headache. Adherence ~0.56. AE: no. CRP 11.8 mg/L; ALT 22 U/L.
P00081,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: yes. CRP 10.3 mg/L; ALT 20 U/L.
P00081,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P00081,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no. CRP 8.6 mg/L; ALT 16 U/L.
P00081,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no.
P00081,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.78. AE: no. CRP 6.1 mg/L; ALT 19 U/L.
P00081,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00081,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.83. AE: no.
P00081,7,positive,Visit 7: Patient on RX-17B at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00082,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no.
P00082,1,neutral,Visit 1: Patient on RX-17A at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no.
P00082,2,negative,Visit 2: Patient on RX-17A at S008. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: no.
P00082,3,neutral,Visit 3: Patient on RX-17A at S008. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no. CRP 6.2 mg/L; ALT 20 U/L.
P00082,4,neutral,Visit 4: Patient on RX-17A at S008. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no.
P00082,5,positive,Visit 5: Patient on RX-17A at S008. energy increasing. Notes: joint pain. Adherence ~0.76. AE: no.
P00083,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: no.
P00083,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.72. AE: no.
P00083,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.94. AE: no.
P00083,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.69. AE: no. CRP 8.7 mg/L; ALT 26 U/L.
P00083,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no. CRP 7.8 mg/L; ALT 28 U/L.
P00084,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: brain fog. Adherence ~0.58. AE: yes. CRP 3.2 mg/L; ALT 31 U/L.
P00084,1,neutral,Visit 1: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.68. AE: no. CRP 3.1 mg/L; ALT 28 U/L.
P00084,2,negative,Visit 2: Patient on RX-17B at S019. increased discomfort. Notes: fatigue. Adherence ~0.87. AE: yes.
P00084,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 2.7 mg/L; ALT 32 U/L.
P00084,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: dizziness. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P00084,5,neutral,Visit 5: Patient on RX-17B at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no.
P00084,6,neutral,Visit 6: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P00085,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: headache. Adherence ~0.64. AE: yes.
P00085,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.56. AE: yes. CRP 2.4 mg/L; ALT 72 U/L.
P00085,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.44. AE: no. CRP 2.1 mg/L; ALT 59 U/L.
P00085,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.48. AE: no.
P00085,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.56. AE: no.
P00086,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.51. AE: no.
P00086,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00086,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.67. AE: no. CRP 10.5 mg/L; ALT 18 U/L.
P00086,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P00087,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no.
P00087,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.87. AE: no. CRP 7.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00087,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00088,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: insomnia. Adherence ~0.52. AE: no.
P00088,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.58. AE: no. CRP 11.7 mg/L; ALT 22 U/L.
P00088,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no. CRP 10.2 mg/L; ALT 24 U/L.
P00088,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.62. AE: no.
P00088,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 25 U/L.
P00088,5,neutral,Visit 5: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P00088,6,neutral,Visit 6: Patient on RX-17B at S019. no major change. Notes: dizziness. Adherence ~0.49. AE: no.
P00088,7,neutral,Visit 7: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.66. AE: yes.
P00089,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no.
P00089,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: headache. Adherence ~0.99. AE: no. CRP 4.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00089,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: yes.
P00089,3,positive,Visit 3: Patient on RX-17B at S005. symptoms improving. Notes: headache. Adherence ~0.93. AE: no.
P00089,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.95. AE: no. CRP 3.1 mg/L; ALT 36 U/L.
P00089,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.90. AE: no.
P00089,6,positive,Visit 6: Patient on RX-17B at S005. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no.
P00089,7,positive,Visit 7: Patient on RX-17B at S005. reports improvement. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P00090,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: fatigue. Adherence ~0.66. AE: no.
P00090,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: yes. CRP 14.2 mg/L; ALT 27 U/L.
P00090,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.68. AE: no. CRP 13.7 mg/L; ALT 26 U/L.
P00090,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no. CRP 10.3 mg/L; ALT 26 U/L.
P00090,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.67. AE: no. CRP 8.9 mg/L; ALT 24 U/L.
P00090,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.68. AE: no. CRP 9.5 mg/L; ALT 27 U/L.
P00091,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: nausea. Adherence ~0.65. AE: yes.
P00091,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.91. AE: no. CRP 9.3 mg/L; ALT 43 U/L.
P00091,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.80. AE: yes.
P00091,3,negative,Visit 3: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.89. AE: no.
P00091,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.64. AE: no.
P00091,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P00091,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.61. AE: no.
P00092,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.66. AE: yes. CRP 6.7 mg/L; ALT 50 U/L.
P00092,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P00092,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.55. AE: yes.
P00092,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P00092,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.62. AE: yes.
P00092,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.56. AE: no.
P00092,6,neutral,Visit 6: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.47. AE: no. CRP 3.5 mg/L; ALT 45 U/L.
P00092,7,neutral,Visit 7: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: yes.
P00093,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.77. AE: no. CRP 8.7 mg/L; ALT 31 U/L.
P00093,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.91. AE: no.
P00093,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 31 U/L.
P00093,3,negative,Visit 3: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.79. AE: no.
P00093,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.99. AE: no.
P00094,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no. CRP 8.7 mg/L; ALT 52 U/L.
P00094,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: no.
P00094,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.3 mg/L; ALT 49 U/L.
P00094,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.91. AE: no.
P00094,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00094,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00094,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P00095,0,neutral,Visit 0: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.63. AE: no. CRP 5.0 mg/L; ALT 43 U/L.
P00095,1,negative,Visit 1: Patient on RX-17A at S001. poor tolerance. Notes: joint pain. Adherence ~0.61. AE: no. CRP 4.3 mg/L; ALT 40 U/L.
P00095,2,negative,Visit 2: Patient on RX-17A at S001. poor tolerance. Notes: brain fog. Adherence ~0.60. AE: yes. CRP 3.7 mg/L; ALT 43 U/L.
P00095,3,neutral,Visit 3: Patient on RX-17A at S001. stable symptoms. Notes: brain fog. Adherence ~0.58. AE: no.
P00095,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: insomnia. Adherence ~0.58. AE: no. CRP 3.5 mg/L; ALT 41 U/L.
P00096,0,negative,Visit 0: Patient on RX-17A at S007. symptoms persist. Notes: abdominal discomfort. Adherence ~0.73. AE: yes. CRP 6.2 mg/L; ALT 55 U/L.
P00096,1,negative,Visit 1: Patient on RX-17A at S007. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: no. CRP 5.2 mg/L; ALT 49 U/L.
P00096,2,neutral,Visit 2: Patient on RX-17A at S007. no major change. Notes: dizziness. Adherence ~0.94. AE: no.
P00096,3,neutral,Visit 3: Patient on RX-17A at S007. reviewed dosing instructions. Notes: headache. Adherence ~0.86. AE: no. CRP 4.7 mg/L; ALT 50 U/L.
P00096,4,neutral,Visit 4: Patient on RX-17A at S007. stable symptoms. Notes: dizziness. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00096,5,positive,Visit 5: Patient on RX-17A at S007. tolerating medication well. Notes: dizziness. Adherence ~0.87. AE: no. CRP 3.7 mg/L; ALT 46 U/L.
P00096,6,neutral,Visit 6: Patient on RX-17A at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.81. AE: no. CRP 3.6 mg/L; ALT 51 U/L.
P00097,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.72. AE: no.
P00097,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.76. AE: no. CRP 7.8 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00097,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: yes.
P00097,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no. CRP 7.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00097,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no.
P00097,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P00097,6,positive,Visit 6: Patient on RX-17B at S004. symptoms improving. Notes: headache. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00097,7,positive,Visit 7: Patient on RX-17B at S004. reports improvement. Notes: fatigue. Adherence ~0.82. AE: no.
P00098,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: fatigue. Adherence ~0.47. AE: no.
P00098,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: insomnia. Adherence ~0.58. AE: no. CRP 5.4 mg/L; ALT 38 U/L.
P00098,2,negative,Visit 2: Patient on RX-17B at S016. symptoms persist. Notes: headache. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00098,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.59. AE: no.
P00098,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: no. CRP 3.8 mg/L; ALT 41 U/L.
P00098,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.41. AE: yes.
P00098,6,neutral,Visit 6: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00099,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P00099,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.75. AE: no. CRP 2.9 mg/L; ALT 23 U/L.
P00099,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.93. AE: no.
P00099,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no. CRP 2.4 mg/L; ALT 22 U/L.
P00099,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no.
P00099,5,negative,Visit 5: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.82. AE: no.
P00100,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00100,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.85. AE: yes.
P00100,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: yes. CRP 6.2 mg/L; ALT 24 U/L.
P00100,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.99. AE: yes.
P00100,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P00100,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.5 mg/L; ALT 22 U/L.
P00101,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: nausea. Adherence ~0.70. AE: no.
P00101,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P00101,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: headache. Adherence ~0.69. AE: no.
P00101,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: headache. Adherence ~0.62. AE: no.
P00101,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: yes.
P00102,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.65. AE: yes.
P00102,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 13.6 mg/L; ALT 22 U/L.
P00102,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: no.
P00102,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P00102,4,positive,Visit 4: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.82. AE: no.
P00102,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no.
P00102,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: yes. CRP 6.2 mg/L; ALT 23 U/L.
P00102,7,positive,Visit 7: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~0.91. AE: no.
P00103,0,neutral,Visit 0: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00103,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: dizziness. Adherence ~0.93. AE: no.
P00103,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~0.75. AE: yes. CRP 8.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00104,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: brain fog. Adherence ~0.47. AE: no. CRP 12.0 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00104,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: fatigue. Adherence ~0.60. AE: no. CRP 10.1 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00104,2,negative,Visit 2: Patient on RX-17A at S018. increased discomfort. Notes: nausea. Adherence ~0.53. AE: no.
P00104,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no.
P00104,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no.
P00104,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.54. AE: no. CRP 6.8 mg/L; ALT 16 U/L.
P00104,6,neutral,Visit 6: Patient on RX-17A at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.60. AE: no.
P00105,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 13.8 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00105,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: fatigue. Adherence ~0.95. AE: no.
P00105,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no. CRP 10.5 mg/L; ALT 25 U/L.
P00105,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. CRP 8.9 mg/L; ALT 22 U/L.
P00105,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no.
P00105,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.63. AE: yes.
P00105,6,neutral,Visit 6: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00105,7,neutral,Visit 7: Patient on RX-17B at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.54. AE: yes.
P00106,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.66. AE: no. CRP 7.6 mg/L; ALT 23 U/L.
P00106,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00106,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00106,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~0.75. AE: no. CRP 5.6 mg/L; ALT 21 U/L.
P00106,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.63. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P00107,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P00107,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no.
P00107,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.98. AE: no. CRP 2.3 mg/L; ALT 25 U/L.
P00107,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.72. AE: no.
P00107,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.74. AE: no.
P00108,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: fatigue. Adherence ~0.94. AE: no.
P00108,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no.
P00108,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.95. AE: no. CRP 10.9 mg/L; ALT 30 U/L.
P00108,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no.
P00108,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P00108,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.97. AE: yes. CRP 8.7 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00109,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P00109,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.75. AE: no.
P00109,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00109,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.93. AE: no. CRP 3.3 mg/L; ALT 35 U/L.
P00109,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00109,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.79. AE: no.
P00109,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00110,0,neutral,Visit 0: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: yes. CRP 4.0 mg/L; ALT 23 U/L.
P00110,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no.
P00110,2,negative,Visit 2: Patient on RX-17B at S013. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: yes.
P00110,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no. CRP 2.7 mg/L; ALT 23 U/L.
P00110,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P00110,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no. CRP 2.4 mg/L; ALT 22 U/L.
P00110,6,positive,Visit 6: Patient on RX-17B at S013. symptoms improving. Notes: fatigue. Adherence ~0.93. AE: no. CRP 2.0 mg/L; ALT 22 U/L.
P00111,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00111,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.57. AE: no. CRP 3.5 mg/L; ALT 24 U/L.
P00111,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P00111,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P00111,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: yes.
P00111,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P00112,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no. CRP 22.7 mg/L; ALT 40 U/L.
P00112,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.54. AE: yes. CRP 25.8 mg/L; ALT 53 U/L.
P00112,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.46. AE: no. CRP 27.1 mg/L; ALT 47 U/L.
P00112,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.46. AE: no. CRP 20.4 mg/L; ALT 46 U/L.
P00112,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.39. AE: no.
P00112,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.62. AE: no.
P00112,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.62. AE: no.
P00112,7,neutral,Visit 7: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.67. AE: no. CRP 11.4 mg/L; ALT 45 U/L.
P00113,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 9.4 mg/L; ALT 56 U/L.
P00113,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no.
P00113,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.79. AE: no. CRP 8.3 mg/L; ALT 53 U/L.
P00113,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.73. AE: no.
P00113,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.98. AE: no. CRP 7.9 mg/L; ALT 64 U/L.
P00113,5,negative,Visit 5: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.67. AE: yes. CRP 6.0 mg/L; ALT 54 U/L.
P00113,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P00113,7,positive,Visit 7: Patient on RX-17A at S015. symptoms improving. Notes: dizziness. Adherence ~0.85. AE: no. CRP 5.7 mg/L; ALT 56 U/L.
P00114,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P00114,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.92. AE: no.
P00114,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.90. AE: no.
P00114,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 47 U/L.
P00114,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00114,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P00115,0,negative,Visit 0: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00115,1,neutral,Visit 1: Patient on RX-17A at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no.
P00115,2,neutral,Visit 2: Patient on RX-17A at S011. stable symptoms. Notes: brain fog. Adherence ~0.83. AE: no. CRP 4.3 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00115,3,negative,Visit 3: Patient on RX-17A at S011. poor tolerance. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00115,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no.
P00115,5,neutral,Visit 5: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no. CRP 3.4 mg/L; ALT 18 U/L.
P00115,6,neutral,Visit 6: Patient on RX-17A at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P00116,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 7.5 mg/L; ALT 46 U/L.
P00116,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: no.
P00116,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no. CRP 6.0 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P00117,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00117,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no.
P00117,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.83. AE: no. CRP 7.2 mg/L; ALT 57 U/L.
P00117,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00117,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 7.1 mg/L; ALT 58 U/L.
P00118,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no.
P00118,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 8.7 mg/L; ALT 19 U/L.
P00118,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P00118,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P00118,4,positive,Visit 4: Patient on RX-17A at S014. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.7 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00118,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P00118,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00118,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: fatigue. Adherence ~0.89. AE: no. CRP 5.0 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00119,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.92. AE: no. CRP 4.5 mg/L; ALT 40 U/L.
P00119,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00119,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00119,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00119,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.76. AE: no.
P00119,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.98. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P00119,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.85. AE: yes. CRP 3.1 mg/L; ALT 42 U/L.
P00119,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.68. AE: no. CRP 2.1 mg/L; ALT 43 U/L.
P00120,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: no. CRP 8.1 mg/L; ALT 32 U/L.
P00120,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.77. AE: no.
P00120,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 7.7 mg/L; ALT 35 U/L.
P00120,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.63. AE: no. CRP 8.0 mg/L; ALT 35 U/L.
P00120,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.96. AE: no.
P00120,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.45. AE: no.
P00120,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P00120,7,neutral,Visit 7: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.55. AE: no.
P00121,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 5.6 mg/L; ALT 26 U/L.
P00121,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no.
P00121,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.53. AE: no.
P00121,3,negative,Visit 3: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.31. AE: no. CRP 4.0 mg/L; ALT 29 U/L.
P00121,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.55. AE: no.
P00122,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: headache. Adherence ~0.95. AE: no.
P00122,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.99. AE: yes.
P00122,2,negative,Visit 2: Patient on RX-17B at S013. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 11.9 mg/L; ALT 34 U/L.
P00122,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no. CRP 10.4 mg/L; ALT 32 U/L.
P00122,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no.
P00122,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P00122,6,positive,Visit 6: Patient on RX-17B at S013. reports improvement. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00123,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.72. AE: no. CRP 7.4 mg/L; ALT 33 U/L.
P00123,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.66. AE: yes. CRP 6.2 mg/L; ALT 38 U/L.
P00123,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00123,3,negative,Visit 3: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.67. AE: yes.
P00124,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.79. AE: no. CRP 4.7 mg/L; ALT 43 U/L.
P00124,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. CRP 4.8 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P00124,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P00124,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.78. AE: no. CRP 3.9 mg/L; ALT 48 U/L.
P00124,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.67. AE: no.
P00124,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.73. AE: no.
P00125,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.62. AE: yes.
P00125,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.62. AE: no.
P00125,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00125,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no.
P00125,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.79. AE: yes. CRP 8.1 mg/L; ALT 44 U/L.
P00125,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no.
P00125,6,positive,Visit 6: Patient on RX-17B at S022. feels better overall. Notes: brain fog. Adherence ~0.79. AE: no.
P00125,7,neutral,Visit 7: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.57. AE: no. CRP 4.4 mg/L; ALT 50 U/L.
P00126,0,neutral,Visit 0: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no. CRP 9.5 mg/L; ALT 18 U/L.
P00126,1,neutral,Visit 1: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 8.6 mg/L; ALT 18 U/L.
P00126,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.82. AE: no.
P00126,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P00126,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.63. AE: yes.
P00126,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.93. AE: yes. CRP 6.4 mg/L; ALT 21 U/L.
P00126,6,neutral,Visit 6: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00126,7,neutral,Visit 7: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no. CRP 3.8 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00127,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.61. AE: no.
P00127,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.52. AE: yes. CRP 5.1 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00127,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.66. AE: no. CRP 4.7 mg/L; ALT 28 U/L.
P00128,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.87. AE: no.
P00128,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.68. AE: no.
P00128,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.61. AE: no. CRP 10.5 mg/L; ALT 33 U/L.
P00128,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P00128,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: no.
P00128,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no. CRP 7.1 mg/L; ALT 34 U/L.
P00129,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no. CRP 11.2 mg/L; ALT 56 U/L.
P00129,1,negative,Visit 1: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.91. AE: no.
P00129,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P00129,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no. CRP 8.2 mg/L; ALT 59 U/L.
P00129,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P00130,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.58. AE: no. CRP 14.3 mg/L; ALT 12 U/L.
P00130,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.51. AE: no. CRP 12.7 mg/L; ALT 12 U/L. Plan: consider dose adjustment; counsel patient.
P00130,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.48. AE: no. CRP 12.0 mg/L; ALT 12 U/L.
P00130,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P00130,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.56. AE: no. CRP 9.3 mg/L; ALT 11 U/L.
P00130,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P00131,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no. CRP 11.6 mg/L; ALT 25 U/L.
P00131,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: headache. Adherence ~0.87. AE: no.
P00131,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 9.5 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00131,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: headache. Adherence ~0.65. AE: no. CRP 7.5 mg/L; ALT 24 U/L.
P00131,4,neutral,Visit 4: Patient on RX-17B at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P00132,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.94. AE: yes.
P00132,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 17 U/L.
P00132,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P00132,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no. CRP 4.5 mg/L; ALT 18 U/L.
P00132,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P00132,5,negative,Visit 5: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P00132,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P00133,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P00133,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: brain fog. Adherence ~0.79. AE: no.
P00133,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.69. AE: no.
P00133,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P00133,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 2.1 mg/L; ALT 20 U/L.
P00133,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: dizziness. Adherence ~0.77. AE: yes.
P00133,6,positive,Visit 6: Patient on RX-17B at S008. energy increasing. Notes: dizziness. Adherence ~0.90. AE: no.
P00134,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.57. AE: no. CRP 8.1 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P00134,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.52. AE: no.
P00134,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.55. AE: yes. CRP 6.9 mg/L; ALT 41 U/L.
P00134,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.36. AE: no.
P00135,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: dizziness. Adherence ~0.96. AE: no.
P00135,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: joint pain. Adherence ~0.91. AE: no.
P00135,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.90. AE: no. CRP 7.6 mg/L; ALT 25 U/L.
P00135,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no. CRP 6.4 mg/L; ALT 25 U/L.
P00135,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.85. AE: no.
P00135,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.99. AE: no.
P00135,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.66. AE: no. CRP 5.7 mg/L; ALT 26 U/L.
P00135,7,neutral,Visit 7: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no.
P00136,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: fatigue. Adherence ~0.57. AE: no.
P00136,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: insomnia. Adherence ~0.85. AE: no. CRP 7.6 mg/L; ALT 12 U/L.
P00136,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P00136,3,negative,Visit 3: Patient on RX-17B at S019. reports worsening. Notes: insomnia. Adherence ~0.62. AE: yes.
P00136,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 5.4 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P00136,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.67. AE: yes. CRP 4.0 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P00137,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.77. AE: yes.
P00137,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: dizziness. Adherence ~0.90. AE: no. CRP 1.3 mg/L; ALT 29 U/L.
P00137,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.74. AE: no. CRP 1.3 mg/L; ALT 30 U/L.
P00137,3,negative,Visit 3: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 1.3 mg/L; ALT 30 U/L.
P00137,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00137,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 0.9 mg/L; ALT 31 U/L.
P00137,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.96. AE: no.
P00138,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: nausea. Adherence ~0.96. AE: no.
P00138,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 9.6 mg/L; ALT 59 U/L.
P00138,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 9.2 mg/L; ALT 60 U/L.
P00138,3,negative,Visit 3: Patient on RX-17A at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00138,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00138,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P00139,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 17 U/L.
P00139,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00139,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: no.
P00139,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.95. AE: no.
P00139,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00139,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: yes.
P00139,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00140,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: dizziness. Adherence ~0.70. AE: no.
P00140,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.78. AE: no.
P00140,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00140,3,negative,Visit 3: Patient on RX-17A at S013. poor tolerance. Notes: abdominal discomfort. Adherence ~0.72. AE: yes.
P00140,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00140,5,negative,Visit 5: Patient on RX-17A at S013. symptoms persist. Notes: headache. Adherence ~0.49. AE: yes. CRP 6.5 mg/L; ALT 39 U/L.
P00141,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.91. AE: yes. CRP 14.7 mg/L; ALT 58 U/L.
P00141,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00141,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.69. AE: yes. CRP 14.6 mg/L; ALT 54 U/L.
P00141,3,negative,Visit 3: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.83. AE: no.
P00141,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.79. AE: no.
P00141,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P00141,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.57. AE: no. CRP 9.4 mg/L; ALT 58 U/L.
P00141,7,positive,Visit 7: Patient on RX-17B at S015. reports improvement. Notes: insomnia. Adherence ~0.82. AE: no.
P00142,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P00142,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: headache. Adherence ~0.78. AE: no. CRP 5.7 mg/L; ALT 33 U/L.
P00142,2,negative,Visit 2: Patient on RX-17B at S019. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no. CRP 5.2 mg/L; ALT 28 U/L.
P00143,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00143,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.92. AE: no.
P00143,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.72. AE: yes.
P00143,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.61. AE: no.
P00143,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.58. AE: yes.
P00144,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: yes.
P00144,1,negative,Visit 1: Patient on RX-17B at S008. feels frustrated. Notes: headache. Adherence ~0.74. AE: yes. CRP 6.6 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00144,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no. CRP 4.7 mg/L; ALT 26 U/L.
P00144,3,neutral,Visit 3: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00144,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.61. AE: no.
P00145,0,neutral,Visit 0: Patient on RX-17A at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.99. AE: no. CRP 10.0 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P00145,1,neutral,Visit 1: Patient on RX-17A at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.88. AE: no.
P00145,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no. CRP 9.0 mg/L; ALT 44 U/L.
P00145,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: no.
P00145,4,neutral,Visit 4: Patient on RX-17A at S008. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.2 mg/L; ALT 51 U/L.
P00145,5,neutral,Visit 5: Patient on RX-17A at S008. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.5 mg/L; ALT 52 U/L.
P00145,6,positive,Visit 6: Patient on RX-17A at S008. symptoms improving. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00145,7,positive,Visit 7: Patient on RX-17A at S008. tolerating medication well. Notes: dizziness. Adherence ~0.98. AE: no.
P00146,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: dizziness. Adherence ~1.00. AE: no.
P00146,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.6 mg/L; ALT 48 U/L.
P00146,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.99. AE: no.
P00146,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00146,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.95. AE: yes. CRP 5.5 mg/L; ALT 52 U/L.
P00147,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: dizziness. Adherence ~0.67. AE: no.
P00147,1,negative,Visit 1: Patient on RX-17A at S018. poor tolerance. Notes: headache. Adherence ~0.78. AE: yes. CRP 5.7 mg/L; ALT 33 U/L.
P00147,2,neutral,Visit 2: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00147,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.56. AE: no.
P00147,4,neutral,Visit 4: Patient on RX-17A at S018. follow-up as scheduled. Notes: nausea. Adherence ~0.88. AE: no.
P00147,5,neutral,Visit 5: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no.
P00148,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.1 mg/L; ALT 18 U/L.
P00148,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 19 U/L.
P00148,2,negative,Visit 2: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00148,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 3.8 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00148,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.93. AE: yes. CRP 3.0 mg/L; ALT 21 U/L.
P00149,0,neutral,Visit 0: Patient on RX-17B at S003. no major change. Notes: brain fog. Adherence ~0.92. AE: no.
P00149,1,negative,Visit 1: Patient on RX-17B at S003. symptoms persist. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00149,2,negative,Visit 2: Patient on RX-17B at S003. poor tolerance. Notes: nausea. Adherence ~1.00. AE: yes.
P00149,3,negative,Visit 3: Patient on RX-17B at S003. feels frustrated. Notes: insomnia. Adherence ~0.83. AE: yes.
P00149,4,positive,Visit 4: Patient on RX-17B at S003. tolerating medication well. Notes: nausea. Adherence ~0.93. AE: no. CRP 10.5 mg/L; ALT 21 U/L.
P00149,5,neutral,Visit 5: Patient on RX-17B at S003. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00149,6,positive,Visit 6: Patient on RX-17B at S003. energy increasing. Notes: headache. Adherence ~0.86. AE: no.
P00149,7,positive,Visit 7: Patient on RX-17B at S003. tolerating medication well. Notes: joint pain. Adherence ~0.94. AE: no.
P00150,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.75. AE: no. CRP 10.2 mg/L; ALT 13 U/L.
P00150,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no.
P00150,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.80. AE: no.
P00150,3,positive,Visit 3: Patient on RX-17A at S015. reports improvement. Notes: headache. Adherence ~0.89. AE: no.
P00150,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no.
P00150,5,positive,Visit 5: Patient on RX-17A at S015. energy increasing. Notes: insomnia. Adherence ~0.84. AE: no. CRP 7.0 mg/L; ALT 13 U/L.
P00150,6,positive,Visit 6: Patient on RX-17A at S015. symptoms improving. Notes: fatigue. Adherence ~0.94. AE: no.
P00151,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: headache. Adherence ~1.00. AE: no. CRP 12.1 mg/L; ALT 35 U/L.
P00151,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no.
P00151,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P00151,3,positive,Visit 3: Patient on RX-17B at S004. energy increasing. Notes: insomnia. Adherence ~0.94. AE: no.
P00152,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: fatigue. Adherence ~0.56. AE: yes.
P00152,1,neutral,Visit 1: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00152,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P00152,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00152,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.55. AE: no.
P00152,5,neutral,Visit 5: Patient on RX-17A at S018. stable symptoms. Notes: headache. Adherence ~0.64. AE: no.
P00153,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.84. AE: no. CRP 12.9 mg/L; ALT 31 U/L.
P00153,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P00153,2,negative,Visit 2: Patient on RX-17B at S012. poor tolerance. Notes: fatigue. Adherence ~0.95. AE: no. CRP 11.0 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00153,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.72. AE: no.
P00153,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.66. AE: no.
P00153,5,positive,Visit 5: Patient on RX-17B at S012. tolerating medication well. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.7 mg/L; ALT 34 U/L.
P00153,6,neutral,Visit 6: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.74. AE: yes.
P00154,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: dizziness. Adherence ~0.94. AE: yes. CRP 4.6 mg/L; ALT 35 U/L.
P00154,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.94. AE: no. CRP 3.8 mg/L; ALT 29 U/L.
P00154,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.92. AE: no.
P00154,3,positive,Visit 3: Patient on RX-17B at S004. reports improvement. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00154,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P00155,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.85. AE: no.
P00155,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.88. AE: no. CRP 6.2 mg/L; ALT 50 U/L.
P00155,2,negative,Visit 2: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no.
P00155,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.86. AE: no.
P00155,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: yes.
P00155,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: yes.
P00156,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: nausea. Adherence ~0.80. AE: no. CRP 9.0 mg/L; ALT 34 U/L.
P00156,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.95. AE: no.
P00156,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: no. CRP 7.8 mg/L; ALT 34 U/L.
P00156,3,negative,Visit 3: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00156,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.92. AE: no.
P00157,0,neutral,Visit 0: Patient on RX-17B at S011. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00157,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.90. AE: no. CRP 13.3 mg/L; ALT 24 U/L.
P00157,2,neutral,Visit 2: Patient on RX-17B at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. CRP 13.4 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00157,3,neutral,Visit 3: Patient on RX-17B at S011. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00157,4,neutral,Visit 4: Patient on RX-17B at S011. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no.
P00157,5,positive,Visit 5: Patient on RX-17B at S011. symptoms improving. Notes: joint pain. Adherence ~0.80. AE: no. CRP 7.5 mg/L; ALT 27 U/L.
P00157,6,positive,Visit 6: Patient on RX-17B at S011. symptoms improving. Notes: fatigue. Adherence ~0.86. AE: no. CRP 6.5 mg/L; ALT 25 U/L.
P00157,7,positive,Visit 7: Patient on RX-17B at S011. tolerating medication well. Notes: fatigue. Adherence ~0.77. AE: no.
P00158,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.80. AE: no. CRP 31.6 mg/L; ALT 32 U/L.
P00158,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.82. AE: no. CRP 27.3 mg/L; ALT 32 U/L.
P00158,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.68. AE: no.
P00158,3,negative,Visit 3: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 29.4 mg/L; ALT 31 U/L.
P00158,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00159,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: fatigue. Adherence ~0.60. AE: yes.
P00159,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P00159,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no.
P00159,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00159,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.82. AE: no.
P00160,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~0.64. AE: no.
P00160,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: nausea. Adherence ~0.48. AE: yes. Plan: consider dose adjustment; counsel patient.
P00160,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: headache. Adherence ~0.49. AE: no. CRP 4.4 mg/L; ALT 41 U/L.
P00160,3,negative,Visit 3: Patient on RX-17B at S002. symptoms persist. Notes: dizziness. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P00160,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P00160,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P00161,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: joint pain. Adherence ~0.91. AE: no. CRP 4.4 mg/L; ALT 28 U/L.
P00161,1,negative,Visit 1: Patient on RX-17B at S002. poor tolerance. Notes: headache. Adherence ~0.71. AE: no.
P00161,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P00161,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~0.89. AE: no.
P00161,4,negative,Visit 4: Patient on RX-17B at S002. increased discomfort. Notes: headache. Adherence ~0.75. AE: no.
P00161,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.70. AE: no.
P00161,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: fatigue. Adherence ~0.88. AE: no.
P00161,7,positive,Visit 7: Patient on RX-17B at S002. symptoms improving. Notes: fatigue. Adherence ~0.82. AE: no.
P00162,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: yes. CRP 4.8 mg/L; ALT 32 U/L.
P00162,1,negative,Visit 1: Patient on RX-17A at S005. increased discomfort. Notes: joint pain. Adherence ~0.51. AE: no.
P00162,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.51. AE: no.
P00162,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~0.39. AE: no.
P00162,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.59. AE: no. CRP 3.2 mg/L; ALT 27 U/L.
P00162,5,negative,Visit 5: Patient on RX-17A at S005. symptoms persist. Notes: brain fog. Adherence ~0.61. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P00162,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no.
P00163,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.88. AE: no. CRP 4.2 mg/L; ALT 37 U/L.
P00163,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.80. AE: yes.
P00163,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no. CRP 3.7 mg/L; ALT 36 U/L.
P00163,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: yes. CRP 3.1 mg/L; ALT 40 U/L.
P00163,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.90. AE: no.
P00163,5,positive,Visit 5: Patient on RX-17B at S002. tolerating medication well. Notes: headache. Adherence ~0.78. AE: no.
P00164,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.82. AE: no.
P00164,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 1.6 mg/L; ALT 28 U/L.
P00164,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.71. AE: no.
P00164,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.86. AE: no.
P00164,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.77. AE: no. CRP 1.1 mg/L; ALT 27 U/L.
P00164,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.83. AE: no.
P00164,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00164,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.67. AE: no. CRP 0.6 mg/L; ALT 31 U/L.
P00165,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no. CRP 4.9 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P00165,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: brain fog. Adherence ~0.95. AE: yes.
P00165,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P00165,3,positive,Visit 3: Patient on RX-17B at S016. reports improvement. Notes: fatigue. Adherence ~0.85. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P00165,4,positive,Visit 4: Patient on RX-17B at S016. reports improvement. Notes: headache. Adherence ~0.81. AE: no.
P00165,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.93. AE: no. CRP 2.8 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00165,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.83. AE: no.
P00166,0,neutral,Visit 0: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.67. AE: no.
P00166,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.67. AE: no. CRP 10.6 mg/L; ALT 30 U/L.
P00166,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P00167,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.96. AE: no. CRP 8.2 mg/L; ALT 50 U/L.
P00167,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: no. CRP 7.4 mg/L; ALT 54 U/L.
P00167,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P00167,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 5.9 mg/L; ALT 51 U/L.
P00167,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00168,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.99. AE: no.
P00168,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P00168,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 40 U/L.
P00168,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.74. AE: no. CRP 5.6 mg/L; ALT 41 U/L.
P00168,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P00169,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 28 U/L.
P00169,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.82. AE: yes.
P00169,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 2.9 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00169,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P00169,4,positive,Visit 4: Patient on RX-17A at S019. reports improvement. Notes: dizziness. Adherence ~0.97. AE: no. CRP 2.4 mg/L; ALT 28 U/L.
P00170,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00170,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: headache. Adherence ~0.88. AE: no. CRP 11.3 mg/L; ALT 41 U/L.
P00170,2,negative,Visit 2: Patient on RX-17B at S019. increased discomfort. Notes: insomnia. Adherence ~0.54. AE: no. CRP 12.2 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00170,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00170,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no.
P00171,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no.
P00171,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: nausea. Adherence ~0.79. AE: no.
P00171,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: fatigue. Adherence ~0.75. AE: no.
P00171,3,negative,Visit 3: Patient on RX-17A at S002. reports worsening. Notes: joint pain. Adherence ~0.63. AE: no.
P00171,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P00171,5,neutral,Visit 5: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no. CRP 6.2 mg/L; ALT 32 U/L.
P00172,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: yes. CRP 7.4 mg/L; ALT 39 U/L.
P00172,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 6.1 mg/L; ALT 34 U/L.
P00172,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.70. AE: no.
P00172,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P00172,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.64. AE: no.
P00172,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P00172,6,positive,Visit 6: Patient on RX-17B at S005. tolerating medication well. Notes: nausea. Adherence ~0.87. AE: no.
P00173,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: dizziness. Adherence ~0.79. AE: no.
P00173,1,neutral,Visit 1: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.98. AE: no.
P00173,2,negative,Visit 2: Patient on RX-17A at S008. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. CRP 1.9 mg/L; ALT 33 U/L.
P00173,3,negative,Visit 3: Patient on RX-17A at S008. symptoms persist. Notes: fatigue. Adherence ~0.77. AE: yes.
P00173,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: brain fog. Adherence ~0.91. AE: no. CRP 1.4 mg/L; ALT 32 U/L.
P00173,5,negative,Visit 5: Patient on RX-17A at S008. symptoms persist. Notes: dizziness. Adherence ~0.83. AE: no. CRP 1.4 mg/L; ALT 34 U/L.
P00173,6,neutral,Visit 6: Patient on RX-17A at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: yes.
P00174,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: headache. Adherence ~0.70. AE: no. CRP 6.4 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00174,1,negative,Visit 1: Patient on RX-17B at S008. feels frustrated. Notes: brain fog. Adherence ~0.82. AE: yes. CRP 5.0 mg/L; ALT 15 U/L.
P00174,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: dizziness. Adherence ~0.62. AE: no.
P00174,3,neutral,Visit 3: Patient on RX-17B at S008. no major change. Notes: fatigue. Adherence ~0.53. AE: no.
P00174,4,positive,Visit 4: Patient on RX-17B at S008. feels better overall. Notes: fatigue. Adherence ~0.88. AE: no.
P00174,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P00175,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.82. AE: no. CRP 8.7 mg/L; ALT 10 U/L.
P00175,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no.
P00175,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.65. AE: no.
P00175,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.69. AE: no.
P00175,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 7.4 mg/L; ALT 9 U/L.
P00175,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no. CRP 7.0 mg/L; ALT 11 U/L.
P00175,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.70. AE: no.
P00176,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P00176,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no.
P00176,2,negative,Visit 2: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.99. AE: no.
P00176,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00176,4,positive,Visit 4: Patient on RX-17A at S013. feels better overall. Notes: joint pain. Adherence ~0.94. AE: no.
P00177,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: nausea. Adherence ~0.96. AE: no.
P00177,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.84. AE: no.
P00177,2,neutral,Visit 2: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.94. AE: no.
P00177,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P00177,4,negative,Visit 4: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~0.74. AE: yes.
P00177,5,positive,Visit 5: Patient on RX-17B at S002. symptoms improving. Notes: insomnia. Adherence ~0.85. AE: no.
P00177,6,neutral,Visit 6: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.70. AE: yes.
P00177,7,neutral,Visit 7: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.80. AE: yes.
P00178,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00178,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.64. AE: no.
P00178,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 8.6 mg/L; ALT 17 U/L.
P00178,3,negative,Visit 3: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.57. AE: yes. CRP 8.9 mg/L; ALT 20 U/L.
P00178,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.33. AE: no. CRP 7.5 mg/L; ALT 17 U/L.
P00179,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.81. AE: yes.
P00179,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 7.3 mg/L; ALT 23 U/L.
P00179,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P00179,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: no.
P00179,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.77. AE: no.
P00180,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00180,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no.
P00180,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.78. AE: no. CRP 7.6 mg/L; ALT 44 U/L.
P00180,3,positive,Visit 3: Patient on RX-17B at S004. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no.
P00180,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.85. AE: no.
P00180,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P00181,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.86. AE: no.
P00181,1,negative,Visit 1: Patient on RX-17A at S019. feels frustrated. Notes: joint pain. Adherence ~0.69. AE: yes.
P00181,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 4.2 mg/L; ALT 37 U/L.
P00181,3,negative,Visit 3: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00181,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: yes.
P00182,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.97. AE: yes.
P00182,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.91. AE: yes. CRP 3.4 mg/L; ALT 37 U/L.
P00182,2,negative,Visit 2: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: yes. CRP 2.9 mg/L; ALT 43 U/L.
P00182,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.88. AE: no.
P00182,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00182,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no. CRP 2.4 mg/L; ALT 42 U/L.
P00183,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00183,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P00183,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.74. AE: yes. CRP 9.2 mg/L; ALT 41 U/L.
P00183,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: yes. CRP 7.7 mg/L; ALT 39 U/L.
P00183,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00183,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no.
P00184,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 9.0 mg/L; ALT 22 U/L.
P00184,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00184,2,positive,Visit 2: Patient on RX-17A at S004. energy increasing. Notes: nausea. Adherence ~1.00. AE: no.
P00184,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.76. AE: no.
P00184,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.93. AE: no.
P00184,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.78. AE: no. CRP 7.2 mg/L; ALT 21 U/L.
P00185,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.80. AE: no.
P00185,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: insomnia. Adherence ~0.60. AE: yes.
P00185,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.56. AE: no. CRP 7.7 mg/L; ALT 40 U/L.
P00185,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.65. AE: no. CRP 7.0 mg/L; ALT 40 U/L.
P00185,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.64. AE: no.
P00185,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.45. AE: no.
P00186,0,negative,Visit 0: Patient on RX-17B at S021. feels frustrated. Notes: dizziness. Adherence ~0.78. AE: yes. CRP 8.4 mg/L; ALT 33 U/L.
P00186,1,neutral,Visit 1: Patient on RX-17B at S021. stable symptoms. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00186,2,neutral,Visit 2: Patient on RX-17B at S021. stable symptoms. Notes: insomnia. Adherence ~0.55. AE: yes.
P00186,3,neutral,Visit 3: Patient on RX-17B at S021. follow-up as scheduled. Notes: fatigue. Adherence ~0.63. AE: no.
P00186,4,neutral,Visit 4: Patient on RX-17B at S021. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no. CRP 5.2 mg/L; ALT 38 U/L.
P00186,5,neutral,Visit 5: Patient on RX-17B at S021. stable symptoms. Notes: joint pain. Adherence ~0.44. AE: no.
P00186,6,neutral,Visit 6: Patient on RX-17B at S021. continues regimen. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00186,7,neutral,Visit 7: Patient on RX-17B at S021. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. CRP 3.7 mg/L; ALT 42 U/L.
P00187,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.99. AE: yes. CRP 6.4 mg/L; ALT 30 U/L.
P00187,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P00187,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.84. AE: no. CRP 5.4 mg/L; ALT 28 U/L.
P00187,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no. CRP 4.3 mg/L; ALT 30 U/L.
P00187,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no.
P00187,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.75. AE: yes.
P00187,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no. CRP 3.9 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00188,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: insomnia. Adherence ~0.81. AE: no.
P00188,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00188,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00188,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P00188,4,positive,Visit 4: Patient on RX-17A at S018. reports improvement. Notes: fatigue. Adherence ~0.85. AE: no.
P00188,5,neutral,Visit 5: Patient on RX-17A at S018. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. CRP 6.6 mg/L; ALT 26 U/L.
P00188,6,positive,Visit 6: Patient on RX-17A at S018. reports improvement. Notes: dizziness. Adherence ~0.88. AE: no.
P00188,7,positive,Visit 7: Patient on RX-17A at S018. symptoms improving. Notes: headache. Adherence ~0.97. AE: no. CRP 4.7 mg/L; ALT 31 U/L.
P00189,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 9.7 mg/L; ALT 36 U/L.
P00189,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.64. AE: no. CRP 8.0 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00189,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.48. AE: yes. CRP 7.4 mg/L; ALT 46 U/L.
P00189,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no.
P00189,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P00189,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.55. AE: no.
P00189,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.66. AE: no.
P00190,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~0.78. AE: no.
P00190,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: nausea. Adherence ~0.52. AE: no.
P00190,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: insomnia. Adherence ~0.67. AE: no.
P00190,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.57. AE: no.
P00190,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00190,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no.
P00190,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.82. AE: yes.
P00191,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.57. AE: no.
P00191,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.59. AE: no.
P00191,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.43. AE: no. Plan: consider dose adjustment; counsel patient.
P00191,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.61. AE: no. CRP 22.8 mg/L; ALT 44 U/L.
P00191,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.48. AE: no. CRP 22.8 mg/L; ALT 47 U/L.
P00192,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: headache. Adherence ~0.70. AE: yes.
P00192,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00192,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: dizziness. Adherence ~0.90. AE: no.
P00192,3,negative,Visit 3: Patient on RX-17B at S004. feels frustrated. Notes: fatigue. Adherence ~0.77. AE: yes.
P00192,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: no.
P00192,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no. CRP 2.6 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P00192,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P00192,7,neutral,Visit 7: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.90. AE: no.
P00193,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.78. AE: yes.
P00193,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.72. AE: no.
P00193,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.61. AE: yes.
P00194,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: no.
P00194,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P00194,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.47. AE: no. CRP 3.0 mg/L; ALT 50 U/L.
P00194,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P00194,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.66. AE: no.
P00194,5,negative,Visit 5: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.70. AE: no. CRP 2.4 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00194,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.72. AE: no.
P00195,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.90. AE: no.
P00195,1,neutral,Visit 1: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.87. AE: no.
P00195,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: nausea. Adherence ~0.79. AE: no.
P00195,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: yes.
P00195,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P00196,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.88. AE: yes.
P00196,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00196,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.77. AE: yes.
P00196,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: no. CRP 2.6 mg/L; ALT 31 U/L.
P00196,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.57. AE: yes.
P00196,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~0.85. AE: no. CRP 2.3 mg/L; ALT 28 U/L.
P00196,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.67. AE: yes. CRP 1.6 mg/L; ALT 32 U/L.
P00196,7,neutral,Visit 7: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no. CRP 1.4 mg/L; ALT 30 U/L.
P00197,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.81. AE: no.
P00197,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.61. AE: no. CRP 8.1 mg/L; ALT 22 U/L.
P00197,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: joint pain. Adherence ~0.72. AE: no. CRP 8.2 mg/L; ALT 25 U/L.
P00197,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.73. AE: no. CRP 7.2 mg/L; ALT 25 U/L.
P00197,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.80. AE: no. CRP 6.1 mg/L; ALT 26 U/L.
P00197,5,negative,Visit 5: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: yes.
P00197,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.65. AE: no.
P00198,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: nausea. Adherence ~0.93. AE: no.
P00198,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: insomnia. Adherence ~0.85. AE: yes.
P00198,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.95. AE: yes.
P00198,3,positive,Visit 3: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~0.89. AE: no.
P00198,4,positive,Visit 4: Patient on RX-17B at S015. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00198,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. CRP 7.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00198,6,positive,Visit 6: Patient on RX-17B at S015. reports improvement. Notes: dizziness. Adherence ~0.95. AE: no.
P00198,7,positive,Visit 7: Patient on RX-17B at S015. reports improvement. Notes: nausea. Adherence ~0.97. AE: no.
P00199,0,negative,Visit 0: Patient on RX-17A at S009. poor tolerance. Notes: dizziness. Adherence ~0.62. AE: no.
P00199,1,neutral,Visit 1: Patient on RX-17A at S009. reviewed dosing instructions. Notes: fatigue. Adherence ~0.51. AE: no.
P00199,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.61. AE: no.
P00199,3,neutral,Visit 3: Patient on RX-17A at S009. no major change. Notes: nausea. Adherence ~0.58. AE: no. CRP 6.6 mg/L; ALT 39 U/L.
P00199,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 46 U/L.
P00199,5,neutral,Visit 5: Patient on RX-17A at S009. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 5.1 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P00200,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.91. AE: no.
P00200,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 12.4 mg/L; ALT 21 U/L.
P00200,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.91. AE: no.
P00200,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00201,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 98 U/L.
P00201,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00201,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.7 mg/L; ALT 99 U/L.
P00201,3,positive,Visit 3: Patient on RX-17B at S014. symptoms improving. Notes: joint pain. Adherence ~0.88. AE: no.
P00201,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.89. AE: no.
P00201,5,positive,Visit 5: Patient on RX-17B at S014. symptoms improving. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00202,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: nausea. Adherence ~0.87. AE: no.
P00202,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00202,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00202,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.65. AE: no.
P00202,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~0.59. AE: no. CRP 1.5 mg/L; ALT 24 U/L.
P00202,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no.
P00202,6,positive,Visit 6: Patient on RX-17B at S013. tolerating medication well. Notes: fatigue. Adherence ~0.91. AE: no.
P00203,0,negative,Visit 0: Patient on RX-17A at S007. reports worsening. Notes: dizziness. Adherence ~0.54. AE: no.
P00203,1,negative,Visit 1: Patient on RX-17A at S007. poor tolerance. Notes: headache. Adherence ~0.70. AE: no.
P00203,2,negative,Visit 2: Patient on RX-17A at S007. reports worsening. Notes: nausea. Adherence ~0.64. AE: no.
P00204,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.75. AE: no. CRP 8.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00204,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no. CRP 6.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00204,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.75. AE: no. CRP 6.4 mg/L; ALT 31 U/L.
P00204,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.99. AE: yes.
P00204,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no. CRP 4.9 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00204,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no.
P00204,6,positive,Visit 6: Patient on RX-17B at S012. reports improvement. Notes: insomnia. Adherence ~0.88. AE: no. CRP 4.7 mg/L; ALT 33 U/L.
P00204,7,neutral,Visit 7: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00205,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00205,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00205,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: no. CRP 4.6 mg/L; ALT 31 U/L.
P00205,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: yes.
P00205,4,positive,Visit 4: Patient on RX-17A at S012. tolerating medication well. Notes: insomnia. Adherence ~0.92. AE: no. CRP 4.0 mg/L; ALT 30 U/L.
P00206,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00206,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.85. AE: no.
P00206,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00206,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00206,4,positive,Visit 4: Patient on RX-17B at S012. energy increasing. Notes: dizziness. Adherence ~0.82. AE: no. CRP 3.7 mg/L; ALT 28 U/L.
P00206,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: brain fog. Adherence ~0.85. AE: no. CRP 3.3 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P00206,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.73. AE: no.
P00206,7,positive,Visit 7: Patient on RX-17B at S012. tolerating medication well. Notes: joint pain. Adherence ~0.90. AE: no.
P00207,0,neutral,Visit 0: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 9.9 mg/L; ALT 48 U/L.
P00207,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00207,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.92. AE: no. CRP 7.4 mg/L; ALT 46 U/L.
P00207,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 7.3 mg/L; ALT 50 U/L.
P00207,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P00207,5,positive,Visit 5: Patient on RX-17B at S012. tolerating medication well. Notes: joint pain. Adherence ~0.86. AE: no.
P00207,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: brain fog. Adherence ~0.86. AE: no.
P00208,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.80. AE: no.
P00208,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.85. AE: yes. CRP 4.1 mg/L; ALT 27 U/L.
P00208,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.65. AE: no. CRP 4.2 mg/L; ALT 26 U/L.
P00208,3,negative,Visit 3: Patient on RX-17A at S016. poor tolerance. Notes: joint pain. Adherence ~0.52. AE: no.
P00209,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: headache. Adherence ~0.97. AE: no. CRP 9.1 mg/L; ALT 16 U/L.
P00209,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.91. AE: no. CRP 9.0 mg/L; ALT 17 U/L.
P00209,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.82. AE: no.
P00209,3,positive,Visit 3: Patient on RX-17B at S012. symptoms improving. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 7.1 mg/L; ALT 16 U/L.
P00209,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: yes.
P00209,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.95. AE: yes.
P00210,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: insomnia. Adherence ~0.73. AE: no.
P00210,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.77. AE: no.
P00210,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.85. AE: no.
P00210,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P00210,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no. CRP 11.9 mg/L; ALT 20 U/L.
P00211,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P00211,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.74. AE: no.
P00211,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00211,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no.
P00211,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.76. AE: no. CRP 16.6 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P00211,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no.
P00212,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. CRP 16.2 mg/L; ALT 47 U/L.
P00212,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.51. AE: no.
P00212,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00212,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.53. AE: no.
P00212,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.36. AE: no.
P00212,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: yes.
P00213,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.72. AE: yes.
P00213,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no.
P00213,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00213,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00213,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P00214,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00214,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.92. AE: no.
P00214,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.86. AE: no.
P00214,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00214,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P00215,0,neutral,Visit 0: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 5.4 mg/L; ALT 15 U/L.
P00215,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no. CRP 6.1 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00215,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no.
P00215,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 4.8 mg/L; ALT 15 U/L.
P00215,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P00215,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: dizziness. Adherence ~0.96. AE: no.
P00215,6,neutral,Visit 6: Patient on RX-17A at S019. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 15 U/L.
P00215,7,neutral,Visit 7: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.82. AE: yes. CRP 2.8 mg/L; ALT 16 U/L.
P00216,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: fatigue. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00216,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.70. AE: no.
P00216,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00216,3,negative,Visit 3: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00216,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.99. AE: yes. CRP 4.3 mg/L; ALT 36 U/L.
P00217,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.75. AE: no.
P00217,1,neutral,Visit 1: Patient on RX-17A at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no.
P00217,2,negative,Visit 2: Patient on RX-17A at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 10.7 mg/L; ALT 21 U/L.
P00217,3,negative,Visit 3: Patient on RX-17A at S018. poor tolerance. Notes: dizziness. Adherence ~0.64. AE: no.
P00217,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.48. AE: no. CRP 9.5 mg/L; ALT 21 U/L.
P00218,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00218,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.75. AE: no.
P00218,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.96. AE: no. CRP 4.9 mg/L; ALT 41 U/L.
P00218,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00218,4,positive,Visit 4: Patient on RX-17B at S014. energy increasing. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00219,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: dizziness. Adherence ~0.46. AE: no.
P00219,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P00219,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P00219,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.45. AE: no. CRP 7.4 mg/L; ALT 36 U/L.
P00219,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.51. AE: no. CRP 6.3 mg/L; ALT 37 U/L.
P00219,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.48. AE: no. CRP 6.3 mg/L; ALT 33 U/L.
P00220,0,neutral,Visit 0: Patient on RX-17B at S011. stable symptoms. Notes: nausea. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P00220,1,negative,Visit 1: Patient on RX-17B at S011. poor tolerance. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P00220,2,negative,Visit 2: Patient on RX-17B at S011. increased discomfort. Notes: headache. Adherence ~0.61. AE: no.
P00220,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: nausea. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P00220,4,negative,Visit 4: Patient on RX-17B at S011. poor tolerance. Notes: brain fog. Adherence ~0.80. AE: yes. CRP 2.5 mg/L; ALT 48 U/L.
P00220,5,neutral,Visit 5: Patient on RX-17B at S011. follow-up as scheduled. Notes: insomnia. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P00220,6,neutral,Visit 6: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~0.56. AE: no.
P00221,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.68. AE: no. CRP 15.3 mg/L; ALT 29 U/L.
P00221,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.66. AE: no.
P00221,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00221,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00221,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00221,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.62. AE: no. CRP 10.6 mg/L; ALT 26 U/L.
P00222,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.83. AE: no.
P00222,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P00222,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 5.5 mg/L; ALT 31 U/L.
P00222,3,negative,Visit 3: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.82. AE: yes. CRP 4.9 mg/L; ALT 30 U/L.
P00222,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.93. AE: no.
P00223,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 11.4 mg/L; ALT 18 U/L.
P00223,1,negative,Visit 1: Patient on RX-17B at S016. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no. CRP 11.3 mg/L; ALT 19 U/L.
P00223,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 12.4 mg/L; ALT 18 U/L.
P00223,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P00223,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.94. AE: no. CRP 8.6 mg/L; ALT 18 U/L.
P00223,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes.
P00224,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: headache. Adherence ~0.80. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P00224,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: insomnia. Adherence ~0.83. AE: no. CRP 4.4 mg/L; ALT 21 U/L.
P00224,2,negative,Visit 2: Patient on RX-17B at S019. symptoms persist. Notes: brain fog. Adherence ~0.74. AE: no. CRP 5.0 mg/L; ALT 21 U/L.
P00224,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.84. AE: no. CRP 3.8 mg/L; ALT 24 U/L.
P00224,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.99. AE: no.
P00224,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.79. AE: no. CRP 2.8 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P00225,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.67. AE: no.
P00225,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: no.
P00225,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.87. AE: no.
P00225,3,negative,Visit 3: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.71. AE: no.
P00225,4,positive,Visit 4: Patient on RX-17A at S004. energy increasing. Notes: fatigue. Adherence ~0.83. AE: no.
P00225,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no.
P00225,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: yes.
P00225,7,positive,Visit 7: Patient on RX-17A at S004. feels better overall. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00226,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.64. AE: yes. CRP 16.3 mg/L; ALT 34 U/L.
P00226,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no.
P00226,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.73. AE: no. CRP 13.1 mg/L; ALT 32 U/L.
P00226,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.62. AE: no.
P00226,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.59. AE: no.
P00226,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.79. AE: no.
P00226,6,positive,Visit 6: Patient on RX-17A at S015. tolerating medication well. Notes: dizziness. Adherence ~0.76. AE: no.
P00226,7,neutral,Visit 7: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00227,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P00227,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P00227,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.91. AE: no.
P00227,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no.
P00227,4,positive,Visit 4: Patient on RX-17A at S004. energy increasing. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00227,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P00227,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.96. AE: yes.
P00228,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.81. AE: yes. CRP 3.2 mg/L; ALT 50 U/L.
P00228,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00228,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.85. AE: no.
P00228,3,negative,Visit 3: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.87. AE: no. CRP 2.3 mg/L; ALT 45 U/L.
P00228,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00228,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00229,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.63. AE: no.
P00229,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P00229,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P00229,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.67. AE: no.
P00230,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no. CRP 12.5 mg/L; ALT 39 U/L.
P00230,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.96. AE: no.
P00230,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no. CRP 10.0 mg/L; ALT 37 U/L.
P00230,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.96. AE: no.
P00230,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00231,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no. CRP 11.5 mg/L; ALT 21 U/L.
P00231,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.81. AE: no. CRP 12.6 mg/L; ALT 21 U/L.
P00231,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00231,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no. CRP 8.5 mg/L; ALT 23 U/L.
P00231,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.90. AE: no.
P00232,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P00232,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.74. AE: yes. CRP 5.0 mg/L; ALT 56 U/L.
P00232,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.78. AE: no.
P00232,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.90. AE: no. CRP 3.6 mg/L; ALT 52 U/L.
P00232,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: dizziness. Adherence ~0.86. AE: no.
P00232,5,negative,Visit 5: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00232,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.64. AE: no. CRP 2.5 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00233,0,neutral,Visit 0: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00233,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no.
P00233,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.90. AE: no.
P00233,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P00233,4,negative,Visit 4: Patient on RX-17B at S018. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 37 U/L.
P00233,5,positive,Visit 5: Patient on RX-17B at S018. symptoms improving. Notes: dizziness. Adherence ~0.97. AE: no.
P00233,6,neutral,Visit 6: Patient on RX-17B at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P00234,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.72. AE: no. CRP 12.0 mg/L; ALT 40 U/L.
P00234,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 10.9 mg/L; ALT 42 U/L.
P00234,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: no. CRP 9.3 mg/L; ALT 42 U/L.
P00234,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no.
P00234,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.73. AE: no.
P00234,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.77. AE: no. CRP 7.1 mg/L; ALT 39 U/L.
P00234,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. CRP 5.9 mg/L; ALT 44 U/L.
P00234,7,neutral,Visit 7: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no.
P00235,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.86. AE: yes.
P00235,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.88. AE: yes.
P00235,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00235,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00235,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.97. AE: no.
P00235,5,positive,Visit 5: Patient on RX-17B at S017. feels better overall. Notes: brain fog. Adherence ~0.92. AE: no. CRP 7.7 mg/L; ALT 26 U/L.
P00235,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: brain fog. Adherence ~0.97. AE: no.
P00235,7,positive,Visit 7: Patient on RX-17B at S017. energy increasing. Notes: headache. Adherence ~0.80. AE: no.
P00236,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no.
P00236,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.85. AE: no. CRP 6.9 mg/L; ALT 66 U/L.
P00236,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no.
P00236,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.80. AE: no. CRP 5.7 mg/L; ALT 68 U/L.
P00236,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no.
P00236,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 4.5 mg/L; ALT 67 U/L.
P00237,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: no.
P00237,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00237,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.45. AE: no. CRP 9.3 mg/L; ALT 63 U/L.
P00238,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00238,1,neutral,Visit 1: Patient on RX-17B at S008. stable symptoms. Notes: headache. Adherence ~0.66. AE: no.
P00238,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: yes. CRP 10.3 mg/L; ALT 38 U/L.
P00238,3,neutral,Visit 3: Patient on RX-17B at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P00238,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P00238,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P00238,6,neutral,Visit 6: Patient on RX-17B at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.67. AE: no.
P00239,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.73. AE: yes.
P00239,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.74. AE: no.
P00239,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.44. AE: no.
P00239,3,negative,Visit 3: Patient on RX-17A at S015. increased discomfort. Notes: fatigue. Adherence ~0.57. AE: no. CRP 20.4 mg/L; ALT 47 U/L.
P00239,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no. CRP 17.5 mg/L; ALT 45 U/L.
P00239,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.62. AE: no. CRP 14.5 mg/L; ALT 49 U/L.
P00239,6,neutral,Visit 6: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.59. AE: yes. CRP 15.9 mg/L; ALT 51 U/L.
P00240,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.97. AE: no.
P00240,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00240,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no.
P00240,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 24 U/L.
P00240,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00240,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: dizziness. Adherence ~0.80. AE: no.
P00240,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.98. AE: no.
P00240,7,positive,Visit 7: Patient on RX-17A at S004. energy increasing. Notes: headache. Adherence ~0.88. AE: no.
P00241,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: joint pain. Adherence ~0.71. AE: no.
P00241,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00241,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.59. AE: no.
P00241,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.69. AE: no. CRP 3.6 mg/L; ALT 21 U/L.
P00241,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.75. AE: yes.
P00241,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 3.0 mg/L; ALT 18 U/L.
P00242,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00242,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: yes.
P00242,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.76. AE: no. CRP 4.2 mg/L; ALT 44 U/L.
P00242,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P00242,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.94. AE: no.
P00242,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.99. AE: no. CRP 3.1 mg/L; ALT 42 U/L.
P00242,6,neutral,Visit 6: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no. CRP 3.0 mg/L; ALT 46 U/L.
P00242,7,positive,Visit 7: Patient on RX-17B at S005. energy increasing. Notes: brain fog. Adherence ~1.00. AE: no.
P00243,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P00243,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.87. AE: no.
P00243,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P00243,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no. CRP 9.4 mg/L; ALT 25 U/L.
P00243,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00243,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.72. AE: no.
P00243,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.83. AE: no. CRP 6.2 mg/L; ALT 26 U/L.
P00243,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no.
P00244,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.88. AE: no.
P00244,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.73. AE: no.
P00244,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00244,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no.
P00244,4,positive,Visit 4: Patient on RX-17A at S014. feels better overall. Notes: headache. Adherence ~0.87. AE: no. CRP 5.2 mg/L; ALT 57 U/L.
P00244,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.80. AE: no. CRP 4.6 mg/L; ALT 52 U/L.
P00245,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no. CRP 8.0 mg/L; ALT 44 U/L.
P00245,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 7.9 mg/L; ALT 47 U/L.
P00245,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00245,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00245,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.92. AE: no.
P00245,5,positive,Visit 5: Patient on RX-17A at S014. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 43 U/L.
P00245,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.94. AE: no.
P00245,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: nausea. Adherence ~0.94. AE: no.
P00246,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.87. AE: no. CRP 8.3 mg/L; ALT 32 U/L.
P00246,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00246,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: no. CRP 6.8 mg/L; ALT 34 U/L.
P00246,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.84. AE: no. CRP 5.3 mg/L; ALT 34 U/L.
P00246,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no. CRP 5.8 mg/L; ALT 29 U/L.
P00247,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.87. AE: no. CRP 7.4 mg/L; ALT 35 U/L.
P00247,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.75. AE: no.
P00247,2,negative,Visit 2: Patient on RX-17A at S017. symptoms persist. Notes: dizziness. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00247,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no.
P00247,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00248,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no.
P00248,1,neutral,Visit 1: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no.
P00248,2,negative,Visit 2: Patient on RX-17B at S018. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: yes.
P00248,3,positive,Visit 3: Patient on RX-17B at S018. energy increasing. Notes: brain fog. Adherence ~0.77. AE: no.
P00248,4,neutral,Visit 4: Patient on RX-17B at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P00248,5,neutral,Visit 5: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.80. AE: no.
P00248,6,neutral,Visit 6: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.87. AE: no.
P00248,7,positive,Visit 7: Patient on RX-17B at S018. reports improvement. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00249,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.85. AE: yes.
P00249,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no. CRP 9.9 mg/L; ALT 33 U/L.
P00249,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.83. AE: yes.
P00249,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00249,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no. CRP 8.7 mg/L; ALT 37 U/L.
P00249,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.61. AE: yes.
P00249,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.67. AE: yes.
P00249,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00250,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.38. AE: no. CRP 4.5 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00250,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P00250,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.69. AE: no.
P00250,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.39. AE: no.
P00250,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no.
P00250,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no.
P00251,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.55. AE: no. CRP 6.7 mg/L; ALT 17 U/L.
P00251,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.37. AE: yes. Plan: consider dose adjustment; counsel patient.
P00251,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.42. AE: no. CRP 6.0 mg/L; ALT 18 U/L.
P00252,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: insomnia. Adherence ~0.77. AE: no. CRP 3.8 mg/L; ALT 40 U/L.
P00252,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no. CRP 2.9 mg/L; ALT 42 U/L.
P00252,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.71. AE: yes. CRP 3.2 mg/L; ALT 52 U/L.
P00253,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00253,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no.
P00253,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P00253,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P00254,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: headache. Adherence ~0.86. AE: yes.
P00254,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.98. AE: yes.
P00254,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 80 U/L.
P00254,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no.
P00254,4,positive,Visit 4: Patient on RX-17B at S004. energy increasing. Notes: dizziness. Adherence ~0.76. AE: no. CRP 4.3 mg/L; ALT 86 U/L. Plan: consider dose adjustment; counsel patient.
P00254,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 78 U/L.
P00255,0,neutral,Visit 0: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00255,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P00255,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.79. AE: no.
P00255,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no. CRP 9.9 mg/L; ALT 33 U/L.
P00255,4,negative,Visit 4: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.73. AE: yes. CRP 8.5 mg/L; ALT 32 U/L.
P00255,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~0.79. AE: no.
P00255,6,positive,Visit 6: Patient on RX-17B at S015. reports improvement. Notes: brain fog. Adherence ~0.78. AE: no. CRP 6.0 mg/L; ALT 30 U/L.
P00255,7,neutral,Visit 7: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~1.00. AE: yes.
P00256,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00256,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: fatigue. Adherence ~0.75. AE: yes. CRP 6.1 mg/L; ALT 36 U/L.
P00256,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.96. AE: no.
P00256,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: no. CRP 5.6 mg/L; ALT 32 U/L.
P00256,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. CRP 5.7 mg/L; ALT 35 U/L.
P00257,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.49. AE: no.
P00257,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.66. AE: no. CRP 5.2 mg/L; ALT 33 U/L.
P00257,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.86. AE: no. CRP 5.2 mg/L; ALT 36 U/L.
P00257,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 4.5 mg/L; ALT 34 U/L.
P00257,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no. CRP 4.4 mg/L; ALT 37 U/L.
P00258,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P00258,1,neutral,Visit 1: Patient on RX-17B at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.93. AE: yes.
P00258,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no.
P00258,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.71. AE: no.
P00258,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.95. AE: no.
P00258,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.77. AE: no.
P00258,6,positive,Visit 6: Patient on RX-17B at S016. reports improvement. Notes: nausea. Adherence ~0.99. AE: no. CRP 3.0 mg/L; ALT 39 U/L.
P00259,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00259,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.56. AE: yes.
P00259,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.52. AE: no.
P00259,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.36. AE: no.
P00259,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.63. AE: yes.
P00260,0,negative,Visit 0: Patient on RX-17B at S021. symptoms persist. Notes: insomnia. Adherence ~0.82. AE: no.
P00260,1,neutral,Visit 1: Patient on RX-17B at S021. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no.
P00260,2,neutral,Visit 2: Patient on RX-17B at S021. no major change. Notes: dizziness. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00260,3,neutral,Visit 3: Patient on RX-17B at S021. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P00260,4,neutral,Visit 4: Patient on RX-17B at S021. reviewed dosing instructions. Notes: insomnia. Adherence ~0.55. AE: no. CRP 2.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00261,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.54. AE: no.
P00261,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: insomnia. Adherence ~0.59. AE: no. CRP 4.5 mg/L; ALT 40 U/L.
P00261,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: no.
P00261,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.49. AE: no. CRP 3.7 mg/L; ALT 44 U/L.
P00261,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: yes.
P00261,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.63. AE: no.
P00261,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.75. AE: yes.
P00262,0,negative,Visit 0: Patient on RX-17B at S010. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: yes.
P00262,1,neutral,Visit 1: Patient on RX-17B at S010. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no.
P00262,2,neutral,Visit 2: Patient on RX-17B at S010. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P00263,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 5.1 mg/L; ALT 40 U/L.
P00263,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.96. AE: no.
P00263,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.94. AE: no.
P00263,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.97. AE: no. CRP 4.2 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00263,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no.
P00263,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.80. AE: no.
P00263,6,positive,Visit 6: Patient on RX-17A at S012. tolerating medication well. Notes: headache. Adherence ~0.96. AE: no.
P00264,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.88. AE: no. CRP 8.5 mg/L; ALT 30 U/L.
P00264,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.55. AE: no.
P00264,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no.
P00264,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.50. AE: no.
P00264,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.63. AE: no. CRP 7.0 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00264,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00264,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.66. AE: yes.
P00265,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.74. AE: no.
P00265,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.98. AE: no.
P00265,2,negative,Visit 2: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.83. AE: no. CRP 5.6 mg/L; ALT 31 U/L.
P00265,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.92. AE: no.
P00266,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~0.49. AE: no.
P00266,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.64. AE: no.
P00266,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no.
P00266,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no. CRP 6.4 mg/L; ALT 44 U/L.
P00266,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.43. AE: yes. CRP 6.1 mg/L; ALT 48 U/L.
P00267,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.99. AE: no.
P00267,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.65. AE: yes. CRP 7.0 mg/L; ALT 29 U/L.
P00267,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.61. AE: no.
P00267,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.78. AE: no.
P00267,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.90. AE: yes.
P00267,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.58. AE: no. CRP 5.8 mg/L; ALT 28 U/L.
P00267,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no.
P00267,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no. CRP 4.9 mg/L; ALT 31 U/L.
P00268,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: yes.
P00268,1,negative,Visit 1: Patient on RX-17B at S013. poor tolerance. Notes: brain fog. Adherence ~0.63. AE: no. CRP 6.0 mg/L; ALT 19 U/L.
P00268,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.64. AE: no.
P00268,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.58. AE: no. CRP 5.4 mg/L; ALT 18 U/L.
P00268,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. CRP 4.8 mg/L; ALT 21 U/L.
P00268,5,neutral,Visit 5: Patient on RX-17B at S013. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 4.0 mg/L; ALT 18 U/L.
P00269,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no.
P00269,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00269,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 30 U/L.
P00269,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.96. AE: no.
P00269,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.81. AE: no. CRP 2.9 mg/L; ALT 29 U/L.
P00269,5,positive,Visit 5: Patient on RX-17A at S012. symptoms improving. Notes: insomnia. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00269,6,positive,Visit 6: Patient on RX-17A at S012. energy increasing. Notes: nausea. Adherence ~0.95. AE: no.
P00269,7,positive,Visit 7: Patient on RX-17A at S012. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no. CRP 1.9 mg/L; ALT 29 U/L.
P00270,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.64. AE: no. CRP 7.2 mg/L; ALT 23 U/L.
P00270,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00270,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.67. AE: no.
P00270,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: no. CRP 5.5 mg/L; ALT 23 U/L.
P00270,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: yes.
P00270,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.74. AE: no. CRP 4.7 mg/L; ALT 24 U/L.
P00270,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no.
P00271,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 2.7 mg/L; ALT 15 U/L.
P00271,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00271,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.91. AE: no. CRP 2.5 mg/L; ALT 14 U/L.
P00271,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P00271,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: fatigue. Adherence ~0.88. AE: no. CRP 2.2 mg/L; ALT 13 U/L.
P00272,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no. CRP 5.5 mg/L; ALT 29 U/L.
P00272,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00272,2,positive,Visit 2: Patient on RX-17A at S022. tolerating medication well. Notes: joint pain. Adherence ~0.80. AE: no. CRP 4.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00272,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P00272,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no. CRP 3.7 mg/L; ALT 27 U/L.
P00272,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00273,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: nausea. Adherence ~1.00. AE: yes. CRP 9.7 mg/L; ALT 37 U/L.
P00273,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P00273,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.95. AE: yes.
P00273,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P00273,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.97. AE: no.
P00273,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.89. AE: no. CRP 6.4 mg/L; ALT 33 U/L.
P00273,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P00274,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.68. AE: no.
P00274,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 13.6 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00274,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.87. AE: no. CRP 11.8 mg/L; ALT 44 U/L.
P00274,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: yes. CRP 11.3 mg/L; ALT 47 U/L.
P00274,4,positive,Visit 4: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~0.95. AE: no.
P00274,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.92. AE: no. CRP 8.9 mg/L; ALT 45 U/L.
P00274,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P00274,7,positive,Visit 7: Patient on RX-17A at S014. tolerating medication well. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00275,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.95. AE: yes.
P00275,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 24.4 mg/L; ALT 20 U/L.
P00275,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~1.00. AE: no.
P00275,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P00275,4,positive,Visit 4: Patient on RX-17B at S012. symptoms improving. Notes: nausea. Adherence ~0.83. AE: no.
P00275,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.98. AE: no.
P00275,6,positive,Visit 6: Patient on RX-17B at S012. reports improvement. Notes: nausea. Adherence ~0.82. AE: no. CRP 11.7 mg/L; ALT 22 U/L.
P00276,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: fatigue. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00276,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.74. AE: no.
P00276,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.85. AE: yes. CRP 4.7 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00276,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P00276,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00276,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 3.5 mg/L; ALT 34 U/L.
P00276,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.90. AE: yes.
P00276,7,neutral,Visit 7: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.95. AE: no. CRP 2.5 mg/L; ALT 33 U/L.
P00277,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.53. AE: no.
P00277,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.49. AE: no.
P00277,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.41. AE: no.
P00277,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.33. AE: no.
P00277,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.53. AE: no. CRP 3.5 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P00277,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.40. AE: no. Plan: consider dose adjustment; counsel patient.
P00277,6,neutral,Visit 6: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.43. AE: no. CRP 2.5 mg/L; ALT 49 U/L.
P00277,7,neutral,Visit 7: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.35. AE: no.
P00278,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.61. AE: no. CRP 9.7 mg/L; ALT 20 U/L.
P00278,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.56. AE: no. CRP 8.5 mg/L; ALT 26 U/L.
P00278,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.57. AE: no.
P00278,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no. CRP 7.5 mg/L; ALT 25 U/L.
P00278,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.73. AE: no. CRP 7.4 mg/L; ALT 26 U/L.
P00278,5,negative,Visit 5: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.63. AE: yes.
P00278,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no.
P00279,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no.
P00279,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00279,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 17.1 mg/L; ALT 34 U/L.
P00280,0,neutral,Visit 0: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: no. CRP 18.2 mg/L; ALT 54 U/L.
P00280,1,neutral,Visit 1: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.97. AE: no.
P00280,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.83. AE: no. CRP 17.6 mg/L; ALT 51 U/L.
P00280,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: dizziness. Adherence ~0.93. AE: no. CRP 14.1 mg/L; ALT 46 U/L.
P00281,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.80. AE: no. CRP 4.5 mg/L; ALT 15 U/L.
P00281,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00281,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.71. AE: no.
P00281,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no.
P00281,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.67. AE: no. CRP 2.5 mg/L; ALT 17 U/L.
P00281,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 2.3 mg/L; ALT 16 U/L.
P00282,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00282,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00282,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00282,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: no. CRP 6.3 mg/L; ALT 30 U/L.
P00282,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. CRP 5.0 mg/L; ALT 34 U/L.
P00282,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: dizziness. Adherence ~0.90. AE: no.
P00282,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no. CRP 3.7 mg/L; ALT 39 U/L.
P00282,7,positive,Visit 7: Patient on RX-17B at S004. tolerating medication well. Notes: headache. Adherence ~0.92. AE: no. CRP 2.9 mg/L; ALT 33 U/L.
P00283,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 13.1 mg/L; ALT 46 U/L.
P00283,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00283,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00283,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: fatigue. Adherence ~0.78. AE: no. CRP 10.2 mg/L; ALT 48 U/L.
P00283,4,positive,Visit 4: Patient on RX-17A at S015. energy increasing. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00284,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: dizziness. Adherence ~0.96. AE: no.
P00284,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: dizziness. Adherence ~0.76. AE: no.
P00284,2,negative,Visit 2: Patient on RX-17A at S016. feels frustrated. Notes: joint pain. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00284,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.82. AE: no. CRP 9.4 mg/L; ALT 28 U/L.
P00284,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00285,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: fatigue. Adherence ~0.64. AE: no.
P00285,1,neutral,Visit 1: Patient on RX-17A at S001. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P00285,2,neutral,Visit 2: Patient on RX-17A at S001. reviewed dosing instructions. Notes: fatigue. Adherence ~0.56. AE: no. CRP 8.8 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P00285,3,neutral,Visit 3: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.52. AE: yes. CRP 8.9 mg/L; ALT 54 U/L.
P00285,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no.
P00285,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no.
P00286,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.24. AE: yes.
P00286,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.80. AE: no.
P00286,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P00286,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.49. AE: no.
P00286,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.49. AE: no.
P00286,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no.
P00286,6,positive,Visit 6: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~0.76. AE: no. CRP 3.3 mg/L; ALT 42 U/L.
P00286,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.46. AE: no.
P00287,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: dizziness. Adherence ~0.57. AE: no.
P00287,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 9.4 mg/L; ALT 59 U/L. Plan: consider dose adjustment; counsel patient.
P00287,2,negative,Visit 2: Patient on RX-17B at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00287,3,positive,Visit 3: Patient on RX-17B at S018. energy increasing. Notes: nausea. Adherence ~0.81. AE: no.
P00287,4,positive,Visit 4: Patient on RX-17B at S018. energy increasing. Notes: nausea. Adherence ~0.77. AE: no.
P00287,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no.
P00287,6,positive,Visit 6: Patient on RX-17B at S018. feels better overall. Notes: abdominal discomfort. Adherence ~0.99. AE: no. CRP 4.7 mg/L; ALT 62 U/L.
P00288,0,negative,Visit 0: Patient on RX-17B at S011. increased discomfort. Notes: headache. Adherence ~0.67. AE: no. CRP 11.9 mg/L; ALT 38 U/L.
P00288,1,negative,Visit 1: Patient on RX-17B at S011. increased discomfort. Notes: headache. Adherence ~0.69. AE: no. CRP 9.5 mg/L; ALT 37 U/L.
P00288,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: fatigue. Adherence ~0.70. AE: no.
P00288,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no.
P00288,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00288,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.72. AE: no. CRP 7.3 mg/L; ALT 38 U/L.
P00288,6,neutral,Visit 6: Patient on RX-17B at S011. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P00288,7,neutral,Visit 7: Patient on RX-17B at S011. follow-up as scheduled. Notes: headache. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P00289,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.91. AE: no. CRP 4.8 mg/L; ALT 62 U/L.
P00289,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no. CRP 4.0 mg/L; ALT 61 U/L. Plan: consider dose adjustment; counsel patient.
P00289,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P00289,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.77. AE: no. CRP 3.6 mg/L; ALT 58 U/L.
P00290,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.81. AE: no.
P00290,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no.
P00290,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 13.2 mg/L; ALT 34 U/L.
P00290,3,positive,Visit 3: Patient on RX-17A at S014. energy increasing. Notes: insomnia. Adherence ~1.00. AE: no. CRP 13.8 mg/L; ALT 34 U/L.
P00290,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.90. AE: no.
P00291,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: headache. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00291,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. CRP 11.6 mg/L; ALT 17 U/L.
P00291,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.84. AE: no.
P00291,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no. CRP 9.1 mg/L; ALT 18 U/L.
P00291,4,positive,Visit 4: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~0.95. AE: no. CRP 9.0 mg/L; ALT 21 U/L.
P00292,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~0.71. AE: yes. CRP 4.7 mg/L; ALT 26 U/L.
P00292,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.49. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P00292,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.63. AE: no.
P00292,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no. CRP 4.1 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00292,4,negative,Visit 4: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.71. AE: yes.
P00293,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00293,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00293,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P00294,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.66. AE: no.
P00294,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.64. AE: no.
P00294,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: nausea. Adherence ~0.67. AE: no.
P00295,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 11.5 mg/L; ALT 26 U/L.
P00295,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.98. AE: yes. CRP 11.7 mg/L; ALT 28 U/L.
P00295,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no.
P00295,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00295,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P00295,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.99. AE: no. CRP 7.8 mg/L; ALT 27 U/L.
P00296,0,negative,Visit 0: Patient on RX-17B at S020. symptoms persist. Notes: headache. Adherence ~0.70. AE: no. CRP 18.6 mg/L; ALT 54 U/L.
P00296,1,negative,Visit 1: Patient on RX-17B at S020. reports worsening. Notes: joint pain. Adherence ~0.81. AE: no.
P00296,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no.
P00296,3,neutral,Visit 3: Patient on RX-17B at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no. CRP 13.0 mg/L; ALT 59 U/L.
P00296,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P00296,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 9.2 mg/L; ALT 65 U/L.
P00297,0,negative,Visit 0: Patient on RX-17B at S011. increased discomfort. Notes: headache. Adherence ~0.69. AE: no. CRP 8.0 mg/L; ALT 27 U/L.
P00297,1,negative,Visit 1: Patient on RX-17B at S011. poor tolerance. Notes: fatigue. Adherence ~0.60. AE: no. CRP 7.2 mg/L; ALT 27 U/L.
P00297,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~0.80. AE: no.
P00297,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: headache. Adherence ~0.71. AE: no.
P00297,4,neutral,Visit 4: Patient on RX-17B at S011. no major change. Notes: nausea. Adherence ~0.48. AE: yes. CRP 5.3 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00298,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 8.2 mg/L; ALT 33 U/L.
P00298,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.34. AE: no. CRP 8.6 mg/L; ALT 38 U/L.
P00298,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.46. AE: no.
P00298,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.50. AE: no. CRP 6.6 mg/L; ALT 41 U/L.
P00298,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.41. AE: no.
P00298,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.47. AE: no. CRP 5.8 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00298,6,neutral,Visit 6: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.33. AE: no.
P00299,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no.
P00299,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.49. AE: no.
P00299,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.47. AE: no. CRP 1.4 mg/L; ALT 34 U/L.
P00299,3,negative,Visit 3: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P00299,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00299,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.75. AE: no. CRP 1.0 mg/L; ALT 40 U/L.
P00300,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00300,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: headache. Adherence ~1.00. AE: no. CRP 12.0 mg/L; ALT 20 U/L.
P00300,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no.
P00300,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00300,4,positive,Visit 4: Patient on RX-17B at S022. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no.
P00300,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no. CRP 7.8 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00300,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.89. AE: yes.
P00301,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.56. AE: no. CRP 14.6 mg/L; ALT 31 U/L.
P00301,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.51. AE: no.
P00301,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.62. AE: no.
P00301,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.55. AE: no. CRP 8.0 mg/L; ALT 33 U/L.
P00301,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.59. AE: no.
P00302,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.74. AE: no. CRP 14.6 mg/L; ALT 66 U/L. Plan: consider dose adjustment; counsel patient.
P00302,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no. CRP 14.4 mg/L; ALT 68 U/L.
P00302,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: joint pain. Adherence ~0.80. AE: no.
P00302,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P00302,4,positive,Visit 4: Patient on RX-17A at S015. symptoms improving. Notes: nausea. Adherence ~0.76. AE: no. CRP 10.4 mg/L; ALT 58 U/L.
P00303,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.80. AE: no.
P00303,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no.
P00303,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 3.5 mg/L; ALT 20 U/L.
P00303,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00303,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P00304,0,negative,Visit 0: Patient on RX-17B at S021. poor tolerance. Notes: dizziness. Adherence ~0.55. AE: no.
P00304,1,neutral,Visit 1: Patient on RX-17B at S021. reviewed dosing instructions. Notes: dizziness. Adherence ~0.53. AE: no.
P00304,2,neutral,Visit 2: Patient on RX-17B at S021. continues regimen. Notes: nausea. Adherence ~0.47. AE: no. CRP 9.9 mg/L; ALT 42 U/L.
P00304,3,neutral,Visit 3: Patient on RX-17B at S021. stable symptoms. Notes: joint pain. Adherence ~0.41. AE: yes.
P00304,4,neutral,Visit 4: Patient on RX-17B at S021. reviewed dosing instructions. Notes: fatigue. Adherence ~0.54. AE: no.
P00305,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.95. AE: no. CRP 12.3 mg/L; ALT 19 U/L.
P00305,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 12.0 mg/L; ALT 21 U/L.
P00305,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00305,3,negative,Visit 3: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.66. AE: no.
P00305,4,negative,Visit 4: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no.
P00305,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00305,6,neutral,Visit 6: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P00305,7,positive,Visit 7: Patient on RX-17A at S002. energy increasing. Notes: brain fog. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00306,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: brain fog. Adherence ~0.73. AE: no.
P00306,1,neutral,Visit 1: Patient on RX-17B at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P00306,2,negative,Visit 2: Patient on RX-17B at S008. symptoms persist. Notes: brain fog. Adherence ~0.83. AE: yes.
P00306,3,neutral,Visit 3: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no. CRP 4.2 mg/L; ALT 21 U/L.
P00306,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no. CRP 3.3 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00306,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.84. AE: no.
P00306,6,neutral,Visit 6: Patient on RX-17B at S008. stable symptoms. Notes: fatigue. Adherence ~0.72. AE: no. CRP 2.5 mg/L; ALT 21 U/L.
P00307,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no. CRP 14.6 mg/L; ALT 18 U/L.
P00307,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no. CRP 12.4 mg/L; ALT 18 U/L.
P00307,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.87. AE: no.
P00307,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00307,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no.
P00307,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no.
P00307,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.52. AE: no.
P00308,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.77. AE: no. CRP 8.9 mg/L; ALT 40 U/L.
P00308,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: yes.
P00308,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.77. AE: no.
P00308,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no. CRP 6.7 mg/L; ALT 45 U/L.
P00308,4,negative,Visit 4: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.82. AE: no. CRP 6.7 mg/L; ALT 40 U/L.
P00308,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.59. AE: no.
P00308,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 5.8 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00309,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: brain fog. Adherence ~0.80. AE: no.
P00309,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.78. AE: no. CRP 3.1 mg/L; ALT 24 U/L.
P00309,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.86. AE: no.
P00309,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.70. AE: no. CRP 2.3 mg/L; ALT 21 U/L.
P00309,4,negative,Visit 4: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no.
P00310,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.60. AE: no. CRP 10.7 mg/L; ALT 43 U/L.
P00310,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.68. AE: no.
P00310,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.50. AE: no.
P00310,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.74. AE: yes. CRP 7.3 mg/L; ALT 53 U/L.
P00310,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no.
P00310,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: no.
P00310,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P00310,7,neutral,Visit 7: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.66. AE: yes.
P00311,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.81. AE: no.
P00311,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.4 mg/L; ALT 27 U/L.
P00311,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.98. AE: yes. Plan: consider dose adjustment; counsel patient.
P00311,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00311,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00311,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00311,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: insomnia. Adherence ~0.85. AE: no.
P00312,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: joint pain. Adherence ~0.72. AE: no. CRP 2.6 mg/L; ALT 34 U/L.
P00312,1,negative,Visit 1: Patient on RX-17B at S002. symptoms persist. Notes: fatigue. Adherence ~0.85. AE: yes.
P00312,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: nausea. Adherence ~0.69. AE: yes.
P00312,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.79. AE: no.
P00312,4,negative,Visit 4: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.90. AE: no. CRP 1.9 mg/L; ALT 32 U/L.
P00312,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 1.9 mg/L; ALT 34 U/L.
P00312,6,neutral,Visit 6: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.69. AE: no. CRP 1.7 mg/L; ALT 33 U/L.
P00312,7,neutral,Visit 7: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.65. AE: no.
P00313,0,negative,Visit 0: Patient on RX-17A at S001. increased discomfort. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00313,1,negative,Visit 1: Patient on RX-17A at S001. symptoms persist. Notes: dizziness. Adherence ~0.72. AE: no.
P00313,2,negative,Visit 2: Patient on RX-17A at S001. feels frustrated. Notes: joint pain. Adherence ~0.81. AE: no.
P00313,3,negative,Visit 3: Patient on RX-17A at S001. reports worsening. Notes: joint pain. Adherence ~0.99. AE: no.
P00313,4,neutral,Visit 4: Patient on RX-17A at S001. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P00313,5,neutral,Visit 5: Patient on RX-17A at S001. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no.
P00314,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 7.2 mg/L; ALT 17 U/L.
P00314,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: joint pain. Adherence ~0.72. AE: no.
P00314,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00314,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00314,4,negative,Visit 4: Patient on RX-17A at S002. symptoms persist. Notes: joint pain. Adherence ~0.78. AE: no.
P00314,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~0.85. AE: no.
P00314,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P00315,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.94. AE: no.
P00315,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.82. AE: no.
P00315,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no. CRP 12.6 mg/L; ALT 33 U/L.
P00316,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00316,1,negative,Visit 1: Patient on RX-17B at S018. symptoms persist. Notes: joint pain. Adherence ~0.74. AE: yes.
P00316,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.79. AE: yes.
P00316,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: no. CRP 6.1 mg/L; ALT 34 U/L.
P00317,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: brain fog. Adherence ~0.65. AE: yes.
P00317,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: insomnia. Adherence ~0.88. AE: no.
P00317,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: dizziness. Adherence ~0.67. AE: yes.
P00317,3,negative,Visit 3: Patient on RX-17B at S008. increased discomfort. Notes: fatigue. Adherence ~0.87. AE: yes.
P00317,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.59. AE: no. CRP 8.6 mg/L; ALT 46 U/L.
P00317,5,neutral,Visit 5: Patient on RX-17B at S008. no major change. Notes: insomnia. Adherence ~0.62. AE: no.
P00317,6,positive,Visit 6: Patient on RX-17B at S008. feels better overall. Notes: brain fog. Adherence ~0.84. AE: no. CRP 5.3 mg/L; ALT 51 U/L.
P00318,0,neutral,Visit 0: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.92. AE: no.
P00318,1,neutral,Visit 1: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.89. AE: no.
P00318,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 9.1 mg/L; ALT 21 U/L.
P00318,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.88. AE: no. CRP 6.4 mg/L; ALT 24 U/L.
P00319,0,neutral,Visit 0: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00319,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.87. AE: no.
P00319,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: fatigue. Adherence ~0.75. AE: no.
P00319,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no.
P00319,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.92. AE: no.
P00319,5,neutral,Visit 5: Patient on RX-17B at S002. continues regimen. Notes: fatigue. Adherence ~0.69. AE: yes. CRP 7.9 mg/L; ALT 25 U/L.
P00319,6,positive,Visit 6: Patient on RX-17B at S002. reports improvement. Notes: joint pain. Adherence ~0.95. AE: no.
P00319,7,positive,Visit 7: Patient on RX-17B at S002. symptoms improving. Notes: insomnia. Adherence ~0.76. AE: no. CRP 4.0 mg/L; ALT 26 U/L.
P00320,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00320,1,negative,Visit 1: Patient on RX-17A at S018. increased discomfort. Notes: headache. Adherence ~0.52. AE: no.
P00320,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P00320,3,neutral,Visit 3: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00320,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: brain fog. Adherence ~0.86. AE: no.
P00320,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00321,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.83. AE: no.
P00321,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no.
P00321,2,positive,Visit 2: Patient on RX-17B at S022. energy increasing. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.8 mg/L; ALT 48 U/L.
P00321,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 6.5 mg/L; ALT 49 U/L.
P00321,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00321,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: headache. Adherence ~0.83. AE: no.
P00321,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 3.7 mg/L; ALT 59 U/L.
P00322,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.68. AE: no.
P00322,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.83. AE: no.
P00322,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.95. AE: no.
P00322,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00322,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: no.
P00322,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no. CRP 4.2 mg/L; ALT 24 U/L.
P00322,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.93. AE: no. CRP 4.2 mg/L; ALT 27 U/L.
P00322,7,positive,Visit 7: Patient on RX-17A at S017. energy increasing. Notes: insomnia. Adherence ~0.92. AE: no.
P00323,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: nausea. Adherence ~0.55. AE: no. CRP 10.4 mg/L; ALT 17 U/L.
P00323,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 9.4 mg/L; ALT 19 U/L.
P00323,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.67. AE: no. CRP 9.3 mg/L; ALT 17 U/L.
P00323,3,negative,Visit 3: Patient on RX-17B at S016. poor tolerance. Notes: insomnia. Adherence ~0.56. AE: yes. Plan: consider dose adjustment; counsel patient.
P00323,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: brain fog. Adherence ~0.52. AE: no.
P00323,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.48. AE: no.
P00324,0,neutral,Visit 0: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~1.00. AE: yes.
P00324,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00324,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no. CRP 7.4 mg/L; ALT 27 U/L.
P00324,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P00324,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00325,0,neutral,Visit 0: Patient on RX-17B at S002. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P00325,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00325,2,neutral,Visit 2: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00325,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 3.2 mg/L; ALT 24 U/L.
P00325,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P00325,5,neutral,Visit 5: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P00325,6,positive,Visit 6: Patient on RX-17B at S002. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00326,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: yes.
P00326,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.87. AE: no.
P00326,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.80. AE: no.
P00326,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P00326,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00326,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.73. AE: yes.
P00326,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.95. AE: yes.
P00326,7,neutral,Visit 7: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P00327,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: headache. Adherence ~0.48. AE: no. CRP 18.1 mg/L; ALT 20 U/L.
P00327,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.49. AE: no. CRP 17.6 mg/L; ALT 20 U/L.
P00327,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.61. AE: no. CRP 13.4 mg/L; ALT 19 U/L.
P00327,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.54. AE: no.
P00327,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no.
P00328,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.75. AE: no.
P00328,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P00328,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P00328,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.94. AE: no.
P00328,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00328,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P00328,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.74. AE: yes.
P00328,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.74. AE: no.
P00329,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.96. AE: no.
P00329,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00329,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.65. AE: no.
P00329,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no.
P00329,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.72. AE: yes. CRP 8.1 mg/L; ALT 34 U/L.
P00330,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.97. AE: no.
P00330,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. CRP 15.0 mg/L; ALT 42 U/L.
P00330,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.84. AE: no.
P00330,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P00330,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no.
P00330,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 9.2 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00331,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: joint pain. Adherence ~0.99. AE: no. CRP 9.1 mg/L; ALT 13 U/L.
P00331,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no. CRP 8.2 mg/L; ALT 13 U/L.
P00331,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.77. AE: yes.
P00331,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.80. AE: no.
P00331,4,negative,Visit 4: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.75. AE: yes.
P00332,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.90. AE: no. CRP 22.1 mg/L; ALT 18 U/L.
P00332,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: no.
P00332,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no. CRP 20.9 mg/L; ALT 14 U/L.
P00332,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.94. AE: no. CRP 18.9 mg/L; ALT 19 U/L.
P00332,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 13.5 mg/L; ALT 16 U/L.
P00332,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: no.
P00332,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00332,7,neutral,Visit 7: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00333,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.73. AE: no.
P00333,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: yes.
P00333,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no.
P00333,3,negative,Visit 3: Patient on RX-17B at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.98. AE: yes. CRP 9.6 mg/L; ALT 57 U/L.
P00333,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 7.5 mg/L; ALT 46 U/L.
P00333,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: yes.
P00333,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no. CRP 4.9 mg/L; ALT 51 U/L.
P00333,7,positive,Visit 7: Patient on RX-17B at S017. energy increasing. Notes: joint pain. Adherence ~0.86. AE: no. CRP 5.1 mg/L; ALT 53 U/L.
P00334,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: yes.
P00334,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.56. AE: no. CRP 7.8 mg/L; ALT 23 U/L.
P00334,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.59. AE: yes.
P00334,3,negative,Visit 3: Patient on RX-17B at S005. reports worsening. Notes: dizziness. Adherence ~0.34. AE: no. CRP 7.0 mg/L; ALT 24 U/L.
P00334,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00334,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.57. AE: no.
P00335,0,negative,Visit 0: Patient on RX-17B at S010. poor tolerance. Notes: headache. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00335,1,negative,Visit 1: Patient on RX-17B at S010. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: no. CRP 5.2 mg/L; ALT 18 U/L.
P00335,2,negative,Visit 2: Patient on RX-17B at S010. symptoms persist. Notes: headache. Adherence ~0.58. AE: yes. Plan: consider dose adjustment; counsel patient.
P00335,3,neutral,Visit 3: Patient on RX-17B at S010. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no. CRP 4.1 mg/L; ALT 18 U/L.
P00335,4,neutral,Visit 4: Patient on RX-17B at S010. reviewed dosing instructions. Notes: nausea. Adherence ~0.84. AE: no. CRP 4.4 mg/L; ALT 19 U/L.
P00335,5,neutral,Visit 5: Patient on RX-17B at S010. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00336,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: fatigue. Adherence ~0.89. AE: yes.
P00336,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P00336,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: nausea. Adherence ~0.90. AE: no.
P00336,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00336,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 7.0 mg/L; ALT 29 U/L.
P00337,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.49. AE: no. CRP 10.3 mg/L; ALT 30 U/L.
P00337,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00337,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.63. AE: no.
P00337,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00337,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no. CRP 6.9 mg/L; ALT 34 U/L.
P00338,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: nausea. Adherence ~0.89. AE: no. CRP 7.9 mg/L; ALT 30 U/L.
P00338,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P00338,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.91. AE: no. CRP 7.2 mg/L; ALT 29 U/L.
P00338,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00338,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 5.3 mg/L; ALT 33 U/L.
P00339,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: nausea. Adherence ~0.91. AE: no.
P00339,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: nausea. Adherence ~0.56. AE: no.
P00339,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~0.79. AE: no. CRP 4.7 mg/L; ALT 35 U/L.
P00339,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P00339,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.95. AE: no.
P00339,5,neutral,Visit 5: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.69. AE: no.
P00340,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~0.71. AE: no. CRP 4.1 mg/L; ALT 36 U/L.
P00340,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.65. AE: no. CRP 3.8 mg/L; ALT 32 U/L.
P00340,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: no.
P00340,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.58. AE: yes.
P00340,4,negative,Visit 4: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.56. AE: no.
P00340,5,negative,Visit 5: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.69. AE: yes.
P00340,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00341,0,neutral,Visit 0: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.99. AE: no.
P00341,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: dizziness. Adherence ~0.69. AE: no. CRP 7.6 mg/L; ALT 30 U/L.
P00341,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 35 U/L.
P00341,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~0.79. AE: no. CRP 7.1 mg/L; ALT 31 U/L.
P00341,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P00341,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: dizziness. Adherence ~0.71. AE: no.
P00341,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.94. AE: no. CRP 4.8 mg/L; ALT 32 U/L.
P00342,0,negative,Visit 0: Patient on RX-17A at S020. feels frustrated. Notes: dizziness. Adherence ~0.44. AE: no.
P00342,1,negative,Visit 1: Patient on RX-17A at S020. feels frustrated. Notes: dizziness. Adherence ~0.56. AE: yes. CRP 3.3 mg/L; ALT 45 U/L.
P00342,2,neutral,Visit 2: Patient on RX-17A at S020. no major change. Notes: brain fog. Adherence ~0.67. AE: no. CRP 2.9 mg/L; ALT 47 U/L.
P00342,3,neutral,Visit 3: Patient on RX-17A at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 2.4 mg/L; ALT 49 U/L.
P00342,4,neutral,Visit 4: Patient on RX-17A at S020. follow-up as scheduled. Notes: headache. Adherence ~0.65. AE: no.
P00343,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.95. AE: no.
P00343,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00343,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00343,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: yes.
P00343,4,positive,Visit 4: Patient on RX-17B at S016. feels better overall. Notes: headache. Adherence ~0.87. AE: no. CRP 3.8 mg/L; ALT 33 U/L.
P00343,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.87. AE: yes.
P00343,6,positive,Visit 6: Patient on RX-17B at S016. reports improvement. Notes: dizziness. Adherence ~0.99. AE: no.
P00344,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.46. AE: no.
P00344,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: headache. Adherence ~0.33. AE: no.
P00344,2,negative,Visit 2: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~0.40. AE: no.
P00344,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.26. AE: no. CRP 1.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00344,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~0.44. AE: no.
P00344,5,negative,Visit 5: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~0.32. AE: no. CRP 1.4 mg/L; ALT 29 U/L.
P00344,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.41. AE: no.
P00344,7,neutral,Visit 7: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.42. AE: no. CRP 1.0 mg/L; ALT 31 U/L.
P00345,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00345,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no. CRP 10.1 mg/L; ALT 38 U/L.
P00345,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: no.
P00345,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no.
P00345,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no.
P00346,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: fatigue. Adherence ~0.36. AE: no. CRP 13.2 mg/L; ALT 33 U/L.
P00346,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: nausea. Adherence ~0.51. AE: yes.
P00346,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.27. AE: no. Plan: consider dose adjustment; counsel patient.
P00346,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.43. AE: no.
P00346,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.22. AE: no.
P00347,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.78. AE: no.
P00347,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00347,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.91. AE: no.
P00347,3,positive,Visit 3: Patient on RX-17B at S022. tolerating medication well. Notes: insomnia. Adherence ~0.97. AE: no. CRP 6.5 mg/L; ALT 21 U/L.
P00347,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no. CRP 5.7 mg/L; ALT 22 U/L.
P00347,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 24 U/L.
P00347,6,positive,Visit 6: Patient on RX-17B at S022. feels better overall. Notes: headache. Adherence ~0.77. AE: no. CRP 3.8 mg/L; ALT 25 U/L.
P00348,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.91. AE: no.
P00348,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.79. AE: no.
P00348,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 14.0 mg/L; ALT 28 U/L.
P00348,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: yes.
P00348,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.98. AE: no.
P00348,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: headache. Adherence ~1.00. AE: no.
P00349,0,neutral,Visit 0: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.83. AE: no. CRP 16.4 mg/L; ALT 36 U/L.
P00349,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: fatigue. Adherence ~0.94. AE: yes. CRP 14.6 mg/L; ALT 42 U/L.
P00349,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.54. AE: no.
P00349,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P00349,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P00350,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.59. AE: yes. CRP 8.9 mg/L; ALT 26 U/L.
P00350,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: yes.
P00350,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00350,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no.
P00350,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.77. AE: no.
P00350,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.84. AE: no.
P00350,6,positive,Visit 6: Patient on RX-17A at S015. feels better overall. Notes: dizziness. Adherence ~0.92. AE: no. CRP 5.7 mg/L; ALT 27 U/L.
P00351,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no.
P00351,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no. CRP 7.3 mg/L; ALT 25 U/L.
P00351,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00351,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P00351,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.88. AE: no.
P00352,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no.
P00352,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P00352,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.87. AE: no. CRP 5.8 mg/L; ALT 20 U/L.
P00352,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: no.
P00352,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.82. AE: no.
P00353,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.64. AE: no.
P00353,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no.
P00353,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~0.63. AE: no.
P00353,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00353,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00354,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~1.00. AE: no. CRP 7.3 mg/L; ALT 25 U/L.
P00354,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00354,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.97. AE: no.
P00354,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: no.
P00354,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P00355,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00355,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P00355,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 8.6 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00355,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.57. AE: yes.
P00355,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no. CRP 7.7 mg/L; ALT 35 U/L.
P00355,5,positive,Visit 5: Patient on RX-17B at S015. reports improvement. Notes: insomnia. Adherence ~0.81. AE: no.
P00355,6,neutral,Visit 6: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: yes. CRP 5.7 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00355,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.65. AE: yes.
P00356,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~0.64. AE: yes. CRP 10.6 mg/L; ALT 21 U/L.
P00356,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: headache. Adherence ~0.58. AE: yes. Plan: consider dose adjustment; counsel patient.
P00356,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no.
P00356,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no.
P00356,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.52. AE: no. CRP 5.5 mg/L; ALT 20 U/L.
P00356,5,positive,Visit 5: Patient on RX-17B at S016. tolerating medication well. Notes: fatigue. Adherence ~0.76. AE: no. CRP 5.9 mg/L; ALT 20 U/L.
P00356,6,neutral,Visit 6: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.58. AE: yes.
P00357,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no. CRP 5.7 mg/L; ALT 49 U/L.
P00357,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.1 mg/L; ALT 54 U/L.
P00357,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P00357,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.93. AE: no.
P00357,4,positive,Visit 4: Patient on RX-17A at S015. reports improvement. Notes: headache. Adherence ~0.87. AE: no.
P00357,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.97. AE: yes.
P00357,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: yes. CRP 3.9 mg/L; ALT 59 U/L.
P00357,7,positive,Visit 7: Patient on RX-17A at S015. energy increasing. Notes: nausea. Adherence ~0.91. AE: no.
P00358,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.67. AE: no. CRP 13.1 mg/L; ALT 21 U/L.
P00358,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.58. AE: no.
P00358,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no.
P00358,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.62. AE: no.
P00358,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.96. AE: yes. Plan: consider dose adjustment; counsel patient.
P00358,5,positive,Visit 5: Patient on RX-17A at S022. reports improvement. Notes: nausea. Adherence ~0.81. AE: no. CRP 8.6 mg/L; ALT 23 U/L.
P00359,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.59. AE: no.
P00359,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.89. AE: no. CRP 6.7 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00359,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no.
P00359,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.72. AE: no.
P00359,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P00360,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.97. AE: no. CRP 8.4 mg/L; ALT 36 U/L.
P00360,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.77. AE: yes. CRP 7.1 mg/L; ALT 39 U/L.
P00360,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P00360,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.91. AE: no. CRP 5.9 mg/L; ALT 38 U/L.
P00360,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00360,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: joint pain. Adherence ~0.95. AE: no.
P00361,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: nausea. Adherence ~0.53. AE: no. CRP 4.4 mg/L; ALT 68 U/L.
P00361,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: fatigue. Adherence ~0.54. AE: no.
P00361,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.48. AE: yes. CRP 3.8 mg/L; ALT 71 U/L.
P00361,3,negative,Visit 3: Patient on RX-17A at S013. symptoms persist. Notes: insomnia. Adherence ~0.65. AE: no. CRP 3.4 mg/L; ALT 59 U/L.
P00361,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.70. AE: yes. CRP 3.0 mg/L; ALT 73 U/L.
P00361,5,negative,Visit 5: Patient on RX-17A at S013. symptoms persist. Notes: fatigue. Adherence ~0.57. AE: yes.
P00361,6,neutral,Visit 6: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.58. AE: no.
P00362,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.90. AE: no.
P00362,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no.
P00362,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.89. AE: no.
P00362,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: no.
P00362,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: yes.
P00362,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no.
P00362,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P00362,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.82. AE: no. CRP 3.5 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00363,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P00363,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P00363,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 20.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00363,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 21.5 mg/L; ALT 17 U/L.
P00363,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 16.0 mg/L; ALT 20 U/L.
P00363,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 15.7 mg/L; ALT 18 U/L.
P00363,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no. CRP 13.9 mg/L; ALT 20 U/L.
P00363,7,neutral,Visit 7: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P00364,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.53. AE: no.
P00364,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: joint pain. Adherence ~0.36. AE: no.
P00364,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: joint pain. Adherence ~0.52. AE: no.
P00364,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.43. AE: no.
P00365,0,neutral,Visit 0: Patient on RX-17A at S011. follow-up as scheduled. Notes: headache. Adherence ~0.69. AE: no. CRP 8.5 mg/L; ALT 54 U/L.
P00365,1,neutral,Visit 1: Patient on RX-17A at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 8.5 mg/L; ALT 52 U/L.
P00365,2,negative,Visit 2: Patient on RX-17A at S011. feels frustrated. Notes: joint pain. Adherence ~0.59. AE: no.
P00365,3,neutral,Visit 3: Patient on RX-17A at S011. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 7.6 mg/L; ALT 52 U/L.
P00365,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: insomnia. Adherence ~0.59. AE: no.
P00366,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 5.7 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00366,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.43. AE: no.
P00366,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.55. AE: no. CRP 5.0 mg/L; ALT 17 U/L.
P00366,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00366,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 3.8 mg/L; ALT 18 U/L.
P00366,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.69. AE: no.
P00366,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.59. AE: no.
P00367,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: nausea. Adherence ~0.79. AE: no.
P00367,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: brain fog. Adherence ~0.65. AE: no.
P00367,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.80. AE: no. CRP 1.8 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00367,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: dizziness. Adherence ~0.92. AE: no.
P00367,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no. CRP 1.4 mg/L; ALT 41 U/L.
P00367,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 1.3 mg/L; ALT 41 U/L.
P00368,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00368,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P00368,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no.
P00368,3,negative,Visit 3: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.75. AE: yes.
P00368,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00368,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00369,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.56. AE: no. CRP 5.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00369,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.62. AE: no.
P00369,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.74. AE: yes. Plan: consider dose adjustment; counsel patient.
P00369,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.47. AE: no.
P00369,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.66. AE: yes.
P00369,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no.
P00369,6,neutral,Visit 6: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00370,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.78. AE: no. CRP 9.0 mg/L; ALT 13 U/L.
P00370,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.77. AE: yes.
P00370,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: yes.
P00370,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no.
P00371,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: brain fog. Adherence ~0.42. AE: no. CRP 13.0 mg/L; ALT 27 U/L.
P00371,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.67. AE: no.
P00371,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P00371,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.67. AE: no.
P00371,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: yes. Plan: consider dose adjustment; counsel patient.
P00372,0,negative,Visit 0: Patient on RX-17B at S006. feels frustrated. Notes: fatigue. Adherence ~0.71. AE: yes. CRP 8.6 mg/L; ALT 26 U/L.
P00372,1,neutral,Visit 1: Patient on RX-17B at S006. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no. CRP 6.5 mg/L; ALT 27 U/L.
P00372,2,negative,Visit 2: Patient on RX-17B at S006. increased discomfort. Notes: nausea. Adherence ~0.49. AE: no.
P00372,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: insomnia. Adherence ~0.47. AE: no.
P00372,4,neutral,Visit 4: Patient on RX-17B at S006. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P00372,5,neutral,Visit 5: Patient on RX-17B at S006. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no. CRP 4.8 mg/L; ALT 28 U/L.
P00373,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P00373,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.54. AE: no.
P00373,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.67. AE: yes. Plan: consider dose adjustment; counsel patient.
P00373,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 6.6 mg/L; ALT 60 U/L.
P00373,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P00374,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.54. AE: no. CRP 4.8 mg/L; ALT 29 U/L.
P00374,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.80. AE: no. CRP 3.9 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00374,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.67. AE: no.
P00374,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.50. AE: no.
P00374,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.62. AE: no. CRP 3.2 mg/L; ALT 32 U/L.
P00374,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P00374,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.95. AE: no.
P00374,7,neutral,Visit 7: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P00375,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no.
P00375,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.95. AE: no.
P00375,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: yes.
P00375,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no. CRP 8.9 mg/L; ALT 26 U/L.
P00375,4,negative,Visit 4: Patient on RX-17A at S002. feels frustrated. Notes: dizziness. Adherence ~0.98. AE: no.
P00376,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no.
P00376,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00376,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.86. AE: no. CRP 6.0 mg/L; ALT 21 U/L.
P00376,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.69. AE: yes. CRP 5.7 mg/L; ALT 27 U/L.
P00376,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.99. AE: no.
P00376,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.61. AE: no.
P00376,6,positive,Visit 6: Patient on RX-17A at S013. tolerating medication well. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00377,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00377,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P00377,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no.
P00377,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.89. AE: no.
P00377,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: no.
P00377,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no.
P00378,0,negative,Visit 0: Patient on RX-17A at S007. feels frustrated. Notes: fatigue. Adherence ~0.59. AE: no.
P00378,1,neutral,Visit 1: Patient on RX-17A at S007. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00378,2,neutral,Visit 2: Patient on RX-17A at S007. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no. CRP 9.3 mg/L; ALT 31 U/L.
P00378,3,neutral,Visit 3: Patient on RX-17A at S007. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 8.9 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00378,4,neutral,Visit 4: Patient on RX-17A at S007. no major change. Notes: insomnia. Adherence ~0.58. AE: no.
P00379,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P00379,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P00379,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 12.2 mg/L; ALT 23 U/L.
P00379,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 10.5 mg/L; ALT 23 U/L.
P00379,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no.
P00379,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: yes. CRP 6.9 mg/L; ALT 24 U/L.
P00380,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no. CRP 16.1 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00380,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.51. AE: yes. CRP 16.1 mg/L; ALT 34 U/L.
P00380,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.48. AE: no. CRP 12.8 mg/L; ALT 34 U/L.
P00380,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P00380,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: no. CRP 9.2 mg/L; ALT 35 U/L.
P00381,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: joint pain. Adherence ~0.84. AE: no.
P00381,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: nausea. Adherence ~0.69. AE: no.
P00381,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: no.
P00381,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no. CRP 20.6 mg/L; ALT 24 U/L.
P00381,4,negative,Visit 4: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.73. AE: no.
P00382,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no.
P00382,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 9.6 mg/L; ALT 12 U/L.
P00382,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.76. AE: no. CRP 9.8 mg/L; ALT 14 U/L.
P00382,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no.
P00382,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no.
P00382,5,positive,Visit 5: Patient on RX-17A at S015. feels better overall. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00383,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 11.6 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P00383,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: no.
P00383,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.91. AE: no. CRP 9.8 mg/L; ALT 36 U/L.
P00383,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.73. AE: no. CRP 6.3 mg/L; ALT 34 U/L.
P00383,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no.
P00383,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no.
P00383,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no. CRP 6.4 mg/L; ALT 38 U/L.
P00384,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.80. AE: yes.
P00384,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.98. AE: no. CRP 12.4 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00384,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.80. AE: no.
P00384,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: yes.
P00384,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no.
P00384,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.67. AE: no.
P00384,6,positive,Visit 6: Patient on RX-17A at S012. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.9 mg/L; ALT 36 U/L.
P00384,7,positive,Visit 7: Patient on RX-17A at S012. tolerating medication well. Notes: brain fog. Adherence ~0.85. AE: no. CRP 6.2 mg/L; ALT 40 U/L.
P00385,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.96. AE: no. CRP 4.7 mg/L; ALT 30 U/L.
P00385,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.92. AE: no. CRP 3.9 mg/L; ALT 34 U/L.
P00385,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no.
P00385,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.84. AE: no. CRP 3.6 mg/L; ALT 31 U/L.
P00385,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: dizziness. Adherence ~0.92. AE: yes. CRP 3.4 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00386,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.40. AE: no.
P00386,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.59. AE: no.
P00386,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.43. AE: no.
P00386,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.38. AE: no. Plan: consider dose adjustment; counsel patient.
P00387,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: yes. CRP 6.1 mg/L; ALT 34 U/L.
P00387,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.58. AE: no. CRP 5.6 mg/L; ALT 29 U/L.
P00387,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00387,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00387,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.68. AE: yes. CRP 4.2 mg/L; ALT 31 U/L.
P00388,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.60. AE: no.
P00388,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.53. AE: no.
P00388,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.63. AE: no.
P00388,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no. CRP 12.5 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00388,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.39. AE: yes.
P00388,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 9.8 mg/L; ALT 38 U/L.
P00388,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 7.5 mg/L; ALT 42 U/L.
P00388,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.62. AE: no.
P00389,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.62. AE: no.
P00389,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.64. AE: no.
P00389,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00390,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.65. AE: no. CRP 8.2 mg/L; ALT 41 U/L.
P00390,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.67. AE: no.
P00390,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.54. AE: no. CRP 7.8 mg/L; ALT 40 U/L.
P00390,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.56. AE: yes. Plan: consider dose adjustment; counsel patient.
P00391,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.69. AE: no. CRP 10.0 mg/L; ALT 18 U/L.
P00391,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 10.1 mg/L; ALT 17 U/L.
P00391,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.74. AE: no. CRP 9.3 mg/L; ALT 19 U/L.
P00391,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 18 U/L.
P00391,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.75. AE: yes. CRP 7.6 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00392,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00392,1,neutral,Visit 1: Patient on RX-17A at S020. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00392,2,neutral,Visit 2: Patient on RX-17A at S020. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P00392,3,neutral,Visit 3: Patient on RX-17A at S020. no major change. Notes: joint pain. Adherence ~0.88. AE: no. CRP 6.7 mg/L; ALT 32 U/L.
P00392,4,negative,Visit 4: Patient on RX-17A at S020. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P00392,5,neutral,Visit 5: Patient on RX-17A at S020. no major change. Notes: nausea. Adherence ~0.87. AE: no.
P00392,6,positive,Visit 6: Patient on RX-17A at S020. energy increasing. Notes: nausea. Adherence ~0.98. AE: no.
P00392,7,neutral,Visit 7: Patient on RX-17A at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: yes.
P00393,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: fatigue. Adherence ~0.67. AE: no.
P00393,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no.
P00393,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no.
P00393,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P00393,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.60. AE: yes.
P00393,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.47. AE: no.
P00393,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.53. AE: no.
P00393,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 1.6 mg/L; ALT 34 U/L.
P00394,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.39. AE: no. CRP 10.0 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00394,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.59. AE: no.
P00394,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.53. AE: no.
P00394,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.93. AE: no. CRP 6.8 mg/L; ALT 41 U/L.
P00394,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.58. AE: no. CRP 7.2 mg/L; ALT 44 U/L.
P00394,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.66. AE: no. CRP 6.1 mg/L; ALT 42 U/L.
P00394,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.69. AE: no. CRP 5.0 mg/L; ALT 47 U/L.
P00395,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: no.
P00395,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.70. AE: no.
P00395,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 5.2 mg/L; ALT 23 U/L.
P00395,3,negative,Visit 3: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: yes. CRP 5.0 mg/L; ALT 24 U/L.
P00395,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: no. CRP 3.9 mg/L; ALT 22 U/L.
P00396,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: insomnia. Adherence ~0.76. AE: no. CRP 20.0 mg/L; ALT 23 U/L.
P00396,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~0.85. AE: no. CRP 17.2 mg/L; ALT 25 U/L.
P00396,2,positive,Visit 2: Patient on RX-17B at S018. reports improvement. Notes: nausea. Adherence ~0.88. AE: no. CRP 13.8 mg/L; ALT 25 U/L.
P00396,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no.
P00396,4,neutral,Visit 4: Patient on RX-17B at S018. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 12.1 mg/L; ALT 24 U/L.
P00396,5,neutral,Visit 5: Patient on RX-17B at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no.
P00397,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.79. AE: no.
P00397,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 12.0 mg/L; ALT 19 U/L.
P00397,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.61. AE: no.
P00397,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.84. AE: no.
P00397,4,positive,Visit 4: Patient on RX-17A at S012. energy increasing. Notes: fatigue. Adherence ~0.87. AE: no. CRP 9.6 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00398,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00398,1,neutral,Visit 1: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.63. AE: no. CRP 5.2 mg/L; ALT 23 U/L.
P00398,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.74. AE: no.
P00398,3,negative,Visit 3: Patient on RX-17A at S019. reports worsening. Notes: insomnia. Adherence ~0.72. AE: no.
P00398,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no. CRP 4.5 mg/L; ALT 24 U/L.
P00398,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.41. AE: no.
P00398,6,neutral,Visit 6: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P00399,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.95. AE: no.
P00399,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no. CRP 19.3 mg/L; ALT 33 U/L.
P00399,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no.
P00399,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 15.4 mg/L; ALT 35 U/L.
P00399,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 14.2 mg/L; ALT 36 U/L.
P00399,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00399,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P00400,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 9.0 mg/L; ALT 16 U/L.
P00400,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.90. AE: no.
P00400,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 8.4 mg/L; ALT 18 U/L.
P00400,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.87. AE: no.
P00400,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.9 mg/L; ALT 17 U/L.
P00400,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00400,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.92. AE: no.
P00401,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: joint pain. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 23 U/L.
P00401,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00401,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no.
P00401,3,negative,Visit 3: Patient on RX-17B at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 2.2 mg/L; ALT 26 U/L.
P00401,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P00402,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.93. AE: yes.
P00402,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: no. CRP 5.9 mg/L; ALT 34 U/L.
P00402,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.86. AE: yes. CRP 5.9 mg/L; ALT 41 U/L.
P00402,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00402,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.82. AE: no.
P00402,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00402,6,neutral,Visit 6: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: yes.
P00403,0,neutral,Visit 0: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00403,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~0.84. AE: no.
P00403,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~0.99. AE: no. CRP 12.0 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00403,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: yes.
P00403,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.94. AE: yes.
P00404,0,negative,Visit 0: Patient on RX-17B at S011. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 29 U/L.
P00404,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no.
P00404,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: dizziness. Adherence ~0.91. AE: yes.
P00405,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.54. AE: no.
P00405,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00405,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: fatigue. Adherence ~0.65. AE: no.
P00405,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.79. AE: no. CRP 5.4 mg/L; ALT 19 U/L.
P00405,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.66. AE: no. CRP 5.0 mg/L; ALT 19 U/L.
P00405,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.89. AE: no. CRP 4.8 mg/L; ALT 21 U/L.
P00405,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no. CRP 3.7 mg/L; ALT 19 U/L.
P00405,7,neutral,Visit 7: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.59. AE: no. CRP 3.2 mg/L; ALT 18 U/L.
P00406,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: joint pain. Adherence ~0.65. AE: yes. CRP 3.7 mg/L; ALT 31 U/L.
P00406,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.53. AE: no.
P00406,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P00406,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00406,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.49. AE: no.
P00406,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.67. AE: no.
P00406,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no. CRP 1.8 mg/L; ALT 30 U/L.
P00407,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.73. AE: no. CRP 4.1 mg/L; ALT 32 U/L.
P00407,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P00407,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.78. AE: no.
P00407,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.7 mg/L; ALT 32 U/L.
P00407,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.61. AE: no.
P00408,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no.
P00408,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.56. AE: no. CRP 4.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00408,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P00408,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00408,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.54. AE: no.
P00408,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 29 U/L.
P00409,0,neutral,Visit 0: Patient on RX-17B at S001. no major change. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00409,1,negative,Visit 1: Patient on RX-17B at S001. feels frustrated. Notes: insomnia. Adherence ~0.83. AE: no.
P00409,2,negative,Visit 2: Patient on RX-17B at S001. increased discomfort. Notes: insomnia. Adherence ~0.98. AE: yes. CRP 3.5 mg/L; ALT 34 U/L.
P00409,3,neutral,Visit 3: Patient on RX-17B at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.65. AE: no. CRP 2.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00409,4,neutral,Visit 4: Patient on RX-17B at S001. no major change. Notes: joint pain. Adherence ~0.68. AE: no.
P00410,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00410,1,neutral,Visit 1: Patient on RX-17B at S018. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no. CRP 4.9 mg/L; ALT 29 U/L.
P00410,2,positive,Visit 2: Patient on RX-17B at S018. tolerating medication well. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00410,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.82. AE: no. CRP 4.4 mg/L; ALT 28 U/L.
P00410,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: yes. CRP 3.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00410,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: yes.
P00410,6,neutral,Visit 6: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.54. AE: yes.
P00411,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: joint pain. Adherence ~0.79. AE: no.
P00411,1,negative,Visit 1: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.41. AE: yes.
P00411,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.53. AE: no.
P00411,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no.
P00412,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00412,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.77. AE: no. CRP 6.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00412,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no. CRP 7.1 mg/L; ALT 21 U/L.
P00412,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no.
P00412,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.78. AE: no.
P00412,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P00412,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.86. AE: no.
P00413,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: joint pain. Adherence ~0.85. AE: no. CRP 12.0 mg/L; ALT 45 U/L.
P00413,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: no.
P00413,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.82. AE: no.
P00413,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: yes.
P00413,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P00413,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.79. AE: yes.
P00413,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.67. AE: yes.
P00414,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 13.7 mg/L; ALT 20 U/L.
P00414,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.43. AE: no. CRP 11.9 mg/L; ALT 18 U/L.
P00414,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.65. AE: no. CRP 11.1 mg/L; ALT 19 U/L.
P00414,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P00414,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00414,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no.
P00414,6,neutral,Visit 6: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.51. AE: no.
P00415,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: no.
P00415,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no.
P00415,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 33 U/L.
P00415,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00415,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.95. AE: no.
P00415,5,positive,Visit 5: Patient on RX-17A at S004. tolerating medication well. Notes: brain fog. Adherence ~0.79. AE: no. CRP 3.0 mg/L; ALT 29 U/L.
P00416,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.36. AE: no.
P00416,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.38. AE: no. CRP 4.5 mg/L; ALT 58 U/L.
P00416,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no.
P00416,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.41. AE: no. CRP 4.2 mg/L; ALT 60 U/L.
P00416,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.73. AE: no.
P00416,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.43. AE: no.
P00417,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P00417,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.65. AE: yes.
P00417,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.63. AE: yes. CRP 8.7 mg/L; ALT 45 U/L.
P00417,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.72. AE: no.
P00417,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.70. AE: no. CRP 8.4 mg/L; ALT 47 U/L.
P00417,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.66. AE: no.
P00418,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.91. AE: yes. Plan: consider dose adjustment; counsel patient.
P00418,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~0.85. AE: no. CRP 4.3 mg/L; ALT 34 U/L.
P00418,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.89. AE: no.
P00418,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.98. AE: no.
P00418,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.83. AE: no.
P00419,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P00419,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.91. AE: no.
P00419,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.86. AE: no.
P00419,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00419,4,positive,Visit 4: Patient on RX-17A at S017. symptoms improving. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 8.1 mg/L; ALT 32 U/L.
P00419,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00419,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00419,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: no. CRP 5.8 mg/L; ALT 36 U/L.
P00420,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.58. AE: yes. CRP 18.7 mg/L; ALT 30 U/L.
P00420,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00420,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.79. AE: yes.
P00420,3,positive,Visit 3: Patient on RX-17B at S012. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00420,4,negative,Visit 4: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.74. AE: yes.
P00420,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.76. AE: no. CRP 11.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00420,6,positive,Visit 6: Patient on RX-17B at S012. energy increasing. Notes: headache. Adherence ~0.76. AE: no. CRP 8.5 mg/L; ALT 34 U/L.
P00421,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: fatigue. Adherence ~0.63. AE: no.
P00421,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: brain fog. Adherence ~0.53. AE: no. CRP 3.1 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00421,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.50. AE: no. CRP 3.0 mg/L; ALT 24 U/L.
P00421,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no.
P00421,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 2.5 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00421,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P00421,6,neutral,Visit 6: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.56. AE: no. CRP 1.8 mg/L; ALT 23 U/L.
P00422,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: dizziness. Adherence ~0.68. AE: no. CRP 7.0 mg/L; ALT 26 U/L.
P00422,1,neutral,Visit 1: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.49. AE: no.
P00422,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no. CRP 5.6 mg/L; ALT 28 U/L.
P00422,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no. CRP 5.1 mg/L; ALT 26 U/L.
P00422,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.58. AE: no.
P00422,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P00422,6,neutral,Visit 6: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.60. AE: yes.
P00423,0,neutral,Visit 0: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00423,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.58. AE: no. CRP 5.9 mg/L; ALT 40 U/L.
P00423,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.89. AE: no.
P00423,3,positive,Visit 3: Patient on RX-17B at S012. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no.
P00423,4,negative,Visit 4: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.80. AE: yes. CRP 4.2 mg/L; ALT 40 U/L.
P00423,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.96. AE: no.
P00424,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.55. AE: no. CRP 5.3 mg/L; ALT 33 U/L.
P00424,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no. CRP 5.3 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00424,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.67. AE: no. CRP 4.7 mg/L; ALT 40 U/L.
P00424,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no.
P00424,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no.
P00424,5,positive,Visit 5: Patient on RX-17A at S015. tolerating medication well. Notes: fatigue. Adherence ~0.79. AE: no.
P00424,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.0 mg/L; ALT 34 U/L.
P00424,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no.
P00425,0,negative,Visit 0: Patient on RX-17B at S001. reports worsening. Notes: brain fog. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P00425,1,positive,Visit 1: Patient on RX-17B at S001. energy increasing. Notes: nausea. Adherence ~0.80. AE: no. CRP 4.5 mg/L; ALT 39 U/L.
P00425,2,neutral,Visit 2: Patient on RX-17B at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.96. AE: no.
P00425,3,neutral,Visit 3: Patient on RX-17B at S001. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P00425,4,negative,Visit 4: Patient on RX-17B at S001. reports worsening. Notes: nausea. Adherence ~1.00. AE: yes. CRP 3.7 mg/L; ALT 45 U/L.
P00425,5,neutral,Visit 5: Patient on RX-17B at S001. no major change. Notes: abdominal discomfort. Adherence ~0.99. AE: yes.
P00425,6,positive,Visit 6: Patient on RX-17B at S001. symptoms improving. Notes: joint pain. Adherence ~0.91. AE: no. CRP 2.5 mg/L; ALT 46 U/L.
P00426,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: fatigue. Adherence ~0.76. AE: yes. CRP 5.4 mg/L; ALT 49 U/L.
P00426,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.54. AE: no. CRP 5.7 mg/L; ALT 42 U/L.
P00426,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.69. AE: no.
P00426,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P00426,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: yes. CRP 3.7 mg/L; ALT 52 U/L.
P00427,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: yes.
P00427,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.74. AE: no. CRP 6.9 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00427,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.53. AE: no. CRP 6.7 mg/L; ALT 26 U/L.
P00427,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.67. AE: yes. CRP 6.6 mg/L; ALT 29 U/L.
P00427,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P00427,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.70. AE: no.
P00428,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.67. AE: no. CRP 8.1 mg/L; ALT 33 U/L.
P00428,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.79. AE: no.
P00428,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P00428,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00428,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no.
P00428,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00428,6,positive,Visit 6: Patient on RX-17A at S005. feels better overall. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00429,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00429,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.71. AE: no.
P00429,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no. CRP 11.1 mg/L; ALT 16 U/L.
P00429,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.87. AE: no.
P00429,4,positive,Visit 4: Patient on RX-17B at S005. symptoms improving. Notes: insomnia. Adherence ~0.86. AE: no. CRP 8.1 mg/L; ALT 17 U/L.
P00429,5,positive,Visit 5: Patient on RX-17B at S005. energy increasing. Notes: insomnia. Adherence ~0.78. AE: no. CRP 6.8 mg/L; ALT 17 U/L.
P00430,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00430,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.79. AE: no. CRP 6.8 mg/L; ALT 66 U/L.
P00430,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no. CRP 6.9 mg/L; ALT 69 U/L.
P00430,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P00430,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.83. AE: no.
P00430,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00430,6,neutral,Visit 6: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.72. AE: no.
P00430,7,neutral,Visit 7: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 69 U/L.
P00431,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no. CRP 12.1 mg/L; ALT 24 U/L.
P00431,1,positive,Visit 1: Patient on RX-17B at S022. energy increasing. Notes: joint pain. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00431,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 11.2 mg/L; ALT 26 U/L.
P00431,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no.
P00431,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.69. AE: no.
P00431,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 6.8 mg/L; ALT 29 U/L.
P00431,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: yes. Plan: consider dose adjustment; counsel patient.
P00431,7,neutral,Visit 7: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P00432,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~0.68. AE: yes.
P00432,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.67. AE: no.
P00432,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.83. AE: no.
P00432,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00432,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no. CRP 3.9 mg/L; ALT 41 U/L.
P00433,0,neutral,Visit 0: Patient on RX-17A at S019. no major change. Notes: headache. Adherence ~0.72. AE: no.
P00433,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 3.4 mg/L; ALT 28 U/L.
P00433,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00433,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 25 U/L.
P00433,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00434,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00434,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.64. AE: yes.
P00434,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00434,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 5.1 mg/L; ALT 26 U/L.
P00434,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.93. AE: no. CRP 4.1 mg/L; ALT 27 U/L.
P00434,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P00435,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.87. AE: no.
P00435,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no.
P00435,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P00435,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.98. AE: no.
P00435,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.94. AE: no. CRP 6.5 mg/L; ALT 30 U/L.
P00436,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P00436,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.76. AE: yes.
P00436,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P00436,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.53. AE: no. CRP 9.1 mg/L; ALT 21 U/L.
P00436,4,negative,Visit 4: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.53. AE: no.
P00436,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00436,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: yes. CRP 7.1 mg/L; ALT 23 U/L.
P00436,7,neutral,Visit 7: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.47. AE: no.
P00437,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 14.3 mg/L; ALT 12 U/L.
P00437,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.78. AE: yes.
P00437,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.54. AE: yes. Plan: consider dose adjustment; counsel patient.
P00437,3,positive,Visit 3: Patient on RX-17A at S012. feels better overall. Notes: dizziness. Adherence ~0.85. AE: no.
P00437,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P00437,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no.
P00437,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: yes. CRP 8.9 mg/L; ALT 15 U/L.
P00438,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no.
P00438,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00438,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P00438,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00438,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.69. AE: no. CRP 7.5 mg/L; ALT 47 U/L.
P00438,5,negative,Visit 5: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.92. AE: yes. Plan: consider dose adjustment; counsel patient.
P00439,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00439,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00439,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: no.
P00439,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00439,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.65. AE: no.
P00439,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P00439,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: yes. Plan: consider dose adjustment; counsel patient.
P00439,7,positive,Visit 7: Patient on RX-17A at S017. tolerating medication well. Notes: brain fog. Adherence ~0.86. AE: no. CRP 6.3 mg/L; ALT 39 U/L.
P00440,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P00440,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00440,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no.
P00440,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: yes.
P00441,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.76. AE: no.
P00441,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P00441,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.84. AE: no. CRP 4.5 mg/L; ALT 38 U/L.
P00442,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00442,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.85. AE: no. CRP 6.6 mg/L; ALT 39 U/L.
P00442,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: no. CRP 5.6 mg/L; ALT 42 U/L.
P00442,3,positive,Visit 3: Patient on RX-17A at S004. tolerating medication well. Notes: joint pain. Adherence ~0.85. AE: no.
P00442,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.95. AE: no.
P00443,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00443,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: joint pain. Adherence ~0.83. AE: no.
P00443,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no.
P00443,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00443,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.87. AE: no.
P00443,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.84. AE: yes. CRP 22.1 mg/L; ALT 26 U/L.
P00443,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P00444,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.59. AE: no.
P00444,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.73. AE: no. CRP 10.3 mg/L; ALT 36 U/L.
P00444,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no.
P00444,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.82. AE: yes.
P00444,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no.
P00444,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00445,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: headache. Adherence ~0.69. AE: yes. CRP 9.4 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P00445,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.82. AE: no. CRP 9.4 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P00445,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: no.
P00445,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: no.
P00445,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.91. AE: no.
P00445,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: fatigue. Adherence ~0.80. AE: no. CRP 7.0 mg/L; ALT 44 U/L.
P00445,6,positive,Visit 6: Patient on RX-17A at S002. feels better overall. Notes: headache. Adherence ~0.94. AE: no. CRP 6.3 mg/L; ALT 43 U/L.
P00445,7,neutral,Visit 7: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no. CRP 5.5 mg/L; ALT 48 U/L.
P00446,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: headache. Adherence ~0.83. AE: no. CRP 11.8 mg/L; ALT 17 U/L.
P00446,1,neutral,Visit 1: Patient on RX-17A at S008. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no.
P00446,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no. CRP 9.6 mg/L; ALT 17 U/L.
P00446,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 10.0 mg/L; ALT 17 U/L.
P00446,4,neutral,Visit 4: Patient on RX-17A at S008. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: yes. CRP 9.2 mg/L; ALT 19 U/L.
P00446,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: joint pain. Adherence ~0.64. AE: no. CRP 8.0 mg/L; ALT 17 U/L.
P00447,0,negative,Visit 0: Patient on RX-17A at S011. increased discomfort. Notes: dizziness. Adherence ~0.88. AE: no.
P00447,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P00447,2,negative,Visit 2: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.94. AE: yes.
P00447,3,negative,Visit 3: Patient on RX-17A at S011. symptoms persist. Notes: abdominal discomfort. Adherence ~0.76. AE: yes.
P00447,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 2.8 mg/L; ALT 38 U/L.
P00447,5,neutral,Visit 5: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P00448,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.70. AE: no. CRP 4.8 mg/L; ALT 34 U/L.
P00448,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P00448,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.73. AE: no. CRP 5.0 mg/L; ALT 35 U/L.
P00448,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.78. AE: no.
P00448,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.60. AE: no.
P00449,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no. CRP 4.2 mg/L; ALT 62 U/L.
P00449,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00449,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.70. AE: no.
P00449,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: no.
P00449,4,positive,Visit 4: Patient on RX-17A at S015. energy increasing. Notes: joint pain. Adherence ~0.76. AE: no. CRP 2.9 mg/L; ALT 62 U/L.
P00449,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.95. AE: no. CRP 2.7 mg/L; ALT 64 U/L.
P00450,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.85. AE: no.
P00450,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no.
P00450,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00450,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.96. AE: no.
P00450,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00451,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.76. AE: yes. CRP 5.4 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00451,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 5.4 mg/L; ALT 23 U/L.
P00451,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P00451,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.81. AE: no.
P00451,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P00452,0,neutral,Visit 0: Patient on RX-17A at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.84. AE: no. CRP 7.5 mg/L; ALT 31 U/L.
P00452,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00452,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: yes.
P00452,3,negative,Visit 3: Patient on RX-17A at S008. feels frustrated. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00452,4,positive,Visit 4: Patient on RX-17A at S008. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no.
P00452,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.90. AE: yes. Plan: consider dose adjustment; counsel patient.
P00453,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.84. AE: no.
P00453,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P00453,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no.
P00453,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P00453,4,positive,Visit 4: Patient on RX-17A at S019. feels better overall. Notes: brain fog. Adherence ~0.91. AE: no.
P00454,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 26 U/L.
P00454,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00454,2,positive,Visit 2: Patient on RX-17B at S015. energy increasing. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00454,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.72. AE: no.
P00454,4,negative,Visit 4: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.62. AE: no. CRP 2.2 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00454,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: yes.
P00454,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00455,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no.
P00455,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: fatigue. Adherence ~0.69. AE: no. CRP 12.0 mg/L; ALT 34 U/L.
P00455,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.89. AE: no.
P00455,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.99. AE: no. CRP 8.9 mg/L; ALT 35 U/L.
P00455,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.78. AE: no. CRP 7.3 mg/L; ALT 41 U/L.
P00455,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: brain fog. Adherence ~0.87. AE: no. CRP 6.0 mg/L; ALT 38 U/L.
P00455,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.2 mg/L; ALT 40 U/L.
P00456,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00456,1,neutral,Visit 1: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no.
P00456,2,positive,Visit 2: Patient on RX-17A at S016. symptoms improving. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00457,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.99. AE: no.
P00457,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~0.99. AE: no. CRP 5.1 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00457,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.86. AE: no.
P00457,3,positive,Visit 3: Patient on RX-17B at S017. symptoms improving. Notes: joint pain. Adherence ~0.95. AE: no.
P00457,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P00457,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00457,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: joint pain. Adherence ~0.81. AE: no.
P00458,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.99. AE: no.
P00458,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.4 mg/L; ALT 45 U/L.
P00458,2,negative,Visit 2: Patient on RX-17B at S002. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00458,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no. CRP 2.7 mg/L; ALT 50 U/L.
P00458,4,positive,Visit 4: Patient on RX-17B at S002. tolerating medication well. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00458,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.62. AE: no.
P00458,6,positive,Visit 6: Patient on RX-17B at S002. energy increasing. Notes: headache. Adherence ~0.90. AE: no.
P00458,7,positive,Visit 7: Patient on RX-17B at S002. reports improvement. Notes: dizziness. Adherence ~0.85. AE: no. CRP 1.6 mg/L; ALT 50 U/L.
P00459,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.65. AE: no. CRP 4.2 mg/L; ALT 31 U/L.
P00459,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00459,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.95. AE: no.
P00459,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 3.4 mg/L; ALT 30 U/L.
P00459,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00460,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.62. AE: no.
P00460,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.91. AE: no.
P00460,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.69. AE: no.
P00460,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P00460,4,negative,Visit 4: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P00460,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no. CRP 6.1 mg/L; ALT 26 U/L.
P00460,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00461,0,neutral,Visit 0: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00461,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.74. AE: no.
P00461,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 11.8 mg/L; ALT 28 U/L.
P00461,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no.
P00461,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.74. AE: no.
P00461,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. CRP 8.2 mg/L; ALT 26 U/L.
P00461,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no.
P00461,7,neutral,Visit 7: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00462,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: brain fog. Adherence ~0.86. AE: no.
P00462,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P00462,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.92. AE: no. CRP 2.5 mg/L; ALT 16 U/L.
P00462,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.3 mg/L; ALT 17 U/L.
P00462,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00462,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no.
P00462,6,positive,Visit 6: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00462,7,positive,Visit 7: Patient on RX-17B at S019. symptoms improving. Notes: dizziness. Adherence ~0.90. AE: no. CRP 1.2 mg/L; ALT 17 U/L.
P00463,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.79. AE: yes.
P00463,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.63. AE: yes.
P00463,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no.
P00463,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00463,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.67. AE: no.
P00463,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.82. AE: yes.
P00463,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.71. AE: no. CRP 3.1 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00463,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00464,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.92. AE: yes. Plan: consider dose adjustment; counsel patient.
P00464,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: headache. Adherence ~0.84. AE: yes. CRP 2.7 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00464,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P00464,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no.
P00464,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00464,5,positive,Visit 5: Patient on RX-17B at S017. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 1.7 mg/L; ALT 36 U/L.
P00464,6,positive,Visit 6: Patient on RX-17B at S017. symptoms improving. Notes: insomnia. Adherence ~0.84. AE: no.
P00464,7,neutral,Visit 7: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.87. AE: yes. CRP 1.2 mg/L; ALT 30 U/L.
P00465,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: insomnia. Adherence ~0.92. AE: no.
P00465,1,negative,Visit 1: Patient on RX-17A at S019. feels frustrated. Notes: dizziness. Adherence ~0.75. AE: yes.
P00465,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no.
P00465,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P00465,4,positive,Visit 4: Patient on RX-17A at S019. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00465,5,positive,Visit 5: Patient on RX-17A at S019. reports improvement. Notes: brain fog. Adherence ~0.79. AE: no. CRP 3.0 mg/L; ALT 20 U/L.
P00465,6,neutral,Visit 6: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00466,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.42. AE: no. CRP 8.2 mg/L; ALT 16 U/L.
P00466,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.55. AE: yes.
P00466,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.53. AE: no.
P00466,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: no. CRP 6.1 mg/L; ALT 14 U/L.
P00466,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.61. AE: no.
P00467,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.90. AE: yes.
P00467,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.65. AE: no. CRP 10.3 mg/L; ALT 30 U/L.
P00467,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 9.8 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00467,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00467,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no. CRP 7.4 mg/L; ALT 33 U/L.
P00467,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 6.7 mg/L; ALT 36 U/L.
P00467,6,positive,Visit 6: Patient on RX-17B at S022. tolerating medication well. Notes: joint pain. Adherence ~0.92. AE: no.
P00468,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 2.4 mg/L; ALT 32 U/L.
P00468,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.92. AE: no. CRP 2.3 mg/L; ALT 31 U/L.
P00468,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P00468,3,negative,Visit 3: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.81. AE: no. CRP 2.1 mg/L; ALT 33 U/L.
P00468,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00468,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P00468,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00468,7,positive,Visit 7: Patient on RX-17A at S015. tolerating medication well. Notes: dizziness. Adherence ~0.76. AE: no.
P00469,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: fatigue. Adherence ~0.82. AE: yes. CRP 10.4 mg/L; ALT 34 U/L.
P00469,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.69. AE: no.
P00469,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: yes. CRP 9.5 mg/L; ALT 38 U/L.
P00469,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00469,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~0.94. AE: no. CRP 5.8 mg/L; ALT 38 U/L.
P00469,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.75. AE: no.
P00470,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.77. AE: no.
P00470,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.72. AE: no.
P00470,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00471,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.99. AE: no.
P00471,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.95. AE: no.
P00471,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: headache. Adherence ~1.00. AE: no.
P00471,3,positive,Visit 3: Patient on RX-17A at S014. feels better overall. Notes: insomnia. Adherence ~1.00. AE: no.
P00471,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P00472,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.87. AE: no. CRP 8.0 mg/L; ALT 28 U/L.
P00472,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00472,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no.
P00472,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.5 mg/L; ALT 31 U/L.
P00472,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.7 mg/L; ALT 30 U/L.
P00472,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.96. AE: no.
P00473,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: no.
P00473,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.90. AE: yes.
P00473,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.82. AE: no. CRP 8.6 mg/L; ALT 41 U/L.
P00473,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.75. AE: no. CRP 7.0 mg/L; ALT 40 U/L.
P00473,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no.
P00473,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no.
P00473,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.88. AE: yes. Plan: consider dose adjustment; counsel patient.
P00474,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: joint pain. Adherence ~0.96. AE: no. CRP 6.5 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00474,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00474,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.95. AE: no.
P00474,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: no. CRP 4.9 mg/L; ALT 21 U/L.
P00474,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00474,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 5.0 mg/L; ALT 25 U/L.
P00474,6,neutral,Visit 6: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: yes.
P00474,7,neutral,Visit 7: Patient on RX-17A at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.98. AE: no. CRP 3.4 mg/L; ALT 22 U/L.
P00475,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.39. AE: yes.
P00475,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.30. AE: no.
P00475,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.34. AE: no.
P00475,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.33. AE: no.
P00475,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.30. AE: no. CRP 3.1 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00475,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.48. AE: no.
P00475,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.41. AE: no.
P00475,7,neutral,Visit 7: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.39. AE: no. CRP 2.1 mg/L; ALT 51 U/L.
P00476,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.52. AE: no. CRP 6.8 mg/L; ALT 54 U/L.
P00476,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00476,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.58. AE: no. CRP 5.9 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P00476,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.63. AE: no. CRP 5.4 mg/L; ALT 49 U/L.
P00476,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.73. AE: no.
P00476,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.62. AE: yes. CRP 4.6 mg/L; ALT 56 U/L.
P00476,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.64. AE: no.
P00477,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.45. AE: yes.
P00477,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.54. AE: no. CRP 5.1 mg/L; ALT 36 U/L.
P00477,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.47. AE: no.
P00477,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.52. AE: no. CRP 4.3 mg/L; ALT 32 U/L.
P00477,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.52. AE: no. CRP 3.1 mg/L; ALT 33 U/L.
P00477,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. CRP 2.8 mg/L; ALT 30 U/L.
P00478,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.90. AE: no.
P00478,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.73. AE: no.
P00478,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.88. AE: no. CRP 8.8 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00478,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.75. AE: yes. CRP 8.1 mg/L; ALT 34 U/L.
P00478,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.86. AE: no.
P00479,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no. CRP 12.4 mg/L; ALT 41 U/L.
P00479,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no. CRP 14.0 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00479,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.99. AE: no.
P00479,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no. CRP 10.4 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00479,4,positive,Visit 4: Patient on RX-17A at S005. symptoms improving. Notes: nausea. Adherence ~0.97. AE: no.
P00479,5,positive,Visit 5: Patient on RX-17A at S005. energy increasing. Notes: insomnia. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00479,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.85. AE: no.
P00479,7,neutral,Visit 7: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: yes. CRP 6.9 mg/L; ALT 37 U/L.
P00480,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00480,1,negative,Visit 1: Patient on RX-17A at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.92. AE: yes.
P00480,2,negative,Visit 2: Patient on RX-17A at S002. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: yes. CRP 10.6 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P00480,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.45. AE: no.
P00480,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: yes.
P00480,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no.
P00481,0,neutral,Visit 0: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no. CRP 6.9 mg/L; ALT 23 U/L.
P00481,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.72. AE: no.
P00481,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no. CRP 6.1 mg/L; ALT 25 U/L.
P00481,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P00481,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no. CRP 5.4 mg/L; ALT 27 U/L.
P00481,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no.
P00482,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00482,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.53. AE: no. CRP 12.2 mg/L; ALT 31 U/L.
P00482,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P00482,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 11.2 mg/L; ALT 32 U/L.
P00482,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.55. AE: no. CRP 9.9 mg/L; ALT 33 U/L.
P00482,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no.
P00483,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.87. AE: no. CRP 3.9 mg/L; ALT 60 U/L.
P00483,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.90. AE: no.
P00483,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.89. AE: no.
P00483,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P00483,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.90. AE: no.
P00484,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00484,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no.
P00484,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no. CRP 20.8 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P00484,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no.
P00484,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.61. AE: no. CRP 13.8 mg/L; ALT 18 U/L.
P00484,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no.
P00485,0,negative,Visit 0: Patient on RX-17A at S001. poor tolerance. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00485,1,neutral,Visit 1: Patient on RX-17A at S001. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no.
P00485,2,neutral,Visit 2: Patient on RX-17A at S001. reviewed dosing instructions. Notes: nausea. Adherence ~0.58. AE: no.
P00485,3,neutral,Visit 3: Patient on RX-17A at S001. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 55 U/L.
P00485,4,neutral,Visit 4: Patient on RX-17A at S001. stable symptoms. Notes: headache. Adherence ~0.70. AE: no.
P00485,5,neutral,Visit 5: Patient on RX-17A at S001. stable symptoms. Notes: dizziness. Adherence ~0.49. AE: no. CRP 2.4 mg/L; ALT 53 U/L.
P00486,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: nausea. Adherence ~0.38. AE: no. Plan: consider dose adjustment; counsel patient.
P00486,1,negative,Visit 1: Patient on RX-17A at S011. feels frustrated. Notes: headache. Adherence ~0.36. AE: no.
P00486,2,negative,Visit 2: Patient on RX-17A at S011. poor tolerance. Notes: headache. Adherence ~0.68. AE: yes. CRP 2.2 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00486,3,neutral,Visit 3: Patient on RX-17A at S011. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 1.9 mg/L; ALT 29 U/L.
P00486,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: brain fog. Adherence ~0.46. AE: no.
P00487,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no.
P00487,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00487,2,positive,Visit 2: Patient on RX-17B at S016. symptoms improving. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00487,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00487,4,negative,Visit 4: Patient on RX-17B at S016. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: no. CRP 10.0 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00487,5,positive,Visit 5: Patient on RX-17B at S016. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no.
P00487,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.76. AE: no.
P00488,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.78. AE: no. CRP 5.0 mg/L; ALT 50 U/L.
P00488,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.92. AE: yes. CRP 4.8 mg/L; ALT 54 U/L.
P00488,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.4 mg/L; ALT 48 U/L.
P00488,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.7 mg/L; ALT 48 U/L.
P00488,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.95. AE: no. CRP 3.6 mg/L; ALT 41 U/L.
P00488,5,negative,Visit 5: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no.
P00488,6,positive,Visit 6: Patient on RX-17A at S015. symptoms improving. Notes: insomnia. Adherence ~1.00. AE: no.
P00489,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: brain fog. Adherence ~0.65. AE: no. CRP 8.2 mg/L; ALT 63 U/L.
P00489,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00489,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.71. AE: no.
P00489,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P00489,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.79. AE: no. CRP 5.2 mg/L; ALT 61 U/L.
P00489,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.65. AE: yes.
P00489,6,neutral,Visit 6: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.66. AE: no. CRP 5.1 mg/L; ALT 67 U/L.
P00489,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.66. AE: no.
P00490,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no. CRP 3.9 mg/L; ALT 32 U/L.
P00490,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: yes.
P00490,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.99. AE: no.
P00490,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.92. AE: no. CRP 2.9 mg/L; ALT 34 U/L.
P00490,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: dizziness. Adherence ~0.84. AE: no.
P00491,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.73. AE: no.
P00491,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no. CRP 25.1 mg/L; ALT 42 U/L.
P00491,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 24.1 mg/L; ALT 44 U/L.
P00491,3,negative,Visit 3: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.67. AE: yes. Plan: consider dose adjustment; counsel patient.
P00491,4,positive,Visit 4: Patient on RX-17B at S014. tolerating medication well. Notes: nausea. Adherence ~0.82. AE: no. CRP 18.8 mg/L; ALT 45 U/L.
P00491,5,positive,Visit 5: Patient on RX-17B at S014. symptoms improving. Notes: nausea. Adherence ~0.82. AE: no. CRP 15.6 mg/L; ALT 47 U/L.
P00491,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00491,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 9.8 mg/L; ALT 50 U/L.
P00492,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.65. AE: no.
P00492,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.66. AE: no. CRP 22.7 mg/L; ALT 20 U/L.
P00492,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00492,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.87. AE: no.
P00492,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P00492,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.62. AE: no.
P00493,0,negative,Visit 0: Patient on RX-17B at S021. symptoms persist. Notes: dizziness. Adherence ~0.39. AE: no.
P00493,1,neutral,Visit 1: Patient on RX-17B at S021. follow-up as scheduled. Notes: nausea. Adherence ~0.58. AE: no. CRP 14.2 mg/L; ALT 24 U/L.
P00493,2,neutral,Visit 2: Patient on RX-17B at S021. follow-up as scheduled. Notes: joint pain. Adherence ~0.37. AE: no.
P00493,3,neutral,Visit 3: Patient on RX-17B at S021. follow-up as scheduled. Notes: fatigue. Adherence ~0.57. AE: yes.
P00493,4,neutral,Visit 4: Patient on RX-17B at S021. stable symptoms. Notes: insomnia. Adherence ~0.52. AE: no. CRP 11.5 mg/L; ALT 26 U/L.
P00493,5,neutral,Visit 5: Patient on RX-17B at S021. follow-up as scheduled. Notes: nausea. Adherence ~0.42. AE: no.
P00494,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.63. AE: yes.
P00494,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00494,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.65. AE: yes. Plan: consider dose adjustment; counsel patient.
P00494,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00494,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00494,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.82. AE: no. CRP 5.6 mg/L; ALT 20 U/L.
P00494,6,negative,Visit 6: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.76. AE: yes. CRP 5.2 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P00495,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.86. AE: no.
P00495,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no.
P00495,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P00495,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P00495,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00495,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00495,6,positive,Visit 6: Patient on RX-17A at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00496,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00496,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.82. AE: yes. CRP 6.3 mg/L; ALT 40 U/L.
P00496,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.76. AE: no. CRP 6.1 mg/L; ALT 35 U/L.
P00496,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.73. AE: no.
P00496,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00496,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P00496,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.91. AE: no.
P00497,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P00497,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.57. AE: no.
P00497,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.61. AE: no. CRP 12.9 mg/L; ALT 32 U/L.
P00497,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00498,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: yes.
P00498,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.57. AE: no. CRP 6.4 mg/L; ALT 59 U/L. Plan: consider dose adjustment; counsel patient.
P00498,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.78. AE: no.
P00498,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.80. AE: no. CRP 5.5 mg/L; ALT 58 U/L.
P00498,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P00499,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.57. AE: no.
P00499,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P00499,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: nausea. Adherence ~0.70. AE: no. CRP 13.4 mg/L; ALT 63 U/L. Plan: consider dose adjustment; counsel patient.
P00499,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.52. AE: no.
P00499,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.67. AE: no. CRP 10.6 mg/L; ALT 64 U/L.
P00499,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.61. AE: no.
P00499,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00499,7,neutral,Visit 7: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.71. AE: yes. CRP 6.1 mg/L; ALT 70 U/L.
P00500,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.23. AE: no. CRP 5.8 mg/L; ALT 28 U/L.
P00500,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.23. AE: no. CRP 5.7 mg/L; ALT 27 U/L.
P00500,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.39. AE: yes.
P00500,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.45. AE: no.
P00500,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.26. AE: no.
P00501,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00501,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.95. AE: no.
P00501,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no.
P00501,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P00502,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no.
P00502,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.75. AE: no.
P00502,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P00502,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no.
P00502,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P00502,5,negative,Visit 5: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P00502,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no. CRP 3.7 mg/L; ALT 42 U/L.
P00503,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.70. AE: no.
P00503,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 7.4 mg/L; ALT 46 U/L.
P00503,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.68. AE: no.
P00503,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00503,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P00503,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: yes. CRP 5.3 mg/L; ALT 57 U/L.
P00503,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.58. AE: no.
P00503,7,positive,Visit 7: Patient on RX-17B at S022. energy increasing. Notes: insomnia. Adherence ~0.94. AE: no.
P00504,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.96. AE: no.
P00504,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no. CRP 4.7 mg/L; ALT 36 U/L.
P00504,2,positive,Visit 2: Patient on RX-17B at S022. symptoms improving. Notes: headache. Adherence ~0.97. AE: no. CRP 4.9 mg/L; ALT 36 U/L.
P00505,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: dizziness. Adherence ~0.83. AE: no.
P00505,1,negative,Visit 1: Patient on RX-17A at S011. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P00505,2,negative,Visit 2: Patient on RX-17A at S011. poor tolerance. Notes: brain fog. Adherence ~0.98. AE: no.
P00505,3,negative,Visit 3: Patient on RX-17A at S011. poor tolerance. Notes: joint pain. Adherence ~0.84. AE: yes.
P00506,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no. CRP 5.2 mg/L; ALT 39 U/L.
P00506,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.68. AE: no.
P00506,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.59. AE: no.
P00506,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00506,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: no. CRP 4.5 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00506,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00506,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: no.
P00506,7,positive,Visit 7: Patient on RX-17A at S017. symptoms improving. Notes: brain fog. Adherence ~0.78. AE: no.
P00507,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.79. AE: no.
P00507,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.75. AE: no.
P00507,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.73. AE: no.
P00507,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P00507,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.79. AE: no.
P00508,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.43. AE: no. CRP 14.2 mg/L; ALT 18 U/L.
P00508,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.61. AE: no. CRP 16.0 mg/L; ALT 20 U/L.
P00508,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no.
P00508,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no. CRP 10.3 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00508,4,positive,Visit 4: Patient on RX-17A at S012. feels better overall. Notes: dizziness. Adherence ~0.88. AE: no. CRP 14.3 mg/L; ALT 20 U/L.
P00508,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no. CRP 10.6 mg/L; ALT 18 U/L.
P00508,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.62. AE: yes. CRP 9.4 mg/L; ALT 23 U/L.
P00508,7,neutral,Visit 7: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no. CRP 8.6 mg/L; ALT 19 U/L.
P00509,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.35. AE: no. CRP 7.5 mg/L; ALT 28 U/L.
P00509,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.52. AE: yes. CRP 6.8 mg/L; ALT 32 U/L.
P00509,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.26. AE: yes.
P00509,3,negative,Visit 3: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.59. AE: yes.
P00509,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00509,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P00509,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.45. AE: no.
P00510,0,neutral,Visit 0: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 27.1 mg/L; ALT 29 U/L.
P00510,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.76. AE: no.
P00510,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.87. AE: no.
P00510,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.89. AE: yes.
P00510,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00510,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.77. AE: no. CRP 20.6 mg/L; ALT 27 U/L.
P00510,6,positive,Visit 6: Patient on RX-17A at S002. tolerating medication well. Notes: insomnia. Adherence ~0.82. AE: no. CRP 14.9 mg/L; ALT 28 U/L.
P00511,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.94. AE: yes.
P00511,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: dizziness. Adherence ~0.86. AE: yes.
P00511,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no. CRP 11.7 mg/L; ALT 32 U/L.
P00511,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no.
P00511,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.84. AE: no.
P00511,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.78. AE: no.
P00511,6,neutral,Visit 6: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.80. AE: no.
P00512,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no. CRP 23.2 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00512,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no.
P00512,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.67. AE: yes. CRP 18.5 mg/L; ALT 32 U/L.
P00512,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00512,4,positive,Visit 4: Patient on RX-17A at S014. symptoms improving. Notes: headache. Adherence ~1.00. AE: no.
P00513,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P00513,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.75. AE: no.
P00513,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no. CRP 6.0 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00513,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P00513,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.86. AE: no. CRP 4.8 mg/L; ALT 15 U/L.
P00513,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P00514,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.36. AE: no.
P00514,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.22. AE: no. CRP 2.6 mg/L; ALT 13 U/L.
P00514,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 2.5 mg/L; ALT 15 U/L.
P00514,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.40. AE: no.
P00514,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P00514,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.50. AE: no.
P00515,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.97. AE: no.
P00515,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.74. AE: no. CRP 4.7 mg/L; ALT 41 U/L.
P00515,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: yes. CRP 4.7 mg/L; ALT 46 U/L.
P00515,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00515,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no. CRP 4.2 mg/L; ALT 40 U/L.
P00515,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00516,0,neutral,Visit 0: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00516,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00516,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00516,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00516,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: no.
P00516,5,positive,Visit 5: Patient on RX-17B at S013. reports improvement. Notes: headache. Adherence ~0.79. AE: no.
P00516,6,neutral,Visit 6: Patient on RX-17B at S013. continues regimen. Notes: insomnia. Adherence ~1.00. AE: yes.
P00517,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P00517,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no.
P00517,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P00517,3,positive,Visit 3: Patient on RX-17A at S017. reports improvement. Notes: headache. Adherence ~0.84. AE: no.
P00517,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.85. AE: no. CRP 3.1 mg/L; ALT 24 U/L.
P00517,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no.
P00518,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.93. AE: no. CRP 2.3 mg/L; ALT 22 U/L.
P00518,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P00518,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no.
P00518,3,negative,Visit 3: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.98. AE: yes. CRP 1.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00518,4,negative,Visit 4: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.90. AE: no. CRP 1.7 mg/L; ALT 25 U/L.
P00518,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: no.
P00518,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00518,7,positive,Visit 7: Patient on RX-17A at S004. energy increasing. Notes: insomnia. Adherence ~0.78. AE: no.
P00519,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.91. AE: no.
P00519,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.95. AE: no.
P00519,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no. CRP 11.0 mg/L; ALT 20 U/L.
P00519,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no. CRP 8.7 mg/L; ALT 21 U/L.
P00519,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no. CRP 7.7 mg/L; ALT 21 U/L.
P00520,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: abdominal discomfort. Adherence ~0.47. AE: no. CRP 2.4 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00520,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no. CRP 2.7 mg/L; ALT 20 U/L.
P00520,2,neutral,Visit 2: Patient on RX-17A at S018. follow-up as scheduled. Notes: headache. Adherence ~0.59. AE: no.
P00520,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: nausea. Adherence ~0.59. AE: no.
P00520,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00520,5,positive,Visit 5: Patient on RX-17A at S018. tolerating medication well. Notes: joint pain. Adherence ~0.80. AE: no. CRP 1.8 mg/L; ALT 24 U/L.
P00520,6,neutral,Visit 6: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.56. AE: yes. CRP 1.4 mg/L; ALT 25 U/L.
P00521,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00521,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.89. AE: no.
P00521,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.94. AE: no.
P00521,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.80. AE: no.
P00521,4,negative,Visit 4: Patient on RX-17B at S022. poor tolerance. Notes: headache. Adherence ~0.97. AE: no.
P00522,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no.
P00522,1,neutral,Visit 1: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.65. AE: no. CRP 23.1 mg/L; ALT 30 U/L.
P00522,2,neutral,Visit 2: Patient on RX-17A at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.91. AE: no.
P00522,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 18.8 mg/L; ALT 27 U/L.
P00522,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.76. AE: no.
P00523,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 4.8 mg/L; ALT 42 U/L.
P00523,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: joint pain. Adherence ~0.63. AE: no. CRP 4.1 mg/L; ALT 40 U/L.
P00523,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: yes.
P00523,3,negative,Visit 3: Patient on RX-17B at S002. symptoms persist. Notes: fatigue. Adherence ~0.70. AE: yes. CRP 3.7 mg/L; ALT 41 U/L.
P00523,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00524,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.92. AE: no. CRP 9.0 mg/L; ALT 40 U/L.
P00524,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.96. AE: yes.
P00524,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. CRP 7.5 mg/L; ALT 36 U/L.
P00524,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00524,4,positive,Visit 4: Patient on RX-17A at S012. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no.
P00524,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P00525,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: nausea. Adherence ~0.69. AE: yes.
P00525,1,negative,Visit 1: Patient on RX-17A at S002. increased discomfort. Notes: dizziness. Adherence ~0.65. AE: no.
P00525,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no.
P00525,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: no.
P00525,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: no.
P00526,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.90. AE: no.
P00526,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no. CRP 12.6 mg/L; ALT 35 U/L.
P00526,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.83. AE: no. CRP 9.2 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00526,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no.
P00526,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no. CRP 7.7 mg/L; ALT 40 U/L.
P00527,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.70. AE: no. CRP 4.1 mg/L; ALT 31 U/L.
P00527,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.3 mg/L; ALT 31 U/L.
P00527,2,negative,Visit 2: Patient on RX-17B at S016. poor tolerance. Notes: fatigue. Adherence ~0.72. AE: yes. CRP 2.9 mg/L; ALT 33 U/L.
P00527,3,negative,Visit 3: Patient on RX-17B at S016. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no.
P00528,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.66. AE: no. CRP 6.9 mg/L; ALT 49 U/L.
P00528,1,negative,Visit 1: Patient on RX-17B at S016. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: yes.
P00528,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.49. AE: no. CRP 5.8 mg/L; ALT 51 U/L.
P00528,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.38. AE: no. CRP 5.3 mg/L; ALT 50 U/L.
P00528,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.41. AE: no. CRP 4.3 mg/L; ALT 48 U/L.
P00528,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 4.1 mg/L; ALT 53 U/L.
P00529,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: headache. Adherence ~0.64. AE: yes.
P00529,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: no.
P00529,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: no.
P00529,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.73. AE: no. CRP 10.0 mg/L; ALT 43 U/L.
P00529,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.71. AE: no.
P00529,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P00530,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.84. AE: no.
P00530,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: insomnia. Adherence ~0.60. AE: no.
P00530,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no.
P00530,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no. CRP 6.1 mg/L; ALT 41 U/L.
P00530,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.80. AE: no.
P00530,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.48. AE: no.
P00531,0,neutral,Visit 0: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P00531,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.57. AE: no.
P00531,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.65. AE: no. CRP 2.1 mg/L; ALT 21 U/L.
P00532,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P00532,1,negative,Visit 1: Patient on RX-17B at S018. increased discomfort. Notes: dizziness. Adherence ~0.52. AE: no. CRP 12.8 mg/L; ALT 36 U/L.
P00532,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00532,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: fatigue. Adherence ~0.59. AE: no.
P00532,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: fatigue. Adherence ~0.68. AE: yes.
P00532,5,neutral,Visit 5: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.44. AE: no.
P00532,6,neutral,Visit 6: Patient on RX-17B at S018. continues regimen. Notes: nausea. Adherence ~0.81. AE: yes.
P00533,0,neutral,Visit 0: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.80. AE: no. CRP 3.3 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P00533,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no. CRP 3.6 mg/L; ALT 13 U/L. Plan: consider dose adjustment; counsel patient.
P00533,2,neutral,Visit 2: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: no.
P00533,3,negative,Visit 3: Patient on RX-17A at S002. reports worsening. Notes: headache. Adherence ~0.82. AE: no. CRP 2.8 mg/L; ALT 15 U/L.
P00533,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no.
P00534,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: fatigue. Adherence ~0.80. AE: no.
P00534,1,negative,Visit 1: Patient on RX-17A at S008. symptoms persist. Notes: headache. Adherence ~0.79. AE: no.
P00534,2,negative,Visit 2: Patient on RX-17A at S008. feels frustrated. Notes: dizziness. Adherence ~1.00. AE: no.
P00534,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P00534,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no. CRP 5.4 mg/L; ALT 49 U/L.
P00534,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no. CRP 5.2 mg/L; ALT 49 U/L.
P00535,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: dizziness. Adherence ~0.79. AE: no.
P00535,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.78. AE: no.
P00535,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00535,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no. CRP 9.3 mg/L; ALT 23 U/L.
P00535,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00536,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 8.3 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P00536,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: headache. Adherence ~0.80. AE: yes.
P00536,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.65. AE: no.
P00536,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00536,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no.
P00537,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 29.4 mg/L; ALT 21 U/L.
P00537,1,negative,Visit 1: Patient on RX-17A at S001. increased discomfort. Notes: fatigue. Adherence ~0.66. AE: yes.
P00537,2,negative,Visit 2: Patient on RX-17A at S001. increased discomfort. Notes: joint pain. Adherence ~0.55. AE: yes.
P00537,3,negative,Visit 3: Patient on RX-17A at S001. poor tolerance. Notes: nausea. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00537,4,negative,Visit 4: Patient on RX-17A at S001. increased discomfort. Notes: joint pain. Adherence ~0.70. AE: yes. CRP 19.7 mg/L; ALT 20 U/L.
P00537,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: nausea. Adherence ~0.69. AE: no. CRP 19.9 mg/L; ALT 19 U/L.
P00537,6,neutral,Visit 6: Patient on RX-17A at S001. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 15.2 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P00538,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: yes. CRP 9.6 mg/L; ALT 30 U/L.
P00538,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.85. AE: no.
P00538,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no.
P00538,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.89. AE: no.
P00538,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.77. AE: no.
P00539,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00539,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: nausea. Adherence ~0.93. AE: yes. CRP 5.5 mg/L; ALT 28 U/L.
P00539,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00539,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no.
P00539,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no. CRP 4.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00540,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: dizziness. Adherence ~0.94. AE: no.
P00540,1,neutral,Visit 1: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P00540,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no. CRP 8.6 mg/L; ALT 63 U/L.
P00540,3,negative,Visit 3: Patient on RX-17A at S002. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P00540,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no.
P00541,0,neutral,Visit 0: Patient on RX-17A at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00541,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: brain fog. Adherence ~0.94. AE: no.
P00541,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: no.
P00541,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 42 U/L.
P00541,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00542,0,negative,Visit 0: Patient on RX-17A at S021. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no. CRP 6.6 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00542,1,neutral,Visit 1: Patient on RX-17A at S021. follow-up as scheduled. Notes: headache. Adherence ~0.74. AE: no.
P00542,2,positive,Visit 2: Patient on RX-17A at S021. energy increasing. Notes: dizziness. Adherence ~0.86. AE: no.
P00542,3,neutral,Visit 3: Patient on RX-17A at S021. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no.
P00543,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: dizziness. Adherence ~0.65. AE: no.
P00543,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 8.0 mg/L; ALT 16 U/L.
P00543,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: no.
P00543,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00543,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.79. AE: no. CRP 5.8 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P00543,5,neutral,Visit 5: Patient on RX-17B at S016. continues regimen. Notes: nausea. Adherence ~0.75. AE: no. CRP 4.7 mg/L; ALT 20 U/L.
P00544,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: fatigue. Adherence ~0.91. AE: no.
P00544,1,negative,Visit 1: Patient on RX-17B at S008. increased discomfort. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 5.6 mg/L; ALT 16 U/L.
P00544,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: dizziness. Adherence ~0.82. AE: no. CRP 5.2 mg/L; ALT 15 U/L.
P00544,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: joint pain. Adherence ~0.86. AE: no.
P00544,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00544,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no.
P00544,6,positive,Visit 6: Patient on RX-17B at S008. reports improvement. Notes: dizziness. Adherence ~0.77. AE: no. CRP 2.9 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00544,7,neutral,Visit 7: Patient on RX-17B at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P00545,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00545,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no.
P00545,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P00545,3,positive,Visit 3: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00545,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00545,5,positive,Visit 5: Patient on RX-17B at S019. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no.
P00545,6,neutral,Visit 6: Patient on RX-17B at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: yes.
P00545,7,positive,Visit 7: Patient on RX-17B at S019. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 4.0 mg/L; ALT 22 U/L.
P00546,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00546,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: joint pain. Adherence ~0.85. AE: no.
P00546,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.92. AE: yes.
P00546,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.98. AE: yes. CRP 3.9 mg/L; ALT 20 U/L.
P00547,0,neutral,Visit 0: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.72. AE: no.
P00547,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: dizziness. Adherence ~0.82. AE: yes.
P00547,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no.
P00547,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00547,4,positive,Visit 4: Patient on RX-17B at S019. reports improvement. Notes: joint pain. Adherence ~0.78. AE: no. CRP 1.6 mg/L; ALT 34 U/L.
P00547,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: nausea. Adherence ~0.74. AE: no. CRP 1.4 mg/L; ALT 34 U/L.
P00548,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.96. AE: yes.
P00548,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P00548,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.97. AE: no. CRP 11.7 mg/L; ALT 31 U/L.
P00548,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00548,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 8.7 mg/L; ALT 31 U/L.
P00548,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: brain fog. Adherence ~0.85. AE: no. CRP 7.8 mg/L; ALT 28 U/L.
P00549,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.55. AE: no. CRP 5.7 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00549,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: nausea. Adherence ~0.73. AE: no. CRP 5.3 mg/L; ALT 32 U/L.
P00549,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00549,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: no.
P00549,4,negative,Visit 4: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.66. AE: no.
P00549,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.76. AE: no.
P00549,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no.
P00549,7,neutral,Visit 7: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no.
P00550,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.94. AE: no. CRP 7.5 mg/L; ALT 20 U/L.
P00550,1,negative,Visit 1: Patient on RX-17A at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.6 mg/L; ALT 21 U/L.
P00550,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: brain fog. Adherence ~0.94. AE: no.
P00550,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.94. AE: no. CRP 6.7 mg/L; ALT 22 U/L.
P00551,0,neutral,Visit 0: Patient on RX-17A at S011. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00551,1,neutral,Visit 1: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.69. AE: no. CRP 4.7 mg/L; ALT 31 U/L.
P00551,2,neutral,Visit 2: Patient on RX-17A at S011. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no.
P00551,3,neutral,Visit 3: Patient on RX-17A at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P00551,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 36 U/L.
P00551,5,neutral,Visit 5: Patient on RX-17A at S011. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no.
P00552,0,negative,Visit 0: Patient on RX-17A at S020. increased discomfort. Notes: headache. Adherence ~0.75. AE: no.
P00552,1,negative,Visit 1: Patient on RX-17A at S020. increased discomfort. Notes: dizziness. Adherence ~0.93. AE: no.
P00552,2,neutral,Visit 2: Patient on RX-17A at S020. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no. CRP 4.4 mg/L; ALT 19 U/L.
P00552,3,neutral,Visit 3: Patient on RX-17A at S020. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: yes.
P00552,4,neutral,Visit 4: Patient on RX-17A at S020. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00552,5,positive,Visit 5: Patient on RX-17A at S020. energy increasing. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00552,6,neutral,Visit 6: Patient on RX-17A at S020. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P00553,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.47. AE: yes.
P00553,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00553,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.52. AE: no.
P00553,3,negative,Visit 3: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.68. AE: no. CRP 3.6 mg/L; ALT 29 U/L.
P00553,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no. CRP 3.2 mg/L; ALT 31 U/L.
P00553,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.61. AE: no.
P00554,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.61. AE: yes. CRP 12.8 mg/L; ALT 42 U/L.
P00554,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: no. CRP 11.3 mg/L; ALT 44 U/L.
P00554,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.74. AE: no.
P00554,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.73. AE: yes.
P00554,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P00555,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00555,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 12.9 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00555,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.75. AE: no. CRP 12.0 mg/L; ALT 29 U/L.
P00555,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no.
P00555,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.97. AE: no.
P00555,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.94. AE: yes. CRP 9.1 mg/L; ALT 28 U/L.
P00556,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.58. AE: no.
P00556,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.80. AE: no. CRP 7.0 mg/L; ALT 37 U/L.
P00556,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.69. AE: no.
P00556,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.78. AE: no.
P00556,4,positive,Visit 4: Patient on RX-17B at S017. tolerating medication well. Notes: nausea. Adherence ~0.79. AE: no.
P00556,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: yes. CRP 4.9 mg/L; ALT 42 U/L.
P00556,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.76. AE: no. CRP 3.4 mg/L; ALT 38 U/L.
P00557,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: fatigue. Adherence ~0.28. AE: no.
P00557,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 4.4 mg/L; ALT 17 U/L.
P00557,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.48. AE: no.
P00557,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.55. AE: no.
P00557,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.58. AE: no.
P00557,5,neutral,Visit 5: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.42. AE: no.
P00557,6,neutral,Visit 6: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.45. AE: no. CRP 3.0 mg/L; ALT 15 U/L.
P00558,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~1.00. AE: yes.
P00558,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 2.6 mg/L; ALT 15 U/L.
P00558,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.97. AE: yes. CRP 2.4 mg/L; ALT 16 U/L.
P00558,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.85. AE: no.
P00558,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.82. AE: no. CRP 2.2 mg/L; ALT 15 U/L.
P00558,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no.
P00558,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no. CRP 1.7 mg/L; ALT 15 U/L.
P00559,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.63. AE: no.
P00559,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.61. AE: no.
P00559,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00559,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.51. AE: yes.
P00559,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00559,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00559,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.59. AE: no.
P00560,0,negative,Visit 0: Patient on RX-17B at S013. reports worsening. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00560,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.91. AE: no.
P00560,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00560,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.92. AE: no.
P00560,4,negative,Visit 4: Patient on RX-17B at S013. feels frustrated. Notes: brain fog. Adherence ~0.90. AE: no. CRP 3.1 mg/L; ALT 44 U/L.
P00561,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.88. AE: no.
P00561,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00561,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.68. AE: no.
P00561,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.0 mg/L; ALT 28 U/L.
P00561,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P00562,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00562,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P00562,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P00562,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.85. AE: no.
P00562,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P00562,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 4.8 mg/L; ALT 63 U/L.
P00563,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.78. AE: yes. CRP 6.1 mg/L; ALT 19 U/L.
P00563,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: insomnia. Adherence ~0.66. AE: no. CRP 7.1 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P00563,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no.
P00563,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: insomnia. Adherence ~0.78. AE: no.
P00563,4,positive,Visit 4: Patient on RX-17A at S022. tolerating medication well. Notes: dizziness. Adherence ~0.97. AE: no.
P00564,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.48. AE: yes. CRP 2.9 mg/L; ALT 23 U/L.
P00564,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.82. AE: no. CRP 2.8 mg/L; ALT 23 U/L.
P00564,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P00564,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.73. AE: yes.
P00564,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00565,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.65. AE: no. CRP 3.2 mg/L; ALT 27 U/L.
P00565,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00565,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no.
P00565,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.74. AE: no. CRP 2.6 mg/L; ALT 30 U/L.
P00565,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.63. AE: no.
P00565,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: brain fog. Adherence ~0.94. AE: no.
P00565,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P00565,7,neutral,Visit 7: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: yes.
P00566,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: headache. Adherence ~0.86. AE: no. CRP 8.9 mg/L; ALT 36 U/L.
P00566,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. CRP 8.0 mg/L; ALT 34 U/L.
P00566,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.94. AE: no.
P00567,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00567,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.92. AE: no.
P00567,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 4.7 mg/L; ALT 26 U/L.
P00567,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no.
P00567,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P00567,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: dizziness. Adherence ~0.84. AE: no. CRP 3.2 mg/L; ALT 26 U/L.
P00568,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: dizziness. Adherence ~0.70. AE: yes. CRP 8.5 mg/L; ALT 22 U/L.
P00568,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.69. AE: no. CRP 9.6 mg/L; ALT 20 U/L.
P00568,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no. CRP 8.6 mg/L; ALT 22 U/L.
P00568,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.77. AE: no.
P00568,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.84. AE: yes.
P00568,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no. CRP 6.3 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P00568,6,positive,Visit 6: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~0.80. AE: no.
P00569,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.87. AE: no. CRP 7.8 mg/L; ALT 39 U/L.
P00569,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.70. AE: no. CRP 6.7 mg/L; ALT 37 U/L.
P00569,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P00569,3,negative,Visit 3: Patient on RX-17B at S004. feels frustrated. Notes: headache. Adherence ~1.00. AE: no. CRP 7.1 mg/L; ALT 37 U/L.
P00569,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no. CRP 5.0 mg/L; ALT 42 U/L.
P00570,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.52. AE: no. CRP 14.3 mg/L; ALT 29 U/L.
P00570,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.38. AE: no.
P00570,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.25. AE: no. CRP 11.9 mg/L; ALT 32 U/L.
P00570,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.43. AE: no.
P00570,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.37. AE: no. CRP 8.8 mg/L; ALT 32 U/L.
P00570,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.59. AE: no. CRP 7.6 mg/L; ALT 33 U/L.
P00570,6,neutral,Visit 6: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.49. AE: no. CRP 6.5 mg/L; ALT 36 U/L.
P00570,7,neutral,Visit 7: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P00571,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P00571,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P00571,2,negative,Visit 2: Patient on RX-17A at S004. symptoms persist. Notes: dizziness. Adherence ~0.91. AE: no.
P00571,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P00571,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.88. AE: no. CRP 3.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00571,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00572,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~1.00. AE: yes.
P00572,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: headache. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00572,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: joint pain. Adherence ~0.90. AE: no.
P00572,3,negative,Visit 3: Patient on RX-17A at S005. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no. CRP 6.7 mg/L; ALT 38 U/L.
P00572,4,positive,Visit 4: Patient on RX-17A at S005. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no.
P00573,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P00573,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no.
P00573,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: dizziness. Adherence ~0.94. AE: no.
P00573,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no. CRP 8.2 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00573,4,negative,Visit 4: Patient on RX-17A at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. CRP 7.0 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00573,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no.
P00573,6,positive,Visit 6: Patient on RX-17A at S002. tolerating medication well. Notes: nausea. Adherence ~0.94. AE: no. CRP 6.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00573,7,positive,Visit 7: Patient on RX-17A at S002. feels better overall. Notes: headache. Adherence ~1.00. AE: no.
P00574,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P00574,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.79. AE: yes.
P00574,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.98. AE: no. CRP 5.1 mg/L; ALT 28 U/L.
P00574,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 4.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00574,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no.
P00574,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P00574,6,positive,Visit 6: Patient on RX-17B at S014. symptoms improving. Notes: insomnia. Adherence ~1.00. AE: no.
P00575,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no. CRP 12.9 mg/L; ALT 29 U/L.
P00575,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.95. AE: no.
P00575,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P00575,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P00575,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: yes.
P00575,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 28 U/L.
P00576,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.95. AE: yes.
P00576,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.82. AE: no.
P00576,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no.
P00576,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~0.71. AE: yes. CRP 2.2 mg/L; ALT 23 U/L.
P00576,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.91. AE: no.
P00577,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.52. AE: no.
P00577,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 4.8 mg/L; ALT 22 U/L.
P00577,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 4.1 mg/L; ALT 22 U/L.
P00577,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.50. AE: no.
P00577,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. CRP 3.4 mg/L; ALT 26 U/L.
P00577,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no.
P00578,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.74. AE: no.
P00578,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.65. AE: no.
P00578,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.80. AE: no. CRP 2.8 mg/L; ALT 27 U/L.
P00578,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.64. AE: no.
P00578,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: nausea. Adherence ~0.81. AE: no. CRP 2.2 mg/L; ALT 26 U/L.
P00579,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.64. AE: no.
P00579,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: joint pain. Adherence ~0.43. AE: yes. CRP 4.4 mg/L; ALT 32 U/L.
P00579,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.51. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P00579,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.47. AE: no.
P00579,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.49. AE: no. CRP 3.3 mg/L; ALT 34 U/L.
P00579,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.40. AE: no. CRP 2.9 mg/L; ALT 33 U/L.
P00580,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.67. AE: no. CRP 7.6 mg/L; ALT 14 U/L.
P00580,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: headache. Adherence ~0.98. AE: no. CRP 5.8 mg/L; ALT 15 U/L.
P00580,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.86. AE: no.
P00580,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: no.
P00580,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.76. AE: no.
P00580,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00581,0,neutral,Visit 0: Patient on RX-17A at S011. stable symptoms. Notes: brain fog. Adherence ~0.37. AE: no.
P00581,1,neutral,Visit 1: Patient on RX-17A at S011. no major change. Notes: brain fog. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00581,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.39. AE: no.
P00581,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.54. AE: yes. CRP 9.4 mg/L; ALT 47 U/L.
P00581,4,negative,Visit 4: Patient on RX-17A at S011. poor tolerance. Notes: joint pain. Adherence ~0.39. AE: no.
P00581,5,neutral,Visit 5: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.43. AE: no. Plan: consider dose adjustment; counsel patient.
P00582,0,neutral,Visit 0: Patient on RX-17B at S021. no major change. Notes: dizziness. Adherence ~0.80. AE: no.
P00582,1,neutral,Visit 1: Patient on RX-17B at S021. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no. CRP 7.0 mg/L; ALT 32 U/L.
P00582,2,neutral,Visit 2: Patient on RX-17B at S021. no major change. Notes: joint pain. Adherence ~0.87. AE: yes. CRP 5.6 mg/L; ALT 30 U/L.
P00582,3,neutral,Visit 3: Patient on RX-17B at S021. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: yes. CRP 5.8 mg/L; ALT 33 U/L.
P00583,0,negative,Visit 0: Patient on RX-17B at S008. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P00583,1,negative,Visit 1: Patient on RX-17B at S008. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 21 U/L.
P00583,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00583,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P00583,4,neutral,Visit 4: Patient on RX-17B at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: yes.
P00584,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.73. AE: no.
P00584,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P00584,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.83. AE: no. CRP 2.7 mg/L; ALT 57 U/L.
P00584,3,negative,Visit 3: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.88. AE: yes. CRP 2.2 mg/L; ALT 61 U/L.
P00584,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00584,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P00584,6,positive,Visit 6: Patient on RX-17B at S012. symptoms improving. Notes: headache. Adherence ~0.83. AE: no.
P00585,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.96. AE: no. CRP 3.6 mg/L; ALT 29 U/L.
P00585,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 32 U/L.
P00585,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no. CRP 3.4 mg/L; ALT 32 U/L.
P00585,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.85. AE: yes.
P00585,4,positive,Visit 4: Patient on RX-17A at S022. feels better overall. Notes: insomnia. Adherence ~0.82. AE: no.
P00585,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.77. AE: no.
P00585,6,positive,Visit 6: Patient on RX-17A at S022. tolerating medication well. Notes: dizziness. Adherence ~0.88. AE: no. CRP 2.2 mg/L; ALT 32 U/L.
P00586,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00586,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 8.2 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00586,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00587,0,neutral,Visit 0: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.94. AE: no.
P00587,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.88. AE: no.
P00587,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.99. AE: no.
P00587,3,positive,Visit 3: Patient on RX-17B at S017. tolerating medication well. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00587,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.93. AE: no. CRP 9.4 mg/L; ALT 49 U/L.
P00588,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 6.3 mg/L; ALT 52 U/L.
P00588,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.72. AE: yes.
P00588,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.76. AE: no. CRP 5.1 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P00588,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.51. AE: no.
P00588,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 5.0 mg/L; ALT 50 U/L.
P00589,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no.
P00589,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.72. AE: no. CRP 13.6 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00589,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.49. AE: no. CRP 13.5 mg/L; ALT 23 U/L.
P00589,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P00589,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.52. AE: no.
P00589,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.62. AE: yes.
P00589,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00590,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.80. AE: no. CRP 4.4 mg/L; ALT 27 U/L.
P00590,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.84. AE: no.
P00590,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: no. CRP 3.2 mg/L; ALT 30 U/L.
P00590,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 3.2 mg/L; ALT 27 U/L.
P00590,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.98. AE: no.
P00590,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: yes.
P00590,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: yes.
P00590,7,positive,Visit 7: Patient on RX-17B at S012. symptoms improving. Notes: abdominal discomfort. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00591,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: joint pain. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P00591,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.45. AE: no. CRP 6.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00591,2,neutral,Visit 2: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.58. AE: no.
P00591,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: brain fog. Adherence ~0.45. AE: no.
P00591,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.48. AE: no. CRP 4.2 mg/L; ALT 25 U/L.
P00591,5,negative,Visit 5: Patient on RX-17A at S008. symptoms persist. Notes: headache. Adherence ~0.48. AE: no.
P00591,6,neutral,Visit 6: Patient on RX-17A at S008. no major change. Notes: nausea. Adherence ~0.51. AE: no.
P00591,7,neutral,Visit 7: Patient on RX-17A at S008. stable symptoms. Notes: nausea. Adherence ~0.55. AE: no. CRP 3.5 mg/L; ALT 26 U/L.
P00592,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.91. AE: no. CRP 6.6 mg/L; ALT 16 U/L.
P00592,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.88. AE: no.
P00592,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00592,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.70. AE: yes.
P00592,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.82. AE: yes.
P00592,5,negative,Visit 5: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.75. AE: no. CRP 4.2 mg/L; ALT 16 U/L.
P00592,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P00592,7,neutral,Visit 7: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no. CRP 3.2 mg/L; ALT 13 U/L.
P00593,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no.
P00593,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00593,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.85. AE: yes.
P00593,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.90. AE: no. CRP 11.4 mg/L; ALT 33 U/L.
P00594,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: dizziness. Adherence ~0.46. AE: no. CRP 7.1 mg/L; ALT 44 U/L.
P00594,1,neutral,Visit 1: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.50. AE: no. CRP 7.7 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P00594,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00594,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.49. AE: no. CRP 6.3 mg/L; ALT 37 U/L.
P00594,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.59. AE: yes.
P00594,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.66. AE: yes.
P00594,6,neutral,Visit 6: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P00594,7,neutral,Visit 7: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no.
P00595,0,negative,Visit 0: Patient on RX-17B at S011. feels frustrated. Notes: brain fog. Adherence ~0.89. AE: yes.
P00595,1,negative,Visit 1: Patient on RX-17B at S011. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P00595,2,neutral,Visit 2: Patient on RX-17B at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: yes.
P00595,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 2.2 mg/L; ALT 41 U/L.
P00595,4,neutral,Visit 4: Patient on RX-17B at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.91. AE: yes.
P00595,5,positive,Visit 5: Patient on RX-17B at S011. energy increasing. Notes: fatigue. Adherence ~0.96. AE: no.
P00596,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.68. AE: no. CRP 13.6 mg/L; ALT 29 U/L.
P00596,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.64. AE: no. CRP 11.5 mg/L; ALT 30 U/L.
P00596,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00596,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.68. AE: no.
P00596,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.64. AE: no.
P00596,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.43. AE: yes.
P00597,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.91. AE: no.
P00597,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.92. AE: no. CRP 19.5 mg/L; ALT 40 U/L.
P00597,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.60. AE: no.
P00597,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. CRP 15.1 mg/L; ALT 46 U/L.
P00597,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no.
P00598,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: yes. CRP 6.1 mg/L; ALT 21 U/L.
P00598,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 7.2 mg/L; ALT 22 U/L.
P00598,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.90. AE: yes. CRP 5.3 mg/L; ALT 23 U/L.
P00598,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.81. AE: no.
P00598,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no. CRP 4.3 mg/L; ALT 20 U/L.
P00598,5,positive,Visit 5: Patient on RX-17B at S017. reports improvement. Notes: nausea. Adherence ~0.80. AE: no.
P00598,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.93. AE: no.
P00599,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no. CRP 4.5 mg/L; ALT 53 U/L. Plan: consider dose adjustment; counsel patient.
P00599,1,negative,Visit 1: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.34. AE: no. CRP 4.7 mg/L; ALT 63 U/L.
P00599,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: headache. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00599,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P00599,4,negative,Visit 4: Patient on RX-17A at S013. increased discomfort. Notes: dizziness. Adherence ~0.52. AE: yes.
P00600,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00600,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.83. AE: no. CRP 11.0 mg/L; ALT 24 U/L.
P00600,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no.
P00600,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.55. AE: no.
P00600,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 8.1 mg/L; ALT 29 U/L.
P00600,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.78. AE: no.
P00601,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no.
P00601,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no. CRP 21.7 mg/L; ALT 24 U/L.
P00601,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.79. AE: no. CRP 18.3 mg/L; ALT 23 U/L.
P00601,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.83. AE: no.
P00601,4,positive,Visit 4: Patient on RX-17A at S022. energy increasing. Notes: fatigue. Adherence ~0.79. AE: no. CRP 16.8 mg/L; ALT 24 U/L.
P00601,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.77. AE: yes.
P00602,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: headache. Adherence ~0.92. AE: yes.
P00602,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: fatigue. Adherence ~0.68. AE: no. CRP 11.1 mg/L; ALT 25 U/L.
P00602,2,negative,Visit 2: Patient on RX-17A at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 10.1 mg/L; ALT 27 U/L.
P00602,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no. CRP 10.2 mg/L; ALT 24 U/L.
P00602,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P00603,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 2.9 mg/L; ALT 21 U/L.
P00603,1,negative,Visit 1: Patient on RX-17A at S018. reports worsening. Notes: fatigue. Adherence ~0.88. AE: yes.
P00603,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.80. AE: no.
P00603,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.84. AE: no.
P00603,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: yes. CRP 2.2 mg/L; ALT 28 U/L.
P00603,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P00604,0,neutral,Visit 0: Patient on RX-17A at S021. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no.
P00604,1,neutral,Visit 1: Patient on RX-17A at S021. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P00604,2,neutral,Visit 2: Patient on RX-17A at S021. no major change. Notes: fatigue. Adherence ~0.89. AE: no. CRP 10.5 mg/L; ALT 26 U/L.
P00604,3,neutral,Visit 3: Patient on RX-17A at S021. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 10.0 mg/L; ALT 29 U/L.
P00604,4,neutral,Visit 4: Patient on RX-17A at S021. reviewed dosing instructions. Notes: brain fog. Adherence ~0.92. AE: no. CRP 9.8 mg/L; ALT 29 U/L.
P00604,5,neutral,Visit 5: Patient on RX-17A at S021. follow-up as scheduled. Notes: brain fog. Adherence ~0.96. AE: no. CRP 7.1 mg/L; ALT 29 U/L.
P00604,6,neutral,Visit 6: Patient on RX-17A at S021. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no. CRP 6.9 mg/L; ALT 28 U/L.
P00604,7,neutral,Visit 7: Patient on RX-17A at S021. stable symptoms. Notes: joint pain. Adherence ~0.71. AE: no.
P00605,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00605,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 7.7 mg/L; ALT 27 U/L.
P00605,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00605,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no. CRP 7.2 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00605,4,positive,Visit 4: Patient on RX-17A at S017. reports improvement. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P00605,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.84. AE: no. CRP 5.9 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00605,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no.
P00605,7,positive,Visit 7: Patient on RX-17A at S017. reports improvement. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00606,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: joint pain. Adherence ~0.64. AE: no.
P00606,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.82. AE: no.
P00606,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.53. AE: yes. CRP 3.5 mg/L; ALT 35 U/L.
P00606,3,negative,Visit 3: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.79. AE: yes.
P00606,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.74. AE: no. CRP 3.1 mg/L; ALT 37 U/L.
P00606,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no. CRP 3.1 mg/L; ALT 33 U/L.
P00607,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00607,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.63. AE: no.
P00607,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.71. AE: no.
P00607,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 9.4 mg/L; ALT 24 U/L.
P00607,4,negative,Visit 4: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.72. AE: yes.
P00607,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no. CRP 7.5 mg/L; ALT 25 U/L.
P00608,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.75. AE: no. CRP 9.1 mg/L; ALT 34 U/L.
P00608,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: no.
P00608,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: fatigue. Adherence ~0.78. AE: yes.
P00608,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.78. AE: no. CRP 7.1 mg/L; ALT 32 U/L.
P00608,4,negative,Visit 4: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.79. AE: yes. CRP 6.9 mg/L; ALT 34 U/L.
P00608,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.80. AE: no.
P00608,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P00609,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.96. AE: no. CRP 15.0 mg/L; ALT 20 U/L.
P00609,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.76. AE: yes.
P00609,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.85. AE: no. CRP 14.8 mg/L; ALT 19 U/L.
P00609,3,negative,Visit 3: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.94. AE: yes.
P00609,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P00610,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no.
P00610,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no.
P00610,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.72. AE: no.
P00610,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.67. AE: no. CRP 2.7 mg/L; ALT 42 U/L.
P00610,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: joint pain. Adherence ~1.00. AE: no.
P00610,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no.
P00610,6,positive,Visit 6: Patient on RX-17B at S022. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no. CRP 2.2 mg/L; ALT 40 U/L.
P00610,7,neutral,Visit 7: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.81. AE: no. CRP 1.7 mg/L; ALT 44 U/L.
P00611,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.82. AE: no.
P00611,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.94. AE: no.
P00611,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no. CRP 6.9 mg/L; ALT 42 U/L.
P00611,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.97. AE: no. CRP 7.2 mg/L; ALT 37 U/L.
P00611,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no.
P00612,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: joint pain. Adherence ~0.84. AE: no.
P00612,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.89. AE: yes.
P00612,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: no.
P00612,3,negative,Visit 3: Patient on RX-17A at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P00612,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: fatigue. Adherence ~0.87. AE: no.
P00612,5,positive,Visit 5: Patient on RX-17A at S013. symptoms improving. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00612,6,positive,Visit 6: Patient on RX-17A at S013. reports improvement. Notes: dizziness. Adherence ~0.83. AE: no. CRP 2.3 mg/L; ALT 28 U/L.
P00613,0,neutral,Visit 0: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.76. AE: no. CRP 9.1 mg/L; ALT 26 U/L.
P00613,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: yes. CRP 7.9 mg/L; ALT 27 U/L.
P00613,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~0.97. AE: no.
P00613,3,negative,Visit 3: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no. CRP 6.2 mg/L; ALT 27 U/L.
P00613,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.77. AE: no.
P00613,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: yes. CRP 4.7 mg/L; ALT 28 U/L.
P00613,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: headache. Adherence ~0.84. AE: no.
P00613,7,neutral,Visit 7: Patient on RX-17B at S002. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: yes.
P00614,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 16.8 mg/L; ALT 32 U/L.
P00614,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.83. AE: no. CRP 16.4 mg/L; ALT 30 U/L.
P00614,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.89. AE: no. CRP 14.3 mg/L; ALT 36 U/L.
P00614,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.98. AE: no.
P00614,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: yes. CRP 11.8 mg/L; ALT 39 U/L.
P00615,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.80. AE: no.
P00615,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: yes. CRP 2.9 mg/L; ALT 25 U/L.
P00615,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.94. AE: no. CRP 3.3 mg/L; ALT 23 U/L.
P00615,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.86. AE: no.
P00615,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P00615,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: nausea. Adherence ~0.99. AE: no.
P00616,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00616,1,negative,Visit 1: Patient on RX-17B at S002. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: yes.
P00616,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: nausea. Adherence ~0.88. AE: yes. CRP 2.9 mg/L; ALT 34 U/L.
P00616,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no.
P00616,4,positive,Visit 4: Patient on RX-17B at S002. symptoms improving. Notes: insomnia. Adherence ~0.88. AE: no.
P00616,5,positive,Visit 5: Patient on RX-17B at S002. feels better overall. Notes: insomnia. Adherence ~0.82. AE: no.
P00616,6,neutral,Visit 6: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.65. AE: no. CRP 1.9 mg/L; ALT 31 U/L.
P00616,7,positive,Visit 7: Patient on RX-17B at S002. symptoms improving. Notes: dizziness. Adherence ~0.98. AE: no.
P00617,0,negative,Visit 0: Patient on RX-17B at S008. symptoms persist. Notes: dizziness. Adherence ~0.72. AE: no.
P00617,1,negative,Visit 1: Patient on RX-17B at S008. poor tolerance. Notes: joint pain. Adherence ~0.76. AE: yes.
P00617,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.72. AE: no.
P00618,0,negative,Visit 0: Patient on RX-17B at S003. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 72 U/L.
P00618,1,negative,Visit 1: Patient on RX-17B at S003. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: no.
P00618,2,negative,Visit 2: Patient on RX-17B at S003. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no.
P00618,3,neutral,Visit 3: Patient on RX-17B at S003. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00618,4,neutral,Visit 4: Patient on RX-17B at S003. stable symptoms. Notes: headache. Adherence ~0.89. AE: no.
P00619,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no.
P00619,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no.
P00619,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: yes. CRP 12.2 mg/L; ALT 20 U/L.
P00619,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.68. AE: no. CRP 10.8 mg/L; ALT 20 U/L.
P00619,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 8.8 mg/L; ALT 22 U/L.
P00619,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00620,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.59. AE: no.
P00620,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.67. AE: no.
P00620,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no.
P00621,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00621,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.94. AE: no.
P00621,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.86. AE: yes.
P00621,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P00621,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 24 U/L.
P00621,5,positive,Visit 5: Patient on RX-17A at S012. energy increasing. Notes: nausea. Adherence ~0.85. AE: no.
P00621,6,positive,Visit 6: Patient on RX-17A at S012. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.2 mg/L; ALT 26 U/L.
P00622,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.98. AE: no. CRP 10.3 mg/L; ALT 16 U/L.
P00622,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00622,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: fatigue. Adherence ~0.80. AE: no. CRP 10.1 mg/L; ALT 18 U/L.
P00622,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.87. AE: no. CRP 8.8 mg/L; ALT 15 U/L.
P00623,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.99. AE: yes. CRP 7.8 mg/L; ALT 28 U/L.
P00623,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: no.
P00623,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.95. AE: no.
P00623,3,positive,Visit 3: Patient on RX-17B at S004. energy increasing. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00623,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.96. AE: no.
P00623,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P00623,6,neutral,Visit 6: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~1.00. AE: yes.
P00623,7,neutral,Visit 7: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.81. AE: yes.
P00624,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.0 mg/L; ALT 20 U/L.
P00624,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P00624,2,positive,Visit 2: Patient on RX-17B at S012. feels better overall. Notes: dizziness. Adherence ~0.90. AE: no.
P00624,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: no.
P00624,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.88. AE: yes.
P00624,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.87. AE: yes.
P00624,6,positive,Visit 6: Patient on RX-17B at S012. symptoms improving. Notes: joint pain. Adherence ~0.89. AE: no.
P00625,0,neutral,Visit 0: Patient on RX-17B at S003. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P00625,1,negative,Visit 1: Patient on RX-17B at S003. feels frustrated. Notes: dizziness. Adherence ~0.82. AE: yes.
P00625,2,neutral,Visit 2: Patient on RX-17B at S003. follow-up as scheduled. Notes: joint pain. Adherence ~0.55. AE: no.
P00625,3,negative,Visit 3: Patient on RX-17B at S003. symptoms persist. Notes: brain fog. Adherence ~0.71. AE: yes.
P00625,4,neutral,Visit 4: Patient on RX-17B at S003. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P00625,5,positive,Visit 5: Patient on RX-17B at S003. symptoms improving. Notes: brain fog. Adherence ~0.86. AE: no.
P00625,6,neutral,Visit 6: Patient on RX-17B at S003. continues regimen. Notes: dizziness. Adherence ~0.56. AE: no.
P00626,0,neutral,Visit 0: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P00626,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 22 U/L.
P00626,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no.
P00626,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no. CRP 6.0 mg/L; ALT 22 U/L.
P00626,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.92. AE: no.
P00627,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: fatigue. Adherence ~0.70. AE: yes.
P00627,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.88. AE: yes.
P00627,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: yes.
P00627,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P00627,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.60. AE: yes. Plan: consider dose adjustment; counsel patient.
P00627,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~0.53. AE: no.
P00628,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.42. AE: no. CRP 9.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00628,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.49. AE: no.
P00628,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.67. AE: no.
P00628,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.49. AE: no. CRP 6.3 mg/L; ALT 32 U/L.
P00628,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.63. AE: no. CRP 5.7 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00629,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no. CRP 9.6 mg/L; ALT 40 U/L.
P00629,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.66. AE: no.
P00629,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.99. AE: no.
P00629,3,negative,Visit 3: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.73. AE: yes.
P00629,4,negative,Visit 4: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.77. AE: yes.
P00630,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00630,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.96. AE: yes. CRP 11.3 mg/L; ALT 35 U/L.
P00630,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.75. AE: no. CRP 8.2 mg/L; ALT 32 U/L.
P00630,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: no. CRP 9.6 mg/L; ALT 32 U/L.
P00630,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 8.6 mg/L; ALT 32 U/L.
P00630,5,positive,Visit 5: Patient on RX-17A at S013. reports improvement. Notes: headache. Adherence ~0.86. AE: no.
P00631,0,negative,Visit 0: Patient on RX-17B at S001. poor tolerance. Notes: joint pain. Adherence ~0.52. AE: no.
P00631,1,neutral,Visit 1: Patient on RX-17B at S001. follow-up as scheduled. Notes: fatigue. Adherence ~0.64. AE: no. CRP 10.6 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00631,2,neutral,Visit 2: Patient on RX-17B at S001. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no. CRP 10.3 mg/L; ALT 46 U/L.
P00631,3,neutral,Visit 3: Patient on RX-17B at S001. follow-up as scheduled. Notes: headache. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00631,4,neutral,Visit 4: Patient on RX-17B at S001. continues regimen. Notes: insomnia. Adherence ~0.61. AE: no.
P00631,5,neutral,Visit 5: Patient on RX-17B at S001. stable symptoms. Notes: nausea. Adherence ~0.72. AE: no.
P00631,6,neutral,Visit 6: Patient on RX-17B at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~0.67. AE: no. CRP 5.8 mg/L; ALT 50 U/L.
P00631,7,neutral,Visit 7: Patient on RX-17B at S001. stable symptoms. Notes: nausea. Adherence ~0.55. AE: no. CRP 4.5 mg/L; ALT 47 U/L.
P00632,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.95. AE: yes.
P00632,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: yes.
P00632,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 28 U/L.
P00632,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: yes.
P00632,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.92. AE: no.
P00633,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: dizziness. Adherence ~0.71. AE: no.
P00633,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.35. AE: no. CRP 2.3 mg/L; ALT 55 U/L.
P00633,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.46. AE: no.
P00634,0,negative,Visit 0: Patient on RX-17A at S001. reports worsening. Notes: fatigue. Adherence ~0.38. AE: no.
P00634,1,negative,Visit 1: Patient on RX-17A at S001. poor tolerance. Notes: dizziness. Adherence ~0.36. AE: yes. CRP 6.8 mg/L; ALT 39 U/L.
P00634,2,neutral,Visit 2: Patient on RX-17A at S001. stable symptoms. Notes: nausea. Adherence ~0.52. AE: no. CRP 8.8 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00634,3,negative,Visit 3: Patient on RX-17A at S001. reports worsening. Notes: headache. Adherence ~0.35. AE: no.
P00634,4,neutral,Visit 4: Patient on RX-17A at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: no.
P00634,5,neutral,Visit 5: Patient on RX-17A at S001. stable symptoms. Notes: insomnia. Adherence ~0.35. AE: no. CRP 7.0 mg/L; ALT 33 U/L.
P00634,6,neutral,Visit 6: Patient on RX-17A at S001. reviewed dosing instructions. Notes: insomnia. Adherence ~0.46. AE: yes.
P00634,7,neutral,Visit 7: Patient on RX-17A at S001. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P00635,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.88. AE: no.
P00635,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 2.4 mg/L; ALT 20 U/L.
P00635,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.59. AE: no. CRP 2.7 mg/L; ALT 24 U/L.
P00635,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.86. AE: no.
P00635,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.74. AE: yes.
P00635,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P00636,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.81. AE: no.
P00636,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no. CRP 13.3 mg/L; ALT 35 U/L.
P00636,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.78. AE: yes. CRP 11.7 mg/L; ALT 44 U/L.
P00636,3,positive,Visit 3: Patient on RX-17A at S014. reports improvement. Notes: headache. Adherence ~0.80. AE: no.
P00636,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: yes. CRP 11.2 mg/L; ALT 41 U/L.
P00636,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.81. AE: no. CRP 9.8 mg/L; ALT 37 U/L.
P00636,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 9.1 mg/L; ALT 38 U/L.
P00637,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P00637,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00637,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P00637,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.90. AE: yes.
P00637,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.84. AE: no.
P00637,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.88. AE: no.
P00637,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00638,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: brain fog. Adherence ~0.64. AE: no.
P00638,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.82. AE: no. CRP 10.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00638,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no.
P00638,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no.
P00638,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00638,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00639,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.71. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P00639,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.98. AE: no.
P00639,2,negative,Visit 2: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.89. AE: no. CRP 4.2 mg/L; ALT 30 U/L.
P00639,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.96. AE: no.
P00639,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00639,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P00639,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.8 mg/L; ALT 32 U/L.
P00640,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: brain fog. Adherence ~0.35. AE: no. CRP 5.5 mg/L; ALT 45 U/L.
P00640,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: fatigue. Adherence ~0.29. AE: no. Plan: consider dose adjustment; counsel patient.
P00640,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.18. AE: no. CRP 4.7 mg/L; ALT 42 U/L.
P00640,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.05. AE: no.
P00641,0,negative,Visit 0: Patient on RX-17A at S009. poor tolerance. Notes: insomnia. Adherence ~0.90. AE: no.
P00641,1,neutral,Visit 1: Patient on RX-17A at S009. continues regimen. Notes: dizziness. Adherence ~0.83. AE: yes. CRP 4.4 mg/L; ALT 16 U/L.
P00641,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no. CRP 4.0 mg/L; ALT 15 U/L.
P00641,3,neutral,Visit 3: Patient on RX-17A at S009. no major change. Notes: joint pain. Adherence ~0.81. AE: no.
P00641,4,neutral,Visit 4: Patient on RX-17A at S009. stable symptoms. Notes: dizziness. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00641,5,neutral,Visit 5: Patient on RX-17A at S009. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 3.1 mg/L; ALT 14 U/L.
P00641,6,neutral,Visit 6: Patient on RX-17A at S009. no major change. Notes: brain fog. Adherence ~0.73. AE: no. CRP 3.1 mg/L; ALT 14 U/L.
P00642,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 10.9 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00642,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.70. AE: no. CRP 11.9 mg/L; ALT 27 U/L.
P00642,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.88. AE: no. CRP 7.9 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00642,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P00642,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00643,0,neutral,Visit 0: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00643,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no.
P00643,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.6 mg/L; ALT 42 U/L.
P00643,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00643,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: dizziness. Adherence ~0.96. AE: no. CRP 3.7 mg/L; ALT 41 U/L.
P00644,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.90. AE: no. CRP 12.3 mg/L; ALT 34 U/L.
P00644,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.68. AE: no.
P00644,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no. CRP 11.2 mg/L; ALT 35 U/L.
P00644,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no.
P00644,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no.
P00644,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: headache. Adherence ~0.76. AE: no.
P00645,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.86. AE: no. CRP 5.6 mg/L; ALT 19 U/L.
P00645,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no. CRP 4.9 mg/L; ALT 21 U/L.
P00645,2,negative,Visit 2: Patient on RX-17B at S016. poor tolerance. Notes: headache. Adherence ~0.81. AE: yes. CRP 3.7 mg/L; ALT 21 U/L.
P00645,3,negative,Visit 3: Patient on RX-17B at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00645,4,negative,Visit 4: Patient on RX-17B at S016. increased discomfort. Notes: nausea. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P00646,0,neutral,Visit 0: Patient on RX-17A at S007. reviewed dosing instructions. Notes: dizziness. Adherence ~0.96. AE: no.
P00646,1,neutral,Visit 1: Patient on RX-17A at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no. CRP 5.8 mg/L; ALT 14 U/L.
P00646,2,neutral,Visit 2: Patient on RX-17A at S007. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00646,3,neutral,Visit 3: Patient on RX-17A at S007. reviewed dosing instructions. Notes: headache. Adherence ~0.94. AE: no. CRP 4.7 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P00646,4,neutral,Visit 4: Patient on RX-17A at S007. no major change. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 5.0 mg/L; ALT 14 U/L.
P00646,5,neutral,Visit 5: Patient on RX-17A at S007. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 4.4 mg/L; ALT 12 U/L.
P00646,6,neutral,Visit 6: Patient on RX-17A at S007. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no.
P00647,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: brain fog. Adherence ~0.71. AE: no.
P00647,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.49. AE: no. CRP 7.2 mg/L; ALT 55 U/L.
P00647,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.42. AE: no.
P00647,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.39. AE: no. Plan: consider dose adjustment; counsel patient.
P00647,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.31. AE: no.
P00647,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.53. AE: no.
P00647,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.54. AE: no.
P00647,7,neutral,Visit 7: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no.
P00648,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no. CRP 6.8 mg/L; ALT 30 U/L.
P00648,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no.
P00648,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: headache. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00648,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.84. AE: yes.
P00649,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 53 U/L. Plan: consider dose adjustment; counsel patient.
P00649,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P00649,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: nausea. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00649,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no. CRP 3.6 mg/L; ALT 52 U/L.
P00649,4,positive,Visit 4: Patient on RX-17A at S002. feels better overall. Notes: nausea. Adherence ~0.82. AE: no.
P00649,5,neutral,Visit 5: Patient on RX-17A at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 3.1 mg/L; ALT 53 U/L.
P00649,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. CRP 2.6 mg/L; ALT 55 U/L.
P00650,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.64. AE: no. CRP 11.0 mg/L; ALT 38 U/L.
P00650,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P00650,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.62. AE: yes. CRP 10.1 mg/L; ALT 39 U/L.
P00651,0,neutral,Visit 0: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P00651,1,negative,Visit 1: Patient on RX-17A at S016. poor tolerance. Notes: headache. Adherence ~0.76. AE: no.
P00651,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P00651,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 4.9 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P00651,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00651,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no.
P00651,6,neutral,Visit 6: Patient on RX-17A at S016. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 23 U/L.
P00652,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: no. CRP 8.9 mg/L; ALT 12 U/L.
P00652,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.86. AE: no.
P00652,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00652,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.95. AE: yes.
P00652,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no.
P00652,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.88. AE: no.
P00652,6,positive,Visit 6: Patient on RX-17A at S004. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P00653,0,neutral,Visit 0: Patient on RX-17B at S002. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no. CRP 8.4 mg/L; ALT 27 U/L.
P00653,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: joint pain. Adherence ~0.91. AE: no.
P00653,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.72. AE: no.
P00653,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.76. AE: yes.
P00653,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.80. AE: no.
P00653,5,neutral,Visit 5: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.81. AE: no.
P00653,6,neutral,Visit 6: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.77. AE: yes.
P00653,7,positive,Visit 7: Patient on RX-17B at S002. energy increasing. Notes: fatigue. Adherence ~0.76. AE: no.
P00654,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: no. CRP 10.7 mg/L; ALT 28 U/L.
P00654,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no. CRP 9.1 mg/L; ALT 31 U/L.
P00654,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00654,3,positive,Visit 3: Patient on RX-17B at S004. tolerating medication well. Notes: joint pain. Adherence ~0.82. AE: no. CRP 8.2 mg/L; ALT 30 U/L.
P00654,4,positive,Visit 4: Patient on RX-17B at S004. reports improvement. Notes: joint pain. Adherence ~0.95. AE: no.
P00655,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: no. CRP 6.0 mg/L; ALT 33 U/L.
P00655,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00655,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no.
P00655,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: no. CRP 4.7 mg/L; ALT 38 U/L.
P00655,4,positive,Visit 4: Patient on RX-17B at S022. reports improvement. Notes: joint pain. Adherence ~0.99. AE: no.
P00656,0,negative,Visit 0: Patient on RX-17A at S001. feels frustrated. Notes: dizziness. Adherence ~0.80. AE: no.
P00656,1,negative,Visit 1: Patient on RX-17A at S001. reports worsening. Notes: insomnia. Adherence ~0.74. AE: no. CRP 4.3 mg/L; ALT 19 U/L.
P00656,2,neutral,Visit 2: Patient on RX-17A at S001. no major change. Notes: insomnia. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P00656,3,positive,Visit 3: Patient on RX-17A at S001. energy increasing. Notes: joint pain. Adherence ~0.80. AE: no. CRP 4.1 mg/L; ALT 18 U/L.
P00656,4,neutral,Visit 4: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00656,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no.
P00656,6,neutral,Visit 6: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.71. AE: no.
P00656,7,neutral,Visit 7: Patient on RX-17A at S001. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no. CRP 3.2 mg/L; ALT 19 U/L.
P00657,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.67. AE: yes. CRP 8.2 mg/L; ALT 38 U/L.
P00657,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no.
P00657,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.89. AE: no.
P00657,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.73. AE: yes.
P00657,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no.
P00657,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.65. AE: no.
P00657,6,neutral,Visit 6: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00657,7,neutral,Visit 7: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P00658,0,neutral,Visit 0: Patient on RX-17B at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00658,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.63. AE: no. CRP 4.9 mg/L; ALT 32 U/L.
P00658,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.44. AE: no. CRP 4.2 mg/L; ALT 31 U/L.
P00658,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.61. AE: no.
P00658,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no.
P00658,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P00658,6,neutral,Visit 6: Patient on RX-17B at S002. continues regimen. Notes: fatigue. Adherence ~0.70. AE: no. CRP 2.7 mg/L; ALT 36 U/L.
P00658,7,neutral,Visit 7: Patient on RX-17B at S002. continues regimen. Notes: headache. Adherence ~0.56. AE: no. CRP 2.4 mg/L; ALT 37 U/L.
P00659,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.84. AE: no.
P00659,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00659,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P00659,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P00659,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.79. AE: no. CRP 12.1 mg/L; ALT 46 U/L.
P00659,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. CRP 11.5 mg/L; ALT 46 U/L.
P00659,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no. CRP 10.4 mg/L; ALT 45 U/L.
P00659,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no. CRP 7.9 mg/L; ALT 46 U/L.
P00660,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00660,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no. CRP 7.4 mg/L; ALT 27 U/L.
P00660,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P00660,3,positive,Visit 3: Patient on RX-17B at S015. feels better overall. Notes: joint pain. Adherence ~0.82. AE: no.
P00660,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00661,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00661,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: headache. Adherence ~0.83. AE: no. CRP 3.2 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00661,2,negative,Visit 2: Patient on RX-17A at S008. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00661,3,negative,Visit 3: Patient on RX-17A at S008. symptoms persist. Notes: nausea. Adherence ~0.91. AE: no. CRP 2.4 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00661,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.90. AE: no.
P00661,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: nausea. Adherence ~0.95. AE: yes.
P00661,6,positive,Visit 6: Patient on RX-17A at S008. reports improvement. Notes: joint pain. Adherence ~0.87. AE: no. CRP 2.5 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00662,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.89. AE: no.
P00662,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.1 mg/L; ALT 28 U/L.
P00662,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00662,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no.
P00662,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P00662,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no. CRP 3.6 mg/L; ALT 36 U/L.
P00662,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 3.4 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00663,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00663,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.76. AE: no. CRP 3.5 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00663,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.79. AE: no.
P00663,3,negative,Visit 3: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: no. CRP 3.2 mg/L; ALT 40 U/L.
P00663,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no.
P00664,0,neutral,Visit 0: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no.
P00664,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.96. AE: no.
P00664,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.98. AE: no. CRP 10.0 mg/L; ALT 22 U/L.
P00664,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: joint pain. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00664,4,positive,Visit 4: Patient on RX-17B at S019. energy increasing. Notes: dizziness. Adherence ~0.98. AE: no.
P00664,5,neutral,Visit 5: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: yes.
P00664,6,neutral,Visit 6: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P00665,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00665,1,neutral,Visit 1: Patient on RX-17B at S001. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P00665,2,negative,Visit 2: Patient on RX-17B at S001. increased discomfort. Notes: nausea. Adherence ~0.99. AE: no. CRP 8.7 mg/L; ALT 10 U/L.
P00665,3,negative,Visit 3: Patient on RX-17B at S001. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no.
P00665,4,positive,Visit 4: Patient on RX-17B at S001. reports improvement. Notes: fatigue. Adherence ~0.91. AE: no.
P00665,5,neutral,Visit 5: Patient on RX-17B at S001. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P00666,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: joint pain. Adherence ~0.86. AE: no. CRP 7.7 mg/L; ALT 27 U/L.
P00666,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P00666,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.94. AE: yes. CRP 5.9 mg/L; ALT 36 U/L.
P00666,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: no. CRP 4.6 mg/L; ALT 30 U/L.
P00666,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P00666,5,neutral,Visit 5: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no.
P00666,6,neutral,Visit 6: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.80. AE: no.
P00666,7,neutral,Visit 7: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.79. AE: yes.
P00667,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no.
P00667,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.58. AE: no.
P00667,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00667,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.87. AE: no.
P00667,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.54. AE: no. CRP 6.5 mg/L; ALT 30 U/L.
P00667,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.84. AE: no.
P00668,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.66. AE: yes. CRP 6.7 mg/L; ALT 20 U/L.
P00668,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: yes.
P00668,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.69. AE: no.
P00668,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.63. AE: no.
P00668,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.68. AE: no.
P00669,0,neutral,Visit 0: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 12.0 mg/L; ALT 18 U/L.
P00669,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. Plan: consider dose adjustment; counsel patient.
P00669,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.78. AE: yes. CRP 10.2 mg/L; ALT 20 U/L.
P00670,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no. CRP 10.5 mg/L; ALT 27 U/L.
P00670,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no. CRP 10.2 mg/L; ALT 25 U/L.
P00670,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: insomnia. Adherence ~0.91. AE: no.
P00671,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: nausea. Adherence ~0.82. AE: no. CRP 9.9 mg/L; ALT 27 U/L.
P00671,1,positive,Visit 1: Patient on RX-17B at S008. feels better overall. Notes: fatigue. Adherence ~0.78. AE: no.
P00671,2,negative,Visit 2: Patient on RX-17B at S008. increased discomfort. Notes: nausea. Adherence ~0.76. AE: yes. CRP 8.3 mg/L; ALT 28 U/L.
P00671,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 7.8 mg/L; ALT 30 U/L.
P00671,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: insomnia. Adherence ~0.61. AE: yes.
P00671,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.93. AE: no.
P00672,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.59. AE: no. CRP 6.1 mg/L; ALT 30 U/L.
P00672,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no.
P00672,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.72. AE: no. CRP 5.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00672,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00672,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00672,5,positive,Visit 5: Patient on RX-17A at S022. feels better overall. Notes: insomnia. Adherence ~0.77. AE: no.
P00672,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P00672,7,positive,Visit 7: Patient on RX-17A at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P00673,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P00673,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 4.9 mg/L; ALT 15 U/L.
P00673,2,positive,Visit 2: Patient on RX-17B at S014. feels better overall. Notes: joint pain. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00673,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: no. CRP 3.6 mg/L; ALT 14 U/L.
P00673,4,negative,Visit 4: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00674,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00674,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.92. AE: no.
P00674,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.96. AE: no.
P00675,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.71. AE: no.
P00675,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no.
P00675,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.79. AE: yes.
P00675,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.64. AE: no. CRP 12.4 mg/L; ALT 40 U/L.
P00675,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no.
P00675,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.89. AE: no.
P00675,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no. CRP 9.9 mg/L; ALT 50 U/L.
P00676,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.92. AE: no. CRP 12.7 mg/L; ALT 28 U/L.
P00676,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00676,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~0.89. AE: no.
P00676,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 10.3 mg/L; ALT 28 U/L.
P00676,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P00677,0,negative,Visit 0: Patient on RX-17A at S018. poor tolerance. Notes: insomnia. Adherence ~0.26. AE: yes.
P00677,1,negative,Visit 1: Patient on RX-17A at S018. feels frustrated. Notes: brain fog. Adherence ~0.31. AE: yes.
P00677,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.36. AE: no. Plan: consider dose adjustment; counsel patient.
P00677,3,negative,Visit 3: Patient on RX-17A at S018. feels frustrated. Notes: headache. Adherence ~0.29. AE: no.
P00677,4,neutral,Visit 4: Patient on RX-17A at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.36. AE: no.
P00678,0,neutral,Visit 0: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.82. AE: no. CRP 7.3 mg/L; ALT 19 U/L.
P00678,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no.
P00678,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.85. AE: no.
P00678,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00678,4,negative,Visit 4: Patient on RX-17B at S012. increased discomfort. Notes: dizziness. Adherence ~0.71. AE: yes.
P00678,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00679,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: nausea. Adherence ~0.51. AE: no. CRP 4.3 mg/L; ALT 29 U/L.
P00679,1,negative,Visit 1: Patient on RX-17A at S018. increased discomfort. Notes: dizziness. Adherence ~0.61. AE: no. CRP 4.3 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00679,2,negative,Visit 2: Patient on RX-17A at S018. reports worsening. Notes: nausea. Adherence ~0.50. AE: no. CRP 4.1 mg/L; ALT 31 U/L.
P00679,3,neutral,Visit 3: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.45. AE: no.
P00679,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: dizziness. Adherence ~0.64. AE: no.
P00679,5,neutral,Visit 5: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.67. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P00679,6,neutral,Visit 6: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.65. AE: no.
P00679,7,neutral,Visit 7: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.43. AE: no.
P00680,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: joint pain. Adherence ~0.66. AE: no.
P00680,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: nausea. Adherence ~0.79. AE: yes. CRP 4.3 mg/L; ALT 30 U/L.
P00680,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.55. AE: no. CRP 4.0 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00681,0,neutral,Visit 0: Patient on RX-17A at S006. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 15.2 mg/L; ALT 24 U/L.
P00681,1,negative,Visit 1: Patient on RX-17A at S006. feels frustrated. Notes: fatigue. Adherence ~0.80. AE: yes. CRP 15.2 mg/L; ALT 25 U/L.
P00681,2,neutral,Visit 2: Patient on RX-17A at S006. no major change. Notes: joint pain. Adherence ~0.91. AE: no.
P00681,3,neutral,Visit 3: Patient on RX-17A at S006. continues regimen. Notes: joint pain. Adherence ~0.99. AE: no.
P00681,4,neutral,Visit 4: Patient on RX-17A at S006. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 11.7 mg/L; ALT 22 U/L.
P00681,5,neutral,Visit 5: Patient on RX-17A at S006. stable symptoms. Notes: nausea. Adherence ~0.80. AE: no. CRP 11.0 mg/L; ALT 24 U/L.
P00681,6,positive,Visit 6: Patient on RX-17A at S006. reports improvement. Notes: brain fog. Adherence ~0.89. AE: no.
P00682,0,negative,Visit 0: Patient on RX-17B at S013. reports worsening. Notes: joint pain. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P00682,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00682,2,negative,Visit 2: Patient on RX-17B at S013. increased discomfort. Notes: headache. Adherence ~0.60. AE: no.
P00682,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~0.53. AE: no.
P00682,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.58. AE: no.
P00682,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: brain fog. Adherence ~0.60. AE: no. CRP 1.9 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00683,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 17.3 mg/L; ALT 20 U/L.
P00683,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.74. AE: no.
P00683,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.43. AE: yes. CRP 15.0 mg/L; ALT 25 U/L.
P00684,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00684,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P00684,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00684,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 3.6 mg/L; ALT 63 U/L.
P00684,4,negative,Visit 4: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00685,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P00685,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.60. AE: no.
P00685,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: dizziness. Adherence ~0.79. AE: no.
P00685,3,neutral,Visit 3: Patient on RX-17A at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.91. AE: no.
P00685,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: no. CRP 15.1 mg/L; ALT 27 U/L.
P00686,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~1.00. AE: yes.
P00686,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: fatigue. Adherence ~0.72. AE: no.
P00686,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no.
P00686,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.77. AE: no.
P00686,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P00686,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.89. AE: no.
P00686,6,positive,Visit 6: Patient on RX-17A at S012. reports improvement. Notes: dizziness. Adherence ~0.83. AE: no.
P00687,0,neutral,Visit 0: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: no.
P00687,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.47. AE: no. CRP 10.5 mg/L; ALT 29 U/L.
P00687,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: fatigue. Adherence ~0.53. AE: no.
P00687,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.46. AE: no.
P00687,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no.
P00687,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.37. AE: no.
P00687,6,neutral,Visit 6: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.69. AE: yes.
P00687,7,neutral,Visit 7: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.44. AE: no.
P00688,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.71. AE: no. CRP 31.2 mg/L; ALT 27 U/L.
P00688,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: insomnia. Adherence ~0.68. AE: no.
P00688,2,negative,Visit 2: Patient on RX-17A at S005. reports worsening. Notes: headache. Adherence ~0.47. AE: no. CRP 26.0 mg/L; ALT 30 U/L.
P00688,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.73. AE: no. CRP 19.1 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00688,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.51. AE: yes. CRP 20.7 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00688,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.54. AE: no.
P00688,6,neutral,Visit 6: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00688,7,neutral,Visit 7: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.52. AE: no. CRP 14.3 mg/L; ALT 30 U/L.
P00689,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00689,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P00689,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 27 U/L.
P00689,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.97. AE: no. CRP 4.7 mg/L; ALT 24 U/L.
P00689,4,positive,Visit 4: Patient on RX-17A at S017. tolerating medication well. Notes: fatigue. Adherence ~0.93. AE: no.
P00689,5,positive,Visit 5: Patient on RX-17A at S017. reports improvement. Notes: nausea. Adherence ~0.83. AE: no.
P00689,6,positive,Visit 6: Patient on RX-17A at S017. feels better overall. Notes: joint pain. Adherence ~0.93. AE: no. CRP 3.7 mg/L; ALT 24 U/L.
P00689,7,positive,Visit 7: Patient on RX-17A at S017. energy increasing. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.7 mg/L; ALT 25 U/L.
P00690,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00690,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.88. AE: no.
P00690,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.90. AE: no.
P00690,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P00690,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.87. AE: no. CRP 3.8 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P00690,5,positive,Visit 5: Patient on RX-17B at S016. symptoms improving. Notes: dizziness. Adherence ~0.99. AE: no. CRP 3.9 mg/L; ALT 57 U/L.
P00690,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.80. AE: no.
P00691,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.82. AE: no.
P00691,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P00691,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no.
P00691,3,positive,Visit 3: Patient on RX-17B at S017. feels better overall. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00691,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00691,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.95. AE: yes.
P00691,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no.
P00691,7,positive,Visit 7: Patient on RX-17B at S017. energy increasing. Notes: fatigue. Adherence ~0.85. AE: no.
P00692,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.51. AE: no. CRP 4.3 mg/L; ALT 23 U/L.
P00692,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.39. AE: no. CRP 3.9 mg/L; ALT 21 U/L.
P00692,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.46. AE: no.
P00692,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.36. AE: no.
P00692,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.53. AE: no.
P00692,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.49. AE: yes. CRP 2.6 mg/L; ALT 25 U/L.
P00692,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.38. AE: no. CRP 2.2 mg/L; ALT 26 U/L.
P00693,0,negative,Visit 0: Patient on RX-17A at S020. poor tolerance. Notes: fatigue. Adherence ~0.45. AE: no.
P00693,1,neutral,Visit 1: Patient on RX-17A at S020. continues regimen. Notes: nausea. Adherence ~0.84. AE: no. CRP 5.9 mg/L; ALT 24 U/L.
P00693,2,neutral,Visit 2: Patient on RX-17A at S020. reviewed dosing instructions. Notes: brain fog. Adherence ~0.59. AE: no. CRP 6.2 mg/L; ALT 29 U/L.
P00693,3,neutral,Visit 3: Patient on RX-17A at S020. no major change. Notes: joint pain. Adherence ~0.61. AE: no.
P00693,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P00693,5,neutral,Visit 5: Patient on RX-17A at S020. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no.
P00693,6,positive,Visit 6: Patient on RX-17A at S020. tolerating medication well. Notes: brain fog. Adherence ~0.92. AE: no.
P00694,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.68. AE: yes.
P00694,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00694,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.88. AE: no.
P00694,3,negative,Visit 3: Patient on RX-17B at S015. poor tolerance. Notes: joint pain. Adherence ~0.84. AE: no.
P00694,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00694,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.88. AE: no.
P00694,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no.
P00695,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P00695,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00695,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P00696,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P00696,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no.
P00696,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.92. AE: yes.
P00696,3,negative,Visit 3: Patient on RX-17A at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00696,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.89. AE: no.
P00696,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00696,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00696,7,positive,Visit 7: Patient on RX-17A at S004. feels better overall. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00697,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P00697,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.46. AE: no. CRP 9.0 mg/L; ALT 36 U/L.
P00697,2,negative,Visit 2: Patient on RX-17A at S016. feels frustrated. Notes: abdominal discomfort. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P00697,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.53. AE: yes. CRP 6.3 mg/L; ALT 36 U/L.
P00697,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P00697,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.50. AE: no. CRP 6.8 mg/L; ALT 37 U/L.
P00698,0,neutral,Visit 0: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.87. AE: no.
P00698,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00698,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.93. AE: no.
P00698,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.96. AE: no.
P00698,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~0.90. AE: no. CRP 3.3 mg/L; ALT 24 U/L.
P00698,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no. CRP 2.8 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P00698,6,positive,Visit 6: Patient on RX-17B at S005. reports improvement. Notes: fatigue. Adherence ~0.98. AE: no.
P00699,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.62. AE: no.
P00699,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.61. AE: no. CRP 6.2 mg/L; ALT 33 U/L.
P00699,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.71. AE: no. CRP 6.0 mg/L; ALT 32 U/L.
P00699,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.62. AE: no. CRP 5.6 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00699,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no.
P00700,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.91. AE: no.
P00700,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no.
P00700,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 12.0 mg/L; ALT 36 U/L.
P00700,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.82. AE: yes.
P00701,0,neutral,Visit 0: Patient on RX-17A at S001. follow-up as scheduled. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00701,1,negative,Visit 1: Patient on RX-17A at S001. reports worsening. Notes: headache. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00701,2,neutral,Visit 2: Patient on RX-17A at S001. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 2.9 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P00701,3,neutral,Visit 3: Patient on RX-17A at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00701,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: dizziness. Adherence ~0.78. AE: yes.
P00702,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00702,1,negative,Visit 1: Patient on RX-17B at S001. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P00702,2,negative,Visit 2: Patient on RX-17B at S001. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P00702,3,neutral,Visit 3: Patient on RX-17B at S001. follow-up as scheduled. Notes: fatigue. Adherence ~0.95. AE: no.
P00702,4,neutral,Visit 4: Patient on RX-17B at S001. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 13.3 mg/L; ALT 40 U/L.
P00702,5,positive,Visit 5: Patient on RX-17B at S001. tolerating medication well. Notes: joint pain. Adherence ~0.92. AE: no.
P00702,6,neutral,Visit 6: Patient on RX-17B at S001. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 10.2 mg/L; ALT 40 U/L.
P00702,7,positive,Visit 7: Patient on RX-17B at S001. energy increasing. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00703,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.91. AE: no.
P00703,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00703,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P00703,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.89. AE: no.
P00703,4,positive,Visit 4: Patient on RX-17A at S022. symptoms improving. Notes: brain fog. Adherence ~0.96. AE: no.
P00703,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no.
P00703,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no.
P00703,7,positive,Visit 7: Patient on RX-17A at S022. tolerating medication well. Notes: dizziness. Adherence ~0.86. AE: no.
P00704,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P00704,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.70. AE: no. CRP 7.8 mg/L; ALT 25 U/L.
P00704,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.79. AE: no.
P00704,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P00705,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: nausea. Adherence ~0.65. AE: no.
P00705,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.86. AE: no.
P00705,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P00705,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.93. AE: no.
P00705,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.87. AE: no. CRP 9.4 mg/L; ALT 35 U/L.
P00705,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no. CRP 10.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00706,0,negative,Visit 0: Patient on RX-17A at S021. increased discomfort. Notes: dizziness. Adherence ~0.88. AE: no.
P00706,1,negative,Visit 1: Patient on RX-17A at S021. reports worsening. Notes: brain fog. Adherence ~0.92. AE: no.
P00706,2,neutral,Visit 2: Patient on RX-17A at S021. no major change. Notes: nausea. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00706,3,negative,Visit 3: Patient on RX-17A at S021. reports worsening. Notes: headache. Adherence ~0.73. AE: yes.
P00706,4,neutral,Visit 4: Patient on RX-17A at S021. reviewed dosing instructions. Notes: insomnia. Adherence ~0.86. AE: no.
P00706,5,positive,Visit 5: Patient on RX-17A at S021. energy increasing. Notes: fatigue. Adherence ~0.91. AE: no. CRP 11.7 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P00706,6,positive,Visit 6: Patient on RX-17A at S021. symptoms improving. Notes: insomnia. Adherence ~0.77. AE: no. CRP 10.5 mg/L; ALT 38 U/L.
P00706,7,neutral,Visit 7: Patient on RX-17A at S021. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no.
P00707,0,negative,Visit 0: Patient on RX-17A at S020. poor tolerance. Notes: brain fog. Adherence ~0.82. AE: no. CRP 9.1 mg/L; ALT 69 U/L. Plan: consider dose adjustment; counsel patient.
P00707,1,negative,Visit 1: Patient on RX-17A at S020. symptoms persist. Notes: nausea. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P00707,2,neutral,Visit 2: Patient on RX-17A at S020. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P00707,3,negative,Visit 3: Patient on RX-17A at S020. increased discomfort. Notes: brain fog. Adherence ~0.65. AE: no. CRP 7.5 mg/L; ALT 66 U/L.
P00707,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no. CRP 7.2 mg/L; ALT 68 U/L. Plan: consider dose adjustment; counsel patient.
P00708,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.82. AE: no.
P00708,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.74. AE: no.
P00708,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no.
P00708,3,positive,Visit 3: Patient on RX-17A at S014. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no.
P00708,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.6 mg/L; ALT 38 U/L.
P00709,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P00709,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.58. AE: no.
P00709,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P00709,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00709,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no. CRP 3.7 mg/L; ALT 43 U/L.
P00709,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.93. AE: yes.
P00709,6,positive,Visit 6: Patient on RX-17A at S015. reports improvement. Notes: nausea. Adherence ~0.85. AE: no. CRP 2.5 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00709,7,neutral,Visit 7: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00710,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: dizziness. Adherence ~0.79. AE: yes. CRP 6.2 mg/L; ALT 34 U/L.
P00710,1,negative,Visit 1: Patient on RX-17A at S011. increased discomfort. Notes: nausea. Adherence ~0.76. AE: no. CRP 5.3 mg/L; ALT 32 U/L.
P00710,2,neutral,Visit 2: Patient on RX-17A at S011. no major change. Notes: headache. Adherence ~0.88. AE: no.
P00710,3,neutral,Visit 3: Patient on RX-17A at S011. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P00710,4,neutral,Visit 4: Patient on RX-17A at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00710,5,neutral,Visit 5: Patient on RX-17A at S011. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 34 U/L.
P00711,0,neutral,Visit 0: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.98. AE: yes.
P00711,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: fatigue. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00711,2,neutral,Visit 2: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no. CRP 15.6 mg/L; ALT 62 U/L.
P00711,3,positive,Visit 3: Patient on RX-17B at S002. energy increasing. Notes: dizziness. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00711,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.75. AE: no.
P00711,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.83. AE: no. CRP 10.5 mg/L; ALT 61 U/L.
P00711,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: fatigue. Adherence ~0.90. AE: no. CRP 11.5 mg/L; ALT 64 U/L.
P00711,7,positive,Visit 7: Patient on RX-17B at S002. feels better overall. Notes: insomnia. Adherence ~0.77. AE: no. CRP 7.1 mg/L; ALT 62 U/L.
P00712,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.98. AE: no.
P00712,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P00712,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00712,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no.
P00712,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 19 U/L.
P00712,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no.
P00713,0,negative,Visit 0: Patient on RX-17A at S011. increased discomfort. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00713,1,negative,Visit 1: Patient on RX-17A at S011. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: yes. Plan: consider dose adjustment; counsel patient.
P00713,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: joint pain. Adherence ~0.83. AE: no.
P00713,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: nausea. Adherence ~0.65. AE: no.
P00713,4,neutral,Visit 4: Patient on RX-17A at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00713,5,positive,Visit 5: Patient on RX-17A at S011. feels better overall. Notes: joint pain. Adherence ~0.85. AE: no.
P00713,6,neutral,Visit 6: Patient on RX-17A at S011. no major change. Notes: insomnia. Adherence ~0.75. AE: yes.
P00713,7,neutral,Visit 7: Patient on RX-17A at S011. no major change. Notes: dizziness. Adherence ~0.72. AE: no. CRP 4.9 mg/L; ALT 18 U/L.
P00714,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: dizziness. Adherence ~0.67. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P00714,1,positive,Visit 1: Patient on RX-17A at S015. reports improvement. Notes: nausea. Adherence ~0.91. AE: no.
P00714,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.85. AE: no.
P00714,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.80. AE: yes.
P00714,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no. CRP 3.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00714,5,positive,Visit 5: Patient on RX-17A at S015. feels better overall. Notes: dizziness. Adherence ~0.78. AE: no.
P00714,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00714,7,positive,Visit 7: Patient on RX-17A at S015. tolerating medication well. Notes: dizziness. Adherence ~0.88. AE: no.
P00715,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: joint pain. Adherence ~0.37. AE: no. CRP 3.7 mg/L; ALT 38 U/L.
P00715,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.30. AE: no.
P00715,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00715,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.56. AE: no. CRP 3.2 mg/L; ALT 35 U/L.
P00715,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.49. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P00715,5,negative,Visit 5: Patient on RX-17A at S019. reports worsening. Notes: fatigue. Adherence ~0.47. AE: yes. CRP 2.8 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00715,6,neutral,Visit 6: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.42. AE: yes.
P00716,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00716,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.86. AE: no. CRP 7.8 mg/L; ALT 12 U/L.
P00716,2,neutral,Visit 2: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.77. AE: no.
P00716,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.65. AE: no. CRP 5.7 mg/L; ALT 12 U/L.
P00716,4,positive,Visit 4: Patient on RX-17B at S002. energy increasing. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00716,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.66. AE: yes. Plan: consider dose adjustment; counsel patient.
P00716,6,neutral,Visit 6: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.95. AE: no.
P00717,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00717,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00717,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no. CRP 5.6 mg/L; ALT 30 U/L.
P00717,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 4.5 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00717,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no.
P00718,0,negative,Visit 0: Patient on RX-17B at S007. feels frustrated. Notes: nausea. Adherence ~0.61. AE: no. CRP 7.1 mg/L; ALT 29 U/L.
P00718,1,neutral,Visit 1: Patient on RX-17B at S007. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no. CRP 6.0 mg/L; ALT 31 U/L.
P00718,2,neutral,Visit 2: Patient on RX-17B at S007. stable symptoms. Notes: abdominal discomfort. Adherence ~0.42. AE: no.
P00718,3,neutral,Visit 3: Patient on RX-17B at S007. stable symptoms. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 4.6 mg/L; ALT 31 U/L.
P00718,4,neutral,Visit 4: Patient on RX-17B at S007. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no. CRP 4.1 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00718,5,neutral,Visit 5: Patient on RX-17B at S007. reviewed dosing instructions. Notes: joint pain. Adherence ~0.51. AE: no. CRP 3.6 mg/L; ALT 30 U/L.
P00719,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: nausea. Adherence ~0.58. AE: no.
P00719,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.52. AE: yes.
P00719,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: joint pain. Adherence ~0.63. AE: no.
P00719,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.65. AE: no. CRP 2.9 mg/L; ALT 45 U/L.
P00719,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no.
P00720,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: fatigue. Adherence ~0.87. AE: no.
P00720,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.81. AE: no. CRP 7.2 mg/L; ALT 35 U/L.
P00720,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.73. AE: no. CRP 6.3 mg/L; ALT 36 U/L.
P00720,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 6.0 mg/L; ALT 35 U/L.
P00720,4,neutral,Visit 4: Patient on RX-17A at S008. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P00720,5,neutral,Visit 5: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P00721,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.75. AE: no.
P00721,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no.
P00721,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.81. AE: yes.
P00721,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 11.5 mg/L; ALT 15 U/L.
P00721,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no.
P00721,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00722,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.96. AE: no.
P00722,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P00722,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.98. AE: no.
P00722,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.96. AE: no.
P00722,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: joint pain. Adherence ~0.97. AE: no. CRP 2.8 mg/L; ALT 21 U/L.
P00722,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~1.00. AE: yes. CRP 2.9 mg/L; ALT 25 U/L.
P00723,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.62. AE: yes. CRP 11.9 mg/L; ALT 26 U/L.
P00723,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00723,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.46. AE: no. CRP 10.4 mg/L; ALT 23 U/L.
P00723,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P00723,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00724,0,neutral,Visit 0: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~0.78. AE: no.
P00724,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.92. AE: no.
P00724,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00724,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no.
P00724,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no.
P00725,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.96. AE: no. CRP 5.2 mg/L; ALT 35 U/L.
P00725,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00725,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.83. AE: no. CRP 4.1 mg/L; ALT 35 U/L.
P00725,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no.
P00725,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00726,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.66. AE: no. CRP 2.6 mg/L; ALT 24 U/L.
P00726,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.54. AE: yes. CRP 2.4 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00726,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.71. AE: yes.
P00726,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.72. AE: yes. CRP 2.0 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P00727,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P00727,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.91. AE: no. CRP 13.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00727,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P00727,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 12.8 mg/L; ALT 30 U/L.
P00727,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00727,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 8.9 mg/L; ALT 34 U/L.
P00728,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.87. AE: no.
P00728,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00728,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00728,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no.
P00728,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.90. AE: no.
P00728,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no. CRP 7.3 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00729,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 4.3 mg/L; ALT 69 U/L.
P00729,1,negative,Visit 1: Patient on RX-17B at S013. poor tolerance. Notes: headache. Adherence ~0.96. AE: no.
P00729,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P00729,3,positive,Visit 3: Patient on RX-17B at S013. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no.
P00729,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.71. AE: no. CRP 2.9 mg/L; ALT 70 U/L. Plan: consider dose adjustment; counsel patient.
P00729,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.73. AE: yes.
P00729,6,neutral,Visit 6: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 2.4 mg/L; ALT 71 U/L.
P00729,7,positive,Visit 7: Patient on RX-17B at S013. energy increasing. Notes: joint pain. Adherence ~0.79. AE: no. CRP 1.8 mg/L; ALT 68 U/L. Plan: consider dose adjustment; counsel patient.
P00730,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P00730,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.63. AE: no. CRP 6.4 mg/L; ALT 34 U/L.
P00730,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.59. AE: no. CRP 7.9 mg/L; ALT 31 U/L.
P00730,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no.
P00730,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no.
P00731,0,negative,Visit 0: Patient on RX-17A at S001. reports worsening. Notes: dizziness. Adherence ~0.60. AE: yes. CRP 15.3 mg/L; ALT 42 U/L.
P00731,1,neutral,Visit 1: Patient on RX-17A at S001. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P00731,2,negative,Visit 2: Patient on RX-17A at S001. symptoms persist. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P00731,3,neutral,Visit 3: Patient on RX-17A at S001. continues regimen. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00731,4,neutral,Visit 4: Patient on RX-17A at S001. continues regimen. Notes: joint pain. Adherence ~0.62. AE: no. CRP 9.9 mg/L; ALT 37 U/L.
P00731,5,neutral,Visit 5: Patient on RX-17A at S001. stable symptoms. Notes: headache. Adherence ~0.64. AE: no.
P00731,6,neutral,Visit 6: Patient on RX-17A at S001. no major change. Notes: brain fog. Adherence ~0.61. AE: no.
P00731,7,negative,Visit 7: Patient on RX-17A at S001. reports worsening. Notes: insomnia. Adherence ~0.52. AE: yes.
P00732,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no.
P00732,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: insomnia. Adherence ~0.56. AE: no.
P00732,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.96. AE: no. CRP 15.1 mg/L; ALT 45 U/L.
P00732,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.76. AE: no. CRP 13.1 mg/L; ALT 53 U/L.
P00732,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P00732,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no. CRP 9.2 mg/L; ALT 47 U/L.
P00732,6,positive,Visit 6: Patient on RX-17A at S017. reports improvement. Notes: nausea. Adherence ~0.76. AE: no. CRP 9.2 mg/L; ALT 50 U/L.
P00732,7,positive,Visit 7: Patient on RX-17A at S017. reports improvement. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00733,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~1.00. AE: no.
P00733,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no.
P00733,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: no. CRP 4.3 mg/L; ALT 42 U/L.
P00733,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.92. AE: no.
P00733,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00734,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P00734,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: yes. CRP 1.8 mg/L; ALT 31 U/L.
P00734,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 1.7 mg/L; ALT 30 U/L.
P00734,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no.
P00734,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.88. AE: no.
P00734,5,positive,Visit 5: Patient on RX-17A at S013. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no. CRP 1.6 mg/L; ALT 33 U/L.
P00734,6,positive,Visit 6: Patient on RX-17A at S013. energy increasing. Notes: dizziness. Adherence ~0.93. AE: no. CRP 1.3 mg/L; ALT 32 U/L.
P00734,7,positive,Visit 7: Patient on RX-17A at S013. feels better overall. Notes: insomnia. Adherence ~1.00. AE: no. CRP 1.4 mg/L; ALT 33 U/L.
P00735,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.81. AE: no. CRP 4.4 mg/L; ALT 28 U/L.
P00735,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: headache. Adherence ~0.81. AE: no. CRP 3.9 mg/L; ALT 28 U/L.
P00735,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.79. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P00735,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00735,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: yes.
P00735,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no.
P00735,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no. CRP 2.4 mg/L; ALT 32 U/L.
P00735,7,neutral,Visit 7: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.97. AE: yes.
P00736,0,negative,Visit 0: Patient on RX-17A at S020. poor tolerance. Notes: fatigue. Adherence ~0.90. AE: no. CRP 11.7 mg/L; ALT 49 U/L.
P00736,1,neutral,Visit 1: Patient on RX-17A at S020. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P00736,2,neutral,Visit 2: Patient on RX-17A at S020. reviewed dosing instructions. Notes: insomnia. Adherence ~0.94. AE: no.
P00736,3,neutral,Visit 3: Patient on RX-17A at S020. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 8.7 mg/L; ALT 52 U/L.
P00736,4,neutral,Visit 4: Patient on RX-17A at S020. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no. CRP 8.0 mg/L; ALT 47 U/L.
P00736,5,neutral,Visit 5: Patient on RX-17A at S020. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00736,6,positive,Visit 6: Patient on RX-17A at S020. energy increasing. Notes: dizziness. Adherence ~0.76. AE: no.
P00737,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00737,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.91. AE: no. CRP 23.9 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00737,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no.
P00737,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.63. AE: no.
P00737,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P00738,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.56. AE: no.
P00738,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.62. AE: no. CRP 7.3 mg/L; ALT 22 U/L.
P00738,2,negative,Visit 2: Patient on RX-17B at S016. increased discomfort. Notes: joint pain. Adherence ~0.69. AE: no.
P00738,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P00738,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P00738,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.63. AE: no. CRP 5.1 mg/L; ALT 24 U/L.
P00738,6,neutral,Visit 6: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.46. AE: no. CRP 3.6 mg/L; ALT 23 U/L.
P00739,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00739,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: joint pain. Adherence ~0.87. AE: no.
P00739,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.79. AE: no.
P00739,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00740,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: nausea. Adherence ~0.71. AE: no. CRP 30.1 mg/L; ALT 21 U/L.
P00740,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.78. AE: no.
P00740,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no.
P00740,3,positive,Visit 3: Patient on RX-17B at S022. tolerating medication well. Notes: dizziness. Adherence ~0.92. AE: no.
P00740,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no.
P00740,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.87. AE: yes.
P00740,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.78. AE: no. CRP 13.2 mg/L; ALT 25 U/L.
P00740,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P00741,0,neutral,Visit 0: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: yes. CRP 8.8 mg/L; ALT 17 U/L.
P00741,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: headache. Adherence ~0.86. AE: no.
P00741,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: dizziness. Adherence ~0.89. AE: no. CRP 6.3 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P00741,3,positive,Visit 3: Patient on RX-17A at S005. energy increasing. Notes: headache. Adherence ~0.79. AE: no. CRP 6.6 mg/L; ALT 16 U/L.
P00741,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.97. AE: no. CRP 6.0 mg/L; ALT 18 U/L.
P00742,0,neutral,Visit 0: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 40 U/L.
P00742,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P00742,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: nausea. Adherence ~0.92. AE: no.
P00742,3,negative,Visit 3: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.89. AE: no.
P00742,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.99. AE: no.
P00742,5,positive,Visit 5: Patient on RX-17A at S005. symptoms improving. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00742,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.99. AE: yes.
P00743,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. CRP 7.2 mg/L; ALT 24 U/L.
P00743,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no.
P00743,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00743,3,negative,Visit 3: Patient on RX-17B at S019. poor tolerance. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 5.3 mg/L; ALT 25 U/L.
P00743,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00743,5,positive,Visit 5: Patient on RX-17B at S019. energy increasing. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00743,6,neutral,Visit 6: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.92. AE: no.
P00743,7,positive,Visit 7: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P00744,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.64. AE: no.
P00744,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.53. AE: yes. CRP 11.8 mg/L; ALT 34 U/L.
P00744,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.51. AE: yes. CRP 10.4 mg/L; ALT 41 U/L.
P00744,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.48. AE: no.
P00744,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.47. AE: no.
P00744,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.45. AE: no.
P00744,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.46. AE: no. CRP 6.7 mg/L; ALT 35 U/L.
P00745,0,neutral,Visit 0: Patient on RX-17B at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P00745,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: joint pain. Adherence ~0.96. AE: no.
P00745,2,neutral,Visit 2: Patient on RX-17B at S006. no major change. Notes: nausea. Adherence ~0.89. AE: no. CRP 6.6 mg/L; ALT 60 U/L.
P00745,3,neutral,Visit 3: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.86. AE: no. CRP 4.6 mg/L; ALT 58 U/L.
P00745,4,neutral,Visit 4: Patient on RX-17B at S006. no major change. Notes: joint pain. Adherence ~0.96. AE: no.
P00745,5,positive,Visit 5: Patient on RX-17B at S006. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 60 U/L.
P00746,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00746,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.77. AE: no.
P00746,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.88. AE: yes.
P00746,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.80. AE: no. CRP 7.0 mg/L; ALT 19 U/L.
P00747,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00747,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.53. AE: no.
P00747,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 2.8 mg/L; ALT 29 U/L.
P00747,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.43. AE: no. CRP 2.6 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00747,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.38. AE: no. CRP 2.1 mg/L; ALT 31 U/L.
P00747,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.49. AE: no.
P00747,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.54. AE: no.
P00747,7,neutral,Visit 7: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no. CRP 1.6 mg/L; ALT 35 U/L.
P00748,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: joint pain. Adherence ~0.68. AE: no.
P00748,1,negative,Visit 1: Patient on RX-17A at S020. feels frustrated. Notes: dizziness. Adherence ~0.74. AE: no.
P00748,2,negative,Visit 2: Patient on RX-17A at S020. symptoms persist. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00748,3,neutral,Visit 3: Patient on RX-17A at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no.
P00748,4,negative,Visit 4: Patient on RX-17A at S020. feels frustrated. Notes: fatigue. Adherence ~0.83. AE: no. CRP 2.4 mg/L; ALT 53 U/L.
P00749,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.61. AE: no. CRP 4.7 mg/L; ALT 41 U/L.
P00749,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no.
P00749,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00749,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P00749,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no.
P00749,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.65. AE: no.
P00750,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.41. AE: no. Plan: consider dose adjustment; counsel patient.
P00750,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P00750,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.58. AE: no. CRP 5.4 mg/L; ALT 26 U/L.
P00750,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.48. AE: no.
P00750,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.54. AE: no.
P00750,5,negative,Visit 5: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.74. AE: no.
P00751,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 9.9 mg/L; ALT 71 U/L.
P00751,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.98. AE: no.
P00751,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.99. AE: no.
P00751,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00751,4,negative,Visit 4: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00752,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.86. AE: no. CRP 9.8 mg/L; ALT 30 U/L.
P00752,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: insomnia. Adherence ~0.91. AE: yes. CRP 9.1 mg/L; ALT 29 U/L.
P00752,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.88. AE: no.
P00752,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.89. AE: no. CRP 7.1 mg/L; ALT 32 U/L.
P00752,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.95. AE: no. CRP 7.7 mg/L; ALT 33 U/L.
P00752,5,positive,Visit 5: Patient on RX-17A at S017. feels better overall. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00753,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00753,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.78. AE: no. CRP 26.2 mg/L; ALT 35 U/L.
P00753,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no. CRP 27.5 mg/L; ALT 37 U/L.
P00753,3,negative,Visit 3: Patient on RX-17B at S017. reports worsening. Notes: brain fog. Adherence ~0.74. AE: yes.
P00753,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00753,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no.
P00753,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.79. AE: yes. CRP 13.2 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00753,7,neutral,Visit 7: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.67. AE: no.
P00754,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no. CRP 5.4 mg/L; ALT 52 U/L.
P00754,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.80. AE: yes. CRP 4.8 mg/L; ALT 58 U/L. Plan: consider dose adjustment; counsel patient.
P00754,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.50. AE: no.
P00755,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: no. CRP 6.2 mg/L; ALT 39 U/L.
P00755,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.94. AE: no. CRP 4.8 mg/L; ALT 42 U/L.
P00755,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no. CRP 5.9 mg/L; ALT 44 U/L.
P00755,3,negative,Visit 3: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.91. AE: no. CRP 4.3 mg/L; ALT 44 U/L.
P00755,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.81. AE: yes. CRP 3.6 mg/L; ALT 45 U/L.
P00755,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no.
P00755,6,positive,Visit 6: Patient on RX-17B at S004. feels better overall. Notes: brain fog. Adherence ~0.93. AE: no. CRP 2.9 mg/L; ALT 51 U/L.
P00756,0,neutral,Visit 0: Patient on RX-17B at S021. no major change. Notes: brain fog. Adherence ~0.65. AE: no.
P00756,1,neutral,Visit 1: Patient on RX-17B at S021. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 48 U/L.
P00756,2,negative,Visit 2: Patient on RX-17B at S021. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: yes. CRP 3.9 mg/L; ALT 53 U/L.
P00757,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P00757,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.83. AE: no. CRP 13.1 mg/L; ALT 23 U/L.
P00757,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00757,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00757,4,negative,Visit 4: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.69. AE: yes.
P00757,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: headache. Adherence ~0.80. AE: no. CRP 9.8 mg/L; ALT 24 U/L.
P00757,6,neutral,Visit 6: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no. CRP 7.6 mg/L; ALT 26 U/L.
P00757,7,neutral,Visit 7: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P00758,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: no. CRP 14.7 mg/L; ALT 48 U/L.
P00758,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~0.61. AE: no.
P00758,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: joint pain. Adherence ~0.65. AE: no. CRP 11.2 mg/L; ALT 47 U/L.
P00759,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.71. AE: no.
P00759,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.88. AE: no. CRP 4.9 mg/L; ALT 36 U/L.
P00759,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.61. AE: no.
P00759,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.75. AE: no.
P00760,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.94. AE: no.
P00760,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00760,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P00760,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no.
P00760,4,negative,Visit 4: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no. CRP 15.6 mg/L; ALT 26 U/L.
P00761,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: dizziness. Adherence ~0.62. AE: no. CRP 4.7 mg/L; ALT 32 U/L.
P00761,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00761,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.57. AE: yes.
P00761,3,negative,Visit 3: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.47. AE: no.
P00761,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P00761,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.63. AE: no.
P00761,6,neutral,Visit 6: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.44. AE: no.
P00762,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: yes.
P00762,1,neutral,Visit 1: Patient on RX-17A at S002. no major change. Notes: dizziness. Adherence ~0.97. AE: no.
P00762,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. CRP 10.9 mg/L; ALT 31 U/L.
P00762,3,negative,Visit 3: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.93. AE: no. CRP 11.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P00762,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no. CRP 10.2 mg/L; ALT 30 U/L.
P00762,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no.
P00763,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.70. AE: no.
P00763,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~0.85. AE: no. CRP 14.7 mg/L; ALT 60 U/L.
P00763,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.99. AE: no.
P00763,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.83. AE: no. CRP 12.2 mg/L; ALT 60 U/L.
P00763,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.57. AE: no.
P00763,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no. CRP 9.8 mg/L; ALT 70 U/L.
P00763,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.74. AE: no. CRP 6.7 mg/L; ALT 62 U/L.
P00764,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P00764,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.83. AE: yes.
P00764,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no.
P00764,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no. CRP 2.6 mg/L; ALT 33 U/L.
P00764,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: no.
P00764,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.64. AE: no.
P00764,6,positive,Visit 6: Patient on RX-17A at S012. symptoms improving. Notes: dizziness. Adherence ~0.81. AE: no.
P00765,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no. CRP 10.1 mg/L; ALT 21 U/L.
P00765,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.82. AE: no. CRP 9.8 mg/L; ALT 22 U/L.
P00765,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 8.0 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00765,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 8.3 mg/L; ALT 24 U/L.
P00765,4,positive,Visit 4: Patient on RX-17B at S017. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P00766,0,neutral,Visit 0: Patient on RX-17B at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.63. AE: no.
P00766,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00766,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no. CRP 1.2 mg/L; ALT 22 U/L.
P00766,3,positive,Visit 3: Patient on RX-17B at S020. energy increasing. Notes: headache. Adherence ~0.87. AE: no.
P00766,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: joint pain. Adherence ~0.63. AE: no.
P00766,5,neutral,Visit 5: Patient on RX-17B at S020. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 0.9 mg/L; ALT 23 U/L.
P00766,6,neutral,Visit 6: Patient on RX-17B at S020. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no.
P00767,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no. CRP 12.1 mg/L; ALT 29 U/L.
P00767,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.91. AE: no. CRP 11.0 mg/L; ALT 27 U/L.
P00767,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00767,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00767,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: no.
P00768,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no. CRP 3.8 mg/L; ALT 18 U/L.
P00768,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: insomnia. Adherence ~0.57. AE: no.
P00768,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P00768,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.63. AE: no.
P00768,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.54. AE: no. CRP 2.7 mg/L; ALT 20 U/L.
P00768,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.58. AE: no.
P00769,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no. CRP 10.1 mg/L; ALT 27 U/L.
P00769,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no.
P00769,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.94. AE: no.
P00769,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00769,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P00770,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.64. AE: no.
P00770,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.89. AE: no.
P00770,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.75. AE: no. CRP 12.1 mg/L; ALT 28 U/L.
P00770,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.90. AE: yes. CRP 10.3 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00770,4,negative,Visit 4: Patient on RX-17A at S015. poor tolerance. Notes: brain fog. Adherence ~0.86. AE: no.
P00771,0,neutral,Visit 0: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 15.6 mg/L; ALT 23 U/L.
P00771,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: headache. Adherence ~0.62. AE: no.
P00771,2,negative,Visit 2: Patient on RX-17B at S013. reports worsening. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P00771,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: no. CRP 11.6 mg/L; ALT 25 U/L.
P00772,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no.
P00772,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P00772,2,positive,Visit 2: Patient on RX-17B at S015. tolerating medication well. Notes: fatigue. Adherence ~1.00. AE: no. CRP 10.7 mg/L; ALT 41 U/L.
P00772,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.74. AE: no. CRP 8.7 mg/L; ALT 43 U/L.
P00772,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.93. AE: yes. CRP 7.5 mg/L; ALT 43 U/L.
P00773,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.97. AE: no. CRP 7.1 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P00773,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no.
P00773,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00773,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: fatigue. Adherence ~0.95. AE: yes. CRP 5.0 mg/L; ALT 25 U/L.
P00773,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no. CRP 5.7 mg/L; ALT 26 U/L.
P00773,5,positive,Visit 5: Patient on RX-17A at S022. tolerating medication well. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00773,6,neutral,Visit 6: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P00774,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 5.8 mg/L; ALT 10 U/L. Plan: consider dose adjustment; counsel patient.
P00774,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.83. AE: no. CRP 5.9 mg/L; ALT 14 U/L.
P00774,2,positive,Visit 2: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.86. AE: no.
P00774,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.96. AE: yes.
P00774,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P00774,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: yes.
P00775,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~1.00. AE: yes.
P00775,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: headache. Adherence ~0.74. AE: no.
P00775,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.62. AE: no.
P00775,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P00775,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.99. AE: no.
P00776,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.84. AE: no. CRP 4.1 mg/L; ALT 31 U/L.
P00776,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: yes.
P00776,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no.
P00776,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 2.7 mg/L; ALT 33 U/L.
P00776,4,positive,Visit 4: Patient on RX-17B at S012. feels better overall. Notes: headache. Adherence ~0.97. AE: no.
P00776,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: brain fog. Adherence ~0.96. AE: no.
P00777,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no. CRP 6.5 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00777,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.79. AE: no.
P00777,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.85. AE: yes. CRP 5.4 mg/L; ALT 28 U/L.
P00778,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 21 U/L.
P00778,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: yes.
P00778,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 5.9 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P00778,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: joint pain. Adherence ~1.00. AE: yes.
P00778,4,positive,Visit 4: Patient on RX-17A at S004. tolerating medication well. Notes: insomnia. Adherence ~0.89. AE: no.
P00778,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 20 U/L.
P00778,6,positive,Visit 6: Patient on RX-17A at S004. feels better overall. Notes: joint pain. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00779,0,neutral,Visit 0: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.63. AE: no. CRP 4.4 mg/L; ALT 62 U/L.
P00779,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no.
P00779,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.76. AE: no. CRP 3.9 mg/L; ALT 58 U/L.
P00779,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: yes.
P00779,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.0 mg/L; ALT 63 U/L.
P00779,5,positive,Visit 5: Patient on RX-17B at S005. tolerating medication well. Notes: brain fog. Adherence ~0.84. AE: no.
P00779,6,positive,Visit 6: Patient on RX-17B at S005. symptoms improving. Notes: insomnia. Adherence ~0.91. AE: no.
P00779,7,positive,Visit 7: Patient on RX-17B at S005. tolerating medication well. Notes: fatigue. Adherence ~0.78. AE: no.
P00780,0,neutral,Visit 0: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.57. AE: no. CRP 3.0 mg/L; ALT 37 U/L.
P00780,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.48. AE: no.
P00780,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no.
P00780,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.40. AE: no. CRP 2.3 mg/L; ALT 46 U/L.
P00780,4,negative,Visit 4: Patient on RX-17A at S016. poor tolerance. Notes: insomnia. Adherence ~0.55. AE: yes.
P00780,5,negative,Visit 5: Patient on RX-17A at S016. feels frustrated. Notes: nausea. Adherence ~0.38. AE: no.
P00781,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.61. AE: no.
P00781,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.65. AE: no.
P00781,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~0.67. AE: no. CRP 3.1 mg/L; ALT 29 U/L.
P00781,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.64. AE: no. CRP 2.6 mg/L; ALT 29 U/L.
P00781,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no.
P00782,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.62. AE: no. CRP 1.1 mg/L; ALT 32 U/L.
P00782,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P00782,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: no.
P00782,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no.
P00782,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no.
P00782,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.66. AE: no.
P00782,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.54. AE: no.
P00783,0,neutral,Visit 0: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: no. CRP 5.4 mg/L; ALT 27 U/L.
P00783,1,neutral,Visit 1: Patient on RX-17A at S008. continues regimen. Notes: brain fog. Adherence ~0.85. AE: no.
P00783,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.85. AE: no.
P00783,3,neutral,Visit 3: Patient on RX-17A at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no.
P00783,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: fatigue. Adherence ~0.88. AE: no. CRP 4.3 mg/L; ALT 26 U/L.
P00783,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. CRP 4.4 mg/L; ALT 27 U/L.
P00783,6,positive,Visit 6: Patient on RX-17A at S008. reports improvement. Notes: brain fog. Adherence ~0.82. AE: no. CRP 3.6 mg/L; ALT 29 U/L.
P00783,7,positive,Visit 7: Patient on RX-17A at S008. energy increasing. Notes: headache. Adherence ~0.83. AE: no. CRP 3.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00784,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00784,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: fatigue. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00784,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.74. AE: no. CRP 7.1 mg/L; ALT 21 U/L.
P00784,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no.
P00784,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.59. AE: no.
P00785,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.90. AE: no. CRP 1.7 mg/L; ALT 45 U/L.
P00785,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.61. AE: no.
P00785,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no.
P00786,0,neutral,Visit 0: Patient on RX-17B at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.35. AE: no. CRP 8.2 mg/L; ALT 40 U/L.
P00786,1,neutral,Visit 1: Patient on RX-17B at S020. continues regimen. Notes: headache. Adherence ~0.45. AE: no.
P00786,2,neutral,Visit 2: Patient on RX-17B at S020. reviewed dosing instructions. Notes: dizziness. Adherence ~0.45. AE: no.
P00786,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: headache. Adherence ~0.35. AE: no. Plan: consider dose adjustment; counsel patient.
P00786,4,neutral,Visit 4: Patient on RX-17B at S020. stable symptoms. Notes: fatigue. Adherence ~0.46. AE: no.
P00787,0,neutral,Visit 0: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P00787,1,neutral,Visit 1: Patient on RX-17A at S011. stable symptoms. Notes: joint pain. Adherence ~0.93. AE: no.
P00787,2,neutral,Visit 2: Patient on RX-17A at S011. stable symptoms. Notes: joint pain. Adherence ~0.94. AE: no. CRP 5.9 mg/L; ALT 13 U/L.
P00787,3,neutral,Visit 3: Patient on RX-17A at S011. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no.
P00787,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.94. AE: no.
P00787,5,neutral,Visit 5: Patient on RX-17A at S011. no major change. Notes: nausea. Adherence ~0.96. AE: yes.
P00788,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 29 U/L.
P00788,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no. CRP 3.3 mg/L; ALT 37 U/L.
P00788,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.87. AE: yes.
P00789,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: no.
P00789,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00789,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.99. AE: no.
P00789,3,negative,Visit 3: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no. CRP 4.4 mg/L; ALT 37 U/L.
P00789,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 4.8 mg/L; ALT 42 U/L.
P00790,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.87. AE: no. CRP 11.8 mg/L; ALT 29 U/L.
P00790,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.94. AE: no.
P00790,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.98. AE: no. CRP 10.5 mg/L; ALT 25 U/L.
P00790,3,positive,Visit 3: Patient on RX-17B at S014. symptoms improving. Notes: brain fog. Adherence ~0.92. AE: no.
P00790,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: brain fog. Adherence ~0.92. AE: no.
P00790,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00790,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.97. AE: no.
P00790,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no.
P00791,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.85. AE: no.
P00791,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: no.
P00791,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. CRP 4.0 mg/L; ALT 64 U/L.
P00791,3,positive,Visit 3: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~0.88. AE: no. CRP 3.3 mg/L; ALT 66 U/L.
P00791,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no.
P00792,0,negative,Visit 0: Patient on RX-17B at S009. increased discomfort. Notes: joint pain. Adherence ~0.85. AE: no. CRP 8.0 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P00792,1,neutral,Visit 1: Patient on RX-17B at S009. no major change. Notes: insomnia. Adherence ~0.77. AE: no.
P00792,2,negative,Visit 2: Patient on RX-17B at S009. symptoms persist. Notes: dizziness. Adherence ~0.92. AE: yes.
P00792,3,neutral,Visit 3: Patient on RX-17B at S009. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00792,4,neutral,Visit 4: Patient on RX-17B at S009. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: yes.
P00792,5,neutral,Visit 5: Patient on RX-17B at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no.
P00792,6,neutral,Visit 6: Patient on RX-17B at S009. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. CRP 3.7 mg/L; ALT 66 U/L. Plan: consider dose adjustment; counsel patient.
P00793,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: nausea. Adherence ~0.58. AE: no. CRP 8.0 mg/L; ALT 28 U/L.
P00793,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: joint pain. Adherence ~0.70. AE: no.
P00793,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.49. AE: no. CRP 8.8 mg/L; ALT 27 U/L.
P00793,3,negative,Visit 3: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.87. AE: yes.
P00794,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P00794,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.77. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P00794,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.90. AE: yes.
P00794,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no.
P00794,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.58. AE: no. CRP 3.0 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00794,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.51. AE: no.
P00795,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.76. AE: no. CRP 12.8 mg/L; ALT 27 U/L.
P00795,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00795,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.49. AE: yes.
P00796,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.81. AE: no.
P00796,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.87. AE: no. CRP 7.3 mg/L; ALT 24 U/L.
P00796,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.79. AE: no.
P00796,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.78. AE: no.
P00797,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P00797,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.1 mg/L; ALT 21 U/L.
P00797,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00797,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 5.3 mg/L; ALT 23 U/L.
P00797,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.98. AE: no.
P00797,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 3.9 mg/L; ALT 21 U/L.
P00797,6,positive,Visit 6: Patient on RX-17A at S014. feels better overall. Notes: nausea. Adherence ~0.90. AE: no. CRP 4.2 mg/L; ALT 22 U/L.
P00797,7,positive,Visit 7: Patient on RX-17A at S014. symptoms improving. Notes: nausea. Adherence ~0.85. AE: no.
P00798,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: headache. Adherence ~0.86. AE: no. CRP 22.4 mg/L; ALT 34 U/L.
P00798,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: fatigue. Adherence ~0.84. AE: no.
P00798,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00798,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P00798,4,positive,Visit 4: Patient on RX-17B at S004. energy increasing. Notes: dizziness. Adherence ~0.81. AE: no.
P00798,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. CRP 11.8 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00799,0,negative,Visit 0: Patient on RX-17A at S008. symptoms persist. Notes: brain fog. Adherence ~0.43. AE: no.
P00799,1,neutral,Visit 1: Patient on RX-17A at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.43. AE: no. CRP 10.4 mg/L; ALT 55 U/L.
P00799,2,neutral,Visit 2: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P00799,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.41. AE: no. Plan: consider dose adjustment; counsel patient.
P00799,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: headache. Adherence ~0.50. AE: no.
P00800,0,neutral,Visit 0: Patient on RX-17B at S011. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00800,1,negative,Visit 1: Patient on RX-17B at S011. increased discomfort. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. CRP 2.6 mg/L; ALT 60 U/L.
P00800,2,negative,Visit 2: Patient on RX-17B at S011. symptoms persist. Notes: insomnia. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00800,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~0.80. AE: no.
P00800,4,neutral,Visit 4: Patient on RX-17B at S011. stable symptoms. Notes: insomnia. Adherence ~0.62. AE: no. CRP 2.0 mg/L; ALT 52 U/L.
P00800,5,neutral,Visit 5: Patient on RX-17B at S011. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no.
P00801,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: headache. Adherence ~1.00. AE: no.
P00801,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no.
P00801,2,negative,Visit 2: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.80. AE: no.
P00801,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00801,4,positive,Visit 4: Patient on RX-17A at S017. tolerating medication well. Notes: brain fog. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00801,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.0 mg/L; ALT 43 U/L.
P00801,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P00801,7,neutral,Visit 7: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no.
P00802,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: dizziness. Adherence ~0.45. AE: no. CRP 27.4 mg/L; ALT 13 U/L.
P00802,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P00802,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.74. AE: no.
P00802,3,negative,Visit 3: Patient on RX-17B at S019. poor tolerance. Notes: nausea. Adherence ~0.64. AE: no.
P00802,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.62. AE: no. CRP 20.5 mg/L; ALT 14 U/L.
P00802,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.63. AE: no.
P00802,6,neutral,Visit 6: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.70. AE: yes.
P00803,0,negative,Visit 0: Patient on RX-17A at S021. poor tolerance. Notes: insomnia. Adherence ~0.96. AE: no. CRP 4.5 mg/L; ALT 15 U/L.
P00803,1,negative,Visit 1: Patient on RX-17A at S021. feels frustrated. Notes: nausea. Adherence ~0.75. AE: no. CRP 3.6 mg/L; ALT 16 U/L.
P00803,2,positive,Visit 2: Patient on RX-17A at S021. energy increasing. Notes: joint pain. Adherence ~0.77. AE: no. CRP 3.8 mg/L; ALT 15 U/L.
P00803,3,neutral,Visit 3: Patient on RX-17A at S021. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00803,4,neutral,Visit 4: Patient on RX-17A at S021. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no. CRP 3.6 mg/L; ALT 15 U/L.
P00803,5,neutral,Visit 5: Patient on RX-17A at S021. stable symptoms. Notes: headache. Adherence ~0.85. AE: no. CRP 3.1 mg/L; ALT 16 U/L.
P00803,6,positive,Visit 6: Patient on RX-17A at S021. symptoms improving. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00803,7,positive,Visit 7: Patient on RX-17A at S021. symptoms improving. Notes: dizziness. Adherence ~0.87. AE: no. CRP 2.1 mg/L; ALT 15 U/L.
P00804,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: nausea. Adherence ~0.63. AE: no. CRP 8.8 mg/L; ALT 44 U/L.
P00804,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no. CRP 7.4 mg/L; ALT 43 U/L.
P00804,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: nausea. Adherence ~0.53. AE: yes. CRP 6.4 mg/L; ALT 53 U/L.
P00804,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P00805,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: no. CRP 14.1 mg/L; ALT 54 U/L.
P00805,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 13.4 mg/L; ALT 51 U/L.
P00805,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.87. AE: no.
P00805,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P00805,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.97. AE: no.
P00805,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P00805,6,positive,Visit 6: Patient on RX-17A at S022. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no.
P00805,7,positive,Visit 7: Patient on RX-17A at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00806,0,neutral,Visit 0: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00806,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.77. AE: yes.
P00806,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.89. AE: no.
P00806,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.95. AE: no.
P00806,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 6.9 mg/L; ALT 38 U/L.
P00806,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.87. AE: yes. CRP 7.4 mg/L; ALT 43 U/L.
P00807,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.59. AE: yes. CRP 10.4 mg/L; ALT 31 U/L.
P00807,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no. CRP 11.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00807,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: brain fog. Adherence ~0.76. AE: no.
P00807,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P00807,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.91. AE: yes. Plan: consider dose adjustment; counsel patient.
P00808,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P00808,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.84. AE: no.
P00808,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no.
P00808,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no. CRP 9.1 mg/L; ALT 47 U/L.
P00808,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.64. AE: no. CRP 8.2 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00808,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 8.0 mg/L; ALT 46 U/L.
P00808,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00809,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.38. AE: yes.
P00809,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~0.36. AE: no.
P00809,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.55. AE: no.
P00809,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.38. AE: no. Plan: consider dose adjustment; counsel patient.
P00809,4,negative,Visit 4: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.40. AE: no.
P00809,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.56. AE: yes.
P00810,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00810,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P00810,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.97. AE: no. CRP 4.1 mg/L; ALT 45 U/L.
P00810,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P00810,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.99. AE: no.
P00811,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00811,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.85. AE: no. CRP 8.7 mg/L; ALT 15 U/L.
P00811,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.93. AE: no.
P00811,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.73. AE: no.
P00811,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no.
P00811,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00811,6,positive,Visit 6: Patient on RX-17A at S004. feels better overall. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 6.9 mg/L; ALT 18 U/L.
P00811,7,positive,Visit 7: Patient on RX-17A at S004. symptoms improving. Notes: fatigue. Adherence ~0.90. AE: no.
P00812,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.46. AE: yes.
P00812,1,neutral,Visit 1: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~0.50. AE: no.
P00812,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.45. AE: yes. CRP 5.1 mg/L; ALT 37 U/L.
P00812,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: headache. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P00812,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.35. AE: no. CRP 4.2 mg/L; ALT 33 U/L.
P00812,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.49. AE: no.
P00813,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: yes. CRP 5.8 mg/L; ALT 58 U/L.
P00813,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.71. AE: no.
P00813,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P00813,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no. CRP 4.1 mg/L; ALT 64 U/L.
P00813,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.81. AE: no.
P00814,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.76. AE: no. CRP 18.2 mg/L; ALT 37 U/L.
P00814,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P00814,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00814,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no. CRP 12.6 mg/L; ALT 39 U/L.
P00814,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P00814,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P00815,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: joint pain. Adherence ~0.58. AE: no.
P00815,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00815,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.4 mg/L; ALT 46 U/L.
P00815,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.64. AE: no.
P00815,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.1 mg/L; ALT 43 U/L.
P00815,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.69. AE: no.
P00815,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no. CRP 2.9 mg/L; ALT 44 U/L.
P00815,7,positive,Visit 7: Patient on RX-17B at S005. reports improvement. Notes: nausea. Adherence ~0.92. AE: no. CRP 2.4 mg/L; ALT 44 U/L.
P00816,0,neutral,Visit 0: Patient on RX-17B at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no.
P00816,1,neutral,Visit 1: Patient on RX-17B at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.86. AE: no. CRP 15.7 mg/L; ALT 32 U/L.
P00816,2,positive,Visit 2: Patient on RX-17B at S008. reports improvement. Notes: nausea. Adherence ~0.88. AE: no. CRP 16.4 mg/L; ALT 30 U/L.
P00817,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no. CRP 8.8 mg/L; ALT 30 U/L.
P00817,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P00817,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.69. AE: no.
P00817,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.84. AE: no. CRP 7.0 mg/L; ALT 33 U/L.
P00817,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.76. AE: no.
P00818,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.54. AE: no.
P00818,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: brain fog. Adherence ~0.42. AE: no.
P00818,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.61. AE: no.
P00818,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no.
P00818,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.57. AE: no.
P00818,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.52. AE: no.
P00818,6,neutral,Visit 6: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.62. AE: no.
P00818,7,neutral,Visit 7: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P00819,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no.
P00819,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P00819,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no.
P00819,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P00819,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.79. AE: no. CRP 1.9 mg/L; ALT 25 U/L.
P00819,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.75. AE: no.
P00820,0,neutral,Visit 0: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no.
P00820,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.76. AE: no. CRP 22.1 mg/L; ALT 25 U/L.
P00820,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.80. AE: no.
P00820,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no.
P00820,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.83. AE: no.
P00820,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P00821,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.64. AE: no.
P00821,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.49. AE: no. CRP 6.4 mg/L; ALT 24 U/L.
P00821,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.77. AE: no. CRP 6.6 mg/L; ALT 25 U/L.
P00821,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no.
P00821,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00821,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no.
P00821,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: no.
P00821,7,neutral,Visit 7: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no. CRP 4.0 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P00822,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.80. AE: no. CRP 2.1 mg/L; ALT 28 U/L.
P00822,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 2.1 mg/L; ALT 31 U/L.
P00822,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: no. CRP 1.8 mg/L; ALT 31 U/L.
P00822,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: no.
P00822,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P00822,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 1.5 mg/L; ALT 34 U/L.
P00822,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00822,7,neutral,Visit 7: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P00823,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no.
P00823,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.78. AE: yes. CRP 11.9 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00823,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.76. AE: no.
P00823,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no. CRP 10.1 mg/L; ALT 18 U/L.
P00823,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.69. AE: yes. CRP 8.2 mg/L; ALT 18 U/L.
P00824,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.83. AE: no.
P00824,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.88. AE: no. CRP 6.6 mg/L; ALT 39 U/L.
P00824,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.88. AE: yes. CRP 5.8 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P00824,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.98. AE: no. CRP 5.3 mg/L; ALT 39 U/L.
P00824,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: no. CRP 4.8 mg/L; ALT 42 U/L.
P00824,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.84. AE: no. CRP 4.5 mg/L; ALT 44 U/L.
P00824,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: yes. CRP 3.8 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00824,7,neutral,Visit 7: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P00825,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.94. AE: no.
P00825,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00825,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: fatigue. Adherence ~0.90. AE: no.
P00825,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 26 U/L.
P00825,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P00826,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: dizziness. Adherence ~0.76. AE: yes. CRP 12.5 mg/L; ALT 49 U/L.
P00826,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.61. AE: no.
P00826,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no.
P00826,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.45. AE: yes. CRP 9.9 mg/L; ALT 43 U/L.
P00826,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P00826,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.57. AE: no. CRP 5.4 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P00827,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.85. AE: no. CRP 1.9 mg/L; ALT 14 U/L.
P00827,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: headache. Adherence ~0.98. AE: no. CRP 1.7 mg/L; ALT 15 U/L.
P00827,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.94. AE: no.
P00827,3,positive,Visit 3: Patient on RX-17B at S022. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no. CRP 1.5 mg/L; ALT 14 U/L.
P00827,4,positive,Visit 4: Patient on RX-17B at S022. symptoms improving. Notes: brain fog. Adherence ~0.92. AE: no.
P00827,5,positive,Visit 5: Patient on RX-17B at S022. reports improvement. Notes: headache. Adherence ~1.00. AE: no. CRP 1.2 mg/L; ALT 16 U/L.
P00828,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.78. AE: yes. CRP 4.3 mg/L; ALT 44 U/L.
P00828,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 5.3 mg/L; ALT 38 U/L.
P00828,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: yes. CRP 4.6 mg/L; ALT 44 U/L.
P00828,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.45. AE: no. CRP 3.6 mg/L; ALT 42 U/L.
P00828,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.93. AE: no.
P00828,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00828,6,positive,Visit 6: Patient on RX-17B at S004. symptoms improving. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 2.7 mg/L; ALT 44 U/L.
P00828,7,neutral,Visit 7: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 2.1 mg/L; ALT 44 U/L.
P00829,0,negative,Visit 0: Patient on RX-17B at S021. poor tolerance. Notes: brain fog. Adherence ~0.99. AE: no.
P00829,1,negative,Visit 1: Patient on RX-17B at S021. increased discomfort. Notes: headache. Adherence ~0.98. AE: no. CRP 5.5 mg/L; ALT 49 U/L.
P00829,2,neutral,Visit 2: Patient on RX-17B at S021. continues regimen. Notes: nausea. Adherence ~0.84. AE: no.
P00830,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.93. AE: no.
P00830,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.96. AE: yes. Plan: consider dose adjustment; counsel patient.
P00830,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.91. AE: no.
P00830,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00830,4,negative,Visit 4: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: yes. CRP 8.6 mg/L; ALT 38 U/L.
P00831,0,neutral,Visit 0: Patient on RX-17A at S009. no major change. Notes: nausea. Adherence ~0.63. AE: no. CRP 27.6 mg/L; ALT 30 U/L.
P00831,1,negative,Visit 1: Patient on RX-17A at S009. feels frustrated. Notes: insomnia. Adherence ~0.74. AE: no.
P00831,2,neutral,Visit 2: Patient on RX-17A at S009. continues regimen. Notes: nausea. Adherence ~0.71. AE: no. CRP 21.6 mg/L; ALT 31 U/L.
P00832,0,neutral,Visit 0: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.90. AE: no.
P00832,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. CRP 6.3 mg/L; ALT 44 U/L.
P00832,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.74. AE: no. CRP 5.0 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P00832,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P00832,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00832,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: no.
P00833,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.55. AE: no. CRP 10.3 mg/L; ALT 44 U/L.
P00833,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.61. AE: no. CRP 10.2 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00833,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.49. AE: no. CRP 8.7 mg/L; ALT 49 U/L.
P00833,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.64. AE: no.
P00833,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no.
P00833,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no.
P00833,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.55. AE: no.
P00833,7,neutral,Visit 7: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P00834,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: dizziness. Adherence ~0.83. AE: no.
P00834,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.87. AE: yes. CRP 31.5 mg/L; ALT 38 U/L.
P00834,2,negative,Visit 2: Patient on RX-17B at S013. increased discomfort. Notes: headache. Adherence ~1.00. AE: no. CRP 30.6 mg/L; ALT 40 U/L.
P00834,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P00834,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 22.0 mg/L; ALT 36 U/L.
P00834,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00834,6,positive,Visit 6: Patient on RX-17B at S013. reports improvement. Notes: brain fog. Adherence ~0.96. AE: no. CRP 16.2 mg/L; ALT 38 U/L.
P00834,7,positive,Visit 7: Patient on RX-17B at S013. symptoms improving. Notes: dizziness. Adherence ~1.00. AE: no. CRP 12.9 mg/L; ALT 43 U/L.
P00835,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: headache. Adherence ~0.84. AE: no. CRP 6.7 mg/L; ALT 38 U/L.
P00835,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.67. AE: no.
P00835,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: no.
P00835,3,negative,Visit 3: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.73. AE: no.
P00835,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00836,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no.
P00836,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00836,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.70. AE: no.
P00836,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no.
P00836,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P00836,5,neutral,Visit 5: Patient on RX-17B at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no. CRP 5.4 mg/L; ALT 51 U/L.
P00836,6,neutral,Visit 6: Patient on RX-17B at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no. CRP 5.1 mg/L; ALT 60 U/L. Plan: consider dose adjustment; counsel patient.
P00836,7,neutral,Visit 7: Patient on RX-17B at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no. CRP 4.1 mg/L; ALT 63 U/L.
P00837,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: insomnia. Adherence ~0.73. AE: no.
P00837,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: no.
P00837,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: headache. Adherence ~0.79. AE: no.
P00837,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00837,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no. CRP 3.0 mg/L; ALT 42 U/L.
P00837,5,positive,Visit 5: Patient on RX-17A at S016. symptoms improving. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00837,6,neutral,Visit 6: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.70. AE: no.
P00838,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: dizziness. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P00838,1,neutral,Visit 1: Patient on RX-17B at S019. stable symptoms. Notes: insomnia. Adherence ~0.73. AE: no.
P00838,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.51. AE: no.
P00838,3,positive,Visit 3: Patient on RX-17B at S019. feels better overall. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00838,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no. CRP 14.0 mg/L; ALT 26 U/L.
P00838,5,positive,Visit 5: Patient on RX-17B at S019. energy increasing. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 11.7 mg/L; ALT 26 U/L.
P00838,6,neutral,Visit 6: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.66. AE: no. CRP 8.1 mg/L; ALT 24 U/L.
P00838,7,neutral,Visit 7: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00839,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P00839,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.48. AE: no. CRP 5.1 mg/L; ALT 47 U/L.
P00839,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: headache. Adherence ~0.52. AE: yes.
P00839,3,negative,Visit 3: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.77. AE: no. CRP 4.0 mg/L; ALT 52 U/L.
P00839,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no.
P00839,5,neutral,Visit 5: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P00840,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.54. AE: no. CRP 10.2 mg/L; ALT 28 U/L.
P00840,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: headache. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P00840,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: no.
P00840,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00840,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no. CRP 6.7 mg/L; ALT 29 U/L.
P00840,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.63. AE: no.
P00840,6,neutral,Visit 6: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.84. AE: no. CRP 5.2 mg/L; ALT 29 U/L.
P00840,7,neutral,Visit 7: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: no.
P00841,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.41. AE: yes.
P00841,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.41. AE: no. CRP 7.3 mg/L; ALT 31 U/L.
P00841,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.31. AE: no.
P00841,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.44. AE: no. CRP 7.5 mg/L; ALT 30 U/L.
P00841,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.28. AE: no. Plan: consider dose adjustment; counsel patient.
P00841,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.44. AE: no. CRP 6.5 mg/L; ALT 30 U/L.
P00842,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.48. AE: no.
P00842,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P00842,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 7.3 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00842,3,neutral,Visit 3: Patient on RX-17B at S008. no major change. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00842,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: nausea. Adherence ~0.62. AE: no.
P00843,0,neutral,Visit 0: Patient on RX-17B at S008. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P00843,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: nausea. Adherence ~0.66. AE: yes. Plan: consider dose adjustment; counsel patient.
P00843,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no. CRP 5.2 mg/L; ALT 42 U/L.
P00843,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: brain fog. Adherence ~0.59. AE: yes.
P00843,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: headache. Adherence ~0.41. AE: yes.
P00843,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.60. AE: yes.
P00844,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: nausea. Adherence ~0.97. AE: no.
P00844,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 7.4 mg/L; ALT 59 U/L.
P00844,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P00844,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no.
P00844,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 6.0 mg/L; ALT 60 U/L.
P00845,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.74. AE: no. CRP 18.9 mg/L; ALT 26 U/L.
P00845,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00845,2,negative,Visit 2: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.64. AE: yes. CRP 16.4 mg/L; ALT 32 U/L.
P00845,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no.
P00845,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.74. AE: no.
P00845,5,positive,Visit 5: Patient on RX-17B at S022. tolerating medication well. Notes: insomnia. Adherence ~0.79. AE: no.
P00845,6,positive,Visit 6: Patient on RX-17B at S022. feels better overall. Notes: headache. Adherence ~0.86. AE: no.
P00846,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: insomnia. Adherence ~0.67. AE: no.
P00846,1,neutral,Visit 1: Patient on RX-17A at S020. continues regimen. Notes: joint pain. Adherence ~0.66. AE: no.
P00846,2,neutral,Visit 2: Patient on RX-17A at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00846,3,neutral,Visit 3: Patient on RX-17A at S020. no major change. Notes: fatigue. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00846,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: headache. Adherence ~0.76. AE: no. CRP 17.3 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00846,5,neutral,Visit 5: Patient on RX-17A at S020. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: yes. CRP 15.5 mg/L; ALT 60 U/L.
P00846,6,positive,Visit 6: Patient on RX-17A at S020. tolerating medication well. Notes: dizziness. Adherence ~0.77. AE: no.
P00847,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no. CRP 6.6 mg/L; ALT 34 U/L.
P00847,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.74. AE: yes.
P00847,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.85. AE: no.
P00847,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. CRP 5.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00847,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no.
P00847,5,positive,Visit 5: Patient on RX-17A at S017. reports improvement. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00847,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.77. AE: yes. CRP 3.5 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P00847,7,positive,Visit 7: Patient on RX-17A at S017. energy increasing. Notes: fatigue. Adherence ~0.90. AE: no. CRP 3.1 mg/L; ALT 34 U/L.
P00848,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.34. AE: no.
P00848,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.56. AE: no.
P00848,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.50. AE: no.
P00848,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.47. AE: no. CRP 4.2 mg/L; ALT 54 U/L.
P00848,4,negative,Visit 4: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.39. AE: no. CRP 3.7 mg/L; ALT 47 U/L.
P00848,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.50. AE: no.
P00849,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00849,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: no.
P00849,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 4.2 mg/L; ALT 34 U/L.
P00849,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00849,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: no.
P00849,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: yes. CRP 3.7 mg/L; ALT 36 U/L.
P00850,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.62. AE: no.
P00850,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.48. AE: yes. CRP 29.8 mg/L; ALT 24 U/L.
P00850,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.53. AE: no.
P00850,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.45. AE: yes.
P00850,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.52. AE: no. CRP 18.7 mg/L; ALT 28 U/L.
P00850,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.55. AE: no.
P00850,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.68. AE: no.
P00851,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no.
P00851,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no.
P00851,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.83. AE: no.
P00851,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00851,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: yes. CRP 5.3 mg/L; ALT 64 U/L.
P00852,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: no.
P00852,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: dizziness. Adherence ~0.95. AE: yes. CRP 12.5 mg/L; ALT 24 U/L.
P00852,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: yes.
P00852,3,positive,Visit 3: Patient on RX-17B at S013. symptoms improving. Notes: dizziness. Adherence ~0.80. AE: no. CRP 9.1 mg/L; ALT 25 U/L.
P00852,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: yes.
P00853,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 10.2 mg/L; ALT 23 U/L.
P00853,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~0.74. AE: yes.
P00853,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.44. AE: no.
P00853,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P00853,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no. CRP 9.1 mg/L; ALT 25 U/L.
P00853,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00854,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.75. AE: yes.
P00854,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.75. AE: no.
P00854,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.81. AE: no.
P00854,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no.
P00854,4,negative,Visit 4: Patient on RX-17A at S004. increased discomfort. Notes: brain fog. Adherence ~0.83. AE: no. CRP 18.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00855,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.82. AE: yes. CRP 5.8 mg/L; ALT 50 U/L.
P00855,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00855,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: yes.
P00855,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00855,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.98. AE: yes.
P00855,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P00856,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.54. AE: yes.
P00856,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.78. AE: yes. CRP 3.6 mg/L; ALT 51 U/L.
P00856,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.71. AE: no. CRP 3.1 mg/L; ALT 53 U/L.
P00856,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.44. AE: no. CRP 3.4 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P00856,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. CRP 3.0 mg/L; ALT 54 U/L.
P00856,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no. CRP 2.5 mg/L; ALT 53 U/L.
P00856,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no. CRP 2.2 mg/L; ALT 54 U/L.
P00857,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P00857,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P00857,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: no.
P00857,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 17.5 mg/L; ALT 35 U/L.
P00857,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: insomnia. Adherence ~0.91. AE: no.
P00857,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P00858,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.63. AE: no.
P00858,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: nausea. Adherence ~0.57. AE: no. CRP 11.8 mg/L; ALT 20 U/L.
P00858,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: yes.
P00858,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P00858,4,negative,Visit 4: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~0.73. AE: yes. CRP 8.8 mg/L; ALT 24 U/L.
P00859,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.76. AE: no. CRP 8.2 mg/L; ALT 31 U/L.
P00859,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.70. AE: no. CRP 9.6 mg/L; ALT 28 U/L.
P00859,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.96. AE: yes.
P00859,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no. CRP 7.5 mg/L; ALT 31 U/L.
P00859,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 6.5 mg/L; ALT 34 U/L.
P00859,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: dizziness. Adherence ~0.90. AE: no. CRP 6.9 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00859,6,positive,Visit 6: Patient on RX-17A at S014. tolerating medication well. Notes: fatigue. Adherence ~0.81. AE: no.
P00860,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.40. AE: no.
P00860,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: insomnia. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00860,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00860,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no.
P00860,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.54. AE: no. CRP 9.4 mg/L; ALT 28 U/L.
P00860,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no.
P00860,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P00861,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: dizziness. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00861,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: yes.
P00861,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no.
P00861,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no.
P00861,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: headache. Adherence ~0.93. AE: no.
P00862,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: insomnia. Adherence ~0.81. AE: no.
P00862,1,positive,Visit 1: Patient on RX-17A at S002. tolerating medication well. Notes: brain fog. Adherence ~0.84. AE: no.
P00862,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.61. AE: no.
P00863,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.97. AE: no.
P00863,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 7.8 mg/L; ALT 39 U/L.
P00863,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.81. AE: no.
P00863,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P00863,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P00863,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.3 mg/L; ALT 34 U/L.
P00863,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no. CRP 4.9 mg/L; ALT 38 U/L.
P00863,7,neutral,Visit 7: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.67. AE: no.
P00864,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00864,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: fatigue. Adherence ~0.60. AE: no.
P00864,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: yes. CRP 12.0 mg/L; ALT 31 U/L.
P00864,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00865,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.67. AE: no. CRP 9.1 mg/L; ALT 31 U/L.
P00865,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.82. AE: no.
P00865,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 34 U/L.
P00865,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.73. AE: no.
P00865,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.70. AE: yes.
P00865,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: yes. CRP 6.1 mg/L; ALT 37 U/L.
P00865,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: yes. CRP 5.1 mg/L; ALT 41 U/L.
P00865,7,positive,Visit 7: Patient on RX-17B at S012. tolerating medication well. Notes: brain fog. Adherence ~0.76. AE: no.
P00866,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.68. AE: no.
P00866,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00866,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.81. AE: no.
P00866,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.46. AE: no. CRP 4.3 mg/L; ALT 15 U/L.
P00866,4,negative,Visit 4: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.71. AE: no. CRP 4.2 mg/L; ALT 15 U/L.
P00866,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P00866,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P00866,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no. CRP 3.7 mg/L; ALT 17 U/L.
P00867,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no.
P00867,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.79. AE: no.
P00867,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.85. AE: no.
P00867,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: yes. CRP 5.4 mg/L; ALT 58 U/L.
P00867,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P00867,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.9 mg/L; ALT 60 U/L.
P00867,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.63. AE: yes.
P00868,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.96. AE: no. CRP 6.2 mg/L; ALT 28 U/L.
P00868,1,negative,Visit 1: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00868,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: nausea. Adherence ~0.87. AE: no.
P00868,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 4.5 mg/L; ALT 28 U/L.
P00868,4,negative,Visit 4: Patient on RX-17A at S013. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.3 mg/L; ALT 29 U/L.
P00868,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P00868,6,positive,Visit 6: Patient on RX-17A at S013. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 25 U/L.
P00869,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~1.00. AE: no.
P00869,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P00869,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00869,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no.
P00869,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no. CRP 5.6 mg/L; ALT 42 U/L.
P00870,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.75. AE: no. CRP 5.7 mg/L; ALT 32 U/L.
P00870,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P00870,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: insomnia. Adherence ~0.62. AE: no.
P00870,3,negative,Visit 3: Patient on RX-17B at S005. reports worsening. Notes: joint pain. Adherence ~0.60. AE: yes.
P00870,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.55. AE: no. CRP 3.7 mg/L; ALT 35 U/L.
P00871,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.84. AE: no. CRP 8.7 mg/L; ALT 36 U/L.
P00871,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P00871,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 9.2 mg/L; ALT 36 U/L.
P00871,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: no.
P00871,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.84. AE: no.
P00871,5,positive,Visit 5: Patient on RX-17A at S022. feels better overall. Notes: insomnia. Adherence ~0.77. AE: no. CRP 6.9 mg/L; ALT 34 U/L.
P00871,6,positive,Visit 6: Patient on RX-17A at S022. energy increasing. Notes: headache. Adherence ~1.00. AE: no.
P00872,0,neutral,Visit 0: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no.
P00872,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.70. AE: no.
P00872,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00872,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.54. AE: no. CRP 7.1 mg/L; ALT 23 U/L.
P00873,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.88. AE: no. CRP 8.1 mg/L; ALT 23 U/L.
P00873,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 7.4 mg/L; ALT 23 U/L.
P00873,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 7.4 mg/L; ALT 22 U/L.
P00873,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.82. AE: no. CRP 6.4 mg/L; ALT 24 U/L.
P00873,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.96. AE: no.
P00873,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no. CRP 4.8 mg/L; ALT 23 U/L.
P00874,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P00874,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.46. AE: no. CRP 7.4 mg/L; ALT 19 U/L.
P00874,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.47. AE: no.
P00874,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.54. AE: no.
P00874,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P00874,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.39. AE: no.
P00875,0,neutral,Visit 0: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P00875,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P00875,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.92. AE: no.
P00875,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00875,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P00875,5,positive,Visit 5: Patient on RX-17B at S005. tolerating medication well. Notes: insomnia. Adherence ~0.78. AE: no.
P00875,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no.
P00876,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: yes.
P00876,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no.
P00876,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P00876,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: no. CRP 5.6 mg/L; ALT 48 U/L.
P00876,4,positive,Visit 4: Patient on RX-17A at S022. symptoms improving. Notes: brain fog. Adherence ~0.91. AE: no.
P00876,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.75. AE: no.
P00876,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P00877,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.56. AE: no.
P00877,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.59. AE: yes. CRP 3.0 mg/L; ALT 38 U/L.
P00877,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no.
P00878,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.98. AE: no. CRP 6.9 mg/L; ALT 23 U/L.
P00878,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 24 U/L.
P00878,2,negative,Visit 2: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no.
P00878,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P00878,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00878,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 22 U/L.
P00879,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.97. AE: no.
P00879,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no.
P00879,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.84. AE: no.
P00879,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P00879,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00879,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: fatigue. Adherence ~0.94. AE: no.
P00880,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P00880,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00880,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: abdominal discomfort. Adherence ~0.69. AE: yes. CRP 7.3 mg/L; ALT 29 U/L.
P00880,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.73. AE: yes.
P00880,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no.
P00881,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00881,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: insomnia. Adherence ~0.85. AE: no. CRP 4.6 mg/L; ALT 26 U/L.
P00881,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no.
P00881,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P00881,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 3.6 mg/L; ALT 26 U/L.
P00881,5,positive,Visit 5: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.8 mg/L; ALT 31 U/L.
P00882,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~0.66. AE: yes. CRP 2.4 mg/L; ALT 31 U/L.
P00882,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.62. AE: yes. CRP 2.3 mg/L; ALT 34 U/L.
P00882,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no. CRP 2.1 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00882,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00882,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.57. AE: no. CRP 1.4 mg/L; ALT 32 U/L.
P00883,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: no.
P00883,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. CRP 21.3 mg/L; ALT 40 U/L.
P00883,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no.
P00883,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no. CRP 18.6 mg/L; ALT 41 U/L.
P00883,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: yes.
P00884,0,neutral,Visit 0: Patient on RX-17B at S006. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no.
P00884,1,negative,Visit 1: Patient on RX-17B at S006. reports worsening. Notes: fatigue. Adherence ~0.98. AE: yes.
P00884,2,neutral,Visit 2: Patient on RX-17B at S006. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no.
P00885,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: headache. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00885,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.57. AE: no.
P00885,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.55. AE: no. CRP 13.7 mg/L; ALT 29 U/L.
P00885,3,negative,Visit 3: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.40. AE: yes.
P00885,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.30. AE: no.
P00885,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00885,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.76. AE: yes. CRP 7.3 mg/L; ALT 29 U/L.
P00886,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: dizziness. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P00886,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.71. AE: no.
P00886,2,negative,Visit 2: Patient on RX-17A at S013. reports worsening. Notes: headache. Adherence ~0.73. AE: no. CRP 3.9 mg/L; ALT 39 U/L.
P00886,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P00886,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no.
P00886,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00886,6,neutral,Visit 6: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00887,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.41. AE: no. CRP 16.7 mg/L; ALT 35 U/L.
P00887,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.46. AE: no.
P00887,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.55. AE: no.
P00887,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.36. AE: no.
P00887,4,negative,Visit 4: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P00887,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.50. AE: no. CRP 12.7 mg/L; ALT 37 U/L.
P00887,6,neutral,Visit 6: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.47. AE: no.
P00887,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 9.0 mg/L; ALT 36 U/L.
P00888,0,negative,Visit 0: Patient on RX-17B at S001. reports worsening. Notes: dizziness. Adherence ~0.58. AE: no. CRP 3.6 mg/L; ALT 46 U/L.
P00888,1,negative,Visit 1: Patient on RX-17B at S001. feels frustrated. Notes: nausea. Adherence ~0.84. AE: no. CRP 3.6 mg/L; ALT 53 U/L.
P00888,2,neutral,Visit 2: Patient on RX-17B at S001. no major change. Notes: brain fog. Adherence ~0.77. AE: no.
P00888,3,neutral,Visit 3: Patient on RX-17B at S001. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P00888,4,neutral,Visit 4: Patient on RX-17B at S001. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: yes. CRP 2.9 mg/L; ALT 52 U/L.
P00889,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.3 mg/L; ALT 50 U/L.
P00889,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P00889,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P00889,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~0.89. AE: no. CRP 5.6 mg/L; ALT 52 U/L.
P00889,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P00889,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.93. AE: no.
P00890,0,negative,Visit 0: Patient on RX-17B at S011. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no.
P00890,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.5 mg/L; ALT 19 U/L.
P00890,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P00890,3,neutral,Visit 3: Patient on RX-17B at S011. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P00890,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: yes.
P00890,5,neutral,Visit 5: Patient on RX-17B at S011. no major change. Notes: fatigue. Adherence ~0.89. AE: no.
P00890,6,positive,Visit 6: Patient on RX-17B at S011. reports improvement. Notes: insomnia. Adherence ~0.92. AE: no.
P00891,0,neutral,Visit 0: Patient on RX-17A at S003. stable symptoms. Notes: insomnia. Adherence ~0.65. AE: no. CRP 33.9 mg/L; ALT 33 U/L.
P00891,1,neutral,Visit 1: Patient on RX-17A at S003. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P00891,2,neutral,Visit 2: Patient on RX-17A at S003. follow-up as scheduled. Notes: insomnia. Adherence ~0.43. AE: no.
P00891,3,neutral,Visit 3: Patient on RX-17A at S003. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 23.2 mg/L; ALT 33 U/L.
P00891,4,neutral,Visit 4: Patient on RX-17A at S003. follow-up as scheduled. Notes: insomnia. Adherence ~0.59. AE: no. CRP 22.5 mg/L; ALT 30 U/L.
P00892,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P00892,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no. CRP 6.0 mg/L; ALT 25 U/L.
P00892,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no.
P00892,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 4.9 mg/L; ALT 27 U/L.
P00892,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no.
P00892,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.70. AE: no. CRP 3.6 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P00893,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.78. AE: yes.
P00893,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no.
P00893,2,positive,Visit 2: Patient on RX-17B at S004. tolerating medication well. Notes: headache. Adherence ~0.85. AE: no. CRP 9.2 mg/L; ALT 19 U/L.
P00893,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 8.6 mg/L; ALT 18 U/L.
P00893,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.74. AE: no. CRP 7.7 mg/L; ALT 22 U/L.
P00893,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P00893,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no.
P00893,7,neutral,Visit 7: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no. CRP 5.0 mg/L; ALT 22 U/L.
P00894,0,neutral,Visit 0: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.86. AE: no.
P00894,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P00894,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P00894,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00894,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P00894,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P00894,6,positive,Visit 6: Patient on RX-17A at S005. energy increasing. Notes: headache. Adherence ~0.78. AE: no. CRP 6.6 mg/L; ALT 24 U/L.
P00894,7,neutral,Visit 7: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.81. AE: yes.
P00895,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: no.
P00895,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no.
P00895,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.54. AE: no.
P00895,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.72. AE: no.
P00895,4,negative,Visit 4: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~0.81. AE: no.
P00895,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.66. AE: no.
P00896,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: fatigue. Adherence ~0.48. AE: no. CRP 9.1 mg/L; ALT 28 U/L.
P00896,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.43. AE: no. Plan: consider dose adjustment; counsel patient.
P00896,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.61. AE: no.
P00896,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00896,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.58. AE: yes.
P00897,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no.
P00897,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: nausea. Adherence ~0.65. AE: no.
P00897,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.59. AE: no.
P00897,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P00897,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.71. AE: no. CRP 11.3 mg/L; ALT 26 U/L.
P00897,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.59. AE: yes.
P00898,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 11.6 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P00898,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no. CRP 10.0 mg/L; ALT 27 U/L.
P00898,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~0.99. AE: no.
P00898,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.91. AE: no.
P00898,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 7.2 mg/L; ALT 33 U/L.
P00898,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.89. AE: no. CRP 7.6 mg/L; ALT 31 U/L.
P00898,6,neutral,Visit 6: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.99. AE: no.
P00898,7,positive,Visit 7: Patient on RX-17A at S012. tolerating medication well. Notes: insomnia. Adherence ~0.94. AE: no. CRP 5.5 mg/L; ALT 33 U/L.
P00899,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: yes. Plan: consider dose adjustment; counsel patient.
P00899,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: dizziness. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 70 U/L.
P00899,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00899,3,positive,Visit 3: Patient on RX-17A at S017. reports improvement. Notes: insomnia. Adherence ~0.78. AE: no. CRP 7.1 mg/L; ALT 72 U/L.
P00899,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.63. AE: no. CRP 5.6 mg/L; ALT 68 U/L. Plan: consider dose adjustment; counsel patient.
P00900,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P00900,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.86. AE: no. CRP 9.3 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P00900,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 8.0 mg/L; ALT 17 U/L.
P00900,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: no. CRP 8.0 mg/L; ALT 15 U/L.
P00900,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P00901,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P00901,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.66. AE: yes.
P00901,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.73. AE: no. CRP 17.9 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P00901,3,positive,Visit 3: Patient on RX-17A at S015. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no. CRP 16.2 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P00901,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.90. AE: no. CRP 16.7 mg/L; ALT 46 U/L.
P00901,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.87. AE: yes. CRP 12.5 mg/L; ALT 52 U/L.
P00902,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.97. AE: no.
P00902,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.93. AE: no. CRP 6.2 mg/L; ALT 27 U/L.
P00902,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.65. AE: no. CRP 5.1 mg/L; ALT 31 U/L.
P00902,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.91. AE: no.
P00902,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P00902,5,positive,Visit 5: Patient on RX-17A at S015. energy increasing. Notes: dizziness. Adherence ~0.77. AE: no.
P00902,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.74. AE: no.
P00902,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.68. AE: no.
P00903,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no. CRP 3.1 mg/L; ALT 24 U/L.
P00903,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: insomnia. Adherence ~0.85. AE: no.
P00903,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no.
P00903,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: no. CRP 2.1 mg/L; ALT 26 U/L.
P00903,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~1.00. AE: yes. CRP 1.7 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00903,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: fatigue. Adherence ~0.94. AE: no. CRP 1.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00903,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.97. AE: no.
P00903,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.94. AE: yes. CRP 1.1 mg/L; ALT 32 U/L.
P00904,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: fatigue. Adherence ~0.92. AE: no. CRP 4.0 mg/L; ALT 14 U/L.
P00904,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 4.1 mg/L; ALT 14 U/L.
P00904,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no.
P00904,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.97. AE: no. CRP 3.1 mg/L; ALT 13 U/L.
P00904,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.99. AE: no. CRP 3.1 mg/L; ALT 18 U/L.
P00904,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: yes. CRP 2.8 mg/L; ALT 17 U/L.
P00905,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.95. AE: no.
P00905,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.56. AE: no. CRP 3.4 mg/L; ALT 39 U/L.
P00905,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.76. AE: no.
P00905,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: yes. Plan: consider dose adjustment; counsel patient.
P00905,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P00905,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.92. AE: yes. CRP 2.6 mg/L; ALT 48 U/L.
P00906,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 4.1 mg/L; ALT 17 U/L.
P00906,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.63. AE: no.
P00906,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: no. CRP 4.2 mg/L; ALT 16 U/L.
P00906,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.66. AE: no.
P00906,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P00906,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.72. AE: no. CRP 2.9 mg/L; ALT 18 U/L.
P00906,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no.
P00906,7,positive,Visit 7: Patient on RX-17A at S005. reports improvement. Notes: insomnia. Adherence ~0.85. AE: no.
P00907,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~1.00. AE: no.
P00907,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00907,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00907,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00908,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.66. AE: yes.
P00908,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.77. AE: no. CRP 6.2 mg/L; ALT 58 U/L.
P00908,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P00908,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P00908,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00909,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: yes. CRP 8.0 mg/L; ALT 20 U/L.
P00909,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.97. AE: no.
P00909,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no. CRP 7.7 mg/L; ALT 18 U/L.
P00909,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no. CRP 6.4 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00909,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.97. AE: no.
P00909,5,negative,Visit 5: Patient on RX-17A at S002. symptoms persist. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00910,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.61. AE: no.
P00910,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.63. AE: no.
P00910,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P00910,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no.
P00910,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.45. AE: no.
P00910,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.62. AE: no. CRP 5.0 mg/L; ALT 44 U/L.
P00910,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P00910,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.57. AE: yes. CRP 3.6 mg/L; ALT 54 U/L.
P00911,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 5.4 mg/L; ALT 29 U/L.
P00911,1,negative,Visit 1: Patient on RX-17A at S020. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.6 mg/L; ALT 31 U/L.
P00911,2,neutral,Visit 2: Patient on RX-17A at S020. stable symptoms. Notes: fatigue. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P00911,3,negative,Visit 3: Patient on RX-17A at S020. reports worsening. Notes: headache. Adherence ~0.88. AE: no.
P00911,4,negative,Visit 4: Patient on RX-17A at S020. feels frustrated. Notes: nausea. Adherence ~1.00. AE: yes.
P00911,5,neutral,Visit 5: Patient on RX-17A at S020. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P00911,6,neutral,Visit 6: Patient on RX-17A at S020. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no. CRP 3.2 mg/L; ALT 31 U/L.
P00912,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.94. AE: no.
P00912,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: dizziness. Adherence ~0.72. AE: yes.
P00912,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.85. AE: no.
P00912,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.69. AE: no.
P00912,4,positive,Visit 4: Patient on RX-17A at S017. feels better overall. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 9.6 mg/L; ALT 15 U/L.
P00913,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.57. AE: no.
P00913,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.59. AE: no.
P00913,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.79. AE: no. CRP 9.0 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P00913,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P00913,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.54. AE: no.
P00913,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.56. AE: no.
P00913,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.50. AE: no. CRP 6.7 mg/L; ALT 19 U/L.
P00913,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: no.
P00914,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.58. AE: no.
P00914,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no.
P00914,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.93. AE: no. CRP 13.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00914,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no. CRP 13.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00914,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no. CRP 12.9 mg/L; ALT 32 U/L.
P00915,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: fatigue. Adherence ~0.72. AE: no.
P00915,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 11.6 mg/L; ALT 34 U/L.
P00915,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: fatigue. Adherence ~0.80. AE: no. CRP 11.4 mg/L; ALT 33 U/L.
P00915,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P00915,4,positive,Visit 4: Patient on RX-17B at S015. tolerating medication well. Notes: dizziness. Adherence ~0.96. AE: no.
P00916,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: fatigue. Adherence ~0.56. AE: no.
P00916,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.49. AE: yes.
P00916,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P00916,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.48. AE: no. CRP 5.2 mg/L; ALT 18 U/L.
P00916,4,negative,Visit 4: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.54. AE: no. CRP 4.4 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00917,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~0.77. AE: no.
P00917,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.44. AE: no.
P00917,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 13.6 mg/L; ALT 32 U/L.
P00917,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.48. AE: no. CRP 12.3 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00917,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.67. AE: no. CRP 11.7 mg/L; ALT 30 U/L.
P00918,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no. CRP 8.4 mg/L; ALT 40 U/L.
P00918,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no. CRP 8.5 mg/L; ALT 41 U/L.
P00918,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00918,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.74. AE: yes.
P00918,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.77. AE: no.
P00918,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: no.
P00918,6,neutral,Visit 6: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no. CRP 6.0 mg/L; ALT 46 U/L.
P00919,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.83. AE: no. CRP 11.5 mg/L; ALT 41 U/L.
P00919,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P00919,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P00919,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.67. AE: no.
P00919,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 7.2 mg/L; ALT 46 U/L.
P00919,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no.
P00919,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.55. AE: no. CRP 5.9 mg/L; ALT 45 U/L.
P00920,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no. CRP 11.2 mg/L; ALT 21 U/L.
P00920,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 10.4 mg/L; ALT 29 U/L.
P00920,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no. CRP 8.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P00920,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P00920,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.83. AE: no.
P00921,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.84. AE: no.
P00921,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.66. AE: no. CRP 6.9 mg/L; ALT 34 U/L.
P00921,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.55. AE: yes. CRP 5.9 mg/L; ALT 36 U/L.
P00921,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.61. AE: no.
P00921,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.77. AE: no.
P00922,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: joint pain. Adherence ~0.69. AE: no.
P00922,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no.
P00922,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no.
P00922,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P00922,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no.
P00922,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no. CRP 4.9 mg/L; ALT 49 U/L.
P00922,6,positive,Visit 6: Patient on RX-17B at S017. reports improvement. Notes: nausea. Adherence ~0.81. AE: no. CRP 4.0 mg/L; ALT 47 U/L.
P00923,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P00923,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 6.9 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P00923,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.64. AE: no.
P00923,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.87. AE: no.
P00923,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.48. AE: no.
P00923,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.77. AE: yes.
P00923,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P00924,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: fatigue. Adherence ~0.70. AE: no.
P00924,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: fatigue. Adherence ~0.60. AE: no.
P00924,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no.
P00924,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no.
P00924,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.67. AE: no.
P00924,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.72. AE: no.
P00925,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P00925,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00925,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: fatigue. Adherence ~0.93. AE: no.
P00925,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.99. AE: no.
P00925,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P00925,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P00925,6,neutral,Visit 6: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 1.7 mg/L; ALT 35 U/L.
P00926,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.62. AE: no.
P00926,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.69. AE: no. CRP 5.2 mg/L; ALT 32 U/L.
P00926,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.88. AE: no.
P00926,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 3.8 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P00926,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: no.
P00927,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00927,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.62. AE: no.
P00927,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00927,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.77. AE: no. CRP 5.9 mg/L; ALT 33 U/L.
P00927,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00928,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.61. AE: no.
P00928,1,neutral,Visit 1: Patient on RX-17A at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no.
P00928,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 12.4 mg/L; ALT 22 U/L.
P00928,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.72. AE: no.
P00928,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.55. AE: no.
P00928,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.60. AE: no.
P00929,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P00929,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.50. AE: no.
P00929,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.51. AE: no. CRP 9.9 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P00929,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00929,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P00929,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no. CRP 6.8 mg/L; ALT 44 U/L.
P00929,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P00930,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P00930,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.99. AE: no.
P00930,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: yes.
P00930,3,positive,Visit 3: Patient on RX-17B at S004. symptoms improving. Notes: joint pain. Adherence ~0.96. AE: no. CRP 5.7 mg/L; ALT 16 U/L.
P00930,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 20 U/L.
P00930,5,positive,Visit 5: Patient on RX-17B at S004. reports improvement. Notes: headache. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00931,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.94. AE: no.
P00931,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: nausea. Adherence ~0.77. AE: no.
P00931,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 3.9 mg/L; ALT 29 U/L.
P00931,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00931,4,negative,Visit 4: Patient on RX-17A at S004. symptoms persist. Notes: dizziness. Adherence ~0.79. AE: no.
P00931,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.86. AE: no. CRP 3.0 mg/L; ALT 26 U/L.
P00931,6,neutral,Visit 6: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no. CRP 2.9 mg/L; ALT 23 U/L.
P00931,7,positive,Visit 7: Patient on RX-17A at S004. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00932,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: nausea. Adherence ~0.91. AE: no.
P00932,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P00932,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P00932,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no. CRP 5.2 mg/L; ALT 28 U/L.
P00932,4,positive,Visit 4: Patient on RX-17B at S016. energy increasing. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00932,5,neutral,Visit 5: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.80. AE: yes.
P00933,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.61. AE: no.
P00933,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no. CRP 3.8 mg/L; ALT 37 U/L.
P00933,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.87. AE: no.
P00933,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.73. AE: no. CRP 3.3 mg/L; ALT 35 U/L.
P00933,4,negative,Visit 4: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.63. AE: yes.
P00933,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 2.4 mg/L; ALT 38 U/L.
P00933,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 2.3 mg/L; ALT 41 U/L.
P00933,7,neutral,Visit 7: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no.
P00934,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.94. AE: no. CRP 2.4 mg/L; ALT 38 U/L.
P00934,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no.
P00934,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.86. AE: no. CRP 2.2 mg/L; ALT 42 U/L.
P00934,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P00934,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00934,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no.
P00935,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: fatigue. Adherence ~0.68. AE: no. CRP 3.1 mg/L; ALT 51 U/L.
P00935,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P00935,2,neutral,Visit 2: Patient on RX-17B at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 2.5 mg/L; ALT 52 U/L.
P00935,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P00935,4,negative,Visit 4: Patient on RX-17B at S002. increased discomfort. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 2.4 mg/L; ALT 59 U/L.
P00935,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.99. AE: no.
P00936,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.76. AE: no. CRP 15.7 mg/L; ALT 28 U/L.
P00936,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00936,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P00936,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.88. AE: no. CRP 12.2 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00936,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00936,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.67. AE: yes. CRP 11.0 mg/L; ALT 34 U/L.
P00936,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: yes.
P00937,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P00937,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.83. AE: no.
P00937,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P00937,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no.
P00937,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P00937,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00937,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.72. AE: yes.
P00938,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.87. AE: yes. CRP 10.5 mg/L; ALT 32 U/L.
P00938,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P00938,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.82. AE: no.
P00938,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.66. AE: yes. CRP 9.1 mg/L; ALT 31 U/L.
P00939,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P00939,1,neutral,Visit 1: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. CRP 7.2 mg/L; ALT 28 U/L.
P00939,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P00939,3,negative,Visit 3: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P00939,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P00939,5,positive,Visit 5: Patient on RX-17A at S019. reports improvement. Notes: nausea. Adherence ~0.90. AE: no. CRP 4.9 mg/L; ALT 27 U/L.
P00939,6,positive,Visit 6: Patient on RX-17A at S019. reports improvement. Notes: dizziness. Adherence ~0.78. AE: no. CRP 4.4 mg/L; ALT 26 U/L.
P00939,7,neutral,Visit 7: Patient on RX-17A at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 3.9 mg/L; ALT 31 U/L.
P00940,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P00940,1,neutral,Visit 1: Patient on RX-17B at S008. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: no. CRP 3.2 mg/L; ALT 35 U/L.
P00940,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P00940,3,neutral,Visit 3: Patient on RX-17B at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no.
P00941,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P00941,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no.
P00941,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 5.4 mg/L; ALT 20 U/L.
P00941,3,negative,Visit 3: Patient on RX-17B at S016. symptoms persist. Notes: nausea. Adherence ~0.72. AE: no. CRP 5.4 mg/L; ALT 21 U/L.
P00941,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no.
P00941,5,positive,Visit 5: Patient on RX-17B at S016. reports improvement. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00942,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P00942,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: fatigue. Adherence ~0.80. AE: no. CRP 9.9 mg/L; ALT 27 U/L.
P00942,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: no. CRP 9.4 mg/L; ALT 28 U/L.
P00942,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00942,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 8.7 mg/L; ALT 28 U/L.
P00943,0,negative,Visit 0: Patient on RX-17A at S011. symptoms persist. Notes: headache. Adherence ~0.78. AE: no. CRP 12.6 mg/L; ALT 54 U/L.
P00943,1,negative,Visit 1: Patient on RX-17A at S011. feels frustrated. Notes: nausea. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00943,2,neutral,Visit 2: Patient on RX-17A at S011. continues regimen. Notes: joint pain. Adherence ~0.59. AE: no.
P00943,3,neutral,Visit 3: Patient on RX-17A at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00943,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: headache. Adherence ~0.62. AE: no.
P00943,5,neutral,Visit 5: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: no.
P00943,6,neutral,Visit 6: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P00944,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P00944,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: no.
P00944,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.95. AE: no.
P00944,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.95. AE: no. CRP 9.2 mg/L; ALT 33 U/L.
P00944,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.87. AE: no.
P00945,0,negative,Visit 0: Patient on RX-17B at S011. symptoms persist. Notes: abdominal discomfort. Adherence ~0.67. AE: yes. Plan: consider dose adjustment; counsel patient.
P00945,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no. CRP 13.7 mg/L; ALT 21 U/L.
P00945,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: nausea. Adherence ~0.69. AE: no.
P00945,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 11.2 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P00945,4,neutral,Visit 4: Patient on RX-17B at S011. no major change. Notes: joint pain. Adherence ~0.68. AE: no. CRP 10.2 mg/L; ALT 22 U/L.
P00945,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: yes. CRP 8.0 mg/L; ALT 24 U/L.
P00945,6,neutral,Visit 6: Patient on RX-17B at S011. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 5.4 mg/L; ALT 21 U/L.
P00945,7,positive,Visit 7: Patient on RX-17B at S011. reports improvement. Notes: headache. Adherence ~0.92. AE: no. CRP 4.6 mg/L; ALT 22 U/L.
P00946,0,neutral,Visit 0: Patient on RX-17B at S016. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P00946,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: brain fog. Adherence ~0.68. AE: yes.
P00946,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.64. AE: no.
P00946,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.64. AE: no. CRP 18.1 mg/L; ALT 30 U/L.
P00946,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: no.
P00947,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P00947,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P00947,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 4.9 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P00947,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P00947,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P00948,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: headache. Adherence ~0.69. AE: no.
P00948,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no. CRP 31.4 mg/L; ALT 28 U/L.
P00948,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no.
P00948,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no. CRP 27.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00948,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no.
P00948,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no. CRP 18.8 mg/L; ALT 31 U/L.
P00948,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no. CRP 20.3 mg/L; ALT 31 U/L.
P00949,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~1.00. AE: no.
P00949,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P00949,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.92. AE: no. CRP 2.3 mg/L; ALT 53 U/L.
P00949,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.99. AE: yes. CRP 1.9 mg/L; ALT 59 U/L.
P00949,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no.
P00950,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: dizziness. Adherence ~0.55. AE: no.
P00950,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P00950,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: yes.
P00950,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.41. AE: no. CRP 3.2 mg/L; ALT 24 U/L.
P00950,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: yes.
P00951,0,neutral,Visit 0: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no.
P00951,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: headache. Adherence ~0.84. AE: no.
P00951,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.97. AE: no.
P00951,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.90. AE: no. CRP 6.6 mg/L; ALT 17 U/L.
P00951,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no. CRP 5.7 mg/L; ALT 18 U/L.
P00952,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P00952,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00952,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~0.78. AE: yes.
P00952,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00952,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 7.0 mg/L; ALT 24 U/L.
P00953,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: insomnia. Adherence ~0.53. AE: no. CRP 6.9 mg/L; ALT 39 U/L.
P00953,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no.
P00953,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P00953,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.56. AE: yes.
P00953,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 4.3 mg/L; ALT 40 U/L.
P00953,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: no. CRP 5.3 mg/L; ALT 44 U/L.
P00953,6,neutral,Visit 6: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.36. AE: no.
P00953,7,neutral,Visit 7: Patient on RX-17A at S008. follow-up as scheduled. Notes: fatigue. Adherence ~0.62. AE: yes. CRP 4.1 mg/L; ALT 49 U/L.
P00954,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P00954,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no.
P00954,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.92. AE: no.
P00954,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P00954,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P00954,5,positive,Visit 5: Patient on RX-17A at S015. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 53 U/L. Plan: consider dose adjustment; counsel patient.
P00954,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no. CRP 3.7 mg/L; ALT 56 U/L.
P00954,7,positive,Visit 7: Patient on RX-17A at S015. tolerating medication well. Notes: joint pain. Adherence ~0.98. AE: no.
P00955,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.95. AE: no. CRP 23.5 mg/L; ALT 36 U/L.
P00955,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: no.
P00955,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.72. AE: no. CRP 23.6 mg/L; ALT 40 U/L.
P00955,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no. CRP 18.9 mg/L; ALT 34 U/L.
P00955,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.96. AE: yes. Plan: consider dose adjustment; counsel patient.
P00955,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P00956,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.73. AE: no. CRP 6.0 mg/L; ALT 20 U/L.
P00956,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 6.3 mg/L; ALT 19 U/L.
P00956,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.61. AE: no.
P00956,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P00956,4,negative,Visit 4: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: no.
P00956,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.70. AE: no. CRP 3.6 mg/L; ALT 20 U/L.
P00957,0,neutral,Visit 0: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P00957,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: joint pain. Adherence ~0.86. AE: no.
P00957,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P00957,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no. CRP 3.0 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P00957,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.88. AE: no.
P00957,5,positive,Visit 5: Patient on RX-17B at S013. feels better overall. Notes: nausea. Adherence ~0.98. AE: no.
P00957,6,neutral,Visit 6: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P00957,7,positive,Visit 7: Patient on RX-17B at S013. feels better overall. Notes: nausea. Adherence ~0.85. AE: no. CRP 1.8 mg/L; ALT 33 U/L.
P00958,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: dizziness. Adherence ~0.84. AE: no.
P00958,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 16.8 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P00958,2,negative,Visit 2: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no. CRP 13.8 mg/L; ALT 53 U/L.
P00958,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no. CRP 14.0 mg/L; ALT 61 U/L.
P00958,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.91. AE: no.
P00959,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P00959,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.87. AE: no. CRP 9.9 mg/L; ALT 28 U/L.
P00959,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 10.3 mg/L; ALT 26 U/L.
P00959,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 7.7 mg/L; ALT 24 U/L.
P00959,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.97. AE: no.
P00960,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: brain fog. Adherence ~0.43. AE: yes.
P00960,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: fatigue. Adherence ~0.41. AE: no.
P00960,2,negative,Visit 2: Patient on RX-17A at S013. reports worsening. Notes: fatigue. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P00960,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.62. AE: no.
P00960,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.50. AE: no.
P00960,5,neutral,Visit 5: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.46. AE: no. CRP 8.3 mg/L; ALT 33 U/L.
P00960,6,neutral,Visit 6: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.39. AE: no.
P00961,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: brain fog. Adherence ~0.72. AE: yes. Plan: consider dose adjustment; counsel patient.
P00961,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: headache. Adherence ~0.81. AE: no.
P00961,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 6.6 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00961,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00961,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no. CRP 5.6 mg/L; ALT 33 U/L.
P00961,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.63. AE: no.
P00961,6,positive,Visit 6: Patient on RX-17B at S019. reports improvement. Notes: dizziness. Adherence ~0.89. AE: no.
P00962,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.79. AE: no.
P00962,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: yes. CRP 2.9 mg/L; ALT 18 U/L.
P00962,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.89. AE: no.
P00962,3,positive,Visit 3: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P00962,4,positive,Visit 4: Patient on RX-17B at S015. reports improvement. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00962,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P00962,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.86. AE: no. CRP 1.6 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P00962,7,positive,Visit 7: Patient on RX-17B at S015. reports improvement. Notes: joint pain. Adherence ~0.91. AE: no. CRP 1.6 mg/L; ALT 18 U/L.
P00963,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00963,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: no.
P00963,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no.
P00963,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no.
P00963,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 5.5 mg/L; ALT 42 U/L.
P00963,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.73. AE: yes.
P00963,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P00963,7,positive,Visit 7: Patient on RX-17A at S014. energy increasing. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P00964,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.58. AE: no.
P00964,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.80. AE: yes.
P00964,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.69. AE: no.
P00964,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P00964,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no. CRP 2.6 mg/L; ALT 42 U/L.
P00964,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no. CRP 2.0 mg/L; ALT 38 U/L.
P00964,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.60. AE: no.
P00965,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: brain fog. Adherence ~0.77. AE: no.
P00965,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 8.2 mg/L; ALT 15 U/L.
P00965,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no. CRP 6.8 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P00965,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no. CRP 6.6 mg/L; ALT 14 U/L.
P00965,4,positive,Visit 4: Patient on RX-17B at S019. feels better overall. Notes: joint pain. Adherence ~0.86. AE: no. CRP 4.6 mg/L; ALT 14 U/L.
P00965,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no.
P00966,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P00966,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 9.2 mg/L; ALT 20 U/L.
P00966,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.69. AE: no.
P00966,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.79. AE: no. CRP 7.9 mg/L; ALT 17 U/L.
P00966,4,positive,Visit 4: Patient on RX-17A at S012. energy increasing. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00967,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.80. AE: no.
P00967,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.74. AE: no.
P00967,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.72. AE: no.
P00967,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P00967,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no.
P00967,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.83. AE: no. CRP 6.5 mg/L; ALT 24 U/L.
P00967,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.76. AE: yes.
P00967,7,positive,Visit 7: Patient on RX-17B at S014. symptoms improving. Notes: fatigue. Adherence ~0.78. AE: no.
P00968,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.97. AE: no. CRP 6.8 mg/L; ALT 38 U/L.
P00968,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.96. AE: no.
P00968,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.6 mg/L; ALT 43 U/L.
P00968,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.97. AE: no. CRP 5.9 mg/L; ALT 40 U/L.
P00968,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 5.9 mg/L; ALT 38 U/L.
P00968,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no.
P00968,6,positive,Visit 6: Patient on RX-17A at S014. energy increasing. Notes: fatigue. Adherence ~0.85. AE: no.
P00969,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no.
P00969,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: joint pain. Adherence ~0.86. AE: yes.
P00969,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no. CRP 9.7 mg/L; ALT 23 U/L.
P00969,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P00969,4,negative,Visit 4: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P00969,5,negative,Visit 5: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: yes.
P00969,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00969,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P00970,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.74. AE: no. CRP 4.9 mg/L; ALT 32 U/L.
P00970,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P00970,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.71. AE: no.
P00970,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.74. AE: no.
P00970,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.64. AE: no. CRP 3.2 mg/L; ALT 38 U/L.
P00971,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: nausea. Adherence ~0.42. AE: no.
P00971,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: nausea. Adherence ~0.51. AE: no.
P00971,2,neutral,Visit 2: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P00971,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.55. AE: no.
P00971,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.45. AE: no. CRP 9.6 mg/L; ALT 30 U/L.
P00972,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.87. AE: yes.
P00972,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.79. AE: yes.
P00972,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P00972,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.99. AE: no.
P00972,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no. CRP 7.8 mg/L; ALT 29 U/L.
P00972,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no. CRP 7.6 mg/L; ALT 31 U/L.
P00972,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no. CRP 6.5 mg/L; ALT 33 U/L.
P00972,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no.
P00973,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no.
P00973,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.78. AE: no.
P00973,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: yes. CRP 4.2 mg/L; ALT 39 U/L.
P00973,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.73. AE: no. CRP 3.9 mg/L; ALT 34 U/L.
P00973,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P00973,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00973,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00973,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.67. AE: no. CRP 2.6 mg/L; ALT 38 U/L.
P00974,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P00974,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.89. AE: no.
P00974,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no.
P00974,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: yes.
P00974,4,negative,Visit 4: Patient on RX-17A at S019. poor tolerance. Notes: headache. Adherence ~0.97. AE: no. CRP 7.5 mg/L; ALT 37 U/L.
P00975,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P00975,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 12.0 mg/L; ALT 32 U/L.
P00975,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.74. AE: no. CRP 10.9 mg/L; ALT 29 U/L.
P00975,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.99. AE: yes. CRP 10.5 mg/L; ALT 34 U/L.
P00975,4,positive,Visit 4: Patient on RX-17A at S022. reports improvement. Notes: dizziness. Adherence ~0.99. AE: no.
P00976,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.45. AE: no.
P00976,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P00976,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P00976,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.53. AE: no. CRP 5.6 mg/L; ALT 37 U/L.
P00976,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.62. AE: no.
P00976,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.59. AE: yes.
P00977,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.87. AE: no.
P00977,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no.
P00977,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P00977,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P00977,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no.
P00977,5,positive,Visit 5: Patient on RX-17A at S017. feels better overall. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P00977,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no.
P00977,7,positive,Visit 7: Patient on RX-17A at S017. energy increasing. Notes: joint pain. Adherence ~0.81. AE: no. CRP 2.5 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P00978,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P00978,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.92. AE: no. CRP 7.5 mg/L; ALT 30 U/L.
P00978,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.70. AE: no. CRP 6.6 mg/L; ALT 30 U/L.
P00978,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 7.2 mg/L; ALT 28 U/L.
P00978,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.92. AE: yes.
P00978,5,negative,Visit 5: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.95. AE: no. CRP 6.2 mg/L; ALT 28 U/L.
P00978,6,positive,Visit 6: Patient on RX-17A at S017. reports improvement. Notes: joint pain. Adherence ~0.81. AE: no.
P00978,7,neutral,Visit 7: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P00979,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.64. AE: no.
P00979,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no.
P00979,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.95. AE: yes.
P00979,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.77. AE: no.
P00979,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P00979,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P00979,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 5.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P00979,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P00980,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.90. AE: no.
P00980,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.98. AE: yes. CRP 4.0 mg/L; ALT 63 U/L.
P00980,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 3.6 mg/L; ALT 62 U/L.
P00980,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no.
P00980,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no.
P00980,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 2.8 mg/L; ALT 61 U/L.
P00980,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: nausea. Adherence ~1.00. AE: no. CRP 2.3 mg/L; ALT 57 U/L.
P00980,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: headache. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P00981,0,negative,Visit 0: Patient on RX-17A at S008. symptoms persist. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 4.1 mg/L; ALT 27 U/L.
P00981,1,negative,Visit 1: Patient on RX-17A at S008. reports worsening. Notes: headache. Adherence ~0.89. AE: yes.
P00981,2,neutral,Visit 2: Patient on RX-17A at S008. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no. CRP 3.6 mg/L; ALT 26 U/L.
P00981,3,neutral,Visit 3: Patient on RX-17A at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P00981,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: headache. Adherence ~0.82. AE: no. CRP 3.4 mg/L; ALT 26 U/L.
P00982,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.55. AE: no.
P00982,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 10.7 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P00982,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.41. AE: no.
P00983,0,neutral,Visit 0: Patient on RX-17B at S011. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no. CRP 11.8 mg/L; ALT 22 U/L.
P00983,1,negative,Visit 1: Patient on RX-17B at S011. symptoms persist. Notes: dizziness. Adherence ~0.32. AE: no.
P00983,2,neutral,Visit 2: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.89. AE: no. CRP 9.1 mg/L; ALT 26 U/L.
P00983,3,neutral,Visit 3: Patient on RX-17B at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00984,0,negative,Visit 0: Patient on RX-17A at S009. symptoms persist. Notes: headache. Adherence ~0.68. AE: no. CRP 24.7 mg/L; ALT 41 U/L.
P00984,1,neutral,Visit 1: Patient on RX-17A at S009. stable symptoms. Notes: nausea. Adherence ~0.94. AE: no.
P00984,2,neutral,Visit 2: Patient on RX-17A at S009. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P00984,3,neutral,Visit 3: Patient on RX-17A at S009. stable symptoms. Notes: headache. Adherence ~0.82. AE: no.
P00984,4,neutral,Visit 4: Patient on RX-17A at S009. stable symptoms. Notes: joint pain. Adherence ~0.71. AE: no.
P00984,5,neutral,Visit 5: Patient on RX-17A at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.88. AE: no.
P00984,6,neutral,Visit 6: Patient on RX-17A at S009. no major change. Notes: headache. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P00984,7,positive,Visit 7: Patient on RX-17A at S009. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P00985,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: joint pain. Adherence ~0.83. AE: yes. CRP 9.1 mg/L; ALT 59 U/L.
P00985,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.70. AE: no.
P00985,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no.
P00985,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 8.0 mg/L; ALT 61 U/L.
P00985,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: yes.
P00985,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.84. AE: no. CRP 7.1 mg/L; ALT 54 U/L.
P00986,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P00986,1,negative,Visit 1: Patient on RX-17B at S013. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no. CRP 3.5 mg/L; ALT 28 U/L.
P00986,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no.
P00986,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P00986,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no.
P00987,0,negative,Visit 0: Patient on RX-17A at S006. feels frustrated. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P00987,1,neutral,Visit 1: Patient on RX-17A at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: no.
P00987,2,neutral,Visit 2: Patient on RX-17A at S006. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 17.5 mg/L; ALT 26 U/L.
P00987,3,neutral,Visit 3: Patient on RX-17A at S006. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no.
P00987,4,positive,Visit 4: Patient on RX-17A at S006. symptoms improving. Notes: nausea. Adherence ~0.83. AE: no.
P00988,0,neutral,Visit 0: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no.
P00988,1,neutral,Visit 1: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.73. AE: no. CRP 11.6 mg/L; ALT 26 U/L.
P00988,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.63. AE: no.
P00988,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: fatigue. Adherence ~0.51. AE: no. CRP 11.3 mg/L; ALT 27 U/L.
P00988,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no.
P00988,5,positive,Visit 5: Patient on RX-17B at S018. reports improvement. Notes: insomnia. Adherence ~0.83. AE: no. CRP 7.4 mg/L; ALT 29 U/L.
P00989,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: dizziness. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P00989,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: no.
P00989,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.84. AE: no. CRP 1.9 mg/L; ALT 31 U/L.
P00989,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.64. AE: no.
P00989,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no.
P00990,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.71. AE: no.
P00990,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.57. AE: no. CRP 3.8 mg/L; ALT 36 U/L.
P00990,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P00990,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.52. AE: yes. CRP 3.0 mg/L; ALT 38 U/L.
P00991,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: fatigue. Adherence ~0.68. AE: no.
P00991,1,neutral,Visit 1: Patient on RX-17A at S001. no major change. Notes: joint pain. Adherence ~0.83. AE: no.
P00991,2,neutral,Visit 2: Patient on RX-17A at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. CRP 4.9 mg/L; ALT 28 U/L.
P00991,3,neutral,Visit 3: Patient on RX-17A at S001. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no.
P00991,4,neutral,Visit 4: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no.
P00991,5,neutral,Visit 5: Patient on RX-17A at S001. follow-up as scheduled. Notes: insomnia. Adherence ~0.54. AE: no. CRP 3.6 mg/L; ALT 32 U/L.
P00992,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.50. AE: no.
P00992,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.35. AE: no. CRP 10.7 mg/L; ALT 27 U/L.
P00992,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.46. AE: no.
P00992,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.48. AE: no. CRP 10.1 mg/L; ALT 24 U/L.
P00993,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.71. AE: no.
P00993,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.82. AE: no.
P00993,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P00993,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P00993,4,negative,Visit 4: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.54. AE: no.
P00993,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no.
P00993,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.67. AE: no.
P00994,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: insomnia. Adherence ~0.75. AE: no. CRP 6.6 mg/L; ALT 26 U/L.
P00994,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: nausea. Adherence ~0.82. AE: no. CRP 5.9 mg/L; ALT 28 U/L.
P00994,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.90. AE: yes. CRP 5.1 mg/L; ALT 32 U/L.
P00994,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P00994,4,negative,Visit 4: Patient on RX-17A at S019. feels frustrated. Notes: insomnia. Adherence ~0.71. AE: no.
P00995,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.64. AE: no.
P00995,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.63. AE: no.
P00995,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.50. AE: no.
P00995,3,negative,Visit 3: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.86. AE: no.
P00995,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P00995,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.71. AE: no.
P00996,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.78. AE: no.
P00996,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.76. AE: no. CRP 1.5 mg/L; ALT 41 U/L.
P00996,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no. CRP 1.3 mg/L; ALT 42 U/L.
P00996,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P00996,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no.
P00997,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.71. AE: no. CRP 10.3 mg/L; ALT 41 U/L.
P00997,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P00997,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P00997,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.70. AE: no.
P00997,4,positive,Visit 4: Patient on RX-17B at S004. reports improvement. Notes: brain fog. Adherence ~0.78. AE: no.
P00997,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.70. AE: yes.
P00998,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.90. AE: no. CRP 11.8 mg/L; ALT 48 U/L.
P00998,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: yes.
P00998,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.97. AE: no. CRP 10.8 mg/L; ALT 47 U/L.
P00998,3,positive,Visit 3: Patient on RX-17B at S012. symptoms improving. Notes: brain fog. Adherence ~0.98. AE: no. CRP 9.5 mg/L; ALT 50 U/L.
P00998,4,positive,Visit 4: Patient on RX-17B at S012. symptoms improving. Notes: headache. Adherence ~0.98. AE: no.
P00998,5,negative,Visit 5: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.91. AE: no. CRP 7.7 mg/L; ALT 51 U/L.
P00999,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P00999,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.77. AE: no. CRP 4.9 mg/L; ALT 62 U/L.
P00999,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.66. AE: no. CRP 3.4 mg/L; ALT 56 U/L.
P00999,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.65. AE: no.
P00999,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no.
P01000,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no.
P01000,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P01000,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: no.
P01000,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01000,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 2.5 mg/L; ALT 34 U/L.
P01000,5,positive,Visit 5: Patient on RX-17B at S005. feels better overall. Notes: nausea. Adherence ~0.85. AE: no.
P01000,6,positive,Visit 6: Patient on RX-17B at S005. energy increasing. Notes: joint pain. Adherence ~0.87. AE: no. CRP 1.8 mg/L; ALT 35 U/L.
P01001,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.97. AE: no.
P01001,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~1.00. AE: no.
P01001,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: no.
P01001,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.94. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P01001,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P01001,5,positive,Visit 5: Patient on RX-17B at S005. energy increasing. Notes: brain fog. Adherence ~0.89. AE: no.
P01001,6,positive,Visit 6: Patient on RX-17B at S005. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.6 mg/L; ALT 29 U/L.
P01001,7,neutral,Visit 7: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no.
P01002,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: fatigue. Adherence ~0.45. AE: no.
P01002,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P01002,2,negative,Visit 2: Patient on RX-17A at S013. reports worsening. Notes: brain fog. Adherence ~0.45. AE: no.
P01002,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 1.3 mg/L; ALT 16 U/L.
P01002,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: fatigue. Adherence ~0.57. AE: no.
P01003,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: nausea. Adherence ~0.99. AE: no. CRP 6.0 mg/L; ALT 20 U/L.
P01003,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.93. AE: yes. CRP 6.2 mg/L; ALT 22 U/L.
P01003,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.5 mg/L; ALT 22 U/L.
P01003,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01003,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.81. AE: no.
P01003,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.89. AE: yes. CRP 3.7 mg/L; ALT 24 U/L.
P01003,6,positive,Visit 6: Patient on RX-17B at S015. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no.
P01004,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: fatigue. Adherence ~0.60. AE: no.
P01004,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01004,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no. CRP 7.1 mg/L; ALT 36 U/L.
P01004,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.50. AE: no.
P01004,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.62. AE: yes.
P01004,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no. CRP 5.8 mg/L; ALT 33 U/L.
P01004,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01005,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.75. AE: yes. CRP 4.2 mg/L; ALT 21 U/L.
P01005,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: no.
P01005,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.79. AE: no.
P01006,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.84. AE: no. CRP 12.7 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01006,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~0.73. AE: no. CRP 11.6 mg/L; ALT 19 U/L.
P01006,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: no.
P01006,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. CRP 8.0 mg/L; ALT 18 U/L.
P01006,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P01006,5,positive,Visit 5: Patient on RX-17B at S004. reports improvement. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01006,6,neutral,Visit 6: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P01006,7,positive,Visit 7: Patient on RX-17B at S004. energy increasing. Notes: brain fog. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 18 U/L.
P01007,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01007,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01007,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.79. AE: no. CRP 6.9 mg/L; ALT 31 U/L.
P01007,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.90. AE: yes.
P01007,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.99. AE: no. CRP 5.9 mg/L; ALT 29 U/L.
P01007,5,positive,Visit 5: Patient on RX-17B at S004. reports improvement. Notes: dizziness. Adherence ~0.90. AE: no.
P01007,6,positive,Visit 6: Patient on RX-17B at S004. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 3.9 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01007,7,positive,Visit 7: Patient on RX-17B at S004. symptoms improving. Notes: joint pain. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01008,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 8.4 mg/L; ALT 40 U/L.
P01008,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: no. CRP 9.0 mg/L; ALT 42 U/L.
P01008,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.92. AE: no.
P01008,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01008,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 38 U/L.
P01009,0,neutral,Visit 0: Patient on RX-17A at S010. reviewed dosing instructions. Notes: brain fog. Adherence ~0.96. AE: no. CRP 6.1 mg/L; ALT 27 U/L.
P01009,1,negative,Visit 1: Patient on RX-17A at S010. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: no.
P01009,2,negative,Visit 2: Patient on RX-17A at S010. increased discomfort. Notes: fatigue. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01009,3,neutral,Visit 3: Patient on RX-17A at S010. continues regimen. Notes: abdominal discomfort. Adherence ~0.70. AE: yes. CRP 4.4 mg/L; ALT 30 U/L.
P01010,0,neutral,Visit 0: Patient on RX-17B at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no.
P01010,1,negative,Visit 1: Patient on RX-17B at S020. feels frustrated. Notes: fatigue. Adherence ~0.83. AE: no.
P01010,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01010,3,negative,Visit 3: Patient on RX-17B at S020. symptoms persist. Notes: nausea. Adherence ~0.80. AE: no.
P01010,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01010,5,neutral,Visit 5: Patient on RX-17B at S020. continues regimen. Notes: headache. Adherence ~0.67. AE: no.
P01010,6,positive,Visit 6: Patient on RX-17B at S020. feels better overall. Notes: dizziness. Adherence ~0.84. AE: no. CRP 6.1 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01011,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no. CRP 15.5 mg/L; ALT 39 U/L.
P01011,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no. CRP 13.9 mg/L; ALT 41 U/L.
P01011,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.92. AE: no.
P01011,3,negative,Visit 3: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 10.7 mg/L; ALT 40 U/L.
P01011,4,negative,Visit 4: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.88. AE: no. CRP 8.3 mg/L; ALT 40 U/L.
P01011,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.91. AE: no.
P01011,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P01011,7,positive,Visit 7: Patient on RX-17B at S015. energy increasing. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01012,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no.
P01012,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no. CRP 5.6 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01012,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P01012,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01012,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no. CRP 3.6 mg/L; ALT 47 U/L.
P01012,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: headache. Adherence ~0.83. AE: no.
P01012,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P01012,7,positive,Visit 7: Patient on RX-17A at S004. symptoms improving. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01013,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01013,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: nausea. Adherence ~0.89. AE: yes. CRP 9.3 mg/L; ALT 70 U/L.
P01013,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 11.9 mg/L; ALT 67 U/L.
P01013,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.3 mg/L; ALT 67 U/L. Plan: consider dose adjustment; counsel patient.
P01013,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01013,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: yes. CRP 6.5 mg/L; ALT 76 U/L.
P01013,6,positive,Visit 6: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01014,0,neutral,Visit 0: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.59. AE: no. CRP 10.6 mg/L; ALT 73 U/L.
P01014,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~0.70. AE: no. CRP 10.8 mg/L; ALT 76 U/L.
P01014,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.63. AE: no. CRP 10.8 mg/L; ALT 84 U/L.
P01014,3,positive,Visit 3: Patient on RX-17A at S005. symptoms improving. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01014,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.53. AE: no. CRP 7.1 mg/L; ALT 77 U/L.
P01014,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P01014,6,positive,Visit 6: Patient on RX-17A at S005. feels better overall. Notes: fatigue. Adherence ~0.86. AE: no.
P01014,7,neutral,Visit 7: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.66. AE: no.
P01015,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: fatigue. Adherence ~0.84. AE: no. CRP 9.1 mg/L; ALT 42 U/L.
P01015,1,neutral,Visit 1: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01015,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.64. AE: no.
P01015,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.66. AE: no.
P01015,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.57. AE: yes.
P01016,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.52. AE: no.
P01016,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.59. AE: no. CRP 18.4 mg/L; ALT 26 U/L.
P01016,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01016,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.55. AE: no.
P01016,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.66. AE: no.
P01016,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.66. AE: no. CRP 12.1 mg/L; ALT 25 U/L.
P01016,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.53. AE: no.
P01017,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P01017,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no. CRP 4.0 mg/L; ALT 30 U/L.
P01017,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01017,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01017,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: no.
P01017,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P01017,6,positive,Visit 6: Patient on RX-17A at S014. energy increasing. Notes: dizziness. Adherence ~0.89. AE: no. CRP 3.1 mg/L; ALT 33 U/L.
P01018,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no.
P01018,1,negative,Visit 1: Patient on RX-17A at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01018,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 53 U/L.
P01018,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.97. AE: yes.
P01018,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01018,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 3.9 mg/L; ALT 53 U/L. Plan: consider dose adjustment; counsel patient.
P01018,6,neutral,Visit 6: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P01019,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P01019,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.71. AE: no. CRP 4.9 mg/L; ALT 21 U/L.
P01019,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P01019,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.45. AE: no.
P01019,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: no.
P01020,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.50. AE: no.
P01020,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.57. AE: yes.
P01020,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01020,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01021,0,neutral,Visit 0: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.54. AE: no.
P01021,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no. CRP 6.2 mg/L; ALT 29 U/L.
P01021,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.53. AE: no.
P01021,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no.
P01021,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.82. AE: no. CRP 4.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01021,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.69. AE: no.
P01021,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.69. AE: no. CRP 3.5 mg/L; ALT 31 U/L.
P01021,7,positive,Visit 7: Patient on RX-17B at S022. energy increasing. Notes: headache. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01022,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.66. AE: yes.
P01022,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.87. AE: no. CRP 4.1 mg/L; ALT 33 U/L.
P01022,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.71. AE: yes.
P01022,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P01022,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P01022,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.73. AE: no.
P01023,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01023,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P01023,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01023,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P01023,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01024,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: brain fog. Adherence ~0.96. AE: yes. CRP 18.1 mg/L; ALT 20 U/L.
P01024,1,positive,Visit 1: Patient on RX-17B at S017. tolerating medication well. Notes: fatigue. Adherence ~0.84. AE: no.
P01024,2,negative,Visit 2: Patient on RX-17B at S017. poor tolerance. Notes: headache. Adherence ~0.88. AE: yes.
P01024,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no. CRP 13.7 mg/L; ALT 19 U/L.
P01024,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.99. AE: no. CRP 12.0 mg/L; ALT 20 U/L.
P01024,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.84. AE: yes. CRP 12.2 mg/L; ALT 21 U/L.
P01024,6,positive,Visit 6: Patient on RX-17B at S017. energy increasing. Notes: headache. Adherence ~1.00. AE: no.
P01024,7,neutral,Visit 7: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.76. AE: yes.
P01025,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: nausea. Adherence ~0.67. AE: no. CRP 6.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01025,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.52. AE: no. CRP 5.9 mg/L; ALT 27 U/L.
P01025,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: yes.
P01025,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.72. AE: no. CRP 4.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01025,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.51. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P01025,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.63. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P01025,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.68. AE: no. CRP 3.2 mg/L; ALT 29 U/L.
P01025,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.69. AE: no.
P01026,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 44 U/L.
P01026,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.59. AE: no. CRP 2.9 mg/L; ALT 51 U/L.
P01026,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no.
P01026,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.47. AE: no. CRP 2.5 mg/L; ALT 51 U/L.
P01026,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01026,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01027,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 20.4 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01027,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~1.00. AE: no. CRP 17.8 mg/L; ALT 24 U/L.
P01027,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01027,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~1.00. AE: no. CRP 14.5 mg/L; ALT 25 U/L.
P01027,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: joint pain. Adherence ~0.90. AE: no. CRP 13.5 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01027,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01028,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: no. CRP 10.7 mg/L; ALT 46 U/L.
P01028,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: no.
P01028,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P01028,3,negative,Visit 3: Patient on RX-17A at S013. symptoms persist. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01028,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.71. AE: no. CRP 6.9 mg/L; ALT 51 U/L.
P01029,0,neutral,Visit 0: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no. CRP 9.8 mg/L; ALT 24 U/L.
P01029,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.81. AE: no. CRP 9.3 mg/L; ALT 25 U/L.
P01029,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~0.77. AE: no.
P01029,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.85. AE: yes.
P01029,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: yes. CRP 6.6 mg/L; ALT 31 U/L.
P01029,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.3 mg/L; ALT 26 U/L.
P01029,6,neutral,Visit 6: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no. CRP 5.3 mg/L; ALT 29 U/L.
P01030,0,neutral,Visit 0: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.79. AE: no. CRP 8.0 mg/L; ALT 19 U/L.
P01030,1,negative,Visit 1: Patient on RX-17A at S016. poor tolerance. Notes: headache. Adherence ~0.78. AE: no.
P01030,2,neutral,Visit 2: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.79. AE: no.
P01030,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no.
P01030,4,negative,Visit 4: Patient on RX-17A at S016. poor tolerance. Notes: insomnia. Adherence ~0.72. AE: no. CRP 5.6 mg/L; ALT 18 U/L.
P01030,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no.
P01030,6,positive,Visit 6: Patient on RX-17A at S016. tolerating medication well. Notes: brain fog. Adherence ~0.76. AE: no. CRP 4.5 mg/L; ALT 23 U/L.
P01030,7,positive,Visit 7: Patient on RX-17A at S016. feels better overall. Notes: joint pain. Adherence ~0.93. AE: no.
P01031,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: insomnia. Adherence ~0.84. AE: yes. CRP 5.1 mg/L; ALT 36 U/L.
P01031,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.99. AE: no.
P01031,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: joint pain. Adherence ~0.83. AE: yes. CRP 4.2 mg/L; ALT 36 U/L.
P01031,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P01031,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.94. AE: no.
P01031,5,positive,Visit 5: Patient on RX-17B at S012. energy increasing. Notes: insomnia. Adherence ~0.78. AE: no.
P01031,6,positive,Visit 6: Patient on RX-17B at S012. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no.
P01031,7,positive,Visit 7: Patient on RX-17B at S012. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01032,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P01032,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.93. AE: no.
P01032,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.7 mg/L; ALT 41 U/L.
P01032,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.94. AE: no.
P01032,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no. CRP 4.3 mg/L; ALT 40 U/L.
P01032,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no. CRP 3.8 mg/L; ALT 43 U/L.
P01032,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P01032,7,neutral,Visit 7: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no. CRP 3.0 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01033,0,neutral,Visit 0: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.57. AE: no. CRP 10.3 mg/L; ALT 30 U/L.
P01033,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: joint pain. Adherence ~0.61. AE: no.
P01033,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. CRP 9.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01033,3,positive,Visit 3: Patient on RX-17A at S019. feels better overall. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01033,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01033,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01033,6,neutral,Visit 6: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.83. AE: yes.
P01033,7,neutral,Visit 7: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.70. AE: no.
P01034,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: nausea. Adherence ~0.64. AE: no.
P01034,1,neutral,Visit 1: Patient on RX-17A at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no. CRP 5.3 mg/L; ALT 30 U/L.
P01034,2,negative,Visit 2: Patient on RX-17A at S018. feels frustrated. Notes: nausea. Adherence ~0.56. AE: no. CRP 4.7 mg/L; ALT 29 U/L.
P01034,3,neutral,Visit 3: Patient on RX-17A at S018. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no. CRP 4.1 mg/L; ALT 33 U/L.
P01034,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: nausea. Adherence ~0.66. AE: no. CRP 4.2 mg/L; ALT 31 U/L.
P01034,5,negative,Visit 5: Patient on RX-17A at S018. symptoms persist. Notes: joint pain. Adherence ~0.79. AE: yes.
P01035,0,neutral,Visit 0: Patient on RX-17B at S013. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no.
P01035,1,negative,Visit 1: Patient on RX-17B at S013. symptoms persist. Notes: brain fog. Adherence ~0.78. AE: no. CRP 7.5 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P01035,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.86. AE: no.
P01036,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: insomnia. Adherence ~0.78. AE: no. CRP 6.9 mg/L; ALT 26 U/L.
P01036,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.83. AE: no. CRP 7.5 mg/L; ALT 29 U/L.
P01036,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01036,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.0 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01036,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P01036,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P01036,6,neutral,Visit 6: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no. CRP 4.1 mg/L; ALT 35 U/L.
P01037,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: no.
P01037,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: joint pain. Adherence ~0.74. AE: no. CRP 3.6 mg/L; ALT 26 U/L.
P01037,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01037,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no.
P01037,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no. CRP 2.9 mg/L; ALT 26 U/L.
P01037,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. CRP 2.3 mg/L; ALT 28 U/L.
P01037,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: yes.
P01038,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: nausea. Adherence ~0.60. AE: no.
P01038,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 19.2 mg/L; ALT 23 U/L.
P01038,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01038,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: yes.
P01038,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no.
P01038,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no. CRP 10.7 mg/L; ALT 22 U/L.
P01038,6,positive,Visit 6: Patient on RX-17B at S018. symptoms improving. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 8.7 mg/L; ALT 22 U/L.
P01038,7,neutral,Visit 7: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01039,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 11.2 mg/L; ALT 52 U/L.
P01039,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P01039,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P01039,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no.
P01039,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 45 U/L.
P01039,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01040,0,negative,Visit 0: Patient on RX-17B at S020. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no.
P01040,1,neutral,Visit 1: Patient on RX-17B at S020. no major change. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01040,2,neutral,Visit 2: Patient on RX-17B at S020. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no.
P01040,3,neutral,Visit 3: Patient on RX-17B at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01040,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01041,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: no.
P01041,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.67. AE: no. CRP 9.4 mg/L; ALT 28 U/L.
P01041,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.77. AE: no. CRP 7.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01041,3,negative,Visit 3: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.89. AE: no. CRP 7.9 mg/L; ALT 28 U/L.
P01041,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: yes. CRP 7.1 mg/L; ALT 30 U/L.
P01041,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 5.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01042,0,negative,Visit 0: Patient on RX-17B at S020. increased discomfort. Notes: insomnia. Adherence ~0.64. AE: no.
P01042,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no. CRP 2.4 mg/L; ALT 45 U/L.
P01042,2,neutral,Visit 2: Patient on RX-17B at S020. no major change. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 2.2 mg/L; ALT 50 U/L.
P01042,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no. CRP 1.9 mg/L; ALT 47 U/L.
P01042,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: nausea. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P01042,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01043,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.82. AE: yes. CRP 5.9 mg/L; ALT 74 U/L.
P01043,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 5.5 mg/L; ALT 66 U/L. Plan: consider dose adjustment; counsel patient.
P01043,2,positive,Visit 2: Patient on RX-17A at S004. tolerating medication well. Notes: insomnia. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01043,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01043,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.94. AE: no. CRP 4.1 mg/L; ALT 66 U/L.
P01043,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.91. AE: no. CRP 3.5 mg/L; ALT 69 U/L.
P01044,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: yes.
P01044,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.58. AE: no.
P01044,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.51. AE: no. CRP 3.0 mg/L; ALT 35 U/L.
P01044,3,negative,Visit 3: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.58. AE: no. CRP 2.4 mg/L; ALT 37 U/L.
P01044,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: no.
P01044,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01044,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P01044,7,neutral,Visit 7: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.62. AE: no. CRP 1.4 mg/L; ALT 35 U/L.
P01045,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.90. AE: no.
P01045,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P01045,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no. CRP 6.4 mg/L; ALT 30 U/L.
P01045,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.48. AE: no. CRP 5.9 mg/L; ALT 28 U/L.
P01045,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P01045,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: dizziness. Adherence ~0.80. AE: no.
P01045,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: joint pain. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01046,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01046,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~0.93. AE: no. CRP 8.3 mg/L; ALT 29 U/L.
P01046,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no. CRP 8.5 mg/L; ALT 28 U/L.
P01046,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01046,4,positive,Visit 4: Patient on RX-17A at S004. energy increasing. Notes: joint pain. Adherence ~0.95. AE: no.
P01047,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: brain fog. Adherence ~0.52. AE: yes. CRP 9.1 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01047,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.68. AE: no.
P01047,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01047,3,negative,Visit 3: Patient on RX-17B at S002. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01047,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.58. AE: yes. CRP 4.9 mg/L; ALT 27 U/L.
P01048,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01048,1,neutral,Visit 1: Patient on RX-17A at S001. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 12.0 mg/L; ALT 27 U/L.
P01048,2,neutral,Visit 2: Patient on RX-17A at S001. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no. CRP 11.9 mg/L; ALT 28 U/L.
P01048,3,neutral,Visit 3: Patient on RX-17A at S001. continues regimen. Notes: brain fog. Adherence ~0.97. AE: no.
P01048,4,positive,Visit 4: Patient on RX-17A at S001. energy increasing. Notes: brain fog. Adherence ~1.00. AE: no. CRP 10.4 mg/L; ALT 27 U/L.
P01048,5,neutral,Visit 5: Patient on RX-17A at S001. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 9.5 mg/L; ALT 29 U/L.
P01048,6,neutral,Visit 6: Patient on RX-17A at S001. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01049,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: fatigue. Adherence ~0.52. AE: yes.
P01049,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no. CRP 3.2 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01049,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.49. AE: no.
P01049,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01049,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.44. AE: no.
P01049,5,neutral,Visit 5: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.54. AE: no.
P01050,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: insomnia. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01050,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.96. AE: no. CRP 4.1 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P01050,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01050,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 50 U/L.
P01050,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no. CRP 3.1 mg/L; ALT 45 U/L.
P01050,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01050,6,positive,Visit 6: Patient on RX-17B at S017. energy increasing. Notes: dizziness. Adherence ~0.95. AE: no.
P01051,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: headache. Adherence ~0.87. AE: no.
P01051,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: yes.
P01051,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: insomnia. Adherence ~0.78. AE: no.
P01051,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.86. AE: yes. CRP 6.6 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01051,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01051,5,positive,Visit 5: Patient on RX-17B at S002. reports improvement. Notes: nausea. Adherence ~0.83. AE: no. CRP 5.8 mg/L; ALT 30 U/L.
P01051,6,neutral,Visit 6: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: yes.
P01051,7,positive,Visit 7: Patient on RX-17B at S002. reports improvement. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01052,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01052,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~1.00. AE: no.
P01052,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no.
P01052,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: no.
P01052,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.97. AE: no. CRP 5.7 mg/L; ALT 49 U/L.
P01053,0,neutral,Visit 0: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.96. AE: no.
P01053,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01053,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01053,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01053,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.82. AE: yes. CRP 2.4 mg/L; ALT 31 U/L.
P01053,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.91. AE: yes.
P01054,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.70. AE: yes.
P01054,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.57. AE: no. CRP 12.2 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01054,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: yes.
P01055,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.78. AE: no.
P01055,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.84. AE: no.
P01055,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~0.84. AE: no.
P01055,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.78. AE: no.
P01055,4,positive,Visit 4: Patient on RX-17A at S004. tolerating medication well. Notes: brain fog. Adherence ~0.90. AE: no. CRP 11.9 mg/L; ALT 46 U/L.
P01056,0,neutral,Visit 0: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.74. AE: no. CRP 8.8 mg/L; ALT 27 U/L.
P01056,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: headache. Adherence ~0.78. AE: no. CRP 9.9 mg/L; ALT 31 U/L.
P01056,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: nausea. Adherence ~0.64. AE: no. CRP 7.3 mg/L; ALT 30 U/L.
P01057,0,negative,Visit 0: Patient on RX-17A at S018. poor tolerance. Notes: brain fog. Adherence ~0.50. AE: no.
P01057,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no.
P01057,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01057,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P01057,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: headache. Adherence ~0.57. AE: no.
P01057,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.44. AE: no.
P01057,6,neutral,Visit 6: Patient on RX-17A at S018. no major change. Notes: brain fog. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01058,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.71. AE: no.
P01058,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P01058,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no.
P01058,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.89. AE: no.
P01058,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.71. AE: no.
P01058,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01058,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.80. AE: no.
P01058,7,neutral,Visit 7: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01059,0,neutral,Visit 0: Patient on RX-17A at S018. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 8.6 mg/L; ALT 50 U/L.
P01059,1,neutral,Visit 1: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P01059,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P01059,3,negative,Visit 3: Patient on RX-17A at S018. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 53 U/L.
P01059,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.81. AE: no.
P01060,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.85. AE: no.
P01060,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01060,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no.
P01060,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01060,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P01060,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 4.0 mg/L; ALT 33 U/L.
P01060,6,neutral,Visit 6: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01060,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 3.5 mg/L; ALT 35 U/L.
P01061,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 15.3 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01061,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.79. AE: yes.
P01061,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.81. AE: yes.
P01061,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no. CRP 10.7 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P01061,4,positive,Visit 4: Patient on RX-17B at S012. reports improvement. Notes: joint pain. Adherence ~0.77. AE: no. CRP 9.7 mg/L; ALT 49 U/L.
P01061,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no.
P01061,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.98. AE: yes.
P01061,7,positive,Visit 7: Patient on RX-17B at S012. reports improvement. Notes: fatigue. Adherence ~0.90. AE: no. CRP 5.4 mg/L; ALT 52 U/L.
P01062,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no. CRP 7.0 mg/L; ALT 30 U/L.
P01062,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: brain fog. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P01062,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no.
P01062,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.81. AE: no. CRP 5.4 mg/L; ALT 31 U/L.
P01062,4,negative,Visit 4: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.70. AE: yes. CRP 3.7 mg/L; ALT 31 U/L.
P01062,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no.
P01063,0,negative,Visit 0: Patient on RX-17A at S009. increased discomfort. Notes: insomnia. Adherence ~0.50. AE: no.
P01063,1,neutral,Visit 1: Patient on RX-17A at S009. continues regimen. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 20.1 mg/L; ALT 46 U/L.
P01063,2,neutral,Visit 2: Patient on RX-17A at S009. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no.
P01064,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: brain fog. Adherence ~0.98. AE: no. CRP 10.6 mg/L; ALT 36 U/L.
P01064,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.90. AE: no.
P01064,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01064,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 8.7 mg/L; ALT 34 U/L.
P01064,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P01064,5,positive,Visit 5: Patient on RX-17B at S017. reports improvement. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01064,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.9 mg/L; ALT 36 U/L.
P01065,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.73. AE: no. CRP 8.9 mg/L; ALT 43 U/L.
P01065,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.82. AE: yes.
P01065,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.92. AE: yes. CRP 7.9 mg/L; ALT 46 U/L.
P01065,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P01065,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: no.
P01065,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P01066,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.65. AE: yes.
P01066,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.58. AE: no.
P01066,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.57. AE: no. CRP 10.2 mg/L; ALT 41 U/L.
P01067,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.95. AE: no.
P01067,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.77. AE: yes.
P01067,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01067,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.79. AE: no.
P01067,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.65. AE: no.
P01067,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P01067,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.86. AE: no. CRP 9.6 mg/L; ALT 20 U/L.
P01067,7,neutral,Visit 7: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: yes.
P01068,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.50. AE: no. CRP 11.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01068,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: brain fog. Adherence ~0.63. AE: yes. CRP 11.9 mg/L; ALT 32 U/L.
P01068,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: no.
P01068,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 8.6 mg/L; ALT 27 U/L.
P01068,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no.
P01068,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01069,0,negative,Visit 0: Patient on RX-17A at S006. increased discomfort. Notes: dizziness. Adherence ~0.90. AE: no. CRP 6.5 mg/L; ALT 39 U/L.
P01069,1,negative,Visit 1: Patient on RX-17A at S006. reports worsening. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01069,2,negative,Visit 2: Patient on RX-17A at S006. feels frustrated. Notes: dizziness. Adherence ~0.92. AE: no.
P01069,3,neutral,Visit 3: Patient on RX-17A at S006. no major change. Notes: joint pain. Adherence ~0.93. AE: no.
P01069,4,neutral,Visit 4: Patient on RX-17A at S006. reviewed dosing instructions. Notes: joint pain. Adherence ~0.89. AE: no. CRP 5.3 mg/L; ALT 47 U/L.
P01069,5,positive,Visit 5: Patient on RX-17A at S006. reports improvement. Notes: joint pain. Adherence ~0.89. AE: no. CRP 4.5 mg/L; ALT 40 U/L.
P01069,6,neutral,Visit 6: Patient on RX-17A at S006. no major change. Notes: fatigue. Adherence ~0.75. AE: no.
P01070,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~0.96. AE: no.
P01070,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.58. AE: no. CRP 4.8 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01070,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.66. AE: no. CRP 4.5 mg/L; ALT 48 U/L.
P01070,3,negative,Visit 3: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01070,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: yes.
P01070,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.96. AE: no.
P01070,6,negative,Visit 6: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.75. AE: no. CRP 2.8 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P01070,7,positive,Visit 7: Patient on RX-17B at S005. tolerating medication well. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01071,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: dizziness. Adherence ~0.67. AE: yes.
P01071,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01071,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.49. AE: no. CRP 3.2 mg/L; ALT 47 U/L.
P01071,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.64. AE: no. CRP 3.0 mg/L; ALT 46 U/L.
P01071,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.74. AE: no.
P01071,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.51. AE: no.
P01072,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P01072,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P01072,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.48. AE: no.
P01073,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: headache. Adherence ~0.84. AE: no. CRP 8.2 mg/L; ALT 48 U/L.
P01073,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: yes. CRP 7.2 mg/L; ALT 56 U/L.
P01073,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P01073,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P01073,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no.
P01073,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no. CRP 5.5 mg/L; ALT 60 U/L.
P01073,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no.
P01074,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01074,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.72. AE: no.
P01074,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.75. AE: no.
P01075,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no.
P01075,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.87. AE: no. CRP 5.4 mg/L; ALT 17 U/L.
P01075,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01075,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no.
P01075,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no. CRP 5.1 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01076,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: insomnia. Adherence ~0.71. AE: yes.
P01076,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: headache. Adherence ~0.53. AE: no.
P01076,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.80. AE: no. CRP 11.6 mg/L; ALT 26 U/L.
P01076,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P01076,4,negative,Visit 4: Patient on RX-17A at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01076,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: yes. CRP 8.7 mg/L; ALT 32 U/L.
P01077,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: fatigue. Adherence ~0.82. AE: no.
P01077,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P01077,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01078,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 18.2 mg/L; ALT 22 U/L.
P01078,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: no. CRP 16.8 mg/L; ALT 20 U/L.
P01078,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.81. AE: no.
P01078,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P01078,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 13.4 mg/L; ALT 24 U/L.
P01078,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no.
P01078,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01078,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01079,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~0.52. AE: no. CRP 5.8 mg/L; ALT 16 U/L.
P01079,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01079,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P01079,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 3.8 mg/L; ALT 18 U/L.
P01079,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.65. AE: no.
P01079,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.61. AE: no.
P01079,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.59. AE: no. CRP 2.8 mg/L; ALT 22 U/L.
P01079,7,neutral,Visit 7: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01080,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.90. AE: no. CRP 4.2 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01080,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.95. AE: no. CRP 4.4 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P01080,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.88. AE: no.
P01080,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.94. AE: yes.
P01080,4,negative,Visit 4: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01081,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 38 U/L.
P01081,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.91. AE: no.
P01081,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.85. AE: no. CRP 3.0 mg/L; ALT 37 U/L.
P01081,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 3.3 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01081,4,positive,Visit 4: Patient on RX-17A at S014. energy increasing. Notes: joint pain. Adherence ~0.88. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P01082,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.69. AE: no. CRP 10.3 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01082,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.49. AE: no.
P01082,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. CRP 9.8 mg/L; ALT 17 U/L.
P01082,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.72. AE: no.
P01082,4,positive,Visit 4: Patient on RX-17B at S012. symptoms improving. Notes: insomnia. Adherence ~0.85. AE: no. CRP 6.7 mg/L; ALT 20 U/L.
P01082,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P01083,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: headache. Adherence ~0.82. AE: no.
P01083,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P01083,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.99. AE: no.
P01083,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01083,4,positive,Visit 4: Patient on RX-17B at S019. energy increasing. Notes: fatigue. Adherence ~0.93. AE: no.
P01083,5,positive,Visit 5: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01083,6,positive,Visit 6: Patient on RX-17B at S019. energy increasing. Notes: brain fog. Adherence ~0.98. AE: no. CRP 5.9 mg/L; ALT 40 U/L.
P01083,7,positive,Visit 7: Patient on RX-17B at S019. tolerating medication well. Notes: joint pain. Adherence ~0.92. AE: no.
P01084,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.78. AE: no.
P01084,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.77. AE: no. CRP 4.5 mg/L; ALT 27 U/L.
P01084,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.75. AE: no. CRP 4.7 mg/L; ALT 29 U/L.
P01084,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.78. AE: no.
P01084,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.69. AE: no.
P01085,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no. CRP 4.3 mg/L; ALT 21 U/L.
P01085,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.85. AE: no. CRP 3.8 mg/L; ALT 24 U/L.
P01085,2,negative,Visit 2: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.89. AE: no. CRP 3.0 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01085,3,positive,Visit 3: Patient on RX-17A at S019. feels better overall. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 3.5 mg/L; ALT 23 U/L.
P01085,4,negative,Visit 4: Patient on RX-17A at S019. poor tolerance. Notes: fatigue. Adherence ~0.73. AE: no.
P01085,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01085,6,neutral,Visit 6: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: yes.
P01086,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.66. AE: no. CRP 19.3 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01086,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: nausea. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01086,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. CRP 13.4 mg/L; ALT 20 U/L.
P01086,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.81. AE: yes. CRP 11.5 mg/L; ALT 25 U/L.
P01086,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.57. AE: no. CRP 11.2 mg/L; ALT 22 U/L.
P01087,0,negative,Visit 0: Patient on RX-17B at S006. increased discomfort. Notes: dizziness. Adherence ~0.81. AE: yes. CRP 3.2 mg/L; ALT 35 U/L.
P01087,1,neutral,Visit 1: Patient on RX-17B at S006. continues regimen. Notes: nausea. Adherence ~0.79. AE: no.
P01087,2,neutral,Visit 2: Patient on RX-17B at S006. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P01087,3,neutral,Visit 3: Patient on RX-17B at S006. no major change. Notes: brain fog. Adherence ~0.81. AE: no.
P01087,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no. CRP 2.1 mg/L; ALT 36 U/L.
P01087,5,neutral,Visit 5: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01087,6,positive,Visit 6: Patient on RX-17B at S006. energy increasing. Notes: fatigue. Adherence ~0.81. AE: no.
P01088,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.69. AE: yes.
P01088,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no.
P01088,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.63. AE: no. CRP 11.6 mg/L; ALT 27 U/L.
P01089,0,neutral,Visit 0: Patient on RX-17B at S011. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no. CRP 5.0 mg/L; ALT 27 U/L.
P01089,1,negative,Visit 1: Patient on RX-17B at S011. reports worsening. Notes: headache. Adherence ~0.94. AE: no.
P01089,2,negative,Visit 2: Patient on RX-17B at S011. symptoms persist. Notes: headache. Adherence ~1.00. AE: yes.
P01089,3,negative,Visit 3: Patient on RX-17B at S011. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01090,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.48. AE: no. CRP 8.7 mg/L; ALT 35 U/L.
P01090,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.48. AE: no.
P01090,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.65. AE: no. CRP 7.8 mg/L; ALT 37 U/L.
P01090,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P01090,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.70. AE: no. CRP 6.9 mg/L; ALT 35 U/L.
P01090,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.67. AE: no. CRP 6.9 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P01090,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.45. AE: no.
P01091,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.74. AE: no.
P01091,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.86. AE: yes.
P01091,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: no. CRP 10.9 mg/L; ALT 36 U/L.
P01091,3,positive,Visit 3: Patient on RX-17B at S014. energy increasing. Notes: abdominal discomfort. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01091,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.62. AE: no.
P01091,5,negative,Visit 5: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.75. AE: yes.
P01091,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.96. AE: yes.
P01091,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~0.78. AE: no. CRP 5.0 mg/L; ALT 41 U/L.
P01092,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01092,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.95. AE: yes.
P01092,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 43 U/L.
P01092,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01092,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.88. AE: yes. CRP 6.8 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01092,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 5.6 mg/L; ALT 41 U/L.
P01093,0,neutral,Visit 0: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P01093,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no.
P01093,2,negative,Visit 2: Patient on RX-17B at S018. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01093,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: no. CRP 5.4 mg/L; ALT 32 U/L.
P01093,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~1.00. AE: yes.
P01094,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no.
P01094,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: nausea. Adherence ~0.73. AE: no. CRP 13.5 mg/L; ALT 21 U/L.
P01094,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.92. AE: no. CRP 13.3 mg/L; ALT 20 U/L.
P01094,3,negative,Visit 3: Patient on RX-17B at S016. feels frustrated. Notes: fatigue. Adherence ~0.89. AE: no.
P01094,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no.
P01094,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.74. AE: no. CRP 9.2 mg/L; ALT 23 U/L.
P01095,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: insomnia. Adherence ~0.44. AE: no. CRP 9.0 mg/L; ALT 38 U/L.
P01095,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: nausea. Adherence ~0.66. AE: yes.
P01095,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: brain fog. Adherence ~0.51. AE: no.
P01095,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 6.7 mg/L; ALT 41 U/L.
P01095,4,negative,Visit 4: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.49. AE: yes. Plan: consider dose adjustment; counsel patient.
P01095,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: dizziness. Adherence ~0.82. AE: no. CRP 4.7 mg/L; ALT 40 U/L.
P01095,6,neutral,Visit 6: Patient on RX-17B at S002. stable symptoms. Notes: joint pain. Adherence ~0.56. AE: no.
P01095,7,neutral,Visit 7: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.63. AE: no.
P01096,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: dizziness. Adherence ~0.91. AE: yes.
P01096,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.85. AE: no. CRP 46.2 mg/L; ALT 42 U/L.
P01096,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01096,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P01096,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: joint pain. Adherence ~0.73. AE: no. CRP 40.5 mg/L; ALT 38 U/L.
P01096,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 33.7 mg/L; ALT 46 U/L.
P01096,6,neutral,Visit 6: Patient on RX-17A at S002. stable symptoms. Notes: headache. Adherence ~0.88. AE: no.
P01096,7,positive,Visit 7: Patient on RX-17A at S002. feels better overall. Notes: joint pain. Adherence ~0.80. AE: no. CRP 26.2 mg/L; ALT 40 U/L.
P01097,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.45. AE: yes. CRP 2.8 mg/L; ALT 31 U/L.
P01097,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.54. AE: no.
P01097,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: no. CRP 2.3 mg/L; ALT 30 U/L.
P01097,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P01097,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no.
P01098,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01098,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 2.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01098,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P01098,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.86. AE: no.
P01098,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01098,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P01098,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01099,0,negative,Visit 0: Patient on RX-17B at S009. reports worsening. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01099,1,neutral,Visit 1: Patient on RX-17B at S009. continues regimen. Notes: brain fog. Adherence ~0.61. AE: no.
P01099,2,neutral,Visit 2: Patient on RX-17B at S009. reviewed dosing instructions. Notes: fatigue. Adherence ~0.56. AE: no.
P01099,3,neutral,Visit 3: Patient on RX-17B at S009. no major change. Notes: abdominal discomfort. Adherence ~0.47. AE: no. CRP 7.6 mg/L; ALT 81 U/L.
P01099,4,neutral,Visit 4: Patient on RX-17B at S009. continues regimen. Notes: dizziness. Adherence ~0.61. AE: yes.
P01099,5,neutral,Visit 5: Patient on RX-17B at S009. no major change. Notes: joint pain. Adherence ~0.46. AE: no.
P01099,6,neutral,Visit 6: Patient on RX-17B at S009. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01100,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: insomnia. Adherence ~0.94. AE: yes.
P01100,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P01100,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P01100,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~0.70. AE: yes.
P01100,4,positive,Visit 4: Patient on RX-17B at S013. reports improvement. Notes: joint pain. Adherence ~0.79. AE: no.
P01101,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: joint pain. Adherence ~0.79. AE: no.
P01101,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~1.00. AE: no.
P01101,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.98. AE: no.
P01101,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.80. AE: no. CRP 8.8 mg/L; ALT 39 U/L.
P01101,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no. CRP 7.8 mg/L; ALT 39 U/L.
P01101,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.81. AE: yes. CRP 6.1 mg/L; ALT 43 U/L.
P01101,6,positive,Visit 6: Patient on RX-17B at S017. energy increasing. Notes: headache. Adherence ~1.00. AE: no.
P01102,0,negative,Visit 0: Patient on RX-17A at S018. feels frustrated. Notes: dizziness. Adherence ~0.87. AE: no. CRP 3.6 mg/L; ALT 42 U/L.
P01102,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01102,2,neutral,Visit 2: Patient on RX-17A at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P01102,3,positive,Visit 3: Patient on RX-17A at S018. feels better overall. Notes: headache. Adherence ~1.00. AE: no. CRP 2.8 mg/L; ALT 44 U/L.
P01102,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: insomnia. Adherence ~0.94. AE: no. CRP 2.8 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P01103,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.54. AE: no.
P01103,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no.
P01103,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.64. AE: no.
P01103,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.71. AE: no.
P01103,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.76. AE: no.
P01103,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.74. AE: no.
P01104,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.89. AE: no.
P01104,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01104,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.61. AE: no.
P01104,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no.
P01105,0,neutral,Visit 0: Patient on RX-17B at S010. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no. CRP 6.1 mg/L; ALT 27 U/L.
P01105,1,neutral,Visit 1: Patient on RX-17B at S010. reviewed dosing instructions. Notes: joint pain. Adherence ~0.56. AE: no. CRP 4.4 mg/L; ALT 26 U/L.
P01105,2,negative,Visit 2: Patient on RX-17B at S010. poor tolerance. Notes: brain fog. Adherence ~0.56. AE: no.
P01105,3,neutral,Visit 3: Patient on RX-17B at S010. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01105,4,negative,Visit 4: Patient on RX-17B at S010. increased discomfort. Notes: insomnia. Adherence ~0.59. AE: yes. CRP 3.9 mg/L; ALT 27 U/L.
P01105,5,neutral,Visit 5: Patient on RX-17B at S010. continues regimen. Notes: nausea. Adherence ~0.51. AE: yes. CRP 3.3 mg/L; ALT 29 U/L.
P01106,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 9.0 mg/L; ALT 31 U/L.
P01106,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.91. AE: no. CRP 7.9 mg/L; ALT 30 U/L.
P01106,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.98. AE: yes. CRP 8.0 mg/L; ALT 33 U/L.
P01106,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01106,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no. CRP 6.3 mg/L; ALT 30 U/L.
P01107,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.65. AE: no. CRP 3.8 mg/L; ALT 45 U/L.
P01107,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: yes. CRP 3.2 mg/L; ALT 46 U/L.
P01107,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01107,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. CRP 2.7 mg/L; ALT 44 U/L.
P01107,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.74. AE: no. CRP 2.3 mg/L; ALT 46 U/L.
P01107,5,positive,Visit 5: Patient on RX-17B at S012. tolerating medication well. Notes: headache. Adherence ~0.87. AE: no.
P01108,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.54. AE: no.
P01108,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.49. AE: no. CRP 8.5 mg/L; ALT 30 U/L.
P01108,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.41. AE: no.
P01109,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01109,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01109,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.99. AE: no.
P01109,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.93. AE: no.
P01109,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.75. AE: no. CRP 12.3 mg/L; ALT 88 U/L.
P01109,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.70. AE: no. CRP 9.9 mg/L; ALT 91 U/L.
P01110,0,neutral,Visit 0: Patient on RX-17A at S003. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no.
P01110,1,negative,Visit 1: Patient on RX-17A at S003. reports worsening. Notes: insomnia. Adherence ~0.75. AE: no. CRP 4.0 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01110,2,neutral,Visit 2: Patient on RX-17A at S003. follow-up as scheduled. Notes: headache. Adherence ~0.43. AE: no.
P01110,3,neutral,Visit 3: Patient on RX-17A at S003. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01110,4,neutral,Visit 4: Patient on RX-17A at S003. no major change. Notes: dizziness. Adherence ~0.62. AE: no. CRP 2.5 mg/L; ALT 26 U/L.
P01111,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: headache. Adherence ~0.86. AE: no.
P01111,1,neutral,Visit 1: Patient on RX-17A at S001. continues regimen. Notes: brain fog. Adherence ~0.77. AE: no.
P01111,2,negative,Visit 2: Patient on RX-17A at S001. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.9 mg/L; ALT 46 U/L.
P01111,3,negative,Visit 3: Patient on RX-17A at S001. poor tolerance. Notes: insomnia. Adherence ~0.87. AE: yes.
P01111,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: yes.
P01112,0,neutral,Visit 0: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no.
P01112,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: insomnia. Adherence ~0.83. AE: no.
P01112,2,negative,Visit 2: Patient on RX-17B at S006. reports worsening. Notes: dizziness. Adherence ~0.90. AE: no. CRP 11.4 mg/L; ALT 37 U/L.
P01112,3,neutral,Visit 3: Patient on RX-17B at S006. continues regimen. Notes: brain fog. Adherence ~0.98. AE: no.
P01112,4,neutral,Visit 4: Patient on RX-17B at S006. no major change. Notes: joint pain. Adherence ~0.91. AE: yes. CRP 9.6 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P01112,5,neutral,Visit 5: Patient on RX-17B at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 7.8 mg/L; ALT 40 U/L.
P01112,6,neutral,Visit 6: Patient on RX-17B at S006. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no.
P01112,7,neutral,Visit 7: Patient on RX-17B at S006. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: yes.
P01113,0,neutral,Visit 0: Patient on RX-17A at S020. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no.
P01113,1,neutral,Visit 1: Patient on RX-17A at S020. no major change. Notes: headache. Adherence ~0.98. AE: no.
P01113,2,neutral,Visit 2: Patient on RX-17A at S020. no major change. Notes: headache. Adherence ~0.83. AE: no.
P01113,3,neutral,Visit 3: Patient on RX-17A at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 2.9 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01114,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.95. AE: no. CRP 11.5 mg/L; ALT 46 U/L.
P01114,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.94. AE: yes. Plan: consider dose adjustment; counsel patient.
P01114,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: yes.
P01114,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~0.98. AE: no.
P01114,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.95. AE: no.
P01115,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 7.3 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01115,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.44. AE: no.
P01115,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: brain fog. Adherence ~0.76. AE: yes.
P01115,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~0.77. AE: no.
P01115,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no. CRP 6.1 mg/L; ALT 17 U/L.
P01115,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no. CRP 4.7 mg/L; ALT 16 U/L.
P01115,6,negative,Visit 6: Patient on RX-17A at S005. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P01115,7,neutral,Visit 7: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.80. AE: no. CRP 3.9 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01116,0,negative,Visit 0: Patient on RX-17B at S020. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: no.
P01116,1,neutral,Visit 1: Patient on RX-17B at S020. continues regimen. Notes: nausea. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01116,2,neutral,Visit 2: Patient on RX-17B at S020. no major change. Notes: brain fog. Adherence ~0.79. AE: no.
P01116,3,neutral,Visit 3: Patient on RX-17B at S020. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no.
P01116,4,negative,Visit 4: Patient on RX-17B at S020. increased discomfort. Notes: nausea. Adherence ~0.63. AE: no.
P01116,5,neutral,Visit 5: Patient on RX-17B at S020. stable symptoms. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01116,6,neutral,Visit 6: Patient on RX-17B at S020. reviewed dosing instructions. Notes: dizziness. Adherence ~0.68. AE: no.
P01116,7,positive,Visit 7: Patient on RX-17B at S020. feels better overall. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01117,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.94. AE: no. CRP 16.9 mg/L; ALT 22 U/L.
P01117,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.64. AE: no.
P01117,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.85. AE: no. CRP 13.8 mg/L; ALT 24 U/L.
P01118,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.99. AE: no.
P01118,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: yes.
P01118,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P01118,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.60. AE: no.
P01118,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: fatigue. Adherence ~0.82. AE: no.
P01119,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~0.88. AE: no. CRP 10.2 mg/L; ALT 23 U/L.
P01119,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.75. AE: yes. CRP 7.9 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01119,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01119,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: yes. CRP 7.0 mg/L; ALT 28 U/L.
P01119,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. CRP 5.3 mg/L; ALT 27 U/L.
P01119,5,positive,Visit 5: Patient on RX-17B at S022. tolerating medication well. Notes: insomnia. Adherence ~0.92. AE: no.
P01120,0,negative,Visit 0: Patient on RX-17B at S003. increased discomfort. Notes: insomnia. Adherence ~0.85. AE: no.
P01120,1,negative,Visit 1: Patient on RX-17B at S003. poor tolerance. Notes: dizziness. Adherence ~0.67. AE: yes. CRP 1.9 mg/L; ALT 25 U/L.
P01120,2,neutral,Visit 2: Patient on RX-17B at S003. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P01120,3,neutral,Visit 3: Patient on RX-17B at S003. no major change. Notes: brain fog. Adherence ~0.91. AE: no. CRP 1.9 mg/L; ALT 22 U/L.
P01120,4,positive,Visit 4: Patient on RX-17B at S003. tolerating medication well. Notes: headache. Adherence ~0.87. AE: no.
P01121,0,negative,Visit 0: Patient on RX-17B at S006. feels frustrated. Notes: nausea. Adherence ~0.49. AE: no.
P01121,1,negative,Visit 1: Patient on RX-17B at S006. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: no.
P01121,2,neutral,Visit 2: Patient on RX-17B at S006. follow-up as scheduled. Notes: headache. Adherence ~0.73. AE: no.
P01121,3,neutral,Visit 3: Patient on RX-17B at S006. continues regimen. Notes: brain fog. Adherence ~0.58. AE: no.
P01121,4,neutral,Visit 4: Patient on RX-17B at S006. no major change. Notes: fatigue. Adherence ~0.62. AE: no. CRP 7.2 mg/L; ALT 17 U/L.
P01121,5,neutral,Visit 5: Patient on RX-17B at S006. continues regimen. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 6.6 mg/L; ALT 20 U/L.
P01122,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~0.88. AE: no.
P01122,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: nausea. Adherence ~0.67. AE: no.
P01122,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P01122,3,negative,Visit 3: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.75. AE: yes.
P01122,4,negative,Visit 4: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.63. AE: yes. CRP 3.0 mg/L; ALT 39 U/L.
P01123,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: nausea. Adherence ~0.93. AE: no. CRP 6.9 mg/L; ALT 29 U/L.
P01123,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P01123,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.82. AE: no.
P01123,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.84. AE: yes. CRP 4.6 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01123,4,positive,Visit 4: Patient on RX-17B at S005. symptoms improving. Notes: joint pain. Adherence ~0.99. AE: no.
P01123,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 3.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01124,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: insomnia. Adherence ~0.58. AE: no. CRP 7.2 mg/L; ALT 28 U/L.
P01124,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: joint pain. Adherence ~0.58. AE: no. CRP 6.8 mg/L; ALT 28 U/L.
P01124,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01124,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. CRP 5.6 mg/L; ALT 28 U/L.
P01124,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no.
P01125,0,negative,Visit 0: Patient on RX-17B at S006. increased discomfort. Notes: nausea. Adherence ~0.96. AE: yes.
P01125,1,negative,Visit 1: Patient on RX-17B at S006. increased discomfort. Notes: dizziness. Adherence ~0.99. AE: no. CRP 17.5 mg/L; ALT 38 U/L.
P01125,2,neutral,Visit 2: Patient on RX-17B at S006. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: yes.
P01125,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01125,4,neutral,Visit 4: Patient on RX-17B at S006. follow-up as scheduled. Notes: fatigue. Adherence ~0.93. AE: yes. CRP 13.1 mg/L; ALT 44 U/L.
P01125,5,positive,Visit 5: Patient on RX-17B at S006. symptoms improving. Notes: nausea. Adherence ~0.99. AE: no.
P01126,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.47. AE: no.
P01126,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.29. AE: no. CRP 6.1 mg/L; ALT 35 U/L.
P01126,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.33. AE: no.
P01126,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.26. AE: no. Plan: consider dose adjustment; counsel patient.
P01126,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.45. AE: no.
P01126,5,negative,Visit 5: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.41. AE: yes.
P01127,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P01127,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P01127,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no. CRP 2.6 mg/L; ALT 29 U/L.
P01127,3,negative,Visit 3: Patient on RX-17B at S005. poor tolerance. Notes: dizziness. Adherence ~0.70. AE: yes. CRP 2.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01127,4,negative,Visit 4: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P01127,5,positive,Visit 5: Patient on RX-17B at S005. energy increasing. Notes: joint pain. Adherence ~0.77. AE: no. CRP 2.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01128,0,neutral,Visit 0: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: yes.
P01128,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no. CRP 14.0 mg/L; ALT 89 U/L.
P01128,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P01128,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: brain fog. Adherence ~0.65. AE: no.
P01128,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.64. AE: no.
P01128,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.60. AE: yes. CRP 8.9 mg/L; ALT 104 U/L.
P01129,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.39. AE: no. CRP 11.3 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01129,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~0.40. AE: no. CRP 9.7 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P01129,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.26. AE: yes. CRP 10.0 mg/L; ALT 45 U/L.
P01129,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.22. AE: no. Plan: consider dose adjustment; counsel patient.
P01129,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.33. AE: no.
P01129,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.29. AE: no.
P01130,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.78. AE: no.
P01130,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: headache. Adherence ~0.88. AE: yes. CRP 10.5 mg/L; ALT 72 U/L. Plan: consider dose adjustment; counsel patient.
P01130,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 7.9 mg/L; ALT 81 U/L.
P01130,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: yes. CRP 10.2 mg/L; ALT 79 U/L.
P01130,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: yes.
P01130,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01131,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: brain fog. Adherence ~0.91. AE: no.
P01131,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: nausea. Adherence ~0.80. AE: no. CRP 16.2 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01131,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01132,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.82. AE: no. CRP 18.5 mg/L; ALT 32 U/L.
P01132,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: no. CRP 20.5 mg/L; ALT 30 U/L.
P01132,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.98. AE: no. CRP 16.3 mg/L; ALT 36 U/L.
P01132,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: no. CRP 14.4 mg/L; ALT 31 U/L.
P01132,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.99. AE: no. CRP 14.3 mg/L; ALT 35 U/L.
P01132,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: yes. CRP 13.3 mg/L; ALT 39 U/L.
P01132,6,positive,Visit 6: Patient on RX-17A at S012. symptoms improving. Notes: brain fog. Adherence ~0.98. AE: no. CRP 12.1 mg/L; ALT 33 U/L.
P01132,7,neutral,Visit 7: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P01133,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.81. AE: no.
P01133,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.80. AE: no.
P01133,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01133,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P01133,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P01133,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.88. AE: no.
P01133,6,neutral,Visit 6: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.82. AE: yes.
P01134,0,neutral,Visit 0: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P01134,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.91. AE: no.
P01134,2,negative,Visit 2: Patient on RX-17A at S002. reports worsening. Notes: joint pain. Adherence ~1.00. AE: yes.
P01134,3,positive,Visit 3: Patient on RX-17A at S002. feels better overall. Notes: joint pain. Adherence ~0.87. AE: no.
P01134,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01134,5,positive,Visit 5: Patient on RX-17A at S002. feels better overall. Notes: joint pain. Adherence ~0.88. AE: no. CRP 2.2 mg/L; ALT 29 U/L.
P01134,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no.
P01135,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no.
P01135,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.79. AE: no.
P01135,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: no. CRP 9.7 mg/L; ALT 24 U/L.
P01135,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.97. AE: no.
P01135,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.88. AE: no.
P01136,0,negative,Visit 0: Patient on RX-17B at S009. increased discomfort. Notes: headache. Adherence ~0.66. AE: no.
P01136,1,negative,Visit 1: Patient on RX-17B at S009. increased discomfort. Notes: dizziness. Adherence ~0.41. AE: no. Plan: consider dose adjustment; counsel patient.
P01136,2,negative,Visit 2: Patient on RX-17B at S009. increased discomfort. Notes: joint pain. Adherence ~0.89. AE: no.
P01136,3,neutral,Visit 3: Patient on RX-17B at S009. stable symptoms. Notes: dizziness. Adherence ~0.71. AE: no.
P01136,4,neutral,Visit 4: Patient on RX-17B at S009. reviewed dosing instructions. Notes: fatigue. Adherence ~0.58. AE: no.
P01137,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.90. AE: no.
P01137,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.88. AE: no.
P01137,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.6 mg/L; ALT 24 U/L.
P01137,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.85. AE: no. CRP 5.5 mg/L; ALT 25 U/L.
P01137,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.99. AE: no.
P01137,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01138,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01138,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: yes.
P01138,2,negative,Visit 2: Patient on RX-17B at S005. symptoms persist. Notes: nausea. Adherence ~0.88. AE: no.
P01138,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no.
P01138,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no.
P01139,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: headache. Adherence ~0.72. AE: no. CRP 11.0 mg/L; ALT 17 U/L.
P01139,1,negative,Visit 1: Patient on RX-17A at S020. poor tolerance. Notes: nausea. Adherence ~0.57. AE: yes. CRP 9.1 mg/L; ALT 21 U/L.
P01139,2,neutral,Visit 2: Patient on RX-17A at S020. continues regimen. Notes: headache. Adherence ~0.59. AE: no.
P01139,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: brain fog. Adherence ~0.47. AE: yes.
P01139,4,neutral,Visit 4: Patient on RX-17A at S020. stable symptoms. Notes: fatigue. Adherence ~0.50. AE: no. CRP 6.7 mg/L; ALT 20 U/L.
P01139,5,neutral,Visit 5: Patient on RX-17A at S020. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no.
P01139,6,neutral,Visit 6: Patient on RX-17A at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.58. AE: no. CRP 5.5 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01140,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P01140,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.57. AE: no.
P01140,2,negative,Visit 2: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.66. AE: no. CRP 7.5 mg/L; ALT 39 U/L.
P01140,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.38. AE: no. CRP 7.4 mg/L; ALT 34 U/L.
P01140,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.42. AE: yes. CRP 6.8 mg/L; ALT 40 U/L.
P01141,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.71. AE: no. CRP 6.9 mg/L; ALT 23 U/L.
P01141,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~0.63. AE: no.
P01141,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no.
P01141,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.96. AE: no.
P01141,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.79. AE: yes. CRP 4.7 mg/L; ALT 24 U/L.
P01141,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.64. AE: yes.
P01142,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01142,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.87. AE: no.
P01142,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01142,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: yes.
P01142,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~1.00. AE: yes.
P01142,5,positive,Visit 5: Patient on RX-17B at S004. feels better overall. Notes: brain fog. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01142,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.94. AE: yes.
P01143,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no.
P01143,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no.
P01143,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: no.
P01143,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 10.9 mg/L; ALT 17 U/L.
P01143,4,positive,Visit 4: Patient on RX-17A at S004. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01144,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.75. AE: no.
P01144,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01144,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.69. AE: no.
P01144,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.76. AE: no. CRP 6.6 mg/L; ALT 29 U/L.
P01144,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: yes.
P01144,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P01144,6,positive,Visit 6: Patient on RX-17A at S015. energy increasing. Notes: joint pain. Adherence ~0.79. AE: no.
P01145,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no.
P01145,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.68. AE: no.
P01145,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.57. AE: no. CRP 12.3 mg/L; ALT 17 U/L.
P01145,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.67. AE: no. CRP 11.4 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P01145,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no.
P01146,0,neutral,Visit 0: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.83. AE: no.
P01146,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P01146,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P01146,3,negative,Visit 3: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.80. AE: no. CRP 1.9 mg/L; ALT 26 U/L.
P01146,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.54. AE: no.
P01146,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.72. AE: yes.
P01147,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01147,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.85. AE: no.
P01147,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: yes.
P01147,3,negative,Visit 3: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01147,4,positive,Visit 4: Patient on RX-17B at S017. feels better overall. Notes: headache. Adherence ~0.79. AE: no.
P01147,5,positive,Visit 5: Patient on RX-17B at S017. tolerating medication well. Notes: headache. Adherence ~0.86. AE: no. CRP 4.2 mg/L; ALT 28 U/L.
P01147,6,positive,Visit 6: Patient on RX-17B at S017. feels better overall. Notes: insomnia. Adherence ~0.92. AE: no.
P01148,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no. CRP 4.7 mg/L; ALT 22 U/L.
P01148,1,neutral,Visit 1: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 24 U/L.
P01148,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.97. AE: no. CRP 3.3 mg/L; ALT 27 U/L.
P01148,3,neutral,Visit 3: Patient on RX-17B at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.94. AE: no.
P01148,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: fatigue. Adherence ~0.91. AE: no. CRP 3.4 mg/L; ALT 26 U/L.
P01148,5,positive,Visit 5: Patient on RX-17B at S018. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no.
P01148,6,positive,Visit 6: Patient on RX-17B at S018. feels better overall. Notes: headache. Adherence ~0.99. AE: no.
P01148,7,neutral,Visit 7: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no.
P01149,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.98. AE: no. CRP 8.0 mg/L; ALT 25 U/L.
P01149,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.95. AE: no.
P01149,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P01149,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01149,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.87. AE: no.
P01150,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P01150,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.68. AE: no.
P01150,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.38. AE: no.
P01150,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.47. AE: no.
P01150,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.59. AE: yes.
P01151,0,neutral,Visit 0: Patient on RX-17A at S002. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no. CRP 8.3 mg/L; ALT 66 U/L.
P01151,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.84. AE: no.
P01151,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P01152,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: brain fog. Adherence ~0.91. AE: yes.
P01152,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: yes. CRP 6.6 mg/L; ALT 36 U/L.
P01152,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: yes.
P01152,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: insomnia. Adherence ~0.83. AE: no.
P01152,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.89. AE: yes. CRP 4.2 mg/L; ALT 40 U/L.
P01152,5,positive,Visit 5: Patient on RX-17B at S013. feels better overall. Notes: headache. Adherence ~0.83. AE: no.
P01152,6,neutral,Visit 6: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01152,7,neutral,Visit 7: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01153,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.56. AE: yes.
P01153,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.59. AE: yes. CRP 7.0 mg/L; ALT 26 U/L.
P01153,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01153,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~1.00. AE: yes.
P01153,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P01154,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.70. AE: no.
P01154,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no.
P01154,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no.
P01154,3,negative,Visit 3: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.97. AE: yes. Plan: consider dose adjustment; counsel patient.
P01154,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: dizziness. Adherence ~0.81. AE: no.
P01154,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P01154,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 1.6 mg/L; ALT 34 U/L.
P01154,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. CRP 1.4 mg/L; ALT 36 U/L.
P01155,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.85. AE: no. CRP 4.2 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01155,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P01155,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no.
P01155,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.89. AE: no.
P01155,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no.
P01155,5,negative,Visit 5: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.71. AE: no. CRP 3.0 mg/L; ALT 26 U/L.
P01155,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.87. AE: no.
P01156,0,negative,Visit 0: Patient on RX-17B at S018. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no.
P01156,1,neutral,Visit 1: Patient on RX-17B at S018. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01156,2,negative,Visit 2: Patient on RX-17B at S018. symptoms persist. Notes: nausea. Adherence ~0.86. AE: no.
P01156,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P01156,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.99. AE: no.
P01156,5,positive,Visit 5: Patient on RX-17B at S018. symptoms improving. Notes: headache. Adherence ~0.93. AE: no.
P01156,6,positive,Visit 6: Patient on RX-17B at S018. energy increasing. Notes: fatigue. Adherence ~0.96. AE: no. CRP 6.5 mg/L; ALT 46 U/L.
P01156,7,positive,Visit 7: Patient on RX-17B at S018. tolerating medication well. Notes: brain fog. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01157,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.75. AE: no. CRP 4.9 mg/L; ALT 33 U/L.
P01157,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P01157,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: headache. Adherence ~0.65. AE: yes.
P01157,3,negative,Visit 3: Patient on RX-17A at S005. poor tolerance. Notes: fatigue. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01157,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01157,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no. CRP 4.0 mg/L; ALT 34 U/L.
P01157,6,neutral,Visit 6: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.75. AE: no. CRP 3.4 mg/L; ALT 33 U/L.
P01157,7,neutral,Visit 7: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.68. AE: no.
P01158,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.77. AE: no.
P01158,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.72. AE: no. CRP 13.4 mg/L; ALT 18 U/L.
P01158,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.92. AE: yes.
P01158,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 10.7 mg/L; ALT 18 U/L.
P01159,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.87. AE: no. CRP 11.7 mg/L; ALT 43 U/L.
P01159,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.84. AE: yes.
P01159,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P01159,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no.
P01159,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01159,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.82. AE: no.
P01160,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.71. AE: no. CRP 12.0 mg/L; ALT 39 U/L.
P01160,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no.
P01160,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no.
P01160,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P01160,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.88. AE: yes.
P01161,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.44. AE: no.
P01161,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.49. AE: no. CRP 9.4 mg/L; ALT 54 U/L.
P01161,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.56. AE: no.
P01161,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.61. AE: no.
P01161,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.64. AE: no. CRP 5.8 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01162,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.54. AE: no.
P01162,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 5.8 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01162,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.46. AE: no. CRP 4.7 mg/L; ALT 28 U/L.
P01162,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: yes. CRP 4.4 mg/L; ALT 27 U/L.
P01162,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01163,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: joint pain. Adherence ~0.73. AE: no. CRP 6.4 mg/L; ALT 30 U/L.
P01163,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no. CRP 6.6 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01163,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no. CRP 6.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01163,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.76. AE: no.
P01163,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.74. AE: no. CRP 5.0 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01163,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no.
P01163,6,neutral,Visit 6: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no.
P01164,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P01164,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.53. AE: no.
P01164,2,negative,Visit 2: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01164,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P01164,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.77. AE: no. CRP 7.4 mg/L; ALT 19 U/L.
P01164,5,positive,Visit 5: Patient on RX-17A at S015. energy increasing. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01164,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.77. AE: no. CRP 6.7 mg/L; ALT 20 U/L.
P01164,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 5.0 mg/L; ALT 20 U/L.
P01165,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.98. AE: no.
P01165,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01165,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P01165,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: yes.
P01165,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.90. AE: no.
P01165,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01165,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01165,7,neutral,Visit 7: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.87. AE: no. CRP 1.1 mg/L; ALT 35 U/L.
P01166,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.91. AE: no.
P01166,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.83. AE: no. CRP 13.7 mg/L; ALT 37 U/L.
P01166,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 13.7 mg/L; ALT 39 U/L.
P01166,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.81. AE: yes.
P01166,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no. CRP 10.3 mg/L; ALT 37 U/L.
P01166,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.94. AE: no.
P01166,6,positive,Visit 6: Patient on RX-17A at S012. symptoms improving. Notes: insomnia. Adherence ~0.86. AE: no. CRP 8.9 mg/L; ALT 38 U/L.
P01167,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.61. AE: no. CRP 5.1 mg/L; ALT 24 U/L.
P01167,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.89. AE: no.
P01167,2,negative,Visit 2: Patient on RX-17B at S005. symptoms persist. Notes: joint pain. Adherence ~0.79. AE: no.
P01167,3,negative,Visit 3: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.72. AE: yes.
P01167,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.65. AE: no.
P01167,5,positive,Visit 5: Patient on RX-17B at S005. energy increasing. Notes: brain fog. Adherence ~0.76. AE: no.
P01167,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P01167,7,positive,Visit 7: Patient on RX-17B at S005. feels better overall. Notes: headache. Adherence ~0.77. AE: no.
P01168,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: fatigue. Adherence ~0.59. AE: no. CRP 6.8 mg/L; ALT 34 U/L.
P01168,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.94. AE: yes. CRP 7.1 mg/L; ALT 33 U/L.
P01168,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01168,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P01168,4,positive,Visit 4: Patient on RX-17A at S004. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no.
P01168,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.85. AE: no.
P01169,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.36. AE: yes.
P01169,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01169,2,negative,Visit 2: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.51. AE: no.
P01169,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: insomnia. Adherence ~0.43. AE: no.
P01169,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: dizziness. Adherence ~0.45. AE: no. CRP 5.9 mg/L; ALT 40 U/L.
P01170,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P01170,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.49. AE: no.
P01170,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: fatigue. Adherence ~0.46. AE: no.
P01170,3,negative,Visit 3: Patient on RX-17B at S015. symptoms persist. Notes: dizziness. Adherence ~0.38. AE: yes.
P01170,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.30. AE: no.
P01171,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.97. AE: no. CRP 3.9 mg/L; ALT 48 U/L.
P01171,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P01171,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01171,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.80. AE: no.
P01171,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P01171,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.74. AE: no.
P01171,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.89. AE: yes. CRP 2.3 mg/L; ALT 58 U/L.
P01172,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P01172,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P01172,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P01172,3,positive,Visit 3: Patient on RX-17B at S013. feels better overall. Notes: brain fog. Adherence ~0.95. AE: no. CRP 5.9 mg/L; ALT 30 U/L.
P01172,4,positive,Visit 4: Patient on RX-17B at S013. reports improvement. Notes: fatigue. Adherence ~0.95. AE: no. CRP 5.9 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01172,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01172,6,positive,Visit 6: Patient on RX-17B at S013. feels better overall. Notes: joint pain. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01172,7,positive,Visit 7: Patient on RX-17B at S013. symptoms improving. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01173,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: brain fog. Adherence ~0.91. AE: yes. Plan: consider dose adjustment; counsel patient.
P01173,1,negative,Visit 1: Patient on RX-17B at S013. symptoms persist. Notes: headache. Adherence ~1.00. AE: no.
P01173,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P01173,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no.
P01174,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no.
P01174,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.98. AE: no.
P01174,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no. CRP 1.7 mg/L; ALT 18 U/L.
P01174,3,positive,Visit 3: Patient on RX-17B at S015. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no. CRP 2.0 mg/L; ALT 18 U/L.
P01174,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.93. AE: yes. CRP 1.6 mg/L; ALT 18 U/L.
P01174,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.80. AE: no.
P01174,6,positive,Visit 6: Patient on RX-17B at S015. symptoms improving. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01174,7,positive,Visit 7: Patient on RX-17B at S015. symptoms improving. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01175,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P01175,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.72. AE: no.
P01175,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.76. AE: yes.
P01175,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: no. CRP 3.0 mg/L; ALT 30 U/L.
P01175,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.95. AE: no.
P01175,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.97. AE: no.
P01175,6,positive,Visit 6: Patient on RX-17A at S022. tolerating medication well. Notes: headache. Adherence ~0.77. AE: no.
P01176,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: fatigue. Adherence ~0.91. AE: yes. CRP 12.0 mg/L; ALT 30 U/L.
P01176,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.90. AE: no. CRP 10.8 mg/L; ALT 24 U/L.
P01176,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P01176,3,negative,Visit 3: Patient on RX-17B at S022. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01176,4,positive,Visit 4: Patient on RX-17B at S022. energy increasing. Notes: nausea. Adherence ~0.77. AE: no.
P01176,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 6.5 mg/L; ALT 30 U/L.
P01176,6,neutral,Visit 6: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P01176,7,positive,Visit 7: Patient on RX-17B at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 4.3 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01177,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: dizziness. Adherence ~0.33. AE: no.
P01177,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~0.50. AE: no.
P01177,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.31. AE: no. CRP 8.3 mg/L; ALT 45 U/L.
P01177,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.45. AE: no.
P01177,4,negative,Visit 4: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~0.26. AE: no.
P01177,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.56. AE: no. CRP 6.3 mg/L; ALT 46 U/L.
P01178,0,neutral,Visit 0: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no. CRP 9.6 mg/L; ALT 20 U/L.
P01178,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01178,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.67. AE: no. CRP 7.0 mg/L; ALT 20 U/L.
P01178,3,negative,Visit 3: Patient on RX-17B at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 6.7 mg/L; ALT 21 U/L.
P01178,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.70. AE: yes. CRP 5.9 mg/L; ALT 22 U/L.
P01178,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: fatigue. Adherence ~0.79. AE: no.
P01179,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no. CRP 5.2 mg/L; ALT 33 U/L.
P01179,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: no.
P01179,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no.
P01179,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.76. AE: no.
P01179,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01179,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01179,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no. CRP 2.8 mg/L; ALT 39 U/L.
P01179,7,neutral,Visit 7: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.89. AE: yes.
P01180,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.61. AE: no. CRP 10.1 mg/L; ALT 14 U/L.
P01180,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.60. AE: no.
P01180,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P01180,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.59. AE: no. CRP 9.7 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P01180,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no. CRP 9.0 mg/L; ALT 14 U/L.
P01181,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.78. AE: no.
P01181,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.76. AE: no.
P01181,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.67. AE: no.
P01181,3,positive,Visit 3: Patient on RX-17B at S014. feels better overall. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01181,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: joint pain. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01182,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.98. AE: no.
P01182,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 5.9 mg/L; ALT 29 U/L.
P01182,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01183,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01183,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.95. AE: no.
P01183,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.76. AE: no. CRP 3.1 mg/L; ALT 35 U/L.
P01183,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.68. AE: no.
P01183,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.83. AE: no.
P01183,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P01183,6,positive,Visit 6: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.2 mg/L; ALT 38 U/L.
P01184,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 7.3 mg/L; ALT 26 U/L.
P01184,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no.
P01184,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: no.
P01184,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no.
P01184,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01184,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.67. AE: no. CRP 4.1 mg/L; ALT 25 U/L.
P01184,6,negative,Visit 6: Patient on RX-17B at S012. reports worsening. Notes: brain fog. Adherence ~0.86. AE: yes.
P01185,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: insomnia. Adherence ~0.84. AE: no.
P01185,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: yes. CRP 4.0 mg/L; ALT 24 U/L.
P01185,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no. CRP 3.2 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01185,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.79. AE: yes.
P01185,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.80. AE: no. CRP 2.8 mg/L; ALT 22 U/L.
P01185,5,negative,Visit 5: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 3.0 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P01186,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no.
P01186,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: no. CRP 8.6 mg/L; ALT 24 U/L.
P01186,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no.
P01186,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01186,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.80. AE: yes.
P01187,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: brain fog. Adherence ~0.51. AE: no. CRP 10.0 mg/L; ALT 33 U/L.
P01187,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.66. AE: no. CRP 8.0 mg/L; ALT 32 U/L.
P01187,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.45. AE: no. CRP 8.1 mg/L; ALT 30 U/L.
P01187,3,negative,Visit 3: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.39. AE: no. CRP 6.9 mg/L; ALT 34 U/L.
P01187,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.51. AE: no. CRP 6.3 mg/L; ALT 36 U/L.
P01187,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.54. AE: no.
P01188,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.77. AE: no.
P01188,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.80. AE: no.
P01188,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no.
P01188,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.53. AE: no. CRP 4.0 mg/L; ALT 38 U/L.
P01188,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no.
P01188,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.81. AE: yes.
P01188,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: yes.
P01189,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: fatigue. Adherence ~0.60. AE: no.
P01189,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no. CRP 13.0 mg/L; ALT 37 U/L.
P01189,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.59. AE: no. CRP 12.8 mg/L; ALT 32 U/L.
P01189,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no.
P01190,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.51. AE: no. CRP 4.2 mg/L; ALT 20 U/L.
P01190,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.57. AE: no.
P01190,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.55. AE: no.
P01190,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01190,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.62. AE: no. CRP 3.2 mg/L; ALT 22 U/L.
P01190,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.50. AE: no.
P01190,6,neutral,Visit 6: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P01191,0,negative,Visit 0: Patient on RX-17A at S006. reports worsening. Notes: headache. Adherence ~0.82. AE: yes.
P01191,1,neutral,Visit 1: Patient on RX-17A at S006. no major change. Notes: headache. Adherence ~0.45. AE: no.
P01191,2,negative,Visit 2: Patient on RX-17A at S006. symptoms persist. Notes: fatigue. Adherence ~0.73. AE: no. CRP 7.0 mg/L; ALT 60 U/L.
P01191,3,negative,Visit 3: Patient on RX-17A at S006. reports worsening. Notes: nausea. Adherence ~0.61. AE: no. CRP 5.9 mg/L; ALT 60 U/L.
P01191,4,neutral,Visit 4: Patient on RX-17A at S006. continues regimen. Notes: joint pain. Adherence ~0.56. AE: no.
P01192,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.98. AE: yes. Plan: consider dose adjustment; counsel patient.
P01192,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.97. AE: no. CRP 4.7 mg/L; ALT 37 U/L.
P01192,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~1.00. AE: yes.
P01193,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: fatigue. Adherence ~0.92. AE: no.
P01193,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01193,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.91. AE: no.
P01193,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.78. AE: no. CRP 9.7 mg/L; ALT 25 U/L.
P01193,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01193,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.96. AE: no. CRP 8.6 mg/L; ALT 22 U/L.
P01193,6,positive,Visit 6: Patient on RX-17A at S017. feels better overall. Notes: joint pain. Adherence ~1.00. AE: no.
P01193,7,positive,Visit 7: Patient on RX-17A at S017. tolerating medication well. Notes: joint pain. Adherence ~0.92. AE: no.
P01194,0,negative,Visit 0: Patient on RX-17B at S009. poor tolerance. Notes: nausea. Adherence ~0.53. AE: yes. CRP 10.5 mg/L; ALT 42 U/L.
P01194,1,neutral,Visit 1: Patient on RX-17B at S009. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P01194,2,neutral,Visit 2: Patient on RX-17B at S009. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no.
P01194,3,neutral,Visit 3: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.62. AE: no.
P01194,4,neutral,Visit 4: Patient on RX-17B at S009. reviewed dosing instructions. Notes: headache. Adherence ~0.58. AE: no.
P01194,5,neutral,Visit 5: Patient on RX-17B at S009. reviewed dosing instructions. Notes: insomnia. Adherence ~0.72. AE: yes.
P01194,6,positive,Visit 6: Patient on RX-17B at S009. feels better overall. Notes: fatigue. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01194,7,positive,Visit 7: Patient on RX-17B at S009. feels better overall. Notes: headache. Adherence ~0.79. AE: no. CRP 4.9 mg/L; ALT 34 U/L.
P01195,0,neutral,Visit 0: Patient on RX-17A at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no.
P01195,1,negative,Visit 1: Patient on RX-17A at S018. feels frustrated. Notes: dizziness. Adherence ~0.78. AE: no.
P01195,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P01195,3,negative,Visit 3: Patient on RX-17A at S018. reports worsening. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 10.4 mg/L; ALT 35 U/L.
P01195,4,positive,Visit 4: Patient on RX-17A at S018. energy increasing. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01196,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.90. AE: yes.
P01196,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 28 U/L.
P01196,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.95. AE: no. CRP 6.7 mg/L; ALT 26 U/L.
P01196,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.81. AE: no. CRP 5.4 mg/L; ALT 30 U/L.
P01196,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01196,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.98. AE: no.
P01196,6,positive,Visit 6: Patient on RX-17B at S022. energy increasing. Notes: joint pain. Adherence ~0.80. AE: no.
P01197,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01197,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.78. AE: no. CRP 1.2 mg/L; ALT 31 U/L.
P01197,2,negative,Visit 2: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.96. AE: no.
P01197,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: no. CRP 1.2 mg/L; ALT 27 U/L.
P01197,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.77. AE: no.
P01197,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P01198,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no. CRP 7.0 mg/L; ALT 43 U/L.
P01198,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.55. AE: yes. CRP 4.8 mg/L; ALT 47 U/L.
P01198,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.66. AE: no.
P01198,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: yes.
P01198,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.70. AE: no. CRP 3.8 mg/L; ALT 47 U/L.
P01198,5,positive,Visit 5: Patient on RX-17B at S016. feels better overall. Notes: insomnia. Adherence ~0.84. AE: no.
P01199,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.84. AE: no.
P01199,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01199,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.77. AE: no.
P01199,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no. CRP 13.3 mg/L; ALT 63 U/L.
P01199,4,negative,Visit 4: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.63. AE: yes.
P01200,0,neutral,Visit 0: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no. CRP 5.8 mg/L; ALT 15 U/L.
P01200,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 5.1 mg/L; ALT 14 U/L.
P01200,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.91. AE: no.
P01200,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no. CRP 4.5 mg/L; ALT 16 U/L.
P01200,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.92. AE: no. CRP 4.7 mg/L; ALT 17 U/L.
P01200,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: fatigue. Adherence ~0.76. AE: no. CRP 3.7 mg/L; ALT 16 U/L.
P01200,6,positive,Visit 6: Patient on RX-17B at S022. reports improvement. Notes: joint pain. Adherence ~0.92. AE: no.
P01201,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~1.00. AE: no.
P01201,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.96. AE: no.
P01201,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no.
P01201,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P01201,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01202,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.95. AE: no. CRP 9.4 mg/L; ALT 30 U/L.
P01202,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.2 mg/L; ALT 30 U/L.
P01202,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P01202,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no. CRP 6.8 mg/L; ALT 32 U/L.
P01202,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no. CRP 6.8 mg/L; ALT 33 U/L.
P01202,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: fatigue. Adherence ~0.86. AE: no.
P01203,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 9.2 mg/L; ALT 30 U/L.
P01203,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.61. AE: no.
P01203,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.67. AE: no.
P01203,3,negative,Visit 3: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 7.2 mg/L; ALT 33 U/L.
P01203,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.71. AE: yes. CRP 6.6 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01204,0,negative,Visit 0: Patient on RX-17A at S001. reports worsening. Notes: nausea. Adherence ~0.93. AE: no.
P01204,1,neutral,Visit 1: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01204,2,neutral,Visit 2: Patient on RX-17A at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01204,3,neutral,Visit 3: Patient on RX-17A at S001. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 48 U/L.
P01204,4,neutral,Visit 4: Patient on RX-17A at S001. continues regimen. Notes: nausea. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01204,5,neutral,Visit 5: Patient on RX-17A at S001. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 3.4 mg/L; ALT 55 U/L.
P01204,6,neutral,Visit 6: Patient on RX-17A at S001. no major change. Notes: nausea. Adherence ~0.77. AE: no.
P01205,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: headache. Adherence ~0.59. AE: no.
P01205,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.47. AE: no. CRP 6.4 mg/L; ALT 12 U/L.
P01205,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.67. AE: no.
P01205,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: yes. Plan: consider dose adjustment; counsel patient.
P01205,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: fatigue. Adherence ~0.53. AE: no.
P01206,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: headache. Adherence ~0.85. AE: no. CRP 4.5 mg/L; ALT 39 U/L.
P01206,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 4.4 mg/L; ALT 38 U/L.
P01206,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no.
P01206,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.99. AE: no.
P01206,4,positive,Visit 4: Patient on RX-17B at S016. tolerating medication well. Notes: brain fog. Adherence ~0.79. AE: no.
P01207,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.66. AE: yes.
P01207,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no.
P01207,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.72. AE: no.
P01207,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.79. AE: no.
P01207,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01207,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.98. AE: yes. CRP 7.1 mg/L; ALT 50 U/L.
P01207,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.63. AE: no.
P01207,7,neutral,Visit 7: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: yes. CRP 5.9 mg/L; ALT 55 U/L.
P01208,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 8.6 mg/L; ALT 24 U/L.
P01208,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.54. AE: no. CRP 7.3 mg/L; ALT 24 U/L.
P01208,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P01208,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no.
P01208,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.61. AE: no.
P01208,5,negative,Visit 5: Patient on RX-17A at S002. feels frustrated. Notes: fatigue. Adherence ~0.52. AE: no.
P01208,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P01208,7,neutral,Visit 7: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no.
P01209,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.71. AE: no.
P01209,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01209,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no. CRP 3.1 mg/L; ALT 18 U/L.
P01209,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no.
P01209,4,positive,Visit 4: Patient on RX-17B at S017. symptoms improving. Notes: fatigue. Adherence ~0.84. AE: no.
P01209,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no. CRP 2.3 mg/L; ALT 20 U/L.
P01209,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.76. AE: no.
P01210,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 7.5 mg/L; ALT 52 U/L.
P01210,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.90. AE: no. CRP 7.0 mg/L; ALT 53 U/L.
P01210,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.70. AE: yes. CRP 6.2 mg/L; ALT 55 U/L.
P01210,3,negative,Visit 3: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.76. AE: no.
P01210,4,negative,Visit 4: Patient on RX-17A at S019. reports worsening. Notes: joint pain. Adherence ~0.83. AE: no.
P01210,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P01211,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 5.1 mg/L; ALT 16 U/L.
P01211,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 4.1 mg/L; ALT 18 U/L.
P01211,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.63. AE: no.
P01211,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.71. AE: no.
P01211,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: no.
P01212,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.96. AE: no. CRP 18.9 mg/L; ALT 35 U/L.
P01212,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.86. AE: yes.
P01212,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.86. AE: yes. Plan: consider dose adjustment; counsel patient.
P01212,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01212,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: insomnia. Adherence ~0.87. AE: no.
P01213,0,negative,Visit 0: Patient on RX-17A at S001. reports worsening. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 13.3 mg/L; ALT 41 U/L.
P01213,1,neutral,Visit 1: Patient on RX-17A at S001. follow-up as scheduled. Notes: insomnia. Adherence ~0.91. AE: no. CRP 12.3 mg/L; ALT 46 U/L.
P01213,2,negative,Visit 2: Patient on RX-17A at S001. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01213,3,neutral,Visit 3: Patient on RX-17A at S001. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 9.8 mg/L; ALT 46 U/L.
P01213,4,neutral,Visit 4: Patient on RX-17A at S001. continues regimen. Notes: headache. Adherence ~0.99. AE: no.
P01213,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01213,6,neutral,Visit 6: Patient on RX-17A at S001. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no.
P01214,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.89. AE: no. CRP 5.7 mg/L; ALT 36 U/L.
P01214,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P01214,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.71. AE: no.
P01214,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. CRP 5.1 mg/L; ALT 36 U/L.
P01214,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.82. AE: no. CRP 5.2 mg/L; ALT 39 U/L.
P01214,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: yes. Plan: consider dose adjustment; counsel patient.
P01215,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no.
P01215,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no.
P01215,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.61. AE: no. CRP 7.2 mg/L; ALT 37 U/L.
P01215,3,positive,Visit 3: Patient on RX-17A at S012. symptoms improving. Notes: insomnia. Adherence ~0.87. AE: no.
P01215,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P01216,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: dizziness. Adherence ~0.77. AE: no.
P01216,1,neutral,Visit 1: Patient on RX-17A at S020. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no. CRP 12.7 mg/L; ALT 28 U/L.
P01216,2,neutral,Visit 2: Patient on RX-17A at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01216,3,negative,Visit 3: Patient on RX-17A at S020. symptoms persist. Notes: dizziness. Adherence ~0.81. AE: no. CRP 10.1 mg/L; ALT 26 U/L.
P01216,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: joint pain. Adherence ~0.69. AE: no. CRP 8.8 mg/L; ALT 29 U/L.
P01217,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.43. AE: no. CRP 6.4 mg/L; ALT 35 U/L.
P01217,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.48. AE: yes. Plan: consider dose adjustment; counsel patient.
P01217,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01217,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.45. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P01217,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.40. AE: no. Plan: consider dose adjustment; counsel patient.
P01218,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.78. AE: no. CRP 11.3 mg/L; ALT 23 U/L.
P01218,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.54. AE: no. CRP 10.2 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01218,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01218,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.94. AE: no.
P01218,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P01218,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no. CRP 7.3 mg/L; ALT 25 U/L.
P01218,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: yes.
P01219,0,negative,Visit 0: Patient on RX-17A at S010. reports worsening. Notes: joint pain. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P01219,1,negative,Visit 1: Patient on RX-17A at S010. symptoms persist. Notes: dizziness. Adherence ~0.53. AE: no. CRP 13.5 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01219,2,negative,Visit 2: Patient on RX-17A at S010. reports worsening. Notes: fatigue. Adherence ~0.51. AE: no.
P01219,3,negative,Visit 3: Patient on RX-17A at S010. reports worsening. Notes: insomnia. Adherence ~0.47. AE: no. CRP 13.4 mg/L; ALT 25 U/L.
P01219,4,neutral,Visit 4: Patient on RX-17A at S010. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no.
P01219,5,neutral,Visit 5: Patient on RX-17A at S010. no major change. Notes: joint pain. Adherence ~0.58. AE: no.
P01219,6,neutral,Visit 6: Patient on RX-17A at S010. no major change. Notes: abdominal discomfort. Adherence ~0.49. AE: no. CRP 10.0 mg/L; ALT 22 U/L.
P01220,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.59. AE: no. CRP 6.6 mg/L; ALT 32 U/L.
P01220,1,neutral,Visit 1: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.42. AE: no. CRP 5.2 mg/L; ALT 33 U/L.
P01220,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.60. AE: no. CRP 4.9 mg/L; ALT 32 U/L.
P01220,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no.
P01220,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no.
P01220,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.45. AE: no.
P01220,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P01221,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.69. AE: no. CRP 14.0 mg/L; ALT 17 U/L.
P01221,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01221,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no. CRP 17.4 mg/L; ALT 16 U/L.
P01221,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.63. AE: no.
P01221,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.69. AE: no. CRP 15.8 mg/L; ALT 19 U/L.
P01222,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 13.6 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01222,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.64. AE: no.
P01222,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.79. AE: no.
P01222,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.60. AE: no.
P01222,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01222,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01222,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.56. AE: no.
P01222,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: insomnia. Adherence ~0.83. AE: no. CRP 4.7 mg/L; ALT 38 U/L.
P01223,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.32. AE: no. CRP 9.4 mg/L; ALT 13 U/L.
P01223,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.46. AE: no.
P01223,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no.
P01223,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.62. AE: yes. CRP 5.7 mg/L; ALT 14 U/L.
P01223,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.66. AE: no. CRP 5.9 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P01223,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.56. AE: no.
P01224,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.69. AE: no.
P01224,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 5.4 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01224,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.74. AE: no. CRP 4.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01224,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 5.2 mg/L; ALT 33 U/L.
P01224,4,positive,Visit 4: Patient on RX-17A at S022. tolerating medication well. Notes: headache. Adherence ~0.81. AE: no.
P01224,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no. CRP 4.3 mg/L; ALT 34 U/L.
P01225,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.75. AE: no. CRP 9.2 mg/L; ALT 35 U/L.
P01225,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no.
P01225,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.57. AE: no.
P01225,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: no.
P01225,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01225,5,negative,Visit 5: Patient on RX-17B at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.70. AE: yes. Plan: consider dose adjustment; counsel patient.
P01225,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.53. AE: no.
P01225,7,neutral,Visit 7: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.78. AE: yes.
P01226,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: headache. Adherence ~0.90. AE: yes.
P01226,1,neutral,Visit 1: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.75. AE: no.
P01226,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 5.8 mg/L; ALT 24 U/L.
P01226,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 5.6 mg/L; ALT 22 U/L.
P01226,4,positive,Visit 4: Patient on RX-17B at S019. tolerating medication well. Notes: brain fog. Adherence ~0.87. AE: no.
P01227,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P01227,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no.
P01227,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.99. AE: yes.
P01227,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01227,4,positive,Visit 4: Patient on RX-17B at S005. energy increasing. Notes: nausea. Adherence ~1.00. AE: no.
P01227,5,positive,Visit 5: Patient on RX-17B at S005. feels better overall. Notes: brain fog. Adherence ~0.82. AE: no. CRP 3.3 mg/L; ALT 20 U/L.
P01228,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: joint pain. Adherence ~0.76. AE: no.
P01228,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.84. AE: no.
P01228,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01229,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.83. AE: no.
P01229,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no. CRP 3.6 mg/L; ALT 39 U/L.
P01229,2,negative,Visit 2: Patient on RX-17B at S019. symptoms persist. Notes: dizziness. Adherence ~0.80. AE: no.
P01229,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: yes. CRP 3.1 mg/L; ALT 40 U/L.
P01229,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P01229,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.74. AE: no.
P01230,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P01230,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.98. AE: no.
P01230,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01230,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: no.
P01230,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.94. AE: no.
P01231,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.76. AE: no.
P01231,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: no.
P01231,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.63. AE: yes.
P01231,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01231,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P01232,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: fatigue. Adherence ~0.65. AE: no.
P01232,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: fatigue. Adherence ~0.64. AE: yes. CRP 2.9 mg/L; ALT 34 U/L.
P01232,2,negative,Visit 2: Patient on RX-17B at S018. reports worsening. Notes: headache. Adherence ~0.83. AE: yes. CRP 3.1 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01232,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: yes.
P01232,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.72. AE: yes. CRP 2.1 mg/L; ALT 33 U/L.
P01232,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01232,6,positive,Visit 6: Patient on RX-17B at S018. energy increasing. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01233,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P01233,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P01233,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.67. AE: no.
P01233,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.82. AE: no. CRP 7.4 mg/L; ALT 37 U/L.
P01233,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: no. CRP 7.6 mg/L; ALT 37 U/L.
P01233,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01234,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.98. AE: no.
P01234,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01234,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01234,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.89. AE: no.
P01234,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no.
P01234,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01235,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~0.97. AE: no.
P01235,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01235,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: no.
P01235,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~1.00. AE: yes.
P01235,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P01236,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 6.3 mg/L; ALT 33 U/L.
P01236,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01236,2,positive,Visit 2: Patient on RX-17B at S015. symptoms improving. Notes: dizziness. Adherence ~0.76. AE: no.
P01236,3,negative,Visit 3: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.58. AE: no.
P01236,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.53. AE: no. CRP 4.5 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01236,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no. CRP 4.4 mg/L; ALT 34 U/L.
P01236,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01237,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.85. AE: no. CRP 5.9 mg/L; ALT 40 U/L.
P01237,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.62. AE: no. CRP 6.1 mg/L; ALT 36 U/L.
P01237,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: headache. Adherence ~0.93. AE: no. CRP 5.3 mg/L; ALT 37 U/L.
P01237,3,negative,Visit 3: Patient on RX-17A at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P01237,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.86. AE: no. CRP 4.4 mg/L; ALT 40 U/L.
P01237,5,negative,Visit 5: Patient on RX-17A at S013. reports worsening. Notes: joint pain. Adherence ~0.73. AE: no. CRP 3.6 mg/L; ALT 43 U/L.
P01237,6,neutral,Visit 6: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.71. AE: no.
P01238,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.62. AE: yes. CRP 4.4 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P01238,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.68. AE: no. CRP 4.3 mg/L; ALT 38 U/L.
P01238,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no.
P01238,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 3.8 mg/L; ALT 39 U/L.
P01238,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.63. AE: no. CRP 3.1 mg/L; ALT 37 U/L.
P01238,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P01239,0,neutral,Visit 0: Patient on RX-17B at S013. no major change. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01239,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 8.6 mg/L; ALT 32 U/L.
P01239,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P01239,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P01239,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.7 mg/L; ALT 38 U/L.
P01239,5,neutral,Visit 5: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P01240,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.71. AE: no.
P01240,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 48 U/L.
P01240,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.3 mg/L; ALT 56 U/L.
P01240,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no.
P01240,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P01241,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.64. AE: no. CRP 10.7 mg/L; ALT 32 U/L.
P01241,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: joint pain. Adherence ~0.66. AE: no.
P01241,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P01241,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.89. AE: no.
P01241,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: yes.
P01241,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no. CRP 7.1 mg/L; ALT 34 U/L.
P01242,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.7 mg/L; ALT 23 U/L.
P01242,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.99. AE: no. CRP 6.8 mg/L; ALT 24 U/L.
P01242,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.78. AE: no. CRP 6.8 mg/L; ALT 23 U/L.
P01242,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.96. AE: no. CRP 5.9 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01242,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P01243,0,negative,Visit 0: Patient on RX-17A at S011. feels frustrated. Notes: insomnia. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P01243,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: nausea. Adherence ~0.94. AE: no. CRP 25.2 mg/L; ALT 22 U/L.
P01243,2,negative,Visit 2: Patient on RX-17A at S011. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no.
P01243,3,neutral,Visit 3: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.84. AE: no.
P01243,4,negative,Visit 4: Patient on RX-17A at S011. poor tolerance. Notes: brain fog. Adherence ~0.78. AE: yes. CRP 17.2 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01244,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no.
P01244,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.86. AE: no. CRP 8.0 mg/L; ALT 31 U/L.
P01244,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no. CRP 8.1 mg/L; ALT 33 U/L.
P01244,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01244,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.79. AE: yes.
P01244,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.96. AE: no. CRP 6.2 mg/L; ALT 36 U/L.
P01245,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: nausea. Adherence ~0.81. AE: no.
P01245,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: nausea. Adherence ~0.64. AE: yes.
P01245,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no. CRP 4.2 mg/L; ALT 18 U/L.
P01245,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: dizziness. Adherence ~0.80. AE: no.
P01245,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: no. CRP 2.7 mg/L; ALT 19 U/L.
P01245,5,positive,Visit 5: Patient on RX-17B at S019. energy increasing. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01246,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: insomnia. Adherence ~0.44. AE: no.
P01246,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: nausea. Adherence ~0.57. AE: no.
P01246,2,neutral,Visit 2: Patient on RX-17A at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.36. AE: no.
P01246,3,neutral,Visit 3: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.48. AE: no.
P01246,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 3.0 mg/L; ALT 24 U/L.
P01246,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.37. AE: no. CRP 2.9 mg/L; ALT 27 U/L.
P01246,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: headache. Adherence ~0.46. AE: no.
P01246,7,neutral,Visit 7: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.49. AE: no. CRP 2.4 mg/L; ALT 27 U/L.
P01247,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.69. AE: no. CRP 10.5 mg/L; ALT 34 U/L.
P01247,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P01247,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.71. AE: yes.
P01247,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: yes.
P01247,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.45. AE: no.
P01247,5,negative,Visit 5: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.63. AE: no.
P01247,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: yes.
P01248,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 4.1 mg/L; ALT 44 U/L.
P01248,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.71. AE: no.
P01248,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: yes.
P01248,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P01248,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 50 U/L.
P01248,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.60. AE: yes. CRP 2.5 mg/L; ALT 49 U/L.
P01248,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no. CRP 2.1 mg/L; ALT 48 U/L.
P01249,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: dizziness. Adherence ~0.80. AE: yes.
P01249,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 10.2 mg/L; ALT 18 U/L.
P01249,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.70. AE: no. CRP 8.7 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01249,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: no.
P01249,4,positive,Visit 4: Patient on RX-17B at S016. reports improvement. Notes: joint pain. Adherence ~0.82. AE: no.
P01249,5,positive,Visit 5: Patient on RX-17B at S016. symptoms improving. Notes: nausea. Adherence ~0.86. AE: no. CRP 6.2 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01250,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.50. AE: no. CRP 10.7 mg/L; ALT 31 U/L.
P01250,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01250,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no. CRP 9.5 mg/L; ALT 33 U/L.
P01250,3,negative,Visit 3: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.75. AE: no. CRP 8.8 mg/L; ALT 35 U/L.
P01250,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.51. AE: no.
P01250,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.61. AE: yes.
P01250,6,neutral,Visit 6: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.78. AE: yes. CRP 5.5 mg/L; ALT 33 U/L.
P01251,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 10.9 mg/L; ALT 30 U/L.
P01251,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: brain fog. Adherence ~0.81. AE: no.
P01251,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.82. AE: yes.
P01251,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no. CRP 8.8 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01251,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01251,5,positive,Visit 5: Patient on RX-17B at S016. feels better overall. Notes: headache. Adherence ~0.94. AE: no. CRP 6.5 mg/L; ALT 30 U/L.
P01252,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 31 U/L.
P01252,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.74. AE: no. CRP 4.7 mg/L; ALT 32 U/L.
P01252,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.91. AE: no.
P01252,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 3.9 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01252,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no. CRP 3.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01252,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.1 mg/L; ALT 31 U/L.
P01253,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.52. AE: no.
P01253,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.41. AE: no.
P01253,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P01254,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P01254,1,neutral,Visit 1: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01254,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: nausea. Adherence ~0.71. AE: no.
P01254,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no.
P01254,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.54. AE: no.
P01254,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.74. AE: no.
P01254,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.56. AE: no.
P01254,7,neutral,Visit 7: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~0.63. AE: no.
P01255,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~0.33. AE: no.
P01255,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P01255,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.51. AE: no.
P01255,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.53. AE: no.
P01256,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.77. AE: no. CRP 6.7 mg/L; ALT 45 U/L.
P01256,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: yes.
P01256,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.88. AE: yes. CRP 5.2 mg/L; ALT 47 U/L.
P01256,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01256,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: yes.
P01256,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: dizziness. Adherence ~0.95. AE: no.
P01256,6,positive,Visit 6: Patient on RX-17B at S014. symptoms improving. Notes: joint pain. Adherence ~0.83. AE: no.
P01257,0,neutral,Visit 0: Patient on RX-17A at S006. no major change. Notes: nausea. Adherence ~0.94. AE: no.
P01257,1,negative,Visit 1: Patient on RX-17A at S006. reports worsening. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01257,2,negative,Visit 2: Patient on RX-17A at S006. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no.
P01257,3,neutral,Visit 3: Patient on RX-17A at S006. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no. CRP 7.6 mg/L; ALT 68 U/L.
P01257,4,negative,Visit 4: Patient on RX-17A at S006. reports worsening. Notes: nausea. Adherence ~0.90. AE: no.
P01257,5,positive,Visit 5: Patient on RX-17A at S006. energy increasing. Notes: headache. Adherence ~0.90. AE: no. CRP 6.2 mg/L; ALT 66 U/L. Plan: consider dose adjustment; counsel patient.
P01257,6,positive,Visit 6: Patient on RX-17A at S006. feels better overall. Notes: headache. Adherence ~0.90. AE: no.
P01257,7,neutral,Visit 7: Patient on RX-17A at S006. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01258,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.45. AE: no.
P01258,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.70. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P01258,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01258,3,negative,Visit 3: Patient on RX-17B at S004. symptoms persist. Notes: brain fog. Adherence ~0.57. AE: yes.
P01258,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: yes. CRP 3.9 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01259,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01259,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.61. AE: no.
P01259,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.76. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P01259,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.65. AE: yes.
P01260,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.96. AE: no.
P01260,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.96. AE: no.
P01260,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 16.0 mg/L; ALT 21 U/L.
P01260,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: no.
P01260,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no.
P01261,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.69. AE: no.
P01261,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no. CRP 11.2 mg/L; ALT 25 U/L.
P01261,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01261,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01261,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.75. AE: no. CRP 8.3 mg/L; ALT 26 U/L.
P01261,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.84. AE: yes.
P01261,6,positive,Visit 6: Patient on RX-17B at S004. reports improvement. Notes: nausea. Adherence ~0.93. AE: no.
P01262,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.81. AE: no.
P01262,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.81. AE: yes.
P01262,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.80. AE: no.
P01262,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01262,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.83. AE: no. CRP 5.8 mg/L; ALT 39 U/L.
P01263,0,neutral,Visit 0: Patient on RX-17B at S013. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no.
P01263,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no.
P01263,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no.
P01263,3,negative,Visit 3: Patient on RX-17B at S013. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.9 mg/L; ALT 42 U/L.
P01263,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.79. AE: no.
P01263,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.65. AE: no.
P01264,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: nausea. Adherence ~0.64. AE: no.
P01264,1,neutral,Visit 1: Patient on RX-17A at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.59. AE: yes.
P01264,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no.
P01264,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: brain fog. Adherence ~0.57. AE: no.
P01264,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.61. AE: no.
P01264,5,neutral,Visit 5: Patient on RX-17A at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01264,6,neutral,Visit 6: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P01264,7,positive,Visit 7: Patient on RX-17A at S018. reports improvement. Notes: fatigue. Adherence ~0.80. AE: no.
P01265,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.80. AE: no.
P01265,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.60. AE: no. CRP 5.6 mg/L; ALT 25 U/L.
P01265,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P01265,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.41. AE: no.
P01265,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.59. AE: no. CRP 3.8 mg/L; ALT 25 U/L.
P01265,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.54. AE: no.
P01265,6,positive,Visit 6: Patient on RX-17A at S022. reports improvement. Notes: headache. Adherence ~0.80. AE: no.
P01266,0,neutral,Visit 0: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.60. AE: no.
P01266,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P01266,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.42. AE: no.
P01267,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.59. AE: no. CRP 8.2 mg/L; ALT 64 U/L.
P01267,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: headache. Adherence ~0.81. AE: no.
P01267,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no.
P01268,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.84. AE: no. CRP 10.4 mg/L; ALT 24 U/L.
P01268,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P01268,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P01268,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01268,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no. CRP 8.1 mg/L; ALT 23 U/L.
P01268,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.87. AE: no.
P01268,6,neutral,Visit 6: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no. CRP 6.3 mg/L; ALT 25 U/L.
P01269,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.99. AE: no. CRP 7.0 mg/L; ALT 48 U/L.
P01269,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P01269,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01269,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01269,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~1.00. AE: yes.
P01270,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01270,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: insomnia. Adherence ~0.93. AE: no.
P01270,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.95. AE: yes. CRP 4.4 mg/L; ALT 36 U/L.
P01271,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P01271,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01271,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01271,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01271,4,positive,Visit 4: Patient on RX-17A at S013. symptoms improving. Notes: fatigue. Adherence ~0.83. AE: no.
P01271,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01271,6,positive,Visit 6: Patient on RX-17A at S013. energy increasing. Notes: fatigue. Adherence ~0.98. AE: no.
P01271,7,neutral,Visit 7: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.98. AE: no.
P01272,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: yes.
P01272,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: brain fog. Adherence ~0.77. AE: no.
P01272,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P01272,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.62. AE: no.
P01272,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no.
P01272,5,positive,Visit 5: Patient on RX-17B at S002. symptoms improving. Notes: insomnia. Adherence ~0.81. AE: no. CRP 8.3 mg/L; ALT 22 U/L.
P01272,6,neutral,Visit 6: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P01272,7,positive,Visit 7: Patient on RX-17B at S002. energy increasing. Notes: joint pain. Adherence ~0.88. AE: no.
P01273,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01273,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.62. AE: no.
P01273,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.59. AE: no.
P01273,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.59. AE: no. CRP 8.3 mg/L; ALT 26 U/L.
P01273,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.60. AE: no. CRP 7.0 mg/L; ALT 25 U/L.
P01273,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01274,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.82. AE: no.
P01274,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01274,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.96. AE: no.
P01274,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.87. AE: no. CRP 6.0 mg/L; ALT 34 U/L.
P01274,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: no. CRP 5.7 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01274,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P01275,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.66. AE: yes. CRP 19.1 mg/L; ALT 24 U/L.
P01275,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.67. AE: yes.
P01275,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no.
P01275,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01275,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.73. AE: yes.
P01275,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01275,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P01275,7,positive,Visit 7: Patient on RX-17B at S022. feels better overall. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01276,0,neutral,Visit 0: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no. CRP 32.7 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P01276,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no.
P01276,2,negative,Visit 2: Patient on RX-17A at S002. reports worsening. Notes: headache. Adherence ~0.69. AE: no.
P01276,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.53. AE: no. CRP 24.6 mg/L; ALT 53 U/L.
P01276,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.39. AE: no.
P01277,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no.
P01277,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01277,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.79. AE: no.
P01277,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01277,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01277,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P01277,6,positive,Visit 6: Patient on RX-17B at S016. tolerating medication well. Notes: fatigue. Adherence ~0.82. AE: no.
P01278,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no.
P01278,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.81. AE: yes.
P01278,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.95. AE: no.
P01278,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01278,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no.
P01278,5,negative,Visit 5: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.66. AE: no.
P01279,0,negative,Visit 0: Patient on RX-17B at S021. symptoms persist. Notes: joint pain. Adherence ~0.70. AE: yes. Plan: consider dose adjustment; counsel patient.
P01279,1,neutral,Visit 1: Patient on RX-17B at S021. stable symptoms. Notes: joint pain. Adherence ~0.66. AE: no.
P01279,2,neutral,Visit 2: Patient on RX-17B at S021. no major change. Notes: brain fog. Adherence ~0.70. AE: no.
P01279,3,negative,Visit 3: Patient on RX-17B at S021. poor tolerance. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P01279,4,neutral,Visit 4: Patient on RX-17B at S021. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01279,5,neutral,Visit 5: Patient on RX-17B at S021. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no. CRP 6.5 mg/L; ALT 36 U/L.
P01279,6,neutral,Visit 6: Patient on RX-17B at S021. no major change. Notes: nausea. Adherence ~0.78. AE: yes. CRP 5.6 mg/L; ALT 45 U/L.
P01280,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: headache. Adherence ~0.85. AE: no. CRP 5.1 mg/L; ALT 57 U/L.
P01280,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: brain fog. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01280,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.96. AE: yes. Plan: consider dose adjustment; counsel patient.
P01280,3,positive,Visit 3: Patient on RX-17B at S002. symptoms improving. Notes: headache. Adherence ~0.88. AE: no. CRP 3.7 mg/L; ALT 55 U/L.
P01280,4,neutral,Visit 4: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P01280,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.75. AE: yes. CRP 2.6 mg/L; ALT 63 U/L.
P01280,6,neutral,Visit 6: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.89. AE: no.
P01281,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.65. AE: no.
P01281,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.76. AE: no.
P01281,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.69. AE: no. CRP 9.2 mg/L; ALT 27 U/L.
P01281,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.82. AE: no. CRP 9.7 mg/L; ALT 28 U/L.
P01281,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.53. AE: no.
P01281,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.52. AE: no.
P01281,6,neutral,Visit 6: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: no.
P01281,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no. CRP 6.2 mg/L; ALT 25 U/L.
P01282,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.94. AE: no. CRP 7.8 mg/L; ALT 33 U/L.
P01282,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 6.5 mg/L; ALT 34 U/L.
P01282,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no.
P01282,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 5.9 mg/L; ALT 31 U/L.
P01282,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.90. AE: no.
P01282,5,positive,Visit 5: Patient on RX-17A at S019. symptoms improving. Notes: joint pain. Adherence ~0.89. AE: no. CRP 4.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01282,6,positive,Visit 6: Patient on RX-17A at S019. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no.
P01283,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.60. AE: no. CRP 8.8 mg/L; ALT 19 U/L.
P01283,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.65. AE: no.
P01283,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.59. AE: no.
P01283,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.63. AE: no.
P01283,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 7.6 mg/L; ALT 18 U/L.
P01283,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.55. AE: no.
P01284,0,negative,Visit 0: Patient on RX-17A at S003. feels frustrated. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01284,1,neutral,Visit 1: Patient on RX-17A at S003. reviewed dosing instructions. Notes: joint pain. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01284,2,neutral,Visit 2: Patient on RX-17A at S003. no major change. Notes: nausea. Adherence ~0.62. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P01284,3,neutral,Visit 3: Patient on RX-17A at S003. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 4.3 mg/L; ALT 32 U/L.
P01284,4,neutral,Visit 4: Patient on RX-17A at S003. no major change. Notes: nausea. Adherence ~0.76. AE: no.
P01284,5,neutral,Visit 5: Patient on RX-17A at S003. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: yes.
P01285,0,neutral,Visit 0: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 5.3 mg/L; ALT 49 U/L.
P01285,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: headache. Adherence ~0.69. AE: no. CRP 5.0 mg/L; ALT 49 U/L.
P01285,2,negative,Visit 2: Patient on RX-17A at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01285,3,positive,Visit 3: Patient on RX-17A at S019. reports improvement. Notes: headache. Adherence ~0.77. AE: no. CRP 3.4 mg/L; ALT 49 U/L.
P01285,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no. CRP 3.4 mg/L; ALT 46 U/L.
P01285,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01286,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no.
P01286,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01286,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: fatigue. Adherence ~0.98. AE: yes.
P01286,3,negative,Visit 3: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.90. AE: yes.
P01286,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.93. AE: no.
P01286,5,negative,Visit 5: Patient on RX-17A at S005. feels frustrated. Notes: brain fog. Adherence ~0.68. AE: no.
P01286,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 1.6 mg/L; ALT 36 U/L.
P01287,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.56. AE: no.
P01287,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.52. AE: yes.
P01287,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.62. AE: no. CRP 14.0 mg/L; ALT 75 U/L.
P01287,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.59. AE: yes.
P01287,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: brain fog. Adherence ~0.84. AE: no. CRP 10.3 mg/L; ALT 81 U/L.
P01287,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.64. AE: no. CRP 8.4 mg/L; ALT 77 U/L.
P01288,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.56. AE: no.
P01288,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 11.5 mg/L; ALT 35 U/L.
P01288,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01288,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.51. AE: yes.
P01288,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.56. AE: yes. CRP 6.6 mg/L; ALT 38 U/L.
P01289,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.75. AE: no.
P01289,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.77. AE: no.
P01289,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. CRP 8.6 mg/L; ALT 26 U/L.
P01289,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. CRP 8.1 mg/L; ALT 27 U/L.
P01289,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01290,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.67. AE: no. CRP 10.0 mg/L; ALT 37 U/L.
P01290,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: no.
P01290,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. CRP 7.6 mg/L; ALT 37 U/L.
P01290,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.54. AE: no. CRP 7.2 mg/L; ALT 38 U/L.
P01290,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: no.
P01291,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no. CRP 2.3 mg/L; ALT 17 U/L.
P01291,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.82. AE: no. CRP 2.1 mg/L; ALT 17 U/L.
P01291,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.94. AE: no.
P01291,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.79. AE: no. CRP 1.5 mg/L; ALT 18 U/L.
P01291,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01291,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01292,0,neutral,Visit 0: Patient on RX-17A at S003. stable symptoms. Notes: insomnia. Adherence ~0.73. AE: no.
P01292,1,neutral,Visit 1: Patient on RX-17A at S003. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P01292,2,neutral,Visit 2: Patient on RX-17A at S003. continues regimen. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01292,3,negative,Visit 3: Patient on RX-17A at S003. poor tolerance. Notes: fatigue. Adherence ~0.69. AE: no. CRP 4.0 mg/L; ALT 24 U/L.
P01292,4,neutral,Visit 4: Patient on RX-17A at S003. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: yes. CRP 3.7 mg/L; ALT 25 U/L.
P01292,5,neutral,Visit 5: Patient on RX-17A at S003. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: yes.
P01292,6,neutral,Visit 6: Patient on RX-17A at S003. stable symptoms. Notes: nausea. Adherence ~0.73. AE: no.
P01293,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01293,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.86. AE: yes. CRP 6.7 mg/L; ALT 24 U/L.
P01293,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01293,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01293,4,positive,Visit 4: Patient on RX-17A at S022. feels better overall. Notes: joint pain. Adherence ~0.87. AE: no.
P01293,5,positive,Visit 5: Patient on RX-17A at S022. feels better overall. Notes: brain fog. Adherence ~0.78. AE: no.
P01294,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.60. AE: no.
P01294,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.84. AE: no.
P01294,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 30 U/L.
P01294,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.74. AE: no.
P01294,4,negative,Visit 4: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.82. AE: yes. CRP 3.5 mg/L; ALT 32 U/L.
P01294,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: yes.
P01295,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: brain fog. Adherence ~0.90. AE: no.
P01295,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 3.0 mg/L; ALT 32 U/L.
P01295,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: joint pain. Adherence ~0.80. AE: yes.
P01295,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.86. AE: no.
P01295,4,negative,Visit 4: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.73. AE: no.
P01295,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01295,6,positive,Visit 6: Patient on RX-17A at S005. reports improvement. Notes: headache. Adherence ~0.92. AE: no.
P01296,0,neutral,Visit 0: Patient on RX-17A at S011. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no. CRP 4.2 mg/L; ALT 43 U/L.
P01296,1,negative,Visit 1: Patient on RX-17A at S011. poor tolerance. Notes: fatigue. Adherence ~0.96. AE: no.
P01296,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no.
P01296,3,negative,Visit 3: Patient on RX-17A at S011. increased discomfort. Notes: nausea. Adherence ~0.91. AE: no.
P01296,4,negative,Visit 4: Patient on RX-17A at S011. increased discomfort. Notes: joint pain. Adherence ~0.86. AE: no.
P01297,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: no.
P01297,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01297,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 6.8 mg/L; ALT 29 U/L.
P01297,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.97. AE: no.
P01297,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P01297,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no.
P01297,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.95. AE: no. CRP 4.8 mg/L; ALT 28 U/L.
P01297,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.8 mg/L; ALT 26 U/L.
P01298,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.84. AE: no.
P01298,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P01298,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.72. AE: no.
P01298,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01298,4,positive,Visit 4: Patient on RX-17B at S004. symptoms improving. Notes: fatigue. Adherence ~0.87. AE: no. CRP 5.3 mg/L; ALT 23 U/L.
P01299,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no.
P01299,1,neutral,Visit 1: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P01299,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no. CRP 10.2 mg/L; ALT 59 U/L. Plan: consider dose adjustment; counsel patient.
P01299,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no.
P01299,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01300,0,neutral,Visit 0: Patient on RX-17A at S016. continues regimen. Notes: fatigue. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01300,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01300,2,negative,Visit 2: Patient on RX-17A at S016. poor tolerance. Notes: brain fog. Adherence ~0.62. AE: no.
P01300,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01300,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P01300,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no. CRP 15.5 mg/L; ALT 12 U/L.
P01301,0,negative,Visit 0: Patient on RX-17B at S018. feels frustrated. Notes: brain fog. Adherence ~0.52. AE: no.
P01301,1,neutral,Visit 1: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P01301,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.65. AE: no.
P01301,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.58. AE: no. CRP 8.8 mg/L; ALT 28 U/L.
P01301,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no. CRP 7.7 mg/L; ALT 30 U/L.
P01301,5,neutral,Visit 5: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.46. AE: no.
P01301,6,neutral,Visit 6: Patient on RX-17B at S018. stable symptoms. Notes: joint pain. Adherence ~0.55. AE: no.
P01301,7,neutral,Visit 7: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no.
P01302,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: no. CRP 6.8 mg/L; ALT 37 U/L.
P01302,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 7.1 mg/L; ALT 32 U/L.
P01302,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.49. AE: no.
P01302,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.56. AE: yes. CRP 5.0 mg/L; ALT 36 U/L.
P01303,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P01303,1,neutral,Visit 1: Patient on RX-17A at S019. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no.
P01303,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.92. AE: no. CRP 15.3 mg/L; ALT 31 U/L.
P01303,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: nausea. Adherence ~0.74. AE: no.
P01303,4,negative,Visit 4: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.86. AE: yes. CRP 13.4 mg/L; ALT 34 U/L.
P01303,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P01304,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.73. AE: no. CRP 2.8 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01304,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.79. AE: yes.
P01304,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P01304,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P01304,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P01304,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01304,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01305,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.59. AE: no. CRP 2.3 mg/L; ALT 34 U/L.
P01305,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.63. AE: no.
P01305,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.71. AE: yes. CRP 2.2 mg/L; ALT 37 U/L.
P01305,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01305,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P01306,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.40. AE: no.
P01306,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.32. AE: no. Plan: consider dose adjustment; counsel patient.
P01306,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no.
P01306,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.43. AE: yes.
P01306,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P01306,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.36. AE: no. CRP 3.4 mg/L; ALT 38 U/L.
P01307,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 12.5 mg/L; ALT 26 U/L.
P01307,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.78. AE: no.
P01307,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P01307,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.56. AE: yes.
P01308,0,positive,Visit 0: Patient on RX-17A at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01308,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.74. AE: no. CRP 7.5 mg/L; ALT 19 U/L.
P01308,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.90. AE: no.
P01308,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.70. AE: no. CRP 6.1 mg/L; ALT 18 U/L.
P01308,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01308,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no.
P01308,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.65. AE: no.
P01308,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01309,0,neutral,Visit 0: Patient on RX-17B at S021. continues regimen. Notes: brain fog. Adherence ~0.97. AE: no. CRP 4.4 mg/L; ALT 27 U/L.
P01309,1,negative,Visit 1: Patient on RX-17B at S021. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P01309,2,neutral,Visit 2: Patient on RX-17B at S021. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P01309,3,neutral,Visit 3: Patient on RX-17B at S021. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P01309,4,neutral,Visit 4: Patient on RX-17B at S021. continues regimen. Notes: headache. Adherence ~0.63. AE: no. CRP 2.5 mg/L; ALT 31 U/L.
P01309,5,neutral,Visit 5: Patient on RX-17B at S021. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01309,6,neutral,Visit 6: Patient on RX-17B at S021. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: yes.
P01310,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P01310,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~0.76. AE: no.
P01310,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01311,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: brain fog. Adherence ~0.81. AE: no.
P01311,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P01311,2,negative,Visit 2: Patient on RX-17A at S016. reports worsening. Notes: dizziness. Adherence ~0.73. AE: no.
P01311,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no.
P01311,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 2.5 mg/L; ALT 26 U/L.
P01312,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.95. AE: no. CRP 4.0 mg/L; ALT 43 U/L.
P01312,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no.
P01312,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.76. AE: no.
P01313,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 17.3 mg/L; ALT 59 U/L.
P01313,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.87. AE: no. CRP 12.7 mg/L; ALT 54 U/L.
P01313,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 15.5 mg/L; ALT 54 U/L.
P01313,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.94. AE: no.
P01313,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01313,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.75. AE: no. CRP 12.9 mg/L; ALT 58 U/L.
P01313,6,positive,Visit 6: Patient on RX-17A at S014. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no. CRP 10.0 mg/L; ALT 52 U/L.
P01313,7,positive,Visit 7: Patient on RX-17A at S014. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01314,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P01314,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no. CRP 5.8 mg/L; ALT 44 U/L.
P01314,2,negative,Visit 2: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.71. AE: no. CRP 5.0 mg/L; ALT 44 U/L.
P01314,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no.
P01314,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.96. AE: no. CRP 4.9 mg/L; ALT 47 U/L.
P01314,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: dizziness. Adherence ~0.77. AE: no.
P01314,6,positive,Visit 6: Patient on RX-17B at S012. symptoms improving. Notes: insomnia. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01314,7,positive,Visit 7: Patient on RX-17B at S012. symptoms improving. Notes: fatigue. Adherence ~0.84. AE: no.
P01315,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.92. AE: no.
P01315,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P01315,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: no.
P01315,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no.
P01315,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no. CRP 13.9 mg/L; ALT 38 U/L.
P01315,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 12.3 mg/L; ALT 46 U/L.
P01316,0,neutral,Visit 0: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.61. AE: no.
P01316,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.62. AE: no. CRP 3.9 mg/L; ALT 32 U/L.
P01316,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.55. AE: no.
P01316,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P01316,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P01316,5,negative,Visit 5: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.82. AE: yes.
P01316,6,positive,Visit 6: Patient on RX-17B at S012. reports improvement. Notes: headache. Adherence ~0.76. AE: no.
P01316,7,neutral,Visit 7: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.64. AE: yes.
P01317,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.94. AE: no.
P01317,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.94. AE: no.
P01317,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P01318,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no. CRP 8.3 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01318,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01318,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.78. AE: no. CRP 6.5 mg/L; ALT 34 U/L.
P01318,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: yes.
P01318,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.65. AE: no. CRP 6.3 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01319,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no. CRP 14.2 mg/L; ALT 61 U/L.
P01319,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: joint pain. Adherence ~0.82. AE: no. CRP 12.2 mg/L; ALT 58 U/L.
P01319,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.85. AE: no.
P01319,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.73. AE: no. CRP 9.9 mg/L; ALT 60 U/L. Plan: consider dose adjustment; counsel patient.
P01319,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P01319,5,positive,Visit 5: Patient on RX-17B at S017. tolerating medication well. Notes: joint pain. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01320,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01320,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.67. AE: no.
P01320,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.88. AE: no.
P01320,3,negative,Visit 3: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.66. AE: no.
P01320,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.97. AE: yes.
P01320,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.69. AE: no. CRP 6.4 mg/L; ALT 24 U/L.
P01320,6,positive,Visit 6: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.87. AE: no. CRP 5.0 mg/L; ALT 20 U/L.
P01321,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: no.
P01321,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01321,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.93. AE: no.
P01321,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no.
P01321,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: headache. Adherence ~0.78. AE: no.
P01321,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: yes. CRP 7.8 mg/L; ALT 44 U/L.
P01322,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.89. AE: no.
P01322,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: fatigue. Adherence ~1.00. AE: yes.
P01322,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P01322,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.81. AE: yes.
P01322,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no. CRP 7.0 mg/L; ALT 21 U/L.
P01322,5,positive,Visit 5: Patient on RX-17B at S015. feels better overall. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 20 U/L.
P01322,6,positive,Visit 6: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.90. AE: no.
P01323,0,neutral,Visit 0: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01323,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.99. AE: no.
P01323,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: insomnia. Adherence ~0.76. AE: yes. CRP 3.1 mg/L; ALT 45 U/L.
P01323,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.86. AE: no.
P01323,4,positive,Visit 4: Patient on RX-17B at S002. energy increasing. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01324,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: fatigue. Adherence ~0.85. AE: yes.
P01324,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01324,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.79. AE: no. CRP 9.1 mg/L; ALT 18 U/L.
P01324,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: yes.
P01324,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no.
P01324,5,negative,Visit 5: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~0.64. AE: yes. Plan: consider dose adjustment; counsel patient.
P01325,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: nausea. Adherence ~0.59. AE: no.
P01325,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01325,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.92. AE: no.
P01325,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P01325,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01325,5,positive,Visit 5: Patient on RX-17A at S005. symptoms improving. Notes: brain fog. Adherence ~0.78. AE: no.
P01326,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.58. AE: no.
P01326,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no. CRP 4.6 mg/L; ALT 20 U/L.
P01326,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P01326,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.58. AE: no. CRP 4.2 mg/L; ALT 20 U/L.
P01326,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01326,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: no.
P01326,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.58. AE: no.
P01326,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.53. AE: no.
P01327,0,negative,Visit 0: Patient on RX-17A at S006. reports worsening. Notes: headache. Adherence ~0.79. AE: no.
P01327,1,neutral,Visit 1: Patient on RX-17A at S006. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no. CRP 9.8 mg/L; ALT 35 U/L.
P01327,2,neutral,Visit 2: Patient on RX-17A at S006. no major change. Notes: headache. Adherence ~0.85. AE: no.
P01327,3,neutral,Visit 3: Patient on RX-17A at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 8.8 mg/L; ALT 32 U/L.
P01327,4,neutral,Visit 4: Patient on RX-17A at S006. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01328,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.80. AE: no. CRP 12.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01328,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.80. AE: yes. CRP 12.7 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01328,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.79. AE: no. CRP 11.3 mg/L; ALT 33 U/L.
P01328,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.94. AE: no.
P01328,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no.
P01328,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.85. AE: no.
P01328,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01328,7,positive,Visit 7: Patient on RX-17A at S014. tolerating medication well. Notes: insomnia. Adherence ~0.87. AE: no. CRP 5.7 mg/L; ALT 35 U/L.
P01329,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.91. AE: no.
P01329,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 4.9 mg/L; ALT 70 U/L.
P01329,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.97. AE: no.
P01329,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 4.6 mg/L; ALT 69 U/L.
P01329,4,positive,Visit 4: Patient on RX-17A at S022. reports improvement. Notes: dizziness. Adherence ~0.90. AE: no. CRP 4.5 mg/L; ALT 77 U/L.
P01330,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.51. AE: no.
P01330,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: headache. Adherence ~0.55. AE: no. CRP 6.0 mg/L; ALT 29 U/L.
P01330,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.34. AE: no. CRP 5.2 mg/L; ALT 30 U/L.
P01330,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: yes.
P01330,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no. CRP 4.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01331,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: headache. Adherence ~0.54. AE: no. CRP 3.0 mg/L; ALT 35 U/L.
P01331,1,negative,Visit 1: Patient on RX-17B at S008. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01331,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: joint pain. Adherence ~0.55. AE: no. CRP 2.9 mg/L; ALT 43 U/L.
P01331,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no.
P01331,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: headache. Adherence ~0.65. AE: no.
P01331,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01331,6,positive,Visit 6: Patient on RX-17B at S008. feels better overall. Notes: brain fog. Adherence ~0.79. AE: no.
P01331,7,positive,Visit 7: Patient on RX-17B at S008. symptoms improving. Notes: headache. Adherence ~0.77. AE: no.
P01332,0,neutral,Visit 0: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01332,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no. CRP 2.4 mg/L; ALT 33 U/L.
P01332,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no.
P01332,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: dizziness. Adherence ~0.60. AE: no.
P01332,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no. CRP 2.2 mg/L; ALT 36 U/L.
P01332,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: yes.
P01333,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.98. AE: yes. CRP 6.8 mg/L; ALT 44 U/L.
P01333,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: brain fog. Adherence ~0.80. AE: no.
P01333,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.6 mg/L; ALT 39 U/L.
P01333,3,negative,Visit 3: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no.
P01333,4,negative,Visit 4: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.77. AE: no.
P01333,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01333,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P01333,7,neutral,Visit 7: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.6 mg/L; ALT 41 U/L.
P01334,0,neutral,Visit 0: Patient on RX-17B at S003. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 10.6 mg/L; ALT 35 U/L.
P01334,1,neutral,Visit 1: Patient on RX-17B at S003. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P01334,2,neutral,Visit 2: Patient on RX-17B at S003. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P01334,3,neutral,Visit 3: Patient on RX-17B at S003. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 9.1 mg/L; ALT 30 U/L.
P01334,4,neutral,Visit 4: Patient on RX-17B at S003. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: yes. CRP 8.6 mg/L; ALT 39 U/L.
P01334,5,positive,Visit 5: Patient on RX-17B at S003. symptoms improving. Notes: nausea. Adherence ~0.99. AE: no.
P01334,6,positive,Visit 6: Patient on RX-17B at S003. reports improvement. Notes: fatigue. Adherence ~0.93. AE: no.
P01334,7,neutral,Visit 7: Patient on RX-17B at S003. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01335,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 5.0 mg/L; ALT 45 U/L.
P01335,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.86. AE: no.
P01335,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.95. AE: no. CRP 5.3 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P01335,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01335,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01336,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01336,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.99. AE: no. CRP 16.2 mg/L; ALT 22 U/L.
P01336,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P01336,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P01336,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P01336,5,positive,Visit 5: Patient on RX-17A at S014. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no.
P01336,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P01336,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: brain fog. Adherence ~0.85. AE: no. CRP 7.9 mg/L; ALT 22 U/L.
P01337,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.87. AE: no.
P01337,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.76. AE: no.
P01337,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.43. AE: no.
P01338,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.41. AE: no. CRP 6.1 mg/L; ALT 35 U/L.
P01338,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.30. AE: no.
P01338,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.20. AE: no. Plan: consider dose adjustment; counsel patient.
P01338,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.33. AE: no.
P01338,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.28. AE: no. CRP 4.9 mg/L; ALT 36 U/L.
P01338,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.27. AE: no.
P01339,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.68. AE: no.
P01339,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.55. AE: no.
P01339,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no. CRP 5.2 mg/L; ALT 14 U/L.
P01339,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. CRP 5.6 mg/L; ALT 16 U/L.
P01339,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.76. AE: no.
P01339,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.54. AE: no.
P01339,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: no.
P01339,7,neutral,Visit 7: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no.
P01340,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: brain fog. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P01340,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: headache. Adherence ~0.71. AE: no. CRP 12.7 mg/L; ALT 42 U/L.
P01340,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.50. AE: no.
P01340,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01340,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01341,0,neutral,Visit 0: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01341,1,neutral,Visit 1: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no.
P01341,2,positive,Visit 2: Patient on RX-17B at S018. symptoms improving. Notes: joint pain. Adherence ~0.87. AE: no.
P01341,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P01341,4,positive,Visit 4: Patient on RX-17B at S018. tolerating medication well. Notes: nausea. Adherence ~0.96. AE: no.
P01341,5,positive,Visit 5: Patient on RX-17B at S018. reports improvement. Notes: nausea. Adherence ~0.90. AE: no.
P01341,6,positive,Visit 6: Patient on RX-17B at S018. feels better overall. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01341,7,positive,Visit 7: Patient on RX-17B at S018. tolerating medication well. Notes: dizziness. Adherence ~0.90. AE: no. CRP 2.3 mg/L; ALT 27 U/L.
P01342,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no.
P01342,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01342,2,positive,Visit 2: Patient on RX-17B at S015. feels better overall. Notes: headache. Adherence ~0.90. AE: no.
P01342,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 5.0 mg/L; ALT 21 U/L.
P01342,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.67. AE: yes.
P01342,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.75. AE: no. CRP 4.0 mg/L; ALT 23 U/L.
P01342,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01342,7,positive,Visit 7: Patient on RX-17B at S015. symptoms improving. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01343,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~1.00. AE: yes.
P01343,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no.
P01343,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.96. AE: no.
P01343,3,negative,Visit 3: Patient on RX-17B at S019. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.7 mg/L; ALT 87 U/L. Plan: consider dose adjustment; counsel patient.
P01343,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: no.
P01344,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.72. AE: yes.
P01344,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01344,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no.
P01344,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.72. AE: no.
P01344,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P01344,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no.
P01344,6,neutral,Visit 6: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01344,7,neutral,Visit 7: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P01345,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.71. AE: yes.
P01345,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.77. AE: no. CRP 7.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01345,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P01345,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.85. AE: yes.
P01346,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.96. AE: no.
P01346,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.84. AE: no.
P01346,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no. CRP 5.7 mg/L; ALT 38 U/L.
P01346,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no. CRP 5.3 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01346,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01346,5,positive,Visit 5: Patient on RX-17A at S004. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P01346,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.88. AE: yes. CRP 4.6 mg/L; ALT 40 U/L.
P01346,7,positive,Visit 7: Patient on RX-17A at S004. feels better overall. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01347,0,neutral,Visit 0: Patient on RX-17B at S007. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P01347,1,neutral,Visit 1: Patient on RX-17B at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no. CRP 11.7 mg/L; ALT 36 U/L.
P01347,2,neutral,Visit 2: Patient on RX-17B at S007. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: yes.
P01347,3,negative,Visit 3: Patient on RX-17B at S007. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01347,4,positive,Visit 4: Patient on RX-17B at S007. tolerating medication well. Notes: joint pain. Adherence ~1.00. AE: no. CRP 8.0 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P01348,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.90. AE: no. CRP 7.5 mg/L; ALT 47 U/L.
P01348,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no. CRP 7.2 mg/L; ALT 44 U/L.
P01348,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 48 U/L.
P01348,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no. CRP 5.3 mg/L; ALT 46 U/L.
P01348,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: no.
P01348,5,neutral,Visit 5: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.91. AE: no.
P01348,6,positive,Visit 6: Patient on RX-17A at S013. symptoms improving. Notes: joint pain. Adherence ~0.86. AE: no. CRP 4.6 mg/L; ALT 47 U/L.
P01349,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no.
P01349,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no.
P01349,2,positive,Visit 2: Patient on RX-17B at S022. energy increasing. Notes: fatigue. Adherence ~0.76. AE: no.
P01349,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01349,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P01349,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. CRP 5.9 mg/L; ALT 21 U/L.
P01350,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.70. AE: no.
P01350,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no. CRP 7.7 mg/L; ALT 37 U/L.
P01350,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01350,3,negative,Visit 3: Patient on RX-17B at S012. poor tolerance. Notes: headache. Adherence ~0.70. AE: yes. CRP 6.4 mg/L; ALT 39 U/L.
P01350,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.95. AE: yes.
P01350,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 35 U/L.
P01351,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.74. AE: no.
P01351,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01351,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P01351,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. CRP 12.2 mg/L; ALT 28 U/L.
P01351,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.56. AE: yes. CRP 8.7 mg/L; ALT 29 U/L.
P01351,5,negative,Visit 5: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.71. AE: yes.
P01351,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: fatigue. Adherence ~0.84. AE: no.
P01351,7,neutral,Visit 7: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.65. AE: no.
P01352,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 6.0 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01352,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.80. AE: no.
P01352,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.80. AE: no. CRP 4.8 mg/L; ALT 22 U/L.
P01352,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01352,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P01352,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 24 U/L.
P01352,6,positive,Visit 6: Patient on RX-17A at S014. energy increasing. Notes: joint pain. Adherence ~0.79. AE: no.
P01353,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: joint pain. Adherence ~0.95. AE: yes. CRP 6.5 mg/L; ALT 32 U/L.
P01353,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no. CRP 5.7 mg/L; ALT 32 U/L.
P01353,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01353,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P01353,4,positive,Visit 4: Patient on RX-17B at S005. energy increasing. Notes: nausea. Adherence ~0.86. AE: no.
P01353,5,positive,Visit 5: Patient on RX-17B at S005. reports improvement. Notes: insomnia. Adherence ~0.81. AE: no.
P01353,6,positive,Visit 6: Patient on RX-17B at S005. tolerating medication well. Notes: brain fog. Adherence ~0.94. AE: no.
P01353,7,neutral,Visit 7: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.93. AE: yes.
P01354,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no.
P01354,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: brain fog. Adherence ~0.82. AE: no.
P01354,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~0.82. AE: no.
P01354,3,negative,Visit 3: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.94. AE: yes.
P01354,4,positive,Visit 4: Patient on RX-17B at S012. feels better overall. Notes: insomnia. Adherence ~0.83. AE: no. CRP 7.0 mg/L; ALT 16 U/L.
P01354,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no. CRP 6.7 mg/L; ALT 16 U/L.
P01355,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.52. AE: no. CRP 5.7 mg/L; ALT 46 U/L.
P01355,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.39. AE: no.
P01355,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.44. AE: no. CRP 5.2 mg/L; ALT 43 U/L.
P01355,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.33. AE: no. CRP 4.6 mg/L; ALT 43 U/L.
P01355,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.46. AE: no.
P01355,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.39. AE: no. CRP 4.4 mg/L; ALT 43 U/L.
P01356,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.41. AE: no.
P01356,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no. CRP 9.7 mg/L; ALT 28 U/L.
P01356,2,negative,Visit 2: Patient on RX-17B at S016. symptoms persist. Notes: joint pain. Adherence ~0.58. AE: yes. CRP 7.7 mg/L; ALT 30 U/L.
P01356,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.41. AE: yes.
P01356,4,negative,Visit 4: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.70. AE: no.
P01356,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.44. AE: no.
P01356,6,neutral,Visit 6: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.51. AE: yes. CRP 5.4 mg/L; ALT 31 U/L.
P01356,7,neutral,Visit 7: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.45. AE: yes. CRP 4.8 mg/L; ALT 32 U/L.
P01357,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P01357,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: headache. Adherence ~0.80. AE: no. CRP 24.9 mg/L; ALT 26 U/L.
P01357,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.80. AE: no.
P01357,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.93. AE: no.
P01357,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 16.4 mg/L; ALT 26 U/L.
P01358,0,negative,Visit 0: Patient on RX-17B at S007. increased discomfort. Notes: joint pain. Adherence ~0.89. AE: no. CRP 4.5 mg/L; ALT 27 U/L.
P01358,1,neutral,Visit 1: Patient on RX-17B at S007. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01358,2,negative,Visit 2: Patient on RX-17B at S007. feels frustrated. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01358,3,neutral,Visit 3: Patient on RX-17B at S007. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P01358,4,neutral,Visit 4: Patient on RX-17B at S007. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P01359,0,neutral,Visit 0: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no. CRP 16.1 mg/L; ALT 27 U/L.
P01359,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.76. AE: yes.
P01359,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no.
P01359,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01359,4,negative,Visit 4: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01359,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no. CRP 11.0 mg/L; ALT 28 U/L.
P01360,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.96. AE: no. CRP 6.0 mg/L; ALT 42 U/L.
P01360,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01360,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.93. AE: yes.
P01360,3,positive,Visit 3: Patient on RX-17B at S005. energy increasing. Notes: brain fog. Adherence ~0.86. AE: no. CRP 4.0 mg/L; ALT 46 U/L.
P01360,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01360,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.77. AE: no.
P01360,6,positive,Visit 6: Patient on RX-17B at S005. energy increasing. Notes: nausea. Adherence ~0.96. AE: no. CRP 3.3 mg/L; ALT 50 U/L.
P01361,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.67. AE: no. CRP 17.0 mg/L; ALT 20 U/L.
P01361,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.52. AE: no.
P01361,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P01361,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.62. AE: no. CRP 12.3 mg/L; ALT 19 U/L.
P01361,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P01361,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.70. AE: no. CRP 8.0 mg/L; ALT 24 U/L.
P01362,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: headache. Adherence ~0.55. AE: yes.
P01362,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: brain fog. Adherence ~0.36. AE: no. CRP 11.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01362,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.65. AE: no.
P01363,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no. CRP 10.2 mg/L; ALT 28 U/L.
P01363,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: no. CRP 10.9 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01363,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no. CRP 8.3 mg/L; ALT 29 U/L.
P01363,3,negative,Visit 3: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.79. AE: no. CRP 8.3 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01363,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01363,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: yes.
P01363,6,positive,Visit 6: Patient on RX-17B at S004. tolerating medication well. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01363,7,neutral,Visit 7: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.72. AE: no.
P01364,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no.
P01364,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01364,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.73. AE: no.
P01364,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01364,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no.
P01365,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.81. AE: no.
P01365,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01365,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01365,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no. CRP 5.0 mg/L; ALT 34 U/L.
P01365,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: no. CRP 5.0 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01365,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.85. AE: yes. CRP 4.1 mg/L; ALT 37 U/L.
P01365,6,positive,Visit 6: Patient on RX-17A at S014. symptoms improving. Notes: insomnia. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01366,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.64. AE: no.
P01366,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01366,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P01366,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P01366,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.82. AE: no.
P01366,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.61. AE: no.
P01366,6,positive,Visit 6: Patient on RX-17A at S014. energy increasing. Notes: headache. Adherence ~0.76. AE: no. CRP 3.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01366,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.73. AE: no. CRP 2.8 mg/L; ALT 27 U/L.
P01367,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: brain fog. Adherence ~0.92. AE: yes.
P01367,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~0.95. AE: no.
P01367,2,negative,Visit 2: Patient on RX-17B at S013. increased discomfort. Notes: joint pain. Adherence ~0.73. AE: no. CRP 5.2 mg/L; ALT 18 U/L.
P01367,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: yes. CRP 5.8 mg/L; ALT 21 U/L.
P01367,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.93. AE: no. CRP 5.5 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01367,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P01367,6,neutral,Visit 6: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.95. AE: no.
P01368,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.91. AE: no.
P01368,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01368,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.99. AE: yes.
P01368,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.86. AE: yes.
P01368,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.64. AE: no. CRP 5.0 mg/L; ALT 40 U/L.
P01369,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.63. AE: yes.
P01369,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.56. AE: no. CRP 7.6 mg/L; ALT 56 U/L.
P01369,2,positive,Visit 2: Patient on RX-17A at S014. reports improvement. Notes: headache. Adherence ~0.77. AE: no.
P01369,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.61. AE: no.
P01369,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. CRP 5.5 mg/L; ALT 49 U/L.
P01369,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.54. AE: no.
P01369,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01370,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 3.4 mg/L; ALT 30 U/L.
P01370,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01370,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01370,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01370,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.57. AE: no. CRP 2.4 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01370,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.83. AE: no. CRP 2.2 mg/L; ALT 30 U/L.
P01370,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no.
P01370,7,neutral,Visit 7: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01371,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: dizziness. Adherence ~0.81. AE: yes.
P01371,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P01371,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.88. AE: no.
P01371,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no.
P01371,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.92. AE: no. CRP 4.5 mg/L; ALT 29 U/L.
P01371,5,negative,Visit 5: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: yes. CRP 5.0 mg/L; ALT 36 U/L.
P01371,6,neutral,Visit 6: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no.
P01371,7,neutral,Visit 7: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01372,0,negative,Visit 0: Patient on RX-17B at S003. increased discomfort. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P01372,1,negative,Visit 1: Patient on RX-17B at S003. reports worsening. Notes: insomnia. Adherence ~0.55. AE: no.
P01372,2,neutral,Visit 2: Patient on RX-17B at S003. no major change. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P01372,3,neutral,Visit 3: Patient on RX-17B at S003. stable symptoms. Notes: joint pain. Adherence ~0.32. AE: no.
P01372,4,neutral,Visit 4: Patient on RX-17B at S003. no major change. Notes: insomnia. Adherence ~0.46. AE: no. CRP 9.2 mg/L; ALT 31 U/L.
P01373,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: dizziness. Adherence ~0.40. AE: no.
P01373,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.52. AE: no.
P01373,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.30. AE: no.
P01373,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.60. AE: no.
P01373,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.52. AE: no. CRP 8.4 mg/L; ALT 26 U/L.
P01374,0,neutral,Visit 0: Patient on RX-17A at S007. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no. CRP 6.8 mg/L; ALT 44 U/L.
P01374,1,neutral,Visit 1: Patient on RX-17A at S007. stable symptoms. Notes: brain fog. Adherence ~0.74. AE: no.
P01374,2,negative,Visit 2: Patient on RX-17A at S007. reports worsening. Notes: brain fog. Adherence ~0.63. AE: no. CRP 7.0 mg/L; ALT 43 U/L.
P01374,3,neutral,Visit 3: Patient on RX-17A at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no. CRP 5.7 mg/L; ALT 46 U/L.
P01374,4,neutral,Visit 4: Patient on RX-17A at S007. no major change. Notes: fatigue. Adherence ~0.63. AE: no. CRP 5.5 mg/L; ALT 48 U/L.
P01374,5,neutral,Visit 5: Patient on RX-17A at S007. stable symptoms. Notes: headache. Adherence ~0.65. AE: no.
P01375,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~0.77. AE: no. CRP 28.9 mg/L; ALT 35 U/L.
P01375,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: dizziness. Adherence ~0.82. AE: no.
P01375,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.55. AE: no.
P01375,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01375,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no.
P01375,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.75. AE: yes.
P01375,6,neutral,Visit 6: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01375,7,neutral,Visit 7: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no. CRP 11.5 mg/L; ALT 34 U/L.
P01376,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: insomnia. Adherence ~0.89. AE: no.
P01376,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01376,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.80. AE: no. CRP 5.2 mg/L; ALT 15 U/L.
P01376,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.88. AE: no.
P01376,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 15 U/L.
P01376,5,positive,Visit 5: Patient on RX-17A at S002. reports improvement. Notes: brain fog. Adherence ~0.99. AE: no. CRP 3.7 mg/L; ALT 14 U/L.
P01376,6,neutral,Visit 6: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.0 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P01376,7,positive,Visit 7: Patient on RX-17A at S002. tolerating medication well. Notes: insomnia. Adherence ~0.92. AE: no. CRP 3.2 mg/L; ALT 16 U/L.
P01377,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.39. AE: no.
P01377,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.51. AE: no. CRP 7.1 mg/L; ALT 44 U/L.
P01377,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.71. AE: no. CRP 5.2 mg/L; ALT 52 U/L.
P01377,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.43. AE: no.
P01377,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.34. AE: yes.
P01377,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.59. AE: no. CRP 5.1 mg/L; ALT 44 U/L.
P01378,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P01378,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.80. AE: no. CRP 3.2 mg/L; ALT 39 U/L.
P01378,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.99. AE: no.
P01378,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. CRP 2.7 mg/L; ALT 39 U/L.
P01378,4,positive,Visit 4: Patient on RX-17B at S014. energy increasing. Notes: nausea. Adherence ~0.87. AE: no. CRP 2.4 mg/L; ALT 44 U/L.
P01379,0,negative,Visit 0: Patient on RX-17B at S021. poor tolerance. Notes: joint pain. Adherence ~0.86. AE: no. CRP 6.0 mg/L; ALT 38 U/L.
P01379,1,neutral,Visit 1: Patient on RX-17B at S021. reviewed dosing instructions. Notes: dizziness. Adherence ~0.94. AE: no. CRP 5.3 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01379,2,negative,Visit 2: Patient on RX-17B at S021. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 5.4 mg/L; ALT 38 U/L.
P01379,3,negative,Visit 3: Patient on RX-17B at S021. feels frustrated. Notes: dizziness. Adherence ~0.83. AE: yes. CRP 4.9 mg/L; ALT 39 U/L.
P01379,4,negative,Visit 4: Patient on RX-17B at S021. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no.
P01379,5,positive,Visit 5: Patient on RX-17B at S021. tolerating medication well. Notes: headache. Adherence ~1.00. AE: no.
P01380,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01380,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 18.1 mg/L; ALT 13 U/L.
P01380,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.93. AE: no.
P01380,3,positive,Visit 3: Patient on RX-17B at S014. symptoms improving. Notes: insomnia. Adherence ~1.00. AE: no. CRP 13.7 mg/L; ALT 13 U/L.
P01380,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01380,5,positive,Visit 5: Patient on RX-17B at S014. symptoms improving. Notes: fatigue. Adherence ~0.84. AE: no.
P01381,0,negative,Visit 0: Patient on RX-17A at S003. feels frustrated. Notes: fatigue. Adherence ~0.71. AE: no.
P01381,1,negative,Visit 1: Patient on RX-17A at S003. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.6 mg/L; ALT 32 U/L.
P01381,2,neutral,Visit 2: Patient on RX-17A at S003. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no. CRP 5.0 mg/L; ALT 32 U/L.
P01381,3,neutral,Visit 3: Patient on RX-17A at S003. reviewed dosing instructions. Notes: fatigue. Adherence ~0.80. AE: no.
P01381,4,neutral,Visit 4: Patient on RX-17A at S003. reviewed dosing instructions. Notes: headache. Adherence ~0.96. AE: no. CRP 4.4 mg/L; ALT 30 U/L.
P01382,0,neutral,Visit 0: Patient on RX-17B at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no.
P01382,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01382,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no.
P01382,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.87. AE: no. CRP 2.5 mg/L; ALT 42 U/L.
P01382,4,positive,Visit 4: Patient on RX-17B at S018. feels better overall. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01382,5,neutral,Visit 5: Patient on RX-17B at S018. stable symptoms. Notes: headache. Adherence ~0.69. AE: no. CRP 1.6 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01382,6,neutral,Visit 6: Patient on RX-17B at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.81. AE: no.
P01383,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.61. AE: no.
P01383,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no.
P01383,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.67. AE: no.
P01383,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: no.
P01383,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no.
P01383,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: joint pain. Adherence ~0.76. AE: no. CRP 6.3 mg/L; ALT 36 U/L.
P01384,0,neutral,Visit 0: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 9.0 mg/L; ALT 36 U/L.
P01384,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.97. AE: no. CRP 8.7 mg/L; ALT 34 U/L.
P01384,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.2 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01384,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P01384,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01384,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P01384,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.97. AE: yes.
P01384,7,positive,Visit 7: Patient on RX-17B at S017. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01385,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P01385,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.88. AE: no. CRP 9.4 mg/L; ALT 42 U/L.
P01385,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no. CRP 10.8 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01385,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.81. AE: no.
P01385,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: yes.
P01385,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P01386,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.87. AE: no.
P01386,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.79. AE: yes. CRP 6.2 mg/L; ALT 35 U/L.
P01386,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01386,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01386,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no. CRP 4.6 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01386,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no. CRP 4.8 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01386,6,negative,Visit 6: Patient on RX-17A at S015. increased discomfort. Notes: dizziness. Adherence ~0.95. AE: no. CRP 3.8 mg/L; ALT 35 U/L.
P01387,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01387,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.93. AE: no. CRP 4.1 mg/L; ALT 45 U/L.
P01387,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.87. AE: no.
P01387,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no. CRP 3.3 mg/L; ALT 49 U/L.
P01387,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.86. AE: yes. CRP 2.8 mg/L; ALT 56 U/L.
P01388,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.87. AE: no.
P01388,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P01388,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P01388,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01388,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.91. AE: yes. CRP 4.6 mg/L; ALT 35 U/L.
P01388,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01388,6,positive,Visit 6: Patient on RX-17B at S015. energy increasing. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01388,7,positive,Visit 7: Patient on RX-17B at S015. energy increasing. Notes: fatigue. Adherence ~0.78. AE: no.
P01389,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 9.2 mg/L; ALT 30 U/L.
P01389,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.68. AE: no. CRP 9.4 mg/L; ALT 30 U/L.
P01389,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no.
P01389,3,positive,Visit 3: Patient on RX-17A at S012. energy increasing. Notes: brain fog. Adherence ~0.89. AE: no.
P01389,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no.
P01389,5,negative,Visit 5: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.52. AE: no.
P01389,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.57. AE: no. CRP 6.8 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01389,7,neutral,Visit 7: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01390,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P01390,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P01390,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: yes.
P01391,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: nausea. Adherence ~0.53. AE: yes.
P01391,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: fatigue. Adherence ~0.79. AE: no.
P01391,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01391,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no.
P01391,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no. CRP 7.0 mg/L; ALT 29 U/L.
P01391,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P01392,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~1.00. AE: no.
P01392,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: yes. CRP 5.3 mg/L; ALT 24 U/L.
P01392,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no.
P01392,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01392,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no.
P01392,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 22 U/L.
P01392,6,positive,Visit 6: Patient on RX-17B at S022. feels better overall. Notes: brain fog. Adherence ~0.86. AE: no. CRP 3.0 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01393,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.92. AE: yes.
P01393,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P01393,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.87. AE: no. CRP 7.3 mg/L; ALT 28 U/L.
P01393,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01393,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.70. AE: no.
P01393,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: yes.
P01393,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.6 mg/L; ALT 33 U/L.
P01394,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: brain fog. Adherence ~0.97. AE: yes.
P01394,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: nausea. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01394,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no. CRP 6.4 mg/L; ALT 37 U/L.
P01394,3,negative,Visit 3: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.94. AE: no. CRP 6.0 mg/L; ALT 39 U/L.
P01394,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no.
P01394,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no.
P01395,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: joint pain. Adherence ~0.70. AE: yes.
P01395,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.60. AE: no.
P01395,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.55. AE: no.
P01395,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01395,4,negative,Visit 4: Patient on RX-17B at S018. reports worsening. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01395,5,neutral,Visit 5: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no.
P01395,6,neutral,Visit 6: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.53. AE: no. CRP 2.6 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01396,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.94. AE: yes.
P01396,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.87. AE: yes.
P01396,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no.
P01396,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no. CRP 6.7 mg/L; ALT 46 U/L.
P01396,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P01397,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.59. AE: no. CRP 5.7 mg/L; ALT 27 U/L.
P01397,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~0.49. AE: no.
P01397,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.51. AE: no.
P01397,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.55. AE: no. CRP 4.7 mg/L; ALT 30 U/L.
P01397,4,negative,Visit 4: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.44. AE: no.
P01397,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.51. AE: no. CRP 3.7 mg/L; ALT 30 U/L.
P01397,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.39. AE: no.
P01397,7,neutral,Visit 7: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.41. AE: no.
P01398,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.73. AE: no.
P01398,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.89. AE: yes. CRP 10.2 mg/L; ALT 30 U/L.
P01398,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.76. AE: no. CRP 9.1 mg/L; ALT 27 U/L.
P01398,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 8.9 mg/L; ALT 30 U/L.
P01398,4,negative,Visit 4: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.83. AE: no.
P01398,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 7.1 mg/L; ALT 31 U/L.
P01398,6,positive,Visit 6: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.3 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01399,0,negative,Visit 0: Patient on RX-17B at S006. increased discomfort. Notes: joint pain. Adherence ~0.87. AE: no. CRP 13.1 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01399,1,negative,Visit 1: Patient on RX-17B at S006. increased discomfort. Notes: insomnia. Adherence ~0.74. AE: no.
P01399,2,negative,Visit 2: Patient on RX-17B at S006. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01399,3,neutral,Visit 3: Patient on RX-17B at S006. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: no.
P01399,4,positive,Visit 4: Patient on RX-17B at S006. tolerating medication well. Notes: brain fog. Adherence ~1.00. AE: no.
P01399,5,positive,Visit 5: Patient on RX-17B at S006. reports improvement. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 7.9 mg/L; ALT 26 U/L.
P01400,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: yes.
P01400,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.85. AE: no.
P01400,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P01400,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.69. AE: yes. CRP 7.6 mg/L; ALT 37 U/L.
P01401,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: yes.
P01401,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P01401,2,negative,Visit 2: Patient on RX-17B at S004. feels frustrated. Notes: joint pain. Adherence ~0.88. AE: no.
P01401,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01401,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.60. AE: no. CRP 2.1 mg/L; ALT 18 U/L.
P01401,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.72. AE: yes. CRP 1.9 mg/L; ALT 18 U/L.
P01401,6,positive,Visit 6: Patient on RX-17B at S004. reports improvement. Notes: headache. Adherence ~0.92. AE: no.
P01402,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01402,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01402,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01402,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.79. AE: no.
P01402,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01402,5,positive,Visit 5: Patient on RX-17B at S005. feels better overall. Notes: fatigue. Adherence ~0.82. AE: no.
P01403,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.67. AE: no.
P01403,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no.
P01403,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: fatigue. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01403,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: yes. CRP 3.9 mg/L; ALT 95 U/L.
P01403,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 3.7 mg/L; ALT 88 U/L.
P01403,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P01404,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.82. AE: yes. CRP 5.1 mg/L; ALT 18 U/L.
P01404,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.92. AE: no.
P01404,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.86. AE: no.
P01404,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P01404,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no.
P01405,0,neutral,Visit 0: Patient on RX-17A at S020. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no. CRP 5.9 mg/L; ALT 30 U/L.
P01405,1,neutral,Visit 1: Patient on RX-17A at S020. continues regimen. Notes: nausea. Adherence ~0.86. AE: no.
P01405,2,neutral,Visit 2: Patient on RX-17A at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 4.9 mg/L; ALT 34 U/L.
P01405,3,neutral,Visit 3: Patient on RX-17A at S020. follow-up as scheduled. Notes: nausea. Adherence ~0.91. AE: no.
P01405,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. CRP 3.8 mg/L; ALT 33 U/L.
P01405,5,neutral,Visit 5: Patient on RX-17A at S020. no major change. Notes: insomnia. Adherence ~0.85. AE: yes.
P01406,0,negative,Visit 0: Patient on RX-17A at S010. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 11.7 mg/L; ALT 35 U/L.
P01406,1,negative,Visit 1: Patient on RX-17A at S010. poor tolerance. Notes: dizziness. Adherence ~0.96. AE: no. CRP 10.6 mg/L; ALT 35 U/L.
P01406,2,neutral,Visit 2: Patient on RX-17A at S010. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no. CRP 9.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01406,3,neutral,Visit 3: Patient on RX-17A at S010. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no. CRP 9.2 mg/L; ALT 32 U/L.
P01406,4,neutral,Visit 4: Patient on RX-17A at S010. no major change. Notes: joint pain. Adherence ~0.76. AE: no.
P01406,5,neutral,Visit 5: Patient on RX-17A at S010. continues regimen. Notes: brain fog. Adherence ~0.66. AE: no.
P01407,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.83. AE: no. CRP 12.1 mg/L; ALT 37 U/L.
P01407,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.71. AE: no.
P01407,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no. CRP 8.6 mg/L; ALT 36 U/L.
P01407,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.74. AE: no.
P01407,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.72. AE: no.
P01408,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01408,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.52. AE: yes.
P01408,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.70. AE: yes. CRP 4.7 mg/L; ALT 26 U/L.
P01408,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 4.6 mg/L; ALT 21 U/L.
P01408,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.76. AE: no.
P01408,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: brain fog. Adherence ~0.78. AE: no.
P01408,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no. CRP 3.4 mg/L; ALT 25 U/L.
P01408,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 2.5 mg/L; ALT 24 U/L.
P01409,0,neutral,Visit 0: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: no. CRP 11.1 mg/L; ALT 36 U/L.
P01409,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: dizziness. Adherence ~0.63. AE: yes.
P01409,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01409,3,positive,Visit 3: Patient on RX-17B at S005. feels better overall. Notes: headache. Adherence ~0.89. AE: no.
P01409,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 6.9 mg/L; ALT 38 U/L.
P01409,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P01409,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no.
P01410,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01410,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.88. AE: no.
P01410,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.76. AE: no.
P01410,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 24 U/L.
P01410,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 6.2 mg/L; ALT 23 U/L.
P01410,5,positive,Visit 5: Patient on RX-17A at S005. feels better overall. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 5.9 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01410,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01410,7,positive,Visit 7: Patient on RX-17A at S005. energy increasing. Notes: joint pain. Adherence ~0.99. AE: no. CRP 5.0 mg/L; ALT 24 U/L.
P01411,0,negative,Visit 0: Patient on RX-17B at S011. reports worsening. Notes: brain fog. Adherence ~0.70. AE: no.
P01411,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no.
P01411,2,neutral,Visit 2: Patient on RX-17B at S011. reviewed dosing instructions. Notes: insomnia. Adherence ~0.91. AE: no.
P01411,3,neutral,Visit 3: Patient on RX-17B at S011. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 5.9 mg/L; ALT 19 U/L.
P01411,4,positive,Visit 4: Patient on RX-17B at S011. symptoms improving. Notes: nausea. Adherence ~0.91. AE: no.
P01411,5,neutral,Visit 5: Patient on RX-17B at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01411,6,neutral,Visit 6: Patient on RX-17B at S011. no major change. Notes: dizziness. Adherence ~0.82. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P01412,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.96. AE: no.
P01412,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P01412,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.98. AE: no.
P01412,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: no.
P01412,4,positive,Visit 4: Patient on RX-17A at S014. symptoms improving. Notes: fatigue. Adherence ~0.79. AE: no.
P01412,5,positive,Visit 5: Patient on RX-17A at S014. tolerating medication well. Notes: fatigue. Adherence ~0.94. AE: no.
P01412,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.97. AE: no.
P01412,7,positive,Visit 7: Patient on RX-17A at S014. reports improvement. Notes: headache. Adherence ~0.96. AE: no.
P01413,0,negative,Visit 0: Patient on RX-17B at S020. increased discomfort. Notes: insomnia. Adherence ~0.96. AE: no.
P01413,1,negative,Visit 1: Patient on RX-17B at S020. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P01413,2,neutral,Visit 2: Patient on RX-17B at S020. no major change. Notes: brain fog. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01413,3,neutral,Visit 3: Patient on RX-17B at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no.
P01413,4,neutral,Visit 4: Patient on RX-17B at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P01413,5,positive,Visit 5: Patient on RX-17B at S020. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no.
P01414,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.79. AE: no. CRP 8.3 mg/L; ALT 20 U/L.
P01414,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.72. AE: no. CRP 6.0 mg/L; ALT 22 U/L.
P01414,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.75. AE: no.
P01414,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P01414,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P01414,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.55. AE: yes.
P01414,6,neutral,Visit 6: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P01415,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: headache. Adherence ~0.79. AE: no. CRP 4.8 mg/L; ALT 25 U/L.
P01415,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01415,2,neutral,Visit 2: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.60. AE: yes.
P01416,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: brain fog. Adherence ~0.73. AE: no. CRP 4.6 mg/L; ALT 25 U/L.
P01416,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01416,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.97. AE: no.
P01416,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.64. AE: no. CRP 3.3 mg/L; ALT 25 U/L.
P01416,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: yes.
P01416,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 2.5 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01417,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01417,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01417,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01417,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no. CRP 2.6 mg/L; ALT 16 U/L.
P01417,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.71. AE: no.
P01417,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01417,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01417,7,positive,Visit 7: Patient on RX-17A at S012. symptoms improving. Notes: fatigue. Adherence ~0.83. AE: no. CRP 1.9 mg/L; ALT 17 U/L.
P01418,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no. CRP 4.0 mg/L; ALT 41 U/L.
P01418,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.77. AE: no. CRP 3.1 mg/L; ALT 42 U/L.
P01418,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.59. AE: no. CRP 4.1 mg/L; ALT 42 U/L.
P01418,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01419,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01419,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.6 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01419,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 40 U/L.
P01419,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: yes.
P01419,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P01419,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.97. AE: no.
P01419,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01420,0,neutral,Visit 0: Patient on RX-17B at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no.
P01420,1,negative,Visit 1: Patient on RX-17B at S011. increased discomfort. Notes: nausea. Adherence ~0.75. AE: yes.
P01420,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01420,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no. CRP 4.8 mg/L; ALT 26 U/L.
P01420,4,neutral,Visit 4: Patient on RX-17B at S011. no major change. Notes: joint pain. Adherence ~0.95. AE: no. CRP 4.3 mg/L; ALT 28 U/L.
P01420,5,positive,Visit 5: Patient on RX-17B at S011. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no.
P01420,6,positive,Visit 6: Patient on RX-17B at S011. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 28 U/L.
P01421,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P01421,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.99. AE: no.
P01421,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.92. AE: no.
P01421,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no.
P01421,4,negative,Visit 4: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.87. AE: no.
P01421,5,positive,Visit 5: Patient on RX-17A at S012. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 31 U/L.
P01421,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: yes. CRP 4.0 mg/L; ALT 29 U/L.
P01422,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01422,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01422,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no.
P01422,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no. CRP 5.2 mg/L; ALT 31 U/L.
P01422,4,negative,Visit 4: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: no. CRP 4.2 mg/L; ALT 30 U/L.
P01422,5,positive,Visit 5: Patient on RX-17A at S004. symptoms improving. Notes: joint pain. Adherence ~0.78. AE: no. CRP 4.4 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01423,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 18.4 mg/L; ALT 31 U/L.
P01423,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.76. AE: no.
P01423,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P01423,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.71. AE: no.
P01423,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.56. AE: no.
P01423,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no.
P01424,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: insomnia. Adherence ~0.98. AE: no.
P01424,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: dizziness. Adherence ~0.78. AE: no.
P01424,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 2.7 mg/L; ALT 20 U/L.
P01424,3,negative,Visit 3: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.87. AE: no. CRP 3.5 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01424,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.94. AE: no.
P01424,5,positive,Visit 5: Patient on RX-17A at S016. energy increasing. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 2.7 mg/L; ALT 18 U/L.
P01424,6,neutral,Visit 6: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no. CRP 2.3 mg/L; ALT 21 U/L.
P01425,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: no. CRP 3.8 mg/L; ALT 38 U/L.
P01425,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.69. AE: no. CRP 3.2 mg/L; ALT 35 U/L.
P01425,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 3.1 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P01425,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no.
P01425,4,negative,Visit 4: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.85. AE: no.
P01425,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01425,6,positive,Visit 6: Patient on RX-17A at S004. symptoms improving. Notes: joint pain. Adherence ~0.96. AE: no. CRP 1.9 mg/L; ALT 33 U/L.
P01426,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no. CRP 4.4 mg/L; ALT 23 U/L.
P01426,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.61. AE: no. CRP 4.5 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01426,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no.
P01426,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.75. AE: no. CRP 3.9 mg/L; ALT 23 U/L.
P01426,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: yes.
P01427,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 7.8 mg/L; ALT 34 U/L.
P01427,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no. CRP 6.5 mg/L; ALT 36 U/L.
P01427,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.56. AE: no. CRP 6.2 mg/L; ALT 40 U/L.
P01427,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.61. AE: no. CRP 5.4 mg/L; ALT 41 U/L.
P01427,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01428,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.80. AE: no.
P01428,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 8.5 mg/L; ALT 24 U/L.
P01428,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01428,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no. CRP 9.7 mg/L; ALT 20 U/L.
P01428,4,negative,Visit 4: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: no.
P01429,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 10.1 mg/L; ALT 21 U/L.
P01429,1,neutral,Visit 1: Patient on RX-17B at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: yes.
P01429,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01430,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.71. AE: no.
P01430,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no.
P01430,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01431,0,neutral,Visit 0: Patient on RX-17B at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no. CRP 6.3 mg/L; ALT 26 U/L.
P01431,1,negative,Visit 1: Patient on RX-17B at S018. feels frustrated. Notes: fatigue. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P01431,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.70. AE: no.
P01431,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.74. AE: no.
P01431,4,positive,Visit 4: Patient on RX-17B at S018. reports improvement. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01432,0,neutral,Visit 0: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P01432,1,neutral,Visit 1: Patient on RX-17A at S008. stable symptoms. Notes: fatigue. Adherence ~0.69. AE: no.
P01432,2,negative,Visit 2: Patient on RX-17A at S008. feels frustrated. Notes: fatigue. Adherence ~0.68. AE: no.
P01432,3,negative,Visit 3: Patient on RX-17A at S008. symptoms persist. Notes: headache. Adherence ~0.60. AE: yes.
P01432,4,negative,Visit 4: Patient on RX-17A at S008. poor tolerance. Notes: fatigue. Adherence ~0.72. AE: no.
P01432,5,neutral,Visit 5: Patient on RX-17A at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.80. AE: no. CRP 4.0 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01433,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.60. AE: no. CRP 20.2 mg/L; ALT 22 U/L.
P01433,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.42. AE: no. CRP 20.0 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01433,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.52. AE: yes.
P01433,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.58. AE: no. CRP 12.9 mg/L; ALT 21 U/L.
P01433,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.66. AE: no.
P01433,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.61. AE: no. CRP 11.1 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01433,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no.
P01434,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: insomnia. Adherence ~0.80. AE: no.
P01434,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.39. AE: no.
P01434,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.72. AE: no.
P01434,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.46. AE: no.
P01434,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P01434,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01435,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no. CRP 7.5 mg/L; ALT 33 U/L.
P01435,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P01435,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01435,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.65. AE: no. CRP 5.5 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01435,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no. CRP 5.5 mg/L; ALT 34 U/L.
P01435,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no.
P01435,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: no. CRP 4.8 mg/L; ALT 33 U/L.
P01435,7,neutral,Visit 7: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no.
P01436,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.92. AE: yes. CRP 9.2 mg/L; ALT 51 U/L.
P01436,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.53. AE: no.
P01436,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P01436,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.91. AE: no.
P01436,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: yes.
P01437,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: headache. Adherence ~0.88. AE: no.
P01437,1,neutral,Visit 1: Patient on RX-17B at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.97. AE: no. CRP 17.7 mg/L; ALT 34 U/L.
P01437,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: headache. Adherence ~0.98. AE: no.
P01437,3,positive,Visit 3: Patient on RX-17B at S008. feels better overall. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01437,4,positive,Visit 4: Patient on RX-17B at S008. tolerating medication well. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01437,5,positive,Visit 5: Patient on RX-17B at S008. symptoms improving. Notes: insomnia. Adherence ~0.81. AE: no.
P01437,6,neutral,Visit 6: Patient on RX-17B at S008. stable symptoms. Notes: fatigue. Adherence ~0.84. AE: yes.
P01438,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: headache. Adherence ~0.92. AE: yes.
P01438,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P01438,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: nausea. Adherence ~0.86. AE: no.
P01438,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no.
P01438,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: yes.
P01438,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no.
P01438,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: brain fog. Adherence ~0.83. AE: no.
P01439,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 17 U/L.
P01439,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01439,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.99. AE: yes.
P01439,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no.
P01439,4,positive,Visit 4: Patient on RX-17B at S012. reports improvement. Notes: insomnia. Adherence ~0.99. AE: no. CRP 3.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01439,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: insomnia. Adherence ~1.00. AE: no.
P01440,0,negative,Visit 0: Patient on RX-17B at S010. symptoms persist. Notes: insomnia. Adherence ~0.96. AE: no. CRP 3.0 mg/L; ALT 19 U/L.
P01440,1,neutral,Visit 1: Patient on RX-17B at S010. no major change. Notes: insomnia. Adherence ~0.89. AE: no. CRP 3.3 mg/L; ALT 17 U/L.
P01440,2,neutral,Visit 2: Patient on RX-17B at S010. no major change. Notes: brain fog. Adherence ~0.91. AE: no. CRP 3.1 mg/L; ALT 19 U/L.
P01440,3,neutral,Visit 3: Patient on RX-17B at S010. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no. CRP 2.7 mg/L; ALT 18 U/L.
P01440,4,neutral,Visit 4: Patient on RX-17B at S010. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P01440,5,positive,Visit 5: Patient on RX-17B at S010. reports improvement. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01440,6,negative,Visit 6: Patient on RX-17B at S010. feels frustrated. Notes: dizziness. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01440,7,neutral,Visit 7: Patient on RX-17B at S010. continues regimen. Notes: fatigue. Adherence ~0.92. AE: yes.
P01441,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: fatigue. Adherence ~0.82. AE: no. CRP 2.7 mg/L; ALT 34 U/L.
P01441,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: no.
P01441,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no.
P01441,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.85. AE: no.
P01441,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P01442,0,neutral,Visit 0: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.35. AE: no. CRP 6.1 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P01442,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: fatigue. Adherence ~0.45. AE: no.
P01442,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.31. AE: no. CRP 5.6 mg/L; ALT 36 U/L.
P01442,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.34. AE: no. CRP 4.0 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01442,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 5.6 mg/L; ALT 44 U/L.
P01443,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.87. AE: no. CRP 11.9 mg/L; ALT 21 U/L.
P01443,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.88. AE: yes. CRP 9.7 mg/L; ALT 23 U/L.
P01443,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no.
P01443,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.90. AE: no. CRP 9.7 mg/L; ALT 19 U/L.
P01443,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01443,5,positive,Visit 5: Patient on RX-17A at S012. tolerating medication well. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01444,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.72. AE: no.
P01444,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01444,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: insomnia. Adherence ~0.79. AE: no. CRP 11.2 mg/L; ALT 36 U/L.
P01444,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01444,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.77. AE: no.
P01444,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01444,6,positive,Visit 6: Patient on RX-17B at S012. reports improvement. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.2 mg/L; ALT 38 U/L.
P01444,7,neutral,Visit 7: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.66. AE: yes.
P01445,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P01445,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no. CRP 5.1 mg/L; ALT 31 U/L.
P01445,2,negative,Visit 2: Patient on RX-17B at S008. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01445,3,positive,Visit 3: Patient on RX-17B at S008. symptoms improving. Notes: brain fog. Adherence ~0.89. AE: no.
P01446,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: no. CRP 10.3 mg/L; ALT 44 U/L.
P01446,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.74. AE: no. CRP 9.8 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01446,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no.
P01446,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P01446,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.58. AE: no.
P01446,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no.
P01446,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.58. AE: no.
P01447,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P01447,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: yes.
P01447,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.77. AE: yes. CRP 6.1 mg/L; ALT 39 U/L.
P01447,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P01447,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01447,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: insomnia. Adherence ~0.94. AE: no. CRP 3.8 mg/L; ALT 42 U/L.
P01447,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: yes. CRP 3.5 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01448,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. CRP 10.0 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P01448,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no. CRP 9.4 mg/L; ALT 13 U/L.
P01448,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: yes.
P01448,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P01448,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.51. AE: yes. CRP 6.9 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P01448,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: yes.
P01448,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.49. AE: no. CRP 5.6 mg/L; ALT 15 U/L.
P01449,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.89. AE: no. CRP 14.3 mg/L; ALT 47 U/L.
P01449,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.91. AE: no.
P01449,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.88. AE: no. CRP 11.9 mg/L; ALT 46 U/L.
P01449,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.87. AE: yes.
P01449,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 9.8 mg/L; ALT 48 U/L.
P01450,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: joint pain. Adherence ~0.52. AE: no.
P01450,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no.
P01450,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no. CRP 6.4 mg/L; ALT 32 U/L.
P01450,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~0.46. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P01451,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.73. AE: yes. CRP 11.7 mg/L; ALT 25 U/L.
P01451,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P01451,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no.
P01452,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01452,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: nausea. Adherence ~0.89. AE: no. CRP 3.1 mg/L; ALT 26 U/L.
P01452,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P01452,3,negative,Visit 3: Patient on RX-17B at S015. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: yes.
P01452,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.92. AE: no. CRP 2.7 mg/L; ALT 25 U/L.
P01452,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.72. AE: no.
P01452,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: fatigue. Adherence ~0.79. AE: no.
P01452,7,neutral,Visit 7: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. CRP 1.6 mg/L; ALT 27 U/L.
P01453,0,negative,Visit 0: Patient on RX-17A at S020. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 9.2 mg/L; ALT 29 U/L.
P01453,1,negative,Visit 1: Patient on RX-17A at S020. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no.
P01453,2,positive,Visit 2: Patient on RX-17A at S020. reports improvement. Notes: nausea. Adherence ~0.83. AE: no. CRP 8.2 mg/L; ALT 30 U/L.
P01453,3,neutral,Visit 3: Patient on RX-17A at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: yes. CRP 7.1 mg/L; ALT 31 U/L.
P01453,4,positive,Visit 4: Patient on RX-17A at S020. tolerating medication well. Notes: fatigue. Adherence ~0.92. AE: no.
P01453,5,neutral,Visit 5: Patient on RX-17A at S020. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 8.1 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01453,6,neutral,Visit 6: Patient on RX-17A at S020. no major change. Notes: insomnia. Adherence ~0.90. AE: no. CRP 6.8 mg/L; ALT 32 U/L.
P01454,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.73. AE: no.
P01454,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P01454,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. CRP 11.7 mg/L; ALT 25 U/L.
P01454,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.69. AE: no. CRP 8.8 mg/L; ALT 24 U/L.
P01454,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no. CRP 10.0 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01455,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.65. AE: no.
P01455,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.61. AE: yes.
P01455,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 11.7 mg/L; ALT 23 U/L.
P01455,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P01455,4,negative,Visit 4: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.94. AE: yes.
P01456,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.84. AE: no.
P01456,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P01456,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P01456,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01456,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.93. AE: no.
P01456,5,positive,Visit 5: Patient on RX-17A at S014. tolerating medication well. Notes: insomnia. Adherence ~0.94. AE: no. CRP 2.6 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01457,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01457,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no.
P01457,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.82. AE: no. CRP 5.5 mg/L; ALT 21 U/L.
P01457,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no. CRP 5.6 mg/L; ALT 22 U/L.
P01457,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.88. AE: no.
P01457,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: dizziness. Adherence ~0.77. AE: no.
P01457,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.77. AE: no.
P01457,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P01458,0,negative,Visit 0: Patient on RX-17A at S001. increased discomfort. Notes: headache. Adherence ~0.66. AE: no.
P01458,1,negative,Visit 1: Patient on RX-17A at S001. symptoms persist. Notes: insomnia. Adherence ~0.56. AE: no.
P01458,2,negative,Visit 2: Patient on RX-17A at S001. increased discomfort. Notes: nausea. Adherence ~0.70. AE: no.
P01458,3,negative,Visit 3: Patient on RX-17A at S001. reports worsening. Notes: dizziness. Adherence ~0.70. AE: no. CRP 7.4 mg/L; ALT 45 U/L.
P01458,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~0.60. AE: no. CRP 6.2 mg/L; ALT 49 U/L.
P01458,5,negative,Visit 5: Patient on RX-17A at S001. feels frustrated. Notes: dizziness. Adherence ~0.34. AE: yes.
P01458,6,neutral,Visit 6: Patient on RX-17A at S001. no major change. Notes: brain fog. Adherence ~0.53. AE: no. CRP 5.1 mg/L; ALT 50 U/L.
P01459,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.68. AE: no.
P01459,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.92. AE: no. CRP 8.1 mg/L; ALT 32 U/L.
P01459,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no. CRP 8.1 mg/L; ALT 32 U/L.
P01459,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: yes.
P01459,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P01459,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: nausea. Adherence ~0.90. AE: no.
P01459,6,positive,Visit 6: Patient on RX-17B at S014. feels better overall. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 4.6 mg/L; ALT 34 U/L.
P01459,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: fatigue. Adherence ~0.82. AE: no.
P01460,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.76. AE: no.
P01460,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.90. AE: no. CRP 7.0 mg/L; ALT 59 U/L.
P01460,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.88. AE: no. CRP 6.4 mg/L; ALT 67 U/L.
P01460,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no.
P01460,4,positive,Visit 4: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.79. AE: no. CRP 6.5 mg/L; ALT 70 U/L.
P01460,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: yes.
P01461,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.93. AE: no. CRP 14.7 mg/L; ALT 35 U/L.
P01461,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.67. AE: no.
P01461,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.79. AE: no. CRP 15.7 mg/L; ALT 34 U/L.
P01461,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.99. AE: no.
P01461,4,negative,Visit 4: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.73. AE: no.
P01462,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 3.4 mg/L; ALT 36 U/L.
P01462,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.99. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P01462,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01462,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: yes.
P01462,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: headache. Adherence ~0.87. AE: no. CRP 2.4 mg/L; ALT 40 U/L.
P01462,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01463,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no.
P01463,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.79. AE: no. CRP 5.6 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01463,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P01463,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01463,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: no.
P01463,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01463,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 3.4 mg/L; ALT 23 U/L.
P01463,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: yes.
P01464,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: insomnia. Adherence ~0.62. AE: no.
P01464,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: dizziness. Adherence ~0.53. AE: no.
P01464,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P01464,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.59. AE: no. CRP 2.5 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01464,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.48. AE: yes. CRP 2.2 mg/L; ALT 34 U/L.
P01465,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.72. AE: no.
P01465,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.48. AE: no.
P01465,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01465,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no. CRP 8.6 mg/L; ALT 31 U/L.
P01465,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no. CRP 8.5 mg/L; ALT 33 U/L.
P01465,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.57. AE: no.
P01466,0,negative,Visit 0: Patient on RX-17B at S007. poor tolerance. Notes: brain fog. Adherence ~0.48. AE: yes.
P01466,1,neutral,Visit 1: Patient on RX-17B at S007. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no.
P01466,2,neutral,Visit 2: Patient on RX-17B at S007. stable symptoms. Notes: joint pain. Adherence ~0.49. AE: no. CRP 8.4 mg/L; ALT 24 U/L.
P01466,3,neutral,Visit 3: Patient on RX-17B at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.46. AE: no.
P01466,4,neutral,Visit 4: Patient on RX-17B at S007. follow-up as scheduled. Notes: dizziness. Adherence ~0.59. AE: yes.
P01466,5,neutral,Visit 5: Patient on RX-17B at S007. stable symptoms. Notes: headache. Adherence ~0.59. AE: yes. CRP 6.1 mg/L; ALT 27 U/L.
P01467,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.86. AE: no.
P01467,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no.
P01467,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.93. AE: yes.
P01467,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.98. AE: no.
P01467,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no. CRP 35.6 mg/L; ALT 28 U/L.
P01467,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.99. AE: no.
P01467,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: no.
P01467,7,positive,Visit 7: Patient on RX-17A at S017. reports improvement. Notes: headache. Adherence ~0.99. AE: no.
P01468,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: joint pain. Adherence ~0.90. AE: yes. Plan: consider dose adjustment; counsel patient.
P01468,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01468,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.90. AE: yes. Plan: consider dose adjustment; counsel patient.
P01468,3,negative,Visit 3: Patient on RX-17B at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P01468,4,positive,Visit 4: Patient on RX-17B at S019. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no.
P01468,5,positive,Visit 5: Patient on RX-17B at S019. energy increasing. Notes: abdominal discomfort. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01468,6,positive,Visit 6: Patient on RX-17B at S019. energy increasing. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01469,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.67. AE: no.
P01469,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~0.88. AE: no.
P01469,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.66. AE: no.
P01469,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.79. AE: yes.
P01469,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no.
P01469,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no.
P01470,0,neutral,Visit 0: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no.
P01470,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 17 U/L.
P01470,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.81. AE: yes.
P01470,3,negative,Visit 3: Patient on RX-17A at S019. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01470,4,positive,Visit 4: Patient on RX-17A at S019. symptoms improving. Notes: joint pain. Adherence ~0.83. AE: no.
P01470,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.92. AE: no. CRP 5.3 mg/L; ALT 18 U/L.
P01471,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: dizziness. Adherence ~0.57. AE: no. CRP 6.7 mg/L; ALT 35 U/L.
P01471,1,neutral,Visit 1: Patient on RX-17A at S020. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no.
P01471,2,negative,Visit 2: Patient on RX-17A at S020. feels frustrated. Notes: insomnia. Adherence ~0.53. AE: yes. Plan: consider dose adjustment; counsel patient.
P01471,3,negative,Visit 3: Patient on RX-17A at S020. feels frustrated. Notes: insomnia. Adherence ~0.44. AE: no.
P01471,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: fatigue. Adherence ~0.61. AE: no.
P01472,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.59. AE: no. CRP 7.8 mg/L; ALT 37 U/L.
P01472,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. CRP 8.2 mg/L; ALT 36 U/L.
P01472,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.42. AE: no.
P01473,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no.
P01473,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: headache. Adherence ~0.96. AE: no. CRP 8.8 mg/L; ALT 26 U/L.
P01473,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 7.1 mg/L; ALT 24 U/L.
P01473,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.77. AE: no.
P01474,0,negative,Visit 0: Patient on RX-17A at S009. symptoms persist. Notes: nausea. Adherence ~0.99. AE: no.
P01474,1,neutral,Visit 1: Patient on RX-17A at S009. no major change. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 2.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01474,2,neutral,Visit 2: Patient on RX-17A at S009. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 2.3 mg/L; ALT 26 U/L.
P01474,3,neutral,Visit 3: Patient on RX-17A at S009. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01474,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: nausea. Adherence ~1.00. AE: yes.
P01474,5,positive,Visit 5: Patient on RX-17A at S009. energy increasing. Notes: brain fog. Adherence ~0.94. AE: no.
P01475,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.75. AE: no.
P01475,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.60. AE: no. CRP 8.1 mg/L; ALT 33 U/L.
P01475,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.74. AE: no. CRP 7.2 mg/L; ALT 35 U/L.
P01475,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.74. AE: no. CRP 6.8 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01475,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.87. AE: no. CRP 5.9 mg/L; ALT 38 U/L.
P01475,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: yes.
P01475,6,positive,Visit 6: Patient on RX-17A at S015. energy increasing. Notes: dizziness. Adherence ~0.95. AE: no.
P01476,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: headache. Adherence ~0.60. AE: no.
P01476,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.74. AE: yes.
P01476,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 7.0 mg/L; ALT 12 U/L.
P01476,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.75. AE: no.
P01476,4,positive,Visit 4: Patient on RX-17B at S022. symptoms improving. Notes: nausea. Adherence ~0.86. AE: no. CRP 4.7 mg/L; ALT 13 U/L.
P01476,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.73. AE: no. CRP 4.1 mg/L; ALT 13 U/L.
P01476,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.68. AE: no.
P01477,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no.
P01477,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: joint pain. Adherence ~0.87. AE: no. CRP 17.9 mg/L; ALT 30 U/L.
P01477,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no.
P01477,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: yes.
P01477,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P01478,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.84. AE: no. CRP 7.5 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P01478,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.71. AE: no.
P01478,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01478,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: yes.
P01479,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P01479,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 4.6 mg/L; ALT 11 U/L.
P01479,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01479,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.70. AE: no. CRP 3.2 mg/L; ALT 12 U/L.
P01479,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.47. AE: no. CRP 3.5 mg/L; ALT 12 U/L.
P01480,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: insomnia. Adherence ~0.85. AE: no.
P01480,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: no.
P01480,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.89. AE: no.
P01480,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 6.6 mg/L; ALT 45 U/L.
P01480,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.80. AE: yes. CRP 6.6 mg/L; ALT 43 U/L.
P01480,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no. CRP 4.8 mg/L; ALT 39 U/L.
P01481,0,neutral,Visit 0: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 8.4 mg/L; ALT 38 U/L.
P01481,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.79. AE: no. CRP 8.0 mg/L; ALT 37 U/L.
P01481,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: yes.
P01482,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: headache. Adherence ~0.70. AE: no. CRP 6.1 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01482,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.55. AE: no. CRP 6.9 mg/L; ALT 17 U/L.
P01482,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 6.3 mg/L; ALT 19 U/L.
P01482,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01482,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.78. AE: no. CRP 5.5 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01482,5,negative,Visit 5: Patient on RX-17A at S002. increased discomfort. Notes: insomnia. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01483,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P01483,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01483,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 3.3 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01483,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01483,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no. CRP 2.5 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01484,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: brain fog. Adherence ~0.77. AE: no.
P01484,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01484,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: no.
P01484,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.75. AE: no.
P01484,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.86. AE: no. CRP 5.0 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P01484,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.62. AE: no. CRP 4.7 mg/L; ALT 48 U/L.
P01484,6,neutral,Visit 6: Patient on RX-17A at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. CRP 4.1 mg/L; ALT 43 U/L.
P01485,0,neutral,Visit 0: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no.
P01485,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.66. AE: no. CRP 4.6 mg/L; ALT 20 U/L.
P01485,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.64. AE: yes.
P01486,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.57. AE: no. CRP 6.6 mg/L; ALT 25 U/L.
P01486,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: dizziness. Adherence ~0.85. AE: no.
P01486,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: dizziness. Adherence ~0.70. AE: no.
P01486,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P01486,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: yes.
P01486,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.70. AE: no. CRP 4.3 mg/L; ALT 20 U/L.
P01486,6,positive,Visit 6: Patient on RX-17A at S016. reports improvement. Notes: fatigue. Adherence ~0.91. AE: no. CRP 4.0 mg/L; ALT 26 U/L.
P01486,7,neutral,Visit 7: Patient on RX-17A at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.76. AE: no. CRP 4.1 mg/L; ALT 24 U/L.
P01487,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.69. AE: no.
P01487,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: insomnia. Adherence ~0.64. AE: yes.
P01487,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.67. AE: no.
P01487,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.57. AE: no.
P01487,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.53. AE: no. CRP 8.0 mg/L; ALT 30 U/L.
P01487,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no.
P01488,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: fatigue. Adherence ~0.56. AE: yes.
P01488,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~0.73. AE: no.
P01488,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.56. AE: no. CRP 4.4 mg/L; ALT 46 U/L.
P01488,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: yes.
P01489,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: joint pain. Adherence ~0.74. AE: no.
P01489,1,negative,Visit 1: Patient on RX-17B at S018. increased discomfort. Notes: headache. Adherence ~0.92. AE: no.
P01489,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.76. AE: no.
P01489,3,neutral,Visit 3: Patient on RX-17B at S018. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: yes. CRP 4.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01489,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.81. AE: no. CRP 3.9 mg/L; ALT 28 U/L.
P01490,0,neutral,Visit 0: Patient on RX-17B at S009. no major change. Notes: insomnia. Adherence ~0.77. AE: no.
P01490,1,negative,Visit 1: Patient on RX-17B at S009. poor tolerance. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 9.5 mg/L; ALT 31 U/L.
P01490,2,negative,Visit 2: Patient on RX-17B at S009. reports worsening. Notes: insomnia. Adherence ~0.65. AE: yes. Plan: consider dose adjustment; counsel patient.
P01490,3,neutral,Visit 3: Patient on RX-17B at S009. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01490,4,neutral,Visit 4: Patient on RX-17B at S009. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: no.
P01490,5,neutral,Visit 5: Patient on RX-17B at S009. continues regimen. Notes: headache. Adherence ~0.77. AE: no.
P01491,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: insomnia. Adherence ~0.89. AE: no. CRP 6.5 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01491,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.95. AE: no.
P01491,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no. CRP 5.2 mg/L; ALT 24 U/L.
P01492,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: joint pain. Adherence ~0.93. AE: no.
P01492,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01492,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no. CRP 22.8 mg/L; ALT 33 U/L.
P01492,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.81. AE: no.
P01492,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.97. AE: no. CRP 19.9 mg/L; ALT 33 U/L.
P01492,5,positive,Visit 5: Patient on RX-17B at S004. tolerating medication well. Notes: headache. Adherence ~1.00. AE: no.
P01492,6,positive,Visit 6: Patient on RX-17B at S004. energy increasing. Notes: joint pain. Adherence ~0.95. AE: no. CRP 15.8 mg/L; ALT 33 U/L.
P01493,0,neutral,Visit 0: Patient on RX-17B at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no.
P01493,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.93. AE: no.
P01493,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.68. AE: no. CRP 6.7 mg/L; ALT 44 U/L.
P01493,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no. CRP 6.8 mg/L; ALT 47 U/L.
P01493,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.57. AE: no. CRP 5.4 mg/L; ALT 46 U/L.
P01494,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: insomnia. Adherence ~0.54. AE: yes. CRP 3.7 mg/L; ALT 34 U/L.
P01494,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01494,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.67. AE: yes. CRP 2.9 mg/L; ALT 35 U/L.
P01494,3,negative,Visit 3: Patient on RX-17B at S018. increased discomfort. Notes: dizziness. Adherence ~0.74. AE: no.
P01494,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P01494,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.37. AE: no. CRP 2.4 mg/L; ALT 35 U/L.
P01495,0,neutral,Visit 0: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.65. AE: no.
P01495,1,neutral,Visit 1: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P01495,2,neutral,Visit 2: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.52. AE: no.
P01495,3,neutral,Visit 3: Patient on RX-17A at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.54. AE: no.
P01495,4,neutral,Visit 4: Patient on RX-17A at S008. stable symptoms. Notes: dizziness. Adherence ~0.65. AE: no. CRP 3.4 mg/L; ALT 28 U/L.
P01495,5,neutral,Visit 5: Patient on RX-17A at S008. continues regimen. Notes: insomnia. Adherence ~0.63. AE: no.
P01495,6,neutral,Visit 6: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.41. AE: no.
P01495,7,neutral,Visit 7: Patient on RX-17A at S008. continues regimen. Notes: fatigue. Adherence ~0.65. AE: no.
P01496,0,neutral,Visit 0: Patient on RX-17A at S011. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 4.2 mg/L; ALT 33 U/L.
P01496,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P01496,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01496,3,negative,Visit 3: Patient on RX-17A at S011. reports worsening. Notes: fatigue. Adherence ~0.48. AE: no.
P01496,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: nausea. Adherence ~0.71. AE: no.
P01497,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~0.82. AE: yes.
P01497,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.71. AE: yes.
P01497,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no.
P01497,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P01497,4,negative,Visit 4: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.71. AE: no.
P01497,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.63. AE: no. CRP 2.8 mg/L; ALT 24 U/L.
P01498,0,negative,Visit 0: Patient on RX-17A at S009. reports worsening. Notes: fatigue. Adherence ~0.72. AE: no.
P01498,1,negative,Visit 1: Patient on RX-17A at S009. symptoms persist. Notes: headache. Adherence ~0.91. AE: no. CRP 8.9 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01498,2,negative,Visit 2: Patient on RX-17A at S009. reports worsening. Notes: insomnia. Adherence ~0.64. AE: yes. CRP 8.8 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01498,3,negative,Visit 3: Patient on RX-17A at S009. increased discomfort. Notes: headache. Adherence ~0.64. AE: no.
P01498,4,negative,Visit 4: Patient on RX-17A at S009. feels frustrated. Notes: dizziness. Adherence ~0.92. AE: yes. CRP 7.1 mg/L; ALT 23 U/L.
P01499,0,neutral,Visit 0: Patient on RX-17B at S013. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. CRP 4.3 mg/L; ALT 43 U/L.
P01499,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no.
P01499,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: insomnia. Adherence ~0.90. AE: no. CRP 2.9 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P01499,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.62. AE: no. CRP 3.1 mg/L; ALT 50 U/L.
P01499,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01499,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.57. AE: yes.
P01499,6,neutral,Visit 6: Patient on RX-17B at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01500,0,neutral,Visit 0: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no. CRP 5.9 mg/L; ALT 52 U/L.
P01500,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.66. AE: no. CRP 5.8 mg/L; ALT 58 U/L.
P01500,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.78. AE: yes. CRP 5.4 mg/L; ALT 56 U/L.
P01500,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no. CRP 4.8 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P01501,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: fatigue. Adherence ~0.60. AE: no.
P01501,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: no.
P01501,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: no.
P01501,3,positive,Visit 3: Patient on RX-17A at S008. feels better overall. Notes: nausea. Adherence ~0.80. AE: no.
P01501,4,positive,Visit 4: Patient on RX-17A at S008. symptoms improving. Notes: fatigue. Adherence ~0.82. AE: no.
P01501,5,positive,Visit 5: Patient on RX-17A at S008. energy increasing. Notes: headache. Adherence ~0.81. AE: no. CRP 8.2 mg/L; ALT 17 U/L.
P01501,6,neutral,Visit 6: Patient on RX-17A at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01501,7,neutral,Visit 7: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 17 U/L.
P01502,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no.
P01502,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P01502,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.98. AE: no. CRP 4.6 mg/L; ALT 37 U/L.
P01502,3,negative,Visit 3: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 40 U/L.
P01503,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.68. AE: no.
P01503,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01503,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.80. AE: no.
P01503,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no. CRP 8.5 mg/L; ALT 39 U/L.
P01503,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01503,5,positive,Visit 5: Patient on RX-17A at S017. reports improvement. Notes: insomnia. Adherence ~0.77. AE: no. CRP 7.0 mg/L; ALT 43 U/L.
P01504,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no.
P01504,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: no.
P01504,2,positive,Visit 2: Patient on RX-17B at S012. reports improvement. Notes: headache. Adherence ~0.76. AE: no.
P01504,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.55. AE: no. CRP 2.1 mg/L; ALT 20 U/L.
P01504,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.67. AE: yes.
P01504,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.53. AE: no.
P01504,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: nausea. Adherence ~0.76. AE: no. CRP 1.4 mg/L; ALT 21 U/L.
P01504,7,neutral,Visit 7: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no. CRP 1.1 mg/L; ALT 21 U/L.
P01505,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01505,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: brain fog. Adherence ~0.90. AE: no.
P01505,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.79. AE: no. CRP 5.2 mg/L; ALT 24 U/L.
P01505,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: yes.
P01505,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no.
P01505,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: dizziness. Adherence ~0.77. AE: no. CRP 3.7 mg/L; ALT 28 U/L.
P01505,6,neutral,Visit 6: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.90. AE: yes.
P01506,0,negative,Visit 0: Patient on RX-17B at S006. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P01506,1,neutral,Visit 1: Patient on RX-17B at S006. reviewed dosing instructions. Notes: nausea. Adherence ~0.97. AE: no. CRP 3.7 mg/L; ALT 23 U/L.
P01506,2,negative,Visit 2: Patient on RX-17B at S006. feels frustrated. Notes: fatigue. Adherence ~0.88. AE: yes. CRP 3.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01506,3,positive,Visit 3: Patient on RX-17B at S006. tolerating medication well. Notes: joint pain. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P01506,4,neutral,Visit 4: Patient on RX-17B at S006. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no.
P01507,0,neutral,Visit 0: Patient on RX-17B at S001. continues regimen. Notes: nausea. Adherence ~0.80. AE: no.
P01507,1,negative,Visit 1: Patient on RX-17B at S001. symptoms persist. Notes: nausea. Adherence ~0.93. AE: no. CRP 8.2 mg/L; ALT 60 U/L.
P01507,2,neutral,Visit 2: Patient on RX-17B at S001. no major change. Notes: nausea. Adherence ~0.98. AE: no.
P01508,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01508,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01508,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.6 mg/L; ALT 57 U/L.
P01508,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.63. AE: no.
P01508,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.86. AE: no. CRP 3.1 mg/L; ALT 61 U/L.
P01508,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no. CRP 2.5 mg/L; ALT 56 U/L.
P01508,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.66. AE: no.
P01508,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.74. AE: yes. CRP 2.2 mg/L; ALT 59 U/L.
P01509,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.91. AE: no.
P01509,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.93. AE: no.
P01509,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01509,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.90. AE: no.
P01509,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. CRP 17.4 mg/L; ALT 25 U/L.
P01509,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01509,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.84. AE: no.
P01510,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: brain fog. Adherence ~0.88. AE: no.
P01510,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no. CRP 2.8 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01510,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.82. AE: no. CRP 2.4 mg/L; ALT 18 U/L.
P01510,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: joint pain. Adherence ~0.90. AE: no.
P01510,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01510,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.74. AE: no.
P01510,6,neutral,Visit 6: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.95. AE: no.
P01510,7,neutral,Visit 7: Patient on RX-17A at S002. stable symptoms. Notes: headache. Adherence ~0.78. AE: yes. CRP 1.6 mg/L; ALT 20 U/L.
P01511,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: insomnia. Adherence ~0.78. AE: no. CRP 13.4 mg/L; ALT 42 U/L.
P01511,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: fatigue. Adherence ~0.67. AE: no.
P01511,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.69. AE: yes.
P01511,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P01511,4,negative,Visit 4: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.63. AE: no. CRP 11.2 mg/L; ALT 40 U/L.
P01511,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.50. AE: no.
P01511,6,neutral,Visit 6: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.61. AE: yes. CRP 6.5 mg/L; ALT 45 U/L.
P01512,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P01512,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.82. AE: no.
P01512,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.84. AE: no. CRP 10.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01512,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no. CRP 9.6 mg/L; ALT 39 U/L.
P01512,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01512,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~0.94. AE: no.
P01512,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: insomnia. Adherence ~0.91. AE: no. CRP 5.2 mg/L; ALT 37 U/L.
P01512,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: fatigue. Adherence ~0.89. AE: no. CRP 5.0 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01513,0,neutral,Visit 0: Patient on RX-17A at S018. stable symptoms. Notes: nausea. Adherence ~0.78. AE: no.
P01513,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: no.
P01513,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: nausea. Adherence ~0.77. AE: no.
P01513,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P01513,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no.
P01513,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.83. AE: no.
P01513,6,neutral,Visit 6: Patient on RX-17A at S018. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01513,7,positive,Visit 7: Patient on RX-17A at S018. symptoms improving. Notes: headache. Adherence ~0.91. AE: no.
P01514,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01514,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.61. AE: no.
P01514,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: brain fog. Adherence ~0.58. AE: yes. CRP 6.6 mg/L; ALT 24 U/L.
P01514,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.96. AE: no. CRP 6.2 mg/L; ALT 17 U/L.
P01514,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no. CRP 4.9 mg/L; ALT 22 U/L.
P01514,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.52. AE: no. CRP 5.3 mg/L; ALT 23 U/L.
P01514,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: no.
P01515,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.80. AE: no. CRP 21.9 mg/L; ALT 41 U/L.
P01515,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: fatigue. Adherence ~0.83. AE: no.
P01515,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01515,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.64. AE: no.
P01515,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P01516,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.56. AE: no. CRP 29.0 mg/L; ALT 23 U/L.
P01516,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.71. AE: no.
P01516,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: headache. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P01516,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no.
P01516,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.67. AE: no.
P01517,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 37 U/L.
P01517,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no.
P01517,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01517,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01517,4,positive,Visit 4: Patient on RX-17A at S012. tolerating medication well. Notes: headache. Adherence ~0.86. AE: no.
P01518,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: no.
P01518,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.74. AE: yes.
P01518,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.98. AE: yes.
P01518,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.68. AE: no. CRP 6.2 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01518,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01518,5,positive,Visit 5: Patient on RX-17B at S005. tolerating medication well. Notes: headache. Adherence ~0.83. AE: no.
P01518,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.78. AE: no.
P01518,7,neutral,Visit 7: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no.
P01519,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~0.82. AE: no. CRP 4.8 mg/L; ALT 57 U/L.
P01519,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P01519,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 4.5 mg/L; ALT 62 U/L. Plan: consider dose adjustment; counsel patient.
P01519,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P01519,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 3.6 mg/L; ALT 61 U/L.
P01519,5,positive,Visit 5: Patient on RX-17B at S005. symptoms improving. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01520,0,neutral,Visit 0: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P01520,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01520,2,negative,Visit 2: Patient on RX-17B at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P01520,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.73. AE: no. CRP 2.9 mg/L; ALT 33 U/L.
P01520,4,negative,Visit 4: Patient on RX-17B at S013. reports worsening. Notes: nausea. Adherence ~0.54. AE: no.
P01520,5,neutral,Visit 5: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01520,6,neutral,Visit 6: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.49. AE: no. CRP 2.1 mg/L; ALT 35 U/L.
P01521,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.90. AE: yes.
P01521,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no. CRP 7.3 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01521,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~1.00. AE: no.
P01521,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01521,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: fatigue. Adherence ~0.91. AE: no.
P01521,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: dizziness. Adherence ~0.89. AE: no. CRP 6.3 mg/L; ALT 28 U/L.
P01521,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.87. AE: yes.
P01521,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.99. AE: yes.
P01522,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: brain fog. Adherence ~0.80. AE: no. CRP 10.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01522,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: joint pain. Adherence ~0.87. AE: no. CRP 8.3 mg/L; ALT 31 U/L.
P01522,2,negative,Visit 2: Patient on RX-17B at S019. poor tolerance. Notes: headache. Adherence ~0.83. AE: no. CRP 7.7 mg/L; ALT 32 U/L.
P01522,3,negative,Visit 3: Patient on RX-17B at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P01522,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~1.00. AE: yes.
P01522,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.74. AE: yes. CRP 5.2 mg/L; ALT 36 U/L.
P01523,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: no.
P01523,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P01523,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.76. AE: yes. CRP 2.8 mg/L; ALT 32 U/L.
P01523,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.63. AE: no. CRP 2.5 mg/L; ALT 32 U/L.
P01523,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no.
P01523,5,positive,Visit 5: Patient on RX-17A at S015. reports improvement. Notes: dizziness. Adherence ~0.77. AE: no.
P01523,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P01523,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.59. AE: no.
P01524,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: dizziness. Adherence ~0.75. AE: no.
P01524,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: headache. Adherence ~0.61. AE: no.
P01524,2,neutral,Visit 2: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.58. AE: yes. CRP 8.6 mg/L; ALT 21 U/L.
P01524,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.49. AE: no.
P01524,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no. CRP 6.4 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01524,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: dizziness. Adherence ~0.62. AE: no.
P01524,6,neutral,Visit 6: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.61. AE: no. CRP 6.3 mg/L; ALT 20 U/L.
P01524,7,neutral,Visit 7: Patient on RX-17A at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.74. AE: no. CRP 5.1 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01525,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P01525,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: yes.
P01525,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no.
P01525,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.50. AE: no. CRP 7.4 mg/L; ALT 68 U/L. Plan: consider dose adjustment; counsel patient.
P01525,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P01525,5,negative,Visit 5: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.49. AE: no. CRP 5.5 mg/L; ALT 56 U/L.
P01525,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: yes. CRP 6.1 mg/L; ALT 68 U/L.
P01526,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: brain fog. Adherence ~0.97. AE: no.
P01526,1,negative,Visit 1: Patient on RX-17B at S013. feels frustrated. Notes: headache. Adherence ~0.77. AE: yes.
P01526,2,negative,Visit 2: Patient on RX-17B at S013. poor tolerance. Notes: fatigue. Adherence ~0.71. AE: no. CRP 4.4 mg/L; ALT 55 U/L.
P01526,3,negative,Visit 3: Patient on RX-17B at S013. reports worsening. Notes: fatigue. Adherence ~0.63. AE: yes.
P01526,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no.
P01526,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: yes. CRP 3.0 mg/L; ALT 62 U/L.
P01526,6,neutral,Visit 6: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.70. AE: no.
P01526,7,neutral,Visit 7: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.64. AE: no. CRP 2.6 mg/L; ALT 53 U/L.
P01527,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: insomnia. Adherence ~0.67. AE: no.
P01527,1,negative,Visit 1: Patient on RX-17B at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 4.0 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01527,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no. CRP 4.1 mg/L; ALT 27 U/L.
P01527,3,negative,Visit 3: Patient on RX-17B at S013. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01527,4,negative,Visit 4: Patient on RX-17B at S013. reports worsening. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 3.5 mg/L; ALT 30 U/L.
P01527,5,neutral,Visit 5: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no. CRP 3.3 mg/L; ALT 29 U/L.
P01527,6,positive,Visit 6: Patient on RX-17B at S013. symptoms improving. Notes: brain fog. Adherence ~0.76. AE: no. CRP 2.5 mg/L; ALT 34 U/L.
P01527,7,neutral,Visit 7: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P01528,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no. CRP 9.0 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01528,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.82. AE: no.
P01528,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01528,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.91. AE: no. CRP 7.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01528,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01528,5,positive,Visit 5: Patient on RX-17B at S022. energy increasing. Notes: insomnia. Adherence ~1.00. AE: no.
P01528,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P01528,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: yes. CRP 4.2 mg/L; ALT 45 U/L.
P01529,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: insomnia. Adherence ~0.96. AE: no. CRP 18.0 mg/L; ALT 67 U/L.
P01529,1,neutral,Visit 1: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01529,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no. CRP 14.0 mg/L; ALT 64 U/L. Plan: consider dose adjustment; counsel patient.
P01529,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no. CRP 12.2 mg/L; ALT 63 U/L.
P01529,4,negative,Visit 4: Patient on RX-17A at S008. symptoms persist. Notes: headache. Adherence ~0.79. AE: no.
P01529,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: brain fog. Adherence ~0.72. AE: yes. CRP 11.2 mg/L; ALT 61 U/L.
P01530,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.98. AE: no.
P01530,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01530,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.73. AE: no. CRP 8.4 mg/L; ALT 50 U/L.
P01530,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.64. AE: yes. Plan: consider dose adjustment; counsel patient.
P01530,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01530,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: no. CRP 5.6 mg/L; ALT 48 U/L.
P01530,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.59. AE: no. CRP 5.3 mg/L; ALT 46 U/L.
P01530,7,neutral,Visit 7: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.63. AE: no.
P01531,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: headache. Adherence ~1.00. AE: no. CRP 12.4 mg/L; ALT 28 U/L.
P01531,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.79. AE: yes. CRP 11.9 mg/L; ALT 30 U/L.
P01531,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no. CRP 11.0 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01532,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: joint pain. Adherence ~0.97. AE: no.
P01532,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.7 mg/L; ALT 30 U/L.
P01532,2,negative,Visit 2: Patient on RX-17A at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~0.92. AE: yes.
P01533,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no. CRP 6.4 mg/L; ALT 17 U/L.
P01533,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01533,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.56. AE: yes.
P01533,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.70. AE: no. CRP 4.6 mg/L; ALT 17 U/L.
P01533,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01533,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.20. AE: no. Plan: consider dose adjustment; counsel patient.
P01534,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01534,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~0.76. AE: no.
P01534,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no.
P01534,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 7.6 mg/L; ALT 43 U/L.
P01534,4,negative,Visit 4: Patient on RX-17A at S005. poor tolerance. Notes: insomnia. Adherence ~0.71. AE: no.
P01534,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.85. AE: no.
P01534,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.90. AE: no.
P01535,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.84. AE: no.
P01535,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~0.63. AE: no.
P01535,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no.
P01535,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.57. AE: no.
P01535,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no.
P01535,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.51. AE: no.
P01536,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: no. CRP 8.8 mg/L; ALT 42 U/L.
P01536,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no.
P01536,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: no.
P01536,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.69. AE: no.
P01536,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P01536,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.81. AE: no.
P01536,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.63. AE: yes. CRP 5.2 mg/L; ALT 49 U/L.
P01536,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: fatigue. Adherence ~0.81. AE: no.
P01537,0,negative,Visit 0: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.91. AE: no. CRP 10.7 mg/L; ALT 39 U/L.
P01537,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P01537,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: headache. Adherence ~0.84. AE: no.
P01537,3,neutral,Visit 3: Patient on RX-17A at S011. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: yes.
P01537,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01537,5,neutral,Visit 5: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no.
P01537,6,neutral,Visit 6: Patient on RX-17A at S011. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P01538,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01538,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.71. AE: yes.
P01538,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.82. AE: no.
P01538,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P01538,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01538,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.97. AE: no.
P01539,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.92. AE: yes.
P01539,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01539,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01539,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P01539,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: nausea. Adherence ~0.92. AE: no. CRP 5.7 mg/L; ALT 21 U/L.
P01539,5,positive,Visit 5: Patient on RX-17B at S022. tolerating medication well. Notes: headache. Adherence ~0.88. AE: no. CRP 4.4 mg/L; ALT 22 U/L.
P01539,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01539,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.75. AE: yes. CRP 3.4 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01540,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: brain fog. Adherence ~0.65. AE: no.
P01540,1,negative,Visit 1: Patient on RX-17A at S018. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: no. CRP 7.5 mg/L; ALT 32 U/L.
P01540,2,neutral,Visit 2: Patient on RX-17A at S018. no major change. Notes: headache. Adherence ~0.43. AE: no. CRP 6.6 mg/L; ALT 34 U/L.
P01540,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: joint pain. Adherence ~0.37. AE: no. CRP 6.2 mg/L; ALT 37 U/L.
P01540,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.40. AE: no.
P01540,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no.
P01541,0,negative,Visit 0: Patient on RX-17B at S009. reports worsening. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01541,1,negative,Visit 1: Patient on RX-17B at S009. increased discomfort. Notes: joint pain. Adherence ~0.69. AE: no.
P01541,2,neutral,Visit 2: Patient on RX-17B at S009. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no. CRP 4.9 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01541,3,neutral,Visit 3: Patient on RX-17B at S009. continues regimen. Notes: nausea. Adherence ~0.82. AE: no.
P01541,4,neutral,Visit 4: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.71. AE: no. CRP 3.8 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01542,0,neutral,Visit 0: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.83. AE: no. CRP 4.3 mg/L; ALT 40 U/L.
P01542,1,negative,Visit 1: Patient on RX-17A at S011. increased discomfort. Notes: dizziness. Adherence ~0.94. AE: no. CRP 3.3 mg/L; ALT 33 U/L.
P01542,2,negative,Visit 2: Patient on RX-17A at S011. feels frustrated. Notes: dizziness. Adherence ~0.77. AE: no.
P01542,3,neutral,Visit 3: Patient on RX-17A at S011. no major change. Notes: brain fog. Adherence ~0.84. AE: no. CRP 3.1 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P01542,4,neutral,Visit 4: Patient on RX-17A at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. CRP 2.8 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01543,0,neutral,Visit 0: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01543,1,neutral,Visit 1: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P01543,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: nausea. Adherence ~0.81. AE: no.
P01543,3,positive,Visit 3: Patient on RX-17B at S008. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.2 mg/L; ALT 22 U/L.
P01543,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no.
P01543,5,neutral,Visit 5: Patient on RX-17B at S008. stable symptoms. Notes: insomnia. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01544,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: joint pain. Adherence ~0.87. AE: no.
P01544,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: no.
P01544,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P01544,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no.
P01544,4,positive,Visit 4: Patient on RX-17B at S004. feels better overall. Notes: insomnia. Adherence ~0.91. AE: no. CRP 10.1 mg/L; ALT 41 U/L.
P01545,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.92. AE: no.
P01545,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 12.1 mg/L; ALT 47 U/L.
P01545,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.71. AE: yes.
P01545,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.72. AE: no. CRP 9.1 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P01545,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no. CRP 9.4 mg/L; ALT 44 U/L.
P01545,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.71. AE: no.
P01545,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.72. AE: yes. CRP 8.5 mg/L; ALT 52 U/L.
P01546,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: headache. Adherence ~0.78. AE: no.
P01546,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: headache. Adherence ~0.96. AE: no. CRP 5.8 mg/L; ALT 35 U/L.
P01546,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.92. AE: yes. CRP 4.9 mg/L; ALT 34 U/L.
P01546,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.64. AE: no.
P01546,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01546,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no.
P01547,0,negative,Visit 0: Patient on RX-17A at S007. poor tolerance. Notes: dizziness. Adherence ~0.98. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P01547,1,neutral,Visit 1: Patient on RX-17A at S007. continues regimen. Notes: insomnia. Adherence ~0.86. AE: no.
P01547,2,neutral,Visit 2: Patient on RX-17A at S007. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P01547,3,neutral,Visit 3: Patient on RX-17A at S007. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no. CRP 4.6 mg/L; ALT 33 U/L.
P01547,4,neutral,Visit 4: Patient on RX-17A at S007. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no.
P01547,5,neutral,Visit 5: Patient on RX-17A at S007. continues regimen. Notes: nausea. Adherence ~0.74. AE: no. CRP 4.2 mg/L; ALT 34 U/L.
P01547,6,neutral,Visit 6: Patient on RX-17A at S007. continues regimen. Notes: fatigue. Adherence ~0.75. AE: no.
P01547,7,positive,Visit 7: Patient on RX-17A at S007. tolerating medication well. Notes: dizziness. Adherence ~0.80. AE: no. CRP 3.0 mg/L; ALT 35 U/L.
P01548,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01548,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: dizziness. Adherence ~0.75. AE: no. CRP 5.1 mg/L; ALT 40 U/L.
P01548,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.70. AE: no. CRP 5.0 mg/L; ALT 39 U/L.
P01548,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.55. AE: no. CRP 4.3 mg/L; ALT 43 U/L.
P01548,4,positive,Visit 4: Patient on RX-17A at S019. reports improvement. Notes: nausea. Adherence ~0.88. AE: no. CRP 4.0 mg/L; ALT 40 U/L.
P01549,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: headache. Adherence ~0.52. AE: no. CRP 6.1 mg/L; ALT 59 U/L.
P01549,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: insomnia. Adherence ~0.92. AE: no.
P01549,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.93. AE: no.
P01549,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.96. AE: no. CRP 4.2 mg/L; ALT 58 U/L.
P01549,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no.
P01550,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.51. AE: no. CRP 9.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01550,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01550,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no. CRP 7.3 mg/L; ALT 28 U/L.
P01550,3,negative,Visit 3: Patient on RX-17B at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01550,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no.
P01550,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.57. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P01551,0,neutral,Visit 0: Patient on RX-17A at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no.
P01551,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.97. AE: yes.
P01551,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.73. AE: no. CRP 11.3 mg/L; ALT 37 U/L.
P01551,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01551,4,negative,Visit 4: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no.
P01551,5,positive,Visit 5: Patient on RX-17A at S005. energy increasing. Notes: brain fog. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01551,6,positive,Visit 6: Patient on RX-17A at S005. feels better overall. Notes: dizziness. Adherence ~0.86. AE: no.
P01551,7,neutral,Visit 7: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no. CRP 6.4 mg/L; ALT 35 U/L.
P01552,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: headache. Adherence ~0.78. AE: no.
P01552,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no. CRP 23.5 mg/L; ALT 47 U/L.
P01552,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.75. AE: no.
P01552,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.92. AE: no.
P01552,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.69. AE: no. CRP 19.0 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P01552,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P01552,6,positive,Visit 6: Patient on RX-17A at S015. reports improvement. Notes: insomnia. Adherence ~0.87. AE: no.
P01552,7,positive,Visit 7: Patient on RX-17A at S015. tolerating medication well. Notes: insomnia. Adherence ~0.77. AE: no. CRP 12.2 mg/L; ALT 50 U/L.
P01553,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P01553,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no.
P01553,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P01553,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.93. AE: no. CRP 3.8 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01553,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.8 mg/L; ALT 36 U/L.
P01553,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.82. AE: yes.
P01553,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 2.9 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01554,0,neutral,Visit 0: Patient on RX-17B at S006. no major change. Notes: insomnia. Adherence ~0.65. AE: no. CRP 11.2 mg/L; ALT 15 U/L.
P01554,1,negative,Visit 1: Patient on RX-17B at S006. poor tolerance. Notes: brain fog. Adherence ~0.67. AE: no.
P01554,2,neutral,Visit 2: Patient on RX-17B at S006. continues regimen. Notes: headache. Adherence ~0.64. AE: no. CRP 9.7 mg/L; ALT 14 U/L.
P01554,3,neutral,Visit 3: Patient on RX-17B at S006. no major change. Notes: insomnia. Adherence ~0.62. AE: no.
P01554,4,neutral,Visit 4: Patient on RX-17B at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 7.7 mg/L; ALT 15 U/L.
P01555,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.79. AE: no. CRP 9.1 mg/L; ALT 26 U/L.
P01555,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~0.79. AE: no.
P01555,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no. CRP 9.7 mg/L; ALT 21 U/L.
P01555,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.63. AE: no. CRP 7.5 mg/L; ALT 23 U/L.
P01555,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P01555,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 6.7 mg/L; ALT 24 U/L.
P01555,6,positive,Visit 6: Patient on RX-17A at S022. feels better overall. Notes: headache. Adherence ~0.77. AE: no. CRP 6.0 mg/L; ALT 26 U/L.
P01555,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no.
P01556,0,neutral,Visit 0: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01556,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P01556,2,negative,Visit 2: Patient on RX-17B at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01556,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.86. AE: no. CRP 4.9 mg/L; ALT 36 U/L.
P01556,4,negative,Visit 4: Patient on RX-17B at S019. symptoms persist. Notes: dizziness. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P01557,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01557,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no. CRP 3.5 mg/L; ALT 25 U/L.
P01557,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01557,3,negative,Visit 3: Patient on RX-17A at S019. reports worsening. Notes: dizziness. Adherence ~0.62. AE: no. CRP 3.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01557,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P01557,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no.
P01557,6,neutral,Visit 6: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.46. AE: no.
P01557,7,neutral,Visit 7: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 2.4 mg/L; ALT 29 U/L.
P01558,0,neutral,Visit 0: Patient on RX-17A at S007. no major change. Notes: fatigue. Adherence ~1.00. AE: no. CRP 9.9 mg/L; ALT 47 U/L.
P01558,1,neutral,Visit 1: Patient on RX-17A at S007. continues regimen. Notes: insomnia. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01558,2,negative,Visit 2: Patient on RX-17A at S007. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.4 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01558,3,positive,Visit 3: Patient on RX-17A at S007. energy increasing. Notes: headache. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01558,4,neutral,Visit 4: Patient on RX-17A at S007. continues regimen. Notes: nausea. Adherence ~0.94. AE: no.
P01558,5,negative,Visit 5: Patient on RX-17A at S007. reports worsening. Notes: insomnia. Adherence ~0.91. AE: no.
P01559,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P01559,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: joint pain. Adherence ~0.92. AE: no.
P01559,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: no.
P01559,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no. CRP 18.0 mg/L; ALT 58 U/L.
P01559,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no. CRP 17.4 mg/L; ALT 47 U/L.
P01559,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no.
P01559,6,positive,Visit 6: Patient on RX-17B at S002. tolerating medication well. Notes: brain fog. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01559,7,positive,Visit 7: Patient on RX-17B at S002. tolerating medication well. Notes: dizziness. Adherence ~0.80. AE: no.
P01560,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.81. AE: yes. CRP 8.8 mg/L; ALT 28 U/L.
P01560,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: headache. Adherence ~0.74. AE: no. CRP 7.8 mg/L; ALT 26 U/L.
P01560,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.79. AE: no.
P01560,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.64. AE: no.
P01560,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P01561,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.81. AE: no. CRP 5.3 mg/L; ALT 22 U/L.
P01561,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: joint pain. Adherence ~0.75. AE: no.
P01561,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P01561,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~0.67. AE: no.
P01561,4,positive,Visit 4: Patient on RX-17B at S012. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 23 U/L.
P01562,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01562,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no.
P01562,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P01562,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01562,4,negative,Visit 4: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.89. AE: yes.
P01562,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01562,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no.
P01562,7,positive,Visit 7: Patient on RX-17B at S015. feels better overall. Notes: brain fog. Adherence ~0.84. AE: no.
P01563,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: dizziness. Adherence ~0.83. AE: no.
P01563,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.88. AE: no.
P01563,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 26 U/L.
P01563,3,negative,Visit 3: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.84. AE: yes. CRP 3.0 mg/L; ALT 31 U/L.
P01563,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no. CRP 2.8 mg/L; ALT 29 U/L.
P01563,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.89. AE: no. CRP 2.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01564,0,neutral,Visit 0: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no.
P01564,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.96. AE: no. CRP 6.1 mg/L; ALT 55 U/L.
P01564,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no.
P01564,3,negative,Visit 3: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.61. AE: yes.
P01564,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01565,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. CRP 10.7 mg/L; ALT 24 U/L.
P01565,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no.
P01565,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no. CRP 8.5 mg/L; ALT 23 U/L.
P01565,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.82. AE: no.
P01565,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. CRP 6.5 mg/L; ALT 22 U/L.
P01565,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.91. AE: no.
P01566,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no.
P01566,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 37 U/L.
P01566,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: yes.
P01566,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.94. AE: no. CRP 4.0 mg/L; ALT 41 U/L.
P01566,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no.
P01566,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no. CRP 3.7 mg/L; ALT 39 U/L.
P01566,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.69. AE: no. CRP 2.7 mg/L; ALT 41 U/L.
P01566,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: no. CRP 2.9 mg/L; ALT 40 U/L.
P01567,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.96. AE: no.
P01567,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01567,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 1.1 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01567,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.87. AE: no.
P01567,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~1.00. AE: yes.
P01568,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no.
P01568,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no. CRP 7.2 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01568,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.64. AE: no.
P01568,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01568,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.73. AE: no. CRP 6.0 mg/L; ALT 41 U/L.
P01569,0,neutral,Visit 0: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.95. AE: no.
P01569,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: dizziness. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 35 U/L.
P01569,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P01569,3,positive,Visit 3: Patient on RX-17B at S019. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P01569,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01569,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.97. AE: yes.
P01570,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.50. AE: no.
P01570,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.54. AE: no. CRP 4.5 mg/L; ALT 30 U/L.
P01570,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.46. AE: no. CRP 4.1 mg/L; ALT 26 U/L.
P01570,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.39. AE: yes. CRP 3.7 mg/L; ALT 32 U/L.
P01570,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.49. AE: no.
P01570,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.59. AE: no.
P01570,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.53. AE: no. CRP 2.6 mg/L; ALT 30 U/L.
P01570,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.32. AE: no.
P01571,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.99. AE: no.
P01571,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: headache. Adherence ~0.79. AE: yes.
P01571,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.96. AE: no. CRP 4.2 mg/L; ALT 64 U/L.
P01571,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.77. AE: no. CRP 3.4 mg/L; ALT 59 U/L.
P01571,4,positive,Visit 4: Patient on RX-17B at S017. feels better overall. Notes: dizziness. Adherence ~0.97. AE: no. CRP 3.2 mg/L; ALT 59 U/L.
P01572,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: insomnia. Adherence ~0.88. AE: yes. CRP 8.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01572,1,negative,Visit 1: Patient on RX-17B at S018. reports worsening. Notes: headache. Adherence ~0.80. AE: yes. CRP 8.8 mg/L; ALT 28 U/L.
P01572,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: no.
P01572,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P01572,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.80. AE: no. CRP 6.7 mg/L; ALT 28 U/L.
P01573,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.92. AE: yes.
P01573,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.73. AE: no.
P01573,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.80. AE: no. CRP 5.5 mg/L; ALT 44 U/L.
P01573,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01573,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no. CRP 4.3 mg/L; ALT 42 U/L.
P01574,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: headache. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01574,1,neutral,Visit 1: Patient on RX-17A at S011. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no. CRP 11.8 mg/L; ALT 29 U/L.
P01574,2,neutral,Visit 2: Patient on RX-17A at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01574,3,neutral,Visit 3: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: yes.
P01574,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no.
P01574,5,neutral,Visit 5: Patient on RX-17A at S011. no major change. Notes: insomnia. Adherence ~0.86. AE: no. CRP 8.2 mg/L; ALT 30 U/L.
P01575,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: fatigue. Adherence ~0.79. AE: yes. CRP 13.0 mg/L; ALT 19 U/L.
P01575,1,positive,Visit 1: Patient on RX-17A at S004. energy increasing. Notes: dizziness. Adherence ~0.85. AE: no. CRP 12.1 mg/L; ALT 16 U/L.
P01575,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 9.8 mg/L; ALT 18 U/L.
P01575,3,positive,Visit 3: Patient on RX-17A at S004. energy increasing. Notes: joint pain. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P01575,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no.
P01575,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no.
P01576,0,neutral,Visit 0: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01576,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: fatigue. Adherence ~0.88. AE: no. CRP 4.9 mg/L; ALT 26 U/L.
P01576,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P01576,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.83. AE: no.
P01576,4,neutral,Visit 4: Patient on RX-17B at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01576,5,positive,Visit 5: Patient on RX-17B at S008. feels better overall. Notes: brain fog. Adherence ~0.77. AE: no.
P01576,6,positive,Visit 6: Patient on RX-17B at S008. symptoms improving. Notes: dizziness. Adherence ~0.79. AE: no.
P01576,7,positive,Visit 7: Patient on RX-17B at S008. symptoms improving. Notes: dizziness. Adherence ~0.99. AE: no.
P01577,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01577,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.89. AE: no.
P01577,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P01577,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.98. AE: no. CRP 4.9 mg/L; ALT 28 U/L.
P01577,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.86. AE: no.
P01577,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no.
P01577,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P01578,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01578,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 7.7 mg/L; ALT 30 U/L.
P01578,2,positive,Visit 2: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 30 U/L.
P01578,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.89. AE: no.
P01578,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no.
P01578,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~0.84. AE: no.
P01578,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P01579,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: no.
P01579,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no. CRP 6.8 mg/L; ALT 24 U/L.
P01579,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 22 U/L.
P01579,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01579,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P01580,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~0.65. AE: no. CRP 2.8 mg/L; ALT 39 U/L.
P01580,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P01580,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01580,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01580,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01580,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: nausea. Adherence ~0.81. AE: no. CRP 1.9 mg/L; ALT 36 U/L.
P01580,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.66. AE: no.
P01581,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.69. AE: yes.
P01581,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no.
P01581,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01581,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 13.9 mg/L; ALT 42 U/L.
P01581,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01581,5,positive,Visit 5: Patient on RX-17B at S017. tolerating medication well. Notes: joint pain. Adherence ~0.85. AE: no.
P01581,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.80. AE: yes.
P01582,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.66. AE: no.
P01582,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.56. AE: no.
P01582,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.64. AE: no.
P01582,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no.
P01582,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: yes.
P01582,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P01583,0,negative,Visit 0: Patient on RX-17B at S008. symptoms persist. Notes: joint pain. Adherence ~0.63. AE: no. CRP 6.2 mg/L; ALT 26 U/L.
P01583,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: yes.
P01583,2,negative,Visit 2: Patient on RX-17B at S008. poor tolerance. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 5.6 mg/L; ALT 30 U/L.
P01583,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01583,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. CRP 3.8 mg/L; ALT 28 U/L.
P01584,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: fatigue. Adherence ~0.65. AE: yes. Plan: consider dose adjustment; counsel patient.
P01584,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.60. AE: no. CRP 2.5 mg/L; ALT 20 U/L.
P01584,2,negative,Visit 2: Patient on RX-17B at S017. poor tolerance. Notes: insomnia. Adherence ~0.67. AE: yes. CRP 2.5 mg/L; ALT 24 U/L.
P01584,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01584,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01584,5,positive,Visit 5: Patient on RX-17B at S017. energy increasing. Notes: insomnia. Adherence ~0.79. AE: no.
P01584,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01585,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: no.
P01585,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: nausea. Adherence ~0.81. AE: no.
P01585,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 29 U/L.
P01585,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01585,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: yes.
P01586,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.65. AE: no. CRP 5.6 mg/L; ALT 48 U/L.
P01586,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.63. AE: yes.
P01586,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.66. AE: no. CRP 4.7 mg/L; ALT 50 U/L.
P01586,3,positive,Visit 3: Patient on RX-17A at S014. reports improvement. Notes: brain fog. Adherence ~0.85. AE: no.
P01587,0,neutral,Visit 0: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01587,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no.
P01587,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 6.0 mg/L; ALT 50 U/L.
P01587,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P01587,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no. CRP 4.5 mg/L; ALT 53 U/L.
P01587,5,positive,Visit 5: Patient on RX-17B at S005. tolerating medication well. Notes: joint pain. Adherence ~0.87. AE: no.
P01587,6,positive,Visit 6: Patient on RX-17B at S005. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P01587,7,positive,Visit 7: Patient on RX-17B at S005. symptoms improving. Notes: dizziness. Adherence ~0.93. AE: no. CRP 3.0 mg/L; ALT 54 U/L.
P01588,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.92. AE: no.
P01588,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.87. AE: no.
P01588,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.97. AE: no.
P01588,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 1.9 mg/L; ALT 25 U/L.
P01588,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: no. CRP 1.5 mg/L; ALT 26 U/L.
P01588,5,positive,Visit 5: Patient on RX-17B at S017. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01588,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no. CRP 1.1 mg/L; ALT 27 U/L.
P01588,7,neutral,Visit 7: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: yes.
P01589,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P01589,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.83. AE: no.
P01589,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.82. AE: no.
P01589,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.74. AE: no.
P01589,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01589,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no. CRP 3.7 mg/L; ALT 68 U/L.
P01590,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.96. AE: no.
P01590,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01590,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.77. AE: no.
P01590,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no. CRP 4.5 mg/L; ALT 25 U/L.
P01590,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P01591,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P01591,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: insomnia. Adherence ~0.81. AE: no.
P01591,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: yes.
P01591,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: no. CRP 5.3 mg/L; ALT 20 U/L.
P01591,4,positive,Visit 4: Patient on RX-17B at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01592,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no. CRP 6.8 mg/L; ALT 19 U/L.
P01592,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no.
P01592,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.60. AE: no.
P01592,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P01592,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 5.0 mg/L; ALT 19 U/L.
P01592,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no.
P01592,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.61. AE: no. CRP 3.6 mg/L; ALT 19 U/L.
P01593,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: dizziness. Adherence ~0.90. AE: no.
P01593,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: yes.
P01593,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: brain fog. Adherence ~0.87. AE: no. CRP 6.4 mg/L; ALT 18 U/L.
P01593,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: yes.
P01593,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: no. CRP 4.9 mg/L; ALT 23 U/L.
P01593,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no.
P01593,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: insomnia. Adherence ~0.98. AE: no.
P01593,7,neutral,Visit 7: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.75. AE: no. CRP 3.4 mg/L; ALT 23 U/L.
P01594,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.87. AE: no.
P01594,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.75. AE: no.
P01594,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01594,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: brain fog. Adherence ~0.73. AE: no. CRP 13.2 mg/L; ALT 35 U/L.
P01594,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no. CRP 12.3 mg/L; ALT 36 U/L.
P01595,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.63. AE: no. CRP 5.3 mg/L; ALT 26 U/L.
P01595,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P01595,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.77. AE: no. CRP 4.6 mg/L; ALT 31 U/L.
P01595,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P01595,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.84. AE: no. CRP 4.7 mg/L; ALT 25 U/L.
P01595,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: dizziness. Adherence ~0.77. AE: no.
P01595,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no.
P01595,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.65. AE: no. CRP 2.6 mg/L; ALT 28 U/L.
P01596,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.73. AE: yes.
P01596,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.57. AE: no. CRP 4.3 mg/L; ALT 25 U/L.
P01596,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.89. AE: no.
P01596,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01596,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 3.8 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01596,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no.
P01596,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01597,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.59. AE: no.
P01597,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: brain fog. Adherence ~0.62. AE: no.
P01597,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01597,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~0.69. AE: no.
P01597,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P01597,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.65. AE: no. CRP 1.9 mg/L; ALT 24 U/L.
P01598,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P01598,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.47. AE: yes.
P01598,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.56. AE: no.
P01598,3,negative,Visit 3: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.51. AE: yes. CRP 4.2 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01598,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.66. AE: no.
P01598,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.41. AE: no.
P01599,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: insomnia. Adherence ~0.71. AE: yes.
P01599,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P01599,2,negative,Visit 2: Patient on RX-17B at S019. reports worsening. Notes: insomnia. Adherence ~0.65. AE: yes.
P01599,3,negative,Visit 3: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01600,0,negative,Visit 0: Patient on RX-17A at S011. feels frustrated. Notes: brain fog. Adherence ~0.85. AE: no. CRP 13.0 mg/L; ALT 43 U/L.
P01600,1,negative,Visit 1: Patient on RX-17A at S011. symptoms persist. Notes: dizziness. Adherence ~0.80. AE: no. CRP 12.3 mg/L; ALT 43 U/L.
P01600,2,neutral,Visit 2: Patient on RX-17A at S011. continues regimen. Notes: dizziness. Adherence ~0.77. AE: no. CRP 11.3 mg/L; ALT 45 U/L.
P01600,3,neutral,Visit 3: Patient on RX-17A at S011. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P01600,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 10.6 mg/L; ALT 43 U/L.
P01600,5,positive,Visit 5: Patient on RX-17A at S011. symptoms improving. Notes: insomnia. Adherence ~0.79. AE: no.
P01600,6,neutral,Visit 6: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.75. AE: no. CRP 7.0 mg/L; ALT 43 U/L.
P01601,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.78. AE: no. CRP 7.1 mg/L; ALT 52 U/L.
P01601,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: joint pain. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01601,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: yes.
P01602,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.69. AE: no.
P01602,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01602,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.74. AE: no. CRP 10.1 mg/L; ALT 54 U/L.
P01602,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.66. AE: no. CRP 8.8 mg/L; ALT 59 U/L.
P01602,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01603,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: nausea. Adherence ~0.87. AE: no.
P01603,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~0.69. AE: no.
P01603,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.84. AE: no. CRP 14.7 mg/L; ALT 37 U/L.
P01603,3,positive,Visit 3: Patient on RX-17B at S022. feels better overall. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01603,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.88. AE: no. CRP 10.1 mg/L; ALT 43 U/L.
P01604,0,positive,Visit 0: Patient on RX-17B at S020. feels better overall. Notes: brain fog. Adherence ~0.94. AE: no.
P01604,1,neutral,Visit 1: Patient on RX-17B at S020. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: no.
P01604,2,negative,Visit 2: Patient on RX-17B at S020. feels frustrated. Notes: joint pain. Adherence ~0.94. AE: no.
P01604,3,neutral,Visit 3: Patient on RX-17B at S020. stable symptoms. Notes: insomnia. Adherence ~0.93. AE: no.
P01604,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: yes. CRP 2.7 mg/L; ALT 29 U/L.
P01604,5,positive,Visit 5: Patient on RX-17B at S020. energy increasing. Notes: dizziness. Adherence ~0.84. AE: no.
P01605,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no.
P01605,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no. CRP 5.7 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01605,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 5.7 mg/L; ALT 22 U/L.
P01605,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.87. AE: yes. CRP 5.4 mg/L; ALT 27 U/L.
P01605,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no. CRP 4.7 mg/L; ALT 26 U/L.
P01605,5,positive,Visit 5: Patient on RX-17A at S012. energy increasing. Notes: dizziness. Adherence ~0.84. AE: no.
P01605,6,negative,Visit 6: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01606,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 15.2 mg/L; ALT 45 U/L.
P01606,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.99. AE: yes. CRP 14.1 mg/L; ALT 40 U/L.
P01606,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.77. AE: no.
P01606,3,positive,Visit 3: Patient on RX-17B at S017. symptoms improving. Notes: joint pain. Adherence ~0.83. AE: no. CRP 11.1 mg/L; ALT 40 U/L.
P01606,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no. CRP 9.9 mg/L; ALT 40 U/L.
P01606,5,positive,Visit 5: Patient on RX-17B at S017. feels better overall. Notes: insomnia. Adherence ~0.80. AE: no.
P01606,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.80. AE: no.
P01607,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.67. AE: no.
P01607,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.62. AE: no. CRP 7.0 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01607,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.64. AE: yes.
P01607,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.49. AE: yes.
P01607,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no.
P01607,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.47. AE: no.
P01607,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P01608,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.74. AE: no.
P01608,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: nausea. Adherence ~0.86. AE: no.
P01608,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: headache. Adherence ~0.57. AE: no.
P01608,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no. CRP 7.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01608,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.59. AE: no.
P01608,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.54. AE: no. CRP 6.5 mg/L; ALT 37 U/L.
P01608,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01608,7,neutral,Visit 7: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P01609,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: yes. Plan: consider dose adjustment; counsel patient.
P01609,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.66. AE: yes. CRP 12.8 mg/L; ALT 63 U/L.
P01609,2,positive,Visit 2: Patient on RX-17A at S015. reports improvement. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01609,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.65. AE: no.
P01609,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: dizziness. Adherence ~0.78. AE: yes.
P01609,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.89. AE: no. CRP 8.6 mg/L; ALT 59 U/L.
P01609,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: yes.
P01609,7,positive,Visit 7: Patient on RX-17A at S015. energy increasing. Notes: insomnia. Adherence ~0.77. AE: no.
P01610,0,neutral,Visit 0: Patient on RX-17A at S018. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P01610,1,negative,Visit 1: Patient on RX-17A at S018. feels frustrated. Notes: fatigue. Adherence ~0.37. AE: yes.
P01610,2,neutral,Visit 2: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.42. AE: no.
P01610,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01610,4,negative,Visit 4: Patient on RX-17A at S018. increased discomfort. Notes: dizziness. Adherence ~0.53. AE: no.
P01611,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: abdominal discomfort. Adherence ~0.45. AE: no. CRP 8.6 mg/L; ALT 69 U/L. Plan: consider dose adjustment; counsel patient.
P01611,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: dizziness. Adherence ~0.44. AE: no. CRP 8.4 mg/L; ALT 66 U/L.
P01611,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.61. AE: no.
P01611,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.64. AE: no.
P01611,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: headache. Adherence ~0.64. AE: no. CRP 6.1 mg/L; ALT 64 U/L.
P01611,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.49. AE: no.
P01612,0,neutral,Visit 0: Patient on RX-17A at S006. stable symptoms. Notes: dizziness. Adherence ~0.94. AE: no.
P01612,1,neutral,Visit 1: Patient on RX-17A at S006. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no.
P01612,2,neutral,Visit 2: Patient on RX-17A at S006. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01612,3,neutral,Visit 3: Patient on RX-17A at S006. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01612,4,negative,Visit 4: Patient on RX-17A at S006. reports worsening. Notes: joint pain. Adherence ~0.93. AE: yes. CRP 10.4 mg/L; ALT 23 U/L.
P01612,5,positive,Visit 5: Patient on RX-17A at S006. reports improvement. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01612,6,neutral,Visit 6: Patient on RX-17A at S006. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01613,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: brain fog. Adherence ~0.91. AE: no. CRP 6.6 mg/L; ALT 37 U/L.
P01613,1,negative,Visit 1: Patient on RX-17B at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01613,2,negative,Visit 2: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no. CRP 6.4 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01613,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01613,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no.
P01613,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.96. AE: no. CRP 4.0 mg/L; ALT 39 U/L.
P01613,6,positive,Visit 6: Patient on RX-17B at S016. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P01614,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: no. CRP 10.3 mg/L; ALT 36 U/L.
P01614,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.77. AE: no. CRP 9.6 mg/L; ALT 36 U/L.
P01614,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.71. AE: no.
P01614,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 7.2 mg/L; ALT 32 U/L.
P01614,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.75. AE: no.
P01614,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.79. AE: no.
P01615,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~0.61. AE: no.
P01615,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 6.0 mg/L; ALT 19 U/L.
P01615,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.62. AE: no.
P01615,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P01615,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.55. AE: no. CRP 4.9 mg/L; ALT 24 U/L.
P01615,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.88. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P01615,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.68. AE: no. CRP 4.4 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P01616,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: brain fog. Adherence ~0.93. AE: no. CRP 12.4 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P01616,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no.
P01616,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no. CRP 11.2 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P01616,3,negative,Visit 3: Patient on RX-17A at S002. symptoms persist. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P01616,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.76. AE: no.
P01616,5,neutral,Visit 5: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no.
P01617,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.71. AE: no.
P01617,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.60. AE: no.
P01617,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.59. AE: no.
P01617,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01617,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no.
P01618,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: nausea. Adherence ~0.69. AE: no.
P01618,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01618,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 2.2 mg/L; ALT 68 U/L.
P01618,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no. CRP 2.2 mg/L; ALT 71 U/L.
P01618,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.95. AE: no. CRP 2.1 mg/L; ALT 68 U/L.
P01618,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: joint pain. Adherence ~0.66. AE: no.
P01618,6,neutral,Visit 6: Patient on RX-17B at S019. no major change. Notes: brain fog. Adherence ~0.71. AE: no. CRP 1.6 mg/L; ALT 69 U/L.
P01619,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: joint pain. Adherence ~0.92. AE: yes.
P01619,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.86. AE: yes.
P01619,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.69. AE: no. CRP 8.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01619,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: brain fog. Adherence ~0.88. AE: no.
P01619,4,neutral,Visit 4: Patient on RX-17B at S002. stable symptoms. Notes: headache. Adherence ~0.97. AE: no.
P01619,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no. CRP 6.5 mg/L; ALT 39 U/L.
P01620,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: insomnia. Adherence ~0.87. AE: no. CRP 3.7 mg/L; ALT 16 U/L.
P01620,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.74. AE: no. CRP 3.7 mg/L; ALT 15 U/L.
P01620,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.61. AE: no.
P01620,3,negative,Visit 3: Patient on RX-17B at S013. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: yes.
P01620,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: yes.
P01621,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.45. AE: no.
P01621,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 3.7 mg/L; ALT 39 U/L.
P01621,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.51. AE: no.
P01621,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.55. AE: yes. CRP 3.0 mg/L; ALT 40 U/L.
P01621,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.55. AE: no. CRP 3.4 mg/L; ALT 39 U/L.
P01621,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.67. AE: no. CRP 2.9 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01621,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.58. AE: no.
P01621,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: no.
P01622,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.55. AE: no.
P01622,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: headache. Adherence ~0.53. AE: no.
P01622,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: dizziness. Adherence ~0.47. AE: yes.
P01622,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.53. AE: no.
P01622,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: fatigue. Adherence ~0.34. AE: no.
P01622,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: brain fog. Adherence ~0.49. AE: no. CRP 9.4 mg/L; ALT 44 U/L.
P01622,6,neutral,Visit 6: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.45. AE: yes.
P01623,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.70. AE: no.
P01623,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no. CRP 11.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01623,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no.
P01623,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.98. AE: no. CRP 7.9 mg/L; ALT 26 U/L.
P01623,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. CRP 7.8 mg/L; ALT 31 U/L.
P01624,0,neutral,Visit 0: Patient on RX-17B at S009. no major change. Notes: nausea. Adherence ~0.61. AE: no.
P01624,1,neutral,Visit 1: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.60. AE: no.
P01624,2,neutral,Visit 2: Patient on RX-17B at S009. stable symptoms. Notes: fatigue. Adherence ~0.57. AE: yes.
P01624,3,negative,Visit 3: Patient on RX-17B at S009. feels frustrated. Notes: fatigue. Adherence ~0.45. AE: yes. CRP 4.0 mg/L; ALT 38 U/L.
P01624,4,neutral,Visit 4: Patient on RX-17B at S009. no major change. Notes: insomnia. Adherence ~0.59. AE: yes. CRP 4.5 mg/L; ALT 34 U/L.
P01624,5,neutral,Visit 5: Patient on RX-17B at S009. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: yes.
P01624,6,neutral,Visit 6: Patient on RX-17B at S009. continues regimen. Notes: insomnia. Adherence ~0.59. AE: no.
P01624,7,neutral,Visit 7: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01625,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: headache. Adherence ~0.60. AE: no.
P01625,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.80. AE: no.
P01625,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: fatigue. Adherence ~0.70. AE: no.
P01625,3,negative,Visit 3: Patient on RX-17A at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01625,4,negative,Visit 4: Patient on RX-17A at S019. reports worsening. Notes: brain fog. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P01626,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.78. AE: no.
P01626,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.70. AE: no. CRP 8.8 mg/L; ALT 30 U/L.
P01626,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.80. AE: no. CRP 9.1 mg/L; ALT 30 U/L.
P01626,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01626,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01626,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.68. AE: no.
P01626,6,positive,Visit 6: Patient on RX-17A at S017. feels better overall. Notes: fatigue. Adherence ~0.78. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P01626,7,neutral,Visit 7: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01627,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: fatigue. Adherence ~0.78. AE: no. CRP 12.4 mg/L; ALT 44 U/L.
P01627,1,neutral,Visit 1: Patient on RX-17A at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P01627,2,neutral,Visit 2: Patient on RX-17A at S020. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 8.4 mg/L; ALT 46 U/L.
P01627,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P01627,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: nausea. Adherence ~0.74. AE: no. CRP 8.1 mg/L; ALT 47 U/L.
P01627,5,neutral,Visit 5: Patient on RX-17A at S020. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no.
P01627,6,neutral,Visit 6: Patient on RX-17A at S020. no major change. Notes: joint pain. Adherence ~0.60. AE: no.
P01628,0,neutral,Visit 0: Patient on RX-17B at S006. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no. CRP 8.8 mg/L; ALT 54 U/L.
P01628,1,neutral,Visit 1: Patient on RX-17B at S006. reviewed dosing instructions. Notes: fatigue. Adherence ~0.84. AE: no.
P01628,2,negative,Visit 2: Patient on RX-17B at S006. poor tolerance. Notes: brain fog. Adherence ~0.87. AE: yes.
P01628,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no.
P01628,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no.
P01629,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.79. AE: no.
P01629,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no. CRP 9.1 mg/L; ALT 20 U/L.
P01629,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P01629,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.90. AE: yes.
P01629,4,positive,Visit 4: Patient on RX-17B at S014. tolerating medication well. Notes: headache. Adherence ~0.92. AE: no.
P01629,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.98. AE: yes. CRP 5.2 mg/L; ALT 23 U/L.
P01629,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: insomnia. Adherence ~0.93. AE: no.
P01629,7,positive,Visit 7: Patient on RX-17B at S014. symptoms improving. Notes: insomnia. Adherence ~0.87. AE: no. CRP 4.2 mg/L; ALT 20 U/L.
P01630,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no.
P01630,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~0.87. AE: no. CRP 6.0 mg/L; ALT 25 U/L.
P01630,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01630,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 25 U/L.
P01630,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.84. AE: no.
P01631,0,neutral,Visit 0: Patient on RX-17B at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no. CRP 6.6 mg/L; ALT 19 U/L.
P01631,1,negative,Visit 1: Patient on RX-17B at S008. feels frustrated. Notes: dizziness. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P01631,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: joint pain. Adherence ~0.85. AE: no.
P01631,3,neutral,Visit 3: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01631,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no.
P01631,5,neutral,Visit 5: Patient on RX-17B at S008. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P01631,6,positive,Visit 6: Patient on RX-17B at S008. energy increasing. Notes: insomnia. Adherence ~0.90. AE: no.
P01632,0,neutral,Visit 0: Patient on RX-17A at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01632,1,negative,Visit 1: Patient on RX-17A at S007. increased discomfort. Notes: nausea. Adherence ~0.51. AE: yes. CRP 4.0 mg/L; ALT 61 U/L.
P01632,2,neutral,Visit 2: Patient on RX-17A at S007. no major change. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01632,3,neutral,Visit 3: Patient on RX-17A at S007. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P01632,4,neutral,Visit 4: Patient on RX-17A at S007. follow-up as scheduled. Notes: nausea. Adherence ~0.58. AE: no.
P01633,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.3 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01633,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no.
P01633,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no. CRP 4.7 mg/L; ALT 43 U/L.
P01633,3,neutral,Visit 3: Patient on RX-17A at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.98. AE: no.
P01633,4,negative,Visit 4: Patient on RX-17A at S002. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no.
P01634,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.96. AE: no.
P01634,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01634,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P01634,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no.
P01634,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.77. AE: no. CRP 6.7 mg/L; ALT 16 U/L.
P01635,0,neutral,Visit 0: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.97. AE: no. CRP 8.6 mg/L; ALT 27 U/L.
P01635,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: dizziness. Adherence ~0.69. AE: no. CRP 9.0 mg/L; ALT 28 U/L.
P01635,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01635,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: brain fog. Adherence ~0.78. AE: no.
P01635,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 6.9 mg/L; ALT 31 U/L.
P01635,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~0.61. AE: no. CRP 7.3 mg/L; ALT 31 U/L.
P01635,6,positive,Visit 6: Patient on RX-17A at S016. feels better overall. Notes: nausea. Adherence ~0.92. AE: no.
P01636,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~0.80. AE: no. CRP 13.2 mg/L; ALT 25 U/L.
P01636,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.72. AE: yes. CRP 10.6 mg/L; ALT 29 U/L.
P01636,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.50. AE: no. CRP 10.4 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01636,3,negative,Visit 3: Patient on RX-17B at S015. symptoms persist. Notes: nausea. Adherence ~0.88. AE: no.
P01636,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.82. AE: no.
P01636,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.69. AE: no. CRP 6.8 mg/L; ALT 31 U/L.
P01636,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.56. AE: no. CRP 5.8 mg/L; ALT 29 U/L.
P01637,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: brain fog. Adherence ~0.91. AE: yes.
P01637,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.92. AE: yes.
P01637,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 26 U/L.
P01637,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P01637,4,positive,Visit 4: Patient on RX-17B at S017. energy increasing. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01638,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.52. AE: no.
P01638,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.36. AE: yes. CRP 2.6 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P01638,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.67. AE: no.
P01638,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.57. AE: no. CRP 2.3 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01638,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.54. AE: yes.
P01639,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01639,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.57. AE: no. CRP 5.7 mg/L; ALT 45 U/L.
P01639,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01639,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no.
P01640,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: yes.
P01640,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. CRP 4.6 mg/L; ALT 35 U/L.
P01640,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P01640,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.94. AE: no. CRP 3.3 mg/L; ALT 33 U/L.
P01640,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.83. AE: no.
P01641,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.95. AE: no.
P01641,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: dizziness. Adherence ~0.84. AE: yes.
P01641,2,negative,Visit 2: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~0.81. AE: no.
P01641,3,positive,Visit 3: Patient on RX-17B at S015. feels better overall. Notes: insomnia. Adherence ~0.99. AE: no.
P01641,4,positive,Visit 4: Patient on RX-17B at S015. symptoms improving. Notes: dizziness. Adherence ~0.96. AE: no.
P01641,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: insomnia. Adherence ~0.77. AE: no.
P01642,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.70. AE: no.
P01642,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: headache. Adherence ~0.86. AE: no.
P01642,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.77. AE: no.
P01642,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01642,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no.
P01642,5,positive,Visit 5: Patient on RX-17A at S005. symptoms improving. Notes: fatigue. Adherence ~0.89. AE: no.
P01642,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no.
P01643,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. CRP 14.6 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01643,1,negative,Visit 1: Patient on RX-17A at S020. feels frustrated. Notes: dizziness. Adherence ~0.92. AE: no.
P01643,2,neutral,Visit 2: Patient on RX-17A at S020. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 10.9 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01643,3,neutral,Visit 3: Patient on RX-17A at S020. continues regimen. Notes: nausea. Adherence ~0.98. AE: no.
P01643,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: nausea. Adherence ~0.82. AE: yes.
P01643,5,neutral,Visit 5: Patient on RX-17A at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 10.1 mg/L; ALT 32 U/L.
P01643,6,positive,Visit 6: Patient on RX-17A at S020. tolerating medication well. Notes: headache. Adherence ~0.95. AE: no.
P01643,7,positive,Visit 7: Patient on RX-17A at S020. reports improvement. Notes: headache. Adherence ~0.88. AE: no.
P01644,0,negative,Visit 0: Patient on RX-17A at S018. feels frustrated. Notes: fatigue. Adherence ~0.68. AE: no. CRP 5.6 mg/L; ALT 23 U/L.
P01644,1,neutral,Visit 1: Patient on RX-17A at S018. stable symptoms. Notes: nausea. Adherence ~0.60. AE: no. CRP 4.3 mg/L; ALT 25 U/L.
P01644,2,negative,Visit 2: Patient on RX-17A at S018. increased discomfort. Notes: nausea. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P01644,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.72. AE: no.
P01644,4,negative,Visit 4: Patient on RX-17A at S018. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no.
P01645,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.55. AE: no.
P01645,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P01645,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01645,3,negative,Visit 3: Patient on RX-17A at S012. feels frustrated. Notes: headache. Adherence ~0.65. AE: yes. CRP 15.7 mg/L; ALT 30 U/L.
P01645,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.36. AE: no.
P01645,5,negative,Visit 5: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.67. AE: no. CRP 13.6 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01645,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no.
P01645,7,neutral,Visit 7: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no.
P01646,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.99. AE: no.
P01646,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.95. AE: no.
P01646,2,negative,Visit 2: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.85. AE: no.
P01646,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01646,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.75. AE: no.
P01646,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.79. AE: yes. CRP 6.3 mg/L; ALT 45 U/L.
P01647,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P01647,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 17 U/L.
P01647,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no.
P01647,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.88. AE: no. CRP 3.4 mg/L; ALT 18 U/L.
P01647,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.69. AE: no. CRP 3.3 mg/L; ALT 16 U/L.
P01647,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01647,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.87. AE: no. CRP 2.6 mg/L; ALT 19 U/L.
P01647,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.64. AE: no. CRP 2.4 mg/L; ALT 19 U/L.
P01648,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.70. AE: no. CRP 20.5 mg/L; ALT 24 U/L.
P01648,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01648,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.54. AE: no.
P01648,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.65. AE: no. CRP 16.8 mg/L; ALT 23 U/L.
P01648,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P01648,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01648,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P01648,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.45. AE: no.
P01649,0,negative,Visit 0: Patient on RX-17A at S021. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P01649,1,neutral,Visit 1: Patient on RX-17A at S021. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no.
P01649,2,positive,Visit 2: Patient on RX-17A at S021. feels better overall. Notes: brain fog. Adherence ~1.00. AE: no. CRP 7.1 mg/L; ALT 28 U/L.
P01650,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.68. AE: no.
P01650,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.82. AE: no. CRP 7.5 mg/L; ALT 50 U/L.
P01650,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no.
P01651,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.93. AE: no. CRP 8.2 mg/L; ALT 42 U/L.
P01651,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.0 mg/L; ALT 38 U/L.
P01651,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: no.
P01651,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~0.88. AE: no.
P01651,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.92. AE: no.
P01651,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~0.95. AE: no. CRP 4.3 mg/L; ALT 41 U/L.
P01651,6,positive,Visit 6: Patient on RX-17A at S012. energy increasing. Notes: headache. Adherence ~0.86. AE: no.
P01652,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01652,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: no.
P01652,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no.
P01652,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~0.66. AE: no. CRP 7.2 mg/L; ALT 31 U/L.
P01652,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.57. AE: no.
P01652,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no.
P01652,6,neutral,Visit 6: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P01652,7,neutral,Visit 7: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: yes.
P01653,0,negative,Visit 0: Patient on RX-17B at S006. increased discomfort. Notes: headache. Adherence ~1.00. AE: no. CRP 10.2 mg/L; ALT 32 U/L.
P01653,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: joint pain. Adherence ~0.99. AE: no.
P01653,2,neutral,Visit 2: Patient on RX-17B at S006. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P01653,3,neutral,Visit 3: Patient on RX-17B at S006. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01653,4,positive,Visit 4: Patient on RX-17B at S006. energy increasing. Notes: nausea. Adherence ~0.96. AE: no.
P01653,5,neutral,Visit 5: Patient on RX-17B at S006. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: yes.
P01653,6,neutral,Visit 6: Patient on RX-17B at S006. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: yes.
P01653,7,positive,Visit 7: Patient on RX-17B at S006. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 39 U/L.
P01654,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.73. AE: yes.
P01654,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.99. AE: no. CRP 3.7 mg/L; ALT 29 U/L.
P01654,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: yes.
P01654,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.96. AE: no.
P01654,4,positive,Visit 4: Patient on RX-17B at S004. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01654,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 3.2 mg/L; ALT 34 U/L.
P01655,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: headache. Adherence ~0.48. AE: no. CRP 6.9 mg/L; ALT 42 U/L.
P01655,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.46. AE: no. CRP 5.1 mg/L; ALT 46 U/L.
P01655,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.58. AE: yes. CRP 6.0 mg/L; ALT 50 U/L.
P01655,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.27. AE: no. CRP 5.5 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P01655,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.67. AE: no. CRP 4.5 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P01655,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.55. AE: no. CRP 3.9 mg/L; ALT 45 U/L.
P01655,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.42. AE: yes. Plan: consider dose adjustment; counsel patient.
P01655,7,neutral,Visit 7: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.68. AE: no.
P01656,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: yes.
P01656,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01656,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.98. AE: yes.
P01657,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: no.
P01657,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.67. AE: no.
P01657,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no.
P01657,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P01657,4,negative,Visit 4: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.74. AE: yes.
P01658,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no.
P01658,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.65. AE: no.
P01658,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.71. AE: no. CRP 8.3 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01658,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: no.
P01658,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.53. AE: no. CRP 6.7 mg/L; ALT 19 U/L.
P01658,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no. CRP 6.2 mg/L; ALT 21 U/L.
P01658,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.58. AE: no.
P01658,7,neutral,Visit 7: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P01659,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: headache. Adherence ~0.91. AE: yes. CRP 8.4 mg/L; ALT 24 U/L.
P01659,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 7.0 mg/L; ALT 26 U/L.
P01659,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.76. AE: no.
P01659,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.82. AE: no.
P01659,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no.
P01660,0,negative,Visit 0: Patient on RX-17B at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.90. AE: yes. CRP 5.3 mg/L; ALT 36 U/L.
P01660,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 5.9 mg/L; ALT 33 U/L.
P01660,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.87. AE: no.
P01660,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: no.
P01660,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01660,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P01660,6,positive,Visit 6: Patient on RX-17B at S018. feels better overall. Notes: fatigue. Adherence ~0.85. AE: no.
P01660,7,positive,Visit 7: Patient on RX-17B at S018. energy increasing. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01661,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01661,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01661,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.58. AE: yes.
P01661,3,positive,Visit 3: Patient on RX-17B at S015. energy increasing. Notes: dizziness. Adherence ~0.79. AE: no. CRP 4.4 mg/L; ALT 38 U/L.
P01661,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 3.5 mg/L; ALT 38 U/L.
P01662,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01662,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01662,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.90. AE: no.
P01662,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.93. AE: yes. CRP 2.9 mg/L; ALT 75 U/L.
P01662,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.91. AE: no.
P01662,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.77. AE: no.
P01662,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no.
P01663,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.46. AE: no. CRP 10.1 mg/L; ALT 18 U/L.
P01663,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~0.41. AE: no.
P01663,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.41. AE: no.
P01663,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~0.51. AE: no.
P01663,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.59. AE: no.
P01663,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.48. AE: no.
P01664,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P01664,1,neutral,Visit 1: Patient on RX-17A at S020. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: yes.
P01664,2,negative,Visit 2: Patient on RX-17A at S020. poor tolerance. Notes: insomnia. Adherence ~0.78. AE: no.
P01664,3,neutral,Visit 3: Patient on RX-17A at S020. continues regimen. Notes: headache. Adherence ~0.92. AE: no. CRP 4.4 mg/L; ALT 33 U/L.
P01664,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P01664,5,neutral,Visit 5: Patient on RX-17A at S020. follow-up as scheduled. Notes: dizziness. Adherence ~0.96. AE: no. CRP 3.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01664,6,positive,Visit 6: Patient on RX-17A at S020. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P01664,7,neutral,Visit 7: Patient on RX-17A at S020. no major change. Notes: nausea. Adherence ~0.98. AE: no.
P01665,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no.
P01665,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P01665,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01665,3,positive,Visit 3: Patient on RX-17B at S015. reports improvement. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01665,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.99. AE: no.
P01666,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01666,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.92. AE: yes. Plan: consider dose adjustment; counsel patient.
P01666,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01666,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P01666,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01667,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01667,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 6.9 mg/L; ALT 48 U/L.
P01667,2,neutral,Visit 2: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no. CRP 6.8 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P01667,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01667,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: headache. Adherence ~0.99. AE: yes.
P01668,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.58. AE: no.
P01668,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.51. AE: yes. CRP 6.2 mg/L; ALT 44 U/L.
P01668,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no.
P01668,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.95. AE: no. CRP 5.6 mg/L; ALT 43 U/L.
P01668,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01668,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.83. AE: no.
P01668,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no.
P01668,7,positive,Visit 7: Patient on RX-17B at S014. energy increasing. Notes: brain fog. Adherence ~0.88. AE: no. CRP 3.3 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P01669,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no.
P01669,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: fatigue. Adherence ~0.84. AE: yes.
P01669,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01669,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 3.6 mg/L; ALT 16 U/L.
P01669,4,negative,Visit 4: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.99. AE: yes.
P01669,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P01669,6,positive,Visit 6: Patient on RX-17B at S012. symptoms improving. Notes: brain fog. Adherence ~0.80. AE: no.
P01669,7,positive,Visit 7: Patient on RX-17B at S012. symptoms improving. Notes: insomnia. Adherence ~0.92. AE: no.
P01670,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P01670,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 7.2 mg/L; ALT 56 U/L.
P01670,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no.
P01670,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.59. AE: no. CRP 6.3 mg/L; ALT 56 U/L.
P01670,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.60. AE: yes.
P01671,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.87. AE: yes.
P01671,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.99. AE: no.
P01671,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.91. AE: no.
P01671,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.79. AE: no.
P01671,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 57 U/L.
P01672,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: headache. Adherence ~0.62. AE: no.
P01672,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: joint pain. Adherence ~0.45. AE: no.
P01672,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.49. AE: no. CRP 6.3 mg/L; ALT 35 U/L.
P01672,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no.
P01672,4,negative,Visit 4: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.60. AE: no. CRP 4.3 mg/L; ALT 33 U/L.
P01672,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.52. AE: no.
P01673,0,neutral,Visit 0: Patient on RX-17A at S009. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: no.
P01673,1,neutral,Visit 1: Patient on RX-17A at S009. no major change. Notes: brain fog. Adherence ~0.82. AE: no. CRP 12.1 mg/L; ALT 18 U/L.
P01673,2,negative,Visit 2: Patient on RX-17A at S009. reports worsening. Notes: dizziness. Adherence ~0.93. AE: no. CRP 13.4 mg/L; ALT 18 U/L.
P01673,3,neutral,Visit 3: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.93. AE: yes.
P01673,4,negative,Visit 4: Patient on RX-17A at S009. symptoms persist. Notes: joint pain. Adherence ~0.98. AE: no.
P01673,5,positive,Visit 5: Patient on RX-17A at S009. feels better overall. Notes: nausea. Adherence ~0.88. AE: no. CRP 7.2 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01673,6,neutral,Visit 6: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P01674,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P01674,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01674,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: nausea. Adherence ~0.66. AE: no. CRP 7.7 mg/L; ALT 28 U/L.
P01674,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. CRP 8.0 mg/L; ALT 30 U/L.
P01674,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no.
P01675,0,negative,Visit 0: Patient on RX-17B at S008. symptoms persist. Notes: insomnia. Adherence ~0.71. AE: no.
P01675,1,neutral,Visit 1: Patient on RX-17B at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01675,2,negative,Visit 2: Patient on RX-17B at S008. increased discomfort. Notes: joint pain. Adherence ~0.71. AE: yes.
P01675,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01675,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01676,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01676,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: nausea. Adherence ~0.70. AE: no.
P01676,2,negative,Visit 2: Patient on RX-17A at S019. symptoms persist. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01676,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01676,4,positive,Visit 4: Patient on RX-17A at S019. tolerating medication well. Notes: fatigue. Adherence ~0.86. AE: no. CRP 4.9 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P01676,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.72. AE: no.
P01676,6,positive,Visit 6: Patient on RX-17A at S019. symptoms improving. Notes: joint pain. Adherence ~0.92. AE: no.
P01676,7,neutral,Visit 7: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: yes.
P01677,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.98. AE: yes.
P01677,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.76. AE: yes.
P01677,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01677,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: no. CRP 13.4 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01677,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.93. AE: yes. CRP 10.4 mg/L; ALT 17 U/L.
P01678,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: fatigue. Adherence ~0.79. AE: no.
P01678,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01678,2,negative,Visit 2: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01678,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. CRP 4.3 mg/L; ALT 24 U/L.
P01678,4,negative,Visit 4: Patient on RX-17B at S016. symptoms persist. Notes: brain fog. Adherence ~0.77. AE: yes. CRP 3.9 mg/L; ALT 24 U/L.
P01679,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: insomnia. Adherence ~0.78. AE: no.
P01679,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.72. AE: no.
P01679,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 42 U/L.
P01679,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.51. AE: no. CRP 7.3 mg/L; ALT 45 U/L.
P01679,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.97. AE: no. CRP 5.6 mg/L; ALT 49 U/L.
P01679,5,positive,Visit 5: Patient on RX-17A at S019. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.4 mg/L; ALT 48 U/L.
P01679,6,negative,Visit 6: Patient on RX-17A at S019. poor tolerance. Notes: fatigue. Adherence ~0.80. AE: no.
P01679,7,positive,Visit 7: Patient on RX-17A at S019. energy increasing. Notes: headache. Adherence ~0.81. AE: no. CRP 5.1 mg/L; ALT 46 U/L.
P01680,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P01680,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.74. AE: no. CRP 10.7 mg/L; ALT 51 U/L.
P01680,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01680,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 9.4 mg/L; ALT 48 U/L.
P01680,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 9.3 mg/L; ALT 49 U/L.
P01680,5,negative,Visit 5: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.98. AE: no. CRP 7.1 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P01680,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.9 mg/L; ALT 55 U/L. Plan: consider dose adjustment; counsel patient.
P01681,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.53. AE: no.
P01681,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.39. AE: no.
P01681,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.37. AE: no.
P01681,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.39. AE: no.
P01681,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.54. AE: no. CRP 6.0 mg/L; ALT 39 U/L.
P01681,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.22. AE: no.
P01681,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.25. AE: no.
P01682,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 6.0 mg/L; ALT 46 U/L.
P01682,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.86. AE: no.
P01682,2,positive,Visit 2: Patient on RX-17A at S012. symptoms improving. Notes: fatigue. Adherence ~0.84. AE: no. CRP 4.5 mg/L; ALT 45 U/L.
P01682,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.94. AE: no.
P01682,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.72. AE: no.
P01682,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01683,0,negative,Visit 0: Patient on RX-17A at S006. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no.
P01683,1,neutral,Visit 1: Patient on RX-17A at S006. stable symptoms. Notes: nausea. Adherence ~0.65. AE: no.
P01683,2,negative,Visit 2: Patient on RX-17A at S006. feels frustrated. Notes: insomnia. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P01683,3,neutral,Visit 3: Patient on RX-17A at S006. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: no. CRP 3.5 mg/L; ALT 36 U/L.
P01683,4,neutral,Visit 4: Patient on RX-17A at S006. no major change. Notes: headache. Adherence ~0.61. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P01683,5,neutral,Visit 5: Patient on RX-17A at S006. stable symptoms. Notes: brain fog. Adherence ~0.56. AE: no. CRP 3.2 mg/L; ALT 37 U/L.
P01683,6,neutral,Visit 6: Patient on RX-17A at S006. no major change. Notes: brain fog. Adherence ~0.61. AE: no. CRP 2.8 mg/L; ALT 36 U/L.
P01683,7,neutral,Visit 7: Patient on RX-17A at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P01684,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: fatigue. Adherence ~0.78. AE: no.
P01684,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no. CRP 6.3 mg/L; ALT 40 U/L.
P01684,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.91. AE: no.
P01684,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no.
P01684,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: headache. Adherence ~0.92. AE: no.
P01684,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no. CRP 5.0 mg/L; ALT 50 U/L.
P01685,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.60. AE: no. CRP 9.2 mg/L; ALT 28 U/L.
P01685,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P01685,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.63. AE: yes.
P01685,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P01685,4,positive,Visit 4: Patient on RX-17A at S022. symptoms improving. Notes: nausea. Adherence ~0.83. AE: no.
P01685,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01686,0,neutral,Visit 0: Patient on RX-17A at S011. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no. CRP 16.4 mg/L; ALT 32 U/L.
P01686,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01686,2,positive,Visit 2: Patient on RX-17A at S011. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no. CRP 11.0 mg/L; ALT 36 U/L.
P01686,3,neutral,Visit 3: Patient on RX-17A at S011. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P01686,4,neutral,Visit 4: Patient on RX-17A at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no. CRP 10.6 mg/L; ALT 35 U/L.
P01686,5,positive,Visit 5: Patient on RX-17A at S011. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no.
P01686,6,neutral,Visit 6: Patient on RX-17A at S011. stable symptoms. Notes: nausea. Adherence ~0.79. AE: no.
P01686,7,neutral,Visit 7: Patient on RX-17A at S011. no major change. Notes: nausea. Adherence ~0.86. AE: no.
P01687,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: no.
P01687,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: no.
P01687,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.65. AE: no. CRP 2.5 mg/L; ALT 21 U/L.
P01687,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.62. AE: no. CRP 2.5 mg/L; ALT 18 U/L.
P01687,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no.
P01687,5,negative,Visit 5: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.2 mg/L; ALT 20 U/L.
P01688,0,neutral,Visit 0: Patient on RX-17A at S011. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01688,1,negative,Visit 1: Patient on RX-17A at S011. increased discomfort. Notes: insomnia. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01688,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.47. AE: no.
P01688,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: headache. Adherence ~0.72. AE: no.
P01688,4,positive,Visit 4: Patient on RX-17A at S011. symptoms improving. Notes: dizziness. Adherence ~0.76. AE: no. CRP 14.6 mg/L; ALT 39 U/L.
P01689,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 6.7 mg/L; ALT 20 U/L.
P01689,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.79. AE: no.
P01689,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no.
P01689,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.67. AE: yes. CRP 5.3 mg/L; ALT 20 U/L.
P01689,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.89. AE: no. CRP 5.1 mg/L; ALT 19 U/L.
P01689,5,positive,Visit 5: Patient on RX-17A at S014. symptoms improving. Notes: joint pain. Adherence ~0.89. AE: no.
P01689,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no.
P01690,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01690,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.90. AE: no.
P01690,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.79. AE: no.
P01691,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.97. AE: no.
P01691,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no.
P01691,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: yes.
P01691,3,positive,Visit 3: Patient on RX-17B at S015. energy increasing. Notes: dizziness. Adherence ~0.84. AE: no.
P01691,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no.
P01692,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~0.67. AE: no. CRP 3.0 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01692,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01692,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.33. AE: yes. CRP 2.6 mg/L; ALT 36 U/L.
P01692,3,negative,Visit 3: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.42. AE: no. CRP 2.3 mg/L; ALT 39 U/L.
P01692,4,negative,Visit 4: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.46. AE: yes.
P01692,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.49. AE: yes.
P01692,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.49. AE: no. CRP 1.3 mg/L; ALT 35 U/L.
P01692,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P01693,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.71. AE: yes.
P01693,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.66. AE: no. CRP 2.9 mg/L; ALT 21 U/L.
P01693,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.70. AE: no. CRP 3.3 mg/L; ALT 22 U/L.
P01693,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.50. AE: no.
P01693,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.55. AE: no. CRP 2.5 mg/L; ALT 22 U/L.
P01693,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.57. AE: no. CRP 2.0 mg/L; ALT 22 U/L.
P01693,6,neutral,Visit 6: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.51. AE: no.
P01694,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no.
P01694,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.95. AE: no.
P01694,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P01695,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: fatigue. Adherence ~0.93. AE: no.
P01695,1,neutral,Visit 1: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 8.9 mg/L; ALT 30 U/L.
P01695,2,negative,Visit 2: Patient on RX-17A at S016. reports worsening. Notes: brain fog. Adherence ~0.86. AE: no. CRP 7.8 mg/L; ALT 35 U/L.
P01695,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01695,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: yes.
P01695,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01695,6,positive,Visit 6: Patient on RX-17A at S016. energy increasing. Notes: fatigue. Adherence ~0.94. AE: no.
P01696,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P01696,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~1.00. AE: yes.
P01696,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 6.0 mg/L; ALT 40 U/L.
P01696,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.97. AE: no. CRP 5.8 mg/L; ALT 40 U/L.
P01696,4,positive,Visit 4: Patient on RX-17B at S016. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P01697,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.95. AE: no.
P01697,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~0.63. AE: no. CRP 6.2 mg/L; ALT 40 U/L.
P01697,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.51. AE: yes.
P01697,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01697,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P01698,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no.
P01698,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no.
P01698,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 9.8 mg/L; ALT 22 U/L.
P01698,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.88. AE: yes.
P01698,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: yes.
P01699,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: no.
P01699,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 6.6 mg/L; ALT 18 U/L.
P01699,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no.
P01699,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01699,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no.
P01699,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.5 mg/L; ALT 18 U/L.
P01699,6,positive,Visit 6: Patient on RX-17A at S013. symptoms improving. Notes: nausea. Adherence ~0.78. AE: no.
P01699,7,neutral,Visit 7: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: no. CRP 4.1 mg/L; ALT 18 U/L.
P01700,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: joint pain. Adherence ~0.99. AE: no.
P01700,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.73. AE: yes.
P01700,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: no.
P01700,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.98. AE: no.
P01700,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no. CRP 6.1 mg/L; ALT 23 U/L.
P01700,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no. CRP 5.9 mg/L; ALT 21 U/L.
P01700,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no.
P01700,7,neutral,Visit 7: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01701,0,negative,Visit 0: Patient on RX-17A at S006. poor tolerance. Notes: nausea. Adherence ~0.81. AE: no.
P01701,1,neutral,Visit 1: Patient on RX-17A at S006. follow-up as scheduled. Notes: fatigue. Adherence ~0.45. AE: no.
P01701,2,neutral,Visit 2: Patient on RX-17A at S006. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no.
P01701,3,neutral,Visit 3: Patient on RX-17A at S006. no major change. Notes: dizziness. Adherence ~0.85. AE: no.
P01701,4,negative,Visit 4: Patient on RX-17A at S006. reports worsening. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 30.0 mg/L; ALT 23 U/L.
P01701,5,neutral,Visit 5: Patient on RX-17A at S006. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01701,6,neutral,Visit 6: Patient on RX-17A at S006. reviewed dosing instructions. Notes: joint pain. Adherence ~0.57. AE: no.
P01702,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.59. AE: no. CRP 6.8 mg/L; ALT 51 U/L.
P01702,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.61. AE: yes.
P01702,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.57. AE: no.
P01702,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.68. AE: no.
P01702,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.78. AE: no.
P01702,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01702,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no. CRP 3.7 mg/L; ALT 52 U/L.
P01703,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 48 U/L.
P01703,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01703,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: no. CRP 3.7 mg/L; ALT 49 U/L.
P01703,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01703,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.63. AE: no. CRP 3.4 mg/L; ALT 49 U/L.
P01704,0,negative,Visit 0: Patient on RX-17A at S008. poor tolerance. Notes: insomnia. Adherence ~0.84. AE: no. CRP 10.9 mg/L; ALT 21 U/L.
P01704,1,negative,Visit 1: Patient on RX-17A at S008. poor tolerance. Notes: fatigue. Adherence ~0.75. AE: no. CRP 9.6 mg/L; ALT 23 U/L.
P01704,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P01704,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: fatigue. Adherence ~0.79. AE: no. CRP 7.8 mg/L; ALT 19 U/L.
P01704,4,positive,Visit 4: Patient on RX-17A at S008. feels better overall. Notes: nausea. Adherence ~0.99. AE: no.
P01704,5,negative,Visit 5: Patient on RX-17A at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 6.5 mg/L; ALT 21 U/L.
P01704,6,neutral,Visit 6: Patient on RX-17A at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no.
P01705,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.82. AE: no.
P01705,1,positive,Visit 1: Patient on RX-17B at S018. reports improvement. Notes: dizziness. Adherence ~0.99. AE: no. CRP 9.6 mg/L; ALT 59 U/L.
P01705,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 9.9 mg/L; ALT 57 U/L.
P01705,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no. CRP 8.4 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P01705,4,positive,Visit 4: Patient on RX-17B at S018. energy increasing. Notes: brain fog. Adherence ~1.00. AE: no.
P01706,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.81. AE: no.
P01706,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.86. AE: yes.
P01706,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01706,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.88. AE: no.
P01707,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.76. AE: yes. CRP 9.3 mg/L; ALT 19 U/L.
P01707,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: yes.
P01707,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no. CRP 8.2 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01707,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.55. AE: no.
P01707,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no. CRP 5.8 mg/L; ALT 17 U/L.
P01708,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.65. AE: no. CRP 18.7 mg/L; ALT 20 U/L.
P01708,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.63. AE: no. CRP 12.6 mg/L; ALT 22 U/L.
P01708,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no.
P01708,3,negative,Visit 3: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.66. AE: yes. Plan: consider dose adjustment; counsel patient.
P01708,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.59. AE: yes. CRP 11.6 mg/L; ALT 23 U/L.
P01708,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 8.3 mg/L; ALT 22 U/L.
P01709,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01709,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P01709,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01709,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.97. AE: no. CRP 13.0 mg/L; ALT 19 U/L.
P01709,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.79. AE: no.
P01709,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P01709,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.93. AE: no. CRP 7.7 mg/L; ALT 18 U/L.
P01709,7,positive,Visit 7: Patient on RX-17A at S014. symptoms improving. Notes: headache. Adherence ~0.84. AE: no.
P01710,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no.
P01710,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.60. AE: no.
P01710,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.86. AE: no.
P01710,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01710,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: yes.
P01710,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: brain fog. Adherence ~0.82. AE: no.
P01710,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01711,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no.
P01711,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.89. AE: no.
P01711,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.87. AE: no.
P01711,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P01711,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no.
P01711,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no. CRP 3.7 mg/L; ALT 31 U/L.
P01712,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.68. AE: no.
P01712,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no. CRP 8.3 mg/L; ALT 31 U/L.
P01712,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no. CRP 8.1 mg/L; ALT 35 U/L.
P01712,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.60. AE: no.
P01712,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.61. AE: no.
P01712,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no.
P01713,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.66. AE: no.
P01713,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.59. AE: no.
P01713,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: yes.
P01713,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.84. AE: no. CRP 4.3 mg/L; ALT 15 U/L.
P01714,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no. CRP 12.4 mg/L; ALT 19 U/L.
P01714,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01714,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.73. AE: no. CRP 10.1 mg/L; ALT 20 U/L.
P01714,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: yes. CRP 8.8 mg/L; ALT 18 U/L.
P01714,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.90. AE: no.
P01714,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no. CRP 6.4 mg/L; ALT 18 U/L.
P01714,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: yes.
P01714,7,neutral,Visit 7: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01715,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no.
P01715,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.81. AE: no.
P01715,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no.
P01715,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.73. AE: no. CRP 7.0 mg/L; ALT 36 U/L.
P01715,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.71. AE: no. CRP 6.7 mg/L; ALT 32 U/L.
P01715,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01716,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01716,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.91. AE: yes.
P01716,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no. CRP 28.0 mg/L; ALT 38 U/L.
P01716,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no. CRP 23.1 mg/L; ALT 39 U/L.
P01716,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: yes.
P01717,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.67. AE: yes. CRP 16.2 mg/L; ALT 16 U/L.
P01717,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.79. AE: no.
P01717,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.62. AE: no.
P01717,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.66. AE: no.
P01717,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.63. AE: no.
P01717,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: yes.
P01718,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~1.00. AE: no.
P01718,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P01718,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.85. AE: no. CRP 3.1 mg/L; ALT 21 U/L.
P01718,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no.
P01718,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 2.9 mg/L; ALT 20 U/L.
P01718,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no.
P01719,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.5 mg/L; ALT 44 U/L.
P01719,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. CRP 5.1 mg/L; ALT 42 U/L.
P01719,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no.
P01719,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01719,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: joint pain. Adherence ~0.87. AE: no. CRP 4.0 mg/L; ALT 47 U/L.
P01719,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.88. AE: no. CRP 3.1 mg/L; ALT 45 U/L.
P01719,6,positive,Visit 6: Patient on RX-17B at S022. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 3.0 mg/L; ALT 48 U/L.
P01720,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.83. AE: no.
P01720,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: yes.
P01720,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.97. AE: no.
P01720,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.87. AE: no. CRP 1.9 mg/L; ALT 23 U/L.
P01720,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: yes.
P01720,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: brain fog. Adherence ~0.84. AE: no.
P01720,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: insomnia. Adherence ~0.89. AE: no. CRP 1.4 mg/L; ALT 18 U/L.
P01721,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 2.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01721,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.58. AE: no. CRP 2.3 mg/L; ALT 32 U/L.
P01721,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.88. AE: no. CRP 2.3 mg/L; ALT 31 U/L.
P01721,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.84. AE: yes.
P01721,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.77. AE: no. CRP 1.7 mg/L; ALT 34 U/L.
P01722,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P01722,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.81. AE: no.
P01722,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.68. AE: no.
P01722,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: no.
P01722,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.85. AE: no.
P01722,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.85. AE: no. CRP 5.5 mg/L; ALT 18 U/L.
P01722,6,neutral,Visit 6: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: no. CRP 4.4 mg/L; ALT 20 U/L.
P01723,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.70. AE: yes. CRP 4.4 mg/L; ALT 42 U/L.
P01723,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 4.0 mg/L; ALT 44 U/L.
P01723,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.61. AE: no. CRP 3.3 mg/L; ALT 44 U/L.
P01723,3,positive,Visit 3: Patient on RX-17B at S014. energy increasing. Notes: brain fog. Adherence ~0.83. AE: no.
P01723,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.70. AE: no.
P01723,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: yes.
P01724,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: brain fog. Adherence ~0.79. AE: no.
P01724,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01724,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.66. AE: no.
P01724,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. CRP 13.8 mg/L; ALT 16 U/L.
P01724,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.77. AE: no. CRP 11.1 mg/L; ALT 15 U/L.
P01724,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no.
P01725,0,negative,Visit 0: Patient on RX-17B at S006. reports worsening. Notes: joint pain. Adherence ~0.88. AE: no. CRP 13.7 mg/L; ALT 28 U/L.
P01725,1,negative,Visit 1: Patient on RX-17B at S006. symptoms persist. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01725,2,neutral,Visit 2: Patient on RX-17B at S006. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P01725,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01725,4,neutral,Visit 4: Patient on RX-17B at S006. no major change. Notes: brain fog. Adherence ~0.79. AE: no. CRP 9.2 mg/L; ALT 28 U/L.
P01726,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.77. AE: no. CRP 6.8 mg/L; ALT 39 U/L.
P01726,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.71. AE: no. CRP 6.3 mg/L; ALT 45 U/L.
P01726,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.59. AE: no. CRP 5.8 mg/L; ALT 43 U/L.
P01726,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no. CRP 5.0 mg/L; ALT 46 U/L.
P01726,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01726,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no.
P01726,6,positive,Visit 6: Patient on RX-17A at S004. feels better overall. Notes: dizziness. Adherence ~0.77. AE: no.
P01727,0,negative,Visit 0: Patient on RX-17A at S001. poor tolerance. Notes: abdominal discomfort. Adherence ~0.37. AE: no.
P01727,1,negative,Visit 1: Patient on RX-17A at S001. reports worsening. Notes: fatigue. Adherence ~0.51. AE: no.
P01727,2,neutral,Visit 2: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01727,3,negative,Visit 3: Patient on RX-17A at S001. feels frustrated. Notes: joint pain. Adherence ~0.75. AE: no.
P01727,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: headache. Adherence ~0.59. AE: yes.
P01727,5,neutral,Visit 5: Patient on RX-17A at S001. stable symptoms. Notes: joint pain. Adherence ~0.50. AE: no.
P01727,6,neutral,Visit 6: Patient on RX-17A at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01727,7,neutral,Visit 7: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.61. AE: no. CRP 3.4 mg/L; ALT 40 U/L.
P01728,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: dizziness. Adherence ~0.78. AE: no. CRP 16.1 mg/L; ALT 24 U/L.
P01728,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: no.
P01728,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: headache. Adherence ~0.89. AE: yes.
P01728,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no.
P01728,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.95. AE: yes.
P01728,5,negative,Visit 5: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.85. AE: no.
P01728,6,neutral,Visit 6: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.87. AE: no. CRP 8.7 mg/L; ALT 25 U/L.
P01728,7,positive,Visit 7: Patient on RX-17A at S013. reports improvement. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01729,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.51. AE: no. CRP 18.0 mg/L; ALT 23 U/L.
P01729,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.42. AE: no. CRP 15.2 mg/L; ALT 24 U/L.
P01729,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P01729,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: no. CRP 14.5 mg/L; ALT 25 U/L.
P01729,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.55. AE: no.
P01729,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 11.5 mg/L; ALT 26 U/L.
P01729,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.55. AE: no. CRP 12.6 mg/L; ALT 25 U/L.
P01729,7,neutral,Visit 7: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.70. AE: no.
P01730,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.77. AE: yes. Plan: consider dose adjustment; counsel patient.
P01730,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01730,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.80. AE: no. CRP 3.6 mg/L; ALT 27 U/L.
P01730,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: yes. CRP 3.1 mg/L; ALT 29 U/L.
P01730,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no.
P01731,0,neutral,Visit 0: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.98. AE: no.
P01731,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: nausea. Adherence ~0.76. AE: no. CRP 4.0 mg/L; ALT 20 U/L.
P01731,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.75. AE: yes. CRP 3.7 mg/L; ALT 20 U/L.
P01731,3,positive,Visit 3: Patient on RX-17A at S002. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no.
P01731,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.78. AE: no. CRP 3.0 mg/L; ALT 17 U/L.
P01732,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: headache. Adherence ~0.63. AE: no.
P01732,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.92. AE: yes. Plan: consider dose adjustment; counsel patient.
P01732,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: fatigue. Adherence ~0.79. AE: no. CRP 5.5 mg/L; ALT 31 U/L.
P01732,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no.
P01732,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01732,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: dizziness. Adherence ~0.76. AE: no.
P01732,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01733,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P01733,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.84. AE: no. CRP 7.5 mg/L; ALT 29 U/L.
P01733,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: insomnia. Adherence ~0.89. AE: no.
P01733,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01733,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no.
P01734,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no. CRP 4.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01734,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.58. AE: no. CRP 4.1 mg/L; ALT 26 U/L.
P01734,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~0.81. AE: no.
P01734,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.62. AE: no.
P01734,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.54. AE: no.
P01735,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no.
P01735,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01735,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no. CRP 8.4 mg/L; ALT 43 U/L.
P01735,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: yes.
P01735,4,positive,Visit 4: Patient on RX-17B at S005. energy increasing. Notes: joint pain. Adherence ~0.86. AE: no. CRP 7.0 mg/L; ALT 47 U/L.
P01735,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P01735,6,positive,Visit 6: Patient on RX-17B at S005. energy increasing. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 5.0 mg/L; ALT 49 U/L.
P01736,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.83. AE: no.
P01736,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.92. AE: no. CRP 21.3 mg/L; ALT 22 U/L.
P01736,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.93. AE: no. CRP 19.1 mg/L; ALT 22 U/L.
P01736,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01736,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no.
P01736,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.94. AE: no.
P01736,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: dizziness. Adherence ~0.79. AE: no. CRP 9.7 mg/L; ALT 23 U/L.
P01736,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.71. AE: no.
P01737,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.67. AE: no.
P01737,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 3.6 mg/L; ALT 15 U/L.
P01737,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.68. AE: no. CRP 3.0 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P01737,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: no.
P01737,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.59. AE: no.
P01738,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: headache. Adherence ~0.97. AE: no.
P01738,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.65. AE: no.
P01738,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no.
P01738,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P01738,4,positive,Visit 4: Patient on RX-17A at S015. symptoms improving. Notes: insomnia. Adherence ~0.78. AE: no.
P01738,5,positive,Visit 5: Patient on RX-17A at S015. symptoms improving. Notes: dizziness. Adherence ~0.96. AE: no. CRP 4.1 mg/L; ALT 28 U/L.
P01738,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01738,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no. CRP 3.4 mg/L; ALT 27 U/L.
P01739,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.47. AE: no.
P01739,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: joint pain. Adherence ~0.58. AE: no.
P01739,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.81. AE: no.
P01739,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.39. AE: no.
P01739,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.46. AE: yes.
P01739,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.31. AE: no.
P01739,6,negative,Visit 6: Patient on RX-17A at S013. symptoms persist. Notes: headache. Adherence ~0.53. AE: no.
P01739,7,neutral,Visit 7: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no.
P01740,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.52. AE: no.
P01740,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no. CRP 3.2 mg/L; ALT 29 U/L.
P01740,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.72. AE: no. CRP 4.2 mg/L; ALT 32 U/L.
P01740,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no. CRP 3.8 mg/L; ALT 32 U/L.
P01740,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.66. AE: no.
P01741,0,neutral,Visit 0: Patient on RX-17B at S007. stable symptoms. Notes: joint pain. Adherence ~0.66. AE: no.
P01741,1,negative,Visit 1: Patient on RX-17B at S007. symptoms persist. Notes: brain fog. Adherence ~0.70. AE: yes.
P01741,2,neutral,Visit 2: Patient on RX-17B at S007. follow-up as scheduled. Notes: joint pain. Adherence ~0.55. AE: no. CRP 5.3 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01741,3,neutral,Visit 3: Patient on RX-17B at S007. continues regimen. Notes: joint pain. Adherence ~0.65. AE: yes. CRP 5.6 mg/L; ALT 33 U/L.
P01741,4,negative,Visit 4: Patient on RX-17B at S007. reports worsening. Notes: headache. Adherence ~0.69. AE: yes. CRP 4.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01741,5,positive,Visit 5: Patient on RX-17B at S007. energy increasing. Notes: joint pain. Adherence ~0.87. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P01742,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P01742,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01742,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 19 U/L.
P01742,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 22 U/L.
P01742,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.97. AE: no.
P01742,5,positive,Visit 5: Patient on RX-17B at S022. symptoms improving. Notes: joint pain. Adherence ~0.91. AE: no.
P01742,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: dizziness. Adherence ~0.92. AE: no.
P01742,7,positive,Visit 7: Patient on RX-17B at S022. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P01743,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.74. AE: yes. Plan: consider dose adjustment; counsel patient.
P01743,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.84. AE: no. CRP 9.4 mg/L; ALT 22 U/L.
P01743,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: no.
P01743,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.67. AE: yes.
P01743,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 6.5 mg/L; ALT 23 U/L.
P01744,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01744,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.57. AE: no.
P01744,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: dizziness. Adherence ~0.65. AE: yes.
P01744,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.67. AE: no.
P01745,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01745,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01745,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: yes.
P01745,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.74. AE: no.
P01745,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no. CRP 6.7 mg/L; ALT 25 U/L.
P01746,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 6.2 mg/L; ALT 42 U/L.
P01746,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~0.38. AE: yes. Plan: consider dose adjustment; counsel patient.
P01746,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.69. AE: no. CRP 4.9 mg/L; ALT 45 U/L.
P01746,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: no.
P01746,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.55. AE: no.
P01747,0,negative,Visit 0: Patient on RX-17B at S007. reports worsening. Notes: brain fog. Adherence ~0.53. AE: no. CRP 5.3 mg/L; ALT 36 U/L.
P01747,1,neutral,Visit 1: Patient on RX-17B at S007. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no.
P01747,2,neutral,Visit 2: Patient on RX-17B at S007. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no.
P01747,3,neutral,Visit 3: Patient on RX-17B at S007. no major change. Notes: headache. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01747,4,neutral,Visit 4: Patient on RX-17B at S007. stable symptoms. Notes: nausea. Adherence ~0.64. AE: yes.
P01748,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 6.5 mg/L; ALT 27 U/L.
P01748,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: no. CRP 4.9 mg/L; ALT 26 U/L.
P01748,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01748,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P01748,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P01748,5,negative,Visit 5: Patient on RX-17A at S011. symptoms persist. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01748,6,neutral,Visit 6: Patient on RX-17A at S011. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: yes.
P01749,0,neutral,Visit 0: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01749,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no.
P01749,2,negative,Visit 2: Patient on RX-17B at S008. reports worsening. Notes: insomnia. Adherence ~0.48. AE: no.
P01749,3,neutral,Visit 3: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.47. AE: yes.
P01749,4,neutral,Visit 4: Patient on RX-17B at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.65. AE: no.
P01749,5,neutral,Visit 5: Patient on RX-17B at S008. stable symptoms. Notes: brain fog. Adherence ~0.53. AE: no. CRP 3.8 mg/L; ALT 48 U/L.
P01749,6,neutral,Visit 6: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P01750,0,neutral,Visit 0: Patient on RX-17A at S009. no major change. Notes: brain fog. Adherence ~0.57. AE: no.
P01750,1,negative,Visit 1: Patient on RX-17A at S009. increased discomfort. Notes: abdominal discomfort. Adherence ~0.56. AE: yes.
P01750,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P01750,3,negative,Visit 3: Patient on RX-17A at S009. poor tolerance. Notes: headache. Adherence ~0.71. AE: yes. CRP 6.6 mg/L; ALT 42 U/L.
P01750,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: nausea. Adherence ~0.53. AE: no. CRP 5.9 mg/L; ALT 36 U/L.
P01751,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.87. AE: yes. CRP 2.3 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01751,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: insomnia. Adherence ~0.87. AE: no. CRP 2.3 mg/L; ALT 20 U/L.
P01751,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.77. AE: no. CRP 2.0 mg/L; ALT 18 U/L.
P01751,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.72. AE: no. CRP 1.8 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01751,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no.
P01751,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.69. AE: no. CRP 1.4 mg/L; ALT 22 U/L.
P01752,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no. CRP 8.2 mg/L; ALT 9 U/L.
P01752,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.55. AE: yes. CRP 7.5 mg/L; ALT 11 U/L. Plan: consider dose adjustment; counsel patient.
P01752,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: no.
P01752,3,negative,Visit 3: Patient on RX-17B at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01752,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P01752,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.72. AE: no.
P01752,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.71. AE: no.
P01753,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P01753,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01753,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.99. AE: no. CRP 4.0 mg/L; ALT 20 U/L.
P01753,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.82. AE: no.
P01753,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01754,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.93. AE: no.
P01754,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no.
P01754,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 4.9 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01754,3,positive,Visit 3: Patient on RX-17B at S014. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.1 mg/L; ALT 39 U/L.
P01754,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01754,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01755,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.90. AE: no.
P01755,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P01755,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: no. CRP 2.2 mg/L; ALT 40 U/L.
P01755,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.98. AE: no.
P01755,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01755,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no. CRP 2.1 mg/L; ALT 46 U/L.
P01755,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.81. AE: no.
P01755,7,positive,Visit 7: Patient on RX-17A at S015. energy increasing. Notes: insomnia. Adherence ~0.92. AE: no. CRP 1.8 mg/L; ALT 46 U/L.
P01756,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: joint pain. Adherence ~0.81. AE: no.
P01756,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.53. AE: no.
P01756,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: nausea. Adherence ~0.71. AE: yes.
P01756,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P01756,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no. CRP 4.0 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P01756,5,neutral,Visit 5: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.67. AE: no.
P01756,6,neutral,Visit 6: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no.
P01756,7,neutral,Visit 7: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no. CRP 3.4 mg/L; ALT 18 U/L.
P01757,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no. CRP 7.0 mg/L; ALT 43 U/L.
P01757,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: headache. Adherence ~0.71. AE: no.
P01757,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.62. AE: no.
P01757,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.61. AE: no.
P01757,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.57. AE: no.
P01757,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.70. AE: no.
P01757,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: yes. CRP 5.6 mg/L; ALT 38 U/L.
P01757,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 4.3 mg/L; ALT 44 U/L.
P01758,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 9.3 mg/L; ALT 36 U/L.
P01758,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no.
P01758,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01758,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no.
P01758,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P01758,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01758,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.66. AE: no. CRP 4.7 mg/L; ALT 39 U/L.
P01759,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01759,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.90. AE: yes.
P01759,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.87. AE: no.
P01759,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01759,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P01759,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 2.5 mg/L; ALT 48 U/L.
P01760,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: joint pain. Adherence ~0.47. AE: no.
P01760,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.31. AE: no. CRP 8.6 mg/L; ALT 42 U/L.
P01760,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.44. AE: no. CRP 8.3 mg/L; ALT 41 U/L.
P01761,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.64. AE: no.
P01761,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.46. AE: no.
P01761,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P01761,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.59. AE: no.
P01761,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.58. AE: no.
P01761,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.43. AE: no. CRP 8.8 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P01761,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.54. AE: no. CRP 8.7 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P01761,7,neutral,Visit 7: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.57. AE: yes.
P01762,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: yes. CRP 5.5 mg/L; ALT 36 U/L.
P01762,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no.
P01762,2,positive,Visit 2: Patient on RX-17A at S013. energy increasing. Notes: dizziness. Adherence ~0.95. AE: no.
P01762,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.92. AE: no. CRP 4.1 mg/L; ALT 35 U/L.
P01762,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no. CRP 3.5 mg/L; ALT 39 U/L.
P01763,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.50. AE: no. CRP 7.4 mg/L; ALT 34 U/L.
P01763,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.59. AE: no.
P01763,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P01763,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.40. AE: no. Plan: consider dose adjustment; counsel patient.
P01763,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.23. AE: no. CRP 6.5 mg/L; ALT 36 U/L.
P01763,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.28. AE: no. CRP 5.1 mg/L; ALT 37 U/L.
P01763,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.49. AE: no.
P01763,7,neutral,Visit 7: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.28. AE: no.
P01764,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.63. AE: no.
P01764,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.69. AE: no. CRP 2.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01764,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.53. AE: no.
P01764,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.55. AE: no. CRP 2.1 mg/L; ALT 28 U/L.
P01764,4,negative,Visit 4: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P01764,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.58. AE: no.
P01764,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.63. AE: no.
P01765,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.76. AE: no.
P01765,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P01765,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~0.64. AE: no.
P01765,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no. CRP 3.1 mg/L; ALT 39 U/L.
P01765,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P01765,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.57. AE: yes. CRP 2.5 mg/L; ALT 45 U/L.
P01766,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: dizziness. Adherence ~0.57. AE: no.
P01766,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: headache. Adherence ~0.53. AE: no.
P01766,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.71. AE: no. CRP 7.4 mg/L; ALT 20 U/L.
P01766,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: headache. Adherence ~0.70. AE: no. CRP 6.8 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P01766,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.55. AE: no.
P01766,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.42. AE: no. CRP 6.0 mg/L; ALT 20 U/L.
P01766,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P01767,0,neutral,Visit 0: Patient on RX-17A at S009. continues regimen. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01767,1,negative,Visit 1: Patient on RX-17A at S009. feels frustrated. Notes: insomnia. Adherence ~0.55. AE: no.
P01767,2,neutral,Visit 2: Patient on RX-17A at S009. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: yes. CRP 9.7 mg/L; ALT 29 U/L.
P01767,3,negative,Visit 3: Patient on RX-17A at S009. increased discomfort. Notes: insomnia. Adherence ~0.57. AE: no. CRP 9.1 mg/L; ALT 30 U/L.
P01767,4,neutral,Visit 4: Patient on RX-17A at S009. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01767,5,neutral,Visit 5: Patient on RX-17A at S009. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01768,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no.
P01768,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P01768,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P01768,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.76. AE: yes.
P01768,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P01768,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.88. AE: no.
P01768,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.92. AE: no.
P01769,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P01769,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01769,2,positive,Visit 2: Patient on RX-17B at S014. feels better overall. Notes: nausea. Adherence ~0.85. AE: no.
P01769,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01770,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.53. AE: no.
P01770,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.63. AE: yes. CRP 7.5 mg/L; ALT 28 U/L.
P01770,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.60. AE: no. CRP 7.5 mg/L; ALT 27 U/L.
P01770,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.54. AE: no.
P01770,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 7.0 mg/L; ALT 30 U/L.
P01771,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.93. AE: no.
P01771,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no.
P01771,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.74. AE: no. CRP 2.9 mg/L; ALT 45 U/L.
P01771,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 2.6 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01771,4,positive,Visit 4: Patient on RX-17B at S014. tolerating medication well. Notes: headache. Adherence ~0.77. AE: no.
P01771,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~0.93. AE: no. CRP 2.2 mg/L; ALT 45 U/L.
P01771,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P01772,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.89. AE: no.
P01772,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.98. AE: no.
P01772,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: yes.
P01772,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no. CRP 10.3 mg/L; ALT 30 U/L.
P01772,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no.
P01772,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. CRP 8.4 mg/L; ALT 29 U/L.
P01772,6,positive,Visit 6: Patient on RX-17A at S015. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 30 U/L.
P01773,0,neutral,Visit 0: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no. CRP 3.2 mg/L; ALT 40 U/L.
P01773,1,negative,Visit 1: Patient on RX-17B at S013. feels frustrated. Notes: headache. Adherence ~0.52. AE: no.
P01773,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: insomnia. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01773,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.47. AE: no.
P01773,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.52. AE: yes.
P01773,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 2.2 mg/L; ALT 47 U/L.
P01773,6,neutral,Visit 6: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P01774,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.53. AE: yes.
P01774,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.80. AE: no. CRP 7.6 mg/L; ALT 22 U/L.
P01774,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P01774,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.36. AE: no.
P01774,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.47. AE: no.
P01774,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01774,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.70. AE: no.
P01775,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.76. AE: yes. CRP 4.5 mg/L; ALT 38 U/L.
P01775,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no. CRP 4.7 mg/L; ALT 38 U/L.
P01775,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no. CRP 3.4 mg/L; ALT 40 U/L.
P01775,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 3.8 mg/L; ALT 36 U/L.
P01775,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01776,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.67. AE: no.
P01776,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: insomnia. Adherence ~0.77. AE: no. CRP 3.6 mg/L; ALT 29 U/L.
P01776,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.97. AE: no.
P01776,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01776,4,negative,Visit 4: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.83. AE: no. CRP 2.7 mg/L; ALT 30 U/L.
P01776,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.92. AE: no.
P01776,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01776,7,neutral,Visit 7: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.57. AE: no.
P01777,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.58. AE: no.
P01777,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P01777,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.64. AE: no.
P01777,3,negative,Visit 3: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.62. AE: no.
P01778,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: insomnia. Adherence ~0.89. AE: no.
P01778,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.56. AE: no.
P01778,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no.
P01778,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.67. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P01778,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no.
P01779,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. CRP 17.5 mg/L; ALT 45 U/L.
P01779,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.54. AE: no. CRP 16.4 mg/L; ALT 46 U/L.
P01779,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01779,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P01779,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no.
P01779,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P01779,6,neutral,Visit 6: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01779,7,neutral,Visit 7: Patient on RX-17B at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.61. AE: no. CRP 7.3 mg/L; ALT 46 U/L.
P01780,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.95. AE: yes.
P01780,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.60. AE: no. CRP 4.4 mg/L; ALT 23 U/L.
P01780,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.79. AE: no. CRP 3.8 mg/L; ALT 24 U/L.
P01780,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: no.
P01780,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P01780,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: insomnia. Adherence ~0.78. AE: no.
P01780,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: headache. Adherence ~0.81. AE: no.
P01781,0,negative,Visit 0: Patient on RX-17A at S007. reports worsening. Notes: fatigue. Adherence ~0.69. AE: no.
P01781,1,negative,Visit 1: Patient on RX-17A at S007. feels frustrated. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01781,2,neutral,Visit 2: Patient on RX-17A at S007. no major change. Notes: fatigue. Adherence ~0.66. AE: no. CRP 2.7 mg/L; ALT 18 U/L.
P01782,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.97. AE: no.
P01782,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: insomnia. Adherence ~0.81. AE: no.
P01782,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01783,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.69. AE: no.
P01783,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01783,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.80. AE: no. CRP 29.7 mg/L; ALT 19 U/L.
P01783,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01783,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.59. AE: no.
P01783,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P01784,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no.
P01784,1,neutral,Visit 1: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.90. AE: no.
P01784,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.77. AE: no.
P01784,3,negative,Visit 3: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.70. AE: no.
P01784,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 9.9 mg/L; ALT 61 U/L.
P01784,5,neutral,Visit 5: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.55. AE: no.
P01785,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.80. AE: no. CRP 11.9 mg/L; ALT 50 U/L.
P01785,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.68. AE: no.
P01785,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.93. AE: no.
P01785,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 55 U/L.
P01785,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 55 U/L. Plan: consider dose adjustment; counsel patient.
P01785,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P01786,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.98. AE: no.
P01786,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~0.90. AE: no. CRP 10.2 mg/L; ALT 47 U/L.
P01786,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P01786,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.84. AE: no.
P01786,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.99. AE: no. CRP 8.3 mg/L; ALT 43 U/L.
P01786,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01787,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P01787,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P01787,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no.
P01787,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.97. AE: no.
P01787,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P01788,0,negative,Visit 0: Patient on RX-17B at S011. increased discomfort. Notes: fatigue. Adherence ~0.61. AE: no.
P01788,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 30.2 mg/L; ALT 53 U/L.
P01788,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P01788,3,neutral,Visit 3: Patient on RX-17B at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no.
P01788,4,neutral,Visit 4: Patient on RX-17B at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.57. AE: no.
P01789,0,negative,Visit 0: Patient on RX-17B at S003. feels frustrated. Notes: nausea. Adherence ~0.82. AE: no.
P01789,1,negative,Visit 1: Patient on RX-17B at S003. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 8.9 mg/L; ALT 47 U/L.
P01789,2,negative,Visit 2: Patient on RX-17B at S003. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 8.9 mg/L; ALT 52 U/L.
P01789,3,neutral,Visit 3: Patient on RX-17B at S003. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P01789,4,neutral,Visit 4: Patient on RX-17B at S003. stable symptoms. Notes: insomnia. Adherence ~0.80. AE: no.
P01790,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: nausea. Adherence ~0.88. AE: no.
P01790,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01790,2,neutral,Visit 2: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no.
P01790,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01790,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P01790,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: insomnia. Adherence ~0.87. AE: no. CRP 5.8 mg/L; ALT 28 U/L.
P01790,6,neutral,Visit 6: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: yes.
P01790,7,positive,Visit 7: Patient on RX-17B at S002. symptoms improving. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 27 U/L.
P01791,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01791,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no.
P01791,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: fatigue. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01791,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P01791,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 8.8 mg/L; ALT 51 U/L.
P01791,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.92. AE: no.
P01791,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P01792,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: headache. Adherence ~0.73. AE: no. CRP 3.9 mg/L; ALT 23 U/L.
P01792,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: nausea. Adherence ~0.68. AE: no.
P01792,2,negative,Visit 2: Patient on RX-17A at S002. reports worsening. Notes: brain fog. Adherence ~0.74. AE: no.
P01792,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P01792,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P01792,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.83. AE: no. CRP 2.5 mg/L; ALT 23 U/L.
P01793,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: joint pain. Adherence ~0.44. AE: no.
P01793,1,negative,Visit 1: Patient on RX-17A at S019. feels frustrated. Notes: insomnia. Adherence ~0.43. AE: no. Plan: consider dose adjustment; counsel patient.
P01793,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 4.0 mg/L; ALT 30 U/L.
P01793,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.58. AE: no. CRP 3.5 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01793,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.56. AE: no.
P01793,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~0.59. AE: no.
P01794,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no. CRP 6.2 mg/L; ALT 16 U/L.
P01794,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.69. AE: no.
P01794,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.54. AE: no.
P01794,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no.
P01794,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.60. AE: no.
P01794,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no. CRP 4.4 mg/L; ALT 16 U/L.
P01795,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.51. AE: no. CRP 14.3 mg/L; ALT 31 U/L.
P01795,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.45. AE: no.
P01795,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.36. AE: no. Plan: consider dose adjustment; counsel patient.
P01795,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P01795,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no.
P01795,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.53. AE: no.
P01795,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.36. AE: no. CRP 7.8 mg/L; ALT 34 U/L.
P01796,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01796,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.80. AE: no. CRP 3.1 mg/L; ALT 28 U/L.
P01796,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01796,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.95. AE: no. CRP 3.3 mg/L; ALT 27 U/L.
P01796,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.98. AE: no.
P01796,5,positive,Visit 5: Patient on RX-17A at S014. energy increasing. Notes: headache. Adherence ~0.76. AE: no. CRP 2.2 mg/L; ALT 27 U/L.
P01797,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.53. AE: yes. CRP 6.2 mg/L; ALT 27 U/L.
P01797,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.67. AE: no.
P01797,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.45. AE: yes. CRP 5.4 mg/L; ALT 30 U/L.
P01797,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.67. AE: no. CRP 5.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01797,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01798,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.56. AE: no.
P01798,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: fatigue. Adherence ~0.50. AE: yes.
P01798,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.61. AE: no.
P01798,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.45. AE: no.
P01798,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no.
P01798,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P01799,0,negative,Visit 0: Patient on RX-17B at S018. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.6 mg/L; ALT 24 U/L.
P01799,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.81. AE: no.
P01799,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.99. AE: no. CRP 2.8 mg/L; ALT 25 U/L.
P01799,3,negative,Visit 3: Patient on RX-17B at S018. poor tolerance. Notes: fatigue. Adherence ~0.74. AE: yes.
P01799,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.96. AE: no.
P01799,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: no.
P01799,6,neutral,Visit 6: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.92. AE: no. CRP 1.5 mg/L; ALT 28 U/L.
P01799,7,neutral,Visit 7: Patient on RX-17B at S018. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: yes.
P01800,0,neutral,Visit 0: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.65. AE: yes. CRP 5.1 mg/L; ALT 33 U/L.
P01800,1,negative,Visit 1: Patient on RX-17B at S020. poor tolerance. Notes: joint pain. Adherence ~0.77. AE: yes. CRP 5.0 mg/L; ALT 35 U/L.
P01800,2,negative,Visit 2: Patient on RX-17B at S020. reports worsening. Notes: nausea. Adherence ~0.82. AE: yes.
P01801,0,negative,Visit 0: Patient on RX-17B at S001. poor tolerance. Notes: fatigue. Adherence ~0.49. AE: yes.
P01801,1,negative,Visit 1: Patient on RX-17B at S001. feels frustrated. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 10.0 mg/L; ALT 44 U/L.
P01801,2,neutral,Visit 2: Patient on RX-17B at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: yes. CRP 8.5 mg/L; ALT 52 U/L.
P01801,3,negative,Visit 3: Patient on RX-17B at S001. increased discomfort. Notes: headache. Adherence ~0.68. AE: no. CRP 7.9 mg/L; ALT 47 U/L.
P01801,4,neutral,Visit 4: Patient on RX-17B at S001. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P01801,5,neutral,Visit 5: Patient on RX-17B at S001. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01802,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no.
P01802,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: no.
P01802,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~0.73. AE: no.
P01802,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: yes. CRP 2.4 mg/L; ALT 22 U/L.
P01802,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P01802,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no. CRP 1.7 mg/L; ALT 24 U/L.
P01802,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no. CRP 1.9 mg/L; ALT 22 U/L.
P01803,0,negative,Visit 0: Patient on RX-17A at S021. increased discomfort. Notes: insomnia. Adherence ~0.75. AE: no. CRP 17.3 mg/L; ALT 43 U/L.
P01803,1,neutral,Visit 1: Patient on RX-17A at S021. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no. CRP 15.2 mg/L; ALT 41 U/L.
P01803,2,negative,Visit 2: Patient on RX-17A at S021. feels frustrated. Notes: dizziness. Adherence ~0.51. AE: no. CRP 14.7 mg/L; ALT 39 U/L.
P01803,3,neutral,Visit 3: Patient on RX-17A at S021. continues regimen. Notes: headache. Adherence ~0.78. AE: no. CRP 12.2 mg/L; ALT 40 U/L.
P01803,4,neutral,Visit 4: Patient on RX-17A at S021. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 14.2 mg/L; ALT 38 U/L.
P01803,5,neutral,Visit 5: Patient on RX-17A at S021. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P01803,6,neutral,Visit 6: Patient on RX-17A at S021. no major change. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P01804,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.76. AE: no.
P01804,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01804,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.54. AE: no.
P01804,3,negative,Visit 3: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.69. AE: yes.
P01804,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no. CRP 7.1 mg/L; ALT 33 U/L.
P01804,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P01804,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.36. AE: no. Plan: consider dose adjustment; counsel patient.
P01804,7,neutral,Visit 7: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.66. AE: no. CRP 5.4 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01805,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: nausea. Adherence ~0.61. AE: no.
P01805,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: insomnia. Adherence ~0.49. AE: no. CRP 7.3 mg/L; ALT 33 U/L.
P01805,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no. CRP 7.5 mg/L; ALT 33 U/L.
P01805,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01805,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P01805,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.44. AE: no. CRP 6.0 mg/L; ALT 34 U/L.
P01806,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: dizziness. Adherence ~0.84. AE: yes. CRP 7.2 mg/L; ALT 34 U/L.
P01806,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no. CRP 6.3 mg/L; ALT 29 U/L.
P01806,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: dizziness. Adherence ~0.83. AE: no.
P01806,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 5.3 mg/L; ALT 30 U/L.
P01806,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.98. AE: no.
P01806,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.91. AE: no.
P01806,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no.
P01806,7,neutral,Visit 7: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: yes.
P01807,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P01807,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 3.7 mg/L; ALT 22 U/L.
P01807,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no.
P01807,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no.
P01807,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no.
P01808,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.97. AE: yes. CRP 4.7 mg/L; ALT 38 U/L.
P01808,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.91. AE: no.
P01808,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no.
P01808,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 3.9 mg/L; ALT 34 U/L.
P01808,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 3.5 mg/L; ALT 38 U/L.
P01809,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01809,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P01809,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: joint pain. Adherence ~0.62. AE: no.
P01809,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no. CRP 6.8 mg/L; ALT 39 U/L.
P01809,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.79. AE: no. CRP 6.5 mg/L; ALT 33 U/L.
P01809,5,positive,Visit 5: Patient on RX-17A at S015. reports improvement. Notes: joint pain. Adherence ~0.84. AE: no.
P01810,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no. CRP 5.4 mg/L; ALT 23 U/L.
P01810,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.68. AE: no. CRP 5.1 mg/L; ALT 20 U/L.
P01810,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 22 U/L.
P01810,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.78. AE: no. CRP 4.4 mg/L; ALT 25 U/L.
P01810,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P01810,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no.
P01811,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.74. AE: no. CRP 9.4 mg/L; ALT 20 U/L.
P01811,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.73. AE: no. CRP 6.4 mg/L; ALT 18 U/L.
P01811,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01811,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.78. AE: no.
P01811,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01811,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~0.90. AE: no.
P01811,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. CRP 4.5 mg/L; ALT 20 U/L.
P01812,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no.
P01812,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01812,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 30 U/L.
P01812,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01812,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P01813,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.93. AE: no.
P01813,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: yes.
P01813,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P01813,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P01813,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: headache. Adherence ~0.85. AE: no.
P01813,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.57. AE: no.
P01814,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~0.92. AE: no. CRP 9.4 mg/L; ALT 42 U/L.
P01814,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01814,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.88. AE: yes. Plan: consider dose adjustment; counsel patient.
P01815,0,negative,Visit 0: Patient on RX-17A at S007. feels frustrated. Notes: nausea. Adherence ~0.70. AE: no.
P01815,1,negative,Visit 1: Patient on RX-17A at S007. poor tolerance. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01815,2,neutral,Visit 2: Patient on RX-17A at S007. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01815,3,positive,Visit 3: Patient on RX-17A at S007. energy increasing. Notes: fatigue. Adherence ~0.82. AE: no.
P01815,4,neutral,Visit 4: Patient on RX-17A at S007. no major change. Notes: dizziness. Adherence ~0.82. AE: no.
P01815,5,neutral,Visit 5: Patient on RX-17A at S007. no major change. Notes: brain fog. Adherence ~0.74. AE: no.
P01815,6,neutral,Visit 6: Patient on RX-17A at S007. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01816,0,neutral,Visit 0: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no.
P01816,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: yes.
P01816,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: headache. Adherence ~0.63. AE: no.
P01816,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no.
P01816,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.59. AE: no. CRP 6.1 mg/L; ALT 33 U/L.
P01817,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.88. AE: no.
P01817,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01817,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.53. AE: no. CRP 2.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01818,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 2.8 mg/L; ALT 28 U/L.
P01818,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.96. AE: no. CRP 2.5 mg/L; ALT 31 U/L.
P01818,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P01818,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01819,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01819,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.61. AE: no.
P01819,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P01819,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no.
P01819,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01819,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.66. AE: no.
P01819,6,neutral,Visit 6: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.68. AE: no.
P01819,7,neutral,Visit 7: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P01820,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.45. AE: no.
P01820,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.62. AE: no. CRP 30.7 mg/L; ALT 22 U/L.
P01820,2,negative,Visit 2: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.66. AE: no. CRP 22.7 mg/L; ALT 24 U/L.
P01820,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no.
P01821,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: no.
P01821,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no.
P01821,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.70. AE: no.
P01821,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.57. AE: no.
P01821,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no. CRP 8.4 mg/L; ALT 29 U/L.
P01822,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 14.1 mg/L; ALT 28 U/L.
P01822,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01822,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.87. AE: no. CRP 13.8 mg/L; ALT 29 U/L.
P01822,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01822,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P01822,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: nausea. Adherence ~1.00. AE: no.
P01822,6,positive,Visit 6: Patient on RX-17B at S015. reports improvement. Notes: insomnia. Adherence ~0.93. AE: no. CRP 6.7 mg/L; ALT 30 U/L.
P01822,7,positive,Visit 7: Patient on RX-17B at S015. tolerating medication well. Notes: insomnia. Adherence ~0.90. AE: no. CRP 5.3 mg/L; ALT 29 U/L.
P01823,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 9.0 mg/L; ALT 36 U/L.
P01823,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.74. AE: no.
P01823,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.82. AE: no. CRP 8.0 mg/L; ALT 29 U/L.
P01823,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01823,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P01823,5,negative,Visit 5: Patient on RX-17B at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01824,0,negative,Visit 0: Patient on RX-17A at S018. feels frustrated. Notes: joint pain. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P01824,1,negative,Visit 1: Patient on RX-17A at S018. reports worsening. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P01824,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01824,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P01824,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.48. AE: no. CRP 5.8 mg/L; ALT 20 U/L.
P01824,5,negative,Visit 5: Patient on RX-17A at S018. poor tolerance. Notes: insomnia. Adherence ~0.54. AE: no.
P01824,6,neutral,Visit 6: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.51. AE: no. CRP 5.7 mg/L; ALT 19 U/L.
P01825,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: headache. Adherence ~0.84. AE: no.
P01825,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no.
P01825,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P01825,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.96. AE: no.
P01825,4,positive,Visit 4: Patient on RX-17B at S016. feels better overall. Notes: brain fog. Adherence ~0.98. AE: no. CRP 7.6 mg/L; ALT 21 U/L.
P01825,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P01825,6,positive,Visit 6: Patient on RX-17B at S016. tolerating medication well. Notes: insomnia. Adherence ~0.78. AE: no.
P01826,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: headache. Adherence ~0.88. AE: no.
P01826,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.99. AE: no.
P01826,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01826,3,negative,Visit 3: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~1.00. AE: yes. CRP 4.0 mg/L; ALT 40 U/L.
P01826,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01827,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.49. AE: no.
P01827,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: dizziness. Adherence ~0.55. AE: no.
P01827,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.59. AE: no.
P01827,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.80. AE: no.
P01827,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.64. AE: no. CRP 6.9 mg/L; ALT 20 U/L.
P01827,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.53. AE: no.
P01827,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no.
P01828,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: no. CRP 17.3 mg/L; ALT 23 U/L.
P01828,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.99. AE: no. CRP 14.8 mg/L; ALT 27 U/L.
P01828,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: yes. CRP 9.9 mg/L; ALT 26 U/L.
P01828,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no.
P01828,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no.
P01828,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: yes. CRP 7.9 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01829,0,neutral,Visit 0: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 10.5 mg/L; ALT 29 U/L.
P01829,1,neutral,Visit 1: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 8.8 mg/L; ALT 34 U/L.
P01829,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no.
P01829,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: dizziness. Adherence ~0.65. AE: no.
P01829,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no. CRP 6.3 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01829,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: dizziness. Adherence ~0.53. AE: no. CRP 6.5 mg/L; ALT 37 U/L.
P01830,0,neutral,Visit 0: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.59. AE: no. CRP 15.3 mg/L; ALT 21 U/L.
P01830,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.56. AE: no.
P01830,2,neutral,Visit 2: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.62. AE: no.
P01830,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.51. AE: no.
P01830,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.40. AE: no.
P01831,0,neutral,Visit 0: Patient on RX-17B at S006. no major change. Notes: insomnia. Adherence ~0.89. AE: no.
P01831,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: dizziness. Adherence ~0.93. AE: no.
P01831,2,positive,Visit 2: Patient on RX-17B at S006. tolerating medication well. Notes: headache. Adherence ~0.95. AE: no. CRP 7.8 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P01831,3,neutral,Visit 3: Patient on RX-17B at S006. continues regimen. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 6.9 mg/L; ALT 46 U/L.
P01831,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no.
P01831,5,neutral,Visit 5: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P01832,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.93. AE: no. CRP 18.6 mg/L; ALT 21 U/L.
P01832,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.93. AE: no.
P01832,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no.
P01832,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01832,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01832,5,positive,Visit 5: Patient on RX-17A at S014. symptoms improving. Notes: fatigue. Adherence ~0.77. AE: no.
P01832,6,positive,Visit 6: Patient on RX-17A at S014. symptoms improving. Notes: joint pain. Adherence ~0.88. AE: no. CRP 10.7 mg/L; ALT 20 U/L.
P01832,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01833,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: headache. Adherence ~0.99. AE: no. CRP 6.5 mg/L; ALT 32 U/L.
P01833,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no.
P01833,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.94. AE: no. CRP 5.8 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01833,3,negative,Visit 3: Patient on RX-17A at S013. reports worsening. Notes: headache. Adherence ~0.88. AE: no. CRP 5.5 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01833,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.94. AE: no.
P01833,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01833,6,neutral,Visit 6: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.98. AE: no.
P01834,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P01834,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.97. AE: no. CRP 20.8 mg/L; ALT 22 U/L.
P01834,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 17.4 mg/L; ALT 27 U/L.
P01834,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.95. AE: no.
P01834,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.95. AE: no.
P01834,5,positive,Visit 5: Patient on RX-17B at S005. symptoms improving. Notes: nausea. Adherence ~0.85. AE: no. CRP 14.5 mg/L; ALT 25 U/L.
P01834,6,positive,Visit 6: Patient on RX-17B at S005. reports improvement. Notes: joint pain. Adherence ~0.91. AE: no. CRP 10.2 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01834,7,positive,Visit 7: Patient on RX-17B at S005. reports improvement. Notes: fatigue. Adherence ~0.92. AE: no. CRP 8.8 mg/L; ALT 24 U/L.
P01835,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.8 mg/L; ALT 32 U/L.
P01835,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no. CRP 8.4 mg/L; ALT 31 U/L.
P01835,2,negative,Visit 2: Patient on RX-17B at S018. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no. CRP 8.3 mg/L; ALT 33 U/L.
P01835,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: fatigue. Adherence ~0.94. AE: no.
P01835,4,positive,Visit 4: Patient on RX-17B at S018. energy increasing. Notes: fatigue. Adherence ~0.80. AE: no. CRP 6.1 mg/L; ALT 33 U/L.
P01835,5,positive,Visit 5: Patient on RX-17B at S018. energy increasing. Notes: headache. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P01836,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.91. AE: yes. Plan: consider dose adjustment; counsel patient.
P01836,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P01836,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no. CRP 5.3 mg/L; ALT 24 U/L.
P01836,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no. CRP 4.6 mg/L; ALT 26 U/L.
P01836,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.4 mg/L; ALT 26 U/L.
P01837,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: insomnia. Adherence ~0.56. AE: no.
P01837,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: joint pain. Adherence ~0.52. AE: yes.
P01837,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.48. AE: no. CRP 3.4 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01837,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P01837,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.55. AE: yes.
P01837,5,neutral,Visit 5: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P01838,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.32. AE: no.
P01838,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no.
P01838,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.39. AE: no. CRP 3.9 mg/L; ALT 44 U/L.
P01838,3,negative,Visit 3: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P01838,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.58. AE: no. CRP 3.2 mg/L; ALT 49 U/L.
P01839,0,neutral,Visit 0: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.9 mg/L; ALT 20 U/L.
P01839,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: nausea. Adherence ~0.76. AE: no.
P01839,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: dizziness. Adherence ~0.75. AE: yes.
P01839,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.84. AE: no.
P01839,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no. CRP 2.8 mg/L; ALT 23 U/L.
P01839,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.92. AE: yes.
P01839,6,positive,Visit 6: Patient on RX-17A at S002. symptoms improving. Notes: fatigue. Adherence ~0.87. AE: no. CRP 2.6 mg/L; ALT 22 U/L.
P01840,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.39. AE: no. CRP 7.0 mg/L; ALT 20 U/L.
P01840,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.69. AE: no.
P01840,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.58. AE: no.
P01840,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.41. AE: no. CRP 5.8 mg/L; ALT 24 U/L.
P01840,4,negative,Visit 4: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.29. AE: no.
P01841,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.74. AE: no. CRP 4.1 mg/L; ALT 25 U/L.
P01841,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: dizziness. Adherence ~0.64. AE: no. CRP 3.4 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P01841,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01841,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no.
P01841,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no.
P01841,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: no.
P01841,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.47. AE: no. CRP 2.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01842,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: insomnia. Adherence ~0.91. AE: yes.
P01842,1,negative,Visit 1: Patient on RX-17B at S001. increased discomfort. Notes: nausea. Adherence ~0.89. AE: yes.
P01842,2,neutral,Visit 2: Patient on RX-17B at S001. continues regimen. Notes: joint pain. Adherence ~0.99. AE: no. CRP 13.4 mg/L; ALT 59 U/L.
P01842,3,neutral,Visit 3: Patient on RX-17B at S001. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P01842,4,neutral,Visit 4: Patient on RX-17B at S001. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P01843,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: fatigue. Adherence ~0.98. AE: no.
P01843,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P01843,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no.
P01843,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P01843,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P01844,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.86. AE: no.
P01844,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no.
P01844,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: no. CRP 8.0 mg/L; ALT 46 U/L.
P01844,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: yes.
P01844,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: no.
P01844,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.72. AE: no. CRP 4.9 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01845,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.99. AE: no.
P01845,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01845,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no. CRP 3.7 mg/L; ALT 32 U/L.
P01845,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: no. CRP 3.2 mg/L; ALT 30 U/L.
P01845,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.85. AE: no.
P01845,5,positive,Visit 5: Patient on RX-17B at S022. tolerating medication well. Notes: joint pain. Adherence ~0.99. AE: no. CRP 2.3 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01846,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no.
P01846,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.57. AE: yes. CRP 4.9 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P01846,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: insomnia. Adherence ~0.67. AE: yes. CRP 4.0 mg/L; ALT 48 U/L.
P01846,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.84. AE: no. CRP 4.2 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01846,4,negative,Visit 4: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 3.6 mg/L; ALT 48 U/L.
P01846,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.63. AE: no. CRP 3.3 mg/L; ALT 52 U/L.
P01846,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no.
P01847,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P01847,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.85. AE: no.
P01847,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.79. AE: yes. CRP 1.8 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01848,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.44. AE: no. CRP 13.3 mg/L; ALT 38 U/L.
P01848,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.49. AE: no. CRP 18.1 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01848,2,negative,Visit 2: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: no. CRP 15.6 mg/L; ALT 38 U/L.
P01848,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.63. AE: no.
P01849,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no. CRP 3.6 mg/L; ALT 19 U/L.
P01849,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: headache. Adherence ~0.69. AE: no.
P01849,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: no. CRP 2.8 mg/L; ALT 19 U/L.
P01849,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.96. AE: no. CRP 2.8 mg/L; ALT 19 U/L.
P01849,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.81. AE: no.
P01850,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01850,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.87. AE: no.
P01850,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.92. AE: no.
P01850,3,positive,Visit 3: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.92. AE: no.
P01850,4,positive,Visit 4: Patient on RX-17B at S015. energy increasing. Notes: brain fog. Adherence ~0.76. AE: no.
P01850,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.83. AE: no. CRP 2.4 mg/L; ALT 20 U/L.
P01851,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P01851,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.84. AE: yes.
P01851,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01852,0,negative,Visit 0: Patient on RX-17B at S013. reports worsening. Notes: insomnia. Adherence ~0.80. AE: no.
P01852,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 7.2 mg/L; ALT 44 U/L.
P01852,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.62. AE: no. CRP 8.6 mg/L; ALT 45 U/L.
P01852,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no.
P01852,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 6.6 mg/L; ALT 50 U/L.
P01853,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01853,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.92. AE: no.
P01853,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no. CRP 6.1 mg/L; ALT 74 U/L.
P01854,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.69. AE: no.
P01854,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.82. AE: no.
P01854,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no.
P01854,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.69. AE: no.
P01854,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: nausea. Adherence ~0.59. AE: yes. CRP 5.7 mg/L; ALT 21 U/L.
P01854,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no.
P01855,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: nausea. Adherence ~0.83. AE: no. CRP 12.7 mg/L; ALT 37 U/L.
P01855,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.69. AE: no.
P01855,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.90. AE: yes. CRP 11.0 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01855,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.95. AE: no. CRP 10.8 mg/L; ALT 37 U/L.
P01855,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: yes. CRP 8.1 mg/L; ALT 43 U/L.
P01855,5,positive,Visit 5: Patient on RX-17B at S017. tolerating medication well. Notes: brain fog. Adherence ~0.99. AE: no. CRP 7.6 mg/L; ALT 38 U/L.
P01856,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.95. AE: yes. CRP 8.0 mg/L; ALT 23 U/L.
P01856,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.86. AE: no. CRP 6.8 mg/L; ALT 20 U/L.
P01856,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.96. AE: no.
P01857,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.90. AE: yes. CRP 2.8 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01857,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: yes.
P01857,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.94. AE: no.
P01857,3,negative,Visit 3: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P01857,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P01858,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~0.67. AE: no. CRP 11.3 mg/L; ALT 26 U/L.
P01858,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.67. AE: no. CRP 11.7 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P01858,2,negative,Visit 2: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.74. AE: no. CRP 10.0 mg/L; ALT 28 U/L.
P01858,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01858,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.69. AE: no. CRP 7.1 mg/L; ALT 29 U/L.
P01859,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.57. AE: no. CRP 10.7 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01859,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: no.
P01859,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.60. AE: no. CRP 8.3 mg/L; ALT 35 U/L.
P01859,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.55. AE: no.
P01859,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.74. AE: no.
P01860,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P01860,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.42. AE: no.
P01860,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.48. AE: no.
P01860,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01860,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.37. AE: no. CRP 9.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01860,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.69. AE: no.
P01860,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no.
P01861,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.51. AE: no.
P01861,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.59. AE: no. CRP 3.5 mg/L; ALT 27 U/L.
P01861,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.60. AE: no.
P01861,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 2.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P01861,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P01861,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P01862,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.69. AE: no.
P01862,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P01862,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.92. AE: no. CRP 4.1 mg/L; ALT 41 U/L.
P01862,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P01862,4,negative,Visit 4: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no.
P01862,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.88. AE: no. CRP 3.7 mg/L; ALT 44 U/L.
P01862,6,positive,Visit 6: Patient on RX-17A at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01862,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 2.8 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P01863,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P01863,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.87. AE: no. CRP 8.3 mg/L; ALT 44 U/L.
P01863,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.87. AE: yes. CRP 8.6 mg/L; ALT 49 U/L.
P01863,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.84. AE: no.
P01863,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.94. AE: no.
P01863,5,positive,Visit 5: Patient on RX-17A at S017. reports improvement. Notes: headache. Adherence ~0.78. AE: no. CRP 6.3 mg/L; ALT 45 U/L.
P01863,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no.
P01863,7,neutral,Visit 7: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.68. AE: no.
P01864,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.65. AE: no.
P01864,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.72. AE: no. CRP 4.0 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01864,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no.
P01864,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P01864,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.63. AE: no. CRP 3.1 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P01865,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: fatigue. Adherence ~0.87. AE: no.
P01865,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: fatigue. Adherence ~0.91. AE: no. CRP 1.9 mg/L; ALT 36 U/L.
P01865,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: yes.
P01865,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.90. AE: no.
P01865,4,positive,Visit 4: Patient on RX-17A at S005. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. CRP 1.6 mg/L; ALT 32 U/L.
P01865,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.78. AE: no. CRP 1.1 mg/L; ALT 36 U/L.
P01865,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P01866,0,negative,Visit 0: Patient on RX-17A at S006. increased discomfort. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 9.0 mg/L; ALT 33 U/L.
P01866,1,negative,Visit 1: Patient on RX-17A at S006. symptoms persist. Notes: insomnia. Adherence ~0.83. AE: yes.
P01866,2,neutral,Visit 2: Patient on RX-17A at S006. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no. CRP 7.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01866,3,neutral,Visit 3: Patient on RX-17A at S006. no major change. Notes: headache. Adherence ~0.90. AE: no.
P01866,4,neutral,Visit 4: Patient on RX-17A at S006. continues regimen. Notes: joint pain. Adherence ~0.59. AE: no. CRP 5.7 mg/L; ALT 27 U/L.
P01866,5,neutral,Visit 5: Patient on RX-17A at S006. no major change. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.0 mg/L; ALT 31 U/L.
P01866,6,neutral,Visit 6: Patient on RX-17A at S006. continues regimen. Notes: insomnia. Adherence ~0.81. AE: no.
P01866,7,neutral,Visit 7: Patient on RX-17A at S006. follow-up as scheduled. Notes: fatigue. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P01867,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no. CRP 14.2 mg/L; ALT 28 U/L.
P01867,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P01867,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.92. AE: no.
P01867,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no. CRP 9.0 mg/L; ALT 27 U/L.
P01867,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.83. AE: yes. CRP 8.1 mg/L; ALT 28 U/L.
P01868,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01868,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P01868,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01868,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 37 U/L.
P01869,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: yes.
P01869,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: headache. Adherence ~0.70. AE: no. CRP 11.5 mg/L; ALT 22 U/L.
P01869,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.67. AE: no.
P01869,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.57. AE: no.
P01869,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.62. AE: no.
P01869,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01869,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.76. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P01870,0,neutral,Visit 0: Patient on RX-17B at S006. stable symptoms. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P01870,1,neutral,Visit 1: Patient on RX-17B at S006. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01870,2,neutral,Visit 2: Patient on RX-17B at S006. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.7 mg/L; ALT 32 U/L.
P01870,3,neutral,Visit 3: Patient on RX-17B at S006. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no.
P01870,4,positive,Visit 4: Patient on RX-17B at S006. feels better overall. Notes: fatigue. Adherence ~0.86. AE: no.
P01870,5,neutral,Visit 5: Patient on RX-17B at S006. continues regimen. Notes: headache. Adherence ~0.74. AE: no.
P01870,6,positive,Visit 6: Patient on RX-17B at S006. tolerating medication well. Notes: joint pain. Adherence ~0.86. AE: no.
P01871,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~1.00. AE: no.
P01871,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.75. AE: yes.
P01871,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: yes.
P01871,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.73. AE: no. CRP 5.7 mg/L; ALT 21 U/L.
P01871,4,negative,Visit 4: Patient on RX-17A at S019. poor tolerance. Notes: fatigue. Adherence ~0.89. AE: no.
P01871,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.93. AE: no.
P01872,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 7.2 mg/L; ALT 30 U/L.
P01872,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.60. AE: yes.
P01872,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 5.5 mg/L; ALT 28 U/L.
P01872,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no.
P01872,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.47. AE: no.
P01873,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.98. AE: no. CRP 16.4 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01873,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.60. AE: no.
P01873,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~0.61. AE: no.
P01873,3,negative,Visit 3: Patient on RX-17A at S019. reports worsening. Notes: brain fog. Adherence ~0.72. AE: yes.
P01873,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no.
P01874,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01874,1,neutral,Visit 1: Patient on RX-17B at S008. stable symptoms. Notes: insomnia. Adherence ~0.65. AE: no. CRP 3.5 mg/L; ALT 30 U/L.
P01874,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: no.
P01874,3,negative,Visit 3: Patient on RX-17B at S008. feels frustrated. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01874,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P01875,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.88. AE: no. CRP 9.9 mg/L; ALT 23 U/L.
P01875,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: fatigue. Adherence ~0.91. AE: no.
P01875,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.90. AE: no. CRP 9.4 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01875,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no.
P01875,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.78. AE: no.
P01876,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.77. AE: no.
P01876,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.78. AE: no. CRP 3.5 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01876,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.72. AE: no.
P01876,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no.
P01876,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P01876,5,negative,Visit 5: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: yes. CRP 2.8 mg/L; ALT 26 U/L.
P01876,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no.
P01876,7,neutral,Visit 7: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no.
P01877,0,negative,Visit 0: Patient on RX-17A at S009. feels frustrated. Notes: headache. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01877,1,negative,Visit 1: Patient on RX-17A at S009. reports worsening. Notes: joint pain. Adherence ~0.87. AE: no.
P01877,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 4.1 mg/L; ALT 26 U/L.
P01877,3,neutral,Visit 3: Patient on RX-17A at S009. no major change. Notes: nausea. Adherence ~0.80. AE: no. CRP 3.8 mg/L; ALT 32 U/L.
P01877,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01878,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: fatigue. Adherence ~0.80. AE: no. CRP 15.5 mg/L; ALT 12 U/L. Plan: consider dose adjustment; counsel patient.
P01878,1,negative,Visit 1: Patient on RX-17B at S016. feels frustrated. Notes: dizziness. Adherence ~0.94. AE: no.
P01878,2,negative,Visit 2: Patient on RX-17B at S016. poor tolerance. Notes: insomnia. Adherence ~0.93. AE: no. CRP 11.8 mg/L; ALT 14 U/L.
P01878,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 9.6 mg/L; ALT 13 U/L.
P01878,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.7 mg/L; ALT 14 U/L.
P01878,5,positive,Visit 5: Patient on RX-17B at S016. feels better overall. Notes: dizziness. Adherence ~0.99. AE: no. CRP 7.5 mg/L; ALT 14 U/L.
P01878,6,positive,Visit 6: Patient on RX-17B at S016. symptoms improving. Notes: headache. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 14 U/L.
P01878,7,positive,Visit 7: Patient on RX-17B at S016. feels better overall. Notes: nausea. Adherence ~1.00. AE: no.
P01879,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.84. AE: no. CRP 3.6 mg/L; ALT 16 U/L.
P01879,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no.
P01879,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.91. AE: no. CRP 3.5 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P01879,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.87. AE: no. CRP 2.7 mg/L; ALT 16 U/L.
P01879,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.81. AE: no.
P01879,5,negative,Visit 5: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no.
P01880,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: joint pain. Adherence ~0.67. AE: no. CRP 7.1 mg/L; ALT 38 U/L.
P01880,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.59. AE: no.
P01880,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.49. AE: no.
P01880,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.53. AE: no.
P01880,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.58. AE: no.
P01880,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.64. AE: no.
P01881,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P01881,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. CRP 26.0 mg/L; ALT 30 U/L.
P01881,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.89. AE: no.
P01881,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: yes.
P01881,4,negative,Visit 4: Patient on RX-17A at S004. poor tolerance. Notes: brain fog. Adherence ~0.65. AE: no.
P01881,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01882,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.64. AE: no. CRP 13.3 mg/L; ALT 21 U/L.
P01882,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.70. AE: yes.
P01882,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P01882,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no. CRP 9.1 mg/L; ALT 23 U/L.
P01882,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P01883,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: yes. CRP 4.6 mg/L; ALT 44 U/L.
P01883,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01883,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P01883,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.91. AE: no.
P01883,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.80. AE: no. CRP 3.9 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P01883,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no. CRP 3.3 mg/L; ALT 41 U/L.
P01883,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no. CRP 2.9 mg/L; ALT 41 U/L.
P01884,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no.
P01884,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.56. AE: no.
P01884,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01884,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.91. AE: no.
P01884,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.81. AE: no.
P01885,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.83. AE: no. CRP 7.5 mg/L; ALT 25 U/L.
P01885,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no.
P01885,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no. CRP 6.4 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01885,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P01885,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: brain fog. Adherence ~0.87. AE: no.
P01885,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no.
P01886,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: fatigue. Adherence ~0.90. AE: yes.
P01886,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 12.7 mg/L; ALT 23 U/L.
P01886,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P01886,3,negative,Visit 3: Patient on RX-17B at S017. poor tolerance. Notes: joint pain. Adherence ~0.97. AE: yes.
P01886,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.94. AE: no.
P01886,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01886,6,positive,Visit 6: Patient on RX-17B at S017. feels better overall. Notes: nausea. Adherence ~0.92. AE: no. CRP 6.2 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P01886,7,positive,Visit 7: Patient on RX-17B at S017. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no.
P01887,0,neutral,Visit 0: Patient on RX-17B at S011. no major change. Notes: joint pain. Adherence ~0.99. AE: no. CRP 4.6 mg/L; ALT 58 U/L.
P01887,1,neutral,Visit 1: Patient on RX-17B at S011. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no.
P01887,2,negative,Visit 2: Patient on RX-17B at S011. reports worsening. Notes: insomnia. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01887,3,negative,Visit 3: Patient on RX-17B at S011. symptoms persist. Notes: joint pain. Adherence ~0.83. AE: no.
P01887,4,negative,Visit 4: Patient on RX-17B at S011. reports worsening. Notes: joint pain. Adherence ~0.84. AE: no.
P01887,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: nausea. Adherence ~0.63. AE: no. CRP 2.4 mg/L; ALT 60 U/L.
P01888,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P01888,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.79. AE: no. CRP 3.8 mg/L; ALT 34 U/L.
P01888,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.71. AE: no.
P01889,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: dizziness. Adherence ~0.73. AE: no. CRP 11.1 mg/L; ALT 31 U/L.
P01889,1,neutral,Visit 1: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P01889,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P01889,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: nausea. Adherence ~0.90. AE: no.
P01889,4,positive,Visit 4: Patient on RX-17B at S019. energy increasing. Notes: brain fog. Adherence ~0.88. AE: no. CRP 6.9 mg/L; ALT 37 U/L.
P01889,5,neutral,Visit 5: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01890,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.78. AE: no. CRP 2.9 mg/L; ALT 36 U/L.
P01890,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.91. AE: no. CRP 3.1 mg/L; ALT 37 U/L.
P01890,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.75. AE: no.
P01890,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P01890,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.68. AE: no.
P01891,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~1.00. AE: no.
P01891,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.93. AE: no.
P01891,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.89. AE: no. CRP 3.9 mg/L; ALT 16 U/L.
P01891,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.85. AE: no.
P01891,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.99. AE: no.
P01891,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01891,6,positive,Visit 6: Patient on RX-17A at S019. symptoms improving. Notes: headache. Adherence ~0.88. AE: no.
P01892,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P01892,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.87. AE: no.
P01892,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: no. CRP 6.0 mg/L; ALT 23 U/L.
P01892,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: no.
P01892,4,negative,Visit 4: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01892,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no.
P01893,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P01893,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01893,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01893,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P01893,4,positive,Visit 4: Patient on RX-17B at S022. reports improvement. Notes: fatigue. Adherence ~0.96. AE: no. CRP 4.3 mg/L; ALT 36 U/L.
P01893,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P01893,6,positive,Visit 6: Patient on RX-17B at S022. reports improvement. Notes: dizziness. Adherence ~0.77. AE: no.
P01893,7,neutral,Visit 7: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.74. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P01894,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: joint pain. Adherence ~0.64. AE: yes. Plan: consider dose adjustment; counsel patient.
P01894,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: no. CRP 3.3 mg/L; ALT 32 U/L.
P01894,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~0.61. AE: no.
P01894,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01894,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.53. AE: no. CRP 2.3 mg/L; ALT 35 U/L.
P01894,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.54. AE: no.
P01895,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.69. AE: no.
P01895,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.80. AE: no. CRP 7.7 mg/L; ALT 66 U/L.
P01895,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.83. AE: no. CRP 7.4 mg/L; ALT 69 U/L. Plan: consider dose adjustment; counsel patient.
P01895,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 66 U/L. Plan: consider dose adjustment; counsel patient.
P01895,4,positive,Visit 4: Patient on RX-17B at S004. feels better overall. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01895,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P01896,0,negative,Visit 0: Patient on RX-17A at S020. poor tolerance. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 10.1 mg/L; ALT 26 U/L.
P01896,1,neutral,Visit 1: Patient on RX-17A at S020. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no.
P01896,2,negative,Visit 2: Patient on RX-17A at S020. reports worsening. Notes: joint pain. Adherence ~0.69. AE: no.
P01896,3,neutral,Visit 3: Patient on RX-17A at S020. continues regimen. Notes: fatigue. Adherence ~0.80. AE: no.
P01896,4,neutral,Visit 4: Patient on RX-17A at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P01896,5,positive,Visit 5: Patient on RX-17A at S020. energy increasing. Notes: headache. Adherence ~0.79. AE: no. CRP 6.9 mg/L; ALT 25 U/L.
P01897,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.68. AE: no. CRP 5.5 mg/L; ALT 36 U/L.
P01897,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.52. AE: no.
P01897,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no. CRP 5.0 mg/L; ALT 45 U/L.
P01897,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01897,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.41. AE: no. CRP 3.9 mg/L; ALT 42 U/L.
P01897,5,negative,Visit 5: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.53. AE: no.
P01897,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.66. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P01898,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 19.6 mg/L; ALT 46 U/L.
P01898,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no.
P01898,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.73. AE: no. CRP 13.3 mg/L; ALT 38 U/L.
P01898,3,positive,Visit 3: Patient on RX-17A at S004. symptoms improving. Notes: dizziness. Adherence ~0.90. AE: no. CRP 14.3 mg/L; ALT 40 U/L.
P01898,4,positive,Visit 4: Patient on RX-17A at S004. feels better overall. Notes: dizziness. Adherence ~0.76. AE: no.
P01898,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: dizziness. Adherence ~0.86. AE: no.
P01898,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01898,7,positive,Visit 7: Patient on RX-17A at S004. energy increasing. Notes: insomnia. Adherence ~0.96. AE: no.
P01899,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.51. AE: yes.
P01899,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: brain fog. Adherence ~0.65. AE: no. CRP 7.5 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01899,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.78. AE: no.
P01899,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.48. AE: no.
P01899,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.52. AE: no.
P01900,0,neutral,Visit 0: Patient on RX-17A at S016. continues regimen. Notes: headache. Adherence ~0.81. AE: no. CRP 4.5 mg/L; ALT 35 U/L.
P01900,1,neutral,Visit 1: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.91. AE: no.
P01900,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no.
P01900,3,negative,Visit 3: Patient on RX-17A at S016. reports worsening. Notes: joint pain. Adherence ~0.78. AE: yes. CRP 3.5 mg/L; ALT 36 U/L.
P01900,4,negative,Visit 4: Patient on RX-17A at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~0.72. AE: yes. CRP 2.9 mg/L; ALT 35 U/L.
P01900,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: no.
P01900,6,neutral,Visit 6: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.69. AE: no.
P01901,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: fatigue. Adherence ~0.95. AE: no. CRP 17.0 mg/L; ALT 29 U/L.
P01901,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 15.3 mg/L; ALT 32 U/L.
P01901,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01901,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. CRP 13.5 mg/L; ALT 31 U/L.
P01901,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01901,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: headache. Adherence ~0.91. AE: yes. CRP 9.4 mg/L; ALT 32 U/L.
P01902,0,neutral,Visit 0: Patient on RX-17B at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.91. AE: no.
P01902,1,neutral,Visit 1: Patient on RX-17B at S011. no major change. Notes: brain fog. Adherence ~0.98. AE: no.
P01902,2,negative,Visit 2: Patient on RX-17B at S011. increased discomfort. Notes: abdominal discomfort. Adherence ~0.80. AE: yes.
P01902,3,neutral,Visit 3: Patient on RX-17B at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no. CRP 3.5 mg/L; ALT 16 U/L.
P01902,4,neutral,Visit 4: Patient on RX-17B at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01902,5,positive,Visit 5: Patient on RX-17B at S011. energy increasing. Notes: headache. Adherence ~0.97. AE: no. CRP 2.9 mg/L; ALT 17 U/L.
P01902,6,positive,Visit 6: Patient on RX-17B at S011. tolerating medication well. Notes: joint pain. Adherence ~0.98. AE: no.
P01902,7,positive,Visit 7: Patient on RX-17B at S011. energy increasing. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01903,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.86. AE: no. CRP 7.6 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01903,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.77. AE: no.
P01903,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no.
P01903,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. CRP 6.6 mg/L; ALT 36 U/L.
P01903,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no.
P01903,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.73. AE: no.
P01903,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~0.88. AE: no.
P01904,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P01904,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P01904,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P01904,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.73. AE: no. CRP 4.8 mg/L; ALT 36 U/L.
P01904,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: no. CRP 4.7 mg/L; ALT 37 U/L.
P01905,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P01905,1,negative,Visit 1: Patient on RX-17B at S013. poor tolerance. Notes: headache. Adherence ~0.52. AE: yes.
P01905,2,negative,Visit 2: Patient on RX-17B at S013. increased discomfort. Notes: nausea. Adherence ~0.66. AE: no.
P01905,3,positive,Visit 3: Patient on RX-17B at S013. symptoms improving. Notes: fatigue. Adherence ~0.81. AE: no. CRP 8.4 mg/L; ALT 41 U/L.
P01905,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.62. AE: no. CRP 6.0 mg/L; ALT 41 U/L.
P01905,5,neutral,Visit 5: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P01906,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.86. AE: no. CRP 5.5 mg/L; ALT 26 U/L.
P01906,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 4.7 mg/L; ALT 30 U/L.
P01906,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.75. AE: no.
P01906,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P01906,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 3.7 mg/L; ALT 35 U/L.
P01906,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P01907,0,negative,Visit 0: Patient on RX-17A at S011. feels frustrated. Notes: brain fog. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P01907,1,negative,Visit 1: Patient on RX-17A at S011. poor tolerance. Notes: nausea. Adherence ~0.74. AE: no. CRP 5.9 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P01907,2,negative,Visit 2: Patient on RX-17A at S011. poor tolerance. Notes: nausea. Adherence ~1.00. AE: yes. CRP 5.0 mg/L; ALT 50 U/L.
P01907,3,neutral,Visit 3: Patient on RX-17A at S011. stable symptoms. Notes: nausea. Adherence ~0.75. AE: no.
P01907,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P01907,5,positive,Visit 5: Patient on RX-17A at S011. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no.
P01907,6,neutral,Visit 6: Patient on RX-17A at S011. stable symptoms. Notes: headache. Adherence ~0.89. AE: no. CRP 3.7 mg/L; ALT 40 U/L.
P01908,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 7.3 mg/L; ALT 22 U/L.
P01908,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 6.2 mg/L; ALT 20 U/L.
P01908,2,neutral,Visit 2: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.96. AE: no.
P01908,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P01908,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: no.
P01908,5,positive,Visit 5: Patient on RX-17A at S002. reports improvement. Notes: headache. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 22 U/L.
P01908,6,neutral,Visit 6: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01908,7,positive,Visit 7: Patient on RX-17A at S002. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P01909,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.81. AE: no.
P01909,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.68. AE: no.
P01909,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no.
P01909,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.72. AE: no.
P01909,4,positive,Visit 4: Patient on RX-17B at S015. symptoms improving. Notes: brain fog. Adherence ~0.82. AE: no. CRP 3.6 mg/L; ALT 59 U/L. Plan: consider dose adjustment; counsel patient.
P01909,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: yes.
P01909,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.72. AE: no.
P01910,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.62. AE: no.
P01910,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.79. AE: no.
P01910,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.90. AE: yes.
P01910,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no.
P01910,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.87. AE: no.
P01910,5,negative,Visit 5: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01910,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no.
P01910,7,positive,Visit 7: Patient on RX-17A at S012. symptoms improving. Notes: fatigue. Adherence ~0.77. AE: no.
P01911,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: fatigue. Adherence ~0.72. AE: no.
P01911,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.87. AE: no. CRP 3.2 mg/L; ALT 32 U/L.
P01911,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.73. AE: no. CRP 3.0 mg/L; ALT 31 U/L.
P01912,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 7.6 mg/L; ALT 37 U/L.
P01912,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.83. AE: no.
P01912,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no.
P01912,3,positive,Visit 3: Patient on RX-17B at S004. energy increasing. Notes: fatigue. Adherence ~0.81. AE: no.
P01912,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.94. AE: no. CRP 5.4 mg/L; ALT 41 U/L.
P01912,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: fatigue. Adherence ~0.83. AE: no.
P01912,6,positive,Visit 6: Patient on RX-17B at S004. reports improvement. Notes: insomnia. Adherence ~0.95. AE: no.
P01912,7,positive,Visit 7: Patient on RX-17B at S004. symptoms improving. Notes: joint pain. Adherence ~0.85. AE: no.
P01913,0,negative,Visit 0: Patient on RX-17A at S001. poor tolerance. Notes: joint pain. Adherence ~0.98. AE: no. CRP 7.6 mg/L; ALT 27 U/L.
P01913,1,neutral,Visit 1: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.69. AE: no.
P01913,2,neutral,Visit 2: Patient on RX-17A at S001. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01914,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P01914,1,neutral,Visit 1: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P01914,2,negative,Visit 2: Patient on RX-17A at S008. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P01914,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P01915,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.92. AE: no.
P01915,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no.
P01915,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: no.
P01915,3,positive,Visit 3: Patient on RX-17B at S014. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no. CRP 8.8 mg/L; ALT 28 U/L.
P01915,4,positive,Visit 4: Patient on RX-17B at S014. energy increasing. Notes: dizziness. Adherence ~0.77. AE: no.
P01915,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.87. AE: no.
P01915,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: fatigue. Adherence ~0.88. AE: no.
P01915,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01916,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01916,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01916,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no.
P01916,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 2.5 mg/L; ALT 33 U/L.
P01916,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.60. AE: no.
P01916,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.90. AE: no.
P01916,6,neutral,Visit 6: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.73. AE: no. CRP 1.5 mg/L; ALT 37 U/L.
P01917,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01917,1,negative,Visit 1: Patient on RX-17A at S018. feels frustrated. Notes: dizziness. Adherence ~0.92. AE: no. CRP 9.4 mg/L; ALT 29 U/L.
P01917,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no. CRP 8.1 mg/L; ALT 27 U/L.
P01917,3,neutral,Visit 3: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P01917,4,neutral,Visit 4: Patient on RX-17A at S018. continues regimen. Notes: fatigue. Adherence ~0.93. AE: no.
P01917,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~0.88. AE: no. CRP 6.1 mg/L; ALT 29 U/L.
P01918,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: joint pain. Adherence ~0.71. AE: no.
P01918,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P01918,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.69. AE: no.
P01918,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01918,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no. CRP 2.5 mg/L; ALT 24 U/L.
P01918,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P01918,6,positive,Visit 6: Patient on RX-17B at S012. feels better overall. Notes: dizziness. Adherence ~0.95. AE: no. CRP 2.1 mg/L; ALT 28 U/L.
P01919,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: no.
P01919,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.80. AE: no.
P01919,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: no.
P01919,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.73. AE: yes. CRP 4.4 mg/L; ALT 71 U/L.
P01919,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P01919,5,positive,Visit 5: Patient on RX-17A at S014. symptoms improving. Notes: joint pain. Adherence ~0.78. AE: no. CRP 3.6 mg/L; ALT 72 U/L.
P01919,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: yes.
P01920,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.5 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01920,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 24 U/L.
P01920,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.97. AE: no. CRP 3.0 mg/L; ALT 22 U/L.
P01920,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.90. AE: no.
P01920,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no.
P01920,5,positive,Visit 5: Patient on RX-17B at S015. symptoms improving. Notes: dizziness. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01921,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: joint pain. Adherence ~0.87. AE: no.
P01921,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: headache. Adherence ~0.57. AE: no. CRP 6.0 mg/L; ALT 14 U/L.
P01921,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.77. AE: yes. CRP 4.8 mg/L; ALT 15 U/L.
P01921,3,negative,Visit 3: Patient on RX-17B at S002. reports worsening. Notes: insomnia. Adherence ~0.95. AE: yes.
P01921,4,neutral,Visit 4: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no.
P01921,5,positive,Visit 5: Patient on RX-17B at S002. reports improvement. Notes: brain fog. Adherence ~0.82. AE: no. CRP 3.9 mg/L; ALT 13 U/L.
P01922,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.59. AE: no.
P01922,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 4.7 mg/L; ALT 25 U/L.
P01922,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.39. AE: no. CRP 5.0 mg/L; ALT 25 U/L.
P01922,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01922,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.59. AE: yes.
P01923,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.63. AE: no.
P01923,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.60. AE: yes. CRP 16.5 mg/L; ALT 36 U/L.
P01923,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.31. AE: no.
P01923,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: yes. CRP 14.8 mg/L; ALT 35 U/L.
P01923,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.51. AE: no.
P01923,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.60. AE: no. CRP 10.7 mg/L; ALT 31 U/L.
P01924,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: fatigue. Adherence ~0.82. AE: no.
P01924,1,neutral,Visit 1: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P01924,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: joint pain. Adherence ~0.96. AE: yes.
P01924,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no. CRP 7.0 mg/L; ALT 25 U/L.
P01924,4,positive,Visit 4: Patient on RX-17A at S013. feels better overall. Notes: brain fog. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 25 U/L.
P01924,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no.
P01924,6,positive,Visit 6: Patient on RX-17A at S013. feels better overall. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P01924,7,positive,Visit 7: Patient on RX-17A at S013. symptoms improving. Notes: nausea. Adherence ~0.88. AE: no.
P01925,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.91. AE: no. CRP 10.3 mg/L; ALT 38 U/L.
P01925,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.71. AE: no.
P01925,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 7.6 mg/L; ALT 43 U/L.
P01925,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no. CRP 6.5 mg/L; ALT 42 U/L.
P01925,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P01925,5,positive,Visit 5: Patient on RX-17B at S004. energy increasing. Notes: headache. Adherence ~0.86. AE: no.
P01925,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.66. AE: no. CRP 5.2 mg/L; ALT 48 U/L.
P01926,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: headache. Adherence ~0.57. AE: no. CRP 4.4 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P01926,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.59. AE: no. CRP 3.0 mg/L; ALT 37 U/L.
P01926,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.45. AE: no.
P01926,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.52. AE: yes.
P01927,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.79. AE: no. CRP 11.7 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01927,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01927,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01927,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no.
P01927,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no.
P01927,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.62. AE: no. CRP 6.6 mg/L; ALT 27 U/L.
P01928,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: nausea. Adherence ~0.72. AE: no.
P01928,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.72. AE: no. CRP 16.8 mg/L; ALT 16 U/L.
P01928,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P01928,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: yes.
P01928,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P01928,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.84. AE: no. CRP 13.4 mg/L; ALT 16 U/L.
P01928,6,positive,Visit 6: Patient on RX-17A at S002. reports improvement. Notes: brain fog. Adherence ~0.81. AE: no.
P01928,7,positive,Visit 7: Patient on RX-17A at S002. symptoms improving. Notes: fatigue. Adherence ~0.81. AE: no.
P01929,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.59. AE: no.
P01929,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: nausea. Adherence ~0.72. AE: no. CRP 10.9 mg/L; ALT 18 U/L.
P01929,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P01929,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.67. AE: no.
P01929,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P01929,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.65. AE: no.
P01930,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no. CRP 3.7 mg/L; ALT 27 U/L.
P01930,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.58. AE: no.
P01930,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no.
P01930,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P01930,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. CRP 2.5 mg/L; ALT 30 U/L.
P01930,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.63. AE: no.
P01931,0,negative,Visit 0: Patient on RX-17A at S011. feels frustrated. Notes: dizziness. Adherence ~0.87. AE: yes. CRP 6.5 mg/L; ALT 17 U/L.
P01931,1,negative,Visit 1: Patient on RX-17A at S011. symptoms persist. Notes: joint pain. Adherence ~0.89. AE: yes. Plan: consider dose adjustment; counsel patient.
P01931,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: joint pain. Adherence ~0.79. AE: no.
P01931,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.4 mg/L; ALT 18 U/L.
P01931,4,neutral,Visit 4: Patient on RX-17A at S011. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P01932,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P01932,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: dizziness. Adherence ~0.96. AE: no.
P01932,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P01932,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.97. AE: yes.
P01932,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01932,5,positive,Visit 5: Patient on RX-17B at S017. symptoms improving. Notes: insomnia. Adherence ~0.98. AE: no.
P01933,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P01933,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: fatigue. Adherence ~0.63. AE: yes.
P01933,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 52 U/L.
P01933,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 4.5 mg/L; ALT 52 U/L.
P01933,4,negative,Visit 4: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.75. AE: no.
P01933,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P01933,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.88. AE: yes.
P01933,7,neutral,Visit 7: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.63. AE: no.
P01934,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.70. AE: yes.
P01934,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no.
P01934,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.96. AE: no.
P01934,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01934,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no. CRP 21.9 mg/L; ALT 38 U/L.
P01935,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no. CRP 5.0 mg/L; ALT 31 U/L.
P01935,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 5.9 mg/L; ALT 31 U/L.
P01935,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.77. AE: yes.
P01935,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.88. AE: no. CRP 4.2 mg/L; ALT 32 U/L.
P01935,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 32 U/L.
P01935,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no.
P01935,6,positive,Visit 6: Patient on RX-17B at S022. energy increasing. Notes: dizziness. Adherence ~0.98. AE: no.
P01936,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: nausea. Adherence ~0.87. AE: no.
P01936,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no.
P01936,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P01936,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no. CRP 6.4 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01936,4,positive,Visit 4: Patient on RX-17A at S002. energy increasing. Notes: fatigue. Adherence ~0.82. AE: no.
P01936,5,positive,Visit 5: Patient on RX-17A at S002. reports improvement. Notes: brain fog. Adherence ~0.78. AE: no.
P01936,6,positive,Visit 6: Patient on RX-17A at S002. tolerating medication well. Notes: insomnia. Adherence ~1.00. AE: no.
P01937,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P01937,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.78. AE: yes. CRP 4.7 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01937,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.80. AE: no. CRP 4.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01937,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P01937,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P01938,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: no.
P01938,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.88. AE: no. CRP 8.4 mg/L; ALT 27 U/L.
P01938,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P01938,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01938,4,negative,Visit 4: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.78. AE: yes.
P01938,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P01938,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P01938,7,positive,Visit 7: Patient on RX-17B at S014. feels better overall. Notes: headache. Adherence ~0.99. AE: no. CRP 3.8 mg/L; ALT 29 U/L.
P01939,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.63. AE: no. CRP 15.3 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P01939,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no. CRP 13.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01939,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.87. AE: no.
P01939,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no. CRP 11.5 mg/L; ALT 32 U/L.
P01939,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.95. AE: yes.
P01940,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P01940,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: insomnia. Adherence ~0.81. AE: no. CRP 7.2 mg/L; ALT 43 U/L.
P01940,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P01940,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01940,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: insomnia. Adherence ~0.85. AE: no. CRP 5.8 mg/L; ALT 40 U/L.
P01940,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~0.77. AE: no. CRP 5.4 mg/L; ALT 38 U/L.
P01941,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P01941,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.88. AE: no.
P01941,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.63. AE: no.
P01941,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.76. AE: no.
P01941,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P01941,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 4.5 mg/L; ALT 45 U/L.
P01941,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.79. AE: no. CRP 4.0 mg/L; ALT 43 U/L.
P01941,7,positive,Visit 7: Patient on RX-17A at S022. symptoms improving. Notes: joint pain. Adherence ~0.88. AE: no. CRP 3.8 mg/L; ALT 42 U/L.
P01942,0,neutral,Visit 0: Patient on RX-17B at S001. stable symptoms. Notes: headache. Adherence ~0.63. AE: no.
P01942,1,negative,Visit 1: Patient on RX-17B at S001. poor tolerance. Notes: headache. Adherence ~0.58. AE: no.
P01942,2,neutral,Visit 2: Patient on RX-17B at S001. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no.
P01942,3,negative,Visit 3: Patient on RX-17B at S001. poor tolerance. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P01943,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 13.8 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01943,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.98. AE: no.
P01943,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.99. AE: yes. CRP 14.0 mg/L; ALT 39 U/L.
P01943,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P01943,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.90. AE: no. CRP 9.8 mg/L; ALT 37 U/L.
P01943,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.95. AE: no.
P01943,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01944,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: headache. Adherence ~0.84. AE: no.
P01944,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.98. AE: no.
P01944,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no.
P01944,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P01944,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 26 U/L.
P01945,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: dizziness. Adherence ~0.75. AE: no.
P01945,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 6.6 mg/L; ALT 52 U/L.
P01945,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.63. AE: no.
P01945,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no.
P01945,4,negative,Visit 4: Patient on RX-17B at S012. poor tolerance. Notes: insomnia. Adherence ~0.82. AE: yes. Plan: consider dose adjustment; counsel patient.
P01945,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: brain fog. Adherence ~0.98. AE: no. CRP 4.1 mg/L; ALT 53 U/L.
P01945,6,neutral,Visit 6: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.67. AE: no. CRP 3.2 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P01946,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.58. AE: no.
P01946,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.89. AE: no. CRP 1.9 mg/L; ALT 23 U/L.
P01946,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: yes. CRP 1.9 mg/L; ALT 24 U/L.
P01946,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.54. AE: no. CRP 1.7 mg/L; ALT 26 U/L.
P01946,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.65. AE: no. CRP 1.5 mg/L; ALT 22 U/L.
P01946,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P01946,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.54. AE: no.
P01947,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no.
P01947,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: fatigue. Adherence ~0.93. AE: no.
P01947,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.2 mg/L; ALT 30 U/L.
P01947,3,negative,Visit 3: Patient on RX-17A at S022. poor tolerance. Notes: fatigue. Adherence ~0.98. AE: yes.
P01947,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01948,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.77. AE: no. CRP 6.5 mg/L; ALT 44 U/L.
P01948,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P01948,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no. CRP 4.5 mg/L; ALT 44 U/L.
P01948,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P01948,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01948,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: insomnia. Adherence ~0.76. AE: no.
P01948,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no.
P01948,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: yes. CRP 2.8 mg/L; ALT 57 U/L.
P01949,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.67. AE: no. CRP 2.9 mg/L; ALT 26 U/L.
P01949,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.68. AE: no.
P01949,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.69. AE: no. CRP 2.3 mg/L; ALT 27 U/L.
P01949,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 2.1 mg/L; ALT 29 U/L.
P01949,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P01949,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.69. AE: no.
P01949,6,positive,Visit 6: Patient on RX-17B at S004. symptoms improving. Notes: fatigue. Adherence ~0.82. AE: no. CRP 1.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01950,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: insomnia. Adherence ~0.89. AE: yes.
P01950,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: insomnia. Adherence ~0.93. AE: no.
P01950,2,neutral,Visit 2: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no.
P01950,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.93. AE: no.
P01950,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 9.7 mg/L; ALT 19 U/L.
P01950,5,positive,Visit 5: Patient on RX-17A at S002. tolerating medication well. Notes: brain fog. Adherence ~0.97. AE: no.
P01950,6,positive,Visit 6: Patient on RX-17A at S002. symptoms improving. Notes: fatigue. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P01950,7,neutral,Visit 7: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.2 mg/L; ALT 17 U/L.
P01951,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 5.2 mg/L; ALT 28 U/L.
P01951,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no.
P01951,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.91. AE: no. CRP 5.8 mg/L; ALT 26 U/L.
P01951,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P01951,4,positive,Visit 4: Patient on RX-17A at S022. symptoms improving. Notes: dizziness. Adherence ~1.00. AE: no.
P01951,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.95. AE: no. CRP 3.8 mg/L; ALT 25 U/L.
P01952,0,negative,Visit 0: Patient on RX-17A at S009. feels frustrated. Notes: dizziness. Adherence ~0.42. AE: no.
P01952,1,negative,Visit 1: Patient on RX-17A at S009. increased discomfort. Notes: brain fog. Adherence ~0.68. AE: yes. CRP 21.7 mg/L; ALT 56 U/L.
P01952,2,negative,Visit 2: Patient on RX-17A at S009. symptoms persist. Notes: insomnia. Adherence ~0.54. AE: yes.
P01952,3,neutral,Visit 3: Patient on RX-17A at S009. stable symptoms. Notes: dizziness. Adherence ~0.36. AE: no. CRP 18.3 mg/L; ALT 50 U/L.
P01952,4,neutral,Visit 4: Patient on RX-17A at S009. follow-up as scheduled. Notes: brain fog. Adherence ~0.39. AE: yes. Plan: consider dose adjustment; counsel patient.
P01953,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P01953,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01953,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no.
P01953,3,positive,Visit 3: Patient on RX-17A at S014. tolerating medication well. Notes: fatigue. Adherence ~0.90. AE: no.
P01953,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.83. AE: no. CRP 12.9 mg/L; ALT 14 U/L.
P01953,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: yes.
P01953,6,positive,Visit 6: Patient on RX-17A at S014. feels better overall. Notes: headache. Adherence ~0.97. AE: no.
P01954,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: yes. CRP 4.5 mg/L; ALT 34 U/L.
P01954,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.94. AE: no.
P01954,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no.
P01954,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.90. AE: no.
P01954,4,positive,Visit 4: Patient on RX-17B at S004. feels better overall. Notes: dizziness. Adherence ~0.94. AE: no. CRP 3.4 mg/L; ALT 34 U/L.
P01955,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: joint pain. Adherence ~0.92. AE: no. CRP 15.2 mg/L; ALT 26 U/L.
P01955,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: brain fog. Adherence ~0.97. AE: no.
P01955,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: nausea. Adherence ~0.90. AE: no.
P01955,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P01955,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: headache. Adherence ~0.73. AE: no. CRP 10.3 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01956,0,neutral,Visit 0: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.62. AE: no.
P01956,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P01956,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.52. AE: no.
P01956,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: yes. CRP 13.0 mg/L; ALT 34 U/L.
P01956,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 11.4 mg/L; ALT 33 U/L.
P01956,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.71. AE: no.
P01957,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no.
P01957,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no. CRP 4.5 mg/L; ALT 27 U/L.
P01957,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.85. AE: no. CRP 4.7 mg/L; ALT 27 U/L.
P01957,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P01957,4,positive,Visit 4: Patient on RX-17B at S014. energy increasing. Notes: nausea. Adherence ~0.86. AE: no. CRP 3.5 mg/L; ALT 31 U/L.
P01957,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01957,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.89. AE: yes. CRP 2.7 mg/L; ALT 33 U/L.
P01957,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: insomnia. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P01958,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.83. AE: no. CRP 4.2 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P01958,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.94. AE: no.
P01958,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no.
P01958,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.82. AE: no. CRP 3.4 mg/L; ALT 42 U/L.
P01958,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.68. AE: no.
P01959,0,negative,Visit 0: Patient on RX-17A at S009. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: no.
P01959,1,neutral,Visit 1: Patient on RX-17A at S009. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 1.9 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P01959,2,neutral,Visit 2: Patient on RX-17A at S009. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P01959,3,negative,Visit 3: Patient on RX-17A at S009. feels frustrated. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P01959,4,neutral,Visit 4: Patient on RX-17A at S009. stable symptoms. Notes: dizziness. Adherence ~0.61. AE: no.
P01959,5,neutral,Visit 5: Patient on RX-17A at S009. continues regimen. Notes: headache. Adherence ~0.82. AE: no. CRP 1.5 mg/L; ALT 31 U/L.
P01959,6,neutral,Visit 6: Patient on RX-17A at S009. no major change. Notes: brain fog. Adherence ~0.63. AE: no.
P01960,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.48. AE: no.
P01960,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.50. AE: no. CRP 9.3 mg/L; ALT 49 U/L.
P01960,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.55. AE: no. CRP 7.1 mg/L; ALT 46 U/L.
P01960,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.50. AE: yes. Plan: consider dose adjustment; counsel patient.
P01960,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: yes.
P01961,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P01961,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no.
P01961,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.83. AE: no. CRP 3.9 mg/L; ALT 50 U/L.
P01961,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 3.7 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P01961,4,positive,Visit 4: Patient on RX-17A at S019. tolerating medication well. Notes: dizziness. Adherence ~0.90. AE: no. CRP 2.7 mg/L; ALT 46 U/L.
P01961,5,positive,Visit 5: Patient on RX-17A at S019. tolerating medication well. Notes: headache. Adherence ~0.79. AE: no. CRP 3.4 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P01961,6,positive,Visit 6: Patient on RX-17A at S019. tolerating medication well. Notes: brain fog. Adherence ~0.91. AE: no.
P01962,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P01962,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.82. AE: no.
P01962,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.73. AE: no. CRP 7.3 mg/L; ALT 33 U/L.
P01962,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no. CRP 8.6 mg/L; ALT 31 U/L.
P01962,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no.
P01962,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01962,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: no. CRP 6.1 mg/L; ALT 32 U/L.
P01962,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P01963,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P01963,1,neutral,Visit 1: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no.
P01963,2,neutral,Visit 2: Patient on RX-17A at S011. no major change. Notes: dizziness. Adherence ~0.70. AE: no. CRP 5.2 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P01963,3,negative,Visit 3: Patient on RX-17A at S011. symptoms persist. Notes: abdominal discomfort. Adherence ~0.78. AE: yes.
P01963,4,neutral,Visit 4: Patient on RX-17A at S011. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no. CRP 3.8 mg/L; ALT 25 U/L.
P01963,5,neutral,Visit 5: Patient on RX-17A at S011. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no.
P01963,6,neutral,Visit 6: Patient on RX-17A at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: yes.
P01963,7,neutral,Visit 7: Patient on RX-17A at S011. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no. CRP 2.6 mg/L; ALT 26 U/L.
P01964,0,neutral,Visit 0: Patient on RX-17A at S019. continues regimen. Notes: joint pain. Adherence ~0.58. AE: no.
P01964,1,neutral,Visit 1: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.63. AE: no.
P01964,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.65. AE: no.
P01964,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P01964,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.48. AE: no.
P01965,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.57. AE: no. CRP 4.9 mg/L; ALT 39 U/L.
P01965,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.70. AE: yes.
P01965,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.56. AE: yes.
P01965,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.67. AE: yes. CRP 4.4 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P01965,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.55. AE: yes.
P01965,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P01965,6,positive,Visit 6: Patient on RX-17B at S012. reports improvement. Notes: insomnia. Adherence ~0.94. AE: no.
P01966,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.85. AE: no. CRP 3.6 mg/L; ALT 20 U/L.
P01966,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01966,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 18 U/L.
P01966,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.93. AE: yes.
P01966,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P01966,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P01967,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no. CRP 5.2 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P01967,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.72. AE: yes. CRP 4.6 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01967,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.75. AE: no. CRP 5.0 mg/L; ALT 34 U/L.
P01967,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.59. AE: yes.
P01967,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.63. AE: no. CRP 3.7 mg/L; ALT 33 U/L.
P01968,0,neutral,Visit 0: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.57. AE: no. CRP 5.2 mg/L; ALT 30 U/L.
P01968,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: no.
P01968,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.77. AE: no.
P01968,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no. CRP 3.6 mg/L; ALT 28 U/L.
P01968,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.44. AE: no.
P01969,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.67. AE: no. CRP 7.1 mg/L; ALT 29 U/L.
P01969,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: no.
P01969,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no. CRP 5.2 mg/L; ALT 26 U/L.
P01969,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.57. AE: no. CRP 5.8 mg/L; ALT 25 U/L.
P01969,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.65. AE: no. CRP 5.5 mg/L; ALT 26 U/L.
P01969,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P01970,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P01970,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: fatigue. Adherence ~0.99. AE: no.
P01970,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P01970,3,positive,Visit 3: Patient on RX-17B at S002. feels better overall. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 6.4 mg/L; ALT 25 U/L.
P01970,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P01971,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 4.0 mg/L; ALT 26 U/L.
P01971,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: dizziness. Adherence ~0.93. AE: no.
P01971,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.93. AE: no. CRP 3.6 mg/L; ALT 24 U/L.
P01971,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.82. AE: no.
P01971,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no.
P01972,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no.
P01972,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~0.95. AE: no.
P01972,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P01972,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no.
P01972,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P01973,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: brain fog. Adherence ~0.75. AE: no.
P01973,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P01973,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: nausea. Adherence ~0.66. AE: no.
P01973,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01973,4,negative,Visit 4: Patient on RX-17A at S016. feels frustrated. Notes: headache. Adherence ~0.81. AE: yes.
P01974,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 16.8 mg/L; ALT 47 U/L.
P01974,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.59. AE: no.
P01974,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: fatigue. Adherence ~0.43. AE: no.
P01974,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.48. AE: no.
P01974,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.54. AE: no.
P01974,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P01974,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: no.
P01975,0,neutral,Visit 0: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.29. AE: no.
P01975,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.14. AE: no. CRP 7.2 mg/L; ALT 31 U/L.
P01975,2,negative,Visit 2: Patient on RX-17B at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.30. AE: no. CRP 6.7 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P01975,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.25. AE: no.
P01975,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: nausea. Adherence ~0.33. AE: no. CRP 5.7 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P01976,0,negative,Visit 0: Patient on RX-17A at S009. feels frustrated. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P01976,1,negative,Visit 1: Patient on RX-17A at S009. symptoms persist. Notes: brain fog. Adherence ~0.72. AE: no.
P01976,2,negative,Visit 2: Patient on RX-17A at S009. feels frustrated. Notes: headache. Adherence ~0.72. AE: no. CRP 6.4 mg/L; ALT 22 U/L.
P01976,3,positive,Visit 3: Patient on RX-17A at S009. feels better overall. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 6.9 mg/L; ALT 22 U/L.
P01976,4,neutral,Visit 4: Patient on RX-17A at S009. stable symptoms. Notes: brain fog. Adherence ~0.58. AE: no.
P01977,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.61. AE: no.
P01977,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.68. AE: no.
P01977,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.89. AE: no. CRP 4.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P01977,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P01977,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.78. AE: yes.
P01978,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: no. CRP 10.4 mg/L; ALT 20 U/L.
P01978,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.81. AE: no. CRP 10.0 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P01978,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.83. AE: no. CRP 9.1 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P01978,3,negative,Visit 3: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.86. AE: no.
P01979,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: dizziness. Adherence ~0.79. AE: no.
P01979,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.70. AE: no.
P01979,2,negative,Visit 2: Patient on RX-17B at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P01979,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.71. AE: yes. CRP 6.1 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P01979,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.58. AE: no.
P01979,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P01979,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P01979,7,neutral,Visit 7: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.71. AE: no.
P01980,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.71. AE: yes.
P01980,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no. CRP 9.6 mg/L; ALT 29 U/L.
P01980,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P01980,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: yes.
P01980,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.53. AE: no.
P01981,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01981,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 14.3 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P01981,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.82. AE: no. CRP 12.5 mg/L; ALT 41 U/L.
P01982,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: headache. Adherence ~0.90. AE: no. CRP 4.1 mg/L; ALT 44 U/L.
P01982,1,negative,Visit 1: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.64. AE: no. CRP 4.6 mg/L; ALT 50 U/L.
P01982,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: no. CRP 3.8 mg/L; ALT 49 U/L.
P01982,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no.
P01982,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P01982,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: no.
P01983,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P01983,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.82. AE: no.
P01983,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 8.4 mg/L; ALT 16 U/L.
P01983,3,negative,Visit 3: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.94. AE: yes. CRP 7.8 mg/L; ALT 19 U/L.
P01983,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.3 mg/L; ALT 16 U/L.
P01983,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: headache. Adherence ~0.80. AE: no. CRP 6.8 mg/L; ALT 18 U/L.
P01984,0,neutral,Visit 0: Patient on RX-17A at S006. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. CRP 9.8 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P01984,1,negative,Visit 1: Patient on RX-17A at S006. poor tolerance. Notes: insomnia. Adherence ~0.97. AE: no.
P01984,2,negative,Visit 2: Patient on RX-17A at S006. reports worsening. Notes: headache. Adherence ~0.96. AE: no.
P01984,3,neutral,Visit 3: Patient on RX-17A at S006. stable symptoms. Notes: headache. Adherence ~0.84. AE: no.
P01984,4,neutral,Visit 4: Patient on RX-17A at S006. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P01984,5,neutral,Visit 5: Patient on RX-17A at S006. stable symptoms. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P01984,6,neutral,Visit 6: Patient on RX-17A at S006. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P01984,7,neutral,Visit 7: Patient on RX-17A at S006. follow-up as scheduled. Notes: headache. Adherence ~0.95. AE: no.
P01985,0,neutral,Visit 0: Patient on RX-17A at S021. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 8.4 mg/L; ALT 20 U/L.
P01985,1,neutral,Visit 1: Patient on RX-17A at S021. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P01985,2,negative,Visit 2: Patient on RX-17A at S021. symptoms persist. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P01985,3,neutral,Visit 3: Patient on RX-17A at S021. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no. CRP 8.1 mg/L; ALT 22 U/L.
P01985,4,neutral,Visit 4: Patient on RX-17A at S021. no major change. Notes: insomnia. Adherence ~0.88. AE: no.
P01985,5,neutral,Visit 5: Patient on RX-17A at S021. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no.
P01986,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.49. AE: no.
P01986,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.58. AE: no.
P01986,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.62. AE: no. CRP 5.4 mg/L; ALT 61 U/L.
P01986,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.46. AE: no.
P01986,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.56. AE: no. CRP 4.4 mg/L; ALT 70 U/L.
P01987,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: headache. Adherence ~0.88. AE: yes. CRP 6.7 mg/L; ALT 28 U/L.
P01987,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no. CRP 5.4 mg/L; ALT 28 U/L.
P01987,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.96. AE: no. CRP 4.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P01987,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P01987,4,positive,Visit 4: Patient on RX-17B at S002. tolerating medication well. Notes: headache. Adherence ~0.82. AE: no. CRP 3.6 mg/L; ALT 27 U/L.
P01987,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: nausea. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P01987,6,neutral,Visit 6: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P01987,7,neutral,Visit 7: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.87. AE: yes. CRP 2.5 mg/L; ALT 30 U/L.
P01988,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.41. AE: no.
P01988,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.68. AE: no. CRP 5.4 mg/L; ALT 19 U/L.
P01988,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.68. AE: no. CRP 4.9 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P01988,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.53. AE: no. CRP 3.7 mg/L; ALT 21 U/L.
P01988,4,negative,Visit 4: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.62. AE: yes.
P01988,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no.
P01988,6,negative,Visit 6: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.72. AE: yes.
P01988,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.64. AE: no.
P01989,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: no.
P01989,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P01989,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.87. AE: yes.
P01989,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~1.00. AE: yes.
P01989,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P01989,5,positive,Visit 5: Patient on RX-17B at S004. energy increasing. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 3.5 mg/L; ALT 67 U/L.
P01990,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: abdominal discomfort. Adherence ~0.63. AE: yes.
P01990,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no. CRP 4.2 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P01990,2,negative,Visit 2: Patient on RX-17B at S008. feels frustrated. Notes: fatigue. Adherence ~0.84. AE: yes. CRP 3.8 mg/L; ALT 26 U/L.
P01990,3,neutral,Visit 3: Patient on RX-17B at S008. no major change. Notes: fatigue. Adherence ~0.96. AE: no.
P01990,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. CRP 3.4 mg/L; ALT 22 U/L.
P01990,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 2.6 mg/L; ALT 27 U/L.
P01990,6,positive,Visit 6: Patient on RX-17B at S008. energy increasing. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P01991,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.69. AE: no.
P01991,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.79. AE: yes.
P01991,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: yes.
P01992,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: headache. Adherence ~0.83. AE: no.
P01992,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: dizziness. Adherence ~0.76. AE: no. CRP 3.9 mg/L; ALT 22 U/L.
P01992,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P01992,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.91. AE: no.
P01992,4,positive,Visit 4: Patient on RX-17B at S004. feels better overall. Notes: nausea. Adherence ~0.88. AE: no. CRP 3.8 mg/L; ALT 20 U/L.
P01992,5,positive,Visit 5: Patient on RX-17B at S004. tolerating medication well. Notes: nausea. Adherence ~0.84. AE: no.
P01992,6,positive,Visit 6: Patient on RX-17B at S004. reports improvement. Notes: fatigue. Adherence ~0.93. AE: no.
P01993,0,neutral,Visit 0: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.91. AE: no. CRP 8.5 mg/L; ALT 34 U/L.
P01993,1,negative,Visit 1: Patient on RX-17B at S018. reports worsening. Notes: headache. Adherence ~1.00. AE: no.
P01993,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: no.
P01993,3,neutral,Visit 3: Patient on RX-17B at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.70. AE: no. CRP 6.3 mg/L; ALT 32 U/L.
P01993,4,neutral,Visit 4: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.90. AE: no. CRP 6.7 mg/L; ALT 37 U/L.
P01993,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.87. AE: no.
P01993,6,neutral,Visit 6: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: yes.
P01994,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.93. AE: no.
P01994,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 7.5 mg/L; ALT 27 U/L.
P01994,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P01994,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P01994,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 5.6 mg/L; ALT 33 U/L.
P01994,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 4.3 mg/L; ALT 31 U/L.
P01994,6,positive,Visit 6: Patient on RX-17B at S022. tolerating medication well. Notes: insomnia. Adherence ~0.93. AE: no.
P01995,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~0.74. AE: no.
P01995,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.68. AE: no.
P01995,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no.
P01995,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.79. AE: no.
P01995,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no. CRP 5.5 mg/L; ALT 24 U/L.
P01995,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no.
P01995,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.78. AE: no.
P01996,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P01996,1,neutral,Visit 1: Patient on RX-17B at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.91. AE: no. CRP 5.5 mg/L; ALT 26 U/L.
P01996,2,negative,Visit 2: Patient on RX-17B at S016. reports worsening. Notes: insomnia. Adherence ~0.76. AE: no.
P01996,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no.
P01996,4,positive,Visit 4: Patient on RX-17B at S016. energy increasing. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P01996,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P01996,6,positive,Visit 6: Patient on RX-17B at S016. reports improvement. Notes: abdominal discomfort. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P01997,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: fatigue. Adherence ~0.70. AE: yes.
P01997,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: dizziness. Adherence ~0.44. AE: no. CRP 7.5 mg/L; ALT 33 U/L.
P01997,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.57. AE: no. CRP 7.1 mg/L; ALT 31 U/L.
P01997,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.37. AE: no. Plan: consider dose adjustment; counsel patient.
P01997,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P01997,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: yes.
P01997,6,positive,Visit 6: Patient on RX-17B at S016. energy increasing. Notes: dizziness. Adherence ~0.76. AE: no.
P01998,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.75. AE: no.
P01998,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: no. CRP 6.2 mg/L; ALT 49 U/L.
P01998,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no.
P01998,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no. CRP 5.7 mg/L; ALT 47 U/L.
P01998,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no.
P01998,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.88. AE: no.
P01998,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 4.1 mg/L; ALT 47 U/L.
P01999,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P01999,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.95. AE: no.
P01999,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no.
P01999,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 8.3 mg/L; ALT 37 U/L.
P01999,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.69. AE: no.
P02000,0,neutral,Visit 0: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02000,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.46. AE: no.
P02000,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.77. AE: no. CRP 5.0 mg/L; ALT 25 U/L.
P02000,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.88. AE: no. CRP 4.8 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02000,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.76. AE: no. CRP 4.8 mg/L; ALT 27 U/L.
P02000,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 3.5 mg/L; ALT 26 U/L.
P02001,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.81. AE: no.
P02001,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.85. AE: no. CRP 8.3 mg/L; ALT 25 U/L.
P02001,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: headache. Adherence ~0.89. AE: yes. CRP 7.4 mg/L; ALT 30 U/L.
P02001,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~1.00. AE: yes.
P02001,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: yes.
P02002,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02002,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 38 U/L.
P02002,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.60. AE: no.
P02002,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.67. AE: no.
P02002,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.67. AE: no.
P02003,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: dizziness. Adherence ~0.69. AE: no.
P02003,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.50. AE: no. CRP 10.8 mg/L; ALT 61 U/L.
P02003,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.40. AE: no.
P02003,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02003,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.50. AE: no.
P02004,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02004,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no. CRP 5.0 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P02004,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P02004,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: yes. CRP 4.1 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02004,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02005,0,neutral,Visit 0: Patient on RX-17A at S001. stable symptoms. Notes: dizziness. Adherence ~0.51. AE: no.
P02005,1,negative,Visit 1: Patient on RX-17A at S001. poor tolerance. Notes: fatigue. Adherence ~0.64. AE: no. CRP 4.4 mg/L; ALT 44 U/L.
P02005,2,negative,Visit 2: Patient on RX-17A at S001. symptoms persist. Notes: joint pain. Adherence ~0.44. AE: no. CRP 4.1 mg/L; ALT 40 U/L.
P02005,3,negative,Visit 3: Patient on RX-17A at S001. symptoms persist. Notes: insomnia. Adherence ~0.58. AE: no. CRP 3.6 mg/L; ALT 44 U/L.
P02005,4,neutral,Visit 4: Patient on RX-17A at S001. no major change. Notes: insomnia. Adherence ~0.52. AE: no. CRP 3.0 mg/L; ALT 47 U/L.
P02006,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: joint pain. Adherence ~0.79. AE: yes.
P02006,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02006,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.67. AE: no.
P02006,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P02006,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: no.
P02006,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no.
P02007,0,negative,Visit 0: Patient on RX-17B at S009. symptoms persist. Notes: headache. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02007,1,negative,Visit 1: Patient on RX-17B at S009. reports worsening. Notes: brain fog. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02007,2,neutral,Visit 2: Patient on RX-17B at S009. reviewed dosing instructions. Notes: joint pain. Adherence ~0.74. AE: no.
P02007,3,neutral,Visit 3: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.61. AE: no.
P02007,4,neutral,Visit 4: Patient on RX-17B at S009. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P02008,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: yes.
P02008,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.69. AE: no.
P02008,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: brain fog. Adherence ~0.91. AE: no. CRP 4.9 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02008,3,negative,Visit 3: Patient on RX-17B at S002. increased discomfort. Notes: headache. Adherence ~0.59. AE: yes.
P02008,4,negative,Visit 4: Patient on RX-17B at S002. reports worsening. Notes: headache. Adherence ~0.74. AE: no.
P02008,5,neutral,Visit 5: Patient on RX-17B at S002. stable symptoms. Notes: joint pain. Adherence ~0.73. AE: no.
P02008,6,positive,Visit 6: Patient on RX-17B at S002. symptoms improving. Notes: headache. Adherence ~0.91. AE: no.
P02009,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.44. AE: no.
P02009,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.45. AE: no.
P02009,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: nausea. Adherence ~0.68. AE: no.
P02009,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.62. AE: no.
P02009,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.77. AE: no.
P02009,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02010,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P02010,1,neutral,Visit 1: Patient on RX-17A at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.47. AE: no. CRP 4.5 mg/L; ALT 47 U/L.
P02010,2,neutral,Visit 2: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P02010,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: brain fog. Adherence ~0.49. AE: no.
P02010,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.47. AE: no.
P02010,5,neutral,Visit 5: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.51. AE: yes.
P02011,0,neutral,Visit 0: Patient on RX-17B at S011. continues regimen. Notes: brain fog. Adherence ~0.58. AE: no.
P02011,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.63. AE: yes. CRP 2.2 mg/L; ALT 28 U/L.
P02011,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P02011,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: yes. CRP 1.6 mg/L; ALT 30 U/L.
P02011,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02011,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no.
P02011,6,neutral,Visit 6: Patient on RX-17B at S011. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02011,7,positive,Visit 7: Patient on RX-17B at S011. symptoms improving. Notes: nausea. Adherence ~0.76. AE: no. CRP 1.0 mg/L; ALT 25 U/L.
P02012,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: brain fog. Adherence ~0.44. AE: no.
P02012,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.39. AE: no. CRP 8.1 mg/L; ALT 26 U/L.
P02012,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: brain fog. Adherence ~0.34. AE: no. CRP 6.9 mg/L; ALT 26 U/L.
P02012,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.23. AE: no. CRP 8.2 mg/L; ALT 30 U/L.
P02012,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.26. AE: no. CRP 6.5 mg/L; ALT 27 U/L.
P02013,0,negative,Visit 0: Patient on RX-17B at S011. reports worsening. Notes: joint pain. Adherence ~0.67. AE: yes. CRP 4.0 mg/L; ALT 18 U/L.
P02013,1,negative,Visit 1: Patient on RX-17B at S011. reports worsening. Notes: dizziness. Adherence ~0.48. AE: no. CRP 3.6 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02013,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: joint pain. Adherence ~0.55. AE: no. CRP 3.6 mg/L; ALT 17 U/L.
P02013,3,neutral,Visit 3: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02013,4,neutral,Visit 4: Patient on RX-17B at S011. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. CRP 3.1 mg/L; ALT 18 U/L.
P02013,5,neutral,Visit 5: Patient on RX-17B at S011. no major change. Notes: brain fog. Adherence ~0.68. AE: no.
P02014,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: insomnia. Adherence ~0.68. AE: no.
P02014,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: brain fog. Adherence ~0.66. AE: no. CRP 9.7 mg/L; ALT 42 U/L.
P02014,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.52. AE: no.
P02014,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no. CRP 7.6 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P02014,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: fatigue. Adherence ~0.75. AE: no.
P02015,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.72. AE: yes. Plan: consider dose adjustment; counsel patient.
P02015,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 5.6 mg/L; ALT 29 U/L.
P02015,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.79. AE: no.
P02015,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.74. AE: no. CRP 4.7 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02015,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~0.59. AE: no.
P02015,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.56. AE: no. CRP 3.8 mg/L; ALT 30 U/L.
P02016,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no. CRP 6.2 mg/L; ALT 19 U/L.
P02016,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P02016,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.81. AE: no.
P02016,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02016,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no. CRP 4.2 mg/L; ALT 16 U/L.
P02016,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.72. AE: no.
P02016,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: no.
P02016,7,positive,Visit 7: Patient on RX-17A at S012. feels better overall. Notes: brain fog. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02017,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: no. CRP 13.3 mg/L; ALT 33 U/L.
P02017,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02017,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 12.3 mg/L; ALT 33 U/L.
P02017,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no. CRP 9.4 mg/L; ALT 30 U/L.
P02017,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.96. AE: no.
P02018,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no.
P02018,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02018,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.57. AE: no.
P02018,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.94. AE: no. CRP 8.4 mg/L; ALT 18 U/L.
P02018,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.77. AE: no.
P02018,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.82. AE: no.
P02018,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.67. AE: yes.
P02019,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: insomnia. Adherence ~0.95. AE: no.
P02019,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~1.00. AE: yes.
P02019,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: joint pain. Adherence ~0.92. AE: no. CRP 2.9 mg/L; ALT 37 U/L.
P02019,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02019,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.63. AE: no.
P02020,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 4.1 mg/L; ALT 22 U/L.
P02020,1,neutral,Visit 1: Patient on RX-17A at S002. stable symptoms. Notes: joint pain. Adherence ~0.89. AE: no.
P02020,2,negative,Visit 2: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.80. AE: yes. CRP 3.5 mg/L; ALT 22 U/L.
P02020,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.97. AE: yes.
P02020,4,negative,Visit 4: Patient on RX-17A at S002. feels frustrated. Notes: joint pain. Adherence ~0.81. AE: no.
P02020,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.69. AE: yes. CRP 2.5 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02021,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.68. AE: no. CRP 3.0 mg/L; ALT 34 U/L.
P02021,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P02021,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: insomnia. Adherence ~0.73. AE: no.
P02021,3,positive,Visit 3: Patient on RX-17A at S005. feels better overall. Notes: headache. Adherence ~0.88. AE: no. CRP 1.9 mg/L; ALT 34 U/L.
P02021,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02021,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P02022,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02022,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no.
P02022,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.98. AE: no.
P02022,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~1.00. AE: yes.
P02022,4,negative,Visit 4: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no.
P02023,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: fatigue. Adherence ~0.85. AE: no.
P02023,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.98. AE: no.
P02023,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.81. AE: no.
P02023,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02023,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.85. AE: no.
P02023,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no. CRP 3.1 mg/L; ALT 12 U/L.
P02023,6,positive,Visit 6: Patient on RX-17A at S022. tolerating medication well. Notes: headache. Adherence ~0.84. AE: no. CRP 2.7 mg/L; ALT 14 U/L.
P02024,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.86. AE: yes.
P02024,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. CRP 13.7 mg/L; ALT 43 U/L.
P02024,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P02024,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P02024,4,positive,Visit 4: Patient on RX-17B at S022. symptoms improving. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02024,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.78. AE: no.
P02024,6,positive,Visit 6: Patient on RX-17B at S022. energy increasing. Notes: insomnia. Adherence ~0.83. AE: no.
P02025,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.59. AE: no.
P02025,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P02025,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.53. AE: no.
P02026,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.92. AE: no.
P02026,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no. CRP 3.3 mg/L; ALT 25 U/L.
P02026,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02026,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: yes. CRP 3.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02026,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.88. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P02026,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.62. AE: yes.
P02026,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.73. AE: no. CRP 2.3 mg/L; ALT 25 U/L.
P02027,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: no.
P02027,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.77. AE: no.
P02027,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P02027,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 6.1 mg/L; ALT 33 U/L.
P02027,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P02027,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.65. AE: no.
P02027,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P02027,7,neutral,Visit 7: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: yes.
P02028,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.59. AE: no. CRP 6.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02028,1,neutral,Visit 1: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no.
P02028,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.73. AE: no.
P02028,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.72. AE: no. CRP 4.1 mg/L; ALT 33 U/L.
P02028,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no.
P02028,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.46. AE: no.
P02028,6,neutral,Visit 6: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no.
P02029,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.92. AE: no.
P02029,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.98. AE: no. CRP 11.1 mg/L; ALT 36 U/L.
P02029,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.97. AE: no.
P02029,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.92. AE: no. CRP 10.3 mg/L; ALT 34 U/L.
P02029,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.93. AE: no. CRP 9.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02029,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.99. AE: no. CRP 8.4 mg/L; ALT 37 U/L.
P02029,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02029,7,neutral,Visit 7: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 7.1 mg/L; ALT 37 U/L.
P02030,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: joint pain. Adherence ~0.65. AE: no. CRP 12.1 mg/L; ALT 55 U/L.
P02030,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.62. AE: no.
P02030,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: headache. Adherence ~0.68. AE: no. CRP 10.5 mg/L; ALT 57 U/L.
P02030,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.70. AE: no. CRP 9.5 mg/L; ALT 51 U/L.
P02030,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.59. AE: no.
P02030,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02031,0,neutral,Visit 0: Patient on RX-17B at S021. no major change. Notes: joint pain. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02031,1,neutral,Visit 1: Patient on RX-17B at S021. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P02031,2,negative,Visit 2: Patient on RX-17B at S021. increased discomfort. Notes: joint pain. Adherence ~0.60. AE: yes.
P02032,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. CRP 2.9 mg/L; ALT 27 U/L.
P02032,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: abdominal discomfort. Adherence ~0.82. AE: yes. CRP 3.0 mg/L; ALT 30 U/L.
P02032,2,positive,Visit 2: Patient on RX-17A at S013. tolerating medication well. Notes: insomnia. Adherence ~0.95. AE: no. CRP 2.9 mg/L; ALT 27 U/L.
P02032,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. CRP 2.8 mg/L; ALT 27 U/L.
P02032,4,negative,Visit 4: Patient on RX-17A at S013. symptoms persist. Notes: brain fog. Adherence ~0.91. AE: yes.
P02033,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02033,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. CRP 3.5 mg/L; ALT 35 U/L.
P02033,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.79. AE: no. CRP 3.5 mg/L; ALT 32 U/L.
P02033,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no.
P02033,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02033,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no.
P02033,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.74. AE: no. CRP 2.2 mg/L; ALT 34 U/L.
P02034,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no.
P02034,1,negative,Visit 1: Patient on RX-17A at S018. poor tolerance. Notes: nausea. Adherence ~0.95. AE: no. CRP 2.4 mg/L; ALT 25 U/L.
P02034,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 1.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02034,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.90. AE: no. CRP 1.7 mg/L; ALT 28 U/L.
P02034,4,negative,Visit 4: Patient on RX-17A at S018. reports worsening. Notes: fatigue. Adherence ~0.74. AE: no. CRP 1.6 mg/L; ALT 24 U/L.
P02034,5,neutral,Visit 5: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no. CRP 1.4 mg/L; ALT 27 U/L.
P02035,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.84. AE: no.
P02035,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.2 mg/L; ALT 19 U/L.
P02035,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.88. AE: no.
P02035,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no.
P02035,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 20 U/L.
P02035,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02035,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 22 U/L.
P02035,7,neutral,Visit 7: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02036,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02036,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no.
P02036,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no. CRP 5.2 mg/L; ALT 49 U/L.
P02036,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02036,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.88. AE: no. CRP 5.7 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P02037,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02037,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.83. AE: no.
P02037,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02037,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.93. AE: no.
P02037,4,positive,Visit 4: Patient on RX-17A at S004. energy increasing. Notes: insomnia. Adherence ~0.91. AE: no. CRP 2.8 mg/L; ALT 36 U/L.
P02037,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.81. AE: no. CRP 2.7 mg/L; ALT 36 U/L.
P02037,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.76. AE: no. CRP 2.3 mg/L; ALT 41 U/L.
P02038,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.74. AE: yes. CRP 3.2 mg/L; ALT 18 U/L.
P02038,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P02038,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.4 mg/L; ALT 14 U/L.
P02038,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P02038,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.70. AE: no.
P02038,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: yes.
P02038,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.88. AE: yes.
P02039,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.68. AE: no. CRP 7.0 mg/L; ALT 23 U/L.
P02039,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: dizziness. Adherence ~0.70. AE: no. CRP 7.0 mg/L; ALT 27 U/L.
P02039,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.66. AE: no.
P02039,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.71. AE: yes. CRP 5.5 mg/L; ALT 26 U/L.
P02040,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02040,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02040,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02040,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 37 U/L.
P02040,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.99. AE: no.
P02040,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 43 U/L.
P02040,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.87. AE: no. CRP 3.3 mg/L; ALT 42 U/L.
P02040,7,positive,Visit 7: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~0.97. AE: no.
P02041,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.59. AE: no.
P02041,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: brain fog. Adherence ~0.74. AE: yes.
P02041,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no.
P02041,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02041,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: no.
P02042,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no.
P02042,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: fatigue. Adherence ~0.95. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P02042,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no.
P02042,3,positive,Visit 3: Patient on RX-17A at S002. feels better overall. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 5.8 mg/L; ALT 22 U/L.
P02042,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 22 U/L.
P02043,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02043,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.76. AE: no.
P02043,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no.
P02044,0,negative,Visit 0: Patient on RX-17A at S018. symptoms persist. Notes: brain fog. Adherence ~0.54. AE: yes.
P02044,1,negative,Visit 1: Patient on RX-17A at S018. increased discomfort. Notes: brain fog. Adherence ~0.57. AE: no.
P02044,2,negative,Visit 2: Patient on RX-17A at S018. symptoms persist. Notes: insomnia. Adherence ~0.57. AE: no.
P02044,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no.
P02044,4,neutral,Visit 4: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.60. AE: no.
P02045,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: joint pain. Adherence ~0.76. AE: yes. CRP 5.7 mg/L; ALT 45 U/L.
P02045,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02045,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02045,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.87. AE: no.
P02045,4,positive,Visit 4: Patient on RX-17B at S015. reports improvement. Notes: insomnia. Adherence ~0.89. AE: no.
P02046,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: no.
P02046,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.53. AE: no.
P02046,2,negative,Visit 2: Patient on RX-17A at S019. reports worsening. Notes: dizziness. Adherence ~0.49. AE: no. CRP 2.2 mg/L; ALT 47 U/L.
P02046,3,negative,Visit 3: Patient on RX-17A at S019. symptoms persist. Notes: nausea. Adherence ~0.49. AE: no.
P02046,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: headache. Adherence ~0.51. AE: no.
P02047,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.60. AE: no.
P02047,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.54. AE: no. CRP 7.1 mg/L; ALT 22 U/L.
P02047,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.49. AE: no.
P02047,3,negative,Visit 3: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~0.46. AE: no.
P02047,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P02047,5,negative,Visit 5: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.52. AE: yes.
P02047,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.42. AE: no.
P02047,7,neutral,Visit 7: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.52. AE: no. CRP 4.0 mg/L; ALT 24 U/L.
P02048,0,negative,Visit 0: Patient on RX-17B at S011. increased discomfort. Notes: headache. Adherence ~0.83. AE: no. CRP 7.1 mg/L; ALT 31 U/L.
P02048,1,neutral,Visit 1: Patient on RX-17B at S011. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no. CRP 8.0 mg/L; ALT 37 U/L.
P02048,2,neutral,Visit 2: Patient on RX-17B at S011. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: no. CRP 5.6 mg/L; ALT 36 U/L.
P02048,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: joint pain. Adherence ~0.88. AE: no.
P02048,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: dizziness. Adherence ~0.88. AE: no.
P02049,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.81. AE: no. CRP 6.7 mg/L; ALT 61 U/L.
P02049,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.89. AE: no.
P02049,2,negative,Visit 2: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.79. AE: no. CRP 6.4 mg/L; ALT 60 U/L.
P02049,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P02049,4,negative,Visit 4: Patient on RX-17A at S013. reports worsening. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 4.7 mg/L; ALT 60 U/L.
P02050,0,neutral,Visit 0: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: no.
P02050,1,neutral,Visit 1: Patient on RX-17B at S002. continues regimen. Notes: headache. Adherence ~0.76. AE: no. CRP 20.2 mg/L; ALT 35 U/L.
P02050,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P02051,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.54. AE: no.
P02051,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.57. AE: no.
P02051,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.60. AE: no.
P02051,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.46. AE: yes.
P02052,0,negative,Visit 0: Patient on RX-17B at S009. increased discomfort. Notes: nausea. Adherence ~0.57. AE: no.
P02052,1,neutral,Visit 1: Patient on RX-17B at S009. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P02052,2,negative,Visit 2: Patient on RX-17B at S009. poor tolerance. Notes: dizziness. Adherence ~0.46. AE: no.
P02052,3,neutral,Visit 3: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.56. AE: no. CRP 5.2 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02052,4,neutral,Visit 4: Patient on RX-17B at S009. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no. CRP 5.6 mg/L; ALT 24 U/L.
P02052,5,neutral,Visit 5: Patient on RX-17B at S009. no major change. Notes: joint pain. Adherence ~0.55. AE: yes.
P02052,6,neutral,Visit 6: Patient on RX-17B at S009. no major change. Notes: dizziness. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 29 U/L.
P02052,7,neutral,Visit 7: Patient on RX-17B at S009. no major change. Notes: headache. Adherence ~0.74. AE: no.
P02053,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.99. AE: yes. Plan: consider dose adjustment; counsel patient.
P02053,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02053,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 7.9 mg/L; ALT 54 U/L.
P02053,3,negative,Visit 3: Patient on RX-17B at S012. feels frustrated. Notes: dizziness. Adherence ~0.82. AE: no.
P02053,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.78. AE: no.
P02053,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P02054,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: no.
P02054,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02054,2,negative,Visit 2: Patient on RX-17A at S013. feels frustrated. Notes: brain fog. Adherence ~0.81. AE: no. CRP 17.4 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02055,0,negative,Visit 0: Patient on RX-17A at S020. reports worsening. Notes: brain fog. Adherence ~0.39. AE: yes. Plan: consider dose adjustment; counsel patient.
P02055,1,neutral,Visit 1: Patient on RX-17A at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.39. AE: no.
P02055,2,negative,Visit 2: Patient on RX-17A at S020. symptoms persist. Notes: dizziness. Adherence ~0.58. AE: no. CRP 7.5 mg/L; ALT 26 U/L.
P02055,3,negative,Visit 3: Patient on RX-17A at S020. feels frustrated. Notes: insomnia. Adherence ~0.71. AE: no.
P02055,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: brain fog. Adherence ~0.74. AE: no.
P02055,5,neutral,Visit 5: Patient on RX-17A at S020. no major change. Notes: dizziness. Adherence ~0.60. AE: no.
P02055,6,negative,Visit 6: Patient on RX-17A at S020. poor tolerance. Notes: fatigue. Adherence ~0.59. AE: no. CRP 4.7 mg/L; ALT 27 U/L.
P02055,7,neutral,Visit 7: Patient on RX-17A at S020. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02056,0,negative,Visit 0: Patient on RX-17B at S010. reports worsening. Notes: insomnia. Adherence ~0.85. AE: no. CRP 2.4 mg/L; ALT 38 U/L.
P02056,1,negative,Visit 1: Patient on RX-17B at S010. feels frustrated. Notes: nausea. Adherence ~0.75. AE: no. CRP 2.0 mg/L; ALT 36 U/L.
P02056,2,negative,Visit 2: Patient on RX-17B at S010. poor tolerance. Notes: headache. Adherence ~0.83. AE: yes.
P02056,3,neutral,Visit 3: Patient on RX-17B at S010. no major change. Notes: headache. Adherence ~0.91. AE: no. CRP 1.8 mg/L; ALT 40 U/L.
P02056,4,neutral,Visit 4: Patient on RX-17B at S010. follow-up as scheduled. Notes: fatigue. Adherence ~0.94. AE: no.
P02056,5,positive,Visit 5: Patient on RX-17B at S010. feels better overall. Notes: brain fog. Adherence ~0.76. AE: no.
P02057,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: no. CRP 10.3 mg/L; ALT 30 U/L.
P02057,1,negative,Visit 1: Patient on RX-17A at S020. poor tolerance. Notes: fatigue. Adherence ~0.98. AE: no.
P02057,2,neutral,Visit 2: Patient on RX-17A at S020. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P02057,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: dizziness. Adherence ~0.98. AE: no.
P02057,4,neutral,Visit 4: Patient on RX-17A at S020. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: no.
P02057,5,neutral,Visit 5: Patient on RX-17A at S020. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P02058,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: joint pain. Adherence ~0.80. AE: no. CRP 4.7 mg/L; ALT 32 U/L.
P02058,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: nausea. Adherence ~0.92. AE: no.
P02058,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: headache. Adherence ~0.86. AE: yes.
P02058,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: no. CRP 3.4 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02058,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.98. AE: no.
P02058,5,neutral,Visit 5: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.88. AE: no.
P02059,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no.
P02059,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P02059,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no. CRP 1.9 mg/L; ALT 35 U/L.
P02060,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.40. AE: no.
P02060,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.27. AE: no. CRP 17.5 mg/L; ALT 16 U/L.
P02060,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.25. AE: no. CRP 17.7 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02060,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.40. AE: no.
P02061,0,neutral,Visit 0: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~0.80. AE: no. CRP 16.7 mg/L; ALT 23 U/L.
P02061,1,neutral,Visit 1: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no.
P02061,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~0.93. AE: no. CRP 15.2 mg/L; ALT 24 U/L.
P02061,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02061,4,positive,Visit 4: Patient on RX-17B at S013. energy increasing. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02062,0,negative,Visit 0: Patient on RX-17A at S009. reports worsening. Notes: fatigue. Adherence ~0.63. AE: no.
P02062,1,negative,Visit 1: Patient on RX-17A at S009. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: no. CRP 4.1 mg/L; ALT 35 U/L.
P02062,2,negative,Visit 2: Patient on RX-17A at S009. symptoms persist. Notes: nausea. Adherence ~1.00. AE: yes.
P02062,3,neutral,Visit 3: Patient on RX-17A at S009. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02062,4,neutral,Visit 4: Patient on RX-17A at S009. reviewed dosing instructions. Notes: headache. Adherence ~0.87. AE: no.
P02062,5,neutral,Visit 5: Patient on RX-17A at S009. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no. CRP 2.5 mg/L; ALT 40 U/L.
P02062,6,neutral,Visit 6: Patient on RX-17A at S009. reviewed dosing instructions. Notes: joint pain. Adherence ~0.66. AE: no. CRP 2.7 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02063,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.53. AE: no.
P02063,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02063,2,positive,Visit 2: Patient on RX-17B at S014. feels better overall. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 3.7 mg/L; ALT 42 U/L.
P02063,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 3.8 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02063,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02063,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: yes. CRP 2.7 mg/L; ALT 48 U/L.
P02064,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: yes.
P02064,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02064,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02064,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.83. AE: no. CRP 6.9 mg/L; ALT 35 U/L.
P02064,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no.
P02065,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: insomnia. Adherence ~0.44. AE: yes.
P02065,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.58. AE: no. CRP 3.6 mg/L; ALT 33 U/L.
P02065,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02065,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no.
P02065,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02065,5,positive,Visit 5: Patient on RX-17B at S012. energy increasing. Notes: dizziness. Adherence ~0.77. AE: no.
P02065,6,neutral,Visit 6: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.66. AE: no.
P02065,7,neutral,Visit 7: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.74. AE: yes.
P02066,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: no. CRP 6.5 mg/L; ALT 36 U/L.
P02066,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.73. AE: no. CRP 7.0 mg/L; ALT 36 U/L.
P02066,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.98. AE: no. CRP 5.5 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02066,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.71. AE: yes. CRP 4.7 mg/L; ALT 39 U/L.
P02066,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.58. AE: yes.
P02067,0,neutral,Visit 0: Patient on RX-17A at S013. follow-up as scheduled. Notes: fatigue. Adherence ~0.57. AE: no.
P02067,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: joint pain. Adherence ~0.61. AE: no. CRP 4.8 mg/L; ALT 45 U/L.
P02067,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02067,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02067,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P02067,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no.
P02067,6,neutral,Visit 6: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.66. AE: no.
P02067,7,neutral,Visit 7: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P02068,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: abdominal discomfort. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02068,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02068,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02068,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~0.80. AE: no.
P02069,0,neutral,Visit 0: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no.
P02069,1,neutral,Visit 1: Patient on RX-17A at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no.
P02069,2,neutral,Visit 2: Patient on RX-17A at S009. no major change. Notes: headache. Adherence ~0.85. AE: no.
P02069,3,neutral,Visit 3: Patient on RX-17A at S009. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: no.
P02069,4,neutral,Visit 4: Patient on RX-17A at S009. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 2.8 mg/L; ALT 27 U/L.
P02069,5,neutral,Visit 5: Patient on RX-17A at S009. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no.
P02069,6,neutral,Visit 6: Patient on RX-17A at S009. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no.
P02070,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.74. AE: yes.
P02070,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.90. AE: yes. CRP 10.5 mg/L; ALT 34 U/L.
P02070,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.83. AE: no.
P02070,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02070,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no. CRP 8.5 mg/L; ALT 28 U/L.
P02070,5,negative,Visit 5: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.80. AE: no. CRP 8.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02070,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.67. AE: no. CRP 7.7 mg/L; ALT 29 U/L.
P02070,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.74. AE: yes.
P02071,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.92. AE: no. CRP 15.0 mg/L; ALT 32 U/L.
P02071,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.96. AE: no.
P02071,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.78. AE: no.
P02072,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.90. AE: no.
P02072,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no. CRP 6.4 mg/L; ALT 14 U/L.
P02072,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02072,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P02072,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: yes.
P02072,5,positive,Visit 5: Patient on RX-17A at S022. energy increasing. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02073,0,neutral,Visit 0: Patient on RX-17A at S019. continues regimen. Notes: headache. Adherence ~0.78. AE: no.
P02073,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02073,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: dizziness. Adherence ~0.84. AE: yes.
P02073,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no.
P02073,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: no.
P02073,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.96. AE: no. CRP 5.5 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02074,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P02074,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: no.
P02074,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.69. AE: no. CRP 9.0 mg/L; ALT 31 U/L.
P02074,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.61. AE: no. CRP 8.3 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02074,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.71. AE: no. CRP 8.2 mg/L; ALT 31 U/L.
P02075,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: no. CRP 7.3 mg/L; ALT 46 U/L.
P02075,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.89. AE: no. CRP 6.5 mg/L; ALT 44 U/L.
P02075,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.67. AE: no.
P02075,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no. CRP 5.3 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02075,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.63. AE: no.
P02075,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no.
P02076,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02076,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: dizziness. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P02076,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.83. AE: no. CRP 16.1 mg/L; ALT 29 U/L.
P02076,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: no. CRP 14.7 mg/L; ALT 29 U/L.
P02076,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.63. AE: no.
P02076,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.58. AE: no.
P02076,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.68. AE: yes. CRP 8.4 mg/L; ALT 27 U/L.
P02077,0,negative,Visit 0: Patient on RX-17B at S018. feels frustrated. Notes: fatigue. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02077,1,negative,Visit 1: Patient on RX-17B at S018. increased discomfort. Notes: insomnia. Adherence ~0.86. AE: yes.
P02077,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P02077,3,negative,Visit 3: Patient on RX-17B at S018. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 23 U/L.
P02077,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 2.2 mg/L; ALT 26 U/L.
P02077,5,positive,Visit 5: Patient on RX-17B at S018. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no.
P02077,6,positive,Visit 6: Patient on RX-17B at S018. energy increasing. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 2.0 mg/L; ALT 25 U/L.
P02078,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.85. AE: yes.
P02078,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no.
P02078,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no. CRP 10.3 mg/L; ALT 36 U/L.
P02078,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 10.3 mg/L; ALT 39 U/L.
P02078,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02079,0,negative,Visit 0: Patient on RX-17A at S009. poor tolerance. Notes: nausea. Adherence ~0.93. AE: no. CRP 6.3 mg/L; ALT 28 U/L.
P02079,1,neutral,Visit 1: Patient on RX-17A at S009. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P02079,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 5.7 mg/L; ALT 26 U/L.
P02079,3,neutral,Visit 3: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no. CRP 5.3 mg/L; ALT 29 U/L.
P02079,4,neutral,Visit 4: Patient on RX-17A at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no.
P02080,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02080,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.50. AE: yes. CRP 3.8 mg/L; ALT 45 U/L.
P02080,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.44. AE: yes.
P02080,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.54. AE: no. CRP 2.8 mg/L; ALT 47 U/L.
P02080,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.56. AE: no.
P02081,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: nausea. Adherence ~0.77. AE: no.
P02081,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02081,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02081,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no.
P02081,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.83. AE: no.
P02082,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P02082,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.56. AE: no.
P02082,2,positive,Visit 2: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~0.81. AE: no.
P02082,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.59. AE: yes. CRP 19.2 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02082,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.55. AE: no.
P02082,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.53. AE: no. CRP 15.6 mg/L; ALT 21 U/L.
P02082,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.72. AE: no. CRP 11.8 mg/L; ALT 23 U/L.
P02083,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: joint pain. Adherence ~0.52. AE: yes.
P02083,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.60. AE: no.
P02083,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.61. AE: no.
P02083,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P02083,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: insomnia. Adherence ~0.46. AE: no. CRP 4.3 mg/L; ALT 53 U/L.
P02083,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02083,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.47. AE: no.
P02083,7,neutral,Visit 7: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P02084,0,negative,Visit 0: Patient on RX-17A at S003. reports worsening. Notes: fatigue. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P02084,1,negative,Visit 1: Patient on RX-17A at S003. poor tolerance. Notes: headache. Adherence ~0.89. AE: no.
P02084,2,neutral,Visit 2: Patient on RX-17A at S003. no major change. Notes: dizziness. Adherence ~0.74. AE: no. CRP 8.1 mg/L; ALT 44 U/L.
P02084,3,negative,Visit 3: Patient on RX-17A at S003. feels frustrated. Notes: headache. Adherence ~0.79. AE: no.
P02084,4,neutral,Visit 4: Patient on RX-17A at S003. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no. CRP 7.2 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P02084,5,neutral,Visit 5: Patient on RX-17A at S003. no major change. Notes: insomnia. Adherence ~0.83. AE: no. CRP 6.8 mg/L; ALT 48 U/L.
P02084,6,neutral,Visit 6: Patient on RX-17A at S003. reviewed dosing instructions. Notes: headache. Adherence ~0.69. AE: no.
P02085,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no. CRP 6.0 mg/L; ALT 24 U/L.
P02085,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: brain fog. Adherence ~0.94. AE: no. CRP 5.2 mg/L; ALT 21 U/L.
P02085,2,positive,Visit 2: Patient on RX-17B at S015. symptoms improving. Notes: headache. Adherence ~0.97. AE: no.
P02085,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no. CRP 4.3 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02085,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no. CRP 3.3 mg/L; ALT 22 U/L.
P02085,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.94. AE: no.
P02086,0,negative,Visit 0: Patient on RX-17A at S018. poor tolerance. Notes: brain fog. Adherence ~0.83. AE: no.
P02086,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.98. AE: no. CRP 5.6 mg/L; ALT 35 U/L.
P02086,2,negative,Visit 2: Patient on RX-17A at S018. feels frustrated. Notes: abdominal discomfort. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P02086,3,positive,Visit 3: Patient on RX-17A at S018. reports improvement. Notes: fatigue. Adherence ~0.87. AE: no. CRP 5.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02087,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.1 mg/L; ALT 28 U/L.
P02087,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.97. AE: no.
P02087,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: dizziness. Adherence ~0.99. AE: yes. CRP 3.1 mg/L; ALT 30 U/L.
P02087,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.98. AE: yes. CRP 3.0 mg/L; ALT 28 U/L.
P02087,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P02087,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no.
P02088,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: yes. CRP 3.8 mg/L; ALT 44 U/L.
P02088,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: dizziness. Adherence ~0.80. AE: no.
P02088,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no. CRP 3.3 mg/L; ALT 36 U/L.
P02088,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.65. AE: yes.
P02089,0,neutral,Visit 0: Patient on RX-17A at S009. no major change. Notes: dizziness. Adherence ~0.79. AE: no. CRP 21.7 mg/L; ALT 22 U/L.
P02089,1,negative,Visit 1: Patient on RX-17A at S009. increased discomfort. Notes: insomnia. Adherence ~0.72. AE: no.
P02089,2,neutral,Visit 2: Patient on RX-17A at S009. follow-up as scheduled. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02089,3,negative,Visit 3: Patient on RX-17A at S009. reports worsening. Notes: brain fog. Adherence ~0.82. AE: no. CRP 17.3 mg/L; ALT 22 U/L.
P02089,4,neutral,Visit 4: Patient on RX-17A at S009. continues regimen. Notes: headache. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02089,5,neutral,Visit 5: Patient on RX-17A at S009. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no. CRP 14.3 mg/L; ALT 22 U/L.
P02090,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: yes.
P02090,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02090,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no.
P02090,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.81. AE: no.
P02090,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.83. AE: no.
P02090,5,positive,Visit 5: Patient on RX-17B at S015. symptoms improving. Notes: insomnia. Adherence ~0.82. AE: no.
P02090,6,positive,Visit 6: Patient on RX-17B at S015. symptoms improving. Notes: insomnia. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02090,7,positive,Visit 7: Patient on RX-17B at S015. symptoms improving. Notes: headache. Adherence ~0.79. AE: no.
P02091,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.56. AE: no.
P02091,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.77. AE: no.
P02091,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.88. AE: yes. CRP 6.4 mg/L; ALT 50 U/L.
P02091,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P02091,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.63. AE: no.
P02091,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P02091,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.62. AE: no.
P02092,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.70. AE: no. CRP 4.1 mg/L; ALT 22 U/L.
P02092,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.53. AE: no.
P02092,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.70. AE: no. CRP 3.7 mg/L; ALT 23 U/L.
P02092,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.71. AE: yes. CRP 3.7 mg/L; ALT 22 U/L.
P02092,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.59. AE: no.
P02092,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02093,0,negative,Visit 0: Patient on RX-17A at S020. feels frustrated. Notes: nausea. Adherence ~0.72. AE: no. CRP 9.0 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02093,1,negative,Visit 1: Patient on RX-17A at S020. reports worsening. Notes: dizziness. Adherence ~0.96. AE: no. CRP 7.3 mg/L; ALT 32 U/L.
P02093,2,neutral,Visit 2: Patient on RX-17A at S020. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no.
P02093,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: joint pain. Adherence ~0.70. AE: no.
P02093,4,neutral,Visit 4: Patient on RX-17A at S020. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no.
P02094,0,neutral,Visit 0: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no.
P02094,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: headache. Adherence ~0.52. AE: no.
P02094,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~0.59. AE: no.
P02094,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. CRP 2.6 mg/L; ALT 45 U/L.
P02094,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.61. AE: no.
P02095,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02095,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~0.93. AE: no. CRP 4.5 mg/L; ALT 19 U/L.
P02095,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.93. AE: no. CRP 3.8 mg/L; ALT 22 U/L.
P02095,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.85. AE: no. CRP 4.3 mg/L; ALT 22 U/L.
P02095,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.98. AE: no.
P02095,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: brain fog. Adherence ~0.91. AE: no.
P02096,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.59. AE: no. CRP 3.9 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02096,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.70. AE: no.
P02096,2,negative,Visit 2: Patient on RX-17B at S015. poor tolerance. Notes: joint pain. Adherence ~0.67. AE: no. CRP 3.3 mg/L; ALT 24 U/L.
P02096,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.65. AE: no.
P02096,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 2.6 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02096,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: yes. CRP 2.5 mg/L; ALT 28 U/L.
P02097,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.57. AE: no. CRP 16.9 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02097,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no.
P02097,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.46. AE: no. CRP 13.1 mg/L; ALT 32 U/L.
P02097,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.48. AE: no.
P02097,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.45. AE: no. CRP 10.7 mg/L; ALT 36 U/L.
P02097,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.50. AE: no. CRP 10.8 mg/L; ALT 37 U/L.
P02097,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P02098,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no.
P02098,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.71. AE: no.
P02098,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no. CRP 2.7 mg/L; ALT 29 U/L.
P02098,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.87. AE: yes.
P02098,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02098,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02098,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 1.8 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02098,7,positive,Visit 7: Patient on RX-17A at S014. tolerating medication well. Notes: fatigue. Adherence ~0.83. AE: no.
P02099,0,neutral,Visit 0: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no.
P02099,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.66. AE: no.
P02099,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: nausea. Adherence ~0.82. AE: no.
P02099,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no.
P02099,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no.
P02099,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: headache. Adherence ~0.93. AE: no.
P02099,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P02100,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.96. AE: no.
P02100,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.87. AE: yes. CRP 2.4 mg/L; ALT 30 U/L.
P02100,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.0 mg/L; ALT 27 U/L.
P02100,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 2.1 mg/L; ALT 28 U/L.
P02100,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.96. AE: no. CRP 1.8 mg/L; ALT 29 U/L.
P02100,5,positive,Visit 5: Patient on RX-17A at S004. feels better overall. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P02101,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no.
P02101,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: insomnia. Adherence ~0.89. AE: no.
P02101,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no. CRP 3.1 mg/L; ALT 60 U/L.
P02101,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no.
P02101,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.67. AE: no. CRP 3.8 mg/L; ALT 57 U/L.
P02101,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: no. CRP 3.2 mg/L; ALT 63 U/L.
P02101,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02101,7,neutral,Visit 7: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: yes.
P02102,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no. CRP 5.7 mg/L; ALT 61 U/L.
P02102,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.84. AE: no.
P02102,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P02102,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P02103,0,neutral,Visit 0: Patient on RX-17B at S019. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no.
P02103,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.68. AE: no.
P02103,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02103,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P02103,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.90. AE: no. CRP 8.2 mg/L; ALT 24 U/L.
P02103,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02104,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.67. AE: no. CRP 6.9 mg/L; ALT 21 U/L.
P02104,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.62. AE: no.
P02104,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.80. AE: no. CRP 6.0 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02104,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P02104,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02104,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 4.5 mg/L; ALT 23 U/L.
P02104,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.63. AE: yes. CRP 4.4 mg/L; ALT 24 U/L.
P02105,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.56. AE: no.
P02105,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.43. AE: no.
P02105,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.59. AE: no. CRP 5.5 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02105,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.42. AE: no.
P02105,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no. CRP 4.2 mg/L; ALT 28 U/L.
P02105,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.48. AE: no.
P02105,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.52. AE: no. CRP 3.7 mg/L; ALT 26 U/L.
P02106,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: headache. Adherence ~0.60. AE: no. CRP 9.4 mg/L; ALT 60 U/L. Plan: consider dose adjustment; counsel patient.
P02106,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.77. AE: yes. CRP 8.7 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P02106,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.73. AE: yes.
P02106,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02106,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P02106,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02107,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.63. AE: no.
P02107,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.82. AE: no. CRP 5.7 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P02107,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.77. AE: no.
P02107,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.68. AE: no.
P02107,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P02108,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02108,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no.
P02108,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.85. AE: no.
P02108,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: yes.
P02109,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02109,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no.
P02109,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02109,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.81. AE: no.
P02109,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.65. AE: yes.
P02109,5,negative,Visit 5: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no.
P02109,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 40 U/L.
P02109,7,negative,Visit 7: Patient on RX-17A at S022. poor tolerance. Notes: joint pain. Adherence ~0.74. AE: no. CRP 2.9 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02110,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.77. AE: no.
P02110,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P02110,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02110,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.86. AE: no.
P02110,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.89. AE: no. CRP 6.4 mg/L; ALT 19 U/L.
P02110,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: nausea. Adherence ~0.98. AE: no.
P02111,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.25. AE: no.
P02111,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.47. AE: no. CRP 9.6 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02111,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.51. AE: no. CRP 10.1 mg/L; ALT 21 U/L.
P02111,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~0.53. AE: no. CRP 9.3 mg/L; ALT 21 U/L.
P02111,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.48. AE: no.
P02111,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.49. AE: no.
P02112,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.75. AE: no.
P02112,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.71. AE: no.
P02112,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.68. AE: no.
P02112,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.72. AE: yes. CRP 4.3 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02112,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.79. AE: no.
P02112,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.68. AE: no.
P02112,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.53. AE: yes.
P02112,7,positive,Visit 7: Patient on RX-17A at S014. tolerating medication well. Notes: joint pain. Adherence ~0.77. AE: no.
P02113,0,neutral,Visit 0: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.91. AE: no.
P02113,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: headache. Adherence ~0.81. AE: no. CRP 8.0 mg/L; ALT 24 U/L.
P02113,2,neutral,Visit 2: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 6.9 mg/L; ALT 23 U/L.
P02113,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.88. AE: no.
P02113,4,positive,Visit 4: Patient on RX-17A at S013. symptoms improving. Notes: headache. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02113,5,positive,Visit 5: Patient on RX-17A at S013. feels better overall. Notes: insomnia. Adherence ~0.84. AE: no.
P02113,6,positive,Visit 6: Patient on RX-17A at S013. feels better overall. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02114,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~0.74. AE: no.
P02114,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02114,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: brain fog. Adherence ~0.83. AE: no.
P02114,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: yes.
P02114,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.59. AE: no. CRP 4.5 mg/L; ALT 23 U/L.
P02114,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 3.1 mg/L; ALT 24 U/L.
P02115,0,negative,Visit 0: Patient on RX-17A at S021. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 8.6 mg/L; ALT 24 U/L.
P02115,1,neutral,Visit 1: Patient on RX-17A at S021. no major change. Notes: joint pain. Adherence ~0.83. AE: no. CRP 7.6 mg/L; ALT 24 U/L.
P02115,2,positive,Visit 2: Patient on RX-17A at S021. symptoms improving. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02115,3,neutral,Visit 3: Patient on RX-17A at S021. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no.
P02115,4,neutral,Visit 4: Patient on RX-17A at S021. no major change. Notes: joint pain. Adherence ~0.77. AE: no.
P02115,5,positive,Visit 5: Patient on RX-17A at S021. feels better overall. Notes: insomnia. Adherence ~0.81. AE: no.
P02116,0,neutral,Visit 0: Patient on RX-17B at S008. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P02116,1,neutral,Visit 1: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P02116,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no.
P02116,3,positive,Visit 3: Patient on RX-17B at S008. tolerating medication well. Notes: headache. Adherence ~0.80. AE: no.
P02116,4,neutral,Visit 4: Patient on RX-17B at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02117,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P02117,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: headache. Adherence ~0.95. AE: no. CRP 7.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02117,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 32 U/L.
P02117,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: headache. Adherence ~0.88. AE: no. CRP 5.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02117,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P02118,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.74. AE: no.
P02118,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.56. AE: yes. CRP 3.4 mg/L; ALT 49 U/L.
P02118,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.74. AE: no.
P02118,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P02118,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.65. AE: yes. CRP 3.2 mg/L; ALT 56 U/L.
P02118,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no.
P02118,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.56. AE: no.
P02119,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.94. AE: no. CRP 19.9 mg/L; ALT 36 U/L.
P02119,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.93. AE: no.
P02119,2,negative,Visit 2: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.85. AE: no.
P02119,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02119,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.93. AE: no.
P02119,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P02119,6,positive,Visit 6: Patient on RX-17A at S002. energy increasing. Notes: brain fog. Adherence ~0.86. AE: no.
P02119,7,neutral,Visit 7: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no.
P02120,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02120,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.86. AE: no.
P02120,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02120,3,negative,Visit 3: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.92. AE: no.
P02120,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02121,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no. CRP 3.2 mg/L; ALT 34 U/L.
P02121,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.78. AE: no.
P02121,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02121,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 2.5 mg/L; ALT 30 U/L.
P02121,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: no.
P02121,5,negative,Visit 5: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.68. AE: no. CRP 2.1 mg/L; ALT 33 U/L.
P02121,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.88. AE: no. CRP 1.9 mg/L; ALT 30 U/L.
P02122,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no. CRP 6.3 mg/L; ALT 20 U/L.
P02122,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.81. AE: no.
P02122,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.52. AE: no. CRP 5.7 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02122,3,negative,Visit 3: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.65. AE: no. CRP 4.4 mg/L; ALT 16 U/L.
P02122,4,positive,Visit 4: Patient on RX-17A at S015. tolerating medication well. Notes: nausea. Adherence ~0.83. AE: no. CRP 3.8 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02122,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02122,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 3.9 mg/L; ALT 19 U/L.
P02123,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.64. AE: no.
P02123,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02123,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.83. AE: yes. CRP 2.9 mg/L; ALT 14 U/L.
P02123,3,negative,Visit 3: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.83. AE: no.
P02123,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.60. AE: no.
P02124,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 12.2 mg/L; ALT 35 U/L.
P02124,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02124,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02124,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.97. AE: no.
P02124,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 8.4 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P02125,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: headache. Adherence ~0.82. AE: yes.
P02125,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 6.2 mg/L; ALT 42 U/L.
P02125,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.80. AE: no.
P02125,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.71. AE: no.
P02125,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P02125,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no.
P02126,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: brain fog. Adherence ~0.80. AE: yes. CRP 7.1 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02126,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: insomnia. Adherence ~0.51. AE: no.
P02126,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.66. AE: no.
P02126,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P02126,4,negative,Visit 4: Patient on RX-17B at S019. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 5.0 mg/L; ALT 37 U/L.
P02127,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.81. AE: no. CRP 4.3 mg/L; ALT 24 U/L.
P02127,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: brain fog. Adherence ~0.94. AE: no.
P02127,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.87. AE: no.
P02127,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02127,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.78. AE: no. CRP 3.8 mg/L; ALT 29 U/L.
P02127,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.87. AE: no. CRP 3.0 mg/L; ALT 28 U/L.
P02127,6,positive,Visit 6: Patient on RX-17A at S004. reports improvement. Notes: brain fog. Adherence ~0.89. AE: no. CRP 2.8 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02127,7,neutral,Visit 7: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.69. AE: no.
P02128,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: dizziness. Adherence ~0.88. AE: no.
P02128,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no.
P02128,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.87. AE: no.
P02128,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.98. AE: no.
P02128,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.73. AE: no. CRP 3.8 mg/L; ALT 20 U/L.
P02128,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02128,6,neutral,Visit 6: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.0 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02128,7,neutral,Visit 7: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.71. AE: yes. CRP 2.2 mg/L; ALT 20 U/L.
P02129,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02129,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~0.83. AE: no.
P02129,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P02129,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.75. AE: no.
P02130,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.93. AE: no.
P02130,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.70. AE: no.
P02130,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02130,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.76. AE: no.
P02130,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.82. AE: no.
P02131,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.79. AE: no.
P02131,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.91. AE: no. CRP 10.8 mg/L; ALT 35 U/L.
P02131,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.94. AE: no.
P02131,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.91. AE: no.
P02131,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.93. AE: no. CRP 9.8 mg/L; ALT 33 U/L.
P02131,5,positive,Visit 5: Patient on RX-17A at S012. feels better overall. Notes: brain fog. Adherence ~1.00. AE: no.
P02131,6,positive,Visit 6: Patient on RX-17A at S012. reports improvement. Notes: dizziness. Adherence ~0.94. AE: no.
P02132,0,negative,Visit 0: Patient on RX-17B at S003. symptoms persist. Notes: headache. Adherence ~0.78. AE: no. CRP 3.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02132,1,negative,Visit 1: Patient on RX-17B at S003. feels frustrated. Notes: insomnia. Adherence ~0.87. AE: no.
P02132,2,negative,Visit 2: Patient on RX-17B at S003. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02132,3,neutral,Visit 3: Patient on RX-17B at S003. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no.
P02132,4,neutral,Visit 4: Patient on RX-17B at S003. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P02132,5,positive,Visit 5: Patient on RX-17B at S003. symptoms improving. Notes: nausea. Adherence ~0.86. AE: no. CRP 2.0 mg/L; ALT 30 U/L.
P02132,6,positive,Visit 6: Patient on RX-17B at S003. symptoms improving. Notes: fatigue. Adherence ~0.93. AE: no.
P02133,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.91. AE: no. CRP 6.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02133,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: dizziness. Adherence ~0.83. AE: no. CRP 5.7 mg/L; ALT 26 U/L.
P02133,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.84. AE: no. CRP 5.9 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02133,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.98. AE: no. CRP 4.8 mg/L; ALT 27 U/L.
P02133,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.69. AE: no.
P02133,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: nausea. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02133,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.65. AE: no.
P02134,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no.
P02134,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: dizziness. Adherence ~0.98. AE: yes.
P02134,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.93. AE: no.
P02134,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no.
P02134,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: joint pain. Adherence ~0.75. AE: yes.
P02134,5,positive,Visit 5: Patient on RX-17B at S008. feels better overall. Notes: insomnia. Adherence ~0.98. AE: no. CRP 4.7 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02134,6,positive,Visit 6: Patient on RX-17B at S008. energy increasing. Notes: fatigue. Adherence ~0.87. AE: no. CRP 4.6 mg/L; ALT 24 U/L.
P02134,7,neutral,Visit 7: Patient on RX-17B at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02135,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.60. AE: no.
P02135,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.44. AE: no.
P02135,2,negative,Visit 2: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~0.55. AE: no.
P02135,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.66. AE: no.
P02135,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.60. AE: no.
P02135,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.51. AE: no.
P02136,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: headache. Adherence ~0.72. AE: no. CRP 2.9 mg/L; ALT 25 U/L.
P02136,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no.
P02136,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no. CRP 2.5 mg/L; ALT 22 U/L.
P02136,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.52. AE: no. CRP 2.4 mg/L; ALT 21 U/L.
P02136,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.67. AE: no. CRP 2.2 mg/L; ALT 27 U/L.
P02136,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.60. AE: no. CRP 2.0 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02136,6,negative,Visit 6: Patient on RX-17A at S005. poor tolerance. Notes: nausea. Adherence ~0.72. AE: yes.
P02136,7,neutral,Visit 7: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no. CRP 1.8 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02137,0,negative,Visit 0: Patient on RX-17B at S009. reports worsening. Notes: nausea. Adherence ~0.77. AE: no.
P02137,1,negative,Visit 1: Patient on RX-17B at S009. feels frustrated. Notes: nausea. Adherence ~0.88. AE: no.
P02137,2,negative,Visit 2: Patient on RX-17B at S009. feels frustrated. Notes: nausea. Adherence ~0.88. AE: yes. CRP 2.5 mg/L; ALT 28 U/L.
P02137,3,neutral,Visit 3: Patient on RX-17B at S009. no major change. Notes: fatigue. Adherence ~0.66. AE: no. CRP 2.6 mg/L; ALT 26 U/L.
P02137,4,neutral,Visit 4: Patient on RX-17B at S009. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: no.
P02137,5,neutral,Visit 5: Patient on RX-17B at S009. continues regimen. Notes: joint pain. Adherence ~0.72. AE: no.
P02137,6,positive,Visit 6: Patient on RX-17B at S009. reports improvement. Notes: brain fog. Adherence ~0.80. AE: no. CRP 1.7 mg/L; ALT 26 U/L.
P02137,7,neutral,Visit 7: Patient on RX-17B at S009. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: yes. CRP 1.5 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02138,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~1.00. AE: no. CRP 17.2 mg/L; ALT 58 U/L.
P02138,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.81. AE: no. CRP 14.2 mg/L; ALT 49 U/L.
P02138,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.97. AE: no.
P02138,3,negative,Visit 3: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02138,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: yes.
P02139,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.58. AE: no.
P02139,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.58. AE: no. CRP 3.7 mg/L; ALT 31 U/L.
P02139,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no.
P02139,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02139,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.47. AE: no. CRP 3.2 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02139,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.53. AE: no. CRP 2.4 mg/L; ALT 28 U/L.
P02139,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no.
P02139,7,neutral,Visit 7: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.64. AE: no. CRP 2.0 mg/L; ALT 31 U/L.
P02140,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: joint pain. Adherence ~0.77. AE: no. CRP 7.7 mg/L; ALT 12 U/L.
P02140,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.66. AE: yes.
P02140,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 6.7 mg/L; ALT 13 U/L.
P02140,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: yes.
P02140,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02140,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P02140,6,neutral,Visit 6: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.74. AE: no.
P02140,7,positive,Visit 7: Patient on RX-17B at S012. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02141,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.59. AE: yes. CRP 5.8 mg/L; ALT 27 U/L.
P02141,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.51. AE: yes.
P02141,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.66. AE: no.
P02141,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.52. AE: no. CRP 5.1 mg/L; ALT 28 U/L.
P02141,4,negative,Visit 4: Patient on RX-17B at S014. poor tolerance. Notes: insomnia. Adherence ~0.66. AE: yes. CRP 4.3 mg/L; ALT 32 U/L.
P02141,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02142,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.91. AE: no.
P02142,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02142,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P02142,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no. CRP 5.5 mg/L; ALT 21 U/L.
P02142,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02142,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no.
P02142,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P02142,7,positive,Visit 7: Patient on RX-17A at S017. tolerating medication well. Notes: joint pain. Adherence ~1.00. AE: no.
P02143,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02143,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.63. AE: yes. Plan: consider dose adjustment; counsel patient.
P02143,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no.
P02143,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P02143,4,negative,Visit 4: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.50. AE: no.
P02143,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no.
P02143,6,negative,Visit 6: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.54. AE: no.
P02144,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02144,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.81. AE: yes.
P02144,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.76. AE: no. CRP 10.0 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02144,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02144,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no.
P02144,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no.
P02144,6,positive,Visit 6: Patient on RX-17A at S015. reports improvement. Notes: brain fog. Adherence ~0.78. AE: no.
P02145,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.94. AE: no. CRP 7.5 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02145,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. CRP 7.8 mg/L; ALT 38 U/L.
P02145,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.86. AE: no.
P02145,3,negative,Visit 3: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.87. AE: yes. CRP 5.0 mg/L; ALT 43 U/L.
P02145,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.92. AE: no.
P02145,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: yes. CRP 4.2 mg/L; ALT 40 U/L.
P02146,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.89. AE: no.
P02146,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.93. AE: yes.
P02146,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.95. AE: yes.
P02146,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02146,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.82. AE: yes. CRP 3.9 mg/L; ALT 29 U/L.
P02146,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.96. AE: yes.
P02147,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.98. AE: no.
P02147,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: yes.
P02147,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 28 U/L.
P02147,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no.
P02147,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: joint pain. Adherence ~1.00. AE: no.
P02147,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.92. AE: yes.
P02148,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.93. AE: no. CRP 3.7 mg/L; ALT 28 U/L.
P02148,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P02148,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: fatigue. Adherence ~0.77. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P02148,3,negative,Visit 3: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.51. AE: no.
P02148,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.78. AE: no.
P02148,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P02148,6,positive,Visit 6: Patient on RX-17B at S017. reports improvement. Notes: headache. Adherence ~0.81. AE: no.
P02149,0,negative,Visit 0: Patient on RX-17B at S003. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02149,1,neutral,Visit 1: Patient on RX-17B at S003. continues regimen. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 9.6 mg/L; ALT 30 U/L.
P02149,2,neutral,Visit 2: Patient on RX-17B at S003. continues regimen. Notes: nausea. Adherence ~0.93. AE: no.
P02149,3,neutral,Visit 3: Patient on RX-17B at S003. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: no.
P02149,4,neutral,Visit 4: Patient on RX-17B at S003. stable symptoms. Notes: nausea. Adherence ~0.82. AE: yes. CRP 6.8 mg/L; ALT 34 U/L.
P02149,5,positive,Visit 5: Patient on RX-17B at S003. energy increasing. Notes: fatigue. Adherence ~0.94. AE: no.
P02150,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: headache. Adherence ~0.94. AE: yes.
P02150,1,negative,Visit 1: Patient on RX-17A at S013. reports worsening. Notes: insomnia. Adherence ~0.91. AE: no.
P02150,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: nausea. Adherence ~0.89. AE: no. CRP 4.0 mg/L; ALT 30 U/L.
P02150,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 27 U/L.
P02150,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.98. AE: no. CRP 4.0 mg/L; ALT 28 U/L.
P02150,5,negative,Visit 5: Patient on RX-17A at S013. reports worsening. Notes: joint pain. Adherence ~0.90. AE: no. CRP 3.8 mg/L; ALT 30 U/L.
P02150,6,positive,Visit 6: Patient on RX-17A at S013. symptoms improving. Notes: brain fog. Adherence ~0.87. AE: no.
P02151,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 5.0 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02151,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no.
P02151,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no. CRP 4.5 mg/L; ALT 28 U/L.
P02151,3,negative,Visit 3: Patient on RX-17A at S016. feels frustrated. Notes: joint pain. Adherence ~0.98. AE: no.
P02151,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.98. AE: no. CRP 4.1 mg/L; ALT 27 U/L.
P02151,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.99. AE: no.
P02151,6,neutral,Visit 6: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.88. AE: no. CRP 2.8 mg/L; ALT 28 U/L.
P02151,7,positive,Visit 7: Patient on RX-17A at S016. reports improvement. Notes: joint pain. Adherence ~0.85. AE: no.
P02152,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.79. AE: no.
P02152,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P02152,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: yes.
P02153,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.92. AE: no.
P02153,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P02153,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.86. AE: no.
P02153,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 4.3 mg/L; ALT 36 U/L.
P02153,4,positive,Visit 4: Patient on RX-17A at S014. feels better overall. Notes: joint pain. Adherence ~1.00. AE: no.
P02154,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.66. AE: yes.
P02154,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: brain fog. Adherence ~0.86. AE: no. CRP 6.2 mg/L; ALT 30 U/L.
P02154,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no.
P02154,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.64. AE: yes.
P02154,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P02154,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02154,6,neutral,Visit 6: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02155,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.98. AE: no.
P02155,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02155,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.76. AE: yes. CRP 11.8 mg/L; ALT 51 U/L.
P02155,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: yes.
P02155,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02155,5,positive,Visit 5: Patient on RX-17B at S014. symptoms improving. Notes: headache. Adherence ~0.77. AE: no.
P02155,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.85. AE: yes.
P02156,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.93. AE: no.
P02156,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: no. CRP 4.0 mg/L; ALT 26 U/L.
P02156,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.79. AE: no.
P02156,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 3.6 mg/L; ALT 26 U/L.
P02156,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.83. AE: no.
P02156,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02157,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no. CRP 9.6 mg/L; ALT 32 U/L.
P02157,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.71. AE: no.
P02157,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P02157,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.43. AE: no.
P02157,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.45. AE: no. CRP 6.4 mg/L; ALT 32 U/L.
P02157,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.43. AE: no. CRP 6.3 mg/L; ALT 32 U/L.
P02157,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.54. AE: no.
P02158,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.83. AE: no.
P02158,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.98. AE: no. CRP 11.9 mg/L; ALT 72 U/L.
P02158,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: yes.
P02158,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: yes.
P02158,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: joint pain. Adherence ~0.93. AE: no.
P02158,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02158,6,positive,Visit 6: Patient on RX-17B at S014. energy increasing. Notes: nausea. Adherence ~0.81. AE: no.
P02159,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02159,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no.
P02159,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: brain fog. Adherence ~0.80. AE: yes. Plan: consider dose adjustment; counsel patient.
P02159,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.87. AE: no.
P02159,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.71. AE: no. CRP 8.3 mg/L; ALT 32 U/L.
P02159,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.86. AE: no.
P02159,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P02160,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no. CRP 25.3 mg/L; ALT 30 U/L.
P02160,1,negative,Visit 1: Patient on RX-17A at S019. reports worsening. Notes: joint pain. Adherence ~0.59. AE: no.
P02160,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: no. CRP 20.5 mg/L; ALT 34 U/L.
P02160,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.54. AE: no.
P02160,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 18.7 mg/L; ALT 32 U/L.
P02161,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: fatigue. Adherence ~0.69. AE: no.
P02161,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.98. AE: no.
P02161,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.80. AE: no. CRP 4.7 mg/L; ALT 18 U/L.
P02161,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no. CRP 4.0 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02161,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.67. AE: yes. Plan: consider dose adjustment; counsel patient.
P02161,5,positive,Visit 5: Patient on RX-17A at S015. tolerating medication well. Notes: fatigue. Adherence ~0.79. AE: no.
P02161,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.74. AE: no.
P02161,7,neutral,Visit 7: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.74. AE: no.
P02162,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: dizziness. Adherence ~0.77. AE: no.
P02162,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P02162,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.68. AE: no. CRP 4.3 mg/L; ALT 25 U/L.
P02162,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no. CRP 3.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02162,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.71. AE: no. CRP 3.1 mg/L; ALT 25 U/L.
P02162,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.62. AE: yes.
P02162,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02162,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.53. AE: no. CRP 2.1 mg/L; ALT 26 U/L.
P02163,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P02163,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.71. AE: no. CRP 10.8 mg/L; ALT 26 U/L.
P02163,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P02163,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.83. AE: no.
P02163,4,positive,Visit 4: Patient on RX-17A at S017. reports improvement. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02164,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: no. CRP 12.2 mg/L; ALT 37 U/L.
P02164,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: brain fog. Adherence ~0.99. AE: no.
P02164,2,negative,Visit 2: Patient on RX-17A at S019. feels frustrated. Notes: brain fog. Adherence ~0.85. AE: no.
P02164,3,positive,Visit 3: Patient on RX-17A at S019. reports improvement. Notes: headache. Adherence ~0.90. AE: no.
P02164,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.75. AE: no.
P02164,5,positive,Visit 5: Patient on RX-17A at S019. feels better overall. Notes: nausea. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02164,6,positive,Visit 6: Patient on RX-17A at S019. tolerating medication well. Notes: headache. Adherence ~0.83. AE: no.
P02165,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: joint pain. Adherence ~0.93. AE: no. CRP 4.3 mg/L; ALT 40 U/L.
P02165,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P02165,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.95. AE: no. CRP 4.2 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02165,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no. CRP 3.6 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P02165,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02166,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: headache. Adherence ~0.91. AE: yes.
P02166,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: fatigue. Adherence ~0.67. AE: no.
P02166,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P02166,3,negative,Visit 3: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.68. AE: no. CRP 7.9 mg/L; ALT 37 U/L.
P02166,4,negative,Visit 4: Patient on RX-17A at S002. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: no.
P02166,5,neutral,Visit 5: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.61. AE: yes.
P02167,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: no. CRP 30.2 mg/L; ALT 37 U/L.
P02167,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02167,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.96. AE: no. CRP 26.2 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P02167,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.75. AE: no.
P02167,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P02167,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~0.89. AE: no.
P02168,0,negative,Visit 0: Patient on RX-17A at S006. feels frustrated. Notes: headache. Adherence ~0.61. AE: yes.
P02168,1,negative,Visit 1: Patient on RX-17A at S006. symptoms persist. Notes: joint pain. Adherence ~0.64. AE: no.
P02168,2,neutral,Visit 2: Patient on RX-17A at S006. follow-up as scheduled. Notes: insomnia. Adherence ~0.37. AE: no.
P02168,3,neutral,Visit 3: Patient on RX-17A at S006. stable symptoms. Notes: abdominal discomfort. Adherence ~0.41. AE: no. CRP 7.0 mg/L; ALT 22 U/L.
P02168,4,neutral,Visit 4: Patient on RX-17A at S006. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P02168,5,negative,Visit 5: Patient on RX-17A at S006. poor tolerance. Notes: insomnia. Adherence ~0.40. AE: yes.
P02168,6,neutral,Visit 6: Patient on RX-17A at S006. stable symptoms. Notes: dizziness. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P02168,7,neutral,Visit 7: Patient on RX-17A at S006. follow-up as scheduled. Notes: headache. Adherence ~0.42. AE: no.
P02169,0,negative,Visit 0: Patient on RX-17B at S019. poor tolerance. Notes: headache. Adherence ~0.95. AE: no.
P02169,1,neutral,Visit 1: Patient on RX-17B at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.96. AE: no.
P02169,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.80. AE: no. CRP 11.1 mg/L; ALT 38 U/L.
P02169,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.79. AE: yes. CRP 8.7 mg/L; ALT 40 U/L.
P02169,4,neutral,Visit 4: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P02169,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no. CRP 6.5 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02170,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.77. AE: no. CRP 18.5 mg/L; ALT 30 U/L.
P02170,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no.
P02170,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: joint pain. Adherence ~0.59. AE: yes.
P02170,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 14.0 mg/L; ALT 32 U/L.
P02170,4,negative,Visit 4: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.66. AE: no.
P02171,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: no. CRP 27.6 mg/L; ALT 30 U/L.
P02171,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: no.
P02171,2,neutral,Visit 2: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.60. AE: no.
P02171,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02171,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.68. AE: no.
P02171,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no. CRP 18.5 mg/L; ALT 29 U/L.
P02171,6,neutral,Visit 6: Patient on RX-17A at S013. no major change. Notes: headache. Adherence ~0.68. AE: no. CRP 16.2 mg/L; ALT 31 U/L.
P02171,7,positive,Visit 7: Patient on RX-17A at S013. energy increasing. Notes: nausea. Adherence ~0.76. AE: no. CRP 14.7 mg/L; ALT 31 U/L.
P02172,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~0.84. AE: no.
P02172,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P02172,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02172,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02172,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.98. AE: no. CRP 6.6 mg/L; ALT 29 U/L.
P02172,5,neutral,Visit 5: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 28 U/L.
P02172,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P02172,7,neutral,Visit 7: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.90. AE: no. CRP 4.7 mg/L; ALT 25 U/L.
P02173,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.56. AE: yes.
P02173,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.66. AE: yes.
P02173,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.27. AE: no.
P02173,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.37. AE: no.
P02173,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P02174,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: dizziness. Adherence ~0.69. AE: yes.
P02174,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02174,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no.
P02174,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.61. AE: no.
P02174,4,negative,Visit 4: Patient on RX-17B at S016. poor tolerance. Notes: nausea. Adherence ~0.46. AE: no.
P02174,5,neutral,Visit 5: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.52. AE: no.
P02174,6,neutral,Visit 6: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.67. AE: no. CRP 2.3 mg/L; ALT 22 U/L.
P02175,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02175,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. CRP 7.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02175,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: nausea. Adherence ~0.70. AE: yes. Plan: consider dose adjustment; counsel patient.
P02175,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 5.8 mg/L; ALT 36 U/L.
P02175,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02175,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: yes.
P02175,6,negative,Visit 6: Patient on RX-17A at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.95. AE: yes.
P02176,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.98. AE: no.
P02176,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.86. AE: no.
P02176,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.89. AE: no. CRP 5.3 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02176,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.87. AE: no. CRP 4.5 mg/L; ALT 40 U/L.
P02176,4,positive,Visit 4: Patient on RX-17B at S004. symptoms improving. Notes: headache. Adherence ~1.00. AE: no.
P02177,0,neutral,Visit 0: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.35. AE: no. Plan: consider dose adjustment; counsel patient.
P02177,1,neutral,Visit 1: Patient on RX-17B at S020. no major change. Notes: brain fog. Adherence ~0.46. AE: no.
P02177,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: headache. Adherence ~0.59. AE: no.
P02177,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: joint pain. Adherence ~0.55. AE: no.
P02177,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: nausea. Adherence ~0.59. AE: no. CRP 1.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02177,5,neutral,Visit 5: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.60. AE: yes. CRP 1.6 mg/L; ALT 34 U/L.
P02178,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.72. AE: yes. CRP 2.8 mg/L; ALT 32 U/L.
P02178,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.78. AE: no.
P02178,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no.
P02178,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: no.
P02178,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 2.0 mg/L; ALT 32 U/L.
P02178,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P02178,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.71. AE: no.
P02179,0,neutral,Visit 0: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P02179,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P02179,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02179,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 7.6 mg/L; ALT 26 U/L.
P02179,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.94. AE: no.
P02179,5,positive,Visit 5: Patient on RX-17A at S005. tolerating medication well. Notes: insomnia. Adherence ~1.00. AE: no.
P02179,6,positive,Visit 6: Patient on RX-17A at S005. feels better overall. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02180,0,neutral,Visit 0: Patient on RX-17A at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: no. CRP 8.2 mg/L; ALT 35 U/L.
P02180,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: headache. Adherence ~0.90. AE: no.
P02180,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no. CRP 7.0 mg/L; ALT 32 U/L.
P02180,3,negative,Visit 3: Patient on RX-17A at S011. feels frustrated. Notes: headache. Adherence ~0.73. AE: yes.
P02180,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no.
P02180,5,neutral,Visit 5: Patient on RX-17A at S011. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 7.1 mg/L; ALT 37 U/L.
P02180,6,neutral,Visit 6: Patient on RX-17A at S011. continues regimen. Notes: headache. Adherence ~0.85. AE: no.
P02181,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02181,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.64. AE: no.
P02181,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.70. AE: no.
P02181,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.59. AE: yes. CRP 3.2 mg/L; ALT 34 U/L.
P02181,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 3.6 mg/L; ALT 28 U/L.
P02181,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.85. AE: no.
P02181,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: yes.
P02181,7,neutral,Visit 7: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P02182,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: joint pain. Adherence ~0.94. AE: no. CRP 17.5 mg/L; ALT 26 U/L.
P02182,1,negative,Visit 1: Patient on RX-17B at S016. feels frustrated. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02182,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02182,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P02182,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.95. AE: no.
P02182,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: yes.
P02182,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: yes.
P02183,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 42 U/L.
P02183,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 43 U/L.
P02183,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 4.1 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P02184,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.83. AE: no.
P02184,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02184,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 7.6 mg/L; ALT 41 U/L.
P02185,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: dizziness. Adherence ~0.66. AE: no. CRP 5.5 mg/L; ALT 18 U/L.
P02185,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no. CRP 5.7 mg/L; ALT 20 U/L.
P02185,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02185,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.69. AE: no.
P02185,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P02186,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02186,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no.
P02186,2,negative,Visit 2: Patient on RX-17A at S002. feels frustrated. Notes: joint pain. Adherence ~0.92. AE: no.
P02186,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 6.0 mg/L; ALT 28 U/L.
P02186,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.86. AE: no.
P02186,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: no. CRP 5.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02186,6,neutral,Visit 6: Patient on RX-17A at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.79. AE: no. CRP 4.6 mg/L; ALT 33 U/L.
P02187,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.66. AE: yes.
P02187,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.58. AE: no. CRP 10.6 mg/L; ALT 23 U/L.
P02187,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02187,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.69. AE: no. CRP 10.2 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02187,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.53. AE: no. CRP 8.3 mg/L; ALT 24 U/L.
P02187,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.51. AE: no.
P02187,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02187,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: no.
P02188,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~0.95. AE: yes.
P02188,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: no.
P02188,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no.
P02188,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no.
P02188,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: yes. CRP 6.2 mg/L; ALT 36 U/L.
P02188,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P02188,6,positive,Visit 6: Patient on RX-17B at S002. symptoms improving. Notes: insomnia. Adherence ~0.90. AE: no.
P02189,0,neutral,Visit 0: Patient on RX-17B at S001. continues regimen. Notes: headache. Adherence ~0.67. AE: no.
P02189,1,negative,Visit 1: Patient on RX-17B at S001. increased discomfort. Notes: insomnia. Adherence ~0.60. AE: yes.
P02189,2,neutral,Visit 2: Patient on RX-17B at S001. continues regimen. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02189,3,neutral,Visit 3: Patient on RX-17B at S001. no major change. Notes: nausea. Adherence ~0.57. AE: no.
P02189,4,neutral,Visit 4: Patient on RX-17B at S001. continues regimen. Notes: insomnia. Adherence ~0.45. AE: no.
P02189,5,neutral,Visit 5: Patient on RX-17B at S001. stable symptoms. Notes: brain fog. Adherence ~0.53. AE: yes.
P02189,6,neutral,Visit 6: Patient on RX-17B at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no.
P02190,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.66. AE: yes.
P02190,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.66. AE: no. CRP 8.0 mg/L; ALT 32 U/L.
P02190,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.63. AE: no.
P02190,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no.
P02190,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.54. AE: no. CRP 6.2 mg/L; ALT 33 U/L.
P02191,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: joint pain. Adherence ~0.75. AE: no.
P02191,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02191,2,negative,Visit 2: Patient on RX-17B at S022. feels frustrated. Notes: fatigue. Adherence ~0.92. AE: yes. CRP 3.1 mg/L; ALT 42 U/L.
P02192,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P02192,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.72. AE: no. CRP 12.7 mg/L; ALT 30 U/L.
P02192,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.58. AE: no. CRP 12.1 mg/L; ALT 32 U/L.
P02192,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02192,4,negative,Visit 4: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.61. AE: no.
P02192,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.58. AE: no.
P02192,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: yes.
P02192,7,neutral,Visit 7: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P02193,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.69. AE: no.
P02193,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P02193,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.70. AE: no.
P02193,3,positive,Visit 3: Patient on RX-17A at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02193,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.88. AE: no.
P02193,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02194,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.95. AE: no. CRP 7.7 mg/L; ALT 57 U/L.
P02194,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.70. AE: yes.
P02194,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02194,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.92. AE: no. CRP 4.9 mg/L; ALT 59 U/L.
P02194,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no. CRP 4.6 mg/L; ALT 61 U/L.
P02194,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02194,6,positive,Visit 6: Patient on RX-17A at S014. feels better overall. Notes: fatigue. Adherence ~0.89. AE: no.
P02194,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 3.7 mg/L; ALT 62 U/L.
P02195,0,neutral,Visit 0: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no. CRP 6.7 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02195,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.96. AE: no.
P02195,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.88. AE: no.
P02195,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: nausea. Adherence ~0.82. AE: no. CRP 5.3 mg/L; ALT 43 U/L.
P02195,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: joint pain. Adherence ~0.82. AE: no.
P02195,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.50. AE: no.
P02195,6,neutral,Visit 6: Patient on RX-17A at S013. no major change. Notes: joint pain. Adherence ~0.75. AE: no. CRP 4.6 mg/L; ALT 46 U/L.
P02195,7,neutral,Visit 7: Patient on RX-17A at S013. no major change. Notes: brain fog. Adherence ~0.86. AE: no.
P02196,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.64. AE: no. CRP 8.9 mg/L; ALT 27 U/L.
P02196,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: headache. Adherence ~0.81. AE: no. CRP 8.1 mg/L; ALT 22 U/L.
P02196,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.92. AE: no. CRP 8.0 mg/L; ALT 26 U/L.
P02196,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 27 U/L.
P02196,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.96. AE: no.
P02197,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.58. AE: no.
P02197,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.91. AE: no. CRP 5.2 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02197,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.96. AE: yes.
P02197,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02197,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.87. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P02198,0,neutral,Visit 0: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.41. AE: no. CRP 6.5 mg/L; ALT 15 U/L.
P02198,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: headache. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P02198,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: fatigue. Adherence ~0.54. AE: yes. CRP 5.9 mg/L; ALT 17 U/L.
P02198,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.47. AE: no.
P02199,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.58. AE: no.
P02199,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.68. AE: no. CRP 14.3 mg/L; ALT 36 U/L.
P02199,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 14.6 mg/L; ALT 38 U/L.
P02199,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 12.5 mg/L; ALT 38 U/L.
P02199,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no. CRP 12.2 mg/L; ALT 41 U/L.
P02199,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no.
P02199,6,neutral,Visit 6: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.62. AE: yes.
P02200,0,neutral,Visit 0: Patient on RX-17A at S021. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no. CRP 3.6 mg/L; ALT 19 U/L.
P02200,1,neutral,Visit 1: Patient on RX-17A at S021. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02200,2,neutral,Visit 2: Patient on RX-17A at S021. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. CRP 3.2 mg/L; ALT 18 U/L.
P02201,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.93. AE: no. CRP 7.7 mg/L; ALT 38 U/L.
P02201,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: nausea. Adherence ~0.77. AE: no. CRP 6.9 mg/L; ALT 40 U/L.
P02201,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02201,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02201,4,positive,Visit 4: Patient on RX-17B at S022. feels better overall. Notes: joint pain. Adherence ~0.94. AE: no.
P02202,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.82. AE: no.
P02202,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.80. AE: yes.
P02202,2,positive,Visit 2: Patient on RX-17B at S004. feels better overall. Notes: headache. Adherence ~0.96. AE: no. CRP 3.3 mg/L; ALT 40 U/L.
P02202,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.66. AE: yes. CRP 3.3 mg/L; ALT 47 U/L.
P02202,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.92. AE: no. CRP 2.4 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P02202,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: insomnia. Adherence ~0.85. AE: no.
P02202,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: yes. CRP 2.0 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P02202,7,neutral,Visit 7: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.71. AE: no.
P02203,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.57. AE: no.
P02203,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.53. AE: yes.
P02203,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P02204,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.55. AE: yes.
P02204,1,neutral,Visit 1: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P02204,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no.
P02204,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P02204,4,negative,Visit 4: Patient on RX-17A at S005. feels frustrated. Notes: headache. Adherence ~0.73. AE: no. CRP 3.3 mg/L; ALT 21 U/L.
P02205,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P02205,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.44. AE: no. CRP 7.0 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P02205,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.66. AE: no.
P02205,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02205,4,negative,Visit 4: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.52. AE: yes.
P02205,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.53. AE: no. CRP 5.8 mg/L; ALT 47 U/L.
P02206,0,negative,Visit 0: Patient on RX-17A at S011. feels frustrated. Notes: dizziness. Adherence ~1.00. AE: no.
P02206,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: fatigue. Adherence ~1.00. AE: yes.
P02206,2,negative,Visit 2: Patient on RX-17A at S011. poor tolerance. Notes: headache. Adherence ~0.94. AE: no. CRP 3.1 mg/L; ALT 32 U/L.
P02206,3,neutral,Visit 3: Patient on RX-17A at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.98. AE: no.
P02206,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02206,5,neutral,Visit 5: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no. CRP 2.4 mg/L; ALT 32 U/L.
P02206,6,positive,Visit 6: Patient on RX-17A at S011. tolerating medication well. Notes: insomnia. Adherence ~0.96. AE: no. CRP 2.0 mg/L; ALT 30 U/L.
P02207,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: nausea. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02207,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 12.9 mg/L; ALT 32 U/L.
P02207,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.66. AE: no. CRP 11.9 mg/L; ALT 32 U/L.
P02208,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.85. AE: no. CRP 7.7 mg/L; ALT 20 U/L.
P02208,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.86. AE: no. CRP 8.2 mg/L; ALT 22 U/L.
P02208,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 6.2 mg/L; ALT 22 U/L.
P02208,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.87. AE: no.
P02208,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P02209,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.60. AE: no.
P02209,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no.
P02209,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.74. AE: yes.
P02209,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02209,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.86. AE: no. CRP 6.2 mg/L; ALT 32 U/L.
P02210,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.64. AE: no.
P02210,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.57. AE: no.
P02210,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: fatigue. Adherence ~0.67. AE: no. CRP 10.2 mg/L; ALT 29 U/L.
P02210,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.50. AE: yes.
P02210,4,negative,Visit 4: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.51. AE: no.
P02211,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no.
P02211,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: fatigue. Adherence ~0.77. AE: no. CRP 2.9 mg/L; ALT 16 U/L.
P02211,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: joint pain. Adherence ~0.72. AE: no. CRP 3.7 mg/L; ALT 19 U/L.
P02211,3,neutral,Visit 3: Patient on RX-17A at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: no. CRP 3.3 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02211,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02211,5,neutral,Visit 5: Patient on RX-17A at S002. no major change. Notes: fatigue. Adherence ~0.85. AE: no. CRP 2.4 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02211,6,neutral,Visit 6: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.53. AE: no. CRP 2.4 mg/L; ALT 19 U/L.
P02212,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: headache. Adherence ~0.82. AE: no. CRP 5.0 mg/L; ALT 55 U/L.
P02212,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P02212,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.79. AE: no.
P02212,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.62. AE: no.
P02212,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 3.0 mg/L; ALT 57 U/L.
P02212,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.64. AE: yes. CRP 3.1 mg/L; ALT 56 U/L.
P02212,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: no. CRP 2.5 mg/L; ALT 55 U/L.
P02212,7,positive,Visit 7: Patient on RX-17B at S004. feels better overall. Notes: insomnia. Adherence ~0.84. AE: no.
P02213,0,neutral,Visit 0: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.60. AE: no. CRP 8.4 mg/L; ALT 54 U/L.
P02213,1,negative,Visit 1: Patient on RX-17B at S013. feels frustrated. Notes: joint pain. Adherence ~0.67. AE: yes.
P02213,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no.
P02213,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: headache. Adherence ~0.51. AE: no. CRP 6.7 mg/L; ALT 60 U/L.
P02213,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.68. AE: no.
P02213,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: brain fog. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02213,6,neutral,Visit 6: Patient on RX-17B at S013. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P02214,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: joint pain. Adherence ~0.68. AE: no. CRP 2.7 mg/L; ALT 40 U/L.
P02214,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.38. AE: no.
P02214,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.68. AE: no. CRP 1.9 mg/L; ALT 47 U/L.
P02214,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P02214,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.48. AE: no.
P02214,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.63. AE: no.
P02214,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.52. AE: no. CRP 1.2 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P02215,0,neutral,Visit 0: Patient on RX-17A at S009. no major change. Notes: brain fog. Adherence ~0.51. AE: no.
P02215,1,neutral,Visit 1: Patient on RX-17A at S009. continues regimen. Notes: insomnia. Adherence ~0.53. AE: no. CRP 2.7 mg/L; ALT 39 U/L.
P02215,2,negative,Visit 2: Patient on RX-17A at S009. symptoms persist. Notes: dizziness. Adherence ~0.55. AE: yes.
P02215,3,neutral,Visit 3: Patient on RX-17A at S009. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P02215,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: insomnia. Adherence ~0.47. AE: no.
P02216,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: yes.
P02216,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.91. AE: no.
P02216,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: fatigue. Adherence ~0.85. AE: yes.
P02216,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.86. AE: yes. CRP 3.5 mg/L; ALT 58 U/L.
P02216,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.82. AE: no.
P02216,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.81. AE: no.
P02216,6,positive,Visit 6: Patient on RX-17B at S022. energy increasing. Notes: insomnia. Adherence ~0.85. AE: no.
P02217,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.85. AE: no.
P02217,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 22 U/L.
P02217,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.56. AE: no. CRP 3.6 mg/L; ALT 24 U/L.
P02217,3,negative,Visit 3: Patient on RX-17B at S005. symptoms persist. Notes: fatigue. Adherence ~0.65. AE: yes.
P02217,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02217,5,positive,Visit 5: Patient on RX-17B at S005. feels better overall. Notes: insomnia. Adherence ~0.85. AE: no. CRP 2.6 mg/L; ALT 22 U/L.
P02217,6,neutral,Visit 6: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. CRP 2.1 mg/L; ALT 24 U/L.
P02218,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: headache. Adherence ~0.82. AE: no. CRP 6.0 mg/L; ALT 19 U/L.
P02218,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.84. AE: no. CRP 5.5 mg/L; ALT 23 U/L.
P02218,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no. CRP 4.9 mg/L; ALT 21 U/L.
P02218,3,positive,Visit 3: Patient on RX-17B at S005. tolerating medication well. Notes: headache. Adherence ~0.76. AE: no.
P02218,4,negative,Visit 4: Patient on RX-17B at S005. poor tolerance. Notes: nausea. Adherence ~0.68. AE: yes.
P02219,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.72. AE: no.
P02219,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.95. AE: yes.
P02219,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: yes.
P02219,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: no.
P02219,4,negative,Visit 4: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.87. AE: no.
P02219,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: brain fog. Adherence ~0.89. AE: no. CRP 5.5 mg/L; ALT 27 U/L.
P02220,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no. CRP 10.5 mg/L; ALT 30 U/L.
P02220,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: no.
P02220,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.74. AE: no.
P02220,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P02220,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.81. AE: no.
P02220,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P02220,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no. CRP 5.3 mg/L; ALT 36 U/L.
P02221,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: dizziness. Adherence ~0.56. AE: yes.
P02221,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.75. AE: no.
P02221,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: fatigue. Adherence ~0.51. AE: yes.
P02221,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.56. AE: yes. Plan: consider dose adjustment; counsel patient.
P02221,4,positive,Visit 4: Patient on RX-17B at S015. tolerating medication well. Notes: nausea. Adherence ~0.77. AE: no.
P02221,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.63. AE: no.
P02221,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.56. AE: yes.
P02222,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02222,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.56. AE: no.
P02222,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no. CRP 7.7 mg/L; ALT 20 U/L.
P02222,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~0.57. AE: no.
P02222,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no. CRP 4.6 mg/L; ALT 21 U/L.
P02222,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02222,6,neutral,Visit 6: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02223,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: headache. Adherence ~0.55. AE: no. CRP 8.6 mg/L; ALT 27 U/L.
P02223,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: fatigue. Adherence ~0.67. AE: yes. CRP 7.6 mg/L; ALT 37 U/L.
P02223,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no.
P02223,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: brain fog. Adherence ~0.55. AE: no.
P02223,4,neutral,Visit 4: Patient on RX-17A at S018. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: no.
P02224,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: insomnia. Adherence ~0.99. AE: no.
P02224,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.83. AE: no. CRP 7.0 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02224,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: joint pain. Adherence ~0.78. AE: no. CRP 6.3 mg/L; ALT 32 U/L.
P02224,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no.
P02224,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 4.7 mg/L; ALT 33 U/L.
P02224,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no. CRP 4.1 mg/L; ALT 30 U/L.
P02224,6,positive,Visit 6: Patient on RX-17B at S004. feels better overall. Notes: fatigue. Adherence ~0.76. AE: no.
P02225,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.61. AE: no. CRP 8.2 mg/L; ALT 43 U/L.
P02225,1,negative,Visit 1: Patient on RX-17A at S013. increased discomfort. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 8.0 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02225,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.59. AE: no.
P02225,3,negative,Visit 3: Patient on RX-17A at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.48. AE: no. CRP 7.3 mg/L; ALT 41 U/L.
P02225,4,negative,Visit 4: Patient on RX-17A at S013. feels frustrated. Notes: headache. Adherence ~0.58. AE: yes.
P02225,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.48. AE: no. CRP 6.4 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02225,6,neutral,Visit 6: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.54. AE: yes.
P02225,7,neutral,Visit 7: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.58. AE: no. CRP 4.4 mg/L; ALT 39 U/L.
P02226,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: joint pain. Adherence ~0.95. AE: no. CRP 10.1 mg/L; ALT 28 U/L.
P02226,1,negative,Visit 1: Patient on RX-17B at S016. symptoms persist. Notes: brain fog. Adherence ~1.00. AE: no. CRP 9.6 mg/L; ALT 30 U/L.
P02226,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no. CRP 7.9 mg/L; ALT 30 U/L.
P02226,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02227,0,neutral,Visit 0: Patient on RX-17B at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.71. AE: no.
P02227,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: headache. Adherence ~0.71. AE: yes.
P02227,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.59. AE: yes.
P02227,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.72. AE: no.
P02227,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.68. AE: no.
P02227,5,positive,Visit 5: Patient on RX-17B at S019. symptoms improving. Notes: fatigue. Adherence ~0.81. AE: no.
P02228,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.92. AE: yes.
P02228,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.79. AE: no.
P02228,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.72. AE: yes.
P02229,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.56. AE: no.
P02229,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P02229,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no.
P02229,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.48. AE: no. CRP 8.8 mg/L; ALT 48 U/L.
P02230,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02230,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 15.2 mg/L; ALT 32 U/L.
P02230,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.85. AE: no. CRP 15.1 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02230,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P02230,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no. CRP 9.5 mg/L; ALT 31 U/L.
P02230,5,positive,Visit 5: Patient on RX-17B at S004. reports improvement. Notes: nausea. Adherence ~0.78. AE: no. CRP 9.4 mg/L; ALT 32 U/L.
P02230,6,positive,Visit 6: Patient on RX-17B at S004. energy increasing. Notes: headache. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02231,0,negative,Visit 0: Patient on RX-17A at S005. increased discomfort. Notes: insomnia. Adherence ~0.60. AE: no. CRP 8.3 mg/L; ALT 43 U/L.
P02231,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.70. AE: no.
P02231,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: fatigue. Adherence ~0.65. AE: no.
P02231,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02231,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no.
P02231,5,negative,Visit 5: Patient on RX-17A at S005. feels frustrated. Notes: insomnia. Adherence ~0.62. AE: no. CRP 4.4 mg/L; ALT 43 U/L.
P02231,6,neutral,Visit 6: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.70. AE: no. CRP 4.3 mg/L; ALT 46 U/L.
P02231,7,neutral,Visit 7: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no.
P02232,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: joint pain. Adherence ~0.97. AE: no.
P02232,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02232,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.97. AE: no.
P02232,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P02232,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.96. AE: no. CRP 3.4 mg/L; ALT 26 U/L.
P02232,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no.
P02233,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.68. AE: no. CRP 6.5 mg/L; ALT 40 U/L.
P02233,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.65. AE: no. CRP 5.0 mg/L; ALT 39 U/L.
P02233,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.52. AE: no.
P02233,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no.
P02233,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02234,0,neutral,Visit 0: Patient on RX-17B at S011. continues regimen. Notes: headache. Adherence ~0.72. AE: no.
P02234,1,negative,Visit 1: Patient on RX-17B at S011. poor tolerance. Notes: headache. Adherence ~0.91. AE: no. CRP 6.0 mg/L; ALT 22 U/L.
P02234,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: brain fog. Adherence ~0.96. AE: no.
P02234,3,neutral,Visit 3: Patient on RX-17B at S011. follow-up as scheduled. Notes: joint pain. Adherence ~0.96. AE: no.
P02234,4,neutral,Visit 4: Patient on RX-17B at S011. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P02235,0,neutral,Visit 0: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.82. AE: no. CRP 3.5 mg/L; ALT 29 U/L.
P02235,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.74. AE: no.
P02235,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.62. AE: no.
P02235,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no. CRP 3.1 mg/L; ALT 29 U/L.
P02235,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.74. AE: no. CRP 3.0 mg/L; ALT 31 U/L.
P02235,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.66. AE: no.
P02236,0,negative,Visit 0: Patient on RX-17B at S003. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: no. CRP 4.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02236,1,neutral,Visit 1: Patient on RX-17B at S003. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P02236,2,negative,Visit 2: Patient on RX-17B at S003. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 4.3 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02236,3,neutral,Visit 3: Patient on RX-17B at S003. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: no.
P02237,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02237,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: nausea. Adherence ~0.73. AE: yes.
P02237,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~0.76. AE: no.
P02237,3,negative,Visit 3: Patient on RX-17A at S019. symptoms persist. Notes: insomnia. Adherence ~0.77. AE: no. CRP 3.1 mg/L; ALT 36 U/L.
P02237,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.83. AE: no.
P02237,5,positive,Visit 5: Patient on RX-17A at S019. reports improvement. Notes: nausea. Adherence ~0.89. AE: no. CRP 2.5 mg/L; ALT 35 U/L.
P02237,6,positive,Visit 6: Patient on RX-17A at S019. tolerating medication well. Notes: fatigue. Adherence ~0.77. AE: no. CRP 2.5 mg/L; ALT 39 U/L.
P02238,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.58. AE: no.
P02238,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no.
P02238,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.42. AE: no.
P02238,3,negative,Visit 3: Patient on RX-17B at S019. symptoms persist. Notes: brain fog. Adherence ~0.63. AE: yes.
P02238,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P02238,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 4.5 mg/L; ALT 24 U/L.
P02239,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~0.62. AE: no.
P02239,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.55. AE: no.
P02239,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.59. AE: no.
P02239,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.72. AE: yes.
P02239,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.49. AE: no.
P02240,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P02240,1,negative,Visit 1: Patient on RX-17A at S002. increased discomfort. Notes: dizziness. Adherence ~0.71. AE: yes.
P02240,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 2.4 mg/L; ALT 35 U/L.
P02240,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P02240,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no.
P02240,5,neutral,Visit 5: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no. CRP 2.0 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02240,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no.
P02240,7,neutral,Visit 7: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no. CRP 1.5 mg/L; ALT 40 U/L.
P02241,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: yes. CRP 5.1 mg/L; ALT 38 U/L.
P02241,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: no.
P02241,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02241,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no. CRP 3.8 mg/L; ALT 34 U/L.
P02241,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 3.6 mg/L; ALT 33 U/L.
P02241,5,negative,Visit 5: Patient on RX-17A at S002. feels frustrated. Notes: dizziness. Adherence ~0.66. AE: no. CRP 3.7 mg/L; ALT 36 U/L.
P02241,6,neutral,Visit 6: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.73. AE: no.
P02242,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no.
P02242,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.98. AE: no. CRP 20.2 mg/L; ALT 33 U/L.
P02242,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no.
P02242,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.83. AE: no.
P02242,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02242,5,positive,Visit 5: Patient on RX-17B at S019. symptoms improving. Notes: nausea. Adherence ~0.83. AE: no.
P02243,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: dizziness. Adherence ~0.71. AE: yes. CRP 12.3 mg/L; ALT 44 U/L.
P02243,1,neutral,Visit 1: Patient on RX-17B at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.96. AE: no.
P02243,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: insomnia. Adherence ~0.93. AE: no. CRP 8.8 mg/L; ALT 45 U/L.
P02243,3,neutral,Visit 3: Patient on RX-17B at S008. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no.
P02243,4,positive,Visit 4: Patient on RX-17B at S008. reports improvement. Notes: nausea. Adherence ~0.81. AE: no.
P02243,5,neutral,Visit 5: Patient on RX-17B at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P02244,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02244,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02244,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.60. AE: yes.
P02244,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.83. AE: yes.
P02244,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.86. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P02244,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~0.88. AE: no.
P02245,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.82. AE: no.
P02245,1,neutral,Visit 1: Patient on RX-17A at S013. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no. CRP 4.4 mg/L; ALT 31 U/L.
P02245,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no.
P02245,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no.
P02245,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no. CRP 3.6 mg/L; ALT 33 U/L.
P02245,5,positive,Visit 5: Patient on RX-17A at S013. feels better overall. Notes: insomnia. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02245,6,neutral,Visit 6: Patient on RX-17A at S013. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: no. CRP 2.8 mg/L; ALT 34 U/L.
P02246,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02246,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: no.
P02246,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: joint pain. Adherence ~0.86. AE: no.
P02246,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02246,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.95. AE: no.
P02246,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 5.3 mg/L; ALT 28 U/L.
P02246,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.97. AE: no.
P02246,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.91. AE: yes. CRP 4.9 mg/L; ALT 29 U/L.
P02247,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: no.
P02247,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.76. AE: no.
P02247,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.69. AE: no. CRP 6.7 mg/L; ALT 28 U/L.
P02247,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.94. AE: no.
P02247,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 5.3 mg/L; ALT 28 U/L.
P02247,5,positive,Visit 5: Patient on RX-17A at S014. tolerating medication well. Notes: headache. Adherence ~0.79. AE: no.
P02248,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 5.1 mg/L; ALT 32 U/L.
P02248,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.63. AE: no.
P02248,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.70. AE: no. CRP 4.1 mg/L; ALT 32 U/L.
P02248,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.65. AE: no.
P02248,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02248,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.2 mg/L; ALT 36 U/L.
P02248,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.61. AE: no. CRP 3.1 mg/L; ALT 35 U/L.
P02248,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.70. AE: yes.
P02249,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no.
P02249,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no. CRP 5.6 mg/L; ALT 63 U/L.
P02249,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 4.7 mg/L; ALT 74 U/L.
P02249,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.97. AE: no. CRP 4.6 mg/L; ALT 68 U/L.
P02249,4,negative,Visit 4: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~1.00. AE: yes.
P02249,5,positive,Visit 5: Patient on RX-17B at S022. reports improvement. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02250,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.53. AE: no.
P02250,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.45. AE: no. CRP 5.0 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02250,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~0.51. AE: no. CRP 5.1 mg/L; ALT 42 U/L.
P02250,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no.
P02250,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.50. AE: no. CRP 4.1 mg/L; ALT 42 U/L.
P02250,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.48. AE: no. CRP 3.6 mg/L; ALT 38 U/L.
P02251,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: dizziness. Adherence ~0.45. AE: no.
P02251,1,neutral,Visit 1: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.60. AE: no. CRP 3.3 mg/L; ALT 37 U/L.
P02251,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.63. AE: yes.
P02251,3,negative,Visit 3: Patient on RX-17B at S018. feels frustrated. Notes: joint pain. Adherence ~0.53. AE: yes. Plan: consider dose adjustment; counsel patient.
P02251,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 2.2 mg/L; ALT 39 U/L.
P02251,5,negative,Visit 5: Patient on RX-17B at S018. increased discomfort. Notes: joint pain. Adherence ~0.58. AE: yes. CRP 2.1 mg/L; ALT 39 U/L.
P02251,6,neutral,Visit 6: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.51. AE: no.
P02252,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02252,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: brain fog. Adherence ~0.99. AE: yes. CRP 3.4 mg/L; ALT 40 U/L.
P02252,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: no.
P02252,3,negative,Visit 3: Patient on RX-17A at S002. reports worsening. Notes: fatigue. Adherence ~0.91. AE: no.
P02252,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P02252,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.74. AE: no. CRP 2.4 mg/L; ALT 39 U/L.
P02253,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02253,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.90. AE: no. CRP 6.0 mg/L; ALT 14 U/L.
P02253,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.66. AE: no.
P02253,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.77. AE: no. CRP 5.4 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P02253,4,negative,Visit 4: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02253,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: yes. CRP 4.1 mg/L; ALT 15 U/L.
P02253,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02254,0,negative,Visit 0: Patient on RX-17A at S020. increased discomfort. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.7 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P02254,1,neutral,Visit 1: Patient on RX-17A at S020. no major change. Notes: joint pain. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02254,2,negative,Visit 2: Patient on RX-17A at S020. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: yes.
P02254,3,negative,Visit 3: Patient on RX-17A at S020. symptoms persist. Notes: headache. Adherence ~0.92. AE: no.
P02254,4,positive,Visit 4: Patient on RX-17A at S020. energy increasing. Notes: headache. Adherence ~0.89. AE: no.
P02254,5,positive,Visit 5: Patient on RX-17A at S020. energy increasing. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02254,6,positive,Visit 6: Patient on RX-17A at S020. symptoms improving. Notes: joint pain. Adherence ~0.92. AE: no.
P02254,7,positive,Visit 7: Patient on RX-17A at S020. reports improvement. Notes: headache. Adherence ~0.86. AE: no. CRP 2.7 mg/L; ALT 32 U/L.
P02255,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.74. AE: no.
P02255,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02255,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P02255,3,negative,Visit 3: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 4.5 mg/L; ALT 41 U/L.
P02255,4,positive,Visit 4: Patient on RX-17A at S015. feels better overall. Notes: brain fog. Adherence ~0.89. AE: no.
P02255,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.76. AE: no.
P02255,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: no.
P02255,7,neutral,Visit 7: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 3.4 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02256,0,neutral,Visit 0: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02256,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: fatigue. Adherence ~0.60. AE: no.
P02256,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.58. AE: no.
P02256,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.61. AE: no. CRP 2.0 mg/L; ALT 34 U/L.
P02256,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: no.
P02256,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: brain fog. Adherence ~0.71. AE: no. CRP 2.1 mg/L; ALT 32 U/L.
P02257,0,neutral,Visit 0: Patient on RX-17B at S009. no major change. Notes: dizziness. Adherence ~0.79. AE: no.
P02257,1,neutral,Visit 1: Patient on RX-17B at S009. no major change. Notes: nausea. Adherence ~0.77. AE: no. CRP 8.6 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02257,2,neutral,Visit 2: Patient on RX-17B at S009. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no. CRP 8.9 mg/L; ALT 28 U/L.
P02258,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: insomnia. Adherence ~0.88. AE: no.
P02258,1,negative,Visit 1: Patient on RX-17B at S013. poor tolerance. Notes: nausea. Adherence ~0.98. AE: no. CRP 21.6 mg/L; ALT 23 U/L.
P02258,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~0.72. AE: no. CRP 18.0 mg/L; ALT 23 U/L.
P02258,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no.
P02259,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.69. AE: no.
P02259,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.55. AE: no.
P02259,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.74. AE: no. CRP 11.5 mg/L; ALT 25 U/L.
P02259,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.67. AE: no. CRP 9.8 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02259,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.88. AE: no. CRP 10.0 mg/L; ALT 26 U/L.
P02259,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.65. AE: no.
P02259,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 7.8 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02260,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.78. AE: no. CRP 12.2 mg/L; ALT 23 U/L.
P02260,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02260,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02260,3,negative,Visit 3: Patient on RX-17A at S014. poor tolerance. Notes: nausea. Adherence ~0.81. AE: no.
P02260,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.51. AE: no.
P02260,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.73. AE: yes.
P02261,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: yes.
P02261,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P02261,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no.
P02261,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no.
P02261,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02261,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.99. AE: no.
P02261,6,positive,Visit 6: Patient on RX-17A at S014. symptoms improving. Notes: insomnia. Adherence ~0.80. AE: no.
P02261,7,positive,Visit 7: Patient on RX-17A at S014. symptoms improving. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02262,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.38. AE: no.
P02262,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~0.42. AE: no.
P02262,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: fatigue. Adherence ~0.64. AE: no. CRP 6.8 mg/L; ALT 47 U/L.
P02262,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.36. AE: no.
P02262,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.51. AE: yes. CRP 6.3 mg/L; ALT 55 U/L.
P02262,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P02262,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.55. AE: no. CRP 4.1 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P02262,7,neutral,Visit 7: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P02263,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.95. AE: no.
P02263,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: headache. Adherence ~0.87. AE: no.
P02263,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.89. AE: no.
P02264,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: fatigue. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P02264,1,negative,Visit 1: Patient on RX-17B at S008. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no.
P02264,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02264,3,positive,Visit 3: Patient on RX-17B at S008. reports improvement. Notes: brain fog. Adherence ~0.82. AE: no.
P02264,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no. CRP 3.3 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02264,5,neutral,Visit 5: Patient on RX-17B at S008. stable symptoms. Notes: nausea. Adherence ~0.87. AE: no.
P02264,6,neutral,Visit 6: Patient on RX-17B at S008. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 2.3 mg/L; ALT 24 U/L.
P02264,7,neutral,Visit 7: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.58. AE: no.
P02265,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02265,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.63. AE: yes. CRP 9.8 mg/L; ALT 27 U/L.
P02265,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.63. AE: no. CRP 9.8 mg/L; ALT 24 U/L.
P02265,3,negative,Visit 3: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.72. AE: no.
P02265,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.72. AE: no.
P02266,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: nausea. Adherence ~0.68. AE: no.
P02266,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02266,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.92. AE: no.
P02267,0,neutral,Visit 0: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.56. AE: no.
P02267,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: nausea. Adherence ~0.53. AE: yes.
P02267,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02267,3,negative,Visit 3: Patient on RX-17B at S019. symptoms persist. Notes: insomnia. Adherence ~0.71. AE: yes. Plan: consider dose adjustment; counsel patient.
P02267,4,neutral,Visit 4: Patient on RX-17B at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no. CRP 2.9 mg/L; ALT 20 U/L.
P02268,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02268,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: joint pain. Adherence ~0.76. AE: no. CRP 9.3 mg/L; ALT 23 U/L.
P02268,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.9 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02268,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.94. AE: no.
P02268,4,positive,Visit 4: Patient on RX-17A at S015. tolerating medication well. Notes: dizziness. Adherence ~0.91. AE: no.
P02268,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.93. AE: no.
P02269,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P02269,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: yes.
P02269,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P02269,3,negative,Visit 3: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.85. AE: no. CRP 4.2 mg/L; ALT 23 U/L.
P02269,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02269,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P02270,0,neutral,Visit 0: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.72. AE: no. CRP 5.0 mg/L; ALT 45 U/L.
P02270,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.65. AE: no. CRP 5.1 mg/L; ALT 37 U/L.
P02270,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: dizziness. Adherence ~0.76. AE: no.
P02270,3,negative,Visit 3: Patient on RX-17A at S016. increased discomfort. Notes: headache. Adherence ~0.78. AE: no.
P02270,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.75. AE: no.
P02270,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: dizziness. Adherence ~0.94. AE: no.
P02270,6,neutral,Visit 6: Patient on RX-17A at S016. continues regimen. Notes: headache. Adherence ~0.57. AE: no. CRP 3.3 mg/L; ALT 40 U/L.
P02270,7,positive,Visit 7: Patient on RX-17A at S016. reports improvement. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 44 U/L.
P02271,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: insomnia. Adherence ~0.95. AE: no. CRP 10.8 mg/L; ALT 24 U/L.
P02271,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P02271,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no.
P02271,3,positive,Visit 3: Patient on RX-17A at S019. reports improvement. Notes: headache. Adherence ~0.84. AE: no.
P02271,4,positive,Visit 4: Patient on RX-17A at S019. energy increasing. Notes: fatigue. Adherence ~0.86. AE: no.
P02271,5,neutral,Visit 5: Patient on RX-17A at S019. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no.
P02271,6,neutral,Visit 6: Patient on RX-17A at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.76. AE: no. CRP 6.7 mg/L; ALT 26 U/L.
P02271,7,positive,Visit 7: Patient on RX-17A at S019. energy increasing. Notes: nausea. Adherence ~0.97. AE: no. CRP 4.9 mg/L; ALT 24 U/L.
P02272,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: nausea. Adherence ~0.96. AE: no.
P02272,1,neutral,Visit 1: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.96. AE: no.
P02272,2,neutral,Visit 2: Patient on RX-17A at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 8.2 mg/L; ALT 41 U/L.
P02272,3,positive,Visit 3: Patient on RX-17A at S008. reports improvement. Notes: headache. Adherence ~0.97. AE: no. CRP 7.9 mg/L; ALT 39 U/L.
P02272,4,neutral,Visit 4: Patient on RX-17A at S008. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no. CRP 6.2 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P02272,5,neutral,Visit 5: Patient on RX-17A at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.89. AE: no. CRP 6.8 mg/L; ALT 46 U/L.
P02272,6,neutral,Visit 6: Patient on RX-17A at S008. stable symptoms. Notes: joint pain. Adherence ~0.94. AE: no.
P02273,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 49 U/L.
P02273,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.51. AE: no.
P02273,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: yes. CRP 5.3 mg/L; ALT 56 U/L.
P02273,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.45. AE: no. CRP 5.0 mg/L; ALT 53 U/L.
P02273,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P02273,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.69. AE: no.
P02273,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.54. AE: no.
P02274,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: joint pain. Adherence ~0.80. AE: no.
P02274,1,neutral,Visit 1: Patient on RX-17A at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no.
P02274,2,neutral,Visit 2: Patient on RX-17A at S001. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02274,3,neutral,Visit 3: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~0.72. AE: no. CRP 5.7 mg/L; ALT 32 U/L.
P02274,4,neutral,Visit 4: Patient on RX-17A at S001. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: no. CRP 4.9 mg/L; ALT 38 U/L.
P02274,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no.
P02274,6,neutral,Visit 6: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.86. AE: no.
P02275,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 8.9 mg/L; ALT 46 U/L.
P02275,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.63. AE: no. CRP 7.7 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P02275,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 6.0 mg/L; ALT 52 U/L.
P02275,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: yes.
P02275,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02275,5,neutral,Visit 5: Patient on RX-17B at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.80. AE: yes. CRP 5.6 mg/L; ALT 52 U/L.
P02276,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.78. AE: no.
P02276,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P02276,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P02276,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 2.3 mg/L; ALT 20 U/L.
P02276,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.86. AE: no.
P02276,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.83. AE: no.
P02277,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.86. AE: no. CRP 4.6 mg/L; ALT 22 U/L.
P02277,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02277,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 4.2 mg/L; ALT 25 U/L.
P02277,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P02278,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: no. CRP 3.7 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02278,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: insomnia. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 32 U/L.
P02278,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 3.2 mg/L; ALT 36 U/L.
P02278,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P02278,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: yes.
P02278,5,negative,Visit 5: Patient on RX-17B at S002. symptoms persist. Notes: joint pain. Adherence ~0.92. AE: no. CRP 2.1 mg/L; ALT 30 U/L.
P02278,6,neutral,Visit 6: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.71. AE: no.
P02279,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02279,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: nausea. Adherence ~0.60. AE: no. CRP 6.1 mg/L; ALT 31 U/L.
P02279,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P02279,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.85. AE: no.
P02279,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no. CRP 5.0 mg/L; ALT 30 U/L.
P02279,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P02279,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P02279,7,neutral,Visit 7: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.87. AE: no. CRP 3.7 mg/L; ALT 32 U/L.
P02280,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02280,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: dizziness. Adherence ~0.66. AE: no.
P02280,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P02280,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no.
P02280,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.65. AE: no. CRP 10.4 mg/L; ALT 50 U/L.
P02280,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.68. AE: no.
P02280,6,positive,Visit 6: Patient on RX-17A at S004. reports improvement. Notes: headache. Adherence ~0.80. AE: no.
P02281,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 10.1 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02281,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P02281,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no.
P02281,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.91. AE: yes.
P02281,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P02281,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 6.1 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02282,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 5.7 mg/L; ALT 26 U/L.
P02282,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.54. AE: yes. Plan: consider dose adjustment; counsel patient.
P02282,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.73. AE: no.
P02282,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02282,4,positive,Visit 4: Patient on RX-17A at S017. reports improvement. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02282,5,negative,Visit 5: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~0.49. AE: no.
P02282,6,negative,Visit 6: Patient on RX-17A at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02283,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: insomnia. Adherence ~0.63. AE: no. CRP 5.6 mg/L; ALT 32 U/L.
P02283,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no.
P02283,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.53. AE: no.
P02284,0,neutral,Visit 0: Patient on RX-17A at S001. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P02284,1,neutral,Visit 1: Patient on RX-17A at S001. stable symptoms. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02284,2,neutral,Visit 2: Patient on RX-17A at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P02284,3,neutral,Visit 3: Patient on RX-17A at S001. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P02284,4,negative,Visit 4: Patient on RX-17A at S001. increased discomfort. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02284,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P02285,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: yes.
P02285,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: headache. Adherence ~0.79. AE: no.
P02285,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 17.6 mg/L; ALT 22 U/L.
P02286,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02286,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.39. AE: no.
P02286,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.71. AE: no.
P02286,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.50. AE: no. Plan: consider dose adjustment; counsel patient.
P02286,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.52. AE: no.
P02286,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.46. AE: yes. CRP 5.1 mg/L; ALT 31 U/L.
P02287,0,negative,Visit 0: Patient on RX-17A at S009. reports worsening. Notes: fatigue. Adherence ~0.52. AE: no.
P02287,1,negative,Visit 1: Patient on RX-17A at S009. poor tolerance. Notes: insomnia. Adherence ~0.62. AE: no.
P02287,2,neutral,Visit 2: Patient on RX-17A at S009. continues regimen. Notes: brain fog. Adherence ~0.70. AE: no.
P02287,3,neutral,Visit 3: Patient on RX-17A at S009. continues regimen. Notes: fatigue. Adherence ~0.56. AE: no.
P02287,4,neutral,Visit 4: Patient on RX-17A at S009. stable symptoms. Notes: headache. Adherence ~0.75. AE: no. CRP 5.5 mg/L; ALT 29 U/L.
P02288,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: headache. Adherence ~0.82. AE: no.
P02288,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: yes. CRP 2.1 mg/L; ALT 55 U/L.
P02288,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.86. AE: no. CRP 2.0 mg/L; ALT 51 U/L.
P02288,3,positive,Visit 3: Patient on RX-17B at S005. tolerating medication well. Notes: headache. Adherence ~0.85. AE: no.
P02288,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no.
P02289,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.99. AE: no.
P02289,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02289,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02289,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02290,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.92. AE: yes.
P02290,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02290,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P02291,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.60. AE: no. CRP 5.4 mg/L; ALT 53 U/L.
P02291,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02291,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 4.7 mg/L; ALT 48 U/L.
P02291,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P02291,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no.
P02291,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. CRP 4.1 mg/L; ALT 45 U/L.
P02291,6,positive,Visit 6: Patient on RX-17A at S015. energy increasing. Notes: headache. Adherence ~0.78. AE: no.
P02292,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: dizziness. Adherence ~0.79. AE: yes.
P02292,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no.
P02292,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.97. AE: no. CRP 6.7 mg/L; ALT 25 U/L.
P02292,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.78. AE: no. CRP 5.6 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02292,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.83. AE: no.
P02292,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.89. AE: no. CRP 5.2 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02292,6,positive,Visit 6: Patient on RX-17B at S017. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no.
P02292,7,positive,Visit 7: Patient on RX-17B at S017. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02293,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.66. AE: yes. CRP 8.3 mg/L; ALT 33 U/L.
P02293,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.48. AE: no.
P02293,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.55. AE: no.
P02293,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02293,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.55. AE: yes.
P02294,0,neutral,Visit 0: Patient on RX-17A at S020. reviewed dosing instructions. Notes: dizziness. Adherence ~0.66. AE: no. CRP 9.3 mg/L; ALT 40 U/L.
P02294,1,neutral,Visit 1: Patient on RX-17A at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no. CRP 10.4 mg/L; ALT 36 U/L.
P02294,2,negative,Visit 2: Patient on RX-17A at S020. poor tolerance. Notes: nausea. Adherence ~0.85. AE: yes.
P02294,3,neutral,Visit 3: Patient on RX-17A at S020. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P02294,4,negative,Visit 4: Patient on RX-17A at S020. symptoms persist. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02294,5,neutral,Visit 5: Patient on RX-17A at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.91. AE: no.
P02294,6,neutral,Visit 6: Patient on RX-17A at S020. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no.
P02295,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: dizziness. Adherence ~0.82. AE: no.
P02295,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.90. AE: no. CRP 2.7 mg/L; ALT 36 U/L.
P02295,2,negative,Visit 2: Patient on RX-17B at S018. reports worsening. Notes: joint pain. Adherence ~0.89. AE: yes.
P02295,3,neutral,Visit 3: Patient on RX-17B at S018. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: yes.
P02295,4,negative,Visit 4: Patient on RX-17B at S018. symptoms persist. Notes: dizziness. Adherence ~0.89. AE: no.
P02296,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: dizziness. Adherence ~0.84. AE: yes. CRP 4.0 mg/L; ALT 32 U/L.
P02296,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 3.8 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02296,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02296,3,neutral,Visit 3: Patient on RX-17A at S008. continues regimen. Notes: brain fog. Adherence ~0.93. AE: no.
P02296,4,neutral,Visit 4: Patient on RX-17A at S008. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 2.9 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02297,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.91. AE: yes.
P02297,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.68. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P02297,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no.
P02297,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.65. AE: no. CRP 6.0 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02297,4,positive,Visit 4: Patient on RX-17A at S014. symptoms improving. Notes: fatigue. Adherence ~0.78. AE: no.
P02297,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.86. AE: no.
P02298,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no. CRP 5.4 mg/L; ALT 38 U/L.
P02298,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.92. AE: no.
P02298,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 39 U/L.
P02299,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.95. AE: yes. CRP 6.9 mg/L; ALT 28 U/L.
P02299,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02299,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: yes.
P02300,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.69. AE: yes.
P02300,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no.
P02300,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02300,3,positive,Visit 3: Patient on RX-17B at S022. energy increasing. Notes: brain fog. Adherence ~0.81. AE: no.
P02300,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.62. AE: no.
P02301,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: insomnia. Adherence ~0.87. AE: no. CRP 4.7 mg/L; ALT 34 U/L.
P02301,1,negative,Visit 1: Patient on RX-17B at S016. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no.
P02301,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.55. AE: no. CRP 4.2 mg/L; ALT 30 U/L.
P02301,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P02301,4,negative,Visit 4: Patient on RX-17B at S016. increased discomfort. Notes: headache. Adherence ~0.82. AE: yes. CRP 3.7 mg/L; ALT 41 U/L.
P02301,5,neutral,Visit 5: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no.
P02301,6,positive,Visit 6: Patient on RX-17B at S016. reports improvement. Notes: dizziness. Adherence ~0.87. AE: no. CRP 2.8 mg/L; ALT 33 U/L.
P02301,7,positive,Visit 7: Patient on RX-17B at S016. energy increasing. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02302,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02302,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no.
P02302,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.95. AE: no. CRP 6.9 mg/L; ALT 39 U/L.
P02302,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.90. AE: no.
P02302,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no.
P02302,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.85. AE: no.
P02302,6,negative,Visit 6: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~1.00. AE: yes.
P02303,0,neutral,Visit 0: Patient on RX-17B at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no.
P02303,1,neutral,Visit 1: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.87. AE: no. CRP 7.7 mg/L; ALT 48 U/L.
P02303,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no.
P02303,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: insomnia. Adherence ~0.91. AE: no. CRP 7.1 mg/L; ALT 66 U/L.
P02303,4,positive,Visit 4: Patient on RX-17B at S013. feels better overall. Notes: headache. Adherence ~1.00. AE: no.
P02303,5,positive,Visit 5: Patient on RX-17B at S013. energy increasing. Notes: joint pain. Adherence ~0.83. AE: no.
P02304,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: yes. CRP 8.6 mg/L; ALT 22 U/L.
P02304,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.81. AE: no.
P02304,2,negative,Visit 2: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.83. AE: yes.
P02304,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02304,4,negative,Visit 4: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P02304,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.73. AE: no. CRP 4.4 mg/L; ALT 23 U/L.
P02304,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: no.
P02305,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02305,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no.
P02305,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02305,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 8.3 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02305,4,positive,Visit 4: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~0.97. AE: no.
P02305,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P02305,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: nausea. Adherence ~0.82. AE: no. CRP 6.5 mg/L; ALT 33 U/L.
P02305,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: insomnia. Adherence ~0.94. AE: no. CRP 4.9 mg/L; ALT 34 U/L.
P02306,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.58. AE: no.
P02306,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: nausea. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02306,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.54. AE: no. CRP 1.7 mg/L; ALT 19 U/L.
P02306,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.76. AE: no.
P02307,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: dizziness. Adherence ~0.87. AE: yes. CRP 4.9 mg/L; ALT 52 U/L.
P02307,1,negative,Visit 1: Patient on RX-17B at S008. poor tolerance. Notes: headache. Adherence ~0.87. AE: yes. CRP 4.6 mg/L; ALT 54 U/L.
P02307,2,neutral,Visit 2: Patient on RX-17B at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.92. AE: no. CRP 5.0 mg/L; ALT 49 U/L.
P02307,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 3.7 mg/L; ALT 59 U/L.
P02307,4,positive,Visit 4: Patient on RX-17B at S008. symptoms improving. Notes: nausea. Adherence ~0.95. AE: no.
P02308,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no.
P02308,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.88. AE: yes. CRP 10.0 mg/L; ALT 38 U/L.
P02308,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.75. AE: no. CRP 10.9 mg/L; ALT 32 U/L.
P02308,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.57. AE: yes.
P02308,4,positive,Visit 4: Patient on RX-17B at S014. symptoms improving. Notes: dizziness. Adherence ~0.77. AE: no.
P02309,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 4.4 mg/L; ALT 27 U/L.
P02309,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~0.59. AE: yes.
P02309,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: insomnia. Adherence ~0.69. AE: no.
P02309,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02309,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.76. AE: no.
P02309,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: headache. Adherence ~0.83. AE: no.
P02310,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: fatigue. Adherence ~0.85. AE: yes.
P02310,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.83. AE: yes.
P02310,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: nausea. Adherence ~1.00. AE: yes. CRP 3.5 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02310,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.86. AE: yes.
P02310,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no.
P02311,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.58. AE: no. CRP 7.1 mg/L; ALT 32 U/L.
P02311,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.83. AE: no. CRP 6.1 mg/L; ALT 32 U/L.
P02311,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.56. AE: no.
P02311,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02311,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 4.8 mg/L; ALT 30 U/L.
P02312,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.88. AE: no.
P02312,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.80. AE: no. CRP 6.7 mg/L; ALT 25 U/L.
P02312,2,negative,Visit 2: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.74. AE: no.
P02312,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02312,4,negative,Visit 4: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.76. AE: yes.
P02312,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: yes.
P02313,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: no.
P02313,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.39. AE: no.
P02313,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.55. AE: no. CRP 4.3 mg/L; ALT 44 U/L.
P02313,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~0.44. AE: no.
P02314,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02314,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no.
P02314,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.53. AE: no.
P02314,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.87. AE: no.
P02314,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no.
P02314,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.82. AE: yes.
P02314,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.71. AE: yes. CRP 9.1 mg/L; ALT 42 U/L.
P02314,7,positive,Visit 7: Patient on RX-17B at S004. symptoms improving. Notes: nausea. Adherence ~0.80. AE: no.
P02315,0,negative,Visit 0: Patient on RX-17A at S021. reports worsening. Notes: nausea. Adherence ~1.00. AE: no. CRP 9.8 mg/L; ALT 41 U/L.
P02315,1,negative,Visit 1: Patient on RX-17A at S021. reports worsening. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02315,2,neutral,Visit 2: Patient on RX-17A at S021. no major change. Notes: fatigue. Adherence ~0.66. AE: no. CRP 7.7 mg/L; ALT 37 U/L.
P02315,3,neutral,Visit 3: Patient on RX-17A at S021. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 6.6 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02315,4,neutral,Visit 4: Patient on RX-17A at S021. no major change. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02316,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.77. AE: no. CRP 5.0 mg/L; ALT 24 U/L.
P02316,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.91. AE: yes.
P02316,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: no. CRP 3.4 mg/L; ALT 24 U/L.
P02316,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 23 U/L.
P02316,4,positive,Visit 4: Patient on RX-17A at S017. symptoms improving. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 25 U/L.
P02317,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.78. AE: no. CRP 3.4 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02317,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02317,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 3.1 mg/L; ALT 24 U/L.
P02317,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02318,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.77. AE: no.
P02318,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: dizziness. Adherence ~0.88. AE: yes.
P02318,2,neutral,Visit 2: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.86. AE: no.
P02318,3,negative,Visit 3: Patient on RX-17A at S016. increased discomfort. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02318,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no.
P02319,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.62. AE: no. CRP 4.8 mg/L; ALT 42 U/L.
P02319,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no. CRP 3.7 mg/L; ALT 45 U/L.
P02319,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.50. AE: yes. CRP 3.1 mg/L; ALT 43 U/L.
P02319,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no. CRP 3.6 mg/L; ALT 40 U/L.
P02319,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02320,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02320,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: no.
P02320,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02320,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no. CRP 16.5 mg/L; ALT 33 U/L.
P02320,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: nausea. Adherence ~0.91. AE: no.
P02320,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.72. AE: no. CRP 14.7 mg/L; ALT 37 U/L.
P02320,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.92. AE: no.
P02320,7,neutral,Visit 7: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.85. AE: no. CRP 11.4 mg/L; ALT 40 U/L.
P02321,0,negative,Visit 0: Patient on RX-17B at S018. increased discomfort. Notes: joint pain. Adherence ~0.98. AE: no.
P02321,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: insomnia. Adherence ~0.93. AE: no.
P02321,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.83. AE: no.
P02321,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: nausea. Adherence ~0.81. AE: no.
P02321,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no.
P02321,5,positive,Visit 5: Patient on RX-17B at S018. energy increasing. Notes: nausea. Adherence ~0.90. AE: no.
P02322,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.81. AE: no. CRP 8.7 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02322,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.87. AE: no.
P02322,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: brain fog. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02322,3,positive,Visit 3: Patient on RX-17B at S017. symptoms improving. Notes: brain fog. Adherence ~0.78. AE: no.
P02322,4,positive,Visit 4: Patient on RX-17B at S017. symptoms improving. Notes: nausea. Adherence ~0.92. AE: no. CRP 6.3 mg/L; ALT 40 U/L.
P02322,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.84. AE: yes. CRP 6.3 mg/L; ALT 45 U/L.
P02322,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.97. AE: yes.
P02323,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: brain fog. Adherence ~0.89. AE: no.
P02323,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.62. AE: no.
P02323,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no.
P02323,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.75. AE: no.
P02323,4,positive,Visit 4: Patient on RX-17A at S015. feels better overall. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 6.0 mg/L; ALT 21 U/L.
P02323,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P02324,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.80. AE: no. CRP 14.5 mg/L; ALT 26 U/L.
P02324,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.92. AE: no.
P02324,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02324,3,negative,Visit 3: Patient on RX-17B at S012. reports worsening. Notes: joint pain. Adherence ~0.56. AE: yes.
P02325,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: dizziness. Adherence ~0.95. AE: no.
P02325,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: nausea. Adherence ~0.75. AE: no. CRP 1.9 mg/L; ALT 30 U/L.
P02325,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no. CRP 1.6 mg/L; ALT 31 U/L.
P02325,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02325,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: headache. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02326,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P02326,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02326,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.78. AE: no.
P02327,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02327,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 13.2 mg/L; ALT 24 U/L.
P02327,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no.
P02327,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.69. AE: no.
P02327,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.79. AE: no.
P02328,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02328,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: brain fog. Adherence ~0.94. AE: no.
P02328,2,positive,Visit 2: Patient on RX-17B at S015. symptoms improving. Notes: dizziness. Adherence ~0.77. AE: no.
P02328,3,negative,Visit 3: Patient on RX-17B at S015. feels frustrated. Notes: fatigue. Adherence ~0.81. AE: no.
P02328,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.74. AE: no. CRP 10.9 mg/L; ALT 50 U/L.
P02328,5,positive,Visit 5: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~0.82. AE: no.
P02329,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: insomnia. Adherence ~0.63. AE: no.
P02329,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.82. AE: no. CRP 3.8 mg/L; ALT 47 U/L.
P02329,2,neutral,Visit 2: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~0.66. AE: yes. CRP 3.5 mg/L; ALT 49 U/L.
P02329,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02329,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P02329,5,neutral,Visit 5: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P02329,6,neutral,Visit 6: Patient on RX-17B at S013. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02330,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 3.1 mg/L; ALT 66 U/L.
P02330,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.76. AE: no.
P02330,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.69. AE: no.
P02330,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02330,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.69. AE: no. CRP 2.0 mg/L; ALT 68 U/L.
P02330,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.51. AE: no. CRP 1.6 mg/L; ALT 74 U/L. Plan: consider dose adjustment; counsel patient.
P02331,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P02331,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no. CRP 7.6 mg/L; ALT 34 U/L.
P02331,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02331,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no.
P02331,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.88. AE: no. CRP 5.2 mg/L; ALT 40 U/L.
P02331,5,positive,Visit 5: Patient on RX-17B at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02331,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P02331,7,positive,Visit 7: Patient on RX-17B at S022. symptoms improving. Notes: nausea. Adherence ~0.85. AE: no.
P02332,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: dizziness. Adherence ~0.81. AE: no. CRP 10.9 mg/L; ALT 36 U/L.
P02332,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no. CRP 8.4 mg/L; ALT 36 U/L.
P02332,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no.
P02332,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.49. AE: no.
P02332,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02332,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: fatigue. Adherence ~0.58. AE: no. CRP 5.9 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P02333,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no.
P02333,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: nausea. Adherence ~0.98. AE: yes. CRP 6.9 mg/L; ALT 29 U/L.
P02333,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~1.00. AE: yes.
P02333,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: yes. CRP 6.0 mg/L; ALT 32 U/L.
P02333,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P02334,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.76. AE: no. CRP 6.5 mg/L; ALT 27 U/L.
P02334,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.2 mg/L; ALT 26 U/L.
P02334,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.60. AE: no.
P02334,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.74. AE: no. CRP 5.0 mg/L; ALT 30 U/L.
P02334,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.8 mg/L; ALT 26 U/L.
P02335,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.78. AE: yes.
P02335,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.71. AE: yes. Plan: consider dose adjustment; counsel patient.
P02335,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.69. AE: no. CRP 2.4 mg/L; ALT 40 U/L.
P02335,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.80. AE: no. CRP 2.2 mg/L; ALT 39 U/L.
P02336,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.68. AE: no. CRP 5.7 mg/L; ALT 51 U/L.
P02336,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.90. AE: no.
P02336,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.77. AE: no.
P02336,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.96. AE: no.
P02336,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no. CRP 5.3 mg/L; ALT 51 U/L.
P02336,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.71. AE: no. CRP 4.4 mg/L; ALT 52 U/L.
P02336,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.87. AE: yes. CRP 3.7 mg/L; ALT 56 U/L.
P02337,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: dizziness. Adherence ~0.91. AE: no. CRP 6.3 mg/L; ALT 40 U/L.
P02337,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.84. AE: no.
P02337,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02337,3,negative,Visit 3: Patient on RX-17B at S002. symptoms persist. Notes: headache. Adherence ~1.00. AE: yes.
P02337,4,positive,Visit 4: Patient on RX-17B at S002. energy increasing. Notes: nausea. Adherence ~0.80. AE: no.
P02337,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 40 U/L.
P02337,6,positive,Visit 6: Patient on RX-17B at S002. tolerating medication well. Notes: insomnia. Adherence ~0.96. AE: no.
P02338,0,neutral,Visit 0: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.92. AE: no. CRP 5.4 mg/L; ALT 19 U/L.
P02338,1,negative,Visit 1: Patient on RX-17B at S013. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: yes.
P02338,2,negative,Visit 2: Patient on RX-17B at S013. increased discomfort. Notes: joint pain. Adherence ~0.81. AE: no.
P02338,3,negative,Visit 3: Patient on RX-17B at S013. feels frustrated. Notes: nausea. Adherence ~0.76. AE: yes.
P02338,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.85. AE: no. CRP 3.9 mg/L; ALT 22 U/L.
P02338,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.72. AE: no.
P02338,6,neutral,Visit 6: Patient on RX-17B at S013. no major change. Notes: brain fog. Adherence ~0.75. AE: yes.
P02339,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no.
P02339,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~0.65. AE: no.
P02339,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02339,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02339,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.65. AE: no.
P02340,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.72. AE: no. CRP 10.8 mg/L; ALT 23 U/L.
P02340,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.82. AE: no.
P02340,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P02340,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.82. AE: no.
P02340,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no.
P02340,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P02340,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: yes. CRP 6.8 mg/L; ALT 26 U/L.
P02340,7,neutral,Visit 7: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: no.
P02341,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02341,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: nausea. Adherence ~0.60. AE: no.
P02341,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.43. AE: no.
P02341,3,negative,Visit 3: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.48. AE: no. CRP 8.6 mg/L; ALT 28 U/L.
P02341,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: yes.
P02342,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.92. AE: no. CRP 5.2 mg/L; ALT 58 U/L.
P02342,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: abdominal discomfort. Adherence ~0.76. AE: yes.
P02342,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no.
P02342,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no.
P02342,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.73. AE: no. CRP 3.5 mg/L; ALT 50 U/L.
P02343,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.97. AE: no.
P02343,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02343,2,positive,Visit 2: Patient on RX-17B at S015. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P02343,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.80. AE: no. CRP 5.3 mg/L; ALT 20 U/L.
P02343,4,positive,Visit 4: Patient on RX-17B at S015. reports improvement. Notes: brain fog. Adherence ~0.88. AE: no. CRP 4.6 mg/L; ALT 20 U/L.
P02343,5,positive,Visit 5: Patient on RX-17B at S015. symptoms improving. Notes: dizziness. Adherence ~0.86. AE: no. CRP 3.9 mg/L; ALT 22 U/L.
P02344,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: insomnia. Adherence ~0.99. AE: yes.
P02344,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.79. AE: no. CRP 5.3 mg/L; ALT 63 U/L.
P02344,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no. CRP 4.3 mg/L; ALT 57 U/L.
P02344,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02344,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no.
P02344,5,negative,Visit 5: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.68. AE: no.
P02344,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.78. AE: no.
P02344,7,positive,Visit 7: Patient on RX-17A at S017. feels better overall. Notes: nausea. Adherence ~0.84. AE: no.
P02345,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.82. AE: no. CRP 5.7 mg/L; ALT 37 U/L.
P02345,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.98. AE: no.
P02345,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P02345,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 4.2 mg/L; ALT 36 U/L.
P02345,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: yes.
P02345,5,positive,Visit 5: Patient on RX-17A at S015. tolerating medication well. Notes: dizziness. Adherence ~0.86. AE: no.
P02346,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.34. AE: no. Plan: consider dose adjustment; counsel patient.
P02346,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.35. AE: no. Plan: consider dose adjustment; counsel patient.
P02346,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: no. CRP 7.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02346,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.34. AE: no. CRP 7.8 mg/L; ALT 25 U/L.
P02347,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.71. AE: no. CRP 8.5 mg/L; ALT 31 U/L.
P02347,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.58. AE: no.
P02347,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.49. AE: no.
P02347,3,negative,Visit 3: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.75. AE: yes. CRP 8.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02347,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02347,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.44. AE: no.
P02347,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P02348,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.95. AE: yes.
P02348,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~0.72. AE: yes.
P02348,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no.
P02348,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.97. AE: no. CRP 10.5 mg/L; ALT 24 U/L.
P02348,4,positive,Visit 4: Patient on RX-17B at S004. symptoms improving. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 8.6 mg/L; ALT 25 U/L.
P02348,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.64. AE: no.
P02348,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P02349,0,negative,Visit 0: Patient on RX-17B at S011. symptoms persist. Notes: abdominal discomfort. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02349,1,negative,Visit 1: Patient on RX-17B at S011. poor tolerance. Notes: brain fog. Adherence ~0.84. AE: no.
P02349,2,neutral,Visit 2: Patient on RX-17B at S011. no major change. Notes: nausea. Adherence ~0.67. AE: no. CRP 10.5 mg/L; ALT 26 U/L.
P02349,3,neutral,Visit 3: Patient on RX-17B at S011. no major change. Notes: dizziness. Adherence ~0.82. AE: no.
P02349,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 30 U/L.
P02349,5,neutral,Visit 5: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02349,6,neutral,Visit 6: Patient on RX-17B at S011. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02350,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.80. AE: yes. CRP 6.9 mg/L; ALT 34 U/L.
P02350,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: no.
P02350,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.85. AE: no.
P02350,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: joint pain. Adherence ~0.77. AE: no. CRP 5.2 mg/L; ALT 31 U/L.
P02350,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.81. AE: yes.
P02350,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no.
P02351,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: fatigue. Adherence ~0.78. AE: yes.
P02351,1,neutral,Visit 1: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02351,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P02351,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~0.82. AE: no. CRP 25.6 mg/L; ALT 28 U/L.
P02351,4,negative,Visit 4: Patient on RX-17B at S019. symptoms persist. Notes: insomnia. Adherence ~0.78. AE: no.
P02352,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: nausea. Adherence ~0.64. AE: no.
P02352,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.56. AE: yes. Plan: consider dose adjustment; counsel patient.
P02352,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: insomnia. Adherence ~0.99. AE: no.
P02352,3,negative,Visit 3: Patient on RX-17A at S016. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: no.
P02352,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.74. AE: no.
P02352,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~0.64. AE: no. CRP 12.7 mg/L; ALT 23 U/L.
P02353,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02353,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.43. AE: no.
P02353,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.43. AE: no. CRP 4.5 mg/L; ALT 28 U/L.
P02353,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02353,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.50. AE: no. CRP 3.4 mg/L; ALT 28 U/L.
P02353,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.41. AE: no.
P02353,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.29. AE: no. Plan: consider dose adjustment; counsel patient.
P02354,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.99. AE: no.
P02354,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 7.2 mg/L; ALT 19 U/L.
P02354,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P02354,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02354,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.88. AE: no.
P02355,0,negative,Visit 0: Patient on RX-17B at S006. feels frustrated. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02355,1,neutral,Visit 1: Patient on RX-17B at S006. stable symptoms. Notes: fatigue. Adherence ~0.65. AE: yes. CRP 2.3 mg/L; ALT 19 U/L.
P02355,2,neutral,Visit 2: Patient on RX-17B at S006. stable symptoms. Notes: nausea. Adherence ~0.55. AE: yes.
P02355,3,neutral,Visit 3: Patient on RX-17B at S006. no major change. Notes: fatigue. Adherence ~0.83. AE: no.
P02355,4,neutral,Visit 4: Patient on RX-17B at S006. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no.
P02355,5,neutral,Visit 5: Patient on RX-17B at S006. continues regimen. Notes: dizziness. Adherence ~0.86. AE: yes.
P02355,6,positive,Visit 6: Patient on RX-17B at S006. feels better overall. Notes: insomnia. Adherence ~0.96. AE: no. CRP 1.1 mg/L; ALT 22 U/L.
P02355,7,neutral,Visit 7: Patient on RX-17B at S006. stable symptoms. Notes: dizziness. Adherence ~0.66. AE: no.
P02356,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02356,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: dizziness. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02356,2,negative,Visit 2: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P02356,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P02356,4,negative,Visit 4: Patient on RX-17A at S017. feels frustrated. Notes: fatigue. Adherence ~0.72. AE: no. CRP 6.4 mg/L; ALT 19 U/L.
P02357,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: dizziness. Adherence ~0.66. AE: no.
P02357,1,neutral,Visit 1: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.55. AE: no.
P02357,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: nausea. Adherence ~0.62. AE: no. CRP 15.7 mg/L; ALT 56 U/L.
P02357,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: joint pain. Adherence ~0.45. AE: no.
P02357,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.48. AE: no.
P02357,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no.
P02357,6,neutral,Visit 6: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.48. AE: no.
P02357,7,neutral,Visit 7: Patient on RX-17B at S018. stable symptoms. Notes: headache. Adherence ~0.53. AE: yes.
P02358,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02358,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: brain fog. Adherence ~0.79. AE: yes.
P02358,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.90. AE: yes.
P02358,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02358,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.74. AE: no.
P02358,5,positive,Visit 5: Patient on RX-17A at S015. energy increasing. Notes: nausea. Adherence ~0.94. AE: no.
P02358,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no. CRP 19.3 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02358,7,positive,Visit 7: Patient on RX-17A at S015. feels better overall. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02359,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.86. AE: no.
P02359,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.72. AE: no. CRP 5.4 mg/L; ALT 40 U/L.
P02359,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no.
P02360,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.78. AE: no.
P02360,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.56. AE: no.
P02360,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.62. AE: yes.
P02360,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no.
P02360,4,positive,Visit 4: Patient on RX-17A at S012. symptoms improving. Notes: dizziness. Adherence ~0.84. AE: no.
P02360,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: no.
P02361,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.78. AE: yes.
P02361,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02361,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: headache. Adherence ~1.00. AE: yes.
P02361,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: no.
P02361,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 6.4 mg/L; ALT 39 U/L.
P02361,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: nausea. Adherence ~0.89. AE: no.
P02361,6,positive,Visit 6: Patient on RX-17B at S014. energy increasing. Notes: insomnia. Adherence ~0.77. AE: no.
P02361,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.87. AE: yes.
P02362,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.83. AE: no.
P02362,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: headache. Adherence ~1.00. AE: no. CRP 19.4 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02362,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no. CRP 18.1 mg/L; ALT 40 U/L.
P02362,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 16.0 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02362,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P02362,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.92. AE: no.
P02363,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.97. AE: no.
P02363,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.91. AE: no.
P02363,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02363,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.68. AE: no.
P02363,4,positive,Visit 4: Patient on RX-17B at S017. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 34 U/L.
P02364,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.54. AE: no.
P02364,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.54. AE: no.
P02364,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.36. AE: no. CRP 27.7 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P02364,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.68. AE: no.
P02364,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.46. AE: no.
P02364,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.48. AE: no.
P02365,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.49. AE: no.
P02365,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no.
P02365,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.46. AE: no.
P02365,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.51. AE: no. CRP 5.0 mg/L; ALT 31 U/L.
P02365,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.58. AE: no.
P02365,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.58. AE: no. CRP 4.1 mg/L; ALT 30 U/L.
P02366,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: dizziness. Adherence ~0.48. AE: no. CRP 4.1 mg/L; ALT 34 U/L.
P02366,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: nausea. Adherence ~0.64. AE: no.
P02366,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.40. AE: no. CRP 3.1 mg/L; ALT 38 U/L.
P02366,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no.
P02366,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: brain fog. Adherence ~0.63. AE: no.
P02366,5,neutral,Visit 5: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.66. AE: no. CRP 2.4 mg/L; ALT 34 U/L.
P02366,6,neutral,Visit 6: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P02367,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: brain fog. Adherence ~0.88. AE: no.
P02367,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.88. AE: no. CRP 5.5 mg/L; ALT 42 U/L.
P02367,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no. CRP 5.8 mg/L; ALT 38 U/L.
P02367,3,negative,Visit 3: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: yes.
P02367,4,positive,Visit 4: Patient on RX-17B at S004. reports improvement. Notes: brain fog. Adherence ~0.95. AE: no. CRP 4.3 mg/L; ALT 39 U/L.
P02368,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.77. AE: no.
P02368,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.91. AE: no. CRP 4.6 mg/L; ALT 22 U/L.
P02368,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~0.87. AE: no. CRP 4.2 mg/L; ALT 21 U/L.
P02368,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: dizziness. Adherence ~0.97. AE: no. CRP 3.8 mg/L; ALT 22 U/L.
P02368,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.95. AE: no. CRP 3.6 mg/L; ALT 22 U/L.
P02368,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 3.0 mg/L; ALT 25 U/L.
P02368,6,positive,Visit 6: Patient on RX-17A at S005. tolerating medication well. Notes: headache. Adherence ~0.98. AE: no. CRP 2.6 mg/L; ALT 24 U/L.
P02369,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.68. AE: no.
P02369,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.50. AE: no. CRP 7.4 mg/L; ALT 32 U/L.
P02369,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.78. AE: no. CRP 8.4 mg/L; ALT 31 U/L.
P02369,3,negative,Visit 3: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.67. AE: no. CRP 7.1 mg/L; ALT 34 U/L.
P02369,4,negative,Visit 4: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.74. AE: no. CRP 5.8 mg/L; ALT 35 U/L.
P02370,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.52. AE: no.
P02370,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.57. AE: no.
P02370,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.74. AE: no.
P02370,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: no. CRP 2.6 mg/L; ALT 16 U/L.
P02370,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.68. AE: no. CRP 2.0 mg/L; ALT 16 U/L.
P02370,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.56. AE: no.
P02371,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02371,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.6 mg/L; ALT 28 U/L.
P02371,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.90. AE: no.
P02371,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02371,4,positive,Visit 4: Patient on RX-17B at S014. reports improvement. Notes: joint pain. Adherence ~0.82. AE: no. CRP 6.0 mg/L; ALT 34 U/L.
P02371,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no.
P02371,6,positive,Visit 6: Patient on RX-17B at S014. symptoms improving. Notes: headache. Adherence ~0.77. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P02372,0,negative,Visit 0: Patient on RX-17A at S008. poor tolerance. Notes: nausea. Adherence ~0.39. AE: no. CRP 10.6 mg/L; ALT 27 U/L.
P02372,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: nausea. Adherence ~0.85. AE: no. CRP 10.9 mg/L; ALT 27 U/L.
P02372,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.56. AE: no. CRP 10.3 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02372,3,negative,Visit 3: Patient on RX-17A at S008. reports worsening. Notes: dizziness. Adherence ~0.77. AE: no. CRP 9.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02372,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.57. AE: no. CRP 7.7 mg/L; ALT 25 U/L.
P02372,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.49. AE: no.
P02373,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P02373,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.85. AE: yes. Plan: consider dose adjustment; counsel patient.
P02373,2,negative,Visit 2: Patient on RX-17B at S004. feels frustrated. Notes: headache. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02373,3,negative,Visit 3: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.82. AE: no.
P02373,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P02373,5,positive,Visit 5: Patient on RX-17B at S004. symptoms improving. Notes: fatigue. Adherence ~0.76. AE: no.
P02374,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.88. AE: yes.
P02374,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P02374,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.84. AE: yes. Plan: consider dose adjustment; counsel patient.
P02374,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no.
P02374,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no.
P02374,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.79. AE: yes.
P02374,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.76. AE: no. CRP 6.8 mg/L; ALT 28 U/L.
P02375,0,neutral,Visit 0: Patient on RX-17A at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.80. AE: no. CRP 15.5 mg/L; ALT 35 U/L.
P02375,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: insomnia. Adherence ~0.99. AE: no. CRP 14.3 mg/L; ALT 36 U/L.
P02375,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.96. AE: no.
P02375,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 12.0 mg/L; ALT 42 U/L.
P02375,4,neutral,Visit 4: Patient on RX-17A at S018. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P02375,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02375,6,positive,Visit 6: Patient on RX-17A at S018. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no.
P02375,7,neutral,Visit 7: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P02376,0,negative,Visit 0: Patient on RX-17B at S012. poor tolerance. Notes: headache. Adherence ~0.67. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P02376,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.59. AE: no. CRP 5.2 mg/L; ALT 22 U/L.
P02376,2,negative,Visit 2: Patient on RX-17B at S012. symptoms persist. Notes: headache. Adherence ~0.60. AE: no. CRP 5.1 mg/L; ALT 22 U/L.
P02376,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.42. AE: no.
P02376,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.48. AE: no.
P02376,5,neutral,Visit 5: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02377,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.57. AE: no.
P02377,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.53. AE: no. CRP 8.2 mg/L; ALT 55 U/L. Plan: consider dose adjustment; counsel patient.
P02377,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.61. AE: yes. CRP 8.0 mg/L; ALT 68 U/L.
P02377,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 7.9 mg/L; ALT 63 U/L.
P02377,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no.
P02377,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no.
P02378,0,neutral,Visit 0: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 2.4 mg/L; ALT 39 U/L.
P02378,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.96. AE: no.
P02378,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02378,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~0.72. AE: no. CRP 1.6 mg/L; ALT 42 U/L.
P02378,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: dizziness. Adherence ~0.95. AE: no. CRP 1.4 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02378,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no.
P02379,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.16. AE: no. CRP 6.8 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02379,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.23. AE: yes.
P02379,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.35. AE: no.
P02379,3,negative,Visit 3: Patient on RX-17B at S004. feels frustrated. Notes: dizziness. Adherence ~0.45. AE: no.
P02379,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.31. AE: no. Plan: consider dose adjustment; counsel patient.
P02380,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02380,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: dizziness. Adherence ~0.82. AE: no.
P02380,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 7.6 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02380,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no. CRP 7.2 mg/L; ALT 42 U/L.
P02381,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.97. AE: yes.
P02381,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P02381,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.93. AE: no.
P02381,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02381,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.88. AE: no.
P02382,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: dizziness. Adherence ~0.87. AE: no.
P02382,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: headache. Adherence ~0.90. AE: no.
P02382,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P02382,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.3 mg/L; ALT 35 U/L.
P02382,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P02382,5,positive,Visit 5: Patient on RX-17B at S013. feels better overall. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02382,6,positive,Visit 6: Patient on RX-17B at S013. symptoms improving. Notes: headache. Adherence ~1.00. AE: no.
P02383,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: headache. Adherence ~0.74. AE: no.
P02383,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02383,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02383,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: dizziness. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P02383,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.60. AE: no. CRP 3.9 mg/L; ALT 21 U/L.
P02384,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.75. AE: no. CRP 6.1 mg/L; ALT 67 U/L.
P02384,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: insomnia. Adherence ~0.95. AE: no.
P02384,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.94. AE: no.
P02384,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P02384,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: no.
P02384,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02385,0,neutral,Visit 0: Patient on RX-17A at S020. continues regimen. Notes: fatigue. Adherence ~0.95. AE: no. CRP 6.4 mg/L; ALT 39 U/L.
P02385,1,negative,Visit 1: Patient on RX-17A at S020. symptoms persist. Notes: brain fog. Adherence ~0.89. AE: yes.
P02385,2,neutral,Visit 2: Patient on RX-17A at S020. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no.
P02385,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no. CRP 4.7 mg/L; ALT 38 U/L.
P02385,4,neutral,Visit 4: Patient on RX-17A at S020. no major change. Notes: brain fog. Adherence ~0.72. AE: no.
P02385,5,positive,Visit 5: Patient on RX-17A at S020. energy increasing. Notes: nausea. Adherence ~0.94. AE: no.
P02385,6,positive,Visit 6: Patient on RX-17A at S020. reports improvement. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02386,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.75. AE: no. CRP 11.5 mg/L; ALT 18 U/L.
P02386,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.61. AE: no.
P02386,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P02386,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.55. AE: no. CRP 8.0 mg/L; ALT 19 U/L.
P02386,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.67. AE: no.
P02387,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02387,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no.
P02387,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.58. AE: no.
P02387,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.60. AE: no. CRP 4.6 mg/L; ALT 36 U/L.
P02387,4,negative,Visit 4: Patient on RX-17B at S014. poor tolerance. Notes: dizziness. Adherence ~0.75. AE: no.
P02387,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.97. AE: no.
P02388,0,negative,Visit 0: Patient on RX-17B at S006. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P02388,1,neutral,Visit 1: Patient on RX-17B at S006. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P02388,2,neutral,Visit 2: Patient on RX-17B at S006. continues regimen. Notes: joint pain. Adherence ~0.78. AE: no. CRP 6.9 mg/L; ALT 30 U/L.
P02388,3,neutral,Visit 3: Patient on RX-17B at S006. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P02388,4,neutral,Visit 4: Patient on RX-17B at S006. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no. CRP 5.0 mg/L; ALT 31 U/L.
P02388,5,positive,Visit 5: Patient on RX-17B at S006. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 29 U/L.
P02389,0,neutral,Visit 0: Patient on RX-17A at S018. no major change. Notes: dizziness. Adherence ~0.79. AE: no.
P02389,1,neutral,Visit 1: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no. CRP 5.1 mg/L; ALT 28 U/L.
P02389,2,neutral,Visit 2: Patient on RX-17A at S018. no major change. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02389,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02389,4,neutral,Visit 4: Patient on RX-17A at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02390,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no.
P02390,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.83. AE: no.
P02390,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P02390,3,negative,Visit 3: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.94. AE: no. CRP 10.0 mg/L; ALT 22 U/L.
P02390,4,positive,Visit 4: Patient on RX-17A at S014. reports improvement. Notes: headache. Adherence ~0.89. AE: no.
P02390,5,positive,Visit 5: Patient on RX-17A at S014. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.0 mg/L; ALT 21 U/L.
P02390,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02390,7,neutral,Visit 7: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: yes.
P02391,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02391,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: headache. Adherence ~0.87. AE: no.
P02391,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.88. AE: no.
P02392,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: joint pain. Adherence ~0.66. AE: no.
P02392,1,neutral,Visit 1: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no.
P02392,2,negative,Visit 2: Patient on RX-17B at S016. reports worsening. Notes: nausea. Adherence ~0.82. AE: no.
P02392,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.90. AE: yes. CRP 4.8 mg/L; ALT 24 U/L.
P02392,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no.
P02392,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.82. AE: no.
P02392,6,neutral,Visit 6: Patient on RX-17B at S016. no major change. Notes: nausea. Adherence ~0.73. AE: no. CRP 3.0 mg/L; ALT 22 U/L.
P02393,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.88. AE: no. CRP 34.9 mg/L; ALT 26 U/L.
P02393,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02393,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 33.6 mg/L; ALT 28 U/L.
P02393,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no.
P02393,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: nausea. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P02393,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.97. AE: no.
P02394,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: fatigue. Adherence ~0.72. AE: no.
P02394,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P02394,2,neutral,Visit 2: Patient on RX-17A at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no.
P02394,3,negative,Visit 3: Patient on RX-17A at S018. reports worsening. Notes: nausea. Adherence ~0.81. AE: yes.
P02394,4,positive,Visit 4: Patient on RX-17A at S018. energy increasing. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02394,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P02394,6,neutral,Visit 6: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.82. AE: yes. CRP 3.0 mg/L; ALT 36 U/L.
P02395,0,neutral,Visit 0: Patient on RX-17A at S011. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no. CRP 12.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02395,1,negative,Visit 1: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.69. AE: no. CRP 11.9 mg/L; ALT 26 U/L.
P02395,2,neutral,Visit 2: Patient on RX-17A at S011. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no. CRP 10.9 mg/L; ALT 26 U/L.
P02395,3,neutral,Visit 3: Patient on RX-17A at S011. stable symptoms. Notes: dizziness. Adherence ~0.51. AE: no.
P02395,4,positive,Visit 4: Patient on RX-17A at S011. reports improvement. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02395,5,neutral,Visit 5: Patient on RX-17A at S011. follow-up as scheduled. Notes: insomnia. Adherence ~0.61. AE: no.
P02395,6,neutral,Visit 6: Patient on RX-17A at S011. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02396,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.67. AE: no.
P02396,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no.
P02396,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: joint pain. Adherence ~0.40. AE: no. CRP 4.0 mg/L; ALT 28 U/L.
P02396,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02396,4,negative,Visit 4: Patient on RX-17A at S002. increased discomfort. Notes: joint pain. Adherence ~0.43. AE: no. CRP 3.5 mg/L; ALT 31 U/L.
P02397,0,neutral,Visit 0: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.58. AE: no.
P02397,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: fatigue. Adherence ~0.43. AE: no.
P02397,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P02397,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: no.
P02397,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P02398,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 10.6 mg/L; ALT 24 U/L.
P02398,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.60. AE: no. CRP 9.1 mg/L; ALT 20 U/L.
P02398,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.66. AE: yes.
P02398,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no. CRP 9.0 mg/L; ALT 20 U/L.
P02398,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: headache. Adherence ~0.62. AE: no.
P02399,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.2 mg/L; ALT 24 U/L.
P02399,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.96. AE: no. CRP 4.2 mg/L; ALT 26 U/L.
P02399,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no.
P02399,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no.
P02399,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no.
P02399,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P02399,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P02400,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: headache. Adherence ~0.83. AE: yes. CRP 6.4 mg/L; ALT 22 U/L.
P02400,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.85. AE: no. CRP 5.8 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P02400,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.77. AE: no.
P02400,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.87. AE: no.
P02400,4,negative,Visit 4: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.86. AE: no.
P02400,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.94. AE: no.
P02401,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.79. AE: no.
P02401,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.80. AE: no.
P02401,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.67. AE: yes.
P02401,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P02401,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 14.1 mg/L; ALT 22 U/L.
P02401,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no.
P02401,6,positive,Visit 6: Patient on RX-17A at S014. symptoms improving. Notes: joint pain. Adherence ~0.81. AE: no.
P02402,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: headache. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02402,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no.
P02402,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no.
P02402,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no. CRP 3.6 mg/L; ALT 34 U/L.
P02403,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.76. AE: no.
P02403,1,positive,Visit 1: Patient on RX-17B at S004. reports improvement. Notes: headache. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02403,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: no.
P02403,3,negative,Visit 3: Patient on RX-17B at S004. poor tolerance. Notes: insomnia. Adherence ~0.87. AE: yes. CRP 7.6 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P02403,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.83. AE: no.
P02403,5,positive,Visit 5: Patient on RX-17B at S004. feels better overall. Notes: brain fog. Adherence ~0.77. AE: no.
P02404,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: dizziness. Adherence ~0.79. AE: yes.
P02404,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02404,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.82. AE: no.
P02404,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.70. AE: no.
P02404,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.80. AE: yes. CRP 6.0 mg/L; ALT 24 U/L.
P02405,0,negative,Visit 0: Patient on RX-17A at S008. poor tolerance. Notes: dizziness. Adherence ~0.84. AE: no. CRP 7.8 mg/L; ALT 35 U/L.
P02405,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.61. AE: no.
P02405,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.75. AE: yes.
P02405,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02405,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no. CRP 5.1 mg/L; ALT 39 U/L.
P02405,5,neutral,Visit 5: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02406,0,neutral,Visit 0: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.82. AE: no. CRP 2.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02406,1,neutral,Visit 1: Patient on RX-17B at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no.
P02406,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.90. AE: no.
P02407,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: fatigue. Adherence ~0.91. AE: no. CRP 10.2 mg/L; ALT 18 U/L.
P02407,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.60. AE: no.
P02407,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.66. AE: no.
P02407,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02407,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P02407,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.80. AE: yes. CRP 6.8 mg/L; ALT 20 U/L.
P02408,0,negative,Visit 0: Patient on RX-17B at S007. reports worsening. Notes: dizziness. Adherence ~0.81. AE: yes. CRP 6.8 mg/L; ALT 37 U/L.
P02408,1,neutral,Visit 1: Patient on RX-17B at S007. no major change. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02408,2,neutral,Visit 2: Patient on RX-17B at S007. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. CRP 6.1 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P02408,3,positive,Visit 3: Patient on RX-17B at S007. energy increasing. Notes: headache. Adherence ~0.87. AE: no. CRP 5.7 mg/L; ALT 38 U/L.
P02408,4,positive,Visit 4: Patient on RX-17B at S007. symptoms improving. Notes: joint pain. Adherence ~0.88. AE: no.
P02408,5,positive,Visit 5: Patient on RX-17B at S007. feels better overall. Notes: headache. Adherence ~0.98. AE: no. CRP 4.9 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02408,6,neutral,Visit 6: Patient on RX-17B at S007. follow-up as scheduled. Notes: brain fog. Adherence ~0.74. AE: no.
P02408,7,positive,Visit 7: Patient on RX-17B at S007. feels better overall. Notes: brain fog. Adherence ~0.87. AE: no.
P02409,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.67. AE: no. CRP 13.0 mg/L; ALT 41 U/L.
P02409,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 12.8 mg/L; ALT 46 U/L.
P02409,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: insomnia. Adherence ~0.72. AE: no.
P02409,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no. CRP 10.4 mg/L; ALT 50 U/L.
P02409,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.48. AE: no.
P02409,5,negative,Visit 5: Patient on RX-17A at S014. increased discomfort. Notes: dizziness. Adherence ~0.45. AE: yes.
P02409,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: no.
P02409,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.69. AE: no.
P02410,0,negative,Visit 0: Patient on RX-17A at S006. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02410,1,negative,Visit 1: Patient on RX-17A at S006. feels frustrated. Notes: headache. Adherence ~0.75. AE: no. CRP 8.1 mg/L; ALT 14 U/L.
P02410,2,neutral,Visit 2: Patient on RX-17A at S006. no major change. Notes: dizziness. Adherence ~0.74. AE: no.
P02410,3,neutral,Visit 3: Patient on RX-17A at S006. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P02410,4,neutral,Visit 4: Patient on RX-17A at S006. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P02410,5,positive,Visit 5: Patient on RX-17A at S006. energy increasing. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 15 U/L.
P02410,6,positive,Visit 6: Patient on RX-17A at S006. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02411,0,neutral,Visit 0: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.79. AE: no.
P02411,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.80. AE: no.
P02411,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: yes. CRP 6.8 mg/L; ALT 62 U/L.
P02412,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.84. AE: yes. CRP 9.7 mg/L; ALT 23 U/L.
P02412,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02412,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.74. AE: no.
P02412,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02412,4,positive,Visit 4: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02412,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.64. AE: yes. CRP 6.5 mg/L; ALT 29 U/L.
P02413,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.58. AE: yes. CRP 4.1 mg/L; ALT 18 U/L.
P02413,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.53. AE: no. CRP 3.5 mg/L; ALT 17 U/L.
P02413,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.59. AE: no.
P02413,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.3 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02413,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.52. AE: no. CRP 2.9 mg/L; ALT 18 U/L.
P02413,5,negative,Visit 5: Patient on RX-17B at S012. poor tolerance. Notes: dizziness. Adherence ~0.59. AE: yes.
P02414,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02414,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~0.81. AE: no.
P02414,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.65. AE: no. CRP 16.0 mg/L; ALT 29 U/L.
P02414,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.78. AE: no.
P02415,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.80. AE: no. CRP 6.3 mg/L; ALT 40 U/L.
P02415,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.95. AE: no. CRP 5.6 mg/L; ALT 40 U/L.
P02415,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 5.1 mg/L; ALT 41 U/L.
P02415,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.72. AE: yes.
P02415,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.86. AE: no.
P02416,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.85. AE: no. CRP 5.9 mg/L; ALT 29 U/L.
P02416,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02416,2,negative,Visit 2: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02416,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.86. AE: no.
P02416,4,negative,Visit 4: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P02417,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.78. AE: no.
P02417,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: nausea. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P02417,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.76. AE: yes. CRP 10.9 mg/L; ALT 34 U/L.
P02417,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.95. AE: no.
P02417,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. CRP 11.1 mg/L; ALT 34 U/L.
P02417,5,positive,Visit 5: Patient on RX-17B at S022. reports improvement. Notes: headache. Adherence ~0.94. AE: no. CRP 8.2 mg/L; ALT 41 U/L.
P02418,0,negative,Visit 0: Patient on RX-17B at S021. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 8.7 mg/L; ALT 68 U/L.
P02418,1,negative,Visit 1: Patient on RX-17B at S021. reports worsening. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 8.6 mg/L; ALT 63 U/L.
P02418,2,neutral,Visit 2: Patient on RX-17B at S021. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no. CRP 6.3 mg/L; ALT 66 U/L.
P02418,3,neutral,Visit 3: Patient on RX-17B at S021. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: yes. CRP 7.5 mg/L; ALT 76 U/L.
P02418,4,neutral,Visit 4: Patient on RX-17B at S021. continues regimen. Notes: headache. Adherence ~0.91. AE: no.
P02418,5,neutral,Visit 5: Patient on RX-17B at S021. reviewed dosing instructions. Notes: dizziness. Adherence ~0.66. AE: yes. CRP 6.1 mg/L; ALT 71 U/L.
P02418,6,positive,Visit 6: Patient on RX-17B at S021. tolerating medication well. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02418,7,positive,Visit 7: Patient on RX-17B at S021. symptoms improving. Notes: brain fog. Adherence ~0.84. AE: no.
P02419,0,neutral,Visit 0: Patient on RX-17B at S018. continues regimen. Notes: insomnia. Adherence ~0.70. AE: no.
P02419,1,negative,Visit 1: Patient on RX-17B at S018. poor tolerance. Notes: dizziness. Adherence ~0.59. AE: no.
P02419,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P02419,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P02419,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.73. AE: yes. CRP 4.3 mg/L; ALT 40 U/L.
P02419,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P02419,6,positive,Visit 6: Patient on RX-17B at S018. reports improvement. Notes: nausea. Adherence ~0.76. AE: no.
P02420,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.53. AE: no. CRP 8.4 mg/L; ALT 85 U/L.
P02420,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.60. AE: no. CRP 8.2 mg/L; ALT 90 U/L.
P02420,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.36. AE: no.
P02420,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.46. AE: no.
P02420,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P02421,0,neutral,Visit 0: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.98. AE: no. CRP 11.7 mg/L; ALT 46 U/L.
P02421,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 10.7 mg/L; ALT 47 U/L.
P02421,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.90. AE: no.
P02421,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no.
P02421,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P02422,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: fatigue. Adherence ~0.47. AE: no.
P02422,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: joint pain. Adherence ~0.67. AE: yes.
P02422,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P02422,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 5.4 mg/L; ALT 33 U/L.
P02422,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.56. AE: no.
P02422,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P02423,0,negative,Visit 0: Patient on RX-17A at S016. reports worsening. Notes: dizziness. Adherence ~0.79. AE: no.
P02423,1,neutral,Visit 1: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: no.
P02423,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: nausea. Adherence ~0.94. AE: no.
P02423,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02423,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: headache. Adherence ~0.83. AE: no.
P02423,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.92. AE: no.
P02424,0,negative,Visit 0: Patient on RX-17B at S001. reports worsening. Notes: fatigue. Adherence ~0.79. AE: no. CRP 4.0 mg/L; ALT 27 U/L.
P02424,1,negative,Visit 1: Patient on RX-17B at S001. reports worsening. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02424,2,neutral,Visit 2: Patient on RX-17B at S001. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: no.
P02424,3,neutral,Visit 3: Patient on RX-17B at S001. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: yes.
P02424,4,positive,Visit 4: Patient on RX-17B at S001. symptoms improving. Notes: brain fog. Adherence ~0.94. AE: no.
P02425,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.80. AE: yes.
P02425,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.91. AE: no. CRP 8.8 mg/L; ALT 31 U/L.
P02425,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: yes.
P02425,3,negative,Visit 3: Patient on RX-17B at S022. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: yes.
P02426,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: nausea. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P02426,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.50. AE: no. CRP 10.4 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02426,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.38. AE: no. CRP 10.5 mg/L; ALT 33 U/L.
P02426,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.41. AE: no.
P02426,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.35. AE: no.
P02427,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P02427,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: dizziness. Adherence ~0.91. AE: no. CRP 10.6 mg/L; ALT 27 U/L.
P02427,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P02427,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no. CRP 8.3 mg/L; ALT 29 U/L.
P02427,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~1.00. AE: yes.
P02427,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.82. AE: no. CRP 6.5 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02427,6,positive,Visit 6: Patient on RX-17A at S017. tolerating medication well. Notes: nausea. Adherence ~0.88. AE: no.
P02428,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.69. AE: no.
P02428,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.57. AE: no. CRP 2.1 mg/L; ALT 17 U/L.
P02428,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 1.9 mg/L; ALT 19 U/L.
P02428,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.55. AE: no.
P02428,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.51. AE: no.
P02428,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.66. AE: no.
P02428,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no. CRP 1.3 mg/L; ALT 18 U/L.
P02429,0,negative,Visit 0: Patient on RX-17B at S001. poor tolerance. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.1 mg/L; ALT 45 U/L.
P02429,1,neutral,Visit 1: Patient on RX-17B at S001. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no. CRP 6.1 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02429,2,neutral,Visit 2: Patient on RX-17B at S001. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02429,3,positive,Visit 3: Patient on RX-17B at S001. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 53 U/L.
P02429,4,negative,Visit 4: Patient on RX-17B at S001. increased discomfort. Notes: nausea. Adherence ~0.84. AE: no.
P02429,5,neutral,Visit 5: Patient on RX-17B at S001. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: yes.
P02430,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~0.77. AE: yes. CRP 4.2 mg/L; ALT 48 U/L.
P02430,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.73. AE: no. CRP 3.4 mg/L; ALT 43 U/L.
P02430,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.72. AE: no. CRP 3.1 mg/L; ALT 47 U/L.
P02430,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P02430,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02431,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no.
P02431,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: nausea. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P02431,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.83. AE: no. CRP 13.4 mg/L; ALT 19 U/L.
P02431,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no.
P02431,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.77. AE: no. CRP 10.2 mg/L; ALT 18 U/L.
P02431,5,positive,Visit 5: Patient on RX-17A at S014. tolerating medication well. Notes: headache. Adherence ~0.92. AE: no. CRP 9.4 mg/L; ALT 20 U/L.
P02431,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02432,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: yes.
P02432,1,negative,Visit 1: Patient on RX-17B at S013. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P02432,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.5 mg/L; ALT 30 U/L.
P02432,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02432,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.81. AE: no.
P02433,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.67. AE: yes.
P02433,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.73. AE: no.
P02433,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.69. AE: yes.
P02433,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.55. AE: yes.
P02433,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.71. AE: no.
P02433,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no.
P02433,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02433,7,positive,Visit 7: Patient on RX-17A at S012. energy increasing. Notes: insomnia. Adherence ~0.94. AE: no.
P02434,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: dizziness. Adherence ~0.67. AE: no. CRP 3.9 mg/L; ALT 43 U/L.
P02434,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: nausea. Adherence ~0.83. AE: no.
P02434,2,negative,Visit 2: Patient on RX-17A at S008. reports worsening. Notes: headache. Adherence ~0.69. AE: no.
P02434,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no. CRP 2.7 mg/L; ALT 43 U/L.
P02434,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: headache. Adherence ~0.67. AE: no.
P02434,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.64. AE: no.
P02435,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no. CRP 9.0 mg/L; ALT 23 U/L.
P02435,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.94. AE: no.
P02435,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.86. AE: yes. CRP 8.1 mg/L; ALT 27 U/L.
P02435,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02435,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02435,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no.
P02436,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 7.3 mg/L; ALT 50 U/L.
P02436,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: headache. Adherence ~0.89. AE: no. CRP 7.0 mg/L; ALT 45 U/L.
P02436,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 5.2 mg/L; ALT 46 U/L.
P02436,3,negative,Visit 3: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.98. AE: yes. CRP 6.0 mg/L; ALT 50 U/L.
P02437,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.87. AE: no. CRP 32.8 mg/L; ALT 31 U/L.
P02437,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: joint pain. Adherence ~0.89. AE: no.
P02437,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02437,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no.
P02437,4,positive,Visit 4: Patient on RX-17B at S022. energy increasing. Notes: headache. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02437,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.70. AE: no.
P02437,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: insomnia. Adherence ~0.94. AE: no. CRP 15.0 mg/L; ALT 31 U/L.
P02437,7,positive,Visit 7: Patient on RX-17B at S022. feels better overall. Notes: insomnia. Adherence ~0.79. AE: no.
P02438,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: brain fog. Adherence ~0.82. AE: no.
P02438,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: no.
P02438,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: nausea. Adherence ~0.61. AE: yes. CRP 12.6 mg/L; ALT 36 U/L.
P02438,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.69. AE: no.
P02438,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.58. AE: no. Plan: consider dose adjustment; counsel patient.
P02439,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 12.5 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02439,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.79. AE: yes.
P02439,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.86. AE: no.
P02439,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: yes.
P02439,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02440,0,neutral,Visit 0: Patient on RX-17B at S011. no major change. Notes: insomnia. Adherence ~0.88. AE: no.
P02440,1,negative,Visit 1: Patient on RX-17B at S011. symptoms persist. Notes: headache. Adherence ~0.89. AE: yes.
P02440,2,neutral,Visit 2: Patient on RX-17B at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no. CRP 19.8 mg/L; ALT 10 U/L.
P02440,3,neutral,Visit 3: Patient on RX-17B at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P02440,4,neutral,Visit 4: Patient on RX-17B at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no. CRP 13.3 mg/L; ALT 11 U/L.
P02440,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.74. AE: no.
P02440,6,neutral,Visit 6: Patient on RX-17B at S011. continues regimen. Notes: nausea. Adherence ~0.96. AE: no. CRP 10.6 mg/L; ALT 11 U/L.
P02440,7,positive,Visit 7: Patient on RX-17B at S011. reports improvement. Notes: headache. Adherence ~0.83. AE: no.
P02441,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.99. AE: no.
P02441,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.80. AE: no.
P02441,2,positive,Visit 2: Patient on RX-17A at S014. symptoms improving. Notes: headache. Adherence ~0.79. AE: no. CRP 8.1 mg/L; ALT 23 U/L.
P02441,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no. CRP 6.5 mg/L; ALT 24 U/L.
P02441,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.70. AE: no.
P02441,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.80. AE: no.
P02442,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02442,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.98. AE: no.
P02442,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.82. AE: no. CRP 4.9 mg/L; ALT 34 U/L.
P02442,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02442,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 37 U/L.
P02442,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.91. AE: no. CRP 4.7 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02442,6,positive,Visit 6: Patient on RX-17A at S014. tolerating medication well. Notes: dizziness. Adherence ~0.86. AE: no.
P02442,7,neutral,Visit 7: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02443,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: joint pain. Adherence ~0.87. AE: no.
P02443,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02443,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.84. AE: no.
P02443,3,negative,Visit 3: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.84. AE: yes. Plan: consider dose adjustment; counsel patient.
P02444,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 37 U/L.
P02444,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.73. AE: no. CRP 7.2 mg/L; ALT 40 U/L.
P02444,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.89. AE: no.
P02444,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.95. AE: no.
P02444,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: headache. Adherence ~0.85. AE: no.
P02444,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.94. AE: no.
P02445,0,neutral,Visit 0: Patient on RX-17B at S011. follow-up as scheduled. Notes: dizziness. Adherence ~0.63. AE: no.
P02445,1,negative,Visit 1: Patient on RX-17B at S011. symptoms persist. Notes: fatigue. Adherence ~0.72. AE: no.
P02445,2,negative,Visit 2: Patient on RX-17B at S011. reports worsening. Notes: brain fog. Adherence ~0.64. AE: yes. CRP 1.2 mg/L; ALT 47 U/L.
P02445,3,neutral,Visit 3: Patient on RX-17B at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.89. AE: no.
P02445,4,neutral,Visit 4: Patient on RX-17B at S011. stable symptoms. Notes: headache. Adherence ~0.56. AE: no.
P02445,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: dizziness. Adherence ~0.81. AE: no.
P02446,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: fatigue. Adherence ~0.78. AE: no.
P02446,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~0.60. AE: no.
P02446,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.42. AE: no. CRP 6.3 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02446,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no.
P02446,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.50. AE: no. CRP 5.5 mg/L; ALT 26 U/L.
P02447,0,neutral,Visit 0: Patient on RX-17A at S002. continues regimen. Notes: brain fog. Adherence ~0.85. AE: no. CRP 7.6 mg/L; ALT 23 U/L.
P02447,1,neutral,Visit 1: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.72. AE: no.
P02447,2,negative,Visit 2: Patient on RX-17A at S002. poor tolerance. Notes: dizziness. Adherence ~0.72. AE: no.
P02448,0,negative,Visit 0: Patient on RX-17B at S009. poor tolerance. Notes: nausea. Adherence ~0.88. AE: no. CRP 7.6 mg/L; ALT 15 U/L.
P02448,1,neutral,Visit 1: Patient on RX-17B at S009. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. CRP 6.3 mg/L; ALT 15 U/L.
P02448,2,neutral,Visit 2: Patient on RX-17B at S009. no major change. Notes: joint pain. Adherence ~0.84. AE: no.
P02448,3,neutral,Visit 3: Patient on RX-17B at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no.
P02448,4,neutral,Visit 4: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.76. AE: yes.
P02448,5,positive,Visit 5: Patient on RX-17B at S009. tolerating medication well. Notes: brain fog. Adherence ~0.94. AE: no.
P02448,6,neutral,Visit 6: Patient on RX-17B at S009. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no.
P02448,7,neutral,Visit 7: Patient on RX-17B at S009. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P02449,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P02449,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 3.0 mg/L; ALT 20 U/L.
P02449,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.94. AE: no.
P02449,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.93. AE: no. CRP 2.6 mg/L; ALT 18 U/L.
P02449,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.89. AE: yes. CRP 2.4 mg/L; ALT 19 U/L.
P02450,0,neutral,Visit 0: Patient on RX-17A at S002. stable symptoms. Notes: headache. Adherence ~0.59. AE: no. CRP 6.5 mg/L; ALT 17 U/L.
P02450,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: insomnia. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02450,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.46. AE: no. CRP 5.5 mg/L; ALT 19 U/L.
P02450,3,negative,Visit 3: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.43. AE: no. CRP 5.8 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02450,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.70. AE: no.
P02451,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: fatigue. Adherence ~0.64. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P02451,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.55. AE: no. CRP 3.2 mg/L; ALT 36 U/L.
P02451,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P02451,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.69. AE: no.
P02451,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P02452,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: headache. Adherence ~0.91. AE: no. CRP 19.5 mg/L; ALT 29 U/L.
P02452,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.93. AE: no.
P02452,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: headache. Adherence ~0.82. AE: no. CRP 16.6 mg/L; ALT 27 U/L.
P02452,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.94. AE: yes. CRP 16.8 mg/L; ALT 26 U/L.
P02452,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02453,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P02453,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no.
P02453,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no.
P02453,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02453,4,negative,Visit 4: Patient on RX-17A at S017. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P02453,5,positive,Visit 5: Patient on RX-17A at S017. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no.
P02453,6,positive,Visit 6: Patient on RX-17A at S017. symptoms improving. Notes: nausea. Adherence ~0.89. AE: no.
P02454,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: no. CRP 2.7 mg/L; ALT 26 U/L.
P02454,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~0.78. AE: yes.
P02454,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.72. AE: no.
P02454,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.93. AE: yes.
P02454,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.57. AE: no.
P02454,5,positive,Visit 5: Patient on RX-17B at S014. symptoms improving. Notes: dizziness. Adherence ~0.85. AE: no. CRP 1.4 mg/L; ALT 26 U/L.
P02455,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: fatigue. Adherence ~0.97. AE: no. CRP 6.2 mg/L; ALT 24 U/L.
P02455,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.9 mg/L; ALT 24 U/L.
P02455,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P02455,3,positive,Visit 3: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~1.00. AE: no.
P02455,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02455,5,positive,Visit 5: Patient on RX-17B at S015. reports improvement. Notes: headache. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02456,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: dizziness. Adherence ~0.93. AE: no.
P02456,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02456,2,negative,Visit 2: Patient on RX-17A at S013. symptoms persist. Notes: fatigue. Adherence ~0.81. AE: no.
P02456,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no.
P02456,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no. CRP 8.9 mg/L; ALT 46 U/L.
P02456,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no.
P02456,6,positive,Visit 6: Patient on RX-17A at S013. symptoms improving. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02457,0,negative,Visit 0: Patient on RX-17A at S002. increased discomfort. Notes: nausea. Adherence ~0.87. AE: no.
P02457,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02457,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: yes. CRP 7.2 mg/L; ALT 36 U/L.
P02457,3,negative,Visit 3: Patient on RX-17A at S002. increased discomfort. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.7 mg/L; ALT 32 U/L.
P02457,4,neutral,Visit 4: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.99. AE: no. CRP 6.2 mg/L; ALT 34 U/L.
P02458,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no.
P02458,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.76. AE: no.
P02458,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.90. AE: no.
P02458,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02458,4,negative,Visit 4: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.86. AE: yes.
P02458,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no. CRP 3.0 mg/L; ALT 46 U/L.
P02458,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.58. AE: yes.
P02458,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.66. AE: no.
P02459,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.75. AE: yes. CRP 4.8 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P02459,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02459,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 4.1 mg/L; ALT 12 U/L.
P02459,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no. CRP 3.9 mg/L; ALT 14 U/L.
P02459,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: no.
P02459,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.60. AE: no.
P02459,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.8 mg/L; ALT 15 U/L.
P02460,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 6.4 mg/L; ALT 38 U/L.
P02460,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.67. AE: no. CRP 6.1 mg/L; ALT 38 U/L.
P02460,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.60. AE: no. CRP 5.5 mg/L; ALT 34 U/L.
P02461,0,neutral,Visit 0: Patient on RX-17B at S001. no major change. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02461,1,neutral,Visit 1: Patient on RX-17B at S001. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P02461,2,neutral,Visit 2: Patient on RX-17B at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02461,3,neutral,Visit 3: Patient on RX-17B at S001. reviewed dosing instructions. Notes: fatigue. Adherence ~0.95. AE: no. CRP 4.9 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02461,4,neutral,Visit 4: Patient on RX-17B at S001. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no. CRP 4.1 mg/L; ALT 26 U/L.
P02461,5,neutral,Visit 5: Patient on RX-17B at S001. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no.
P02461,6,neutral,Visit 6: Patient on RX-17B at S001. no major change. Notes: joint pain. Adherence ~0.74. AE: no.
P02462,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.63. AE: no. CRP 3.4 mg/L; ALT 27 U/L.
P02462,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.69. AE: yes.
P02462,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no.
P02462,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.58. AE: no.
P02462,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.61. AE: no.
P02462,5,negative,Visit 5: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.67. AE: no.
P02462,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.63. AE: no. CRP 2.3 mg/L; ALT 27 U/L.
P02463,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: insomnia. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02463,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: nausea. Adherence ~0.80. AE: yes.
P02463,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.82. AE: no.
P02463,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 6.1 mg/L; ALT 53 U/L.
P02463,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.57. AE: yes.
P02463,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02463,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.78. AE: yes. CRP 3.3 mg/L; ALT 52 U/L.
P02463,7,positive,Visit 7: Patient on RX-17B at S017. reports improvement. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02464,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 3.1 mg/L; ALT 29 U/L.
P02464,1,negative,Visit 1: Patient on RX-17B at S018. feels frustrated. Notes: headache. Adherence ~0.94. AE: no.
P02464,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: nausea. Adherence ~0.91. AE: no.
P02464,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no.
P02464,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02464,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.74. AE: no. CRP 2.3 mg/L; ALT 29 U/L.
P02465,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02465,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.63. AE: no.
P02465,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02465,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no. CRP 7.6 mg/L; ALT 37 U/L.
P02465,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.75. AE: yes.
P02465,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no.
P02466,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.74. AE: no. CRP 13.1 mg/L; ALT 21 U/L.
P02466,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02466,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02466,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.97. AE: yes.
P02466,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.59. AE: no. CRP 9.2 mg/L; ALT 23 U/L.
P02466,5,negative,Visit 5: Patient on RX-17A at S015. symptoms persist. Notes: dizziness. Adherence ~0.65. AE: no.
P02467,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no.
P02467,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.85. AE: no.
P02467,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P02467,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: nausea. Adherence ~0.73. AE: yes. CRP 3.1 mg/L; ALT 34 U/L.
P02467,4,negative,Visit 4: Patient on RX-17B at S016. increased discomfort. Notes: headache. Adherence ~0.82. AE: no. CRP 2.9 mg/L; ALT 34 U/L.
P02467,5,positive,Visit 5: Patient on RX-17B at S016. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no.
P02467,6,neutral,Visit 6: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.78. AE: yes.
P02468,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: headache. Adherence ~0.72. AE: no.
P02468,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02468,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 4.9 mg/L; ALT 17 U/L.
P02468,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.76. AE: yes.
P02468,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02468,5,neutral,Visit 5: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.75. AE: no.
P02468,6,neutral,Visit 6: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02469,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.93. AE: no.
P02469,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P02469,2,positive,Visit 2: Patient on RX-17A at S004. reports improvement. Notes: joint pain. Adherence ~0.87. AE: no. CRP 5.0 mg/L; ALT 29 U/L.
P02469,3,positive,Visit 3: Patient on RX-17A at S004. tolerating medication well. Notes: joint pain. Adherence ~1.00. AE: no.
P02470,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.59. AE: yes.
P02470,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~0.78. AE: no. CRP 6.5 mg/L; ALT 34 U/L.
P02470,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no. CRP 6.3 mg/L; ALT 36 U/L.
P02470,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 5.9 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02470,4,neutral,Visit 4: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.67. AE: no.
P02470,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.71. AE: no. CRP 4.7 mg/L; ALT 35 U/L.
P02470,6,neutral,Visit 6: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P02470,7,neutral,Visit 7: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no. CRP 3.0 mg/L; ALT 40 U/L.
P02471,0,neutral,Visit 0: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02471,1,neutral,Visit 1: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.83. AE: no.
P02471,2,negative,Visit 2: Patient on RX-17A at S002. reports worsening. Notes: headache. Adherence ~0.92. AE: no.
P02471,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no.
P02471,4,negative,Visit 4: Patient on RX-17A at S002. feels frustrated. Notes: nausea. Adherence ~0.92. AE: yes. CRP 5.3 mg/L; ALT 48 U/L.
P02472,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P02472,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 8.4 mg/L; ALT 27 U/L.
P02472,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.74. AE: no. CRP 7.1 mg/L; ALT 25 U/L.
P02472,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no. CRP 7.6 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02472,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.77. AE: no. CRP 5.5 mg/L; ALT 22 U/L.
P02473,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~0.67. AE: no.
P02473,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.72. AE: no. CRP 9.6 mg/L; ALT 25 U/L.
P02473,2,negative,Visit 2: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.72. AE: no.
P02473,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.59. AE: no.
P02473,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 6.8 mg/L; ALT 29 U/L.
P02473,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02473,6,neutral,Visit 6: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.66. AE: yes.
P02474,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: brain fog. Adherence ~0.93. AE: no. CRP 16.4 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02474,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no. CRP 18.8 mg/L; ALT 24 U/L.
P02474,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P02474,3,negative,Visit 3: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.84. AE: no.
P02474,4,negative,Visit 4: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02475,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: joint pain. Adherence ~0.80. AE: no.
P02475,1,negative,Visit 1: Patient on RX-17A at S001. symptoms persist. Notes: joint pain. Adherence ~0.76. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P02475,2,neutral,Visit 2: Patient on RX-17A at S001. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no. CRP 7.7 mg/L; ALT 29 U/L.
P02475,3,negative,Visit 3: Patient on RX-17A at S001. reports worsening. Notes: fatigue. Adherence ~0.95. AE: no.
P02475,4,neutral,Visit 4: Patient on RX-17A at S001. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 5.2 mg/L; ALT 28 U/L.
P02475,5,neutral,Visit 5: Patient on RX-17A at S001. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P02475,6,neutral,Visit 6: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no. CRP 4.3 mg/L; ALT 26 U/L.
P02476,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P02476,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.81. AE: no.
P02476,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.83. AE: yes. CRP 3.0 mg/L; ALT 22 U/L.
P02476,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: yes. CRP 3.0 mg/L; ALT 24 U/L.
P02476,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.89. AE: no.
P02476,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.77. AE: yes. CRP 2.0 mg/L; ALT 24 U/L.
P02476,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.61. AE: no.
P02476,7,positive,Visit 7: Patient on RX-17B at S014. feels better overall. Notes: insomnia. Adherence ~0.79. AE: no.
P02477,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 3.1 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P02477,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.99. AE: yes.
P02477,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P02477,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.86. AE: no.
P02477,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no.
P02477,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02477,6,positive,Visit 6: Patient on RX-17A at S012. feels better overall. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P02477,7,positive,Visit 7: Patient on RX-17A at S012. feels better overall. Notes: dizziness. Adherence ~0.86. AE: no. CRP 1.7 mg/L; ALT 14 U/L.
P02478,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~0.77. AE: no. CRP 17.0 mg/L; ALT 21 U/L.
P02478,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: dizziness. Adherence ~0.73. AE: no. CRP 18.7 mg/L; ALT 21 U/L.
P02478,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02478,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no. CRP 15.2 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02478,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02478,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.75. AE: no.
P02478,6,neutral,Visit 6: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.74. AE: no. CRP 11.1 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02479,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~0.99. AE: no.
P02479,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.93. AE: no.
P02479,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: no. CRP 7.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02479,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P02479,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no.
P02479,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no.
P02480,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02480,1,negative,Visit 1: Patient on RX-17A at S013. poor tolerance. Notes: dizziness. Adherence ~0.63. AE: no. CRP 7.6 mg/L; ALT 26 U/L.
P02480,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P02480,3,neutral,Visit 3: Patient on RX-17A at S013. continues regimen. Notes: brain fog. Adherence ~0.47. AE: no. CRP 6.4 mg/L; ALT 29 U/L.
P02480,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: fatigue. Adherence ~0.52. AE: no. CRP 6.1 mg/L; ALT 28 U/L.
P02481,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.76. AE: no.
P02481,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.75. AE: no. CRP 8.0 mg/L; ALT 43 U/L.
P02481,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.61. AE: no.
P02481,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.81. AE: yes. CRP 7.5 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02481,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.86. AE: no.
P02481,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no.
P02481,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.62. AE: no.
P02481,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.87. AE: no.
P02482,0,negative,Visit 0: Patient on RX-17B at S020. symptoms persist. Notes: insomnia. Adherence ~0.54. AE: no. CRP 7.2 mg/L; ALT 37 U/L.
P02482,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: insomnia. Adherence ~0.41. AE: no. CRP 7.5 mg/L; ALT 42 U/L.
P02482,2,neutral,Visit 2: Patient on RX-17B at S020. no major change. Notes: nausea. Adherence ~0.38. AE: no. CRP 6.1 mg/L; ALT 37 U/L.
P02482,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: insomnia. Adherence ~0.53. AE: no.
P02482,4,neutral,Visit 4: Patient on RX-17B at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.51. AE: no. CRP 5.9 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02482,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: headache. Adherence ~0.47. AE: yes. Plan: consider dose adjustment; counsel patient.
P02483,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: fatigue. Adherence ~0.93. AE: yes. CRP 10.0 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02483,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no. CRP 10.0 mg/L; ALT 26 U/L.
P02483,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: insomnia. Adherence ~0.87. AE: no.
P02483,3,negative,Visit 3: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.89. AE: yes. CRP 7.9 mg/L; ALT 29 U/L.
P02483,4,positive,Visit 4: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~0.88. AE: no.
P02483,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: joint pain. Adherence ~0.98. AE: no. CRP 6.1 mg/L; ALT 28 U/L.
P02483,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: headache. Adherence ~0.90. AE: no. CRP 5.2 mg/L; ALT 29 U/L.
P02483,7,neutral,Visit 7: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02484,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.92. AE: no.
P02484,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.94. AE: no.
P02484,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.90. AE: no.
P02484,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 19 U/L.
P02484,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.82. AE: no.
P02484,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.82. AE: no. CRP 3.9 mg/L; ALT 19 U/L.
P02485,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02485,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.84. AE: no.
P02485,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: no. CRP 11.4 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02485,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.85. AE: no.
P02485,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~1.00. AE: no. CRP 9.2 mg/L; ALT 36 U/L.
P02485,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02486,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.82. AE: no.
P02486,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: nausea. Adherence ~1.00. AE: yes.
P02486,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.78. AE: yes.
P02486,3,positive,Visit 3: Patient on RX-17B at S022. symptoms improving. Notes: joint pain. Adherence ~0.90. AE: no. CRP 4.3 mg/L; ALT 33 U/L.
P02486,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.91. AE: yes. Plan: consider dose adjustment; counsel patient.
P02486,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: nausea. Adherence ~0.90. AE: no.
P02486,6,positive,Visit 6: Patient on RX-17B at S022. symptoms improving. Notes: nausea. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 31 U/L.
P02487,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.76. AE: no. CRP 4.5 mg/L; ALT 30 U/L.
P02487,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.92. AE: no. CRP 3.6 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02487,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02487,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no.
P02487,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.94. AE: no.
P02487,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no.
P02487,6,positive,Visit 6: Patient on RX-17B at S004. energy increasing. Notes: brain fog. Adherence ~0.92. AE: no.
P02487,7,positive,Visit 7: Patient on RX-17B at S004. feels better overall. Notes: dizziness. Adherence ~0.96. AE: no.
P02488,0,negative,Visit 0: Patient on RX-17A at S013. reports worsening. Notes: headache. Adherence ~0.77. AE: no.
P02488,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.4 mg/L; ALT 40 U/L.
P02488,2,neutral,Visit 2: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P02488,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no. CRP 2.5 mg/L; ALT 46 U/L.
P02488,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02488,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: yes. CRP 2.0 mg/L; ALT 48 U/L.
P02488,6,positive,Visit 6: Patient on RX-17A at S013. symptoms improving. Notes: fatigue. Adherence ~0.89. AE: no.
P02488,7,positive,Visit 7: Patient on RX-17A at S013. symptoms improving. Notes: insomnia. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02489,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.73. AE: no. CRP 6.8 mg/L; ALT 33 U/L.
P02489,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.76. AE: no.
P02489,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.66. AE: no.
P02489,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.81. AE: yes.
P02490,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.81. AE: no.
P02490,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.79. AE: no.
P02490,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.73. AE: no.
P02490,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no.
P02490,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: joint pain. Adherence ~0.87. AE: no.
P02490,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.88. AE: yes.
P02490,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.93. AE: no. CRP 6.9 mg/L; ALT 34 U/L.
P02490,7,positive,Visit 7: Patient on RX-17B at S022. reports improvement. Notes: headache. Adherence ~0.91. AE: no.
P02491,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: no.
P02491,1,neutral,Visit 1: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~0.62. AE: no. CRP 5.5 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02491,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: dizziness. Adherence ~0.89. AE: no.
P02491,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.67. AE: yes.
P02491,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02491,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no.
P02491,6,positive,Visit 6: Patient on RX-17B at S013. symptoms improving. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02491,7,neutral,Visit 7: Patient on RX-17B at S013. stable symptoms. Notes: headache. Adherence ~0.95. AE: yes.
P02492,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: headache. Adherence ~0.89. AE: no. CRP 3.2 mg/L; ALT 40 U/L.
P02492,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: joint pain. Adherence ~0.89. AE: no.
P02492,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no.
P02492,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.98. AE: no.
P02492,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P02492,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~0.93. AE: no. CRP 2.3 mg/L; ALT 40 U/L.
P02493,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~0.81. AE: no.
P02493,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.69. AE: no. CRP 8.7 mg/L; ALT 24 U/L.
P02493,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.70. AE: no.
P02493,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.55. AE: no.
P02493,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.72. AE: no.
P02493,5,positive,Visit 5: Patient on RX-17B at S014. reports improvement. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02493,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.68. AE: no.
P02494,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no.
P02494,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: insomnia. Adherence ~0.59. AE: no. CRP 4.2 mg/L; ALT 23 U/L.
P02494,2,neutral,Visit 2: Patient on RX-17B at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.59. AE: yes. CRP 4.3 mg/L; ALT 23 U/L.
P02494,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: yes.
P02494,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: insomnia. Adherence ~0.73. AE: no.
P02494,5,neutral,Visit 5: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P02494,6,neutral,Visit 6: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.46. AE: no. CRP 2.6 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02494,7,neutral,Visit 7: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.61. AE: no. CRP 2.0 mg/L; ALT 24 U/L.
P02495,0,negative,Visit 0: Patient on RX-17B at S002. reports worsening. Notes: insomnia. Adherence ~0.65. AE: no.
P02495,1,neutral,Visit 1: Patient on RX-17B at S002. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 14.0 mg/L; ALT 27 U/L.
P02495,2,negative,Visit 2: Patient on RX-17B at S002. increased discomfort. Notes: fatigue. Adherence ~0.59. AE: yes.
P02496,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: no. CRP 13.6 mg/L; ALT 20 U/L.
P02496,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.68. AE: yes.
P02496,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.80. AE: yes.
P02496,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.82. AE: no.
P02496,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.56. AE: no. CRP 7.4 mg/L; ALT 20 U/L.
P02496,5,positive,Visit 5: Patient on RX-17B at S004. reports improvement. Notes: brain fog. Adherence ~0.78. AE: no. CRP 7.8 mg/L; ALT 22 U/L.
P02497,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.62. AE: no. CRP 3.6 mg/L; ALT 32 U/L.
P02497,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.90. AE: no. CRP 3.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02497,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P02497,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.60. AE: no.
P02497,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02498,0,negative,Visit 0: Patient on RX-17A at S007. symptoms persist. Notes: insomnia. Adherence ~0.85. AE: no. CRP 6.2 mg/L; ALT 30 U/L.
P02498,1,negative,Visit 1: Patient on RX-17A at S007. poor tolerance. Notes: insomnia. Adherence ~0.97. AE: yes.
P02498,2,negative,Visit 2: Patient on RX-17A at S007. feels frustrated. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02498,3,positive,Visit 3: Patient on RX-17A at S007. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02498,4,neutral,Visit 4: Patient on RX-17A at S007. stable symptoms. Notes: headache. Adherence ~0.71. AE: no. CRP 5.0 mg/L; ALT 31 U/L.
P02498,5,neutral,Visit 5: Patient on RX-17A at S007. stable symptoms. Notes: brain fog. Adherence ~0.94. AE: no.
P02498,6,positive,Visit 6: Patient on RX-17A at S007. tolerating medication well. Notes: insomnia. Adherence ~0.80. AE: no.
P02499,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no. CRP 4.8 mg/L; ALT 28 U/L.
P02499,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P02499,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.88. AE: no.
P02499,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 3.5 mg/L; ALT 32 U/L.
P02499,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: insomnia. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02499,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no.
P02499,6,positive,Visit 6: Patient on RX-17B at S015. symptoms improving. Notes: joint pain. Adherence ~0.94. AE: no.
P02499,7,neutral,Visit 7: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: yes. CRP 2.5 mg/L; ALT 34 U/L.
P02500,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.63. AE: yes. CRP 3.9 mg/L; ALT 26 U/L.
P02500,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: headache. Adherence ~0.70. AE: no.
P02500,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: fatigue. Adherence ~0.61. AE: yes.
P02500,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.74. AE: no. CRP 3.2 mg/L; ALT 29 U/L.
P02500,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02501,0,negative,Visit 0: Patient on RX-17B at S020. feels frustrated. Notes: nausea. Adherence ~0.59. AE: yes. CRP 7.0 mg/L; ALT 59 U/L.
P02501,1,negative,Visit 1: Patient on RX-17B at S020. reports worsening. Notes: dizziness. Adherence ~0.53. AE: no.
P02501,2,neutral,Visit 2: Patient on RX-17B at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P02501,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: nausea. Adherence ~0.43. AE: no.
P02501,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: yes.
P02501,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.38. AE: no. CRP 4.7 mg/L; ALT 56 U/L.
P02502,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02502,1,neutral,Visit 1: Patient on RX-17A at S018. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P02502,2,negative,Visit 2: Patient on RX-17A at S018. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02502,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.91. AE: no. CRP 8.5 mg/L; ALT 43 U/L.
P02502,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.87. AE: no.
P02503,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.90. AE: no.
P02503,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.86. AE: no.
P02503,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: headache. Adherence ~0.85. AE: yes.
P02504,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 4.2 mg/L; ALT 29 U/L.
P02504,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 5.3 mg/L; ALT 31 U/L.
P02504,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02504,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: joint pain. Adherence ~0.74. AE: yes. CRP 3.6 mg/L; ALT 36 U/L.
P02504,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.80. AE: no. CRP 3.9 mg/L; ALT 33 U/L.
P02504,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: no. CRP 3.7 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02505,0,negative,Visit 0: Patient on RX-17B at S010. symptoms persist. Notes: headache. Adherence ~1.00. AE: no. CRP 2.1 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02505,1,negative,Visit 1: Patient on RX-17B at S010. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.1 mg/L; ALT 47 U/L.
P02505,2,neutral,Visit 2: Patient on RX-17B at S010. no major change. Notes: fatigue. Adherence ~0.98. AE: no.
P02505,3,positive,Visit 3: Patient on RX-17B at S010. reports improvement. Notes: joint pain. Adherence ~0.94. AE: no.
P02505,4,positive,Visit 4: Patient on RX-17B at S010. reports improvement. Notes: headache. Adherence ~0.87. AE: no. CRP 1.4 mg/L; ALT 47 U/L.
P02505,5,positive,Visit 5: Patient on RX-17B at S010. tolerating medication well. Notes: nausea. Adherence ~1.00. AE: no.
P02506,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.1 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02506,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no.
P02506,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02506,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02506,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02507,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~1.00. AE: no. CRP 10.6 mg/L; ALT 20 U/L.
P02507,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 9.7 mg/L; ALT 22 U/L.
P02507,2,negative,Visit 2: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no. CRP 9.7 mg/L; ALT 22 U/L.
P02507,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 8.4 mg/L; ALT 21 U/L.
P02507,4,positive,Visit 4: Patient on RX-17A at S005. reports improvement. Notes: headache. Adherence ~0.89. AE: no.
P02508,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: brain fog. Adherence ~0.46. AE: no.
P02508,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: nausea. Adherence ~0.46. AE: no.
P02508,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.63. AE: no. CRP 3.1 mg/L; ALT 31 U/L.
P02508,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.48. AE: no. CRP 2.7 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02508,4,negative,Visit 4: Patient on RX-17A at S019. increased discomfort. Notes: insomnia. Adherence ~0.54. AE: yes. CRP 2.8 mg/L; ALT 37 U/L.
P02508,5,neutral,Visit 5: Patient on RX-17A at S019. continues regimen. Notes: nausea. Adherence ~0.55. AE: no.
P02509,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: nausea. Adherence ~0.88. AE: no. CRP 15.5 mg/L; ALT 36 U/L.
P02509,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.83. AE: no. CRP 14.8 mg/L; ALT 33 U/L.
P02509,2,negative,Visit 2: Patient on RX-17A at S018. feels frustrated. Notes: nausea. Adherence ~0.80. AE: no. CRP 13.8 mg/L; ALT 36 U/L.
P02509,3,negative,Visit 3: Patient on RX-17A at S018. poor tolerance. Notes: fatigue. Adherence ~0.81. AE: yes. CRP 12.7 mg/L; ALT 37 U/L.
P02510,0,neutral,Visit 0: Patient on RX-17A at S021. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: no. CRP 5.4 mg/L; ALT 32 U/L.
P02510,1,negative,Visit 1: Patient on RX-17A at S021. reports worsening. Notes: fatigue. Adherence ~0.75. AE: no.
P02510,2,positive,Visit 2: Patient on RX-17A at S021. symptoms improving. Notes: fatigue. Adherence ~0.92. AE: no.
P02510,3,neutral,Visit 3: Patient on RX-17A at S021. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: no.
P02510,4,neutral,Visit 4: Patient on RX-17A at S021. stable symptoms. Notes: joint pain. Adherence ~0.77. AE: no.
P02510,5,neutral,Visit 5: Patient on RX-17A at S021. follow-up as scheduled. Notes: fatigue. Adherence ~0.62. AE: no.
P02510,6,neutral,Visit 6: Patient on RX-17A at S021. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: no.
P02511,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.69. AE: no.
P02511,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.82. AE: no.
P02511,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: yes.
P02511,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: no.
P02511,4,neutral,Visit 4: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 6.6 mg/L; ALT 38 U/L.
P02511,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: dizziness. Adherence ~0.87. AE: no.
P02511,6,neutral,Visit 6: Patient on RX-17A at S019. no major change. Notes: insomnia. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02512,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 24 U/L.
P02512,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~1.00. AE: no. CRP 5.2 mg/L; ALT 24 U/L.
P02512,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no.
P02512,3,positive,Visit 3: Patient on RX-17B at S022. symptoms improving. Notes: headache. Adherence ~0.97. AE: no.
P02512,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.93. AE: no.
P02513,0,negative,Visit 0: Patient on RX-17A at S007. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: yes. Plan: consider dose adjustment; counsel patient.
P02513,1,neutral,Visit 1: Patient on RX-17A at S007. no major change. Notes: headache. Adherence ~0.71. AE: no.
P02513,2,negative,Visit 2: Patient on RX-17A at S007. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no.
P02513,3,neutral,Visit 3: Patient on RX-17A at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no.
P02513,4,negative,Visit 4: Patient on RX-17A at S007. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: no. CRP 2.9 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02513,5,neutral,Visit 5: Patient on RX-17A at S007. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P02514,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no. CRP 10.0 mg/L; ALT 24 U/L.
P02514,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.98. AE: yes.
P02514,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02514,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.96. AE: no.
P02514,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.91. AE: no.
P02514,5,positive,Visit 5: Patient on RX-17B at S022. reports improvement. Notes: fatigue. Adherence ~0.88. AE: no.
P02514,6,neutral,Visit 6: Patient on RX-17B at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02515,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~1.00. AE: yes.
P02515,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P02515,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 40 U/L.
P02515,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.98. AE: yes. CRP 4.1 mg/L; ALT 41 U/L.
P02515,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.8 mg/L; ALT 38 U/L.
P02515,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: no.
P02515,6,positive,Visit 6: Patient on RX-17A at S014. energy increasing. Notes: brain fog. Adherence ~1.00. AE: no.
P02515,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: brain fog. Adherence ~0.91. AE: no.
P02516,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: nausea. Adherence ~0.75. AE: yes.
P02516,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: brain fog. Adherence ~0.69. AE: no.
P02516,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no.
P02516,3,neutral,Visit 3: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P02516,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~0.73. AE: no.
P02516,5,neutral,Visit 5: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02517,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.81. AE: no.
P02517,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.96. AE: no. CRP 1.9 mg/L; ALT 16 U/L.
P02517,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.83. AE: no.
P02517,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P02517,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02518,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.58. AE: no. CRP 15.2 mg/L; ALT 33 U/L.
P02518,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.73. AE: no.
P02518,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.85. AE: no.
P02518,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no.
P02518,4,negative,Visit 4: Patient on RX-17A at S012. reports worsening. Notes: nausea. Adherence ~0.76. AE: yes.
P02518,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 8.8 mg/L; ALT 31 U/L.
P02518,6,positive,Visit 6: Patient on RX-17A at S012. reports improvement. Notes: brain fog. Adherence ~0.83. AE: no.
P02518,7,neutral,Visit 7: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.85. AE: no. CRP 8.5 mg/L; ALT 32 U/L.
P02519,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: insomnia. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02519,1,negative,Visit 1: Patient on RX-17A at S011. symptoms persist. Notes: insomnia. Adherence ~0.87. AE: no.
P02519,2,neutral,Visit 2: Patient on RX-17A at S011. follow-up as scheduled. Notes: headache. Adherence ~0.97. AE: no. CRP 6.6 mg/L; ALT 24 U/L.
P02519,3,neutral,Visit 3: Patient on RX-17A at S011. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no.
P02519,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: dizziness. Adherence ~0.78. AE: no.
P02519,5,neutral,Visit 5: Patient on RX-17A at S011. no major change. Notes: dizziness. Adherence ~0.99. AE: yes.
P02520,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: brain fog. Adherence ~0.91. AE: no.
P02520,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: headache. Adherence ~0.93. AE: no.
P02520,2,neutral,Visit 2: Patient on RX-17B at S008. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02520,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 10.5 mg/L; ALT 18 U/L.
P02520,4,positive,Visit 4: Patient on RX-17B at S008. feels better overall. Notes: nausea. Adherence ~0.95. AE: no.
P02520,5,positive,Visit 5: Patient on RX-17B at S008. energy increasing. Notes: dizziness. Adherence ~0.92. AE: no. CRP 6.5 mg/L; ALT 19 U/L.
P02520,6,positive,Visit 6: Patient on RX-17B at S008. energy increasing. Notes: insomnia. Adherence ~0.83. AE: no.
P02520,7,positive,Visit 7: Patient on RX-17B at S008. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02521,0,neutral,Visit 0: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.94. AE: no. CRP 9.8 mg/L; ALT 29 U/L.
P02521,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: nausea. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02521,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 9.4 mg/L; ALT 32 U/L.
P02521,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~1.00. AE: yes. CRP 8.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02521,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no. CRP 8.5 mg/L; ALT 32 U/L.
P02522,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.87. AE: no. CRP 15.2 mg/L; ALT 24 U/L.
P02522,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.68. AE: no. CRP 10.7 mg/L; ALT 28 U/L.
P02522,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 10.5 mg/L; ALT 25 U/L.
P02522,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.91. AE: yes.
P02522,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no. CRP 9.2 mg/L; ALT 25 U/L.
P02523,0,negative,Visit 0: Patient on RX-17B at S020. symptoms persist. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 5.5 mg/L; ALT 45 U/L.
P02523,1,negative,Visit 1: Patient on RX-17B at S020. feels frustrated. Notes: brain fog. Adherence ~0.72. AE: yes.
P02523,2,negative,Visit 2: Patient on RX-17B at S020. symptoms persist. Notes: nausea. Adherence ~0.64. AE: no.
P02523,3,neutral,Visit 3: Patient on RX-17B at S020. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no. CRP 4.3 mg/L; ALT 58 U/L.
P02523,4,neutral,Visit 4: Patient on RX-17B at S020. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P02523,5,neutral,Visit 5: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.78. AE: no.
P02523,6,neutral,Visit 6: Patient on RX-17B at S020. no major change. Notes: nausea. Adherence ~0.69. AE: yes.
P02523,7,neutral,Visit 7: Patient on RX-17B at S020. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: yes. Plan: consider dose adjustment; counsel patient.
P02524,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P02524,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.80. AE: no.
P02524,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: no. CRP 2.9 mg/L; ALT 28 U/L.
P02524,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P02524,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no.
P02524,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.89. AE: no. CRP 2.1 mg/L; ALT 33 U/L.
P02524,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02524,7,positive,Visit 7: Patient on RX-17A at S015. reports improvement. Notes: dizziness. Adherence ~1.00. AE: no.
P02525,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.90. AE: no. CRP 12.2 mg/L; ALT 38 U/L.
P02525,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.87. AE: no. CRP 8.6 mg/L; ALT 38 U/L.
P02525,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.95. AE: no.
P02525,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~1.00. AE: no.
P02525,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 8.2 mg/L; ALT 39 U/L.
P02525,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no.
P02526,0,negative,Visit 0: Patient on RX-17A at S013. feels frustrated. Notes: joint pain. Adherence ~0.51. AE: no. CRP 8.8 mg/L; ALT 30 U/L.
P02526,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02526,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: nausea. Adherence ~0.73. AE: yes. CRP 7.0 mg/L; ALT 34 U/L.
P02526,3,negative,Visit 3: Patient on RX-17A at S013. feels frustrated. Notes: joint pain. Adherence ~0.43. AE: no.
P02526,4,negative,Visit 4: Patient on RX-17A at S013. poor tolerance. Notes: fatigue. Adherence ~0.56. AE: no. CRP 6.4 mg/L; ALT 31 U/L.
P02526,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.57. AE: no.
P02527,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P02527,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.51. AE: no. CRP 5.3 mg/L; ALT 25 U/L.
P02527,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.63. AE: no.
P02527,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.71. AE: no. CRP 4.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02527,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no. CRP 4.0 mg/L; ALT 24 U/L.
P02527,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.78. AE: no. CRP 3.8 mg/L; ALT 26 U/L.
P02528,0,neutral,Visit 0: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.64. AE: yes.
P02528,1,neutral,Visit 1: Patient on RX-17B at S006. continues regimen. Notes: brain fog. Adherence ~0.55. AE: no.
P02528,2,neutral,Visit 2: Patient on RX-17B at S006. reviewed dosing instructions. Notes: nausea. Adherence ~0.58. AE: no.
P02528,3,neutral,Visit 3: Patient on RX-17B at S006. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P02528,4,neutral,Visit 4: Patient on RX-17B at S006. no major change. Notes: headache. Adherence ~0.45. AE: no.
P02528,5,neutral,Visit 5: Patient on RX-17B at S006. stable symptoms. Notes: headache. Adherence ~0.71. AE: no.
P02528,6,neutral,Visit 6: Patient on RX-17B at S006. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.62. AE: yes. CRP 6.4 mg/L; ALT 33 U/L.
P02529,0,negative,Visit 0: Patient on RX-17A at S018. reports worsening. Notes: brain fog. Adherence ~0.87. AE: no.
P02529,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02529,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. CRP 8.4 mg/L; ALT 43 U/L.
P02529,3,negative,Visit 3: Patient on RX-17A at S018. symptoms persist. Notes: dizziness. Adherence ~0.91. AE: no. CRP 6.7 mg/L; ALT 43 U/L.
P02529,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 6.6 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02529,5,neutral,Visit 5: Patient on RX-17A at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.99. AE: no.
P02529,6,positive,Visit 6: Patient on RX-17A at S018. energy increasing. Notes: headache. Adherence ~1.00. AE: no.
P02529,7,positive,Visit 7: Patient on RX-17A at S018. energy increasing. Notes: fatigue. Adherence ~0.93. AE: no.
P02530,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.84. AE: yes.
P02530,1,neutral,Visit 1: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: no. CRP 11.3 mg/L; ALT 39 U/L.
P02530,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.85. AE: no. CRP 7.8 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02530,3,negative,Visit 3: Patient on RX-17B at S005. poor tolerance. Notes: dizziness. Adherence ~0.65. AE: yes.
P02530,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.81. AE: yes.
P02530,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.73. AE: yes.
P02531,0,neutral,Visit 0: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02531,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02531,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02531,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: yes. CRP 3.7 mg/L; ALT 19 U/L.
P02531,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: headache. Adherence ~0.81. AE: no.
P02531,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no.
P02531,6,neutral,Visit 6: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.88. AE: no.
P02532,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: headache. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P02532,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.30. AE: no. CRP 11.0 mg/L; ALT 20 U/L.
P02532,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.48. AE: no.
P02532,3,negative,Visit 3: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.50. AE: no. CRP 8.5 mg/L; ALT 18 U/L.
P02532,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.63. AE: no.
P02532,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.63. AE: no. CRP 7.2 mg/L; ALT 20 U/L.
P02533,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.53. AE: no.
P02533,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no. CRP 6.7 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02533,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no. CRP 7.7 mg/L; ALT 20 U/L.
P02533,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.72. AE: no.
P02533,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02533,5,neutral,Visit 5: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P02534,0,negative,Visit 0: Patient on RX-17A at S019. feels frustrated. Notes: headache. Adherence ~1.00. AE: yes.
P02534,1,negative,Visit 1: Patient on RX-17A at S019. increased discomfort. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02534,2,neutral,Visit 2: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02534,3,neutral,Visit 3: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P02534,4,positive,Visit 4: Patient on RX-17A at S019. tolerating medication well. Notes: fatigue. Adherence ~1.00. AE: no.
P02534,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02535,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02535,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: insomnia. Adherence ~0.66. AE: no.
P02535,2,negative,Visit 2: Patient on RX-17A at S011. increased discomfort. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02535,3,neutral,Visit 3: Patient on RX-17A at S011. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no. CRP 9.8 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02535,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02535,5,positive,Visit 5: Patient on RX-17A at S011. energy increasing. Notes: dizziness. Adherence ~0.76. AE: no. CRP 8.0 mg/L; ALT 17 U/L.
P02535,6,neutral,Visit 6: Patient on RX-17A at S011. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02535,7,positive,Visit 7: Patient on RX-17A at S011. reports improvement. Notes: insomnia. Adherence ~0.90. AE: no.
P02536,0,negative,Visit 0: Patient on RX-17B at S020. poor tolerance. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P02536,1,negative,Visit 1: Patient on RX-17B at S020. reports worsening. Notes: nausea. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02536,2,positive,Visit 2: Patient on RX-17B at S020. energy increasing. Notes: headache. Adherence ~0.78. AE: no. CRP 8.9 mg/L; ALT 38 U/L.
P02536,3,negative,Visit 3: Patient on RX-17B at S020. feels frustrated. Notes: fatigue. Adherence ~0.62. AE: no.
P02536,4,neutral,Visit 4: Patient on RX-17B at S020. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: yes. CRP 7.7 mg/L; ALT 45 U/L.
P02537,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02537,1,negative,Visit 1: Patient on RX-17B at S017. feels frustrated. Notes: dizziness. Adherence ~0.81. AE: no. CRP 6.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02537,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.94. AE: no.
P02537,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 5.6 mg/L; ALT 38 U/L.
P02537,4,neutral,Visit 4: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no.
P02538,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.58. AE: no.
P02538,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: yes.
P02538,2,negative,Visit 2: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.79. AE: no.
P02538,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02538,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no. CRP 8.2 mg/L; ALT 32 U/L.
P02538,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02539,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.83. AE: yes.
P02539,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.78. AE: no. CRP 11.5 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02539,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no. CRP 11.1 mg/L; ALT 24 U/L.
P02539,3,negative,Visit 3: Patient on RX-17A at S015. reports worsening. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02539,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.64. AE: no. CRP 10.1 mg/L; ALT 26 U/L.
P02539,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.58. AE: no.
P02539,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no.
P02539,7,positive,Visit 7: Patient on RX-17A at S015. energy increasing. Notes: joint pain. Adherence ~0.81. AE: no.
P02540,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no. CRP 11.4 mg/L; ALT 41 U/L.
P02540,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02540,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02540,3,negative,Visit 3: Patient on RX-17A at S019. feels frustrated. Notes: nausea. Adherence ~0.67. AE: yes. CRP 8.7 mg/L; ALT 52 U/L.
P02540,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no.
P02540,5,positive,Visit 5: Patient on RX-17A at S019. energy increasing. Notes: headache. Adherence ~0.80. AE: no. CRP 8.0 mg/L; ALT 46 U/L.
P02540,6,neutral,Visit 6: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.58. AE: no.
P02541,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02541,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no.
P02541,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: fatigue. Adherence ~0.93. AE: no.
P02541,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no.
P02541,4,neutral,Visit 4: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.61. AE: no. CRP 5.8 mg/L; ALT 31 U/L.
P02541,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no. CRP 5.7 mg/L; ALT 33 U/L.
P02541,6,neutral,Visit 6: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.73. AE: no. CRP 4.8 mg/L; ALT 29 U/L.
P02541,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no.
P02542,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: brain fog. Adherence ~0.81. AE: no.
P02542,1,neutral,Visit 1: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02542,2,neutral,Visit 2: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.53. AE: no. CRP 8.3 mg/L; ALT 20 U/L.
P02542,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02542,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.67. AE: no. CRP 7.7 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P02543,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: headache. Adherence ~1.00. AE: no. CRP 5.9 mg/L; ALT 18 U/L.
P02543,1,neutral,Visit 1: Patient on RX-17B at S018. no major change. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 4.8 mg/L; ALT 21 U/L.
P02543,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.5 mg/L; ALT 19 U/L.
P02543,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no.
P02543,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02543,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: yes.
P02543,6,neutral,Visit 6: Patient on RX-17B at S018. reviewed dosing instructions. Notes: dizziness. Adherence ~0.82. AE: yes. CRP 2.8 mg/L; ALT 22 U/L.
P02544,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.89. AE: no.
P02544,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.94. AE: no.
P02544,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02544,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no.
P02544,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.93. AE: no. CRP 12.2 mg/L; ALT 18 U/L.
P02544,5,negative,Visit 5: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.84. AE: no.
P02544,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~0.95. AE: no. CRP 10.3 mg/L; ALT 18 U/L.
P02544,7,positive,Visit 7: Patient on RX-17A at S017. energy increasing. Notes: fatigue. Adherence ~0.85. AE: no.
P02545,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.14. AE: no.
P02545,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.38. AE: no. Plan: consider dose adjustment; counsel patient.
P02545,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.01. AE: no. Plan: consider dose adjustment; counsel patient.
P02545,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.11. AE: no.
P02545,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.24. AE: no.
P02545,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.18. AE: no.
P02545,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.31. AE: no.
P02545,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.09. AE: no. CRP 1.2 mg/L; ALT 54 U/L.
P02546,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.88. AE: no.
P02546,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02546,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~0.90. AE: no.
P02546,3,positive,Visit 3: Patient on RX-17B at S022. symptoms improving. Notes: fatigue. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02546,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 52 U/L.
P02546,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.84. AE: no.
P02547,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.76. AE: no. CRP 5.7 mg/L; ALT 46 U/L.
P02547,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02547,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no.
P02547,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.71. AE: no. CRP 4.5 mg/L; ALT 53 U/L.
P02548,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.84. AE: no. CRP 5.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02548,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.68. AE: no.
P02548,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.49. AE: yes. CRP 4.8 mg/L; ALT 32 U/L.
P02548,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.51. AE: yes.
P02549,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~0.64. AE: no.
P02549,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.70. AE: yes.
P02549,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02549,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.60. AE: no.
P02549,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.63. AE: no. CRP 7.1 mg/L; ALT 19 U/L. Plan: consider dose adjustment; counsel patient.
P02549,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.62. AE: no.
P02549,6,neutral,Visit 6: Patient on RX-17B at S004. stable symptoms. Notes: joint pain. Adherence ~0.69. AE: no.
P02550,0,negative,Visit 0: Patient on RX-17B at S007. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no.
P02550,1,neutral,Visit 1: Patient on RX-17B at S007. continues regimen. Notes: joint pain. Adherence ~0.66. AE: yes. CRP 4.1 mg/L; ALT 22 U/L.
P02550,2,neutral,Visit 2: Patient on RX-17B at S007. continues regimen. Notes: joint pain. Adherence ~0.56. AE: no. CRP 3.3 mg/L; ALT 23 U/L.
P02550,3,neutral,Visit 3: Patient on RX-17B at S007. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.48. AE: no.
P02550,4,positive,Visit 4: Patient on RX-17B at S007. reports improvement. Notes: joint pain. Adherence ~0.86. AE: no.
P02550,5,positive,Visit 5: Patient on RX-17B at S007. energy increasing. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02550,6,neutral,Visit 6: Patient on RX-17B at S007. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no. CRP 2.1 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02551,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: fatigue. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02551,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02551,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.93. AE: no. CRP 19.2 mg/L; ALT 21 U/L.
P02551,3,negative,Visit 3: Patient on RX-17A at S019. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: yes.
P02551,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.67. AE: no. CRP 17.0 mg/L; ALT 23 U/L.
P02551,5,neutral,Visit 5: Patient on RX-17A at S019. follow-up as scheduled. Notes: fatigue. Adherence ~0.99. AE: no.
P02552,0,negative,Visit 0: Patient on RX-17B at S013. reports worsening. Notes: joint pain. Adherence ~0.75. AE: no. CRP 3.2 mg/L; ALT 31 U/L.
P02552,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: joint pain. Adherence ~0.70. AE: no. CRP 3.3 mg/L; ALT 31 U/L.
P02552,2,neutral,Visit 2: Patient on RX-17B at S013. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02552,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02552,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.79. AE: no. CRP 2.2 mg/L; ALT 34 U/L.
P02552,5,neutral,Visit 5: Patient on RX-17B at S013. continues regimen. Notes: dizziness. Adherence ~0.76. AE: yes.
P02553,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: brain fog. Adherence ~0.59. AE: no.
P02553,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.64. AE: no. CRP 4.2 mg/L; ALT 53 U/L.
P02553,2,negative,Visit 2: Patient on RX-17B at S012. poor tolerance. Notes: fatigue. Adherence ~0.66. AE: no.
P02553,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no.
P02553,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.58. AE: no. CRP 3.0 mg/L; ALT 54 U/L.
P02554,0,negative,Visit 0: Patient on RX-17B at S008. poor tolerance. Notes: fatigue. Adherence ~0.52. AE: yes.
P02554,1,negative,Visit 1: Patient on RX-17B at S008. increased discomfort. Notes: fatigue. Adherence ~0.68. AE: no.
P02554,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.81. AE: no. CRP 3.6 mg/L; ALT 50 U/L. Plan: consider dose adjustment; counsel patient.
P02554,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: nausea. Adherence ~0.60. AE: no.
P02554,4,neutral,Visit 4: Patient on RX-17B at S008. continues regimen. Notes: headache. Adherence ~0.67. AE: no.
P02554,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no.
P02554,6,neutral,Visit 6: Patient on RX-17B at S008. stable symptoms. Notes: nausea. Adherence ~0.76. AE: no.
P02554,7,neutral,Visit 7: Patient on RX-17B at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.59. AE: no.
P02555,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: headache. Adherence ~0.59. AE: no. CRP 9.1 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02555,1,neutral,Visit 1: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.45. AE: no.
P02555,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.59. AE: no.
P02555,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.42. AE: no. CRP 6.7 mg/L; ALT 32 U/L.
P02555,4,negative,Visit 4: Patient on RX-17B at S014. poor tolerance. Notes: insomnia. Adherence ~0.64. AE: yes.
P02556,0,negative,Visit 0: Patient on RX-17A at S018. feels frustrated. Notes: headache. Adherence ~0.93. AE: no.
P02556,1,neutral,Visit 1: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02556,2,negative,Visit 2: Patient on RX-17A at S018. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no. CRP 12.3 mg/L; ALT 15 U/L.
P02557,0,negative,Visit 0: Patient on RX-17B at S020. increased discomfort. Notes: headache. Adherence ~0.91. AE: no.
P02557,1,neutral,Visit 1: Patient on RX-17B at S020. follow-up as scheduled. Notes: brain fog. Adherence ~0.66. AE: no.
P02557,2,neutral,Visit 2: Patient on RX-17B at S020. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: yes.
P02557,3,neutral,Visit 3: Patient on RX-17B at S020. no major change. Notes: dizziness. Adherence ~0.89. AE: no. CRP 8.5 mg/L; ALT 22 U/L.
P02557,4,negative,Visit 4: Patient on RX-17B at S020. increased discomfort. Notes: joint pain. Adherence ~0.51. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P02557,5,neutral,Visit 5: Patient on RX-17B at S020. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no.
P02558,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.60. AE: yes.
P02558,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~0.42. AE: yes.
P02558,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.36. AE: no. CRP 13.9 mg/L; ALT 45 U/L.
P02558,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.51. AE: no.
P02558,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.65. AE: no. CRP 11.8 mg/L; ALT 44 U/L.
P02558,5,negative,Visit 5: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.23. AE: yes. CRP 9.6 mg/L; ALT 51 U/L.
P02559,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.68. AE: no.
P02559,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.65. AE: yes.
P02559,2,neutral,Visit 2: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.55. AE: no. CRP 4.1 mg/L; ALT 29 U/L.
P02559,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.58. AE: no.
P02559,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02559,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02560,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.58. AE: no.
P02560,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.75. AE: no.
P02560,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02560,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.64. AE: no.
P02560,4,negative,Visit 4: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~0.52. AE: no. CRP 7.7 mg/L; ALT 27 U/L.
P02561,0,neutral,Visit 0: Patient on RX-17B at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02561,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.96. AE: no.
P02561,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 5.4 mg/L; ALT 26 U/L.
P02561,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.86. AE: no.
P02561,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no. CRP 4.2 mg/L; ALT 24 U/L.
P02561,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no.
P02561,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P02562,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.71. AE: no.
P02562,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no. CRP 7.0 mg/L; ALT 26 U/L.
P02562,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.81. AE: no. CRP 7.4 mg/L; ALT 24 U/L.
P02562,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no.
P02562,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no.
P02563,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: nausea. Adherence ~0.77. AE: yes.
P02563,1,negative,Visit 1: Patient on RX-17A at S013. symptoms persist. Notes: fatigue. Adherence ~0.72. AE: no.
P02563,2,negative,Visit 2: Patient on RX-17A at S013. increased discomfort. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02563,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.66. AE: no.
P02563,4,neutral,Visit 4: Patient on RX-17A at S013. no major change. Notes: headache. Adherence ~0.84. AE: no.
P02563,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02563,6,positive,Visit 6: Patient on RX-17A at S013. feels better overall. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 8.5 mg/L; ALT 21 U/L.
P02564,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.92. AE: no.
P02564,1,negative,Visit 1: Patient on RX-17B at S014. increased discomfort. Notes: insomnia. Adherence ~0.84. AE: no. CRP 2.9 mg/L; ALT 58 U/L.
P02564,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.90. AE: no. CRP 2.5 mg/L; ALT 63 U/L.
P02564,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no. CRP 2.1 mg/L; ALT 63 U/L.
P02564,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.96. AE: yes. CRP 1.9 mg/L; ALT 71 U/L.
P02565,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: joint pain. Adherence ~0.83. AE: no.
P02565,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no.
P02565,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P02565,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P02565,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P02566,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.79. AE: no.
P02566,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: headache. Adherence ~0.57. AE: no.
P02566,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.84. AE: no.
P02566,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: brain fog. Adherence ~0.61. AE: no.
P02566,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.72. AE: no.
P02566,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.58. AE: no.
P02566,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: dizziness. Adherence ~0.85. AE: no.
P02567,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.70. AE: no. CRP 3.0 mg/L; ALT 16 U/L.
P02567,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: no.
P02567,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02567,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. CRP 2.5 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02567,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no. CRP 2.2 mg/L; ALT 15 U/L.
P02568,0,negative,Visit 0: Patient on RX-17B at S018. symptoms persist. Notes: brain fog. Adherence ~0.71. AE: no. CRP 5.0 mg/L; ALT 29 U/L.
P02568,1,neutral,Visit 1: Patient on RX-17B at S018. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P02568,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.67. AE: yes.
P02568,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no.
P02568,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 3.4 mg/L; ALT 33 U/L.
P02568,5,neutral,Visit 5: Patient on RX-17B at S018. no major change. Notes: nausea. Adherence ~0.59. AE: no.
P02568,6,positive,Visit 6: Patient on RX-17B at S018. symptoms improving. Notes: insomnia. Adherence ~0.77. AE: no. CRP 2.6 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02568,7,neutral,Visit 7: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.70. AE: no.
P02569,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.94. AE: no. CRP 7.4 mg/L; ALT 29 U/L.
P02569,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.92. AE: no. CRP 7.5 mg/L; ALT 32 U/L.
P02569,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.95. AE: no. CRP 6.8 mg/L; ALT 27 U/L.
P02569,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P02569,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02569,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.97. AE: no.
P02569,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.92. AE: no.
P02569,7,positive,Visit 7: Patient on RX-17A at S017. reports improvement. Notes: nausea. Adherence ~0.90. AE: no.
P02570,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.86. AE: no.
P02570,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.72. AE: no. CRP 4.9 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02570,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.74. AE: no. CRP 4.6 mg/L; ALT 41 U/L.
P02570,3,neutral,Visit 3: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no.
P02570,4,negative,Visit 4: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.71. AE: no. CRP 2.8 mg/L; ALT 36 U/L.
P02570,5,neutral,Visit 5: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.74. AE: no.
P02571,0,neutral,Visit 0: Patient on RX-17A at S018. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P02571,1,negative,Visit 1: Patient on RX-17A at S018. symptoms persist. Notes: dizziness. Adherence ~0.85. AE: no.
P02571,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no. CRP 2.0 mg/L; ALT 36 U/L.
P02571,3,negative,Visit 3: Patient on RX-17A at S018. poor tolerance. Notes: brain fog. Adherence ~0.87. AE: no.
P02571,4,negative,Visit 4: Patient on RX-17A at S018. poor tolerance. Notes: joint pain. Adherence ~0.73. AE: no.
P02571,5,neutral,Visit 5: Patient on RX-17A at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.64. AE: no.
P02572,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P02572,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: headache. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02572,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.77. AE: no. CRP 6.5 mg/L; ALT 20 U/L.
P02572,3,positive,Visit 3: Patient on RX-17B at S019. reports improvement. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02572,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P02573,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no. CRP 5.3 mg/L; ALT 42 U/L.
P02573,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: joint pain. Adherence ~0.80. AE: no. CRP 4.7 mg/L; ALT 45 U/L.
P02573,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02573,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02573,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.80. AE: no.
P02573,5,positive,Visit 5: Patient on RX-17B at S005. feels better overall. Notes: insomnia. Adherence ~0.80. AE: no.
P02574,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P02574,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02574,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~0.61. AE: no.
P02574,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no. CRP 8.7 mg/L; ALT 29 U/L.
P02574,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no.
P02574,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no. CRP 7.6 mg/L; ALT 29 U/L.
P02575,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: insomnia. Adherence ~0.68. AE: no.
P02575,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: fatigue. Adherence ~0.79. AE: yes. CRP 4.0 mg/L; ALT 42 U/L.
P02575,2,negative,Visit 2: Patient on RX-17A at S011. symptoms persist. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.3 mg/L; ALT 36 U/L.
P02575,3,negative,Visit 3: Patient on RX-17A at S011. increased discomfort. Notes: dizziness. Adherence ~0.59. AE: no. CRP 3.1 mg/L; ALT 40 U/L.
P02575,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: no.
P02576,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: fatigue. Adherence ~0.72. AE: no.
P02576,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: fatigue. Adherence ~0.60. AE: no.
P02576,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: yes.
P02576,3,negative,Visit 3: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: yes. CRP 19.1 mg/L; ALT 29 U/L.
P02576,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no.
P02576,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02576,6,neutral,Visit 6: Patient on RX-17B at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P02576,7,neutral,Visit 7: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.55. AE: no.
P02577,0,neutral,Visit 0: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P02577,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P02577,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.50. AE: no.
P02577,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P02577,4,neutral,Visit 4: Patient on RX-17A at S008. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 8.1 mg/L; ALT 44 U/L.
P02577,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02577,6,neutral,Visit 6: Patient on RX-17A at S008. continues regimen. Notes: nausea. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02578,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.68. AE: no.
P02578,1,neutral,Visit 1: Patient on RX-17A at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02578,2,neutral,Visit 2: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: yes.
P02579,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: joint pain. Adherence ~0.88. AE: no.
P02579,1,negative,Visit 1: Patient on RX-17A at S008. poor tolerance. Notes: headache. Adherence ~0.84. AE: no.
P02579,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no. CRP 8.7 mg/L; ALT 42 U/L.
P02579,3,neutral,Visit 3: Patient on RX-17A at S008. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.1 mg/L; ALT 37 U/L.
P02579,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02579,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: brain fog. Adherence ~0.74. AE: no. CRP 7.2 mg/L; ALT 42 U/L.
P02580,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.66. AE: no. CRP 2.8 mg/L; ALT 19 U/L.
P02580,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.90. AE: no.
P02580,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.92. AE: no.
P02580,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02580,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: yes.
P02580,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no. CRP 1.8 mg/L; ALT 23 U/L.
P02581,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.51. AE: no. CRP 5.5 mg/L; ALT 33 U/L.
P02581,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.67. AE: no.
P02581,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.68. AE: no. CRP 4.6 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02581,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.69. AE: no.
P02581,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.66. AE: no. CRP 3.3 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02581,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 2.9 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02582,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no. CRP 21.1 mg/L; ALT 49 U/L.
P02582,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.73. AE: no.
P02582,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02582,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 15.7 mg/L; ALT 48 U/L.
P02582,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.99. AE: no. CRP 16.0 mg/L; ALT 49 U/L.
P02582,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~1.00. AE: yes.
P02583,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P02583,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: headache. Adherence ~0.89. AE: no.
P02583,2,neutral,Visit 2: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes. CRP 4.9 mg/L; ALT 26 U/L.
P02583,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P02583,4,positive,Visit 4: Patient on RX-17B at S019. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02584,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.93. AE: no.
P02584,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no.
P02584,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.77. AE: yes. CRP 5.9 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02585,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: fatigue. Adherence ~0.57. AE: no.
P02585,1,neutral,Visit 1: Patient on RX-17B at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no.
P02585,2,negative,Visit 2: Patient on RX-17B at S019. increased discomfort. Notes: headache. Adherence ~0.90. AE: yes.
P02585,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: insomnia. Adherence ~0.95. AE: no. CRP 4.3 mg/L; ALT 28 U/L.
P02585,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.70. AE: no. CRP 4.5 mg/L; ALT 29 U/L.
P02585,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~0.88. AE: no.
P02585,6,neutral,Visit 6: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no. CRP 2.9 mg/L; ALT 28 U/L.
P02586,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.91. AE: yes. CRP 17.4 mg/L; ALT 25 U/L.
P02586,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02586,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P02586,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02586,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 10.4 mg/L; ALT 28 U/L.
P02586,5,positive,Visit 5: Patient on RX-17B at S005. symptoms improving. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02586,6,positive,Visit 6: Patient on RX-17B at S005. reports improvement. Notes: joint pain. Adherence ~0.98. AE: no.
P02587,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: brain fog. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02587,1,negative,Visit 1: Patient on RX-17B at S018. symptoms persist. Notes: joint pain. Adherence ~0.74. AE: no.
P02587,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: no.
P02587,3,neutral,Visit 3: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.71. AE: no.
P02587,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no.
P02587,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.71. AE: yes.
P02587,6,neutral,Visit 6: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: no.
P02588,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no.
P02588,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: nausea. Adherence ~0.87. AE: no.
P02588,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: fatigue. Adherence ~0.98. AE: no.
P02588,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: headache. Adherence ~0.84. AE: yes. CRP 2.9 mg/L; ALT 36 U/L.
P02588,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no.
P02588,5,neutral,Visit 5: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.75. AE: no.
P02589,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.82. AE: no. CRP 27.8 mg/L; ALT 34 U/L.
P02589,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.77. AE: yes. Plan: consider dose adjustment; counsel patient.
P02589,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02590,0,neutral,Visit 0: Patient on RX-17B at S019. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P02590,1,neutral,Visit 1: Patient on RX-17B at S019. stable symptoms. Notes: dizziness. Adherence ~0.88. AE: no.
P02590,2,positive,Visit 2: Patient on RX-17B at S019. symptoms improving. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02590,3,neutral,Visit 3: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02590,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.99. AE: no.
P02590,5,neutral,Visit 5: Patient on RX-17B at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02590,6,positive,Visit 6: Patient on RX-17B at S019. feels better overall. Notes: headache. Adherence ~0.90. AE: no. CRP 2.0 mg/L; ALT 40 U/L.
P02590,7,positive,Visit 7: Patient on RX-17B at S019. reports improvement. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02591,0,neutral,Visit 0: Patient on RX-17B at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.97. AE: no. CRP 6.3 mg/L; ALT 22 U/L.
P02591,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.71. AE: no. CRP 6.9 mg/L; ALT 22 U/L.
P02591,2,negative,Visit 2: Patient on RX-17B at S016. symptoms persist. Notes: nausea. Adherence ~0.98. AE: no.
P02591,3,negative,Visit 3: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02591,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.99. AE: no.
P02591,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02591,6,positive,Visit 6: Patient on RX-17B at S016. energy increasing. Notes: headache. Adherence ~0.84. AE: no. CRP 4.0 mg/L; ALT 26 U/L.
P02591,7,positive,Visit 7: Patient on RX-17B at S016. reports improvement. Notes: dizziness. Adherence ~0.90. AE: no.
P02592,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no. CRP 5.0 mg/L; ALT 22 U/L.
P02592,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.84. AE: no.
P02592,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02593,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02593,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no.
P02593,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02593,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.64. AE: yes.
P02594,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no.
P02594,1,neutral,Visit 1: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 3.7 mg/L; ALT 28 U/L.
P02594,2,negative,Visit 2: Patient on RX-17B at S018. increased discomfort. Notes: headache. Adherence ~0.86. AE: no. CRP 4.0 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02594,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.94. AE: yes.
P02594,4,neutral,Visit 4: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.98. AE: no.
P02595,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: nausea. Adherence ~0.88. AE: yes. CRP 5.7 mg/L; ALT 31 U/L.
P02595,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02595,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.95. AE: yes. Plan: consider dose adjustment; counsel patient.
P02596,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.78. AE: yes.
P02596,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02596,2,positive,Visit 2: Patient on RX-17A at S014. reports improvement. Notes: fatigue. Adherence ~0.89. AE: no. CRP 10.3 mg/L; ALT 24 U/L.
P02596,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02596,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.86. AE: yes.
P02596,5,positive,Visit 5: Patient on RX-17A at S014. tolerating medication well. Notes: headache. Adherence ~0.84. AE: no. CRP 6.9 mg/L; ALT 22 U/L.
P02596,6,positive,Visit 6: Patient on RX-17A at S014. tolerating medication well. Notes: insomnia. Adherence ~0.99. AE: no.
P02596,7,positive,Visit 7: Patient on RX-17A at S014. tolerating medication well. Notes: headache. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02597,0,neutral,Visit 0: Patient on RX-17B at S020. stable symptoms. Notes: headache. Adherence ~0.99. AE: no. CRP 2.6 mg/L; ALT 35 U/L.
P02597,1,neutral,Visit 1: Patient on RX-17B at S020. reviewed dosing instructions. Notes: nausea. Adherence ~0.83. AE: no.
P02597,2,negative,Visit 2: Patient on RX-17B at S020. reports worsening. Notes: headache. Adherence ~1.00. AE: yes.
P02597,3,negative,Visit 3: Patient on RX-17B at S020. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no.
P02597,4,neutral,Visit 4: Patient on RX-17B at S020. no major change. Notes: abdominal discomfort. Adherence ~0.77. AE: yes.
P02598,0,neutral,Visit 0: Patient on RX-17A at S007. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no. CRP 13.4 mg/L; ALT 22 U/L.
P02598,1,neutral,Visit 1: Patient on RX-17A at S007. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no.
P02598,2,neutral,Visit 2: Patient on RX-17A at S007. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 12.5 mg/L; ALT 20 U/L.
P02598,3,neutral,Visit 3: Patient on RX-17A at S007. no major change. Notes: dizziness. Adherence ~1.00. AE: no. CRP 10.1 mg/L; ALT 22 U/L.
P02598,4,positive,Visit 4: Patient on RX-17A at S007. symptoms improving. Notes: headache. Adherence ~1.00. AE: no.
P02598,5,neutral,Visit 5: Patient on RX-17A at S007. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: no. CRP 10.1 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02598,6,neutral,Visit 6: Patient on RX-17A at S007. follow-up as scheduled. Notes: headache. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02598,7,positive,Visit 7: Patient on RX-17A at S007. tolerating medication well. Notes: headache. Adherence ~1.00. AE: no.
P02599,0,negative,Visit 0: Patient on RX-17A at S005. symptoms persist. Notes: headache. Adherence ~0.74. AE: no. CRP 11.9 mg/L; ALT 28 U/L.
P02599,1,neutral,Visit 1: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P02599,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no. CRP 13.1 mg/L; ALT 25 U/L.
P02599,3,neutral,Visit 3: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02599,4,negative,Visit 4: Patient on RX-17A at S005. poor tolerance. Notes: dizziness. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P02600,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.94. AE: no. CRP 8.2 mg/L; ALT 24 U/L.
P02600,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02600,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.81. AE: no.
P02600,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.78. AE: no.
P02600,4,negative,Visit 4: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.72. AE: no.
P02600,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no. CRP 6.5 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02600,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.76. AE: no.
P02601,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.97. AE: no. CRP 8.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02601,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P02601,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02601,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P02601,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.87. AE: no.
P02601,5,neutral,Visit 5: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.92. AE: no. CRP 5.3 mg/L; ALT 28 U/L.
P02602,0,negative,Visit 0: Patient on RX-17B at S008. reports worsening. Notes: insomnia. Adherence ~0.47. AE: no.
P02602,1,neutral,Visit 1: Patient on RX-17B at S008. continues regimen. Notes: joint pain. Adherence ~0.51. AE: no.
P02602,2,negative,Visit 2: Patient on RX-17B at S008. poor tolerance. Notes: insomnia. Adherence ~0.47. AE: no. CRP 7.0 mg/L; ALT 44 U/L.
P02602,3,negative,Visit 3: Patient on RX-17B at S008. increased discomfort. Notes: headache. Adherence ~0.52. AE: no.
P02602,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 6.3 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P02603,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: nausea. Adherence ~0.61. AE: no.
P02603,1,negative,Visit 1: Patient on RX-17B at S008. symptoms persist. Notes: brain fog. Adherence ~0.63. AE: no.
P02603,2,neutral,Visit 2: Patient on RX-17B at S008. stable symptoms. Notes: nausea. Adherence ~0.57. AE: no. CRP 12.4 mg/L; ALT 20 U/L.
P02603,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: joint pain. Adherence ~0.66. AE: yes. CRP 9.8 mg/L; ALT 23 U/L.
P02603,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P02603,5,neutral,Visit 5: Patient on RX-17B at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 9.5 mg/L; ALT 20 U/L.
P02603,6,neutral,Visit 6: Patient on RX-17B at S008. follow-up as scheduled. Notes: headache. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02603,7,positive,Visit 7: Patient on RX-17B at S008. tolerating medication well. Notes: fatigue. Adherence ~0.82. AE: no. CRP 5.5 mg/L; ALT 21 U/L.
P02604,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: dizziness. Adherence ~0.95. AE: no.
P02604,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: nausea. Adherence ~0.94. AE: no. CRP 2.5 mg/L; ALT 14 U/L.
P02604,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02604,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.78. AE: no. CRP 2.3 mg/L; ALT 12 U/L.
P02604,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no.
P02604,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 1.9 mg/L; ALT 13 U/L.
P02605,0,negative,Visit 0: Patient on RX-17A at S019. reports worsening. Notes: headache. Adherence ~0.52. AE: yes. CRP 10.4 mg/L; ALT 28 U/L.
P02605,1,negative,Visit 1: Patient on RX-17A at S019. poor tolerance. Notes: insomnia. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02605,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 10.2 mg/L; ALT 26 U/L.
P02605,3,positive,Visit 3: Patient on RX-17A at S019. symptoms improving. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02605,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 8.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02605,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02605,6,positive,Visit 6: Patient on RX-17A at S019. symptoms improving. Notes: fatigue. Adherence ~0.90. AE: no.
P02606,0,neutral,Visit 0: Patient on RX-17A at S007. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 4.5 mg/L; ALT 18 U/L.
P02606,1,neutral,Visit 1: Patient on RX-17A at S007. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no. CRP 4.5 mg/L; ALT 19 U/L.
P02606,2,neutral,Visit 2: Patient on RX-17A at S007. reviewed dosing instructions. Notes: joint pain. Adherence ~0.76. AE: no.
P02606,3,neutral,Visit 3: Patient on RX-17A at S007. continues regimen. Notes: headache. Adherence ~0.83. AE: no.
P02606,4,negative,Visit 4: Patient on RX-17A at S007. symptoms persist. Notes: dizziness. Adherence ~0.68. AE: yes.
P02607,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.61. AE: no.
P02607,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.56. AE: yes.
P02607,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: no. CRP 9.4 mg/L; ALT 10 U/L.
P02607,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 8.4 mg/L; ALT 10 U/L.
P02607,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.82. AE: no.
P02608,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02608,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: insomnia. Adherence ~0.87. AE: no. CRP 5.5 mg/L; ALT 65 U/L.
P02608,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no. CRP 4.4 mg/L; ALT 63 U/L.
P02608,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.72. AE: no. CRP 4.2 mg/L; ALT 54 U/L.
P02608,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02609,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02609,1,negative,Visit 1: Patient on RX-17B at S001. poor tolerance. Notes: joint pain. Adherence ~0.68. AE: yes.
P02609,2,neutral,Visit 2: Patient on RX-17B at S001. stable symptoms. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P02609,3,negative,Visit 3: Patient on RX-17B at S001. reports worsening. Notes: nausea. Adherence ~0.82. AE: no.
P02609,4,negative,Visit 4: Patient on RX-17B at S001. increased discomfort. Notes: headache. Adherence ~0.63. AE: no. CRP 6.8 mg/L; ALT 38 U/L.
P02609,5,positive,Visit 5: Patient on RX-17B at S001. reports improvement. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02610,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.95. AE: no.
P02610,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.83. AE: no.
P02610,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02610,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P02610,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no.
P02610,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no. CRP 2.1 mg/L; ALT 41 U/L.
P02610,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.3 mg/L; ALT 41 U/L.
P02610,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: abdominal discomfort. Adherence ~0.99. AE: no. CRP 1.5 mg/L; ALT 37 U/L.
P02611,0,neutral,Visit 0: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02611,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02611,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: fatigue. Adherence ~0.92. AE: no.
P02611,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.90. AE: no. CRP 2.0 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02611,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02611,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: yes.
P02612,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: fatigue. Adherence ~1.00. AE: yes.
P02612,1,negative,Visit 1: Patient on RX-17B at S018. reports worsening. Notes: nausea. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02612,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.87. AE: no. CRP 5.7 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02612,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P02612,4,neutral,Visit 4: Patient on RX-17B at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 5.3 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02612,5,neutral,Visit 5: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P02612,6,neutral,Visit 6: Patient on RX-17B at S018. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: yes.
P02612,7,positive,Visit 7: Patient on RX-17B at S018. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02613,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.91. AE: yes. CRP 16.6 mg/L; ALT 25 U/L.
P02613,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no.
P02613,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: insomnia. Adherence ~0.98. AE: yes. Plan: consider dose adjustment; counsel patient.
P02614,0,neutral,Visit 0: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02614,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: insomnia. Adherence ~0.81. AE: yes.
P02614,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: insomnia. Adherence ~0.81. AE: no.
P02614,3,negative,Visit 3: Patient on RX-17B at S013. reports worsening. Notes: dizziness. Adherence ~0.71. AE: no.
P02614,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02614,5,neutral,Visit 5: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02614,6,neutral,Visit 6: Patient on RX-17B at S013. continues regimen. Notes: joint pain. Adherence ~0.72. AE: no.
P02614,7,positive,Visit 7: Patient on RX-17B at S013. energy increasing. Notes: insomnia. Adherence ~0.96. AE: no.
P02615,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.91. AE: no.
P02615,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: nausea. Adherence ~0.94. AE: no.
P02615,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: fatigue. Adherence ~0.84. AE: no.
P02615,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P02615,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.79. AE: yes. CRP 6.3 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02616,0,neutral,Visit 0: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.25. AE: no. CRP 9.7 mg/L; ALT 29 U/L.
P02616,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.50. AE: no.
P02616,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.47. AE: no. CRP 11.0 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02616,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: joint pain. Adherence ~0.36. AE: no.
P02616,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.34. AE: no.
P02616,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.56. AE: yes. Plan: consider dose adjustment; counsel patient.
P02616,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.52. AE: no.
P02616,7,neutral,Visit 7: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.54. AE: no. CRP 6.4 mg/L; ALT 33 U/L.
P02617,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.56. AE: no. CRP 6.2 mg/L; ALT 34 U/L.
P02617,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: insomnia. Adherence ~0.77. AE: yes. CRP 6.0 mg/L; ALT 35 U/L.
P02617,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02618,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.68. AE: yes.
P02618,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P02618,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no.
P02618,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.47. AE: no.
P02619,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02619,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02619,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02619,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no.
P02619,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P02619,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.0 mg/L; ALT 34 U/L.
P02619,6,positive,Visit 6: Patient on RX-17B at S012. tolerating medication well. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02620,0,negative,Visit 0: Patient on RX-17B at S020. increased discomfort. Notes: nausea. Adherence ~0.83. AE: yes. CRP 6.5 mg/L; ALT 23 U/L.
P02620,1,neutral,Visit 1: Patient on RX-17B at S020. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no.
P02620,2,negative,Visit 2: Patient on RX-17B at S020. increased discomfort. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02620,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P02620,4,neutral,Visit 4: Patient on RX-17B at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02620,5,neutral,Visit 5: Patient on RX-17B at S020. reviewed dosing instructions. Notes: dizziness. Adherence ~0.83. AE: no. CRP 3.9 mg/L; ALT 21 U/L.
P02621,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P02621,1,negative,Visit 1: Patient on RX-17B at S001. increased discomfort. Notes: fatigue. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02621,2,negative,Visit 2: Patient on RX-17B at S001. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: no.
P02621,3,neutral,Visit 3: Patient on RX-17B at S001. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 37 U/L.
P02621,4,neutral,Visit 4: Patient on RX-17B at S001. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no. CRP 4.5 mg/L; ALT 37 U/L.
P02622,0,negative,Visit 0: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.93. AE: no. CRP 5.9 mg/L; ALT 37 U/L.
P02622,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: no. CRP 5.1 mg/L; ALT 36 U/L.
P02622,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no.
P02622,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.88. AE: no.
P02622,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no. CRP 3.6 mg/L; ALT 41 U/L.
P02623,0,neutral,Visit 0: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.90. AE: no.
P02623,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.92. AE: no. CRP 6.5 mg/L; ALT 26 U/L.
P02623,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.87. AE: no.
P02623,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.66. AE: no.
P02623,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no.
P02623,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no.
P02623,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.85. AE: no.
P02623,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: yes. CRP 3.8 mg/L; ALT 32 U/L.
P02624,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.72. AE: no. CRP 5.5 mg/L; ALT 30 U/L.
P02624,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no. CRP 5.8 mg/L; ALT 28 U/L.
P02624,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no. CRP 6.2 mg/L; ALT 32 U/L.
P02624,3,negative,Visit 3: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.72. AE: no.
P02624,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.72. AE: no.
P02624,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02625,0,negative,Visit 0: Patient on RX-17A at S010. feels frustrated. Notes: joint pain. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02625,1,negative,Visit 1: Patient on RX-17A at S010. feels frustrated. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 4.8 mg/L; ALT 20 U/L.
P02625,2,negative,Visit 2: Patient on RX-17A at S010. feels frustrated. Notes: headache. Adherence ~0.78. AE: no.
P02625,3,negative,Visit 3: Patient on RX-17A at S010. reports worsening. Notes: headache. Adherence ~0.69. AE: yes. CRP 3.6 mg/L; ALT 24 U/L.
P02625,4,negative,Visit 4: Patient on RX-17A at S010. increased discomfort. Notes: insomnia. Adherence ~0.59. AE: yes. CRP 4.1 mg/L; ALT 21 U/L.
P02625,5,neutral,Visit 5: Patient on RX-17A at S010. continues regimen. Notes: headache. Adherence ~0.62. AE: no.
P02625,6,neutral,Visit 6: Patient on RX-17A at S010. reviewed dosing instructions. Notes: headache. Adherence ~0.39. AE: no.
P02625,7,neutral,Visit 7: Patient on RX-17A at S010. no major change. Notes: fatigue. Adherence ~0.63. AE: no. CRP 2.8 mg/L; ALT 23 U/L.
P02626,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.60. AE: no.
P02626,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.42. AE: yes.
P02626,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: fatigue. Adherence ~0.58. AE: no.
P02626,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.61. AE: no. CRP 5.7 mg/L; ALT 33 U/L.
P02626,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: nausea. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02626,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.41. AE: no.
P02626,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.57. AE: no.
P02627,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.60. AE: no. CRP 8.1 mg/L; ALT 21 U/L.
P02627,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no. CRP 8.0 mg/L; ALT 20 U/L.
P02627,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: dizziness. Adherence ~0.84. AE: no.
P02627,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.72. AE: no. CRP 6.5 mg/L; ALT 17 U/L.
P02627,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P02627,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.57. AE: no.
P02628,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.88. AE: no.
P02628,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.82. AE: no.
P02628,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.79. AE: no.
P02629,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: fatigue. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02629,1,neutral,Visit 1: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02629,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: no.
P02629,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.91. AE: no. CRP 6.5 mg/L; ALT 25 U/L.
P02629,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02629,5,negative,Visit 5: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 6.3 mg/L; ALT 23 U/L.
P02629,6,neutral,Visit 6: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no. CRP 5.8 mg/L; ALT 24 U/L.
P02630,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.58. AE: yes.
P02630,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P02630,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02630,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.56. AE: no.
P02630,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.59. AE: no.
P02630,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.72. AE: yes.
P02631,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.94. AE: no.
P02631,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.85. AE: no. CRP 7.1 mg/L; ALT 51 U/L.
P02631,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.62. AE: no. CRP 7.7 mg/L; ALT 52 U/L.
P02631,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no.
P02631,4,negative,Visit 4: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~0.76. AE: yes.
P02631,5,positive,Visit 5: Patient on RX-17A at S004. tolerating medication well. Notes: fatigue. Adherence ~0.98. AE: no.
P02631,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.72. AE: no. CRP 5.1 mg/L; ALT 52 U/L.
P02631,7,positive,Visit 7: Patient on RX-17A at S004. tolerating medication well. Notes: dizziness. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P02632,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: brain fog. Adherence ~0.98. AE: no. CRP 4.9 mg/L; ALT 20 U/L.
P02632,1,neutral,Visit 1: Patient on RX-17A at S019. stable symptoms. Notes: fatigue. Adherence ~0.80. AE: no.
P02632,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02632,3,negative,Visit 3: Patient on RX-17A at S019. reports worsening. Notes: joint pain. Adherence ~0.98. AE: yes. CRP 3.6 mg/L; ALT 23 U/L.
P02632,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02632,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.85. AE: yes.
P02633,0,neutral,Visit 0: Patient on RX-17B at S005. continues regimen. Notes: fatigue. Adherence ~0.64. AE: no. CRP 13.1 mg/L; ALT 32 U/L.
P02633,1,neutral,Visit 1: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.86. AE: no.
P02633,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.66. AE: yes. Plan: consider dose adjustment; counsel patient.
P02633,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.59. AE: no.
P02633,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.55. AE: yes. CRP 8.9 mg/L; ALT 32 U/L.
P02634,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: dizziness. Adherence ~0.80. AE: no.
P02634,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: insomnia. Adherence ~0.73. AE: no. CRP 11.0 mg/L; ALT 26 U/L.
P02634,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.94. AE: no.
P02634,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.97. AE: no. CRP 9.8 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02634,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02634,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.74. AE: yes.
P02634,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P02634,7,positive,Visit 7: Patient on RX-17A at S017. feels better overall. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 29 U/L.
P02635,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.79. AE: no. CRP 4.3 mg/L; ALT 31 U/L.
P02635,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02635,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.70. AE: no. CRP 3.7 mg/L; ALT 36 U/L.
P02635,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.74. AE: no.
P02635,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.56. AE: no. CRP 2.7 mg/L; ALT 42 U/L.
P02636,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no.
P02636,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P02636,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P02636,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02636,4,positive,Visit 4: Patient on RX-17A at S017. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 33 U/L.
P02636,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.98. AE: no.
P02637,0,neutral,Visit 0: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no. CRP 17.2 mg/L; ALT 25 U/L.
P02637,1,neutral,Visit 1: Patient on RX-17A at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.48. AE: no. CRP 15.7 mg/L; ALT 24 U/L.
P02637,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no.
P02637,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P02637,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.57. AE: no. CRP 12.9 mg/L; ALT 27 U/L.
P02638,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: fatigue. Adherence ~0.72. AE: no. CRP 4.7 mg/L; ALT 31 U/L.
P02638,1,negative,Visit 1: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.76. AE: no. CRP 3.6 mg/L; ALT 30 U/L.
P02638,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.61. AE: no. CRP 4.0 mg/L; ALT 33 U/L.
P02638,3,negative,Visit 3: Patient on RX-17A at S005. poor tolerance. Notes: insomnia. Adherence ~0.48. AE: no.
P02638,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.81. AE: no. CRP 3.6 mg/L; ALT 31 U/L.
P02638,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.79. AE: yes. CRP 3.2 mg/L; ALT 36 U/L.
P02639,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 4.2 mg/L; ALT 28 U/L.
P02639,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: no.
P02639,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.69. AE: no.
P02639,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: headache. Adherence ~0.58. AE: no. CRP 3.9 mg/L; ALT 31 U/L.
P02639,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no.
P02639,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02639,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.89. AE: no. CRP 2.9 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02639,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no.
P02640,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.56. AE: no. CRP 11.2 mg/L; ALT 55 U/L.
P02640,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.60. AE: no. CRP 10.8 mg/L; ALT 51 U/L.
P02640,2,negative,Visit 2: Patient on RX-17B at S002. symptoms persist. Notes: insomnia. Adherence ~0.61. AE: no. CRP 9.6 mg/L; ALT 49 U/L.
P02640,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no. CRP 7.2 mg/L; ALT 54 U/L.
P02640,4,neutral,Visit 4: Patient on RX-17B at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P02640,5,positive,Visit 5: Patient on RX-17B at S002. tolerating medication well. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02640,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: insomnia. Adherence ~0.81. AE: no. CRP 6.7 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P02641,0,neutral,Visit 0: Patient on RX-17B at S007. no major change. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02641,1,neutral,Visit 1: Patient on RX-17B at S007. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 22 U/L.
P02641,2,neutral,Visit 2: Patient on RX-17B at S007. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no.
P02641,3,neutral,Visit 3: Patient on RX-17B at S007. no major change. Notes: brain fog. Adherence ~0.71. AE: no.
P02641,4,neutral,Visit 4: Patient on RX-17B at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no.
P02641,5,neutral,Visit 5: Patient on RX-17B at S007. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P02641,6,positive,Visit 6: Patient on RX-17B at S007. symptoms improving. Notes: insomnia. Adherence ~0.81. AE: no.
P02642,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~0.97. AE: yes.
P02642,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: headache. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 34 U/L.
P02642,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02642,3,neutral,Visit 3: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02642,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.84. AE: no.
P02642,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.63. AE: no. CRP 2.8 mg/L; ALT 32 U/L.
P02642,6,neutral,Visit 6: Patient on RX-17A at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.91. AE: no. CRP 2.9 mg/L; ALT 35 U/L.
P02643,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.67. AE: no.
P02643,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: insomnia. Adherence ~0.72. AE: yes.
P02643,2,neutral,Visit 2: Patient on RX-17B at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P02643,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no.
P02643,4,neutral,Visit 4: Patient on RX-17B at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: no.
P02643,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no.
P02644,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no. CRP 10.8 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02644,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02644,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.83. AE: no.
P02644,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.51. AE: no.
P02644,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: insomnia. Adherence ~0.74. AE: no. CRP 7.5 mg/L; ALT 39 U/L.
P02645,0,negative,Visit 0: Patient on RX-17B at S020. symptoms persist. Notes: insomnia. Adherence ~0.72. AE: no.
P02645,1,negative,Visit 1: Patient on RX-17B at S020. feels frustrated. Notes: dizziness. Adherence ~0.63. AE: no.
P02645,2,neutral,Visit 2: Patient on RX-17B at S020. reviewed dosing instructions. Notes: dizziness. Adherence ~0.60. AE: no.
P02645,3,negative,Visit 3: Patient on RX-17B at S020. reports worsening. Notes: fatigue. Adherence ~0.54. AE: no.
P02645,4,neutral,Visit 4: Patient on RX-17B at S020. stable symptoms. Notes: nausea. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02645,5,neutral,Visit 5: Patient on RX-17B at S020. continues regimen. Notes: dizziness. Adherence ~0.55. AE: yes. CRP 3.2 mg/L; ALT 32 U/L.
P02645,6,neutral,Visit 6: Patient on RX-17B at S020. no major change. Notes: brain fog. Adherence ~0.36. AE: no. CRP 2.8 mg/L; ALT 29 U/L.
P02645,7,neutral,Visit 7: Patient on RX-17B at S020. continues regimen. Notes: nausea. Adherence ~0.57. AE: no.
P02646,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.63. AE: no.
P02646,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: brain fog. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02646,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.54. AE: no. CRP 5.5 mg/L; ALT 52 U/L.
P02646,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.78. AE: no.
P02646,4,positive,Visit 4: Patient on RX-17A at S017. energy increasing. Notes: brain fog. Adherence ~0.77. AE: no.
P02646,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: nausea. Adherence ~0.71. AE: yes. Plan: consider dose adjustment; counsel patient.
P02647,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 5.8 mg/L; ALT 15 U/L.
P02647,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: fatigue. Adherence ~0.67. AE: no.
P02647,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.80. AE: no.
P02647,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: yes. Plan: consider dose adjustment; counsel patient.
P02647,4,neutral,Visit 4: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.84. AE: no. CRP 3.4 mg/L; ALT 15 U/L. Plan: consider dose adjustment; counsel patient.
P02647,5,neutral,Visit 5: Patient on RX-17A at S019. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P02647,6,negative,Visit 6: Patient on RX-17A at S019. increased discomfort. Notes: dizziness. Adherence ~0.74. AE: yes.
P02648,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: insomnia. Adherence ~0.60. AE: no.
P02648,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: joint pain. Adherence ~0.60. AE: no.
P02648,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.71. AE: no. CRP 13.3 mg/L; ALT 20 U/L.
P02648,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02648,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no. CRP 11.8 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02648,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.65. AE: no.
P02649,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: insomnia. Adherence ~0.82. AE: no.
P02649,1,neutral,Visit 1: Patient on RX-17A at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02649,2,negative,Visit 2: Patient on RX-17A at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.92. AE: yes. Plan: consider dose adjustment; counsel patient.
P02649,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02649,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 3.4 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P02650,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.92. AE: no. CRP 3.5 mg/L; ALT 20 U/L.
P02650,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: brain fog. Adherence ~1.00. AE: no.
P02650,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.78. AE: no. CRP 2.8 mg/L; ALT 22 U/L.
P02650,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02650,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.74. AE: no. CRP 1.9 mg/L; ALT 22 U/L.
P02650,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.98. AE: no.
P02651,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: insomnia. Adherence ~0.91. AE: no.
P02651,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02651,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02651,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.6 mg/L; ALT 22 U/L.
P02651,4,positive,Visit 4: Patient on RX-17A at S015. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P02651,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.93. AE: no. CRP 2.1 mg/L; ALT 23 U/L.
P02651,6,positive,Visit 6: Patient on RX-17A at S015. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no. CRP 2.0 mg/L; ALT 24 U/L.
P02651,7,neutral,Visit 7: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.86. AE: yes.
P02652,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~0.68. AE: no.
P02652,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.62. AE: no.
P02652,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.66. AE: no.
P02652,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.69. AE: no.
P02652,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.63. AE: no.
P02652,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.59. AE: no.
P02652,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.58. AE: no.
P02652,7,neutral,Visit 7: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.61. AE: no.
P02653,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.57. AE: no. CRP 9.8 mg/L; ALT 24 U/L.
P02653,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.46. AE: no. CRP 9.9 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02653,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.37. AE: no.
P02653,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.39. AE: no. Plan: consider dose adjustment; counsel patient.
P02653,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.49. AE: yes. Plan: consider dose adjustment; counsel patient.
P02654,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: yes.
P02654,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.83. AE: no. CRP 13.1 mg/L; ALT 37 U/L.
P02654,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 13.3 mg/L; ALT 40 U/L.
P02654,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.84. AE: no.
P02654,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.74. AE: no.
P02655,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: dizziness. Adherence ~0.85. AE: no. CRP 3.7 mg/L; ALT 40 U/L.
P02655,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.77. AE: yes. CRP 3.8 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P02655,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02656,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: no. CRP 6.5 mg/L; ALT 28 U/L.
P02656,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.49. AE: no. CRP 5.9 mg/L; ALT 31 U/L.
P02656,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.36. AE: no.
P02656,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.46. AE: no.
P02656,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.44. AE: no.
P02657,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P02657,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P02657,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no.
P02657,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P02657,4,positive,Visit 4: Patient on RX-17A at S014. feels better overall. Notes: brain fog. Adherence ~0.93. AE: no.
P02657,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.99. AE: no.
P02658,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 7.2 mg/L; ALT 19 U/L.
P02658,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.68. AE: no.
P02658,2,neutral,Visit 2: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.56. AE: no.
P02658,3,negative,Visit 3: Patient on RX-17A at S016. increased discomfort. Notes: insomnia. Adherence ~0.71. AE: no.
P02658,4,neutral,Visit 4: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 4.6 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02659,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: brain fog. Adherence ~0.86. AE: no.
P02659,1,negative,Visit 1: Patient on RX-17B at S019. reports worsening. Notes: brain fog. Adherence ~0.66. AE: yes.
P02659,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no. CRP 5.0 mg/L; ALT 28 U/L.
P02659,3,negative,Visit 3: Patient on RX-17B at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02659,4,negative,Visit 4: Patient on RX-17B at S019. reports worsening. Notes: nausea. Adherence ~0.89. AE: no.
P02659,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02659,6,positive,Visit 6: Patient on RX-17B at S019. reports improvement. Notes: brain fog. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02660,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: joint pain. Adherence ~0.99. AE: no. CRP 8.8 mg/L; ALT 44 U/L.
P02660,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.7 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P02660,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.79. AE: yes.
P02660,3,negative,Visit 3: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.97. AE: no. CRP 6.3 mg/L; ALT 50 U/L.
P02660,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.97. AE: no.
P02660,5,positive,Visit 5: Patient on RX-17A at S022. tolerating medication well. Notes: dizziness. Adherence ~0.89. AE: no.
P02660,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~0.72. AE: no.
P02660,7,positive,Visit 7: Patient on RX-17A at S022. symptoms improving. Notes: joint pain. Adherence ~1.00. AE: no.
P02661,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: no. CRP 9.5 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P02661,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~0.98. AE: yes.
P02661,2,neutral,Visit 2: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~0.94. AE: no. CRP 8.0 mg/L; ALT 42 U/L.
P02661,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P02661,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P02661,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.90. AE: yes. CRP 5.6 mg/L; ALT 50 U/L.
P02661,6,neutral,Visit 6: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.93. AE: yes.
P02661,7,positive,Visit 7: Patient on RX-17B at S005. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 51 U/L.
P02662,0,neutral,Visit 0: Patient on RX-17A at S018. stable symptoms. Notes: brain fog. Adherence ~0.79. AE: no.
P02662,1,neutral,Visit 1: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.54. AE: no.
P02662,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P02662,3,neutral,Visit 3: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02662,4,neutral,Visit 4: Patient on RX-17A at S018. follow-up as scheduled. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02662,5,neutral,Visit 5: Patient on RX-17A at S018. no major change. Notes: dizziness. Adherence ~0.51. AE: no.
P02663,0,neutral,Visit 0: Patient on RX-17B at S020. continues regimen. Notes: nausea. Adherence ~0.76. AE: no. CRP 5.2 mg/L; ALT 21 U/L.
P02663,1,negative,Visit 1: Patient on RX-17B at S020. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: no.
P02663,2,negative,Visit 2: Patient on RX-17B at S020. feels frustrated. Notes: dizziness. Adherence ~0.73. AE: no.
P02663,3,neutral,Visit 3: Patient on RX-17B at S020. stable symptoms. Notes: joint pain. Adherence ~0.65. AE: no.
P02663,4,neutral,Visit 4: Patient on RX-17B at S020. continues regimen. Notes: headache. Adherence ~0.81. AE: no. CRP 3.6 mg/L; ALT 25 U/L.
P02663,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no. CRP 3.4 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02663,6,neutral,Visit 6: Patient on RX-17B at S020. continues regimen. Notes: joint pain. Adherence ~0.59. AE: no.
P02664,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: joint pain. Adherence ~0.61. AE: no. CRP 5.5 mg/L; ALT 40 U/L.
P02664,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~0.57. AE: no.
P02664,2,negative,Visit 2: Patient on RX-17B at S002. reports worsening. Notes: nausea. Adherence ~0.61. AE: no.
P02664,3,negative,Visit 3: Patient on RX-17B at S002. reports worsening. Notes: fatigue. Adherence ~0.68. AE: yes.
P02664,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.45. AE: no.
P02664,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.64. AE: no.
P02664,6,neutral,Visit 6: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.42. AE: no. CRP 3.2 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02665,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no. CRP 6.7 mg/L; ALT 24 U/L.
P02665,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.85. AE: no.
P02665,2,positive,Visit 2: Patient on RX-17B at S017. energy increasing. Notes: dizziness. Adherence ~0.79. AE: no. CRP 6.1 mg/L; ALT 26 U/L.
P02666,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02666,1,negative,Visit 1: Patient on RX-17B at S012. increased discomfort. Notes: headache. Adherence ~0.69. AE: yes. CRP 4.3 mg/L; ALT 40 U/L.
P02666,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.88. AE: no.
P02666,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02666,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: no.
P02667,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no.
P02667,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no.
P02667,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: dizziness. Adherence ~0.69. AE: no.
P02667,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.80. AE: no. CRP 3.1 mg/L; ALT 52 U/L.
P02667,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no.
P02667,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.81. AE: no.
P02668,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.91. AE: no.
P02668,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~1.00. AE: no. CRP 20.4 mg/L; ALT 25 U/L.
P02668,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: headache. Adherence ~1.00. AE: no.
P02668,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.94. AE: yes. CRP 15.5 mg/L; ALT 25 U/L.
P02668,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.78. AE: yes. CRP 13.4 mg/L; ALT 23 U/L.
P02668,5,positive,Visit 5: Patient on RX-17A at S014. energy increasing. Notes: headache. Adherence ~0.96. AE: no. CRP 12.9 mg/L; ALT 24 U/L.
P02668,6,positive,Visit 6: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.95. AE: no. CRP 11.5 mg/L; ALT 25 U/L.
P02669,0,neutral,Visit 0: Patient on RX-17B at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.66. AE: no.
P02669,1,neutral,Visit 1: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.46. AE: no. CRP 5.8 mg/L; ALT 15 U/L.
P02669,2,neutral,Visit 2: Patient on RX-17B at S009. stable symptoms. Notes: dizziness. Adherence ~0.37. AE: no. CRP 5.4 mg/L; ALT 17 U/L.
P02670,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: dizziness. Adherence ~0.51. AE: no.
P02670,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P02670,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.42. AE: no.
P02670,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.52. AE: no.
P02670,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.51. AE: no.
P02671,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02671,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 5.9 mg/L; ALT 32 U/L.
P02671,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.92. AE: no. CRP 5.5 mg/L; ALT 35 U/L.
P02671,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02671,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02672,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: no. CRP 6.4 mg/L; ALT 28 U/L.
P02672,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 6.4 mg/L; ALT 28 U/L.
P02672,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.93. AE: no.
P02672,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.3 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02672,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no.
P02673,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.82. AE: yes.
P02673,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 9.1 mg/L; ALT 27 U/L.
P02673,2,positive,Visit 2: Patient on RX-17A at S015. tolerating medication well. Notes: brain fog. Adherence ~0.95. AE: no.
P02673,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no. CRP 8.4 mg/L; ALT 29 U/L.
P02674,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.97. AE: no. CRP 5.4 mg/L; ALT 15 U/L.
P02674,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.57. AE: yes.
P02674,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P02674,3,negative,Visit 3: Patient on RX-17A at S012. feels frustrated. Notes: headache. Adherence ~0.94. AE: yes.
P02674,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 4.5 mg/L; ALT 16 U/L.
P02674,5,neutral,Visit 5: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 4.4 mg/L; ALT 16 U/L.
P02674,6,neutral,Visit 6: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.82. AE: no.
P02675,0,negative,Visit 0: Patient on RX-17B at S006. feels frustrated. Notes: insomnia. Adherence ~0.82. AE: yes.
P02675,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: brain fog. Adherence ~1.00. AE: no. CRP 13.4 mg/L; ALT 32 U/L.
P02675,2,positive,Visit 2: Patient on RX-17B at S006. feels better overall. Notes: dizziness. Adherence ~0.93. AE: no.
P02675,3,positive,Visit 3: Patient on RX-17B at S006. tolerating medication well. Notes: nausea. Adherence ~0.95. AE: no.
P02675,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 10.0 mg/L; ALT 34 U/L.
P02675,5,positive,Visit 5: Patient on RX-17B at S006. symptoms improving. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02676,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02676,1,negative,Visit 1: Patient on RX-17B at S016. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no.
P02676,2,negative,Visit 2: Patient on RX-17B at S016. feels frustrated. Notes: brain fog. Adherence ~0.92. AE: yes.
P02677,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: headache. Adherence ~0.85. AE: no.
P02677,1,neutral,Visit 1: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.60. AE: no.
P02677,2,negative,Visit 2: Patient on RX-17B at S016. poor tolerance. Notes: insomnia. Adherence ~0.92. AE: yes.
P02677,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.73. AE: no.
P02677,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.82. AE: no. CRP 4.6 mg/L; ALT 34 U/L.
P02677,5,neutral,Visit 5: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.76. AE: yes.
P02678,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no.
P02678,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P02678,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P02678,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P02678,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P02679,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.94. AE: yes.
P02679,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.79. AE: no.
P02679,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.79. AE: no. CRP 12.0 mg/L; ALT 10 U/L.
P02679,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.90. AE: no.
P02679,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.64. AE: no.
P02679,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: nausea. Adherence ~0.94. AE: no.
P02680,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.76. AE: no. CRP 5.7 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02680,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~0.65. AE: no. CRP 6.2 mg/L; ALT 36 U/L.
P02680,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no.
P02680,3,negative,Visit 3: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.78. AE: no. CRP 5.8 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02680,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.52. AE: no. CRP 4.5 mg/L; ALT 36 U/L.
P02680,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.80. AE: no.
P02680,6,positive,Visit 6: Patient on RX-17A at S012. energy increasing. Notes: insomnia. Adherence ~0.90. AE: no.
P02681,0,negative,Visit 0: Patient on RX-17B at S019. symptoms persist. Notes: abdominal discomfort. Adherence ~0.83. AE: yes. CRP 3.9 mg/L; ALT 33 U/L.
P02681,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: dizziness. Adherence ~0.51. AE: no.
P02681,2,negative,Visit 2: Patient on RX-17B at S019. reports worsening. Notes: insomnia. Adherence ~0.62. AE: no.
P02681,3,neutral,Visit 3: Patient on RX-17B at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.58. AE: no. CRP 3.0 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02681,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: dizziness. Adherence ~0.58. AE: yes.
P02681,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: brain fog. Adherence ~0.59. AE: no.
P02682,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 13.4 mg/L; ALT 36 U/L.
P02682,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.96. AE: no.
P02682,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no.
P02682,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.97. AE: no.
P02682,4,positive,Visit 4: Patient on RX-17A at S004. reports improvement. Notes: fatigue. Adherence ~0.92. AE: no.
P02682,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no.
P02682,6,positive,Visit 6: Patient on RX-17A at S004. feels better overall. Notes: brain fog. Adherence ~0.87. AE: no.
P02683,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: fatigue. Adherence ~0.69. AE: no. CRP 4.6 mg/L; ALT 28 U/L.
P02683,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: nausea. Adherence ~0.57. AE: no.
P02683,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: yes.
P02683,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P02683,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02683,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.56. AE: no.
P02684,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no.
P02684,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~0.87. AE: no.
P02684,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.90. AE: no. CRP 9.7 mg/L; ALT 34 U/L.
P02684,3,negative,Visit 3: Patient on RX-17B at S022. reports worsening. Notes: insomnia. Adherence ~0.89. AE: no.
P02684,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.92. AE: no.
P02685,0,neutral,Visit 0: Patient on RX-17B at S019. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 1.7 mg/L; ALT 32 U/L.
P02685,1,negative,Visit 1: Patient on RX-17B at S019. increased discomfort. Notes: insomnia. Adherence ~0.80. AE: yes. CRP 1.7 mg/L; ALT 37 U/L.
P02685,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.71. AE: no.
P02685,3,negative,Visit 3: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: yes.
P02685,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no.
P02686,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.57. AE: yes.
P02686,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.65. AE: yes. CRP 5.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02686,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.60. AE: no. CRP 5.6 mg/L; ALT 34 U/L.
P02686,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P02687,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.93. AE: no.
P02687,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P02687,2,negative,Visit 2: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.76. AE: yes.
P02687,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~1.00. AE: yes.
P02687,4,positive,Visit 4: Patient on RX-17B at S015. tolerating medication well. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02687,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no.
P02687,6,neutral,Visit 6: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P02688,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: joint pain. Adherence ~0.87. AE: no. CRP 6.5 mg/L; ALT 31 U/L.
P02688,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.75. AE: no.
P02688,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. CRP 5.7 mg/L; ALT 34 U/L.
P02688,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02688,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.81. AE: no.
P02688,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.88. AE: no.
P02688,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.59. AE: no.
P02689,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: dizziness. Adherence ~0.70. AE: no. CRP 9.0 mg/L; ALT 58 U/L.
P02689,1,negative,Visit 1: Patient on RX-17A at S016. increased discomfort. Notes: dizziness. Adherence ~0.66. AE: no. CRP 11.3 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P02689,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: dizziness. Adherence ~0.58. AE: no.
P02689,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no. CRP 8.0 mg/L; ALT 52 U/L.
P02689,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.56. AE: no. CRP 8.4 mg/L; ALT 60 U/L.
P02689,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: fatigue. Adherence ~0.70. AE: no. CRP 7.0 mg/L; ALT 56 U/L.
P02690,0,negative,Visit 0: Patient on RX-17B at S017. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P02690,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.80. AE: yes. CRP 3.4 mg/L; ALT 25 U/L.
P02690,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: headache. Adherence ~0.67. AE: yes. CRP 3.8 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02690,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no.
P02690,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.84. AE: no.
P02691,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.62. AE: yes. Plan: consider dose adjustment; counsel patient.
P02691,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.68. AE: no. CRP 11.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02691,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.53. AE: no. CRP 6.9 mg/L; ALT 26 U/L.
P02691,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02691,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.80. AE: no.
P02691,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.61. AE: no.
P02692,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no.
P02692,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.65. AE: no. CRP 5.9 mg/L; ALT 56 U/L.
P02692,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.72. AE: no. CRP 5.3 mg/L; ALT 54 U/L.
P02692,3,negative,Visit 3: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.76. AE: no.
P02692,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.69. AE: no.
P02692,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.76. AE: no. CRP 5.3 mg/L; ALT 57 U/L.
P02692,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.50. AE: no. CRP 4.3 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P02693,0,negative,Visit 0: Patient on RX-17A at S003. increased discomfort. Notes: nausea. Adherence ~0.75. AE: no.
P02693,1,neutral,Visit 1: Patient on RX-17A at S003. follow-up as scheduled. Notes: dizziness. Adherence ~0.79. AE: yes. Plan: consider dose adjustment; counsel patient.
P02693,2,negative,Visit 2: Patient on RX-17A at S003. increased discomfort. Notes: brain fog. Adherence ~0.77. AE: no.
P02693,3,neutral,Visit 3: Patient on RX-17A at S003. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no. CRP 7.7 mg/L; ALT 26 U/L.
P02693,4,neutral,Visit 4: Patient on RX-17A at S003. stable symptoms. Notes: nausea. Adherence ~0.97. AE: no.
P02694,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: dizziness. Adherence ~0.82. AE: yes. CRP 25.1 mg/L; ALT 45 U/L.
P02694,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.92. AE: no.
P02694,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.94. AE: no.
P02694,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.75. AE: no.
P02694,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.71. AE: no. CRP 12.5 mg/L; ALT 37 U/L.
P02695,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no. CRP 14.7 mg/L; ALT 31 U/L.
P02695,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02695,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.77. AE: no.
P02696,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: headache. Adherence ~0.99. AE: no.
P02696,1,negative,Visit 1: Patient on RX-17A at S008. poor tolerance. Notes: dizziness. Adherence ~0.84. AE: no.
P02696,2,negative,Visit 2: Patient on RX-17A at S008. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P02696,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: nausea. Adherence ~0.91. AE: no. CRP 9.7 mg/L; ALT 25 U/L.
P02696,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.87. AE: no. CRP 9.3 mg/L; ALT 27 U/L.
P02696,5,positive,Visit 5: Patient on RX-17A at S008. reports improvement. Notes: dizziness. Adherence ~0.84. AE: no.
P02697,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02697,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no.
P02697,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no. CRP 11.0 mg/L; ALT 42 U/L.
P02697,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. CRP 9.1 mg/L; ALT 44 U/L.
P02698,0,negative,Visit 0: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: no. CRP 4.2 mg/L; ALT 38 U/L.
P02698,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: insomnia. Adherence ~0.82. AE: no. CRP 4.1 mg/L; ALT 39 U/L.
P02698,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.80. AE: no.
P02698,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P02698,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02698,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no.
P02698,6,neutral,Visit 6: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.89. AE: yes.
P02698,7,positive,Visit 7: Patient on RX-17A at S017. tolerating medication well. Notes: dizziness. Adherence ~0.90. AE: no.
P02699,0,neutral,Visit 0: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no. CRP 5.5 mg/L; ALT 18 U/L.
P02699,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: brain fog. Adherence ~0.78. AE: yes.
P02699,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02699,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 18 U/L.
P02699,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02700,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.69. AE: no. CRP 3.0 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02700,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: joint pain. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02700,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.93. AE: yes. CRP 2.9 mg/L; ALT 34 U/L.
P02700,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.90. AE: no. CRP 2.4 mg/L; ALT 34 U/L.
P02700,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P02701,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: nausea. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02701,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: insomnia. Adherence ~0.69. AE: no. CRP 3.1 mg/L; ALT 21 U/L.
P02701,2,neutral,Visit 2: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.53. AE: no. CRP 2.8 mg/L; ALT 21 U/L.
P02701,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: dizziness. Adherence ~0.57. AE: no. CRP 2.7 mg/L; ALT 22 U/L.
P02701,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: headache. Adherence ~0.57. AE: no. CRP 3.0 mg/L; ALT 22 U/L.
P02702,0,negative,Visit 0: Patient on RX-17A at S019. poor tolerance. Notes: joint pain. Adherence ~0.83. AE: yes.
P02702,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02702,2,neutral,Visit 2: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.86. AE: no.
P02702,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02702,4,neutral,Visit 4: Patient on RX-17A at S019. stable symptoms. Notes: nausea. Adherence ~0.72. AE: no. CRP 3.5 mg/L; ALT 50 U/L.
P02702,5,negative,Visit 5: Patient on RX-17A at S019. increased discomfort. Notes: brain fog. Adherence ~0.71. AE: no.
P02702,6,neutral,Visit 6: Patient on RX-17A at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.61. AE: no. CRP 3.0 mg/L; ALT 54 U/L.
P02703,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.92. AE: no. CRP 8.8 mg/L; ALT 60 U/L.
P02703,1,neutral,Visit 1: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02703,2,negative,Visit 2: Patient on RX-17A at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.4 mg/L; ALT 56 U/L.
P02703,3,neutral,Visit 3: Patient on RX-17A at S016. stable symptoms. Notes: nausea. Adherence ~0.83. AE: no. CRP 5.3 mg/L; ALT 60 U/L.
P02703,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: fatigue. Adherence ~0.96. AE: no. CRP 5.2 mg/L; ALT 58 U/L.
P02703,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no.
P02703,6,neutral,Visit 6: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~1.00. AE: yes. CRP 4.6 mg/L; ALT 68 U/L.
P02703,7,neutral,Visit 7: Patient on RX-17A at S016. reviewed dosing instructions. Notes: insomnia. Adherence ~0.83. AE: no.
P02704,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.85. AE: yes. CRP 3.7 mg/L; ALT 60 U/L.
P02704,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: fatigue. Adherence ~0.76. AE: no.
P02704,2,neutral,Visit 2: Patient on RX-17B at S002. stable symptoms. Notes: nausea. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 63 U/L. Plan: consider dose adjustment; counsel patient.
P02704,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.57. AE: no. CRP 3.5 mg/L; ALT 57 U/L.
P02704,4,positive,Visit 4: Patient on RX-17B at S002. feels better overall. Notes: fatigue. Adherence ~1.00. AE: no.
P02704,5,negative,Visit 5: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.87. AE: no.
P02705,0,neutral,Visit 0: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 6.7 mg/L; ALT 30 U/L.
P02705,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P02705,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: brain fog. Adherence ~0.82. AE: yes.
P02705,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: headache. Adherence ~0.99. AE: no.
P02705,4,neutral,Visit 4: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no. CRP 6.0 mg/L; ALT 32 U/L.
P02705,5,positive,Visit 5: Patient on RX-17A at S002. energy increasing. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 4.7 mg/L; ALT 38 U/L.
P02706,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.80. AE: no. CRP 7.1 mg/L; ALT 25 U/L.
P02706,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no. CRP 5.7 mg/L; ALT 25 U/L.
P02706,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02706,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P02706,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02706,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.62. AE: no. CRP 3.8 mg/L; ALT 30 U/L.
P02706,6,neutral,Visit 6: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02707,0,negative,Visit 0: Patient on RX-17B at S011. poor tolerance. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.5 mg/L; ALT 35 U/L.
P02707,1,negative,Visit 1: Patient on RX-17B at S011. poor tolerance. Notes: headache. Adherence ~0.77. AE: no.
P02707,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: insomnia. Adherence ~0.89. AE: no.
P02707,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 3.4 mg/L; ALT 36 U/L.
P02707,4,positive,Visit 4: Patient on RX-17B at S011. reports improvement. Notes: insomnia. Adherence ~0.99. AE: no. CRP 2.4 mg/L; ALT 37 U/L.
P02707,5,positive,Visit 5: Patient on RX-17B at S011. feels better overall. Notes: headache. Adherence ~0.87. AE: no.
P02708,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: nausea. Adherence ~0.96. AE: no.
P02708,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: brain fog. Adherence ~0.93. AE: no.
P02708,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: nausea. Adherence ~0.83. AE: no.
P02708,3,negative,Visit 3: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.91. AE: no.
P02708,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 10.2 mg/L; ALT 22 U/L.
P02708,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no.
P02708,6,positive,Visit 6: Patient on RX-17A at S015. reports improvement. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02709,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: headache. Adherence ~0.92. AE: no. CRP 4.0 mg/L; ALT 74 U/L. Plan: consider dose adjustment; counsel patient.
P02709,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.6 mg/L; ALT 77 U/L. Plan: consider dose adjustment; counsel patient.
P02709,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.97. AE: no. CRP 3.1 mg/L; ALT 72 U/L.
P02709,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02709,4,neutral,Visit 4: Patient on RX-17A at S013. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P02709,5,neutral,Visit 5: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02709,6,positive,Visit 6: Patient on RX-17A at S013. tolerating medication well. Notes: dizziness. Adherence ~1.00. AE: no.
P02710,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.55. AE: no. CRP 11.9 mg/L; ALT 42 U/L.
P02710,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P02710,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P02710,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.58. AE: no.
P02710,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.59. AE: no.
P02710,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.64. AE: no.
P02710,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.72. AE: no.
P02710,7,negative,Visit 7: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P02711,0,neutral,Visit 0: Patient on RX-17B at S011. no major change. Notes: dizziness. Adherence ~0.86. AE: no. CRP 2.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02711,1,negative,Visit 1: Patient on RX-17B at S011. increased discomfort. Notes: insomnia. Adherence ~0.95. AE: no.
P02711,2,negative,Visit 2: Patient on RX-17B at S011. reports worsening. Notes: brain fog. Adherence ~0.76. AE: yes. CRP 1.9 mg/L; ALT 36 U/L.
P02711,3,neutral,Visit 3: Patient on RX-17B at S011. no major change. Notes: nausea. Adherence ~0.74. AE: no. CRP 1.7 mg/L; ALT 33 U/L.
P02711,4,neutral,Visit 4: Patient on RX-17B at S011. reviewed dosing instructions. Notes: brain fog. Adherence ~0.83. AE: no.
P02712,0,negative,Visit 0: Patient on RX-17B at S016. increased discomfort. Notes: headache. Adherence ~0.87. AE: yes.
P02712,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P02712,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.79. AE: no.
P02712,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no. CRP 4.6 mg/L; ALT 47 U/L.
P02712,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: yes.
P02712,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02713,0,negative,Visit 0: Patient on RX-17B at S002. symptoms persist. Notes: brain fog. Adherence ~0.84. AE: no. CRP 3.8 mg/L; ALT 24 U/L.
P02713,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no. CRP 4.1 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02713,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.94. AE: no. CRP 3.2 mg/L; ALT 26 U/L.
P02713,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.99. AE: no.
P02713,4,negative,Visit 4: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: yes.
P02713,5,positive,Visit 5: Patient on RX-17B at S002. reports improvement. Notes: nausea. Adherence ~0.91. AE: no.
P02713,6,neutral,Visit 6: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P02714,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: fatigue. Adherence ~0.62. AE: no.
P02714,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P02714,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02714,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.64. AE: yes.
P02714,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.65. AE: no.
P02714,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: nausea. Adherence ~0.80. AE: no.
P02715,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 20.1 mg/L; ALT 14 U/L.
P02715,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.61. AE: yes. CRP 16.9 mg/L; ALT 15 U/L.
P02715,2,negative,Visit 2: Patient on RX-17B at S022. symptoms persist. Notes: joint pain. Adherence ~0.73. AE: no. CRP 17.8 mg/L; ALT 13 U/L.
P02715,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.63. AE: no.
P02715,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.67. AE: no.
P02715,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.54. AE: no.
P02715,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.43. AE: no. CRP 9.2 mg/L; ALT 15 U/L.
P02715,7,neutral,Visit 7: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.40. AE: yes.
P02716,0,negative,Visit 0: Patient on RX-17B at S017. increased discomfort. Notes: dizziness. Adherence ~0.85. AE: yes. CRP 6.5 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02716,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 6.7 mg/L; ALT 32 U/L.
P02716,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02716,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no. CRP 4.4 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02716,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no. CRP 4.4 mg/L; ALT 34 U/L.
P02717,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.77. AE: no.
P02717,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.91. AE: no.
P02717,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P02718,0,neutral,Visit 0: Patient on RX-17B at S006. continues regimen. Notes: nausea. Adherence ~0.86. AE: no. CRP 8.2 mg/L; ALT 36 U/L.
P02718,1,neutral,Visit 1: Patient on RX-17B at S006. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 8.1 mg/L; ALT 37 U/L.
P02718,2,neutral,Visit 2: Patient on RX-17B at S006. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P02718,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: brain fog. Adherence ~0.88. AE: no. CRP 7.7 mg/L; ALT 42 U/L.
P02718,4,positive,Visit 4: Patient on RX-17B at S006. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 35 U/L.
P02719,0,neutral,Visit 0: Patient on RX-17A at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: no. CRP 6.2 mg/L; ALT 31 U/L.
P02719,1,neutral,Visit 1: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02719,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: dizziness. Adherence ~0.96. AE: no.
P02719,3,neutral,Visit 3: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 5.0 mg/L; ALT 29 U/L.
P02719,4,neutral,Visit 4: Patient on RX-17A at S018. no major change. Notes: insomnia. Adherence ~0.64. AE: yes.
P02720,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02720,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no. CRP 8.9 mg/L; ALT 38 U/L.
P02720,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no.
P02720,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.61. AE: no.
P02720,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.61. AE: no. CRP 5.6 mg/L; ALT 38 U/L.
P02720,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 5.6 mg/L; ALT 41 U/L.
P02720,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: no.
P02720,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: no.
P02721,0,neutral,Visit 0: Patient on RX-17B at S006. follow-up as scheduled. Notes: joint pain. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02721,1,negative,Visit 1: Patient on RX-17B at S006. symptoms persist. Notes: fatigue. Adherence ~0.40. AE: no.
P02721,2,neutral,Visit 2: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.37. AE: no.
P02721,3,neutral,Visit 3: Patient on RX-17B at S006. follow-up as scheduled. Notes: dizziness. Adherence ~0.48. AE: no.
P02721,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: brain fog. Adherence ~0.40. AE: no. CRP 2.7 mg/L; ALT 42 U/L.
P02721,5,neutral,Visit 5: Patient on RX-17B at S006. no major change. Notes: abdominal discomfort. Adherence ~0.52. AE: no.
P02722,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.53. AE: no.
P02722,1,neutral,Visit 1: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.70. AE: no. CRP 3.8 mg/L; ALT 16 U/L.
P02722,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no. CRP 3.5 mg/L; ALT 19 U/L.
P02722,3,negative,Visit 3: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.44. AE: no. CRP 3.5 mg/L; ALT 20 U/L.
P02722,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.68. AE: no.
P02723,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.87. AE: no. CRP 5.2 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02723,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P02723,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.88. AE: yes.
P02723,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.70. AE: no.
P02723,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.86. AE: no. CRP 3.5 mg/L; ALT 42 U/L.
P02724,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.62. AE: no.
P02724,1,negative,Visit 1: Patient on RX-17B at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.65. AE: yes.
P02724,2,neutral,Visit 2: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02724,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: fatigue. Adherence ~0.71. AE: yes.
P02724,4,neutral,Visit 4: Patient on RX-17B at S018. no major change. Notes: joint pain. Adherence ~0.58. AE: no.
P02725,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.5 mg/L; ALT 34 U/L.
P02725,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: joint pain. Adherence ~0.84. AE: no. CRP 6.4 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P02725,2,negative,Visit 2: Patient on RX-17B at S016. reports worsening. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02725,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02725,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.94. AE: yes. CRP 4.0 mg/L; ALT 43 U/L.
P02725,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no.
P02725,6,positive,Visit 6: Patient on RX-17B at S016. symptoms improving. Notes: nausea. Adherence ~1.00. AE: no.
P02725,7,positive,Visit 7: Patient on RX-17B at S016. energy increasing. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 2.8 mg/L; ALT 39 U/L.
P02726,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.80. AE: no.
P02726,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.8 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02726,2,positive,Visit 2: Patient on RX-17A at S015. feels better overall. Notes: dizziness. Adherence ~0.81. AE: no.
P02726,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: nausea. Adherence ~0.75. AE: no. CRP 3.5 mg/L; ALT 41 U/L.
P02726,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: yes.
P02727,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.56. AE: no.
P02727,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.60. AE: no. CRP 8.1 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02727,2,negative,Visit 2: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~0.56. AE: no.
P02727,3,negative,Visit 3: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.45. AE: no.
P02727,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.50. AE: no.
P02728,0,negative,Visit 0: Patient on RX-17A at S010. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: yes.
P02728,1,negative,Visit 1: Patient on RX-17A at S010. increased discomfort. Notes: nausea. Adherence ~1.00. AE: no. CRP 7.0 mg/L; ALT 32 U/L.
P02728,2,negative,Visit 2: Patient on RX-17A at S010. increased discomfort. Notes: dizziness. Adherence ~0.95. AE: yes. CRP 6.7 mg/L; ALT 35 U/L.
P02729,0,neutral,Visit 0: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no.
P02729,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: brain fog. Adherence ~0.41. AE: yes.
P02729,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.61. AE: yes.
P02729,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.56. AE: no.
P02730,0,neutral,Visit 0: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P02730,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no.
P02730,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.55. AE: no. CRP 4.4 mg/L; ALT 43 U/L.
P02730,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.68. AE: no. CRP 4.0 mg/L; ALT 41 U/L.
P02731,0,neutral,Visit 0: Patient on RX-17B at S017. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 7.3 mg/L; ALT 15 U/L.
P02731,1,negative,Visit 1: Patient on RX-17B at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.4 mg/L; ALT 18 U/L.
P02731,2,negative,Visit 2: Patient on RX-17B at S017. increased discomfort. Notes: fatigue. Adherence ~0.60. AE: yes. CRP 5.5 mg/L; ALT 19 U/L.
P02731,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: fatigue. Adherence ~0.87. AE: no.
P02731,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02732,0,neutral,Visit 0: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no.
P02732,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no.
P02732,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: insomnia. Adherence ~0.81. AE: no.
P02732,3,negative,Visit 3: Patient on RX-17A at S013. increased discomfort. Notes: joint pain. Adherence ~0.91. AE: no.
P02732,4,positive,Visit 4: Patient on RX-17A at S013. feels better overall. Notes: joint pain. Adherence ~0.77. AE: no.
P02732,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02733,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: fatigue. Adherence ~0.65. AE: no.
P02733,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no.
P02733,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.58. AE: no.
P02733,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no.
P02733,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no.
P02733,5,neutral,Visit 5: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02734,0,negative,Visit 0: Patient on RX-17A at S008. increased discomfort. Notes: joint pain. Adherence ~0.70. AE: no.
P02734,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.66. AE: no.
P02734,2,neutral,Visit 2: Patient on RX-17A at S008. no major change. Notes: headache. Adherence ~0.78. AE: no. CRP 9.6 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02734,3,neutral,Visit 3: Patient on RX-17A at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no.
P02734,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no.
P02734,5,neutral,Visit 5: Patient on RX-17A at S008. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no.
P02734,6,neutral,Visit 6: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P02734,7,neutral,Visit 7: Patient on RX-17A at S008. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no.
P02735,0,negative,Visit 0: Patient on RX-17A at S006. poor tolerance. Notes: dizziness. Adherence ~0.94. AE: yes. CRP 8.1 mg/L; ALT 28 U/L.
P02735,1,negative,Visit 1: Patient on RX-17A at S006. reports worsening. Notes: brain fog. Adherence ~0.72. AE: yes. CRP 6.4 mg/L; ALT 32 U/L.
P02735,2,neutral,Visit 2: Patient on RX-17A at S006. stable symptoms. Notes: brain fog. Adherence ~0.80. AE: no. CRP 6.7 mg/L; ALT 29 U/L.
P02735,3,neutral,Visit 3: Patient on RX-17A at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.81. AE: no.
P02735,4,neutral,Visit 4: Patient on RX-17A at S006. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P02735,5,neutral,Visit 5: Patient on RX-17A at S006. continues regimen. Notes: joint pain. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02736,0,negative,Visit 0: Patient on RX-17B at S015. increased discomfort. Notes: dizziness. Adherence ~0.80. AE: yes.
P02736,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: abdominal discomfort. Adherence ~0.92. AE: no. CRP 3.5 mg/L; ALT 25 U/L.
P02736,2,negative,Visit 2: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.60. AE: yes.
P02737,0,negative,Visit 0: Patient on RX-17B at S007. increased discomfort. Notes: joint pain. Adherence ~0.68. AE: no.
P02737,1,negative,Visit 1: Patient on RX-17B at S007. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P02737,2,neutral,Visit 2: Patient on RX-17B at S007. continues regimen. Notes: fatigue. Adherence ~0.78. AE: no.
P02737,3,neutral,Visit 3: Patient on RX-17B at S007. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no.
P02737,4,positive,Visit 4: Patient on RX-17B at S007. symptoms improving. Notes: brain fog. Adherence ~0.77. AE: no. CRP 2.7 mg/L; ALT 36 U/L.
P02737,5,neutral,Visit 5: Patient on RX-17B at S007. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: yes. CRP 2.5 mg/L; ALT 33 U/L.
P02737,6,neutral,Visit 6: Patient on RX-17B at S007. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no. CRP 2.1 mg/L; ALT 31 U/L.
P02738,0,neutral,Visit 0: Patient on RX-17B at S003. reviewed dosing instructions. Notes: fatigue. Adherence ~0.72. AE: no. CRP 6.2 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02738,1,neutral,Visit 1: Patient on RX-17B at S003. no major change. Notes: dizziness. Adherence ~0.86. AE: no.
P02738,2,negative,Visit 2: Patient on RX-17B at S003. poor tolerance. Notes: joint pain. Adherence ~0.64. AE: no.
P02738,3,negative,Visit 3: Patient on RX-17B at S003. reports worsening. Notes: brain fog. Adherence ~0.81. AE: no.
P02738,4,neutral,Visit 4: Patient on RX-17B at S003. follow-up as scheduled. Notes: brain fog. Adherence ~0.69. AE: no.
P02739,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 5.6 mg/L; ALT 41 U/L.
P02739,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.73. AE: no.
P02739,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.84. AE: no. CRP 4.7 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P02739,3,negative,Visit 3: Patient on RX-17B at S017. poor tolerance. Notes: dizziness. Adherence ~0.64. AE: no.
P02739,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.81. AE: no.
P02739,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.70. AE: yes.
P02739,6,positive,Visit 6: Patient on RX-17B at S017. tolerating medication well. Notes: headache. Adherence ~0.89. AE: no.
P02739,7,neutral,Visit 7: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: yes.
P02740,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.73. AE: no.
P02740,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: no. CRP 10.4 mg/L; ALT 36 U/L.
P02740,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.69. AE: no. CRP 9.0 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02740,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.69. AE: no. CRP 9.0 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02740,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.56. AE: yes. CRP 7.5 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02740,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no.
P02740,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.61. AE: no. CRP 6.3 mg/L; ALT 38 U/L.
P02741,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. CRP 7.0 mg/L; ALT 29 U/L.
P02741,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P02741,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02741,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P02741,4,negative,Visit 4: Patient on RX-17A at S012. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 32 U/L.
P02741,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.90. AE: no.
P02742,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: no.
P02742,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: headache. Adherence ~0.99. AE: no.
P02742,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.87. AE: yes.
P02742,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.69. AE: yes. Plan: consider dose adjustment; counsel patient.
P02742,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P02742,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no.
P02742,6,positive,Visit 6: Patient on RX-17B at S013. feels better overall. Notes: brain fog. Adherence ~0.76. AE: no.
P02743,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: fatigue. Adherence ~0.87. AE: yes.
P02743,1,negative,Visit 1: Patient on RX-17B at S018. symptoms persist. Notes: insomnia. Adherence ~0.63. AE: no. CRP 3.6 mg/L; ALT 31 U/L.
P02743,2,negative,Visit 2: Patient on RX-17B at S018. symptoms persist. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02743,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.88. AE: yes. Plan: consider dose adjustment; counsel patient.
P02743,4,neutral,Visit 4: Patient on RX-17B at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02743,5,positive,Visit 5: Patient on RX-17B at S018. energy increasing. Notes: brain fog. Adherence ~0.91. AE: no.
P02743,6,neutral,Visit 6: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: yes. CRP 2.3 mg/L; ALT 34 U/L.
P02744,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.65. AE: no.
P02744,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: brain fog. Adherence ~0.74. AE: no. CRP 7.2 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02744,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: insomnia. Adherence ~0.65. AE: no. CRP 5.9 mg/L; ALT 30 U/L.
P02744,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.76. AE: no. CRP 6.8 mg/L; ALT 29 U/L.
P02745,0,neutral,Visit 0: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.52. AE: no.
P02745,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: headache. Adherence ~0.37. AE: yes.
P02745,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: brain fog. Adherence ~0.68. AE: no. CRP 12.5 mg/L; ALT 78 U/L.
P02745,3,neutral,Visit 3: Patient on RX-17B at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.61. AE: no.
P02745,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.59. AE: yes.
P02745,5,neutral,Visit 5: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P02745,6,neutral,Visit 6: Patient on RX-17B at S017. no major change. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P02745,7,neutral,Visit 7: Patient on RX-17B at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 5.3 mg/L; ALT 84 U/L.
P02746,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: nausea. Adherence ~0.50. AE: no. CRP 6.3 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02746,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.68. AE: no.
P02746,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.46. AE: no. CRP 5.8 mg/L; ALT 20 U/L.
P02746,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.56. AE: no.
P02746,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.55. AE: no.
P02746,5,neutral,Visit 5: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.48. AE: no. CRP 3.7 mg/L; ALT 19 U/L.
P02747,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: fatigue. Adherence ~0.92. AE: yes.
P02747,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~0.67. AE: yes.
P02747,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02748,0,neutral,Visit 0: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no.
P02748,1,negative,Visit 1: Patient on RX-17A at S013. feels frustrated. Notes: nausea. Adherence ~0.73. AE: no. CRP 4.6 mg/L; ALT 22 U/L.
P02748,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.78. AE: no. CRP 3.5 mg/L; ALT 20 U/L.
P02748,3,neutral,Visit 3: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.70. AE: no.
P02749,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02749,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02749,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.93. AE: no. CRP 6.6 mg/L; ALT 30 U/L. Plan: consider dose adjustment; counsel patient.
P02749,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~1.00. AE: no.
P02749,4,negative,Visit 4: Patient on RX-17A at S017. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02749,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P02749,6,positive,Visit 6: Patient on RX-17A at S017. feels better overall. Notes: brain fog. Adherence ~0.97. AE: no. CRP 4.0 mg/L; ALT 33 U/L.
P02750,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02750,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P02750,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02750,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.92. AE: no.
P02751,0,neutral,Visit 0: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P02751,1,neutral,Visit 1: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.67. AE: no. CRP 3.5 mg/L; ALT 22 U/L.
P02751,2,neutral,Visit 2: Patient on RX-17A at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02751,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no.
P02751,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.80. AE: no. CRP 2.6 mg/L; ALT 24 U/L.
P02751,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.96. AE: no.
P02752,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.62. AE: no.
P02752,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P02752,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.57. AE: no. CRP 7.0 mg/L; ALT 42 U/L.
P02752,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.44. AE: no. CRP 6.0 mg/L; ALT 39 U/L.
P02752,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.46. AE: no. Plan: consider dose adjustment; counsel patient.
P02752,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.56. AE: no. CRP 4.8 mg/L; ALT 42 U/L.
P02753,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.67. AE: no.
P02753,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.53. AE: no.
P02753,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: nausea. Adherence ~0.75. AE: no. CRP 2.4 mg/L; ALT 38 U/L.
P02753,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no.
P02753,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.71. AE: no.
P02753,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.88. AE: yes. CRP 1.9 mg/L; ALT 41 U/L.
P02754,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no.
P02754,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02754,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.96. AE: no.
P02754,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02754,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.77. AE: no.
P02754,5,positive,Visit 5: Patient on RX-17A at S004. symptoms improving. Notes: headache. Adherence ~0.76. AE: no. CRP 3.7 mg/L; ALT 39 U/L.
P02754,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~1.00. AE: no. CRP 3.8 mg/L; ALT 37 U/L.
P02754,7,positive,Visit 7: Patient on RX-17A at S004. energy increasing. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02755,0,negative,Visit 0: Patient on RX-17A at S013. increased discomfort. Notes: insomnia. Adherence ~0.95. AE: no. CRP 7.3 mg/L; ALT 38 U/L.
P02755,1,neutral,Visit 1: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.56. AE: yes.
P02755,2,negative,Visit 2: Patient on RX-17A at S013. reports worsening. Notes: fatigue. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02755,3,neutral,Visit 3: Patient on RX-17A at S013. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 7.2 mg/L; ALT 45 U/L.
P02755,4,neutral,Visit 4: Patient on RX-17A at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.66. AE: no.
P02755,5,positive,Visit 5: Patient on RX-17A at S013. feels better overall. Notes: nausea. Adherence ~0.94. AE: no. CRP 5.7 mg/L; ALT 47 U/L.
P02755,6,positive,Visit 6: Patient on RX-17A at S013. feels better overall. Notes: brain fog. Adherence ~0.76. AE: no.
P02755,7,positive,Visit 7: Patient on RX-17A at S013. energy increasing. Notes: fatigue. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02756,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 3.2 mg/L; ALT 13 U/L.
P02756,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.81. AE: yes.
P02756,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02756,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P02756,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P02757,0,negative,Visit 0: Patient on RX-17A at S013. poor tolerance. Notes: fatigue. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02757,1,neutral,Visit 1: Patient on RX-17A at S013. no major change. Notes: dizziness. Adherence ~0.50. AE: yes.
P02757,2,neutral,Visit 2: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.45. AE: no. CRP 4.6 mg/L; ALT 35 U/L.
P02757,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 4.6 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02757,4,neutral,Visit 4: Patient on RX-17A at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.49. AE: no. CRP 4.7 mg/L; ALT 36 U/L.
P02757,5,neutral,Visit 5: Patient on RX-17A at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P02757,6,neutral,Visit 6: Patient on RX-17A at S013. follow-up as scheduled. Notes: dizziness. Adherence ~0.47. AE: no.
P02757,7,neutral,Visit 7: Patient on RX-17A at S013. no major change. Notes: insomnia. Adherence ~0.36. AE: no.
P02758,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.67. AE: no.
P02758,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02758,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.60. AE: no. CRP 8.0 mg/L; ALT 20 U/L.
P02758,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.62. AE: no.
P02758,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 6.1 mg/L; ALT 22 U/L.
P02758,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02758,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.60. AE: no. CRP 4.9 mg/L; ALT 21 U/L.
P02759,0,neutral,Visit 0: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: no.
P02759,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.75. AE: no. CRP 6.8 mg/L; ALT 33 U/L.
P02759,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.86. AE: no.
P02759,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no.
P02759,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.81. AE: no. CRP 5.1 mg/L; ALT 34 U/L.
P02759,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02760,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: headache. Adherence ~0.80. AE: no. CRP 8.9 mg/L; ALT 28 U/L.
P02760,1,neutral,Visit 1: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no.
P02760,2,negative,Visit 2: Patient on RX-17A at S002. reports worsening. Notes: brain fog. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02760,3,neutral,Visit 3: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.96. AE: no.
P02760,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02760,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no.
P02761,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.75. AE: no.
P02761,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.90. AE: no. CRP 4.1 mg/L; ALT 31 U/L.
P02761,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.94. AE: no.
P02761,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.65. AE: no. CRP 3.4 mg/L; ALT 34 U/L.
P02761,4,negative,Visit 4: Patient on RX-17A at S015. increased discomfort. Notes: insomnia. Adherence ~0.86. AE: yes.
P02761,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.97. AE: no. CRP 2.7 mg/L; ALT 30 U/L.
P02761,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.78. AE: no. CRP 2.4 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02761,7,positive,Visit 7: Patient on RX-17A at S015. reports improvement. Notes: fatigue. Adherence ~0.76. AE: no.
P02762,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.90. AE: no.
P02762,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.64. AE: no.
P02762,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no.
P02762,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. CRP 8.0 mg/L; ALT 20 U/L.
P02762,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.73. AE: no.
P02762,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.72. AE: no.
P02763,0,neutral,Visit 0: Patient on RX-17A at S002. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no.
P02763,1,neutral,Visit 1: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02763,2,negative,Visit 2: Patient on RX-17A at S002. symptoms persist. Notes: headache. Adherence ~0.84. AE: yes. Plan: consider dose adjustment; counsel patient.
P02763,3,neutral,Visit 3: Patient on RX-17A at S002. stable symptoms. Notes: fatigue. Adherence ~0.87. AE: no. CRP 4.6 mg/L; ALT 45 U/L.
P02763,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P02763,5,neutral,Visit 5: Patient on RX-17A at S002. stable symptoms. Notes: nausea. Adherence ~0.63. AE: no.
P02763,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.56. AE: no.
P02763,7,neutral,Visit 7: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02764,0,negative,Visit 0: Patient on RX-17A at S008. reports worsening. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02764,1,negative,Visit 1: Patient on RX-17A at S008. poor tolerance. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02764,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no. CRP 8.3 mg/L; ALT 19 U/L.
P02764,3,neutral,Visit 3: Patient on RX-17A at S008. no major change. Notes: nausea. Adherence ~0.91. AE: no.
P02764,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: fatigue. Adherence ~0.87. AE: no.
P02765,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.80. AE: no.
P02765,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.82. AE: no.
P02765,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P02765,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~0.96. AE: no.
P02765,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 1.6 mg/L; ALT 46 U/L.
P02765,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.89. AE: no.
P02766,0,negative,Visit 0: Patient on RX-17B at S006. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P02766,1,neutral,Visit 1: Patient on RX-17B at S006. stable symptoms. Notes: headache. Adherence ~0.87. AE: no. CRP 5.8 mg/L; ALT 17 U/L.
P02766,2,negative,Visit 2: Patient on RX-17B at S006. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 18 U/L.
P02766,3,negative,Visit 3: Patient on RX-17B at S006. increased discomfort. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02766,4,neutral,Visit 4: Patient on RX-17B at S006. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 19 U/L.
P02767,0,negative,Visit 0: Patient on RX-17B at S011. feels frustrated. Notes: joint pain. Adherence ~0.73. AE: no.
P02767,1,negative,Visit 1: Patient on RX-17B at S011. reports worsening. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 6.5 mg/L; ALT 33 U/L.
P02767,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02767,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 5.4 mg/L; ALT 35 U/L.
P02767,4,neutral,Visit 4: Patient on RX-17B at S011. stable symptoms. Notes: fatigue. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P02767,5,neutral,Visit 5: Patient on RX-17B at S011. follow-up as scheduled. Notes: nausea. Adherence ~0.92. AE: no.
P02767,6,neutral,Visit 6: Patient on RX-17B at S011. no major change. Notes: insomnia. Adherence ~0.42. AE: no.
P02767,7,positive,Visit 7: Patient on RX-17B at S011. feels better overall. Notes: headache. Adherence ~0.79. AE: no.
P02768,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: nausea. Adherence ~0.57. AE: no.
P02768,1,neutral,Visit 1: Patient on RX-17A at S013. continues regimen. Notes: dizziness. Adherence ~0.47. AE: yes.
P02768,2,negative,Visit 2: Patient on RX-17A at S013. symptoms persist. Notes: dizziness. Adherence ~0.84. AE: no.
P02768,3,neutral,Visit 3: Patient on RX-17A at S013. no major change. Notes: fatigue. Adherence ~0.72. AE: no. CRP 12.3 mg/L; ALT 59 U/L.
P02768,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: nausea. Adherence ~0.55. AE: no. CRP 10.0 mg/L; ALT 55 U/L. Plan: consider dose adjustment; counsel patient.
P02768,5,neutral,Visit 5: Patient on RX-17A at S013. stable symptoms. Notes: headache. Adherence ~0.70. AE: no.
P02769,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.93. AE: no. CRP 8.1 mg/L; ALT 71 U/L.
P02769,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: brain fog. Adherence ~0.96. AE: no. CRP 7.0 mg/L; ALT 72 U/L.
P02769,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: nausea. Adherence ~0.83. AE: no.
P02769,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no.
P02770,0,negative,Visit 0: Patient on RX-17B at S001. feels frustrated. Notes: joint pain. Adherence ~0.52. AE: no. Plan: consider dose adjustment; counsel patient.
P02770,1,neutral,Visit 1: Patient on RX-17B at S001. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.54. AE: no. CRP 8.2 mg/L; ALT 17 U/L.
P02770,2,neutral,Visit 2: Patient on RX-17B at S001. reviewed dosing instructions. Notes: insomnia. Adherence ~0.72. AE: no.
P02770,3,neutral,Visit 3: Patient on RX-17B at S001. reviewed dosing instructions. Notes: nausea. Adherence ~0.60. AE: no.
P02770,4,neutral,Visit 4: Patient on RX-17B at S001. stable symptoms. Notes: brain fog. Adherence ~0.62. AE: no.
P02770,5,neutral,Visit 5: Patient on RX-17B at S001. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02770,6,neutral,Visit 6: Patient on RX-17B at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.50. AE: yes.
P02771,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02771,1,negative,Visit 1: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.71. AE: no.
P02771,2,negative,Visit 2: Patient on RX-17B at S005. symptoms persist. Notes: joint pain. Adherence ~0.55. AE: no. CRP 7.6 mg/L; ALT 24 U/L.
P02772,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.86. AE: no. CRP 12.7 mg/L; ALT 27 U/L.
P02772,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.73. AE: no.
P02772,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.85. AE: no.
P02772,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.78. AE: no. CRP 12.4 mg/L; ALT 24 U/L.
P02772,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P02772,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.64. AE: no. CRP 10.1 mg/L; ALT 26 U/L.
P02772,6,positive,Visit 6: Patient on RX-17A at S004. reports improvement. Notes: nausea. Adherence ~0.85. AE: no.
P02772,7,positive,Visit 7: Patient on RX-17A at S004. symptoms improving. Notes: headache. Adherence ~0.86. AE: no.
P02773,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: nausea. Adherence ~0.78. AE: no.
P02773,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no.
P02773,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.64. AE: no.
P02773,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.53. AE: no. CRP 4.7 mg/L; ALT 76 U/L.
P02773,4,neutral,Visit 4: Patient on RX-17B at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P02773,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: fatigue. Adherence ~0.68. AE: no. CRP 3.4 mg/L; ALT 67 U/L.
P02774,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: insomnia. Adherence ~0.76. AE: no.
P02774,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: yes. CRP 3.1 mg/L; ALT 30 U/L.
P02774,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.93. AE: no.
P02774,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: insomnia. Adherence ~0.85. AE: no. CRP 2.9 mg/L; ALT 30 U/L.
P02774,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02774,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02775,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P02775,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P02775,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.93. AE: no. CRP 2.3 mg/L; ALT 43 U/L.
P02775,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 2.5 mg/L; ALT 44 U/L.
P02775,4,positive,Visit 4: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P02775,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: no. CRP 1.8 mg/L; ALT 45 U/L.
P02775,6,positive,Visit 6: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02775,7,neutral,Visit 7: Patient on RX-17B at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.93. AE: yes. Plan: consider dose adjustment; counsel patient.
P02776,0,negative,Visit 0: Patient on RX-17B at S006. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: no.
P02776,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02776,2,negative,Visit 2: Patient on RX-17B at S006. feels frustrated. Notes: brain fog. Adherence ~0.96. AE: no.
P02776,3,negative,Visit 3: Patient on RX-17B at S006. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no.
P02776,4,neutral,Visit 4: Patient on RX-17B at S006. reviewed dosing instructions. Notes: fatigue. Adherence ~0.75. AE: no.
P02777,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: nausea. Adherence ~0.81. AE: yes. CRP 8.1 mg/L; ALT 22 U/L.
P02777,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02777,2,negative,Visit 2: Patient on RX-17B at S002. poor tolerance. Notes: joint pain. Adherence ~0.94. AE: yes. CRP 7.7 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02777,3,neutral,Visit 3: Patient on RX-17B at S002. follow-up as scheduled. Notes: headache. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02777,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.83. AE: no. CRP 6.3 mg/L; ALT 20 U/L.
P02777,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no.
P02777,6,positive,Visit 6: Patient on RX-17B at S002. reports improvement. Notes: dizziness. Adherence ~1.00. AE: no.
P02778,0,neutral,Visit 0: Patient on RX-17A at S022. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02778,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.83. AE: no.
P02778,2,neutral,Visit 2: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.53. AE: yes.
P02778,3,neutral,Visit 3: Patient on RX-17A at S022. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P02778,4,negative,Visit 4: Patient on RX-17A at S022. symptoms persist. Notes: dizziness. Adherence ~0.63. AE: no. CRP 4.8 mg/L; ALT 16 U/L.
P02778,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P02778,6,positive,Visit 6: Patient on RX-17A at S022. symptoms improving. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.6 mg/L; ALT 14 U/L.
P02778,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02779,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: brain fog. Adherence ~0.73. AE: no.
P02779,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: yes. CRP 4.7 mg/L; ALT 26 U/L.
P02779,2,negative,Visit 2: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.82. AE: no. CRP 4.2 mg/L; ALT 25 U/L.
P02779,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.68. AE: no.
P02779,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02779,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.67. AE: no.
P02780,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02780,1,negative,Visit 1: Patient on RX-17A at S004. feels frustrated. Notes: headache. Adherence ~0.97. AE: no. CRP 7.9 mg/L; ALT 76 U/L.
P02780,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02780,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: headache. Adherence ~0.96. AE: no.
P02780,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P02780,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.85. AE: no.
P02780,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02781,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02781,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.57. AE: no.
P02781,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.73. AE: no.
P02781,3,negative,Visit 3: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.65. AE: no.
P02781,4,positive,Visit 4: Patient on RX-17B at S004. tolerating medication well. Notes: fatigue. Adherence ~0.89. AE: no. CRP 5.0 mg/L; ALT 34 U/L.
P02782,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: nausea. Adherence ~0.74. AE: no.
P02782,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no.
P02782,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.70. AE: no.
P02782,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 7.5 mg/L; ALT 44 U/L.
P02782,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.55. AE: no. CRP 7.6 mg/L; ALT 45 U/L.
P02783,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~0.88. AE: no. CRP 4.1 mg/L; ALT 19 U/L.
P02783,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.78. AE: no. CRP 3.6 mg/L; ALT 19 U/L.
P02783,2,negative,Visit 2: Patient on RX-17A at S015. feels frustrated. Notes: dizziness. Adherence ~0.90. AE: no.
P02783,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 3.9 mg/L; ALT 18 U/L.
P02783,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.75. AE: no.
P02783,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.6 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02784,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~0.78. AE: no.
P02784,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 2.4 mg/L; ALT 25 U/L.
P02784,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02784,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: no. CRP 2.4 mg/L; ALT 27 U/L.
P02784,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no. CRP 2.1 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02784,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: headache. Adherence ~1.00. AE: no.
P02784,6,negative,Visit 6: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~0.82. AE: yes.
P02784,7,neutral,Visit 7: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02785,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: nausea. Adherence ~0.87. AE: no. CRP 4.2 mg/L; ALT 40 U/L.
P02785,1,neutral,Visit 1: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02785,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P02785,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.61. AE: no.
P02785,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02785,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 39 U/L.
P02785,6,neutral,Visit 6: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P02786,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: fatigue. Adherence ~0.77. AE: no. CRP 3.1 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02786,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: insomnia. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02786,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P02786,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: nausea. Adherence ~0.90. AE: no.
P02786,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: headache. Adherence ~0.93. AE: no.
P02787,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.76. AE: no.
P02787,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.74. AE: no.
P02787,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no.
P02787,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02788,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: insomnia. Adherence ~0.87. AE: no.
P02788,1,negative,Visit 1: Patient on RX-17A at S005. increased discomfort. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02788,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.89. AE: yes.
P02788,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.83. AE: no.
P02788,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.75. AE: no.
P02788,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.84. AE: no. CRP 12.8 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02788,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 8.7 mg/L; ALT 25 U/L.
P02788,7,neutral,Visit 7: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.72. AE: no.
P02789,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.83. AE: no.
P02789,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: brain fog. Adherence ~0.84. AE: no. CRP 2.2 mg/L; ALT 46 U/L.
P02789,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.90. AE: no.
P02789,3,negative,Visit 3: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.96. AE: no.
P02789,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.90. AE: no.
P02790,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: brain fog. Adherence ~0.60. AE: no. CRP 9.3 mg/L; ALT 36 U/L.
P02790,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: brain fog. Adherence ~0.66. AE: no. CRP 8.0 mg/L; ALT 31 U/L.
P02790,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02791,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.46. AE: no. CRP 10.1 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02791,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: yes.
P02791,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.62. AE: no.
P02791,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 9.1 mg/L; ALT 41 U/L.
P02792,0,neutral,Visit 0: Patient on RX-17A at S022. no major change. Notes: joint pain. Adherence ~0.83. AE: no. CRP 13.1 mg/L; ALT 38 U/L.
P02792,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: dizziness. Adherence ~0.97. AE: no. CRP 10.1 mg/L; ALT 39 U/L.
P02792,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02792,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.81. AE: no.
P02792,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02792,5,negative,Visit 5: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.83. AE: yes. CRP 7.9 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02793,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02793,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: joint pain. Adherence ~0.64. AE: no.
P02793,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.74. AE: no. CRP 6.6 mg/L; ALT 27 U/L.
P02793,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.62. AE: no.
P02793,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.54. AE: no. CRP 6.0 mg/L; ALT 28 U/L.
P02793,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.56. AE: yes.
P02793,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.62. AE: no. CRP 4.9 mg/L; ALT 28 U/L.
P02793,7,neutral,Visit 7: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.58. AE: no. CRP 4.5 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02794,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: insomnia. Adherence ~0.91. AE: no. CRP 15.6 mg/L; ALT 40 U/L.
P02794,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02794,2,neutral,Visit 2: Patient on RX-17A at S022. no major change. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02794,3,negative,Visit 3: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.85. AE: no. CRP 10.5 mg/L; ALT 45 U/L.
P02794,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no. CRP 11.5 mg/L; ALT 41 U/L.
P02795,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no.
P02795,1,neutral,Visit 1: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02795,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02795,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no.
P02795,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.86. AE: no.
P02795,5,positive,Visit 5: Patient on RX-17A at S012. tolerating medication well. Notes: dizziness. Adherence ~0.78. AE: no. CRP 12.6 mg/L; ALT 25 U/L.
P02795,6,positive,Visit 6: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02796,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.95. AE: no.
P02796,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.93. AE: no.
P02796,2,positive,Visit 2: Patient on RX-17B at S015. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no.
P02796,3,positive,Visit 3: Patient on RX-17B at S015. tolerating medication well. Notes: brain fog. Adherence ~0.79. AE: no. CRP 4.5 mg/L; ALT 36 U/L.
P02797,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.93. AE: no. CRP 10.9 mg/L; ALT 17 U/L.
P02797,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: fatigue. Adherence ~0.81. AE: no. CRP 9.7 mg/L; ALT 15 U/L.
P02797,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~0.89. AE: no.
P02798,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02798,1,neutral,Visit 1: Patient on RX-17B at S002. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02798,2,negative,Visit 2: Patient on RX-17B at S002. symptoms persist. Notes: nausea. Adherence ~0.72. AE: yes. CRP 11.6 mg/L; ALT 28 U/L.
P02798,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: no.
P02798,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 9.2 mg/L; ALT 24 U/L.
P02799,0,neutral,Visit 0: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no.
P02799,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 74 U/L.
P02799,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.79. AE: no.
P02799,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.96. AE: no.
P02799,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02799,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P02799,6,positive,Visit 6: Patient on RX-17B at S022. energy increasing. Notes: insomnia. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02799,7,neutral,Visit 7: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.99. AE: no. CRP 1.9 mg/L; ALT 79 U/L.
P02800,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02800,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.65. AE: no.
P02800,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: yes.
P02800,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 6.2 mg/L; ALT 37 U/L.
P02800,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: no.
P02801,0,neutral,Visit 0: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P02801,1,neutral,Visit 1: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P02801,2,negative,Visit 2: Patient on RX-17B at S016. symptoms persist. Notes: joint pain. Adherence ~0.84. AE: no. CRP 3.9 mg/L; ALT 38 U/L.
P02801,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 38 U/L.
P02801,4,negative,Visit 4: Patient on RX-17B at S016. feels frustrated. Notes: insomnia. Adherence ~0.94. AE: yes.
P02801,5,positive,Visit 5: Patient on RX-17B at S016. energy increasing. Notes: nausea. Adherence ~1.00. AE: no. CRP 3.3 mg/L; ALT 44 U/L.
P02801,6,positive,Visit 6: Patient on RX-17B at S016. symptoms improving. Notes: nausea. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02801,7,positive,Visit 7: Patient on RX-17B at S016. reports improvement. Notes: joint pain. Adherence ~0.85. AE: no.
P02802,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.46. AE: yes. CRP 9.1 mg/L; ALT 25 U/L.
P02802,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.40. AE: no.
P02802,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.56. AE: no. CRP 9.7 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02803,0,neutral,Visit 0: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 2.6 mg/L; ALT 22 U/L.
P02803,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: insomnia. Adherence ~0.91. AE: no. CRP 2.2 mg/L; ALT 24 U/L.
P02803,2,negative,Visit 2: Patient on RX-17B at S014. reports worsening. Notes: insomnia. Adherence ~0.90. AE: yes.
P02804,0,negative,Visit 0: Patient on RX-17A at S016. increased discomfort. Notes: fatigue. Adherence ~0.33. AE: yes.
P02804,1,neutral,Visit 1: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.43. AE: no.
P02804,2,neutral,Visit 2: Patient on RX-17A at S016. no major change. Notes: dizziness. Adherence ~0.50. AE: no.
P02804,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.49. AE: no. CRP 12.2 mg/L; ALT 29 U/L.
P02804,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.19. AE: no. CRP 11.3 mg/L; ALT 26 U/L.
P02804,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: fatigue. Adherence ~0.49. AE: no. CRP 11.2 mg/L; ALT 29 U/L.
P02805,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: fatigue. Adherence ~0.83. AE: yes. CRP 9.0 mg/L; ALT 31 U/L.
P02805,1,negative,Visit 1: Patient on RX-17B at S014. feels frustrated. Notes: insomnia. Adherence ~0.69. AE: yes.
P02805,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.92. AE: no.
P02805,3,negative,Visit 3: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.72. AE: yes.
P02806,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.61. AE: yes. CRP 9.6 mg/L; ALT 65 U/L.
P02806,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P02806,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: headache. Adherence ~0.82. AE: yes.
P02806,3,positive,Visit 3: Patient on RX-17B at S005. energy increasing. Notes: headache. Adherence ~0.85. AE: no.
P02806,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02806,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02806,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: joint pain. Adherence ~0.81. AE: yes.
P02807,0,neutral,Visit 0: Patient on RX-17B at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.99. AE: no.
P02807,1,negative,Visit 1: Patient on RX-17B at S008. feels frustrated. Notes: joint pain. Adherence ~0.81. AE: yes.
P02807,2,neutral,Visit 2: Patient on RX-17B at S008. continues regimen. Notes: nausea. Adherence ~0.87. AE: no.
P02807,3,neutral,Visit 3: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 1.5 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02807,4,neutral,Visit 4: Patient on RX-17B at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.65. AE: no. CRP 1.3 mg/L; ALT 48 U/L.
P02807,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02807,6,neutral,Visit 6: Patient on RX-17B at S008. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: no. CRP 0.9 mg/L; ALT 46 U/L.
P02807,7,neutral,Visit 7: Patient on RX-17B at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: yes.
P02808,0,neutral,Visit 0: Patient on RX-17A at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.44. AE: no. CRP 4.1 mg/L; ALT 29 U/L.
P02808,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: insomnia. Adherence ~0.47. AE: no. CRP 3.9 mg/L; ALT 31 U/L.
P02808,2,negative,Visit 2: Patient on RX-17A at S019. poor tolerance. Notes: abdominal discomfort. Adherence ~0.40. AE: no.
P02808,3,neutral,Visit 3: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02808,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: joint pain. Adherence ~0.58. AE: no. CRP 3.0 mg/L; ALT 31 U/L.
P02809,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: brain fog. Adherence ~0.47. AE: no. CRP 17.2 mg/L; ALT 30 U/L.
P02809,1,negative,Visit 1: Patient on RX-17A at S002. reports worsening. Notes: joint pain. Adherence ~0.46. AE: yes.
P02809,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: fatigue. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02809,3,negative,Visit 3: Patient on RX-17A at S002. increased discomfort. Notes: brain fog. Adherence ~0.39. AE: no. CRP 12.6 mg/L; ALT 33 U/L.
P02809,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: abdominal discomfort. Adherence ~0.50. AE: yes.
P02810,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: joint pain. Adherence ~0.93. AE: no.
P02810,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: insomnia. Adherence ~0.88. AE: no. CRP 5.9 mg/L; ALT 36 U/L.
P02810,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P02810,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: yes. CRP 5.0 mg/L; ALT 42 U/L.
P02810,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.98. AE: no. CRP 4.8 mg/L; ALT 39 U/L.
P02810,5,positive,Visit 5: Patient on RX-17B at S016. energy increasing. Notes: fatigue. Adherence ~0.96. AE: no. CRP 3.9 mg/L; ALT 44 U/L.
P02810,6,positive,Visit 6: Patient on RX-17B at S016. reports improvement. Notes: nausea. Adherence ~1.00. AE: no.
P02811,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: dizziness. Adherence ~0.86. AE: yes.
P02811,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.83. AE: no.
P02811,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02811,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: insomnia. Adherence ~0.91. AE: no.
P02811,4,positive,Visit 4: Patient on RX-17A at S022. symptoms improving. Notes: fatigue. Adherence ~0.83. AE: no.
P02811,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 1.8 mg/L; ALT 20 U/L.
P02811,6,positive,Visit 6: Patient on RX-17A at S022. symptoms improving. Notes: joint pain. Adherence ~0.91. AE: no. CRP 1.8 mg/L; ALT 20 U/L.
P02812,0,negative,Visit 0: Patient on RX-17A at S001. increased discomfort. Notes: dizziness. Adherence ~0.73. AE: yes. Plan: consider dose adjustment; counsel patient.
P02812,1,negative,Visit 1: Patient on RX-17A at S001. feels frustrated. Notes: fatigue. Adherence ~0.72. AE: no.
P02812,2,neutral,Visit 2: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~0.84. AE: no. CRP 7.1 mg/L; ALT 16 U/L.
P02812,3,neutral,Visit 3: Patient on RX-17A at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.50. AE: no. CRP 7.3 mg/L; ALT 15 U/L.
P02812,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: brain fog. Adherence ~0.68. AE: no. CRP 5.9 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02813,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.88. AE: no.
P02813,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: brain fog. Adherence ~0.55. AE: no.
P02813,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no. CRP 9.0 mg/L; ALT 36 U/L.
P02813,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~0.91. AE: yes.
P02813,4,negative,Visit 4: Patient on RX-17A at S005. reports worsening. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02813,5,neutral,Visit 5: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no. CRP 6.6 mg/L; ALT 37 U/L.
P02814,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: brain fog. Adherence ~0.45. AE: yes.
P02814,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: fatigue. Adherence ~0.71. AE: no.
P02814,2,neutral,Visit 2: Patient on RX-17B at S016. stable symptoms. Notes: insomnia. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P02814,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 7.3 mg/L; ALT 31 U/L.
P02814,4,neutral,Visit 4: Patient on RX-17B at S016. stable symptoms. Notes: headache. Adherence ~0.41. AE: no.
P02814,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: brain fog. Adherence ~0.48. AE: no.
P02814,6,neutral,Visit 6: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.61. AE: no.
P02815,0,negative,Visit 0: Patient on RX-17A at S003. poor tolerance. Notes: headache. Adherence ~1.00. AE: no.
P02815,1,neutral,Visit 1: Patient on RX-17A at S003. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P02815,2,negative,Visit 2: Patient on RX-17A at S003. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P02815,3,neutral,Visit 3: Patient on RX-17A at S003. stable symptoms. Notes: brain fog. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P02815,4,neutral,Visit 4: Patient on RX-17A at S003. no major change. Notes: insomnia. Adherence ~0.86. AE: no.
P02816,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.85. AE: no.
P02816,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.69. AE: no.
P02816,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.90. AE: no. CRP 12.3 mg/L; ALT 16 U/L.
P02816,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no. CRP 11.3 mg/L; ALT 13 U/L.
P02816,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.97. AE: no. CRP 9.7 mg/L; ALT 15 U/L.
P02816,5,negative,Visit 5: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.76. AE: no. CRP 9.3 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02816,6,positive,Visit 6: Patient on RX-17A at S015. symptoms improving. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 7.8 mg/L; ALT 15 U/L.
P02817,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02817,1,neutral,Visit 1: Patient on RX-17B at S016. continues regimen. Notes: dizziness. Adherence ~0.87. AE: no. CRP 4.8 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P02817,2,negative,Visit 2: Patient on RX-17B at S016. feels frustrated. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 4.1 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P02817,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: yes.
P02817,4,positive,Visit 4: Patient on RX-17B at S016. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02817,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: yes. CRP 3.2 mg/L; ALT 48 U/L.
P02818,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.84. AE: no.
P02818,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: no.
P02818,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no.
P02818,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.88. AE: no. CRP 6.8 mg/L; ALT 25 U/L.
P02818,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.91. AE: no.
P02818,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P02819,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02819,1,neutral,Visit 1: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P02819,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02819,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.91. AE: no.
P02819,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: yes.
P02819,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no.
P02819,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.98. AE: no. CRP 5.0 mg/L; ALT 34 U/L.
P02820,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: fatigue. Adherence ~0.98. AE: no.
P02820,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P02820,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: yes. CRP 6.0 mg/L; ALT 26 U/L.
P02820,3,neutral,Visit 3: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02820,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no.
P02820,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: headache. Adherence ~0.76. AE: no.
P02821,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02821,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: brain fog. Adherence ~0.79. AE: no.
P02821,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 34 U/L.
P02821,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 5.1 mg/L; ALT 30 U/L.
P02821,4,positive,Visit 4: Patient on RX-17B at S015. tolerating medication well. Notes: fatigue. Adherence ~0.94. AE: no. CRP 3.6 mg/L; ALT 33 U/L.
P02821,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02821,6,positive,Visit 6: Patient on RX-17B at S015. reports improvement. Notes: headache. Adherence ~0.97. AE: no.
P02822,0,neutral,Visit 0: Patient on RX-17A at S005. continues regimen. Notes: insomnia. Adherence ~0.92. AE: no.
P02822,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: fatigue. Adherence ~0.93. AE: no. CRP 5.5 mg/L; ALT 26 U/L.
P02822,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: headache. Adherence ~0.91. AE: no. CRP 4.7 mg/L; ALT 26 U/L.
P02822,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02822,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.93. AE: no.
P02823,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: dizziness. Adherence ~0.66. AE: no.
P02823,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.84. AE: yes.
P02823,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no. CRP 5.8 mg/L; ALT 32 U/L.
P02823,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P02823,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.61. AE: yes. CRP 5.2 mg/L; ALT 32 U/L.
P02823,5,neutral,Visit 5: Patient on RX-17A at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P02824,0,negative,Visit 0: Patient on RX-17A at S020. symptoms persist. Notes: headache. Adherence ~0.89. AE: no.
P02824,1,neutral,Visit 1: Patient on RX-17A at S020. follow-up as scheduled. Notes: fatigue. Adherence ~0.85. AE: no.
P02824,2,neutral,Visit 2: Patient on RX-17A at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.91. AE: no.
P02824,3,neutral,Visit 3: Patient on RX-17A at S020. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no.
P02824,4,neutral,Visit 4: Patient on RX-17A at S020. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P02825,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no.
P02825,1,neutral,Visit 1: Patient on RX-17B at S015. stable symptoms. Notes: joint pain. Adherence ~0.72. AE: no.
P02825,2,neutral,Visit 2: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.62. AE: no.
P02825,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.76. AE: yes.
P02825,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: headache. Adherence ~0.74. AE: no.
P02825,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no. CRP 5.9 mg/L; ALT 29 U/L.
P02825,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: headache. Adherence ~0.75. AE: no.
P02825,7,neutral,Visit 7: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P02826,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: brain fog. Adherence ~0.69. AE: yes.
P02826,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02826,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.45. AE: no. CRP 5.5 mg/L; ALT 28 U/L.
P02827,0,neutral,Visit 0: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.90. AE: no.
P02827,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: fatigue. Adherence ~0.84. AE: no. CRP 18.0 mg/L; ALT 38 U/L.
P02827,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no.
P02827,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: brain fog. Adherence ~0.92. AE: no. CRP 15.9 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P02827,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 13.9 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P02828,0,negative,Visit 0: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.76. AE: no.
P02828,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: nausea. Adherence ~0.81. AE: no. CRP 5.0 mg/L; ALT 43 U/L.
P02828,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.76. AE: no. CRP 3.5 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02828,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.54. AE: no. CRP 4.1 mg/L; ALT 42 U/L.
P02828,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.70. AE: no.
P02829,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: fatigue. Adherence ~0.52. AE: no.
P02829,1,neutral,Visit 1: Patient on RX-17B at S008. no major change. Notes: dizziness. Adherence ~0.47. AE: no.
P02829,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: nausea. Adherence ~0.61. AE: no.
P02829,3,neutral,Visit 3: Patient on RX-17B at S008. stable symptoms. Notes: abdominal discomfort. Adherence ~0.40. AE: no.
P02829,4,neutral,Visit 4: Patient on RX-17B at S008. no major change. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 8.5 mg/L; ALT 26 U/L.
P02830,0,negative,Visit 0: Patient on RX-17B at S001. increased discomfort. Notes: insomnia. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02830,1,negative,Visit 1: Patient on RX-17B at S001. symptoms persist. Notes: joint pain. Adherence ~0.62. AE: yes.
P02830,2,neutral,Visit 2: Patient on RX-17B at S001. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no.
P02830,3,negative,Visit 3: Patient on RX-17B at S001. symptoms persist. Notes: brain fog. Adherence ~0.47. AE: no.
P02830,4,neutral,Visit 4: Patient on RX-17B at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.55. AE: no. CRP 7.8 mg/L; ALT 34 U/L.
P02830,5,negative,Visit 5: Patient on RX-17B at S001. reports worsening. Notes: nausea. Adherence ~0.67. AE: no. CRP 6.9 mg/L; ALT 32 U/L.
P02830,6,neutral,Visit 6: Patient on RX-17B at S001. no major change. Notes: dizziness. Adherence ~0.72. AE: no.
P02831,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.89. AE: no. CRP 8.6 mg/L; ALT 28 U/L.
P02831,1,negative,Visit 1: Patient on RX-17A at S022. poor tolerance. Notes: dizziness. Adherence ~0.99. AE: no. CRP 7.4 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02831,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P02831,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.74. AE: no. CRP 6.8 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02831,4,negative,Visit 4: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.65. AE: no.
P02831,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.74. AE: no.
P02832,0,negative,Visit 0: Patient on RX-17B at S006. poor tolerance. Notes: fatigue. Adherence ~0.53. AE: yes.
P02832,1,neutral,Visit 1: Patient on RX-17B at S006. no major change. Notes: fatigue. Adherence ~0.76. AE: yes.
P02832,2,negative,Visit 2: Patient on RX-17B at S006. symptoms persist. Notes: dizziness. Adherence ~0.63. AE: yes. CRP 6.1 mg/L; ALT 34 U/L.
P02833,0,neutral,Visit 0: Patient on RX-17B at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.66. AE: no. CRP 4.9 mg/L; ALT 50 U/L.
P02833,1,negative,Visit 1: Patient on RX-17B at S018. feels frustrated. Notes: brain fog. Adherence ~0.47. AE: yes.
P02833,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.46. AE: no.
P02833,3,negative,Visit 3: Patient on RX-17B at S018. reports worsening. Notes: insomnia. Adherence ~0.45. AE: no. CRP 4.1 mg/L; ALT 48 U/L.
P02833,4,neutral,Visit 4: Patient on RX-17B at S018. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: yes.
P02834,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P02834,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: joint pain. Adherence ~0.75. AE: no.
P02834,2,negative,Visit 2: Patient on RX-17B at S005. poor tolerance. Notes: insomnia. Adherence ~0.78. AE: no.
P02834,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.68. AE: yes. CRP 4.1 mg/L; ALT 38 U/L.
P02834,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no.
P02834,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: no.
P02834,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: headache. Adherence ~0.58. AE: no.
P02835,0,negative,Visit 0: Patient on RX-17A at S011. symptoms persist. Notes: insomnia. Adherence ~0.76. AE: no. CRP 8.8 mg/L; ALT 61 U/L. Plan: consider dose adjustment; counsel patient.
P02835,1,negative,Visit 1: Patient on RX-17A at S011. reports worsening. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 8.0 mg/L; ALT 66 U/L.
P02835,2,negative,Visit 2: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.80. AE: no. CRP 8.0 mg/L; ALT 63 U/L.
P02835,3,negative,Visit 3: Patient on RX-17A at S011. increased discomfort. Notes: headache. Adherence ~0.82. AE: yes.
P02835,4,neutral,Visit 4: Patient on RX-17A at S011. no major change. Notes: dizziness. Adherence ~0.80. AE: no.
P02835,5,negative,Visit 5: Patient on RX-17A at S011. reports worsening. Notes: dizziness. Adherence ~0.55. AE: no. CRP 4.9 mg/L; ALT 64 U/L.
P02835,6,neutral,Visit 6: Patient on RX-17A at S011. stable symptoms. Notes: headache. Adherence ~0.57. AE: no. CRP 5.2 mg/L; ALT 64 U/L.
P02836,0,negative,Visit 0: Patient on RX-17A at S013. symptoms persist. Notes: nausea. Adherence ~0.58. AE: yes.
P02836,1,neutral,Visit 1: Patient on RX-17A at S013. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no. CRP 7.4 mg/L; ALT 32 U/L.
P02836,2,negative,Visit 2: Patient on RX-17A at S013. poor tolerance. Notes: dizziness. Adherence ~0.52. AE: no.
P02836,3,neutral,Visit 3: Patient on RX-17A at S013. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: no.
P02836,4,neutral,Visit 4: Patient on RX-17A at S013. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no.
P02836,5,neutral,Visit 5: Patient on RX-17A at S013. no major change. Notes: abdominal discomfort. Adherence ~0.54. AE: no.
P02836,6,neutral,Visit 6: Patient on RX-17A at S013. stable symptoms. Notes: joint pain. Adherence ~0.33. AE: no. CRP 4.8 mg/L; ALT 31 U/L.
P02836,7,neutral,Visit 7: Patient on RX-17A at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.50. AE: no.
P02837,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: headache. Adherence ~0.69. AE: no. CRP 15.5 mg/L; ALT 29 U/L.
P02837,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P02837,2,positive,Visit 2: Patient on RX-17B at S012. tolerating medication well. Notes: joint pain. Adherence ~1.00. AE: no.
P02837,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 9.9 mg/L; ALT 31 U/L.
P02837,4,neutral,Visit 4: Patient on RX-17B at S012. follow-up as scheduled. Notes: headache. Adherence ~0.81. AE: no.
P02837,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: yes.
P02837,6,positive,Visit 6: Patient on RX-17B at S012. symptoms improving. Notes: abdominal discomfort. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02838,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: nausea. Adherence ~0.84. AE: yes. CRP 6.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02838,1,negative,Visit 1: Patient on RX-17B at S017. symptoms persist. Notes: headache. Adherence ~0.68. AE: no. CRP 4.6 mg/L; ALT 30 U/L.
P02838,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.78. AE: no.
P02838,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P02838,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.6 mg/L; ALT 34 U/L.
P02839,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.89. AE: no.
P02839,1,neutral,Visit 1: Patient on RX-17A at S022. stable symptoms. Notes: joint pain. Adherence ~0.93. AE: no. CRP 5.2 mg/L; ALT 34 U/L.
P02839,2,negative,Visit 2: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02839,3,positive,Visit 3: Patient on RX-17A at S022. tolerating medication well. Notes: nausea. Adherence ~1.00. AE: no. CRP 4.2 mg/L; ALT 36 U/L.
P02839,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.96. AE: no.
P02839,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02839,6,positive,Visit 6: Patient on RX-17A at S022. feels better overall. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02839,7,positive,Visit 7: Patient on RX-17A at S022. feels better overall. Notes: dizziness. Adherence ~0.93. AE: no. CRP 3.4 mg/L; ALT 34 U/L.
P02840,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 3.2 mg/L; ALT 33 U/L.
P02840,1,negative,Visit 1: Patient on RX-17B at S019. feels frustrated. Notes: dizziness. Adherence ~1.00. AE: yes. CRP 2.6 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02840,2,negative,Visit 2: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~0.70. AE: no. CRP 2.5 mg/L; ALT 34 U/L.
P02840,3,negative,Visit 3: Patient on RX-17B at S019. symptoms persist. Notes: nausea. Adherence ~1.00. AE: yes. CRP 2.4 mg/L; ALT 36 U/L.
P02840,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.85. AE: no.
P02840,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 1.6 mg/L; ALT 39 U/L.
P02840,6,positive,Visit 6: Patient on RX-17B at S019. energy increasing. Notes: dizziness. Adherence ~1.00. AE: no.
P02841,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~1.00. AE: no. CRP 10.0 mg/L; ALT 22 U/L.
P02841,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02841,2,neutral,Visit 2: Patient on RX-17A at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P02841,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no. CRP 8.3 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02841,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P02841,5,positive,Visit 5: Patient on RX-17A at S005. feels better overall. Notes: nausea. Adherence ~0.92. AE: no. CRP 7.6 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02842,0,negative,Visit 0: Patient on RX-17B at S017. symptoms persist. Notes: fatigue. Adherence ~0.69. AE: no.
P02842,1,negative,Visit 1: Patient on RX-17B at S017. increased discomfort. Notes: nausea. Adherence ~0.80. AE: no.
P02842,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 8.4 mg/L; ALT 29 U/L.
P02843,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no. CRP 13.6 mg/L; ALT 25 U/L.
P02843,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 12.5 mg/L; ALT 23 U/L.
P02843,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02843,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.77. AE: no. CRP 11.4 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02843,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02844,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 16.2 mg/L; ALT 37 U/L.
P02844,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.92. AE: yes. CRP 13.7 mg/L; ALT 47 U/L.
P02844,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P02844,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02844,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.84. AE: no. CRP 8.3 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P02844,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02844,6,positive,Visit 6: Patient on RX-17A at S022. energy increasing. Notes: nausea. Adherence ~0.82. AE: no.
P02844,7,neutral,Visit 7: Patient on RX-17A at S022. no major change. Notes: fatigue. Adherence ~0.71. AE: no. CRP 6.8 mg/L; ALT 46 U/L.
P02845,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.81. AE: no.
P02845,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: fatigue. Adherence ~0.86. AE: no.
P02845,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no. CRP 9.9 mg/L; ALT 14 U/L.
P02845,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: fatigue. Adherence ~0.81. AE: no. CRP 8.0 mg/L; ALT 15 U/L.
P02845,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.53. AE: no.
P02846,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.66. AE: no.
P02846,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.89. AE: no. CRP 11.4 mg/L; ALT 32 U/L.
P02846,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.66. AE: no.
P02846,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.65. AE: no. CRP 9.8 mg/L; ALT 31 U/L.
P02846,4,neutral,Visit 4: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.53. AE: no.
P02846,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: nausea. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P02846,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no. CRP 6.8 mg/L; ALT 36 U/L.
P02846,7,neutral,Visit 7: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.52. AE: yes. CRP 6.5 mg/L; ALT 37 U/L.
P02847,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.44. AE: yes.
P02847,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: insomnia. Adherence ~0.60. AE: no. CRP 10.0 mg/L; ALT 18 U/L.
P02847,2,negative,Visit 2: Patient on RX-17B at S005. symptoms persist. Notes: dizziness. Adherence ~0.36. AE: no. CRP 7.0 mg/L; ALT 18 U/L.
P02847,3,negative,Visit 3: Patient on RX-17B at S005. increased discomfort. Notes: nausea. Adherence ~0.27. AE: yes. Plan: consider dose adjustment; counsel patient.
P02847,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.50. AE: no.
P02847,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: abdominal discomfort. Adherence ~0.42. AE: no. Plan: consider dose adjustment; counsel patient.
P02847,6,neutral,Visit 6: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.54. AE: no.
P02847,7,neutral,Visit 7: Patient on RX-17B at S005. stable symptoms. Notes: insomnia. Adherence ~0.38. AE: no.
P02848,0,neutral,Visit 0: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.94. AE: no.
P02848,1,neutral,Visit 1: Patient on RX-17A at S001. continues regimen. Notes: insomnia. Adherence ~0.88. AE: no.
P02848,2,neutral,Visit 2: Patient on RX-17A at S001. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02848,3,neutral,Visit 3: Patient on RX-17A at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02848,4,neutral,Visit 4: Patient on RX-17A at S001. stable symptoms. Notes: fatigue. Adherence ~0.94. AE: no.
P02848,5,neutral,Visit 5: Patient on RX-17A at S001. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02848,6,neutral,Visit 6: Patient on RX-17A at S001. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no.
P02849,0,neutral,Visit 0: Patient on RX-17A at S008. continues regimen. Notes: headache. Adherence ~0.75. AE: no. CRP 2.7 mg/L; ALT 26 U/L.
P02849,1,neutral,Visit 1: Patient on RX-17A at S008. continues regimen. Notes: nausea. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02849,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no.
P02849,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: brain fog. Adherence ~0.61. AE: no.
P02849,4,neutral,Visit 4: Patient on RX-17A at S008. no major change. Notes: fatigue. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02849,5,neutral,Visit 5: Patient on RX-17A at S008. no major change. Notes: nausea. Adherence ~0.71. AE: no. CRP 1.7 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02850,0,negative,Visit 0: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: yes.
P02850,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.78. AE: no.
P02850,2,positive,Visit 2: Patient on RX-17A at S022. reports improvement. Notes: joint pain. Adherence ~0.77. AE: no.
P02850,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: joint pain. Adherence ~0.63. AE: no.
P02850,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02850,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: yes. CRP 3.1 mg/L; ALT 17 U/L.
P02850,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.81. AE: no.
P02850,7,positive,Visit 7: Patient on RX-17A at S022. symptoms improving. Notes: nausea. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02851,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.76. AE: yes. CRP 3.8 mg/L; ALT 46 U/L.
P02851,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02851,2,negative,Visit 2: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.85. AE: no. CRP 3.4 mg/L; ALT 43 U/L.
P02851,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: headache. Adherence ~0.73. AE: no.
P02851,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.66. AE: no. CRP 2.7 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02851,5,positive,Visit 5: Patient on RX-17A at S017. tolerating medication well. Notes: fatigue. Adherence ~0.96. AE: no.
P02852,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P02852,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.80. AE: no. CRP 15.6 mg/L; ALT 13 U/L.
P02852,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~1.00. AE: no.
P02852,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.86. AE: yes.
P02852,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: no.
P02852,5,positive,Visit 5: Patient on RX-17A at S022. energy increasing. Notes: abdominal discomfort. Adherence ~0.81. AE: no.
P02852,6,positive,Visit 6: Patient on RX-17A at S022. symptoms improving. Notes: dizziness. Adherence ~0.89. AE: no. CRP 8.7 mg/L; ALT 12 U/L.
P02853,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: joint pain. Adherence ~0.44. AE: no. Plan: consider dose adjustment; counsel patient.
P02853,1,neutral,Visit 1: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.29. AE: no.
P02853,2,negative,Visit 2: Patient on RX-17B at S004. poor tolerance. Notes: fatigue. Adherence ~0.21. AE: no. CRP 4.2 mg/L; ALT 30 U/L.
P02853,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.33. AE: no.
P02853,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.47. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P02853,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.38. AE: no.
P02853,6,neutral,Visit 6: Patient on RX-17B at S004. continues regimen. Notes: fatigue. Adherence ~0.57. AE: no. CRP 2.5 mg/L; ALT 33 U/L.
P02854,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.57. AE: no. CRP 5.3 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02854,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.80. AE: yes.
P02854,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02854,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P02854,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.77. AE: no.
P02854,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.67. AE: no. CRP 3.5 mg/L; ALT 38 U/L.
P02855,0,negative,Visit 0: Patient on RX-17B at S009. reports worsening. Notes: headache. Adherence ~0.89. AE: no.
P02855,1,negative,Visit 1: Patient on RX-17B at S009. feels frustrated. Notes: nausea. Adherence ~0.92. AE: yes. CRP 7.8 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P02855,2,negative,Visit 2: Patient on RX-17B at S009. reports worsening. Notes: insomnia. Adherence ~0.82. AE: no.
P02855,3,positive,Visit 3: Patient on RX-17B at S009. reports improvement. Notes: headache. Adherence ~0.84. AE: no. CRP 5.8 mg/L; ALT 50 U/L.
P02855,4,neutral,Visit 4: Patient on RX-17B at S009. stable symptoms. Notes: fatigue. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02855,5,neutral,Visit 5: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02855,6,positive,Visit 6: Patient on RX-17B at S009. feels better overall. Notes: insomnia. Adherence ~0.83. AE: no.
P02856,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.41. AE: no.
P02856,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.24. AE: no. CRP 3.3 mg/L; ALT 16 U/L.
P02856,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.60. AE: no.
P02856,3,negative,Visit 3: Patient on RX-17A at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.43. AE: no.
P02856,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.56. AE: no. CRP 2.8 mg/L; ALT 16 U/L.
P02856,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~0.54. AE: yes.
P02856,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.50. AE: no.
P02856,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.50. AE: no.
P02857,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.74. AE: no.
P02857,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.67. AE: no. CRP 7.8 mg/L; ALT 24 U/L.
P02857,2,neutral,Visit 2: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.63. AE: no.
P02857,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.77. AE: no. CRP 7.4 mg/L; ALT 24 U/L.
P02857,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: dizziness. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02857,5,positive,Visit 5: Patient on RX-17A at S012. reports improvement. Notes: insomnia. Adherence ~0.79. AE: no.
P02857,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.65. AE: no.
P02857,7,neutral,Visit 7: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.59. AE: no.
P02858,0,negative,Visit 0: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.99. AE: no.
P02858,1,negative,Visit 1: Patient on RX-17A at S011. increased discomfort. Notes: joint pain. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02858,2,neutral,Visit 2: Patient on RX-17A at S011. no major change. Notes: joint pain. Adherence ~0.74. AE: no.
P02858,3,negative,Visit 3: Patient on RX-17A at S011. symptoms persist. Notes: insomnia. Adherence ~0.77. AE: no.
P02858,4,neutral,Visit 4: Patient on RX-17A at S011. no major change. Notes: fatigue. Adherence ~0.76. AE: no.
P02858,5,positive,Visit 5: Patient on RX-17A at S011. symptoms improving. Notes: dizziness. Adherence ~0.90. AE: no. CRP 1.4 mg/L; ALT 44 U/L.
P02858,6,negative,Visit 6: Patient on RX-17A at S011. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: no. CRP 1.5 mg/L; ALT 48 U/L.
P02859,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 3.9 mg/L; ALT 48 U/L.
P02859,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 46 U/L.
P02859,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.96. AE: no.
P02859,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 2.8 mg/L; ALT 43 U/L.
P02859,4,negative,Visit 4: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.97. AE: no. CRP 3.0 mg/L; ALT 49 U/L.
P02860,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~0.88. AE: no. CRP 8.2 mg/L; ALT 47 U/L.
P02860,1,negative,Visit 1: Patient on RX-17A at S005. reports worsening. Notes: joint pain. Adherence ~1.00. AE: no.
P02860,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.96. AE: yes. CRP 7.2 mg/L; ALT 52 U/L.
P02860,3,neutral,Visit 3: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.92. AE: no.
P02860,4,neutral,Visit 4: Patient on RX-17A at S005. no major change. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02860,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.91. AE: no.
P02860,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.89. AE: no.
P02860,7,neutral,Visit 7: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.74. AE: yes. CRP 4.2 mg/L; ALT 57 U/L.
P02861,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P02861,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~0.79. AE: no.
P02861,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.55. AE: no.
P02861,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: headache. Adherence ~0.71. AE: no. CRP 3.0 mg/L; ALT 72 U/L.
P02861,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.67. AE: no.
P02861,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no.
P02861,6,neutral,Visit 6: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.61. AE: yes.
P02862,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P02862,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: fatigue. Adherence ~0.95. AE: no. CRP 14.8 mg/L; ALT 26 U/L.
P02862,2,negative,Visit 2: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.88. AE: no. CRP 11.7 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02862,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: yes. CRP 9.8 mg/L; ALT 29 U/L.
P02862,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 9.3 mg/L; ALT 25 U/L.
P02862,5,positive,Visit 5: Patient on RX-17B at S015. feels better overall. Notes: headache. Adherence ~0.88. AE: no. CRP 8.8 mg/L; ALT 27 U/L.
P02863,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: headache. Adherence ~0.58. AE: no.
P02863,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.47. AE: no. CRP 8.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02863,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.30. AE: no.
P02863,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.48. AE: no.
P02863,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.41. AE: no.
P02863,5,negative,Visit 5: Patient on RX-17A at S004. symptoms persist. Notes: nausea. Adherence ~0.50. AE: no.
P02863,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.55. AE: no.
P02863,7,neutral,Visit 7: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.50. AE: no. CRP 4.6 mg/L; ALT 35 U/L.
P02864,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: brain fog. Adherence ~0.47. AE: no. CRP 13.1 mg/L; ALT 25 U/L.
P02864,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: nausea. Adherence ~0.32. AE: no.
P02864,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.33. AE: no. CRP 11.1 mg/L; ALT 24 U/L.
P02864,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.48. AE: no. Plan: consider dose adjustment; counsel patient.
P02864,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.51. AE: no. CRP 8.4 mg/L; ALT 28 U/L.
P02865,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.81. AE: no.
P02865,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: insomnia. Adherence ~0.55. AE: no.
P02865,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.64. AE: no.
P02865,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no.
P02865,4,negative,Visit 4: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.59. AE: no.
P02865,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.54. AE: no. CRP 7.0 mg/L; ALT 14 U/L. Plan: consider dose adjustment; counsel patient.
P02865,6,neutral,Visit 6: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.54. AE: no.
P02866,0,negative,Visit 0: Patient on RX-17B at S018. poor tolerance. Notes: brain fog. Adherence ~0.33. AE: no.
P02866,1,negative,Visit 1: Patient on RX-17B at S018. symptoms persist. Notes: headache. Adherence ~0.45. AE: no. CRP 7.4 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02866,2,neutral,Visit 2: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.62. AE: no.
P02866,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: insomnia. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02866,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.75. AE: no.
P02866,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: brain fog. Adherence ~0.51. AE: no.
P02867,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: headache. Adherence ~0.79. AE: no. CRP 4.3 mg/L; ALT 16 U/L.
P02867,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.71. AE: no.
P02867,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no. CRP 4.2 mg/L; ALT 14 U/L.
P02867,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: fatigue. Adherence ~0.67. AE: no. CRP 3.4 mg/L; ALT 14 U/L.
P02867,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: brain fog. Adherence ~0.63. AE: no.
P02868,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: yes.
P02868,1,negative,Visit 1: Patient on RX-17A at S016. symptoms persist. Notes: fatigue. Adherence ~0.84. AE: no.
P02868,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.85. AE: no.
P02868,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02868,4,negative,Visit 4: Patient on RX-17A at S016. reports worsening. Notes: headache. Adherence ~0.84. AE: no. CRP 9.9 mg/L; ALT 27 U/L.
P02869,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: headache. Adherence ~0.95. AE: yes.
P02869,1,neutral,Visit 1: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no. CRP 9.2 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02869,2,positive,Visit 2: Patient on RX-17A at S016. energy increasing. Notes: joint pain. Adherence ~0.90. AE: no.
P02869,3,negative,Visit 3: Patient on RX-17A at S016. reports worsening. Notes: headache. Adherence ~0.83. AE: yes.
P02870,0,negative,Visit 0: Patient on RX-17B at S019. increased discomfort. Notes: nausea. Adherence ~0.66. AE: no.
P02870,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: headache. Adherence ~0.71. AE: no. CRP 19.4 mg/L; ALT 35 U/L.
P02870,2,neutral,Visit 2: Patient on RX-17B at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.64. AE: no.
P02870,3,negative,Visit 3: Patient on RX-17B at S019. poor tolerance. Notes: joint pain. Adherence ~0.45. AE: no. CRP 16.2 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02870,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: headache. Adherence ~0.55. AE: no. CRP 12.9 mg/L; ALT 36 U/L.
P02870,5,neutral,Visit 5: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~0.64. AE: no.
P02870,6,neutral,Visit 6: Patient on RX-17B at S019. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 9.9 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P02870,7,neutral,Visit 7: Patient on RX-17B at S019. no major change. Notes: abdominal discomfort. Adherence ~0.37. AE: yes.
P02871,0,neutral,Visit 0: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no.
P02871,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no.
P02871,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: yes.
P02871,3,negative,Visit 3: Patient on RX-17B at S015. poor tolerance. Notes: brain fog. Adherence ~0.95. AE: yes.
P02871,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02872,0,neutral,Visit 0: Patient on RX-17A at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.42. AE: no.
P02872,1,negative,Visit 1: Patient on RX-17A at S011. poor tolerance. Notes: brain fog. Adherence ~0.19. AE: no.
P02872,2,negative,Visit 2: Patient on RX-17A at S011. symptoms persist. Notes: nausea. Adherence ~0.39. AE: no.
P02872,3,neutral,Visit 3: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.39. AE: no. CRP 4.3 mg/L; ALT 17 U/L.
P02872,4,neutral,Visit 4: Patient on RX-17A at S011. stable symptoms. Notes: fatigue. Adherence ~0.21. AE: no.
P02872,5,neutral,Visit 5: Patient on RX-17A at S011. no major change. Notes: abdominal discomfort. Adherence ~0.46. AE: no. CRP 4.0 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02873,0,neutral,Visit 0: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.85. AE: no.
P02873,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.71. AE: no. CRP 7.5 mg/L; ALT 39 U/L.
P02873,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: no.
P02873,3,positive,Visit 3: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~0.90. AE: no.
P02873,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.82. AE: no.
P02873,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.61. AE: no.
P02873,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02874,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.74. AE: no.
P02874,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: insomnia. Adherence ~0.77. AE: no.
P02874,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: yes.
P02874,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.88. AE: no. CRP 7.2 mg/L; ALT 26 U/L.
P02874,4,positive,Visit 4: Patient on RX-17B at S015. reports improvement. Notes: nausea. Adherence ~0.84. AE: no.
P02874,5,neutral,Visit 5: Patient on RX-17B at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.93. AE: no. CRP 6.0 mg/L; ALT 25 U/L.
P02874,6,positive,Visit 6: Patient on RX-17B at S015. feels better overall. Notes: dizziness. Adherence ~0.90. AE: no.
P02874,7,neutral,Visit 7: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P02875,0,negative,Visit 0: Patient on RX-17B at S003. poor tolerance. Notes: fatigue. Adherence ~0.54. AE: no.
P02875,1,negative,Visit 1: Patient on RX-17B at S003. feels frustrated. Notes: headache. Adherence ~0.34. AE: no.
P02875,2,neutral,Visit 2: Patient on RX-17B at S003. reviewed dosing instructions. Notes: insomnia. Adherence ~0.47. AE: no.
P02876,0,neutral,Visit 0: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.75. AE: no.
P02876,1,neutral,Visit 1: Patient on RX-17A at S008. continues regimen. Notes: brain fog. Adherence ~0.79. AE: no. CRP 14.2 mg/L; ALT 21 U/L.
P02876,2,neutral,Visit 2: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02876,3,neutral,Visit 3: Patient on RX-17A at S008. reviewed dosing instructions. Notes: headache. Adherence ~0.96. AE: no.
P02876,4,neutral,Visit 4: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.88. AE: no.
P02877,0,neutral,Visit 0: Patient on RX-17A at S003. follow-up as scheduled. Notes: headache. Adherence ~0.70. AE: no. CRP 6.6 mg/L; ALT 43 U/L. Plan: consider dose adjustment; counsel patient.
P02877,1,negative,Visit 1: Patient on RX-17A at S003. feels frustrated. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P02877,2,neutral,Visit 2: Patient on RX-17A at S003. stable symptoms. Notes: joint pain. Adherence ~0.50. AE: no.
P02877,3,neutral,Visit 3: Patient on RX-17A at S003. no major change. Notes: joint pain. Adherence ~0.80. AE: no. CRP 5.9 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P02877,4,neutral,Visit 4: Patient on RX-17A at S003. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no.
P02878,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: brain fog. Adherence ~0.75. AE: no. CRP 4.2 mg/L; ALT 34 U/L.
P02878,1,negative,Visit 1: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.82. AE: no. CRP 3.7 mg/L; ALT 31 U/L.
P02878,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: headache. Adherence ~0.73. AE: no.
P02878,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: nausea. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02878,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.86. AE: no.
P02879,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no. CRP 2.8 mg/L; ALT 23 U/L.
P02879,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no.
P02879,2,negative,Visit 2: Patient on RX-17A at S005. feels frustrated. Notes: insomnia. Adherence ~0.87. AE: no. CRP 2.1 mg/L; ALT 29 U/L.
P02879,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: brain fog. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02879,4,negative,Visit 4: Patient on RX-17A at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 1.9 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P02879,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: no. CRP 1.7 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P02879,6,positive,Visit 6: Patient on RX-17A at S005. feels better overall. Notes: insomnia. Adherence ~0.94. AE: no.
P02879,7,positive,Visit 7: Patient on RX-17A at S005. reports improvement. Notes: dizziness. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02880,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.90. AE: no. CRP 3.9 mg/L; ALT 16 U/L.
P02880,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.75. AE: no.
P02880,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: headache. Adherence ~1.00. AE: yes. CRP 3.3 mg/L; ALT 16 U/L.
P02880,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02880,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02880,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no.
P02880,6,positive,Visit 6: Patient on RX-17A at S015. energy increasing. Notes: insomnia. Adherence ~0.85. AE: no. CRP 2.5 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02880,7,neutral,Visit 7: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P02881,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.70. AE: no.
P02881,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: headache. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 71 U/L. Plan: consider dose adjustment; counsel patient.
P02881,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P02881,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 3.9 mg/L; ALT 82 U/L.
P02881,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.79. AE: no. CRP 4.2 mg/L; ALT 75 U/L.
P02882,0,negative,Visit 0: Patient on RX-17A at S018. increased discomfort. Notes: headache. Adherence ~0.89. AE: no.
P02882,1,negative,Visit 1: Patient on RX-17A at S018. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no.
P02882,2,negative,Visit 2: Patient on RX-17A at S018. increased discomfort. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02882,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: headache. Adherence ~0.84. AE: no.
P02882,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: fatigue. Adherence ~0.95. AE: yes.
P02883,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.94. AE: no.
P02883,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: headache. Adherence ~0.79. AE: no. CRP 13.1 mg/L; ALT 52 U/L.
P02883,2,neutral,Visit 2: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.94. AE: yes.
P02883,3,negative,Visit 3: Patient on RX-17B at S012. poor tolerance. Notes: nausea. Adherence ~0.87. AE: no.
P02883,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no. CRP 10.5 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P02884,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: headache. Adherence ~0.79. AE: no.
P02884,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 11.5 mg/L; ALT 21 U/L.
P02884,2,negative,Visit 2: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02884,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: brain fog. Adherence ~0.54. AE: yes.
P02885,0,neutral,Visit 0: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P02885,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.59. AE: no.
P02885,2,negative,Visit 2: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 13.0 mg/L; ALT 24 U/L.
P02885,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.71. AE: no.
P02885,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.82. AE: no.
P02886,0,negative,Visit 0: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.76. AE: no.
P02886,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 4.5 mg/L; ALT 33 U/L.
P02886,2,negative,Visit 2: Patient on RX-17B at S014. poor tolerance. Notes: brain fog. Adherence ~0.85. AE: no. CRP 3.9 mg/L; ALT 32 U/L.
P02886,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.56. AE: yes. CRP 3.0 mg/L; ALT 39 U/L.
P02886,4,neutral,Visit 4: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P02886,5,neutral,Visit 5: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no.
P02886,6,positive,Visit 6: Patient on RX-17B at S014. symptoms improving. Notes: fatigue. Adherence ~0.77. AE: no.
P02886,7,positive,Visit 7: Patient on RX-17B at S014. tolerating medication well. Notes: brain fog. Adherence ~0.80. AE: no.
P02887,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: brain fog. Adherence ~0.82. AE: no. CRP 3.2 mg/L; ALT 21 U/L.
P02887,1,positive,Visit 1: Patient on RX-17A at S015. feels better overall. Notes: brain fog. Adherence ~0.78. AE: no. CRP 3.1 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02887,2,neutral,Visit 2: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no.
P02887,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~0.85. AE: yes. CRP 2.6 mg/L; ALT 25 U/L.
P02887,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.77. AE: yes.
P02888,0,negative,Visit 0: Patient on RX-17A at S006. reports worsening. Notes: dizziness. Adherence ~0.44. AE: no. CRP 4.5 mg/L; ALT 22 U/L.
P02888,1,neutral,Visit 1: Patient on RX-17A at S006. stable symptoms. Notes: nausea. Adherence ~0.46. AE: no.
P02888,2,negative,Visit 2: Patient on RX-17A at S006. poor tolerance. Notes: headache. Adherence ~0.55. AE: no.
P02888,3,neutral,Visit 3: Patient on RX-17A at S006. continues regimen. Notes: dizziness. Adherence ~0.40. AE: yes.
P02889,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: headache. Adherence ~0.84. AE: no.
P02889,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: headache. Adherence ~0.78. AE: no.
P02889,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: brain fog. Adherence ~0.87. AE: no. CRP 2.2 mg/L; ALT 56 U/L. Plan: consider dose adjustment; counsel patient.
P02889,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P02889,4,negative,Visit 4: Patient on RX-17A at S022. increased discomfort. Notes: abdominal discomfort. Adherence ~0.63. AE: no.
P02889,5,neutral,Visit 5: Patient on RX-17A at S022. no major change. Notes: insomnia. Adherence ~0.96. AE: no. CRP 1.7 mg/L; ALT 50 U/L.
P02889,6,neutral,Visit 6: Patient on RX-17A at S022. continues regimen. Notes: fatigue. Adherence ~0.83. AE: no.
P02889,7,positive,Visit 7: Patient on RX-17A at S022. energy increasing. Notes: nausea. Adherence ~0.93. AE: no. CRP 1.4 mg/L; ALT 59 U/L.
P02890,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: headache. Adherence ~0.66. AE: no. CRP 3.5 mg/L; ALT 31 U/L.
P02890,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: joint pain. Adherence ~0.86. AE: no. CRP 3.6 mg/L; ALT 30 U/L.
P02890,2,negative,Visit 2: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.63. AE: no.
P02890,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.63. AE: no.
P02890,4,negative,Visit 4: Patient on RX-17A at S004. symptoms persist. Notes: dizziness. Adherence ~0.49. AE: no. CRP 3.2 mg/L; ALT 31 U/L.
P02890,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.58. AE: no.
P02890,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no. CRP 2.7 mg/L; ALT 31 U/L.
P02890,7,neutral,Visit 7: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.65. AE: no.
P02891,0,neutral,Visit 0: Patient on RX-17A at S018. no major change. Notes: abdominal discomfort. Adherence ~0.62. AE: no.
P02891,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: insomnia. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P02891,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.78. AE: no. CRP 4.7 mg/L; ALT 22 U/L.
P02891,3,negative,Visit 3: Patient on RX-17A at S018. increased discomfort. Notes: joint pain. Adherence ~0.83. AE: yes. CRP 4.6 mg/L; ALT 21 U/L.
P02891,4,neutral,Visit 4: Patient on RX-17A at S018. stable symptoms. Notes: abdominal discomfort. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02892,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~1.00. AE: no.
P02892,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02892,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P02892,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~1.00. AE: no. CRP 6.6 mg/L; ALT 44 U/L.
P02892,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.94. AE: no.
P02892,5,neutral,Visit 5: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.94. AE: yes.
P02892,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02892,7,positive,Visit 7: Patient on RX-17A at S015. symptoms improving. Notes: headache. Adherence ~0.92. AE: no.
P02893,0,neutral,Visit 0: Patient on RX-17A at S008. no major change. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P02893,1,negative,Visit 1: Patient on RX-17A at S008. increased discomfort. Notes: insomnia. Adherence ~0.68. AE: no.
P02893,2,neutral,Visit 2: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P02893,3,negative,Visit 3: Patient on RX-17A at S008. symptoms persist. Notes: abdominal discomfort. Adherence ~0.65. AE: no. CRP 6.4 mg/L; ALT 24 U/L.
P02893,4,neutral,Visit 4: Patient on RX-17A at S008. follow-up as scheduled. Notes: headache. Adherence ~0.63. AE: no.
P02893,5,neutral,Visit 5: Patient on RX-17A at S008. continues regimen. Notes: nausea. Adherence ~0.58. AE: no. CRP 5.3 mg/L; ALT 24 U/L.
P02893,6,neutral,Visit 6: Patient on RX-17A at S008. reviewed dosing instructions. Notes: insomnia. Adherence ~0.46. AE: yes.
P02894,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.84. AE: no. CRP 5.4 mg/L; ALT 16 U/L.
P02894,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 4.5 mg/L; ALT 14 U/L.
P02894,2,negative,Visit 2: Patient on RX-17B at S017. symptoms persist. Notes: brain fog. Adherence ~0.91. AE: yes. CRP 4.5 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P02894,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: fatigue. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02894,4,positive,Visit 4: Patient on RX-17B at S017. feels better overall. Notes: insomnia. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 15 U/L.
P02895,0,neutral,Visit 0: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.91. AE: no. CRP 9.6 mg/L; ALT 21 U/L.
P02895,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~0.77. AE: no.
P02895,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.88. AE: no. CRP 9.0 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02895,3,negative,Visit 3: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.88. AE: no.
P02895,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: yes.
P02895,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: headache. Adherence ~0.85. AE: no.
P02895,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.2 mg/L; ALT 20 U/L.
P02896,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.76. AE: no.
P02896,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.66. AE: no.
P02896,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02896,3,negative,Visit 3: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.63. AE: yes. CRP 4.2 mg/L; ALT 28 U/L.
P02897,0,negative,Visit 0: Patient on RX-17B at S015. poor tolerance. Notes: insomnia. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P02897,1,negative,Visit 1: Patient on RX-17B at S015. feels frustrated. Notes: headache. Adherence ~0.50. AE: no. CRP 7.0 mg/L; ALT 35 U/L.
P02897,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.46. AE: no. CRP 6.1 mg/L; ALT 39 U/L.
P02897,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.58. AE: yes.
P02898,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.62. AE: no.
P02898,1,negative,Visit 1: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.55. AE: no.
P02898,2,neutral,Visit 2: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02898,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.84. AE: no.
P02898,4,neutral,Visit 4: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.48. AE: no.
P02898,5,neutral,Visit 5: Patient on RX-17B at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.86. AE: no. CRP 2.6 mg/L; ALT 34 U/L.
P02898,6,neutral,Visit 6: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.75. AE: no.
P02898,7,neutral,Visit 7: Patient on RX-17B at S004. continues regimen. Notes: dizziness. Adherence ~0.74. AE: yes.
P02899,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.85. AE: no. CRP 11.6 mg/L; ALT 49 U/L.
P02899,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.49. AE: no.
P02899,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: fatigue. Adherence ~0.75. AE: no. CRP 10.1 mg/L; ALT 53 U/L.
P02899,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no.
P02899,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: yes. CRP 10.2 mg/L; ALT 48 U/L.
P02899,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.76. AE: no.
P02900,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.71. AE: no. CRP 8.1 mg/L; ALT 27 U/L.
P02900,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.74. AE: no.
P02900,2,neutral,Visit 2: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no. CRP 5.8 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02900,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.59. AE: no.
P02900,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~0.67. AE: no. CRP 5.2 mg/L; ALT 27 U/L.
P02900,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.74. AE: no.
P02900,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no.
P02900,7,neutral,Visit 7: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.52. AE: no. CRP 4.2 mg/L; ALT 31 U/L.
P02901,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: abdominal discomfort. Adherence ~0.57. AE: yes.
P02901,1,neutral,Visit 1: Patient on RX-17A at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.62. AE: no.
P02901,2,negative,Visit 2: Patient on RX-17A at S011. feels frustrated. Notes: dizziness. Adherence ~0.49. AE: yes. CRP 8.5 mg/L; ALT 30 U/L.
P02901,3,negative,Visit 3: Patient on RX-17A at S011. poor tolerance. Notes: headache. Adherence ~0.59. AE: no.
P02901,4,neutral,Visit 4: Patient on RX-17A at S011. no major change. Notes: headache. Adherence ~0.58. AE: no. CRP 7.1 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P02902,0,neutral,Visit 0: Patient on RX-17B at S020. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no. CRP 4.1 mg/L; ALT 46 U/L.
P02902,1,negative,Visit 1: Patient on RX-17B at S020. symptoms persist. Notes: headache. Adherence ~0.57. AE: no. CRP 3.8 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P02902,2,neutral,Visit 2: Patient on RX-17B at S020. no major change. Notes: joint pain. Adherence ~0.51. AE: no.
P02902,3,neutral,Visit 3: Patient on RX-17B at S020. stable symptoms. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 3.0 mg/L; ALT 48 U/L.
P02902,4,negative,Visit 4: Patient on RX-17B at S020. symptoms persist. Notes: nausea. Adherence ~0.44. AE: no.
P02902,5,neutral,Visit 5: Patient on RX-17B at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.60. AE: no. CRP 2.5 mg/L; ALT 51 U/L.
P02903,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.72. AE: yes. Plan: consider dose adjustment; counsel patient.
P02903,1,neutral,Visit 1: Patient on RX-17B at S017. follow-up as scheduled. Notes: headache. Adherence ~0.83. AE: no. CRP 7.5 mg/L; ALT 41 U/L.
P02903,2,neutral,Visit 2: Patient on RX-17B at S017. no major change. Notes: dizziness. Adherence ~0.97. AE: no. CRP 6.9 mg/L; ALT 46 U/L.
P02903,3,positive,Visit 3: Patient on RX-17B at S017. symptoms improving. Notes: dizziness. Adherence ~0.86. AE: no. CRP 5.8 mg/L; ALT 44 U/L.
P02903,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: dizziness. Adherence ~0.81. AE: no.
P02903,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.88. AE: no.
P02903,6,neutral,Visit 6: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no. CRP 4.2 mg/L; ALT 45 U/L.
P02904,0,neutral,Visit 0: Patient on RX-17B at S016. continues regimen. Notes: brain fog. Adherence ~0.89. AE: no. CRP 9.8 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02904,1,negative,Visit 1: Patient on RX-17B at S016. reports worsening. Notes: abdominal discomfort. Adherence ~0.68. AE: no. CRP 10.8 mg/L; ALT 25 U/L.
P02904,2,negative,Visit 2: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.78. AE: no.
P02904,3,neutral,Visit 3: Patient on RX-17B at S016. no major change. Notes: dizziness. Adherence ~0.71. AE: no.
P02904,4,neutral,Visit 4: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.78. AE: no. CRP 7.6 mg/L; ALT 29 U/L.
P02905,0,negative,Visit 0: Patient on RX-17B at S011. poor tolerance. Notes: brain fog. Adherence ~0.52. AE: no.
P02905,1,negative,Visit 1: Patient on RX-17B at S011. symptoms persist. Notes: insomnia. Adherence ~0.52. AE: no.
P02905,2,neutral,Visit 2: Patient on RX-17B at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.34. AE: no. CRP 2.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P02906,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02906,1,neutral,Visit 1: Patient on RX-17A at S016. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no. CRP 14.4 mg/L; ALT 28 U/L.
P02906,2,positive,Visit 2: Patient on RX-17A at S016. tolerating medication well. Notes: insomnia. Adherence ~0.87. AE: no.
P02906,3,negative,Visit 3: Patient on RX-17A at S016. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: yes.
P02906,4,positive,Visit 4: Patient on RX-17A at S016. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no.
P02906,5,positive,Visit 5: Patient on RX-17A at S016. tolerating medication well. Notes: fatigue. Adherence ~0.89. AE: no.
P02906,6,neutral,Visit 6: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.96. AE: no. CRP 7.6 mg/L; ALT 28 U/L.
P02907,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.85. AE: no.
P02907,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: headache. Adherence ~0.71. AE: no. CRP 3.3 mg/L; ALT 18 U/L.
P02907,2,neutral,Visit 2: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.95. AE: no. CRP 3.5 mg/L; ALT 20 U/L.
P02907,3,negative,Visit 3: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.88. AE: no. CRP 2.9 mg/L; ALT 20 U/L.
P02907,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: nausea. Adherence ~0.95. AE: no.
P02907,5,positive,Visit 5: Patient on RX-17A at S022. symptoms improving. Notes: dizziness. Adherence ~0.82. AE: no.
P02907,6,positive,Visit 6: Patient on RX-17A at S022. reports improvement. Notes: insomnia. Adherence ~0.79. AE: no. CRP 2.2 mg/L; ALT 22 U/L.
P02908,0,neutral,Visit 0: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P02908,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02908,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no.
P02908,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.90. AE: no. CRP 6.6 mg/L; ALT 72 U/L.
P02908,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.96. AE: no.
P02908,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02908,6,neutral,Visit 6: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.85. AE: no.
P02908,7,neutral,Visit 7: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.80. AE: no.
P02909,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.95. AE: no.
P02909,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: joint pain. Adherence ~0.91. AE: yes.
P02909,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.74. AE: no.
P02909,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.95. AE: no.
P02909,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02910,0,negative,Visit 0: Patient on RX-17B at S008. feels frustrated. Notes: insomnia. Adherence ~0.70. AE: no.
P02910,1,neutral,Visit 1: Patient on RX-17B at S008. no major change. Notes: dizziness. Adherence ~0.73. AE: no.
P02910,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: insomnia. Adherence ~0.73. AE: no. CRP 10.7 mg/L; ALT 33 U/L.
P02910,3,positive,Visit 3: Patient on RX-17B at S008. feels better overall. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 9.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02910,4,negative,Visit 4: Patient on RX-17B at S008. increased discomfort. Notes: joint pain. Adherence ~0.96. AE: no. CRP 7.9 mg/L; ALT 36 U/L.
P02910,5,neutral,Visit 5: Patient on RX-17B at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.67. AE: no. CRP 6.7 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02911,0,neutral,Visit 0: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02911,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: insomnia. Adherence ~0.87. AE: no. CRP 3.0 mg/L; ALT 17 U/L.
P02911,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 2.9 mg/L; ALT 18 U/L.
P02911,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no.
P02911,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.94. AE: no. CRP 2.4 mg/L; ALT 18 U/L.
P02912,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: insomnia. Adherence ~0.71. AE: yes.
P02912,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.64. AE: no.
P02912,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: headache. Adherence ~0.78. AE: no.
P02912,3,neutral,Visit 3: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no.
P02912,4,neutral,Visit 4: Patient on RX-17B at S017. no major change. Notes: nausea. Adherence ~0.60. AE: no.
P02912,5,neutral,Visit 5: Patient on RX-17B at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: yes.
P02912,6,positive,Visit 6: Patient on RX-17B at S017. reports improvement. Notes: insomnia. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P02913,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: yes. CRP 14.6 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02913,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.73. AE: yes.
P02913,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 11.9 mg/L; ALT 20 U/L.
P02913,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no. CRP 10.8 mg/L; ALT 20 U/L.
P02913,4,positive,Visit 4: Patient on RX-17A at S014. energy increasing. Notes: insomnia. Adherence ~1.00. AE: no.
P02913,5,positive,Visit 5: Patient on RX-17A at S014. feels better overall. Notes: fatigue. Adherence ~0.98. AE: no.
P02913,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.97. AE: no. CRP 7.4 mg/L; ALT 21 U/L.
P02913,7,positive,Visit 7: Patient on RX-17A at S014. feels better overall. Notes: dizziness. Adherence ~0.95. AE: no. CRP 7.8 mg/L; ALT 19 U/L.
P02914,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no. CRP 4.5 mg/L; ALT 53 U/L.
P02914,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no. Plan: consider dose adjustment; counsel patient.
P02914,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.73. AE: no.
P02914,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P02914,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.72. AE: no. CRP 3.2 mg/L; ALT 58 U/L.
P02915,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02915,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: headache. Adherence ~0.66. AE: no.
P02915,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: joint pain. Adherence ~0.84. AE: no. CRP 5.1 mg/L; ALT 64 U/L.
P02915,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: joint pain. Adherence ~0.82. AE: no.
P02915,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no. CRP 4.7 mg/L; ALT 65 U/L.
P02915,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: fatigue. Adherence ~0.87. AE: no.
P02916,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.63. AE: yes. CRP 5.3 mg/L; ALT 38 U/L.
P02916,1,negative,Visit 1: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.70. AE: no.
P02916,2,neutral,Visit 2: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P02916,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.62. AE: no. Plan: consider dose adjustment; counsel patient.
P02916,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02917,0,neutral,Visit 0: Patient on RX-17B at S009. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: yes. CRP 11.4 mg/L; ALT 38 U/L.
P02917,1,neutral,Visit 1: Patient on RX-17B at S009. stable symptoms. Notes: insomnia. Adherence ~0.69. AE: no. CRP 9.5 mg/L; ALT 29 U/L.
P02917,2,neutral,Visit 2: Patient on RX-17B at S009. no major change. Notes: insomnia. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02917,3,neutral,Visit 3: Patient on RX-17B at S009. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no.
P02917,4,neutral,Visit 4: Patient on RX-17B at S009. continues regimen. Notes: nausea. Adherence ~0.81. AE: no.
P02917,5,neutral,Visit 5: Patient on RX-17B at S009. stable symptoms. Notes: dizziness. Adherence ~0.78. AE: no.
P02917,6,neutral,Visit 6: Patient on RX-17B at S009. follow-up as scheduled. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P02917,7,neutral,Visit 7: Patient on RX-17B at S009. continues regimen. Notes: joint pain. Adherence ~0.65. AE: no.
P02918,0,negative,Visit 0: Patient on RX-17A at S019. symptoms persist. Notes: brain fog. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02918,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P02918,2,negative,Visit 2: Patient on RX-17A at S019. increased discomfort. Notes: headache. Adherence ~0.83. AE: no.
P02918,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: brain fog. Adherence ~0.77. AE: yes.
P02918,4,neutral,Visit 4: Patient on RX-17A at S019. continues regimen. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 2.5 mg/L; ALT 28 U/L.
P02918,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02918,6,neutral,Visit 6: Patient on RX-17A at S019. stable symptoms. Notes: headache. Adherence ~0.91. AE: no.
P02919,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.83. AE: no.
P02919,1,neutral,Visit 1: Patient on RX-17B at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.79. AE: no.
P02919,2,negative,Visit 2: Patient on RX-17B at S015. increased discomfort. Notes: joint pain. Adherence ~0.79. AE: no. CRP 9.3 mg/L; ALT 29 U/L.
P02919,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.89. AE: no. CRP 8.2 mg/L; ALT 33 U/L.
P02919,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no.
P02919,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.55. AE: no.
P02919,6,neutral,Visit 6: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P02919,7,neutral,Visit 7: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.73. AE: no. CRP 4.5 mg/L; ALT 33 U/L.
P02920,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.68. AE: yes.
P02920,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.55. AE: no. CRP 4.1 mg/L; ALT 33 U/L.
P02920,2,negative,Visit 2: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.70. AE: no.
P02920,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.47. AE: no.
P02920,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.51. AE: yes. CRP 3.9 mg/L; ALT 39 U/L.
P02920,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 3.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02920,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P02921,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~0.78. AE: no. CRP 6.6 mg/L; ALT 32 U/L.
P02921,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02921,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.77. AE: no.
P02921,3,neutral,Visit 3: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02921,4,negative,Visit 4: Patient on RX-17B at S017. poor tolerance. Notes: brain fog. Adherence ~0.66. AE: no. CRP 5.1 mg/L; ALT 33 U/L.
P02921,5,neutral,Visit 5: Patient on RX-17B at S017. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no. CRP 4.3 mg/L; ALT 33 U/L.
P02921,6,positive,Visit 6: Patient on RX-17B at S017. symptoms improving. Notes: brain fog. Adherence ~0.82. AE: no.
P02921,7,positive,Visit 7: Patient on RX-17B at S017. energy increasing. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P02922,0,neutral,Visit 0: Patient on RX-17B at S003. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: yes.
P02922,1,negative,Visit 1: Patient on RX-17B at S003. symptoms persist. Notes: insomnia. Adherence ~0.90. AE: no.
P02922,2,negative,Visit 2: Patient on RX-17B at S003. reports worsening. Notes: nausea. Adherence ~0.92. AE: yes. CRP 6.0 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P02922,3,neutral,Visit 3: Patient on RX-17B at S003. reviewed dosing instructions. Notes: headache. Adherence ~0.74. AE: no.
P02922,4,neutral,Visit 4: Patient on RX-17B at S003. no major change. Notes: dizziness. Adherence ~0.98. AE: no. CRP 4.2 mg/L; ALT 50 U/L.
P02922,5,positive,Visit 5: Patient on RX-17B at S003. reports improvement. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 3.6 mg/L; ALT 43 U/L.
P02922,6,positive,Visit 6: Patient on RX-17B at S003. energy increasing. Notes: fatigue. Adherence ~0.77. AE: no. CRP 3.5 mg/L; ALT 47 U/L.
P02923,0,neutral,Visit 0: Patient on RX-17A at S008. stable symptoms. Notes: brain fog. Adherence ~0.99. AE: no. CRP 10.9 mg/L; ALT 22 U/L.
P02923,1,neutral,Visit 1: Patient on RX-17A at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P02923,2,neutral,Visit 2: Patient on RX-17A at S008. no major change. Notes: dizziness. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P02923,3,neutral,Visit 3: Patient on RX-17A at S008. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P02923,4,neutral,Visit 4: Patient on RX-17A at S008. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no.
P02924,0,neutral,Visit 0: Patient on RX-17B at S007. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no. CRP 7.4 mg/L; ALT 52 U/L.
P02924,1,neutral,Visit 1: Patient on RX-17B at S007. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: yes. CRP 5.3 mg/L; ALT 55 U/L.
P02924,2,neutral,Visit 2: Patient on RX-17B at S007. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02924,3,neutral,Visit 3: Patient on RX-17B at S007. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: no. CRP 5.7 mg/L; ALT 50 U/L.
P02924,4,neutral,Visit 4: Patient on RX-17B at S007. reviewed dosing instructions. Notes: insomnia. Adherence ~0.95. AE: no. CRP 5.4 mg/L; ALT 54 U/L.
P02924,5,neutral,Visit 5: Patient on RX-17B at S007. follow-up as scheduled. Notes: headache. Adherence ~1.00. AE: no.
P02924,6,positive,Visit 6: Patient on RX-17B at S007. reports improvement. Notes: fatigue. Adherence ~0.96. AE: no.
P02925,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: nausea. Adherence ~0.44. AE: yes. CRP 17.8 mg/L; ALT 26 U/L.
P02925,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.51. AE: no.
P02925,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.51. AE: no. CRP 12.7 mg/L; ALT 28 U/L.
P02925,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.48. AE: no. CRP 11.2 mg/L; ALT 25 U/L.
P02925,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.48. AE: no.
P02925,5,negative,Visit 5: Patient on RX-17B at S022. poor tolerance. Notes: insomnia. Adherence ~0.42. AE: yes.
P02925,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.57. AE: no.
P02926,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.87. AE: no.
P02926,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: fatigue. Adherence ~0.81. AE: no.
P02926,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P02926,3,positive,Visit 3: Patient on RX-17A at S016. symptoms improving. Notes: insomnia. Adherence ~0.88. AE: no.
P02926,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~1.00. AE: yes.
P02926,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.73. AE: no.
P02927,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: no. CRP 5.2 mg/L; ALT 30 U/L.
P02927,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: insomnia. Adherence ~0.94. AE: no.
P02927,2,negative,Visit 2: Patient on RX-17A at S015. poor tolerance. Notes: fatigue. Adherence ~0.85. AE: no. CRP 4.2 mg/L; ALT 32 U/L.
P02927,3,negative,Visit 3: Patient on RX-17A at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P02927,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.97. AE: no.
P02927,5,positive,Visit 5: Patient on RX-17A at S015. symptoms improving. Notes: nausea. Adherence ~0.97. AE: no.
P02927,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no.
P02927,7,positive,Visit 7: Patient on RX-17A at S015. symptoms improving. Notes: brain fog. Adherence ~1.00. AE: no. CRP 2.9 mg/L; ALT 35 U/L.
P02928,0,negative,Visit 0: Patient on RX-17A at S001. symptoms persist. Notes: fatigue. Adherence ~0.68. AE: no. CRP 15.4 mg/L; ALT 32 U/L.
P02928,1,negative,Visit 1: Patient on RX-17A at S001. increased discomfort. Notes: headache. Adherence ~0.94. AE: no. CRP 15.3 mg/L; ALT 32 U/L.
P02928,2,neutral,Visit 2: Patient on RX-17A at S001. no major change. Notes: insomnia. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P02928,3,negative,Visit 3: Patient on RX-17A at S001. feels frustrated. Notes: joint pain. Adherence ~0.44. AE: yes. CRP 11.2 mg/L; ALT 36 U/L.
P02928,4,neutral,Visit 4: Patient on RX-17A at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.79. AE: no. CRP 11.2 mg/L; ALT 36 U/L.
P02929,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: nausea. Adherence ~0.91. AE: no.
P02929,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.93. AE: yes.
P02929,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.1 mg/L; ALT 17 U/L.
P02929,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02929,4,positive,Visit 4: Patient on RX-17B at S005. symptoms improving. Notes: headache. Adherence ~0.87. AE: no.
P02929,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.89. AE: no.
P02930,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02930,1,negative,Visit 1: Patient on RX-17B at S015. symptoms persist. Notes: headache. Adherence ~0.84. AE: yes.
P02930,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 7.3 mg/L; ALT 27 U/L.
P02930,3,neutral,Visit 3: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P02930,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: fatigue. Adherence ~0.87. AE: no.
P02931,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: fatigue. Adherence ~0.83. AE: no. CRP 11.2 mg/L; ALT 16 U/L.
P02931,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: yes. CRP 11.3 mg/L; ALT 16 U/L.
P02931,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no.
P02931,3,neutral,Visit 3: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.70. AE: no. CRP 9.1 mg/L; ALT 15 U/L.
P02931,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.88. AE: no.
P02932,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02932,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: joint pain. Adherence ~0.65. AE: no. CRP 4.0 mg/L; ALT 22 U/L.
P02932,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: brain fog. Adherence ~0.65. AE: no.
P02932,3,neutral,Visit 3: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.52. AE: no.
P02932,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 2.8 mg/L; ALT 24 U/L.
P02932,5,neutral,Visit 5: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no. CRP 2.7 mg/L; ALT 25 U/L.
P02933,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no.
P02933,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: brain fog. Adherence ~0.97. AE: no.
P02933,2,neutral,Visit 2: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.86. AE: no.
P02933,3,neutral,Visit 3: Patient on RX-17B at S017. no major change. Notes: joint pain. Adherence ~0.93. AE: no.
P02933,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~0.89. AE: no.
P02934,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: dizziness. Adherence ~0.47. AE: no.
P02934,1,neutral,Visit 1: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.50. AE: no.
P02934,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.58. AE: no.
P02934,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.70. AE: no. CRP 6.2 mg/L; ALT 35 U/L.
P02934,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P02934,5,neutral,Visit 5: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02934,6,neutral,Visit 6: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.51. AE: no. CRP 4.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P02934,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.51. AE: no. Plan: consider dose adjustment; counsel patient.
P02935,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: fatigue. Adherence ~0.86. AE: no. CRP 4.9 mg/L; ALT 23 U/L.
P02935,1,neutral,Visit 1: Patient on RX-17B at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P02935,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P02935,3,positive,Visit 3: Patient on RX-17B at S017. energy increasing. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P02935,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.95. AE: no.
P02935,5,positive,Visit 5: Patient on RX-17B at S017. symptoms improving. Notes: joint pain. Adherence ~0.90. AE: no.
P02936,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: fatigue. Adherence ~0.81. AE: no.
P02936,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.95. AE: no.
P02936,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.84. AE: yes.
P02936,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.81. AE: no.
P02937,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.95. AE: no.
P02937,1,negative,Visit 1: Patient on RX-17A at S014. feels frustrated. Notes: joint pain. Adherence ~1.00. AE: no.
P02937,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P02937,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.74. AE: no.
P02937,4,neutral,Visit 4: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02937,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 3.5 mg/L; ALT 46 U/L.
P02937,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: no.
P02937,7,neutral,Visit 7: Patient on RX-17A at S014. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 2.7 mg/L; ALT 46 U/L.
P02938,0,neutral,Visit 0: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.76. AE: no.
P02938,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: nausea. Adherence ~0.72. AE: yes.
P02938,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: brain fog. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02938,3,negative,Visit 3: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.61. AE: yes.
P02938,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: insomnia. Adherence ~0.88. AE: no.
P02938,5,positive,Visit 5: Patient on RX-17A at S015. symptoms improving. Notes: insomnia. Adherence ~0.81. AE: no.
P02938,6,neutral,Visit 6: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.71. AE: yes.
P02939,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.81. AE: yes. CRP 8.1 mg/L; ALT 23 U/L.
P02939,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.83. AE: no.
P02939,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.95. AE: no. CRP 7.0 mg/L; ALT 22 U/L.
P02939,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: yes. CRP 5.8 mg/L; ALT 23 U/L.
P02940,0,negative,Visit 0: Patient on RX-17A at S008. feels frustrated. Notes: headache. Adherence ~0.84. AE: no.
P02940,1,neutral,Visit 1: Patient on RX-17A at S008. no major change. Notes: headache. Adherence ~0.81. AE: no. CRP 13.4 mg/L; ALT 38 U/L.
P02940,2,negative,Visit 2: Patient on RX-17A at S008. symptoms persist. Notes: brain fog. Adherence ~0.87. AE: yes.
P02940,3,neutral,Visit 3: Patient on RX-17A at S008. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P02940,4,positive,Visit 4: Patient on RX-17A at S008. symptoms improving. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02940,5,neutral,Visit 5: Patient on RX-17A at S008. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. CRP 9.0 mg/L; ALT 46 U/L.
P02940,6,neutral,Visit 6: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.73. AE: no. CRP 9.5 mg/L; ALT 42 U/L.
P02940,7,positive,Visit 7: Patient on RX-17A at S008. reports improvement. Notes: brain fog. Adherence ~0.92. AE: no.
P02941,0,neutral,Visit 0: Patient on RX-17B at S020. follow-up as scheduled. Notes: brain fog. Adherence ~0.68. AE: no.
P02941,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: brain fog. Adherence ~0.88. AE: no. CRP 3.9 mg/L; ALT 36 U/L.
P02941,2,neutral,Visit 2: Patient on RX-17B at S020. follow-up as scheduled. Notes: joint pain. Adherence ~0.71. AE: yes. CRP 3.6 mg/L; ALT 37 U/L.
P02941,3,neutral,Visit 3: Patient on RX-17B at S020. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no.
P02941,4,neutral,Visit 4: Patient on RX-17B at S020. reviewed dosing instructions. Notes: nausea. Adherence ~0.54. AE: no. CRP 2.5 mg/L; ALT 40 U/L.
P02942,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~0.70. AE: no. CRP 3.7 mg/L; ALT 17 U/L.
P02942,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.56. AE: no. CRP 2.7 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02942,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.67. AE: no. CRP 2.4 mg/L; ALT 16 U/L.
P02942,3,neutral,Visit 3: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P02942,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no. CRP 2.3 mg/L; ALT 16 U/L.
P02942,5,neutral,Visit 5: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no.
P02942,6,neutral,Visit 6: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.64. AE: no. CRP 1.8 mg/L; ALT 17 U/L.
P02942,7,neutral,Visit 7: Patient on RX-17A at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.61. AE: no. CRP 1.9 mg/L; ALT 17 U/L.
P02943,0,negative,Visit 0: Patient on RX-17B at S015. symptoms persist. Notes: nausea. Adherence ~0.83. AE: yes.
P02943,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: fatigue. Adherence ~0.95. AE: no.
P02943,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.78. AE: no. CRP 12.8 mg/L; ALT 22 U/L.
P02943,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.78. AE: no. CRP 12.1 mg/L; ALT 23 U/L.
P02943,4,neutral,Visit 4: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.94. AE: no.
P02943,5,neutral,Visit 5: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.63. AE: no.
P02944,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.51. AE: no. CRP 7.6 mg/L; ALT 11 U/L. Plan: consider dose adjustment; counsel patient.
P02944,1,neutral,Visit 1: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.50. AE: no.
P02944,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P02944,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.69. AE: no.
P02944,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.68. AE: no. CRP 5.7 mg/L; ALT 10 U/L. Plan: consider dose adjustment; counsel patient.
P02944,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no.
P02945,0,neutral,Visit 0: Patient on RX-17B at S015. continues regimen. Notes: fatigue. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P02945,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.68. AE: no.
P02945,2,negative,Visit 2: Patient on RX-17B at S015. feels frustrated. Notes: brain fog. Adherence ~0.89. AE: no. CRP 9.2 mg/L; ALT 33 U/L.
P02945,3,neutral,Visit 3: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.88. AE: yes.
P02945,4,positive,Visit 4: Patient on RX-17B at S015. symptoms improving. Notes: joint pain. Adherence ~0.87. AE: no. CRP 8.6 mg/L; ALT 34 U/L.
P02945,5,neutral,Visit 5: Patient on RX-17B at S015. no major change. Notes: brain fog. Adherence ~0.87. AE: no.
P02945,6,neutral,Visit 6: Patient on RX-17B at S015. no major change. Notes: nausea. Adherence ~0.83. AE: yes. Plan: consider dose adjustment; counsel patient.
P02946,0,negative,Visit 0: Patient on RX-17A at S014. feels frustrated. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02946,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 10.9 mg/L; ALT 22 U/L.
P02946,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.69. AE: no. CRP 9.5 mg/L; ALT 20 U/L.
P02946,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no.
P02946,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 8.6 mg/L; ALT 22 U/L.
P02946,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P02946,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02946,7,neutral,Visit 7: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.80. AE: yes. CRP 5.9 mg/L; ALT 25 U/L.
P02947,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P02947,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: joint pain. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P02947,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.71. AE: no. CRP 11.4 mg/L; ALT 33 U/L.
P02947,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P02947,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P02947,5,neutral,Visit 5: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P02948,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.78. AE: no. CRP 5.9 mg/L; ALT 73 U/L.
P02948,1,negative,Visit 1: Patient on RX-17B at S004. poor tolerance. Notes: dizziness. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P02948,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: no.
P02948,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.90. AE: no.
P02948,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no. CRP 4.1 mg/L; ALT 75 U/L.
P02948,5,positive,Visit 5: Patient on RX-17B at S004. tolerating medication well. Notes: joint pain. Adherence ~0.83. AE: no.
P02949,0,negative,Visit 0: Patient on RX-17B at S006. symptoms persist. Notes: fatigue. Adherence ~0.89. AE: no. CRP 5.0 mg/L; ALT 58 U/L. Plan: consider dose adjustment; counsel patient.
P02949,1,negative,Visit 1: Patient on RX-17B at S006. increased discomfort. Notes: brain fog. Adherence ~0.69. AE: yes. CRP 4.9 mg/L; ALT 55 U/L.
P02949,2,neutral,Visit 2: Patient on RX-17B at S006. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no.
P02949,3,neutral,Visit 3: Patient on RX-17B at S006. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P02949,4,neutral,Visit 4: Patient on RX-17B at S006. continues regimen. Notes: insomnia. Adherence ~0.84. AE: no.
P02949,5,neutral,Visit 5: Patient on RX-17B at S006. reviewed dosing instructions. Notes: insomnia. Adherence ~0.62. AE: yes.
P02949,6,neutral,Visit 6: Patient on RX-17B at S006. follow-up as scheduled. Notes: dizziness. Adherence ~0.83. AE: no.
P02949,7,neutral,Visit 7: Patient on RX-17B at S006. stable symptoms. Notes: fatigue. Adherence ~0.73. AE: no.
P02950,0,neutral,Visit 0: Patient on RX-17B at S010. continues regimen. Notes: brain fog. Adherence ~0.94. AE: no.
P02950,1,negative,Visit 1: Patient on RX-17B at S010. symptoms persist. Notes: abdominal discomfort. Adherence ~0.98. AE: no.
P02950,2,neutral,Visit 2: Patient on RX-17B at S010. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P02950,3,neutral,Visit 3: Patient on RX-17B at S010. no major change. Notes: insomnia. Adherence ~1.00. AE: no.
P02950,4,neutral,Visit 4: Patient on RX-17B at S010. no major change. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 1.8 mg/L; ALT 26 U/L.
P02950,5,positive,Visit 5: Patient on RX-17B at S010. feels better overall. Notes: insomnia. Adherence ~1.00. AE: no.
P02950,6,neutral,Visit 6: Patient on RX-17B at S010. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: yes. CRP 1.2 mg/L; ALT 27 U/L.
P02950,7,neutral,Visit 7: Patient on RX-17B at S010. no major change. Notes: headache. Adherence ~0.91. AE: no.
P02951,0,neutral,Visit 0: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.89. AE: no.
P02951,1,neutral,Visit 1: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P02951,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: joint pain. Adherence ~0.77. AE: no.
P02951,3,negative,Visit 3: Patient on RX-17A at S015. symptoms persist. Notes: brain fog. Adherence ~0.86. AE: no.
P02951,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~0.79. AE: no.
P02951,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.82. AE: no. CRP 2.7 mg/L; ALT 22 U/L.
P02951,6,positive,Visit 6: Patient on RX-17A at S015. symptoms improving. Notes: headache. Adherence ~0.88. AE: no.
P02952,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02952,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: nausea. Adherence ~0.82. AE: yes.
P02952,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.93. AE: no.
P02952,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: joint pain. Adherence ~0.83. AE: no. CRP 6.0 mg/L; ALT 48 U/L.
P02952,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: headache. Adherence ~0.69. AE: no.
P02953,0,neutral,Visit 0: Patient on RX-17B at S008. stable symptoms. Notes: brain fog. Adherence ~0.92. AE: no.
P02953,1,neutral,Visit 1: Patient on RX-17B at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.93. AE: yes. CRP 4.7 mg/L; ALT 25 U/L.
P02953,2,neutral,Visit 2: Patient on RX-17B at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.75. AE: no. CRP 4.0 mg/L; ALT 20 U/L.
P02953,3,positive,Visit 3: Patient on RX-17B at S008. feels better overall. Notes: nausea. Adherence ~0.93. AE: no.
P02953,4,positive,Visit 4: Patient on RX-17B at S008. feels better overall. Notes: headache. Adherence ~0.84. AE: no.
P02953,5,neutral,Visit 5: Patient on RX-17B at S008. continues regimen. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 21 U/L.
P02953,6,positive,Visit 6: Patient on RX-17B at S008. reports improvement. Notes: insomnia. Adherence ~0.98. AE: no. CRP 2.6 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P02954,0,neutral,Visit 0: Patient on RX-17B at S020. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P02954,1,negative,Visit 1: Patient on RX-17B at S020. increased discomfort. Notes: fatigue. Adherence ~0.80. AE: yes.
P02954,2,neutral,Visit 2: Patient on RX-17B at S020. continues regimen. Notes: dizziness. Adherence ~0.74. AE: no. CRP 3.3 mg/L; ALT 42 U/L.
P02954,3,neutral,Visit 3: Patient on RX-17B at S020. continues regimen. Notes: brain fog. Adherence ~0.75. AE: no.
P02954,4,positive,Visit 4: Patient on RX-17B at S020. reports improvement. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02954,5,neutral,Visit 5: Patient on RX-17B at S020. continues regimen. Notes: fatigue. Adherence ~0.70. AE: yes. Plan: consider dose adjustment; counsel patient.
P02954,6,positive,Visit 6: Patient on RX-17B at S020. feels better overall. Notes: fatigue. Adherence ~0.78. AE: no. CRP 1.9 mg/L; ALT 51 U/L.
P02955,0,neutral,Visit 0: Patient on RX-17B at S012. no major change. Notes: fatigue. Adherence ~0.67. AE: no.
P02955,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 6.5 mg/L; ALT 79 U/L.
P02955,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.57. AE: no.
P02955,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no. CRP 5.9 mg/L; ALT 77 U/L.
P02955,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P02955,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: brain fog. Adherence ~0.72. AE: yes. CRP 4.5 mg/L; ALT 104 U/L.
P02955,6,neutral,Visit 6: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P02955,7,neutral,Visit 7: Patient on RX-17B at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.57. AE: no. CRP 3.4 mg/L; ALT 78 U/L.
P02956,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.76. AE: no.
P02956,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.84. AE: no.
P02956,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02956,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no. Plan: consider dose adjustment; counsel patient.
P02956,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no.
P02957,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: insomnia. Adherence ~0.99. AE: no.
P02957,1,negative,Visit 1: Patient on RX-17B at S013. increased discomfort. Notes: brain fog. Adherence ~1.00. AE: no. CRP 6.9 mg/L; ALT 45 U/L.
P02957,2,neutral,Visit 2: Patient on RX-17B at S013. no major change. Notes: brain fog. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02957,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P02957,4,neutral,Visit 4: Patient on RX-17B at S013. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02957,5,neutral,Visit 5: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.65. AE: no. CRP 3.8 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P02957,6,neutral,Visit 6: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.74. AE: yes. CRP 3.6 mg/L; ALT 50 U/L.
P02957,7,positive,Visit 7: Patient on RX-17B at S013. tolerating medication well. Notes: fatigue. Adherence ~0.90. AE: no. CRP 2.7 mg/L; ALT 45 U/L.
P02958,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.51. AE: no.
P02958,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: nausea. Adherence ~0.53. AE: no.
P02958,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no. CRP 2.9 mg/L; ALT 48 U/L.
P02958,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.64. AE: no.
P02958,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.67. AE: no.
P02958,5,neutral,Visit 5: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.51. AE: no.
P02958,6,neutral,Visit 6: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.61. AE: no.
P02958,7,neutral,Visit 7: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.58. AE: no.
P02959,0,neutral,Visit 0: Patient on RX-17A at S017. follow-up as scheduled. Notes: headache. Adherence ~0.44. AE: no.
P02959,1,neutral,Visit 1: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.64. AE: no. Plan: consider dose adjustment; counsel patient.
P02959,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.44. AE: no.
P02959,3,negative,Visit 3: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.48. AE: yes. CRP 10.5 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P02959,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.48. AE: yes.
P02959,5,neutral,Visit 5: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.45. AE: no.
P02959,6,neutral,Visit 6: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.73. AE: no. CRP 8.6 mg/L; ALT 26 U/L.
P02960,0,negative,Visit 0: Patient on RX-17A at S014. reports worsening. Notes: joint pain. Adherence ~0.99. AE: no.
P02960,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: dizziness. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P02960,2,neutral,Visit 2: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.77. AE: no.
P02960,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.92. AE: no. CRP 4.0 mg/L; ALT 30 U/L.
P02960,4,negative,Visit 4: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.93. AE: no.
P02960,5,positive,Visit 5: Patient on RX-17A at S014. reports improvement. Notes: joint pain. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02961,0,negative,Visit 0: Patient on RX-17A at S001. poor tolerance. Notes: dizziness. Adherence ~0.84. AE: yes. CRP 16.3 mg/L; ALT 19 U/L.
P02961,1,negative,Visit 1: Patient on RX-17A at S001. symptoms persist. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02961,2,negative,Visit 2: Patient on RX-17A at S001. symptoms persist. Notes: headache. Adherence ~1.00. AE: no.
P02961,3,neutral,Visit 3: Patient on RX-17A at S001. no major change. Notes: fatigue. Adherence ~0.83. AE: no. CRP 11.3 mg/L; ALT 23 U/L.
P02961,4,neutral,Visit 4: Patient on RX-17A at S001. follow-up as scheduled. Notes: dizziness. Adherence ~0.94. AE: yes. CRP 12.0 mg/L; ALT 25 U/L.
P02961,5,neutral,Visit 5: Patient on RX-17A at S001. no major change. Notes: dizziness. Adherence ~0.94. AE: yes.
P02962,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.82. AE: yes.
P02962,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.78. AE: yes. CRP 6.3 mg/L; ALT 56 U/L.
P02962,2,neutral,Visit 2: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.79. AE: no.
P02962,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.70. AE: yes. CRP 5.0 mg/L; ALT 58 U/L.
P02962,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.73. AE: no.
P02963,0,neutral,Visit 0: Patient on RX-17B at S018. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 8.5 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P02963,1,neutral,Visit 1: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~0.96. AE: no. CRP 7.0 mg/L; ALT 18 U/L.
P02963,2,negative,Visit 2: Patient on RX-17B at S018. symptoms persist. Notes: dizziness. Adherence ~0.86. AE: yes.
P02963,3,neutral,Visit 3: Patient on RX-17B at S018. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 6.2 mg/L; ALT 21 U/L.
P02963,4,positive,Visit 4: Patient on RX-17B at S018. reports improvement. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.7 mg/L; ALT 24 U/L.
P02963,5,positive,Visit 5: Patient on RX-17B at S018. tolerating medication well. Notes: fatigue. Adherence ~0.90. AE: no. CRP 4.7 mg/L; ALT 22 U/L.
P02964,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: joint pain. Adherence ~0.64. AE: no.
P02964,1,negative,Visit 1: Patient on RX-17A at S017. feels frustrated. Notes: brain fog. Adherence ~0.77. AE: no. CRP 13.7 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02964,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: dizziness. Adherence ~0.81. AE: no. CRP 16.1 mg/L; ALT 43 U/L.
P02964,3,negative,Visit 3: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.59. AE: no. Plan: consider dose adjustment; counsel patient.
P02964,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.94. AE: no.
P02965,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: fatigue. Adherence ~1.00. AE: no.
P02965,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: fatigue. Adherence ~1.00. AE: no.
P02965,2,neutral,Visit 2: Patient on RX-17B at S019. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: no. CRP 3.0 mg/L; ALT 46 U/L.
P02966,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.37. AE: no.
P02966,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: dizziness. Adherence ~0.57. AE: no.
P02966,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: abdominal discomfort. Adherence ~0.57. AE: yes.
P02966,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.66. AE: no.
P02966,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.47. AE: no.
P02967,0,negative,Visit 0: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.97. AE: no. CRP 5.8 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02967,1,neutral,Visit 1: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no.
P02967,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 4.9 mg/L; ALT 24 U/L.
P02967,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.98. AE: no. CRP 4.0 mg/L; ALT 22 U/L.
P02967,4,positive,Visit 4: Patient on RX-17B at S012. tolerating medication well. Notes: nausea. Adherence ~0.87. AE: no.
P02968,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 6.0 mg/L; ALT 28 U/L.
P02968,1,negative,Visit 1: Patient on RX-17B at S015. increased discomfort. Notes: fatigue. Adherence ~0.65. AE: yes. CRP 5.9 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P02968,2,neutral,Visit 2: Patient on RX-17B at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.90. AE: yes.
P02968,3,neutral,Visit 3: Patient on RX-17B at S015. reviewed dosing instructions. Notes: insomnia. Adherence ~0.90. AE: no. CRP 5.2 mg/L; ALT 27 U/L.
P02968,4,neutral,Visit 4: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no.
P02968,5,neutral,Visit 5: Patient on RX-17B at S015. continues regimen. Notes: insomnia. Adherence ~0.74. AE: no.
P02969,0,negative,Visit 0: Patient on RX-17A at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P02969,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.88. AE: yes. CRP 27.9 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P02969,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no.
P02969,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P02969,4,neutral,Visit 4: Patient on RX-17A at S015. stable symptoms. Notes: insomnia. Adherence ~0.81. AE: no. CRP 22.6 mg/L; ALT 24 U/L.
P02969,5,neutral,Visit 5: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.78. AE: no. CRP 19.3 mg/L; ALT 21 U/L.
P02970,0,neutral,Visit 0: Patient on RX-17B at S009. no major change. Notes: insomnia. Adherence ~0.60. AE: no. CRP 4.2 mg/L; ALT 30 U/L.
P02970,1,neutral,Visit 1: Patient on RX-17B at S009. continues regimen. Notes: abdominal discomfort. Adherence ~0.35. AE: no. Plan: consider dose adjustment; counsel patient.
P02970,2,neutral,Visit 2: Patient on RX-17B at S009. no major change. Notes: fatigue. Adherence ~0.69. AE: no.
P02970,3,neutral,Visit 3: Patient on RX-17B at S009. no major change. Notes: abdominal discomfort. Adherence ~0.41. AE: no. Plan: consider dose adjustment; counsel patient.
P02970,4,neutral,Visit 4: Patient on RX-17B at S009. no major change. Notes: dizziness. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P02970,5,neutral,Visit 5: Patient on RX-17B at S009. follow-up as scheduled. Notes: brain fog. Adherence ~0.36. AE: no. CRP 2.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02970,6,neutral,Visit 6: Patient on RX-17B at S009. follow-up as scheduled. Notes: dizziness. Adherence ~0.52. AE: no. CRP 2.2 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P02970,7,neutral,Visit 7: Patient on RX-17B at S009. reviewed dosing instructions. Notes: headache. Adherence ~0.48. AE: yes. CRP 2.0 mg/L; ALT 37 U/L.
P02971,0,negative,Visit 0: Patient on RX-17B at S006. reports worsening. Notes: insomnia. Adherence ~0.87. AE: no. CRP 3.2 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P02971,1,negative,Visit 1: Patient on RX-17B at S006. increased discomfort. Notes: brain fog. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P02971,2,negative,Visit 2: Patient on RX-17B at S006. feels frustrated. Notes: dizziness. Adherence ~0.77. AE: yes.
P02971,3,neutral,Visit 3: Patient on RX-17B at S006. no major change. Notes: dizziness. Adherence ~0.89. AE: no.
P02971,4,positive,Visit 4: Patient on RX-17B at S006. reports improvement. Notes: joint pain. Adherence ~0.92. AE: no. CRP 2.5 mg/L; ALT 21 U/L.
P02972,0,neutral,Visit 0: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.71. AE: no.
P02972,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.70. AE: no. CRP 4.2 mg/L; ALT 22 U/L.
P02972,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~0.72. AE: no.
P02973,0,neutral,Visit 0: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P02973,1,neutral,Visit 1: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.97. AE: no.
P02973,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 8.9 mg/L; ALT 38 U/L.
P02973,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P02973,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.78. AE: no.
P02974,0,neutral,Visit 0: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P02974,1,negative,Visit 1: Patient on RX-17B at S017. reports worsening. Notes: joint pain. Adherence ~0.59. AE: no.
P02974,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: insomnia. Adherence ~0.72. AE: no.
P02974,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no.
P02974,4,neutral,Visit 4: Patient on RX-17B at S017. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: no. CRP 6.0 mg/L; ALT 42 U/L.
P02974,5,neutral,Visit 5: Patient on RX-17B at S017. no major change. Notes: headache. Adherence ~0.71. AE: no.
P02975,0,negative,Visit 0: Patient on RX-17A at S017. reports worsening. Notes: abdominal discomfort. Adherence ~0.65. AE: yes.
P02975,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.54. AE: no.
P02975,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: insomnia. Adherence ~0.71. AE: no. CRP 4.7 mg/L; ALT 26 U/L.
P02975,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.61. AE: no.
P02975,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.60. AE: no.
P02975,5,neutral,Visit 5: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.59. AE: no. CRP 3.3 mg/L; ALT 27 U/L.
P02975,6,neutral,Visit 6: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.50. AE: no.
P02976,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.87. AE: no.
P02976,1,negative,Visit 1: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.73. AE: yes.
P02976,2,neutral,Visit 2: Patient on RX-17B at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no. CRP 6.7 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02976,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.67. AE: no.
P02976,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~0.67. AE: yes.
P02976,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.79. AE: yes.
P02977,0,negative,Visit 0: Patient on RX-17B at S005. reports worsening. Notes: headache. Adherence ~0.84. AE: no.
P02977,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02977,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: brain fog. Adherence ~0.59. AE: yes.
P02977,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.75. AE: no.
P02977,4,neutral,Visit 4: Patient on RX-17B at S005. continues regimen. Notes: fatigue. Adherence ~0.70. AE: no.
P02978,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.55. AE: no. Plan: consider dose adjustment; counsel patient.
P02978,1,negative,Visit 1: Patient on RX-17A at S014. increased discomfort. Notes: fatigue. Adherence ~0.70. AE: no. CRP 6.1 mg/L; ALT 25 U/L.
P02978,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: fatigue. Adherence ~0.69. AE: yes.
P02978,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.70. AE: no.
P02978,4,neutral,Visit 4: Patient on RX-17A at S014. continues regimen. Notes: dizziness. Adherence ~0.73. AE: no. CRP 5.7 mg/L; ALT 25 U/L.
P02978,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: yes. CRP 5.2 mg/L; ALT 28 U/L. Plan: consider dose adjustment; counsel patient.
P02979,0,neutral,Visit 0: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P02979,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: headache. Adherence ~0.97. AE: no.
P02979,2,negative,Visit 2: Patient on RX-17A at S014. reports worsening. Notes: insomnia. Adherence ~0.69. AE: no. CRP 7.5 mg/L; ALT 65 U/L. Plan: consider dose adjustment; counsel patient.
P02979,3,neutral,Visit 3: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P02979,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.89. AE: no.
P02979,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.72. AE: yes. Plan: consider dose adjustment; counsel patient.
P02980,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P02980,1,neutral,Visit 1: Patient on RX-17A at S022. continues regimen. Notes: headache. Adherence ~0.95. AE: no. Plan: consider dose adjustment; counsel patient.
P02980,2,negative,Visit 2: Patient on RX-17A at S022. feels frustrated. Notes: dizziness. Adherence ~0.84. AE: yes.
P02981,0,neutral,Visit 0: Patient on RX-17B at S019. continues regimen. Notes: brain fog. Adherence ~0.81. AE: no.
P02981,1,neutral,Visit 1: Patient on RX-17B at S019. continues regimen. Notes: dizziness. Adherence ~0.96. AE: no.
P02981,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: insomnia. Adherence ~0.98. AE: no.
P02981,3,neutral,Visit 3: Patient on RX-17B at S019. stable symptoms. Notes: joint pain. Adherence ~1.00. AE: no. CRP 3.8 mg/L; ALT 34 U/L.
P02981,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: nausea. Adherence ~0.89. AE: no. CRP 3.6 mg/L; ALT 34 U/L.
P02981,5,neutral,Visit 5: Patient on RX-17B at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.82. AE: no.
P02981,6,neutral,Visit 6: Patient on RX-17B at S019. stable symptoms. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P02981,7,positive,Visit 7: Patient on RX-17B at S019. reports improvement. Notes: joint pain. Adherence ~1.00. AE: no.
P02982,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.45. AE: no.
P02982,1,neutral,Visit 1: Patient on RX-17B at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.40. AE: no.
P02982,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.50. AE: no.
P02982,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: joint pain. Adherence ~0.35. AE: no. CRP 3.9 mg/L; ALT 27 U/L.
P02982,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.53. AE: no.
P02982,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: headache. Adherence ~0.45. AE: yes.
P02982,6,neutral,Visit 6: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.27. AE: yes. CRP 2.6 mg/L; ALT 31 U/L.
P02983,0,neutral,Visit 0: Patient on RX-17A at S019. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: no.
P02983,1,negative,Visit 1: Patient on RX-17A at S019. symptoms persist. Notes: dizziness. Adherence ~0.79. AE: no. CRP 4.8 mg/L; ALT 32 U/L.
P02983,2,neutral,Visit 2: Patient on RX-17A at S019. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P02983,3,neutral,Visit 3: Patient on RX-17A at S019. no major change. Notes: dizziness. Adherence ~0.70. AE: no. CRP 3.9 mg/L; ALT 30 U/L.
P02983,4,negative,Visit 4: Patient on RX-17A at S019. reports worsening. Notes: abdominal discomfort. Adherence ~0.93. AE: no.
P02984,0,neutral,Visit 0: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P02984,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.83. AE: no. CRP 5.0 mg/L; ALT 110 U/L.
P02984,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.95. AE: no.
P02984,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 107 U/L.
P02984,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.92. AE: yes. CRP 3.7 mg/L; ALT 116 U/L.
P02985,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P02985,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~0.89. AE: yes.
P02985,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no.
P02985,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: joint pain. Adherence ~0.89. AE: no.
P02985,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P02985,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: headache. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P02985,6,neutral,Visit 6: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.90. AE: no.
P02985,7,positive,Visit 7: Patient on RX-17B at S014. reports improvement. Notes: dizziness. Adherence ~0.82. AE: no. CRP 1.2 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P02986,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: nausea. Adherence ~0.75. AE: no.
P02986,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.82. AE: no.
P02986,2,negative,Visit 2: Patient on RX-17B at S002. increased discomfort. Notes: dizziness. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P02986,3,neutral,Visit 3: Patient on RX-17B at S002. stable symptoms. Notes: fatigue. Adherence ~0.71. AE: no. CRP 6.7 mg/L; ALT 49 U/L.
P02986,4,neutral,Visit 4: Patient on RX-17B at S002. no major change. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P02986,5,positive,Visit 5: Patient on RX-17B at S002. tolerating medication well. Notes: fatigue. Adherence ~0.80. AE: no.
P02986,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: fatigue. Adherence ~0.77. AE: no.
P02986,7,neutral,Visit 7: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: yes.
P02987,0,negative,Visit 0: Patient on RX-17B at S004. symptoms persist. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02987,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P02987,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: headache. Adherence ~0.83. AE: yes.
P02988,0,neutral,Visit 0: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P02988,1,negative,Visit 1: Patient on RX-17B at S012. poor tolerance. Notes: fatigue. Adherence ~0.64. AE: no. CRP 6.4 mg/L; ALT 46 U/L.
P02988,2,negative,Visit 2: Patient on RX-17B at S012. increased discomfort. Notes: brain fog. Adherence ~0.54. AE: no. CRP 6.2 mg/L; ALT 41 U/L.
P02988,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 4.5 mg/L; ALT 41 U/L. Plan: consider dose adjustment; counsel patient.
P02988,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: dizziness. Adherence ~0.36. AE: no. CRP 4.9 mg/L; ALT 48 U/L.
P02988,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P02989,0,negative,Visit 0: Patient on RX-17A at S009. symptoms persist. Notes: insomnia. Adherence ~0.81. AE: no. CRP 8.4 mg/L; ALT 14 U/L.
P02989,1,negative,Visit 1: Patient on RX-17A at S009. poor tolerance. Notes: nausea. Adherence ~0.91. AE: no.
P02989,2,negative,Visit 2: Patient on RX-17A at S009. increased discomfort. Notes: dizziness. Adherence ~0.94. AE: no. CRP 7.6 mg/L; ALT 16 U/L.
P02989,3,neutral,Visit 3: Patient on RX-17A at S009. reviewed dosing instructions. Notes: brain fog. Adherence ~0.94. AE: no. CRP 6.8 mg/L; ALT 16 U/L.
P02989,4,neutral,Visit 4: Patient on RX-17A at S009. no major change. Notes: insomnia. Adherence ~0.98. AE: no. CRP 5.5 mg/L; ALT 16 U/L. Plan: consider dose adjustment; counsel patient.
P02989,5,neutral,Visit 5: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.78. AE: no.
P02989,6,neutral,Visit 6: Patient on RX-17A at S009. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no. CRP 5.0 mg/L; ALT 17 U/L. Plan: consider dose adjustment; counsel patient.
P02989,7,neutral,Visit 7: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P02990,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.90. AE: no.
P02990,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~1.00. AE: no. CRP 7.8 mg/L; ALT 64 U/L.
P02990,2,negative,Visit 2: Patient on RX-17A at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.98. AE: yes. CRP 7.5 mg/L; ALT 66 U/L.
P02990,3,negative,Visit 3: Patient on RX-17A at S005. feels frustrated. Notes: dizziness. Adherence ~0.92. AE: no. CRP 7.6 mg/L; ALT 60 U/L. Plan: consider dose adjustment; counsel patient.
P02990,4,neutral,Visit 4: Patient on RX-17A at S005. continues regimen. Notes: nausea. Adherence ~0.89. AE: no.
P02991,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 4.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P02991,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.94. AE: no.
P02991,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 33 U/L.
P02991,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P02991,4,positive,Visit 4: Patient on RX-17B at S022. tolerating medication well. Notes: headache. Adherence ~0.87. AE: no.
P02992,0,negative,Visit 0: Patient on RX-17A at S005. poor tolerance. Notes: fatigue. Adherence ~0.59. AE: no. CRP 8.2 mg/L; ALT 29 U/L.
P02992,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: joint pain. Adherence ~0.77. AE: no.
P02992,2,negative,Visit 2: Patient on RX-17A at S005. poor tolerance. Notes: joint pain. Adherence ~0.63. AE: no.
P02993,0,neutral,Visit 0: Patient on RX-17A at S022. continues regimen. Notes: joint pain. Adherence ~0.81. AE: no. CRP 10.3 mg/L; ALT 43 U/L.
P02993,1,negative,Visit 1: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.71. AE: no. CRP 8.4 mg/L; ALT 40 U/L.
P02993,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.85. AE: yes. CRP 9.3 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P02993,3,positive,Visit 3: Patient on RX-17A at S022. feels better overall. Notes: headache. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P02993,4,negative,Visit 4: Patient on RX-17A at S022. symptoms persist. Notes: nausea. Adherence ~0.87. AE: no. CRP 7.6 mg/L; ALT 41 U/L.
P02993,5,neutral,Visit 5: Patient on RX-17A at S022. follow-up as scheduled. Notes: fatigue. Adherence ~0.85. AE: no. CRP 6.7 mg/L; ALT 40 U/L.
P02994,0,neutral,Visit 0: Patient on RX-17A at S017. no major change. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 2.8 mg/L; ALT 34 U/L.
P02994,1,negative,Visit 1: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.67. AE: no.
P02994,2,neutral,Visit 2: Patient on RX-17A at S017. no major change. Notes: dizziness. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P02994,3,neutral,Visit 3: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.75. AE: no.
P02994,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.75. AE: no.
P02994,5,neutral,Visit 5: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no. CRP 2.4 mg/L; ALT 31 U/L.
P02995,0,neutral,Visit 0: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.78. AE: no. CRP 17.2 mg/L; ALT 19 U/L.
P02995,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P02995,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.71. AE: no.
P02995,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 11.5 mg/L; ALT 20 U/L.
P02995,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~0.82. AE: no. CRP 11.4 mg/L; ALT 18 U/L.
P02996,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P02996,1,negative,Visit 1: Patient on RX-17A at S016. increased discomfort. Notes: joint pain. Adherence ~0.96. AE: no.
P02996,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: joint pain. Adherence ~0.86. AE: no.
P02996,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: headache. Adherence ~0.88. AE: no.
P02996,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no.
P02996,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: joint pain. Adherence ~0.82. AE: no.
P02996,6,neutral,Visit 6: Patient on RX-17A at S016. follow-up as scheduled. Notes: insomnia. Adherence ~0.92. AE: no. CRP 2.7 mg/L; ALT 14 U/L.
P02997,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.92. AE: no.
P02997,1,negative,Visit 1: Patient on RX-17B at S012. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: no. CRP 3.9 mg/L; ALT 58 U/L.
P02997,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 2.8 mg/L; ALT 54 U/L.
P02997,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.88. AE: no. CRP 2.9 mg/L; ALT 58 U/L.
P02997,4,positive,Visit 4: Patient on RX-17B at S012. symptoms improving. Notes: fatigue. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P02997,5,positive,Visit 5: Patient on RX-17B at S012. reports improvement. Notes: abdominal discomfort. Adherence ~0.80. AE: no.
P02998,0,negative,Visit 0: Patient on RX-17A at S015. feels frustrated. Notes: headache. Adherence ~0.59. AE: no.
P02998,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: nausea. Adherence ~0.66. AE: no.
P02998,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: brain fog. Adherence ~0.86. AE: no.
P02998,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. CRP 7.3 mg/L; ALT 28 U/L.
P02998,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.75. AE: no.
P02999,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P02999,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: dizziness. Adherence ~0.99. AE: yes. CRP 9.7 mg/L; ALT 24 U/L.
P02999,2,neutral,Visit 2: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P02999,3,neutral,Visit 3: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.94. AE: no.
P02999,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~1.00. AE: yes.
P03000,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.80. AE: no.
P03000,1,negative,Visit 1: Patient on RX-17B at S022. reports worsening. Notes: headache. Adherence ~1.00. AE: no. CRP 9.6 mg/L; ALT 25 U/L.
P03000,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no. CRP 9.3 mg/L; ALT 23 U/L.
P03000,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.80. AE: no.
P03000,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no. CRP 7.5 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P03000,5,neutral,Visit 5: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.88. AE: no.
P03001,0,negative,Visit 0: Patient on RX-17B at S012. symptoms persist. Notes: nausea. Adherence ~0.70. AE: no. CRP 9.5 mg/L; ALT 49 U/L.
P03001,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: dizziness. Adherence ~0.94. AE: no.
P03001,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.85. AE: no. CRP 8.7 mg/L; ALT 49 U/L. Plan: consider dose adjustment; counsel patient.
P03001,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.71. AE: yes.
P03001,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: insomnia. Adherence ~0.60. AE: no.
P03001,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.69. AE: no.
P03001,6,neutral,Visit 6: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no.
P03001,7,positive,Visit 7: Patient on RX-17B at S012. tolerating medication well. Notes: fatigue. Adherence ~0.94. AE: no. CRP 4.0 mg/L; ALT 54 U/L.
P03002,0,neutral,Visit 0: Patient on RX-17A at S008. no major change. Notes: insomnia. Adherence ~0.76. AE: no.
P03002,1,neutral,Visit 1: Patient on RX-17A at S008. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P03002,2,neutral,Visit 2: Patient on RX-17A at S008. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 4.9 mg/L; ALT 26 U/L.
P03003,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: insomnia. Adherence ~0.80. AE: no.
P03003,1,neutral,Visit 1: Patient on RX-17B at S016. stable symptoms. Notes: brain fog. Adherence ~0.67. AE: no. CRP 7.1 mg/L; ALT 44 U/L.
P03003,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P03003,3,negative,Visit 3: Patient on RX-17B at S016. poor tolerance. Notes: headache. Adherence ~0.60. AE: no. CRP 5.4 mg/L; ALT 40 U/L.
P03003,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: insomnia. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P03003,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: no.
P03004,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: nausea. Adherence ~0.56. AE: no.
P03004,1,negative,Visit 1: Patient on RX-17B at S015. poor tolerance. Notes: headache. Adherence ~0.50. AE: yes.
P03004,2,neutral,Visit 2: Patient on RX-17B at S015. stable symptoms. Notes: brain fog. Adherence ~0.57. AE: no. CRP 5.2 mg/L; ALT 28 U/L.
P03004,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.54. AE: no. Plan: consider dose adjustment; counsel patient.
P03004,4,neutral,Visit 4: Patient on RX-17B at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.50. AE: no. CRP 4.7 mg/L; ALT 27 U/L.
P03005,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.65. AE: no. CRP 9.1 mg/L; ALT 18 U/L.
P03005,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: dizziness. Adherence ~0.64. AE: yes.
P03005,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: insomnia. Adherence ~0.49. AE: no. CRP 7.5 mg/L; ALT 21 U/L.
P03006,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: fatigue. Adherence ~0.57. AE: no. CRP 6.9 mg/L; ALT 41 U/L.
P03006,1,negative,Visit 1: Patient on RX-17A at S015. reports worsening. Notes: brain fog. Adherence ~0.70. AE: yes.
P03006,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.71. AE: yes. CRP 5.3 mg/L; ALT 42 U/L.
P03006,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P03006,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.60. AE: no. CRP 5.2 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P03006,5,positive,Visit 5: Patient on RX-17A at S015. symptoms improving. Notes: abdominal discomfort. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03006,6,neutral,Visit 6: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.99. AE: no.
P03006,7,neutral,Visit 7: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.64. AE: no.
P03007,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: insomnia. Adherence ~0.66. AE: yes. CRP 5.3 mg/L; ALT 48 U/L.
P03007,1,negative,Visit 1: Patient on RX-17B at S005. reports worsening. Notes: brain fog. Adherence ~0.92. AE: yes.
P03007,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no. CRP 5.4 mg/L; ALT 45 U/L. Plan: consider dose adjustment; counsel patient.
P03007,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.94. AE: no. CRP 3.6 mg/L; ALT 44 U/L.
P03007,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.93. AE: no.
P03007,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.80. AE: yes.
P03007,6,neutral,Visit 6: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no. CRP 2.7 mg/L; ALT 48 U/L.
P03008,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~0.92. AE: yes.
P03008,1,neutral,Visit 1: Patient on RX-17B at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: no.
P03008,2,negative,Visit 2: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~0.86. AE: no. CRP 5.1 mg/L; ALT 26 U/L.
P03008,3,negative,Visit 3: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~0.97. AE: no. CRP 4.2 mg/L; ALT 24 U/L.
P03008,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P03008,5,positive,Visit 5: Patient on RX-17B at S016. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 3.3 mg/L; ALT 24 U/L.
P03008,6,positive,Visit 6: Patient on RX-17B at S016. energy increasing. Notes: abdominal discomfort. Adherence ~0.96. AE: no. CRP 3.2 mg/L; ALT 24 U/L.
P03008,7,neutral,Visit 7: Patient on RX-17B at S016. no major change. Notes: fatigue. Adherence ~0.70. AE: no. CRP 3.2 mg/L; ALT 25 U/L.
P03009,0,negative,Visit 0: Patient on RX-17A at S010. poor tolerance. Notes: joint pain. Adherence ~0.75. AE: no. CRP 2.6 mg/L; ALT 32 U/L.
P03009,1,neutral,Visit 1: Patient on RX-17A at S010. no major change. Notes: headache. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03009,2,negative,Visit 2: Patient on RX-17A at S010. reports worsening. Notes: dizziness. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P03009,3,neutral,Visit 3: Patient on RX-17A at S010. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no.
P03009,4,neutral,Visit 4: Patient on RX-17A at S010. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no.
P03010,0,neutral,Visit 0: Patient on RX-17B at S010. follow-up as scheduled. Notes: brain fog. Adherence ~0.71. AE: no.
P03010,1,negative,Visit 1: Patient on RX-17B at S010. reports worsening. Notes: brain fog. Adherence ~0.70. AE: no.
P03010,2,neutral,Visit 2: Patient on RX-17B at S010. continues regimen. Notes: nausea. Adherence ~0.87. AE: no. CRP 10.7 mg/L; ALT 28 U/L.
P03010,3,negative,Visit 3: Patient on RX-17B at S010. increased discomfort. Notes: joint pain. Adherence ~0.79. AE: yes.
P03010,4,neutral,Visit 4: Patient on RX-17B at S010. continues regimen. Notes: fatigue. Adherence ~0.54. AE: no.
P03010,5,neutral,Visit 5: Patient on RX-17B at S010. continues regimen. Notes: nausea. Adherence ~0.65. AE: yes. CRP 7.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P03011,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~0.94. AE: no.
P03011,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no. CRP 8.2 mg/L; ALT 39 U/L.
P03011,2,neutral,Visit 2: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.93. AE: no. CRP 6.8 mg/L; ALT 37 U/L.
P03011,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: brain fog. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03011,4,neutral,Visit 4: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no. CRP 6.2 mg/L; ALT 34 U/L.
P03011,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: headache. Adherence ~0.86. AE: no.
P03011,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: headache. Adherence ~0.89. AE: no. CRP 6.2 mg/L; ALT 37 U/L.
P03012,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.72. AE: no.
P03012,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P03012,2,negative,Visit 2: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 1.9 mg/L; ALT 58 U/L.
P03012,3,negative,Visit 3: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.60. AE: yes.
P03012,4,negative,Visit 4: Patient on RX-17A at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~0.53. AE: no. CRP 1.6 mg/L; ALT 56 U/L.
P03012,5,neutral,Visit 5: Patient on RX-17A at S012. stable symptoms. Notes: nausea. Adherence ~0.79. AE: no. CRP 1.4 mg/L; ALT 63 U/L.
P03013,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.46. AE: no.
P03013,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: joint pain. Adherence ~0.79. AE: no.
P03013,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~0.69. AE: no.
P03013,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P03013,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.55. AE: no. CRP 8.2 mg/L; ALT 26 U/L.
P03014,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: headache. Adherence ~0.69. AE: no.
P03014,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: dizziness. Adherence ~0.67. AE: yes.
P03014,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.44. AE: no.
P03014,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 5.7 mg/L; ALT 24 U/L.
P03014,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: dizziness. Adherence ~0.59. AE: no.
P03014,5,neutral,Visit 5: Patient on RX-17A at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.65. AE: no.
P03014,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.55. AE: no.
P03015,0,negative,Visit 0: Patient on RX-17A at S005. reports worsening. Notes: insomnia. Adherence ~0.92. AE: yes. CRP 4.0 mg/L; ALT 29 U/L.
P03015,1,negative,Visit 1: Patient on RX-17A at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.66. AE: no. CRP 4.1 mg/L; ALT 28 U/L.
P03015,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: dizziness. Adherence ~0.74. AE: no.
P03015,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: joint pain. Adherence ~0.80. AE: no.
P03015,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: brain fog. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P03015,5,positive,Visit 5: Patient on RX-17A at S005. feels better overall. Notes: dizziness. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 30 U/L.
P03015,6,neutral,Visit 6: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P03016,0,negative,Visit 0: Patient on RX-17B at S005. symptoms persist. Notes: abdominal discomfort. Adherence ~0.64. AE: no. CRP 4.3 mg/L; ALT 23 U/L.
P03016,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: brain fog. Adherence ~0.68. AE: no.
P03016,2,neutral,Visit 2: Patient on RX-17B at S005. follow-up as scheduled. Notes: fatigue. Adherence ~0.52. AE: no.
P03016,3,neutral,Visit 3: Patient on RX-17B at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P03016,4,neutral,Visit 4: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.70. AE: no. CRP 2.5 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P03017,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: brain fog. Adherence ~0.98. AE: yes. CRP 5.0 mg/L; ALT 19 U/L.
P03017,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: dizziness. Adherence ~0.86. AE: no.
P03017,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.86. AE: no.
P03017,3,neutral,Visit 3: Patient on RX-17A at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no.
P03017,4,neutral,Visit 4: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.88. AE: no.
P03017,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.94. AE: no.
P03018,0,neutral,Visit 0: Patient on RX-17A at S004. no major change. Notes: brain fog. Adherence ~0.95. AE: no.
P03018,1,negative,Visit 1: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~0.95. AE: no. CRP 4.5 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P03018,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.62. AE: no.
P03018,3,neutral,Visit 3: Patient on RX-17A at S004. continues regimen. Notes: headache. Adherence ~0.84. AE: no.
P03018,4,negative,Visit 4: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.77. AE: no.
P03018,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no. CRP 3.1 mg/L; ALT 32 U/L.
P03018,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: brain fog. Adherence ~0.89. AE: yes.
P03018,7,neutral,Visit 7: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 2.5 mg/L; ALT 35 U/L.
P03019,0,negative,Visit 0: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.68. AE: no.
P03019,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: abdominal discomfort. Adherence ~0.55. AE: no. CRP 4.3 mg/L; ALT 36 U/L.
P03019,2,neutral,Visit 2: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 3.8 mg/L; ALT 37 U/L.
P03019,3,neutral,Visit 3: Patient on RX-17B at S016. continues regimen. Notes: insomnia. Adherence ~0.86. AE: yes.
P03019,4,neutral,Visit 4: Patient on RX-17B at S016. no major change. Notes: joint pain. Adherence ~0.92. AE: no. CRP 3.4 mg/L; ALT 38 U/L.
P03019,5,neutral,Visit 5: Patient on RX-17B at S016. no major change. Notes: headache. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P03019,6,negative,Visit 6: Patient on RX-17B at S016. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: yes.
P03019,7,neutral,Visit 7: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.56. AE: no.
P03020,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.76. AE: no. CRP 18.2 mg/L; ALT 30 U/L.
P03020,1,negative,Visit 1: Patient on RX-17B at S022. increased discomfort. Notes: joint pain. Adherence ~0.79. AE: yes.
P03020,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.84. AE: no. CRP 15.8 mg/L; ALT 30 U/L.
P03020,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: joint pain. Adherence ~0.69. AE: yes.
P03020,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.85. AE: no.
P03020,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.62. AE: no.
P03021,0,negative,Visit 0: Patient on RX-17B at S013. feels frustrated. Notes: brain fog. Adherence ~0.81. AE: no.
P03021,1,neutral,Visit 1: Patient on RX-17B at S013. reviewed dosing instructions. Notes: fatigue. Adherence ~0.83. AE: no. CRP 8.1 mg/L; ALT 31 U/L.
P03021,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: brain fog. Adherence ~0.81. AE: yes. CRP 7.3 mg/L; ALT 32 U/L.
P03021,3,neutral,Visit 3: Patient on RX-17B at S013. continues regimen. Notes: brain fog. Adherence ~0.80. AE: no.
P03021,4,neutral,Visit 4: Patient on RX-17B at S013. continues regimen. Notes: nausea. Adherence ~0.69. AE: no.
P03021,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: headache. Adherence ~0.75. AE: no. CRP 6.1 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P03021,6,neutral,Visit 6: Patient on RX-17B at S013. stable symptoms. Notes: fatigue. Adherence ~0.67. AE: no. Plan: consider dose adjustment; counsel patient.
P03022,0,negative,Visit 0: Patient on RX-17B at S021. poor tolerance. Notes: joint pain. Adherence ~0.76. AE: no.
P03022,1,neutral,Visit 1: Patient on RX-17B at S021. continues regimen. Notes: headache. Adherence ~0.71. AE: no. CRP 20.1 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P03022,2,neutral,Visit 2: Patient on RX-17B at S021. no major change. Notes: insomnia. Adherence ~0.62. AE: no. CRP 19.4 mg/L; ALT 23 U/L.
P03022,3,neutral,Visit 3: Patient on RX-17B at S021. continues regimen. Notes: joint pain. Adherence ~0.70. AE: no.
P03022,4,neutral,Visit 4: Patient on RX-17B at S021. continues regimen. Notes: fatigue. Adherence ~0.68. AE: no.
P03023,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: headache. Adherence ~0.94. AE: no.
P03023,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: joint pain. Adherence ~0.52. AE: no.
P03023,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: nausea. Adherence ~0.70. AE: yes.
P03024,0,negative,Visit 0: Patient on RX-17B at S002. poor tolerance. Notes: dizziness. Adherence ~0.65. AE: yes.
P03024,1,negative,Visit 1: Patient on RX-17B at S002. increased discomfort. Notes: nausea. Adherence ~0.72. AE: no. CRP 10.5 mg/L; ALT 33 U/L.
P03024,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 9.0 mg/L; ALT 30 U/L.
P03024,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: dizziness. Adherence ~0.84. AE: no.
P03024,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P03024,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: joint pain. Adherence ~0.79. AE: no. CRP 6.0 mg/L; ALT 32 U/L.
P03024,6,neutral,Visit 6: Patient on RX-17B at S002. reviewed dosing instructions. Notes: brain fog. Adherence ~0.62. AE: no.
P03025,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.88. AE: no. CRP 4.8 mg/L; ALT 36 U/L.
P03025,1,positive,Visit 1: Patient on RX-17A at S017. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.91. AE: no.
P03025,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.95. AE: no. CRP 3.5 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P03025,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: brain fog. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03025,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03025,5,negative,Visit 5: Patient on RX-17A at S017. reports worsening. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.7 mg/L; ALT 34 U/L.
P03025,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: headache. Adherence ~0.89. AE: no. CRP 2.7 mg/L; ALT 36 U/L.
P03025,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.79. AE: no.
P03026,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: headache. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P03026,1,neutral,Visit 1: Patient on RX-17B at S017. no major change. Notes: fatigue. Adherence ~0.62. AE: no.
P03026,2,neutral,Visit 2: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~0.91. AE: no.
P03026,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.99. AE: no.
P03026,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.82. AE: no. CRP 4.7 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P03026,5,positive,Visit 5: Patient on RX-17B at S017. feels better overall. Notes: brain fog. Adherence ~0.84. AE: no.
P03026,6,positive,Visit 6: Patient on RX-17B at S017. energy increasing. Notes: brain fog. Adherence ~0.99. AE: no. CRP 3.1 mg/L; ALT 34 U/L.
P03027,0,negative,Visit 0: Patient on RX-17B at S019. reports worsening. Notes: insomnia. Adherence ~0.86. AE: no. CRP 5.5 mg/L; ALT 36 U/L.
P03027,1,negative,Visit 1: Patient on RX-17B at S019. symptoms persist. Notes: nausea. Adherence ~0.84. AE: yes. Plan: consider dose adjustment; counsel patient.
P03027,2,neutral,Visit 2: Patient on RX-17B at S019. no major change. Notes: joint pain. Adherence ~0.86. AE: no.
P03027,3,neutral,Visit 3: Patient on RX-17B at S019. continues regimen. Notes: insomnia. Adherence ~0.66. AE: no. CRP 4.8 mg/L; ALT 40 U/L. Plan: consider dose adjustment; counsel patient.
P03027,4,neutral,Visit 4: Patient on RX-17B at S019. no major change. Notes: fatigue. Adherence ~0.83. AE: no. CRP 4.6 mg/L; ALT 36 U/L.
P03027,5,neutral,Visit 5: Patient on RX-17B at S019. no major change. Notes: brain fog. Adherence ~0.84. AE: no.
P03028,0,negative,Visit 0: Patient on RX-17A at S002. symptoms persist. Notes: nausea. Adherence ~0.98. AE: no. CRP 12.1 mg/L; ALT 47 U/L.
P03028,1,neutral,Visit 1: Patient on RX-17A at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P03028,2,neutral,Visit 2: Patient on RX-17A at S002. no major change. Notes: insomnia. Adherence ~0.56. AE: no.
P03028,3,neutral,Visit 3: Patient on RX-17A at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P03028,4,neutral,Visit 4: Patient on RX-17A at S002. stable symptoms. Notes: insomnia. Adherence ~0.93. AE: no.
P03028,5,neutral,Visit 5: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.71. AE: no.
P03029,0,neutral,Visit 0: Patient on RX-17A at S017. stable symptoms. Notes: dizziness. Adherence ~0.81. AE: no.
P03029,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P03029,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.77. AE: no.
P03029,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: joint pain. Adherence ~0.80. AE: no.
P03029,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no. CRP 5.8 mg/L; ALT 37 U/L.
P03029,5,positive,Visit 5: Patient on RX-17A at S017. reports improvement. Notes: headache. Adherence ~0.85. AE: no.
P03029,6,positive,Visit 6: Patient on RX-17A at S017. tolerating medication well. Notes: insomnia. Adherence ~0.88. AE: no.
P03030,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.84. AE: no.
P03030,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.83. AE: no.
P03030,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.89. AE: no. CRP 8.3 mg/L; ALT 35 U/L.
P03031,0,neutral,Visit 0: Patient on RX-17A at S012. stable symptoms. Notes: dizziness. Adherence ~0.69. AE: no. CRP 9.1 mg/L; ALT 16 U/L.
P03031,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: insomnia. Adherence ~0.54. AE: no. CRP 8.6 mg/L; ALT 16 U/L.
P03031,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.56. AE: no.
P03031,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.60. AE: no.
P03031,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.69. AE: no.
P03032,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: headache. Adherence ~0.47. AE: yes. Plan: consider dose adjustment; counsel patient.
P03032,1,neutral,Visit 1: Patient on RX-17A at S005. stable symptoms. Notes: fatigue. Adherence ~0.66. AE: no. CRP 4.9 mg/L; ALT 46 U/L.
P03032,2,neutral,Visit 2: Patient on RX-17A at S005. no major change. Notes: nausea. Adherence ~0.37. AE: no.
P03032,3,negative,Visit 3: Patient on RX-17A at S005. reports worsening. Notes: nausea. Adherence ~0.43. AE: no. CRP 5.0 mg/L; ALT 46 U/L.
P03032,4,neutral,Visit 4: Patient on RX-17A at S005. stable symptoms. Notes: brain fog. Adherence ~0.64. AE: no.
P03032,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.53. AE: no. CRP 4.3 mg/L; ALT 43 U/L.
P03032,6,neutral,Visit 6: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.61. AE: no. CRP 3.2 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P03032,7,neutral,Visit 7: Patient on RX-17A at S005. reviewed dosing instructions. Notes: fatigue. Adherence ~0.66. AE: no.
P03033,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.60. AE: no.
P03033,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.50. AE: no.
P03033,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.62. AE: no.
P03033,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.72. AE: no. CRP 4.4 mg/L; ALT 31 U/L.
P03033,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no.
P03034,0,negative,Visit 0: Patient on RX-17B at S003. feels frustrated. Notes: nausea. Adherence ~0.86. AE: no.
P03034,1,neutral,Visit 1: Patient on RX-17B at S003. continues regimen. Notes: fatigue. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P03034,2,negative,Visit 2: Patient on RX-17B at S003. reports worsening. Notes: fatigue. Adherence ~0.61. AE: yes.
P03034,3,neutral,Visit 3: Patient on RX-17B at S003. continues regimen. Notes: joint pain. Adherence ~0.57. AE: no.
P03034,4,negative,Visit 4: Patient on RX-17B at S003. feels frustrated. Notes: abdominal discomfort. Adherence ~0.94. AE: no. CRP 3.5 mg/L; ALT 31 U/L.
P03035,0,neutral,Visit 0: Patient on RX-17A at S018. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P03035,1,neutral,Visit 1: Patient on RX-17A at S018. continues regimen. Notes: brain fog. Adherence ~1.00. AE: no.
P03035,2,neutral,Visit 2: Patient on RX-17A at S018. stable symptoms. Notes: insomnia. Adherence ~0.97. AE: no.
P03035,3,neutral,Visit 3: Patient on RX-17A at S018. reviewed dosing instructions. Notes: brain fog. Adherence ~0.93. AE: no. CRP 11.1 mg/L; ALT 20 U/L.
P03035,4,positive,Visit 4: Patient on RX-17A at S018. feels better overall. Notes: headache. Adherence ~0.97. AE: no.
P03035,5,positive,Visit 5: Patient on RX-17A at S018. reports improvement. Notes: dizziness. Adherence ~0.83. AE: no.
P03036,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.67. AE: no. CRP 6.5 mg/L; ALT 64 U/L. Plan: consider dose adjustment; counsel patient.
P03036,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: joint pain. Adherence ~0.86. AE: no.
P03036,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: dizziness. Adherence ~0.66. AE: no.
P03036,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.66. AE: no.
P03036,4,negative,Visit 4: Patient on RX-17A at S015. symptoms persist. Notes: abdominal discomfort. Adherence ~0.81. AE: yes. CRP 4.4 mg/L; ALT 70 U/L.
P03036,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: headache. Adherence ~0.79. AE: no. CRP 4.3 mg/L; ALT 61 U/L. Plan: consider dose adjustment; counsel patient.
P03036,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.69. AE: no.
P03036,7,neutral,Visit 7: Patient on RX-17A at S015. no major change. Notes: dizziness. Adherence ~0.68. AE: no. CRP 3.5 mg/L; ALT 61 U/L.
P03037,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.74. AE: no.
P03037,1,neutral,Visit 1: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.82. AE: no.
P03037,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no.
P03037,3,negative,Visit 3: Patient on RX-17A at S017. poor tolerance. Notes: fatigue. Adherence ~0.78. AE: yes. CRP 7.1 mg/L; ALT 14 U/L.
P03037,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.80. AE: no.
P03037,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: brain fog. Adherence ~0.87. AE: no. CRP 5.8 mg/L; ALT 13 U/L.
P03037,6,positive,Visit 6: Patient on RX-17A at S017. tolerating medication well. Notes: nausea. Adherence ~0.78. AE: no. CRP 5.8 mg/L; ALT 13 U/L.
P03038,0,negative,Visit 0: Patient on RX-17B at S016. reports worsening. Notes: dizziness. Adherence ~1.00. AE: yes.
P03038,1,neutral,Visit 1: Patient on RX-17B at S016. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 5.6 mg/L; ALT 53 U/L.
P03038,2,neutral,Visit 2: Patient on RX-17B at S016. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no. CRP 6.4 mg/L; ALT 53 U/L.
P03038,3,neutral,Visit 3: Patient on RX-17B at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.98. AE: yes. CRP 5.2 mg/L; ALT 57 U/L.
P03038,4,positive,Visit 4: Patient on RX-17B at S016. feels better overall. Notes: joint pain. Adherence ~0.88. AE: no. CRP 5.0 mg/L; ALT 56 U/L.
P03038,5,neutral,Visit 5: Patient on RX-17B at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.86. AE: no. CRP 4.1 mg/L; ALT 58 U/L.
P03038,6,positive,Visit 6: Patient on RX-17B at S016. feels better overall. Notes: nausea. Adherence ~0.91. AE: no. CRP 3.4 mg/L; ALT 49 U/L.
P03039,0,negative,Visit 0: Patient on RX-17A at S019. increased discomfort. Notes: dizziness. Adherence ~0.85. AE: no.
P03039,1,neutral,Visit 1: Patient on RX-17A at S019. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.77. AE: no. CRP 12.7 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P03039,2,neutral,Visit 2: Patient on RX-17A at S019. continues regimen. Notes: dizziness. Adherence ~0.68. AE: no.
P03039,3,neutral,Visit 3: Patient on RX-17A at S019. follow-up as scheduled. Notes: nausea. Adherence ~0.77. AE: no. CRP 10.3 mg/L; ALT 37 U/L.
P03039,4,neutral,Visit 4: Patient on RX-17A at S019. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P03040,0,neutral,Visit 0: Patient on RX-17B at S005. no major change. Notes: headache. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P03040,1,neutral,Visit 1: Patient on RX-17B at S005. reviewed dosing instructions. Notes: dizziness. Adherence ~0.61. AE: no.
P03040,2,neutral,Visit 2: Patient on RX-17B at S005. continues regimen. Notes: nausea. Adherence ~0.63. AE: no.
P03040,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P03040,4,neutral,Visit 4: Patient on RX-17B at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P03040,5,neutral,Visit 5: Patient on RX-17B at S005. follow-up as scheduled. Notes: headache. Adherence ~0.51. AE: no.
P03040,6,neutral,Visit 6: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.67. AE: no.
P03040,7,neutral,Visit 7: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.64. AE: no.
P03041,0,negative,Visit 0: Patient on RX-17A at S001. poor tolerance. Notes: fatigue. Adherence ~0.81. AE: no. CRP 8.8 mg/L; ALT 54 U/L.
P03041,1,negative,Visit 1: Patient on RX-17A at S001. increased discomfort. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 8.2 mg/L; ALT 63 U/L.
P03041,2,negative,Visit 2: Patient on RX-17A at S001. increased discomfort. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P03041,3,neutral,Visit 3: Patient on RX-17A at S001. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P03041,4,neutral,Visit 4: Patient on RX-17A at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.86. AE: no. CRP 6.3 mg/L; ALT 57 U/L.
P03041,5,negative,Visit 5: Patient on RX-17A at S001. symptoms persist. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P03041,6,neutral,Visit 6: Patient on RX-17A at S001. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03041,7,neutral,Visit 7: Patient on RX-17A at S001. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.8 mg/L; ALT 63 U/L.
P03042,0,neutral,Visit 0: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03042,1,neutral,Visit 1: Patient on RX-17B at S015. continues regimen. Notes: joint pain. Adherence ~0.80. AE: no. CRP 3.2 mg/L; ALT 34 U/L.
P03042,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P03042,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.91. AE: no. CRP 2.9 mg/L; ALT 41 U/L.
P03042,4,neutral,Visit 4: Patient on RX-17B at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.99. AE: no.
P03042,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: insomnia. Adherence ~0.91. AE: no. CRP 2.5 mg/L; ALT 38 U/L.
P03043,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: joint pain. Adherence ~0.72. AE: no.
P03043,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: headache. Adherence ~0.81. AE: no.
P03043,2,negative,Visit 2: Patient on RX-17A at S012. feels frustrated. Notes: fatigue. Adherence ~0.81. AE: no.
P03043,3,neutral,Visit 3: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.76. AE: no. CRP 6.4 mg/L; ALT 13 U/L. Plan: consider dose adjustment; counsel patient.
P03043,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.82. AE: no. CRP 8.3 mg/L; ALT 13 U/L.
P03044,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.70. AE: no. CRP 6.8 mg/L; ALT 25 U/L.
P03044,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P03044,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.77. AE: no. CRP 5.8 mg/L; ALT 25 U/L.
P03044,3,negative,Visit 3: Patient on RX-17B at S004. feels frustrated. Notes: insomnia. Adherence ~0.93. AE: no. CRP 5.1 mg/L; ALT 30 U/L.
P03044,4,neutral,Visit 4: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no. CRP 5.0 mg/L; ALT 24 U/L.
P03044,5,neutral,Visit 5: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.82. AE: yes.
P03045,0,negative,Visit 0: Patient on RX-17A at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.92. AE: no.
P03045,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: brain fog. Adherence ~0.68. AE: no.
P03045,2,neutral,Visit 2: Patient on RX-17A at S005. continues regimen. Notes: abdominal discomfort. Adherence ~0.48. AE: no.
P03045,3,neutral,Visit 3: Patient on RX-17A at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.84. AE: no. CRP 2.5 mg/L; ALT 38 U/L. Plan: consider dose adjustment; counsel patient.
P03045,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: headache. Adherence ~0.81. AE: no.
P03045,5,neutral,Visit 5: Patient on RX-17A at S005. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P03045,6,positive,Visit 6: Patient on RX-17A at S005. tolerating medication well. Notes: fatigue. Adherence ~0.84. AE: no.
P03045,7,positive,Visit 7: Patient on RX-17A at S005. tolerating medication well. Notes: insomnia. Adherence ~0.83. AE: no.
P03046,0,neutral,Visit 0: Patient on RX-17B at S012. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P03046,1,neutral,Visit 1: Patient on RX-17B at S012. continues regimen. Notes: nausea. Adherence ~0.64. AE: no. CRP 7.7 mg/L; ALT 55 U/L.
P03046,2,negative,Visit 2: Patient on RX-17B at S012. reports worsening. Notes: nausea. Adherence ~0.86. AE: yes.
P03046,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: brain fog. Adherence ~0.78. AE: no. CRP 7.1 mg/L; ALT 59 U/L.
P03046,4,neutral,Visit 4: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.64. AE: no. CRP 6.5 mg/L; ALT 60 U/L.
P03046,5,positive,Visit 5: Patient on RX-17B at S012. symptoms improving. Notes: dizziness. Adherence ~0.77. AE: no.
P03046,6,neutral,Visit 6: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: yes.
P03047,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P03047,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: fatigue. Adherence ~0.60. AE: no.
P03047,2,negative,Visit 2: Patient on RX-17B at S004. reports worsening. Notes: abdominal discomfort. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P03047,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.63. AE: no. CRP 6.2 mg/L; ALT 27 U/L.
P03047,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.76. AE: no. CRP 5.1 mg/L; ALT 26 U/L.
P03047,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: headache. Adherence ~0.65. AE: yes.
P03047,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.59. AE: yes.
P03048,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: fatigue. Adherence ~0.65. AE: no.
P03048,1,negative,Visit 1: Patient on RX-17B at S002. feels frustrated. Notes: brain fog. Adherence ~0.53. AE: no. CRP 5.7 mg/L; ALT 12 U/L.
P03048,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.57. AE: no.
P03048,3,neutral,Visit 3: Patient on RX-17B at S002. continues regimen. Notes: headache. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P03048,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no. CRP 4.8 mg/L; ALT 13 U/L.
P03048,5,neutral,Visit 5: Patient on RX-17B at S002. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no. CRP 4.1 mg/L; ALT 12 U/L.
P03048,6,neutral,Visit 6: Patient on RX-17B at S002. reviewed dosing instructions. Notes: fatigue. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P03048,7,neutral,Visit 7: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.56. AE: no.
P03049,0,negative,Visit 0: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.79. AE: yes.
P03049,1,negative,Visit 1: Patient on RX-17B at S022. poor tolerance. Notes: dizziness. Adherence ~0.87. AE: no.
P03049,2,negative,Visit 2: Patient on RX-17B at S022. reports worsening. Notes: abdominal discomfort. Adherence ~0.72. AE: yes.
P03049,3,neutral,Visit 3: Patient on RX-17B at S022. continues regimen. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P03049,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.81. AE: no.
P03049,5,neutral,Visit 5: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.85. AE: no. CRP 3.5 mg/L; ALT 54 U/L.
P03049,6,neutral,Visit 6: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.71. AE: no.
P03050,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: brain fog. Adherence ~0.47. AE: no.
P03050,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.45. AE: no. CRP 7.0 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P03050,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: abdominal discomfort. Adherence ~0.39. AE: no. CRP 6.7 mg/L; ALT 38 U/L.
P03050,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.45. AE: no. Plan: consider dose adjustment; counsel patient.
P03050,4,neutral,Visit 4: Patient on RX-17A at S012. reviewed dosing instructions. Notes: joint pain. Adherence ~0.41. AE: no. CRP 5.2 mg/L; ALT 34 U/L.
P03050,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.56. AE: no. CRP 5.1 mg/L; ALT 37 U/L.
P03050,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: joint pain. Adherence ~0.41. AE: no.
P03050,7,neutral,Visit 7: Patient on RX-17A at S012. follow-up as scheduled. Notes: dizziness. Adherence ~0.43. AE: no.
P03051,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: brain fog. Adherence ~0.81. AE: no.
P03051,1,negative,Visit 1: Patient on RX-17A at S022. feels frustrated. Notes: headache. Adherence ~0.86. AE: no.
P03051,2,negative,Visit 2: Patient on RX-17A at S022. reports worsening. Notes: nausea. Adherence ~0.82. AE: no.
P03051,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.77. AE: no.
P03051,4,neutral,Visit 4: Patient on RX-17A at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P03051,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.84. AE: no. CRP 9.2 mg/L; ALT 15 U/L.
P03052,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no.
P03052,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.94. AE: no.
P03052,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: dizziness. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P03052,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~1.00. AE: no.
P03052,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no. CRP 3.8 mg/L; ALT 34 U/L.
P03053,0,negative,Visit 0: Patient on RX-17B at S004. increased discomfort. Notes: brain fog. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P03053,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: headache. Adherence ~0.58. AE: no.
P03053,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.67. AE: no.
P03053,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: joint pain. Adherence ~0.66. AE: no. CRP 8.8 mg/L; ALT 35 U/L.
P03053,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.79. AE: no.
P03053,5,neutral,Visit 5: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 6.9 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P03053,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.74. AE: yes.
P03053,7,neutral,Visit 7: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.67. AE: yes.
P03054,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.67. AE: no. CRP 8.0 mg/L; ALT 28 U/L.
P03054,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.69. AE: no. CRP 5.8 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P03054,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.63. AE: no.
P03054,3,negative,Visit 3: Patient on RX-17A at S016. feels frustrated. Notes: nausea. Adherence ~0.47. AE: yes.
P03054,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: brain fog. Adherence ~0.80. AE: no.
P03054,5,neutral,Visit 5: Patient on RX-17A at S016. continues regimen. Notes: fatigue. Adherence ~0.67. AE: no.
P03054,6,neutral,Visit 6: Patient on RX-17A at S016. reviewed dosing instructions. Notes: headache. Adherence ~0.72. AE: no.
P03055,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.86. AE: no. CRP 14.7 mg/L; ALT 23 U/L.
P03055,1,negative,Visit 1: Patient on RX-17A at S015. feels frustrated. Notes: joint pain. Adherence ~0.93. AE: no.
P03055,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: joint pain. Adherence ~0.93. AE: no. CRP 14.3 mg/L; ALT 20 U/L.
P03055,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.87. AE: no. CRP 10.9 mg/L; ALT 23 U/L.
P03055,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.80. AE: no. CRP 10.8 mg/L; ALT 20 U/L.
P03056,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: headache. Adherence ~0.39. AE: yes.
P03056,1,neutral,Visit 1: Patient on RX-17A at S016. stable symptoms. Notes: dizziness. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P03056,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.55. AE: no. CRP 6.1 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P03056,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: dizziness. Adherence ~0.43. AE: no.
P03056,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: dizziness. Adherence ~0.25. AE: no. Plan: consider dose adjustment; counsel patient.
P03057,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~0.99. AE: no.
P03057,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~1.00. AE: no.
P03057,2,negative,Visit 2: Patient on RX-17A at S004. symptoms persist. Notes: fatigue. Adherence ~1.00. AE: no.
P03057,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~1.00. AE: no.
P03057,4,positive,Visit 4: Patient on RX-17A at S004. tolerating medication well. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.9 mg/L; ALT 28 U/L.
P03057,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: insomnia. Adherence ~0.98. AE: no. CRP 3.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P03057,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 2.8 mg/L; ALT 28 U/L.
P03058,0,neutral,Visit 0: Patient on RX-17A at S005. follow-up as scheduled. Notes: dizziness. Adherence ~1.00. AE: no. CRP 4.3 mg/L; ALT 35 U/L.
P03058,1,negative,Visit 1: Patient on RX-17A at S005. poor tolerance. Notes: dizziness. Adherence ~0.86. AE: no.
P03058,2,negative,Visit 2: Patient on RX-17A at S005. symptoms persist. Notes: fatigue. Adherence ~0.75. AE: no.
P03058,3,neutral,Visit 3: Patient on RX-17A at S005. no major change. Notes: abdominal discomfort. Adherence ~0.70. AE: no.
P03058,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no. CRP 2.7 mg/L; ALT 37 U/L.
P03058,5,neutral,Visit 5: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P03059,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: joint pain. Adherence ~0.81. AE: no. CRP 7.8 mg/L; ALT 39 U/L.
P03059,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~0.64. AE: no. CRP 7.0 mg/L; ALT 42 U/L.
P03059,2,neutral,Visit 2: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no. CRP 6.2 mg/L; ALT 41 U/L.
P03060,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: dizziness. Adherence ~0.99. AE: no.
P03060,1,neutral,Visit 1: Patient on RX-17A at S015. no major change. Notes: fatigue. Adherence ~0.71. AE: no.
P03060,2,negative,Visit 2: Patient on RX-17A at S015. reports worsening. Notes: insomnia. Adherence ~0.85. AE: no.
P03060,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: joint pain. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P03060,4,neutral,Visit 4: Patient on RX-17A at S015. no major change. Notes: insomnia. Adherence ~0.74. AE: no.
P03061,0,negative,Visit 0: Patient on RX-17A at S022. reports worsening. Notes: joint pain. Adherence ~0.69. AE: no.
P03061,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: brain fog. Adherence ~0.53. AE: no. CRP 14.7 mg/L; ALT 34 U/L.
P03061,2,neutral,Visit 2: Patient on RX-17A at S022. continues regimen. Notes: dizziness. Adherence ~0.78. AE: no. CRP 12.3 mg/L; ALT 31 U/L.
P03061,3,neutral,Visit 3: Patient on RX-17A at S022. stable symptoms. Notes: brain fog. Adherence ~0.76. AE: no.
P03061,4,positive,Visit 4: Patient on RX-17A at S022. reports improvement. Notes: dizziness. Adherence ~1.00. AE: no.
P03062,0,neutral,Visit 0: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.66. AE: no.
P03062,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: joint pain. Adherence ~0.95. AE: no. CRP 4.9 mg/L; ALT 37 U/L.
P03062,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.4 mg/L; ALT 35 U/L.
P03062,3,negative,Visit 3: Patient on RX-17A at S016. reports worsening. Notes: nausea. Adherence ~0.92. AE: no.
P03062,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.95. AE: no. CRP 3.4 mg/L; ALT 32 U/L.
P03062,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P03063,0,neutral,Visit 0: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.4 mg/L; ALT 34 U/L.
P03063,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.88. AE: no. CRP 5.2 mg/L; ALT 29 U/L.
P03063,2,negative,Visit 2: Patient on RX-17A at S016. symptoms persist. Notes: headache. Adherence ~0.91. AE: no.
P03063,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.1 mg/L; ALT 30 U/L.
P03063,4,neutral,Visit 4: Patient on RX-17A at S016. stable symptoms. Notes: joint pain. Adherence ~0.64. AE: no. CRP 3.7 mg/L; ALT 34 U/L.
P03064,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: nausea. Adherence ~0.35. AE: no.
P03064,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.74. AE: no. CRP 8.5 mg/L; ALT 26 U/L.
P03064,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.57. AE: no.
P03064,3,neutral,Visit 3: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.36. AE: no.
P03064,4,neutral,Visit 4: Patient on RX-17B at S022. reviewed dosing instructions. Notes: brain fog. Adherence ~0.51. AE: no.
P03065,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: headache. Adherence ~0.87. AE: no.
P03065,1,negative,Visit 1: Patient on RX-17A at S016. increased discomfort. Notes: fatigue. Adherence ~0.80. AE: no.
P03065,2,negative,Visit 2: Patient on RX-17A at S016. poor tolerance. Notes: brain fog. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P03065,3,neutral,Visit 3: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.90. AE: no.
P03065,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.92. AE: yes. CRP 9.7 mg/L; ALT 51 U/L. Plan: consider dose adjustment; counsel patient.
P03065,5,neutral,Visit 5: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03065,6,positive,Visit 6: Patient on RX-17A at S016. reports improvement. Notes: fatigue. Adherence ~0.91. AE: no.
P03065,7,neutral,Visit 7: Patient on RX-17A at S016. stable symptoms. Notes: brain fog. Adherence ~0.75. AE: no. CRP 6.9 mg/L; ALT 46 U/L. Plan: consider dose adjustment; counsel patient.
P03066,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.94. AE: no.
P03066,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: brain fog. Adherence ~0.74. AE: yes.
P03066,2,neutral,Visit 2: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.83. AE: no.
P03066,3,neutral,Visit 3: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.81. AE: no.
P03066,4,neutral,Visit 4: Patient on RX-17B at S002. follow-up as scheduled. Notes: fatigue. Adherence ~0.92. AE: no.
P03067,0,neutral,Visit 0: Patient on RX-17A at S019. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no.
P03067,1,neutral,Visit 1: Patient on RX-17A at S019. no major change. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P03067,2,neutral,Visit 2: Patient on RX-17A at S019. reviewed dosing instructions. Notes: dizziness. Adherence ~0.99. AE: no. CRP 11.4 mg/L; ALT 27 U/L.
P03067,3,neutral,Visit 3: Patient on RX-17A at S019. reviewed dosing instructions. Notes: insomnia. Adherence ~0.85. AE: no.
P03067,4,positive,Visit 4: Patient on RX-17A at S019. energy increasing. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P03067,5,neutral,Visit 5: Patient on RX-17A at S019. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no. CRP 9.1 mg/L; ALT 26 U/L.
P03067,6,neutral,Visit 6: Patient on RX-17A at S019. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no.
P03067,7,positive,Visit 7: Patient on RX-17A at S019. energy increasing. Notes: brain fog. Adherence ~0.89. AE: no. CRP 6.5 mg/L; ALT 25 U/L.
P03068,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.60. AE: no.
P03068,1,neutral,Visit 1: Patient on RX-17B at S012. stable symptoms. Notes: fatigue. Adherence ~0.70. AE: no.
P03068,2,neutral,Visit 2: Patient on RX-17B at S012. stable symptoms. Notes: abdominal discomfort. Adherence ~0.47. AE: no. Plan: consider dose adjustment; counsel patient.
P03068,3,negative,Visit 3: Patient on RX-17B at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.44. AE: no.
P03068,4,neutral,Visit 4: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P03069,0,neutral,Visit 0: Patient on RX-17A at S001. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no. CRP 7.9 mg/L; ALT 39 U/L.
P03069,1,negative,Visit 1: Patient on RX-17A at S001. symptoms persist. Notes: dizziness. Adherence ~0.75. AE: no. CRP 6.5 mg/L; ALT 37 U/L.
P03069,2,negative,Visit 2: Patient on RX-17A at S001. poor tolerance. Notes: joint pain. Adherence ~0.61. AE: yes. Plan: consider dose adjustment; counsel patient.
P03069,3,positive,Visit 3: Patient on RX-17A at S001. reports improvement. Notes: nausea. Adherence ~0.77. AE: no. CRP 5.3 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P03069,4,negative,Visit 4: Patient on RX-17A at S001. feels frustrated. Notes: fatigue. Adherence ~0.68. AE: no. CRP 5.3 mg/L; ALT 37 U/L.
P03069,5,neutral,Visit 5: Patient on RX-17A at S001. continues regimen. Notes: brain fog. Adherence ~0.59. AE: no.
P03070,0,neutral,Visit 0: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03070,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: insomnia. Adherence ~1.00. AE: no.
P03070,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P03070,3,neutral,Visit 3: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.92. AE: no.
P03070,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: brain fog. Adherence ~0.89. AE: yes. CRP 13.5 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P03070,5,neutral,Visit 5: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.70. AE: no.
P03070,6,neutral,Visit 6: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.93. AE: yes.
P03071,0,negative,Visit 0: Patient on RX-17B at S022. reports worsening. Notes: dizziness. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P03071,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: fatigue. Adherence ~0.83. AE: no.
P03071,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: joint pain. Adherence ~1.00. AE: no.
P03071,3,positive,Visit 3: Patient on RX-17B at S022. reports improvement. Notes: nausea. Adherence ~0.94. AE: no.
P03071,4,neutral,Visit 4: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no.
P03072,0,neutral,Visit 0: Patient on RX-17A at S009. stable symptoms. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 12.1 mg/L; ALT 21 U/L.
P03072,1,neutral,Visit 1: Patient on RX-17A at S009. follow-up as scheduled. Notes: joint pain. Adherence ~0.81. AE: no. CRP 9.2 mg/L; ALT 22 U/L.
P03072,2,neutral,Visit 2: Patient on RX-17A at S009. stable symptoms. Notes: headache. Adherence ~0.75. AE: no.
P03072,3,neutral,Visit 3: Patient on RX-17A at S009. continues regimen. Notes: nausea. Adherence ~0.69. AE: no.
P03072,4,positive,Visit 4: Patient on RX-17A at S009. reports improvement. Notes: joint pain. Adherence ~0.86. AE: no.
P03072,5,neutral,Visit 5: Patient on RX-17A at S009. continues regimen. Notes: brain fog. Adherence ~0.86. AE: no. CRP 7.0 mg/L; ALT 22 U/L.
P03072,6,positive,Visit 6: Patient on RX-17A at S009. tolerating medication well. Notes: dizziness. Adherence ~0.78. AE: no.
P03072,7,neutral,Visit 7: Patient on RX-17A at S009. continues regimen. Notes: nausea. Adherence ~0.80. AE: yes.
P03073,0,neutral,Visit 0: Patient on RX-17B at S014. no major change. Notes: headache. Adherence ~0.97. AE: no. CRP 15.4 mg/L; ALT 31 U/L.
P03073,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.74. AE: yes. CRP 11.9 mg/L; ALT 40 U/L.
P03073,2,negative,Visit 2: Patient on RX-17B at S014. feels frustrated. Notes: dizziness. Adherence ~0.78. AE: no.
P03073,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~1.00. AE: no.
P03073,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: insomnia. Adherence ~0.85. AE: no.
P03073,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.8 mg/L; ALT 35 U/L.
P03074,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.86. AE: no. CRP 10.9 mg/L; ALT 20 U/L.
P03074,1,negative,Visit 1: Patient on RX-17B at S005. symptoms persist. Notes: brain fog. Adherence ~0.76. AE: no.
P03074,2,neutral,Visit 2: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.62. AE: no. CRP 9.7 mg/L; ALT 21 U/L.
P03074,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: nausea. Adherence ~0.85. AE: no.
P03074,4,positive,Visit 4: Patient on RX-17B at S005. reports improvement. Notes: dizziness. Adherence ~0.87. AE: no.
P03075,0,negative,Visit 0: Patient on RX-17A at S002. reports worsening. Notes: insomnia. Adherence ~0.91. AE: no. CRP 4.0 mg/L; ALT 16 U/L.
P03075,1,negative,Visit 1: Patient on RX-17A at S002. poor tolerance. Notes: fatigue. Adherence ~0.66. AE: no. CRP 3.2 mg/L; ALT 15 U/L.
P03075,2,neutral,Visit 2: Patient on RX-17A at S002. continues regimen. Notes: insomnia. Adherence ~0.76. AE: no. CRP 3.0 mg/L; ALT 17 U/L.
P03075,3,negative,Visit 3: Patient on RX-17A at S002. feels frustrated. Notes: joint pain. Adherence ~0.67. AE: yes.
P03075,4,neutral,Visit 4: Patient on RX-17A at S002. no major change. Notes: nausea. Adherence ~0.65. AE: no.
P03075,5,negative,Visit 5: Patient on RX-17A at S002. feels frustrated. Notes: abdominal discomfort. Adherence ~0.61. AE: no.
P03076,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~0.72. AE: no.
P03076,1,neutral,Visit 1: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.64. AE: no.
P03076,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P03076,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no. CRP 5.3 mg/L; ALT 22 U/L.
P03076,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P03076,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.85. AE: yes.
P03076,6,neutral,Visit 6: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: yes.
P03077,0,negative,Visit 0: Patient on RX-17B at S017. poor tolerance. Notes: insomnia. Adherence ~0.92. AE: no.
P03077,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03077,2,neutral,Visit 2: Patient on RX-17B at S017. continues regimen. Notes: dizziness. Adherence ~0.89. AE: no. Plan: consider dose adjustment; counsel patient.
P03077,3,neutral,Visit 3: Patient on RX-17B at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: yes.
P03077,4,neutral,Visit 4: Patient on RX-17B at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P03077,5,positive,Visit 5: Patient on RX-17B at S017. symptoms improving. Notes: headache. Adherence ~0.96. AE: no.
P03077,6,positive,Visit 6: Patient on RX-17B at S017. energy increasing. Notes: brain fog. Adherence ~0.83. AE: no. CRP 7.6 mg/L; ALT 39 U/L.
P03078,0,negative,Visit 0: Patient on RX-17B at S019. feels frustrated. Notes: abdominal discomfort. Adherence ~0.48. AE: yes.
P03078,1,negative,Visit 1: Patient on RX-17B at S019. poor tolerance. Notes: fatigue. Adherence ~0.75. AE: no.
P03078,2,negative,Visit 2: Patient on RX-17B at S019. reports worsening. Notes: dizziness. Adherence ~0.44. AE: no.
P03078,3,neutral,Visit 3: Patient on RX-17B at S019. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: yes. CRP 8.0 mg/L; ALT 62 U/L.
P03078,4,neutral,Visit 4: Patient on RX-17B at S019. stable symptoms. Notes: nausea. Adherence ~0.34. AE: no. CRP 7.3 mg/L; ALT 52 U/L. Plan: consider dose adjustment; counsel patient.
P03079,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.92. AE: no. CRP 7.9 mg/L; ALT 23 U/L.
P03079,1,neutral,Visit 1: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.87. AE: no. CRP 7.0 mg/L; ALT 22 U/L.
P03079,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P03079,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 5.2 mg/L; ALT 25 U/L.
P03079,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.80. AE: yes.
P03079,5,neutral,Visit 5: Patient on RX-17A at S004. no major change. Notes: headache. Adherence ~0.95. AE: no. CRP 4.8 mg/L; ALT 24 U/L.
P03079,6,positive,Visit 6: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~0.80. AE: no. Plan: consider dose adjustment; counsel patient.
P03079,7,positive,Visit 7: Patient on RX-17A at S004. feels better overall. Notes: fatigue. Adherence ~0.84. AE: no. CRP 3.9 mg/L; ALT 23 U/L.
P03080,0,negative,Visit 0: Patient on RX-17B at S011. increased discomfort. Notes: joint pain. Adherence ~0.93. AE: no. CRP 17.3 mg/L; ALT 28 U/L.
P03080,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: nausea. Adherence ~1.00. AE: no.
P03080,2,neutral,Visit 2: Patient on RX-17B at S011. stable symptoms. Notes: brain fog. Adherence ~0.98. AE: no. CRP 12.3 mg/L; ALT 28 U/L.
P03080,3,neutral,Visit 3: Patient on RX-17B at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: no. Plan: consider dose adjustment; counsel patient.
P03080,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03080,5,positive,Visit 5: Patient on RX-17B at S011. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no.
P03080,6,positive,Visit 6: Patient on RX-17B at S011. tolerating medication well. Notes: joint pain. Adherence ~0.99. AE: no. CRP 7.5 mg/L; ALT 33 U/L.
P03081,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: brain fog. Adherence ~0.73. AE: yes.
P03081,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.71. AE: no. CRP 8.1 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P03081,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: insomnia. Adherence ~0.86. AE: yes.
P03081,3,neutral,Visit 3: Patient on RX-17B at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.66. AE: no. CRP 7.1 mg/L; ALT 33 U/L.
P03081,4,neutral,Visit 4: Patient on RX-17B at S005. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 6.4 mg/L; ALT 34 U/L.
P03081,5,neutral,Visit 5: Patient on RX-17B at S005. stable symptoms. Notes: dizziness. Adherence ~0.79. AE: yes. CRP 5.7 mg/L; ALT 36 U/L.
P03081,6,positive,Visit 6: Patient on RX-17B at S005. symptoms improving. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P03081,7,positive,Visit 7: Patient on RX-17B at S005. reports improvement. Notes: brain fog. Adherence ~0.77. AE: no. CRP 3.7 mg/L; ALT 36 U/L.
P03082,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: brain fog. Adherence ~0.87. AE: no.
P03082,1,negative,Visit 1: Patient on RX-17B at S002. reports worsening. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03082,2,neutral,Visit 2: Patient on RX-17B at S002. continues regimen. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P03082,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: insomnia. Adherence ~0.89. AE: no.
P03082,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.91. AE: no.
P03082,5,positive,Visit 5: Patient on RX-17B at S002. energy increasing. Notes: joint pain. Adherence ~0.82. AE: no. CRP 7.6 mg/L; ALT 24 U/L.
P03082,6,positive,Visit 6: Patient on RX-17B at S002. reports improvement. Notes: brain fog. Adherence ~0.93. AE: no. Plan: consider dose adjustment; counsel patient.
P03082,7,positive,Visit 7: Patient on RX-17B at S002. symptoms improving. Notes: dizziness. Adherence ~0.80. AE: no. CRP 3.9 mg/L; ALT 26 U/L.
P03083,0,neutral,Visit 0: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.78. AE: no.
P03083,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: brain fog. Adherence ~0.72. AE: no.
P03083,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no.
P03083,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no. CRP 6.6 mg/L; ALT 23 U/L.
P03083,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: fatigue. Adherence ~0.76. AE: no.
P03083,5,neutral,Visit 5: Patient on RX-17A at S014. reviewed dosing instructions. Notes: joint pain. Adherence ~0.64. AE: no.
P03083,6,neutral,Visit 6: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.83. AE: yes.
P03084,0,neutral,Visit 0: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.70. AE: no. CRP 9.0 mg/L; ALT 34 U/L.
P03084,1,negative,Visit 1: Patient on RX-17A at S016. reports worsening. Notes: brain fog. Adherence ~0.71. AE: no. Plan: consider dose adjustment; counsel patient.
P03084,2,neutral,Visit 2: Patient on RX-17A at S016. stable symptoms. Notes: abdominal discomfort. Adherence ~0.81. AE: yes.
P03084,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: nausea. Adherence ~0.70. AE: no.
P03084,4,neutral,Visit 4: Patient on RX-17A at S016. follow-up as scheduled. Notes: headache. Adherence ~0.87. AE: no.
P03084,5,neutral,Visit 5: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 7.6 mg/L; ALT 34 U/L.
P03084,6,neutral,Visit 6: Patient on RX-17A at S016. no major change. Notes: insomnia. Adherence ~0.97. AE: yes. CRP 6.6 mg/L; ALT 36 U/L.
P03085,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: dizziness. Adherence ~0.92. AE: no. Plan: consider dose adjustment; counsel patient.
P03085,1,neutral,Visit 1: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.74. AE: no.
P03085,2,negative,Visit 2: Patient on RX-17A at S015. increased discomfort. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P03085,3,neutral,Visit 3: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.76. AE: no.
P03085,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: joint pain. Adherence ~1.00. AE: no.
P03085,5,positive,Visit 5: Patient on RX-17A at S015. feels better overall. Notes: abdominal discomfort. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P03085,6,neutral,Visit 6: Patient on RX-17A at S015. no major change. Notes: brain fog. Adherence ~0.81. AE: no. CRP 6.4 mg/L; ALT 18 U/L.
P03086,0,neutral,Visit 0: Patient on RX-17A at S012. continues regimen. Notes: headache. Adherence ~0.79. AE: no.
P03086,1,positive,Visit 1: Patient on RX-17A at S012. symptoms improving. Notes: fatigue. Adherence ~0.82. AE: no.
P03086,2,negative,Visit 2: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.83. AE: yes. CRP 13.4 mg/L; ALT 26 U/L.
P03086,3,negative,Visit 3: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.95. AE: no.
P03086,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.89. AE: no.
P03086,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P03086,6,neutral,Visit 6: Patient on RX-17A at S012. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no. CRP 9.3 mg/L; ALT 23 U/L.
P03086,7,positive,Visit 7: Patient on RX-17A at S012. energy increasing. Notes: headache. Adherence ~0.83. AE: no. CRP 7.8 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P03087,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: insomnia. Adherence ~0.58. AE: no.
P03087,1,negative,Visit 1: Patient on RX-17A at S014. symptoms persist. Notes: nausea. Adherence ~0.76. AE: no.
P03087,2,neutral,Visit 2: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no.
P03087,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no. Plan: consider dose adjustment; counsel patient.
P03087,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: brain fog. Adherence ~0.93. AE: no. CRP 11.6 mg/L; ALT 31 U/L. Plan: consider dose adjustment; counsel patient.
P03087,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.66. AE: no. CRP 11.7 mg/L; ALT 31 U/L.
P03087,6,neutral,Visit 6: Patient on RX-17A at S014. follow-up as scheduled. Notes: dizziness. Adherence ~0.80. AE: no.
P03087,7,positive,Visit 7: Patient on RX-17A at S014. energy increasing. Notes: insomnia. Adherence ~0.87. AE: no. CRP 8.4 mg/L; ALT 31 U/L.
P03088,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: headache. Adherence ~0.76. AE: no. Plan: consider dose adjustment; counsel patient.
P03088,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: insomnia. Adherence ~0.76. AE: no.
P03088,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.73. AE: no.
P03088,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: fatigue. Adherence ~0.72. AE: yes.
P03088,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: dizziness. Adherence ~0.82. AE: no.
P03088,5,negative,Visit 5: Patient on RX-17A at S004. increased discomfort. Notes: brain fog. Adherence ~0.90. AE: yes. CRP 3.9 mg/L; ALT 35 U/L.
P03088,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.78. AE: yes.
P03088,7,neutral,Visit 7: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: yes. CRP 3.5 mg/L; ALT 37 U/L.
P03089,0,negative,Visit 0: Patient on RX-17B at S005. poor tolerance. Notes: abdominal discomfort. Adherence ~0.59. AE: yes.
P03089,1,neutral,Visit 1: Patient on RX-17B at S005. no major change. Notes: insomnia. Adherence ~0.83. AE: yes. CRP 8.1 mg/L; ALT 19 U/L.
P03089,2,negative,Visit 2: Patient on RX-17B at S005. increased discomfort. Notes: headache. Adherence ~0.44. AE: yes.
P03089,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: fatigue. Adherence ~0.51. AE: no. CRP 5.6 mg/L; ALT 18 U/L.
P03089,4,positive,Visit 4: Patient on RX-17B at S005. symptoms improving. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P03089,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: dizziness. Adherence ~0.60. AE: yes. CRP 4.8 mg/L; ALT 20 U/L.
P03090,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: brain fog. Adherence ~0.72. AE: no. CRP 13.1 mg/L; ALT 28 U/L.
P03090,1,negative,Visit 1: Patient on RX-17B at S022. symptoms persist. Notes: headache. Adherence ~0.67. AE: no. CRP 14.3 mg/L; ALT 28 U/L.
P03090,2,neutral,Visit 2: Patient on RX-17B at S022. no major change. Notes: fatigue. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P03090,3,positive,Visit 3: Patient on RX-17B at S022. feels better overall. Notes: headache. Adherence ~0.87. AE: no.
P03090,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: headache. Adherence ~0.75. AE: yes. Plan: consider dose adjustment; counsel patient.
P03091,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: brain fog. Adherence ~0.64. AE: no. CRP 6.3 mg/L; ALT 21 U/L.
P03091,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: brain fog. Adherence ~0.40. AE: no.
P03091,2,neutral,Visit 2: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.59. AE: no.
P03091,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~0.79. AE: no.
P03091,4,neutral,Visit 4: Patient on RX-17A at S017. reviewed dosing instructions. Notes: brain fog. Adherence ~0.78. AE: no. CRP 5.9 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P03092,0,neutral,Visit 0: Patient on RX-17A at S022. reviewed dosing instructions. Notes: headache. Adherence ~0.66. AE: no.
P03092,1,neutral,Visit 1: Patient on RX-17A at S022. follow-up as scheduled. Notes: brain fog. Adherence ~0.48. AE: no.
P03092,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.59. AE: no.
P03092,3,negative,Visit 3: Patient on RX-17A at S022. increased discomfort. Notes: fatigue. Adherence ~0.63. AE: no.
P03092,4,neutral,Visit 4: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.51. AE: yes. CRP 2.9 mg/L; ALT 28 U/L.
P03093,0,neutral,Visit 0: Patient on RX-17B at S022. continues regimen. Notes: brain fog. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03093,1,neutral,Visit 1: Patient on RX-17B at S022. stable symptoms. Notes: abdominal discomfort. Adherence ~0.88. AE: no.
P03093,2,neutral,Visit 2: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03093,3,negative,Visit 3: Patient on RX-17B at S022. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03093,4,negative,Visit 4: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.75. AE: yes.
P03093,5,neutral,Visit 5: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.97. AE: no.
P03094,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: yes. CRP 4.5 mg/L; ALT 32 U/L.
P03094,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.92. AE: no.
P03094,2,positive,Visit 2: Patient on RX-17A at S015. reports improvement. Notes: headache. Adherence ~0.93. AE: no.
P03094,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: dizziness. Adherence ~0.97. AE: no.
P03094,4,neutral,Visit 4: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.97. AE: no. CRP 3.6 mg/L; ALT 31 U/L.
P03095,0,negative,Visit 0: Patient on RX-17A at S022. feels frustrated. Notes: fatigue. Adherence ~0.41. AE: no. CRP 5.9 mg/L; ALT 52 U/L.
P03095,1,neutral,Visit 1: Patient on RX-17A at S022. reviewed dosing instructions. Notes: dizziness. Adherence ~0.26. AE: no.
P03095,2,negative,Visit 2: Patient on RX-17A at S022. poor tolerance. Notes: nausea. Adherence ~0.29. AE: no.
P03095,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: insomnia. Adherence ~0.39. AE: no.
P03095,4,negative,Visit 4: Patient on RX-17A at S022. reports worsening. Notes: headache. Adherence ~0.54. AE: no. CRP 3.9 mg/L; ALT 61 U/L.
P03096,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: headache. Adherence ~0.76. AE: no. CRP 5.1 mg/L; ALT 27 U/L.
P03096,1,negative,Visit 1: Patient on RX-17B at S013. poor tolerance. Notes: dizziness. Adherence ~0.98. AE: yes. CRP 4.1 mg/L; ALT 32 U/L.
P03096,2,negative,Visit 2: Patient on RX-17B at S013. symptoms persist. Notes: dizziness. Adherence ~0.62. AE: no.
P03096,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.57. AE: no. CRP 3.7 mg/L; ALT 30 U/L.
P03096,4,positive,Visit 4: Patient on RX-17B at S013. symptoms improving. Notes: headache. Adherence ~0.79. AE: no.
P03096,5,negative,Visit 5: Patient on RX-17B at S013. symptoms persist. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 2.8 mg/L; ALT 35 U/L.
P03096,6,neutral,Visit 6: Patient on RX-17B at S013. continues regimen. Notes: fatigue. Adherence ~0.74. AE: no.
P03096,7,positive,Visit 7: Patient on RX-17B at S013. feels better overall. Notes: nausea. Adherence ~0.91. AE: no.
P03097,0,neutral,Visit 0: Patient on RX-17B at S001. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no.
P03097,1,neutral,Visit 1: Patient on RX-17B at S001. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.90. AE: no.
P03097,2,neutral,Visit 2: Patient on RX-17B at S001. no major change. Notes: brain fog. Adherence ~0.99. AE: no.
P03097,3,neutral,Visit 3: Patient on RX-17B at S001. follow-up as scheduled. Notes: brain fog. Adherence ~0.87. AE: no. Plan: consider dose adjustment; counsel patient.
P03097,4,positive,Visit 4: Patient on RX-17B at S001. reports improvement. Notes: fatigue. Adherence ~0.84. AE: no. Plan: consider dose adjustment; counsel patient.
P03097,5,neutral,Visit 5: Patient on RX-17B at S001. no major change. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P03097,6,neutral,Visit 6: Patient on RX-17B at S001. continues regimen. Notes: joint pain. Adherence ~0.72. AE: yes. CRP 6.2 mg/L; ALT 47 U/L. Plan: consider dose adjustment; counsel patient.
P03097,7,positive,Visit 7: Patient on RX-17B at S001. feels better overall. Notes: fatigue. Adherence ~0.90. AE: no.
P03098,0,negative,Visit 0: Patient on RX-17B at S003. poor tolerance. Notes: brain fog. Adherence ~0.80. AE: yes. CRP 6.4 mg/L; ALT 44 U/L.
P03098,1,negative,Visit 1: Patient on RX-17B at S003. increased discomfort. Notes: joint pain. Adherence ~0.64. AE: no.
P03098,2,neutral,Visit 2: Patient on RX-17B at S003. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.64. AE: no.
P03098,3,neutral,Visit 3: Patient on RX-17B at S003. no major change. Notes: joint pain. Adherence ~0.63. AE: no.
P03098,4,neutral,Visit 4: Patient on RX-17B at S003. no major change. Notes: brain fog. Adherence ~0.79. AE: no.
P03098,5,neutral,Visit 5: Patient on RX-17B at S003. follow-up as scheduled. Notes: brain fog. Adherence ~0.58. AE: no.
P03098,6,neutral,Visit 6: Patient on RX-17B at S003. follow-up as scheduled. Notes: insomnia. Adherence ~0.78. AE: yes. CRP 3.3 mg/L; ALT 46 U/L.
P03099,0,neutral,Visit 0: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no.
P03099,1,neutral,Visit 1: Patient on RX-17B at S004. stable symptoms. Notes: brain fog. Adherence ~0.89. AE: no.
P03099,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 11.3 mg/L; ALT 28 U/L.
P03099,3,positive,Visit 3: Patient on RX-17B at S004. feels better overall. Notes: nausea. Adherence ~0.96. AE: no. Plan: consider dose adjustment; counsel patient.
P03099,4,neutral,Visit 4: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.90. AE: no.
P03099,5,neutral,Visit 5: Patient on RX-17B at S004. no major change. Notes: brain fog. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P03099,6,neutral,Visit 6: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.89. AE: no. CRP 7.6 mg/L; ALT 34 U/L.
P03099,7,positive,Visit 7: Patient on RX-17B at S004. energy increasing. Notes: dizziness. Adherence ~0.92. AE: no. CRP 5.1 mg/L; ALT 35 U/L.
P03100,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~0.91. AE: no. Plan: consider dose adjustment; counsel patient.
P03100,1,negative,Visit 1: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~0.88. AE: no.
P03100,2,neutral,Visit 2: Patient on RX-17B at S004. stable symptoms. Notes: fatigue. Adherence ~0.93. AE: yes.
P03100,3,neutral,Visit 3: Patient on RX-17B at S004. continues regimen. Notes: joint pain. Adherence ~0.90. AE: no. Plan: consider dose adjustment; counsel patient.
P03100,4,neutral,Visit 4: Patient on RX-17B at S004. continues regimen. Notes: insomnia. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P03100,5,positive,Visit 5: Patient on RX-17B at S004. tolerating medication well. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P03101,0,neutral,Visit 0: Patient on RX-17B at S012. no major change. Notes: joint pain. Adherence ~1.00. AE: no.
P03101,1,positive,Visit 1: Patient on RX-17B at S012. symptoms improving. Notes: brain fog. Adherence ~0.81. AE: no.
P03101,2,positive,Visit 2: Patient on RX-17B at S012. energy increasing. Notes: nausea. Adherence ~1.00. AE: no. CRP 5.0 mg/L; ALT 30 U/L.
P03101,3,neutral,Visit 3: Patient on RX-17B at S012. stable symptoms. Notes: insomnia. Adherence ~0.88. AE: no. CRP 4.7 mg/L; ALT 31 U/L.
P03101,4,negative,Visit 4: Patient on RX-17B at S012. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P03102,0,negative,Visit 0: Patient on RX-17B at S016. feels frustrated. Notes: insomnia. Adherence ~0.86. AE: no.
P03102,1,negative,Visit 1: Patient on RX-17B at S016. poor tolerance. Notes: joint pain. Adherence ~0.95. AE: no.
P03102,2,neutral,Visit 2: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no. CRP 6.2 mg/L; ALT 25 U/L. Plan: consider dose adjustment; counsel patient.
P03102,3,neutral,Visit 3: Patient on RX-17B at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.89. AE: no.
P03102,4,neutral,Visit 4: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.94. AE: no.
P03102,5,positive,Visit 5: Patient on RX-17B at S016. reports improvement. Notes: insomnia. Adherence ~1.00. AE: no.
P03102,6,positive,Visit 6: Patient on RX-17B at S016. tolerating medication well. Notes: nausea. Adherence ~0.89. AE: no.
P03102,7,positive,Visit 7: Patient on RX-17B at S016. reports improvement. Notes: brain fog. Adherence ~1.00. AE: no.
P03103,0,negative,Visit 0: Patient on RX-17A at S017. feels frustrated. Notes: nausea. Adherence ~0.79. AE: no.
P03103,1,negative,Visit 1: Patient on RX-17A at S017. increased discomfort. Notes: fatigue. Adherence ~0.91. AE: no. CRP 11.5 mg/L; ALT 23 U/L.
P03103,2,negative,Visit 2: Patient on RX-17A at S017. feels frustrated. Notes: insomnia. Adherence ~0.96. AE: no.
P03103,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P03103,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: fatigue. Adherence ~1.00. AE: yes.
P03103,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.74. AE: no. CRP 8.3 mg/L; ALT 27 U/L.
P03104,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.96. AE: no. CRP 15.3 mg/L; ALT 30 U/L.
P03104,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: headache. Adherence ~1.00. AE: no. CRP 13.4 mg/L; ALT 32 U/L.
P03104,2,neutral,Visit 2: Patient on RX-17A at S015. continues regimen. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P03104,3,neutral,Visit 3: Patient on RX-17A at S015. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: no.
P03105,0,neutral,Visit 0: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~0.96. AE: no.
P03105,1,neutral,Visit 1: Patient on RX-17B at S004. reviewed dosing instructions. Notes: brain fog. Adherence ~0.85. AE: no. CRP 4.8 mg/L; ALT 18 U/L. Plan: consider dose adjustment; counsel patient.
P03105,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.98. AE: no. CRP 4.2 mg/L; ALT 19 U/L.
P03105,3,neutral,Visit 3: Patient on RX-17B at S004. stable symptoms. Notes: insomnia. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P03105,4,positive,Visit 4: Patient on RX-17B at S004. energy increasing. Notes: nausea. Adherence ~0.94. AE: no.
P03105,5,neutral,Visit 5: Patient on RX-17B at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.93. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P03106,0,negative,Visit 0: Patient on RX-17A at S017. poor tolerance. Notes: abdominal discomfort. Adherence ~0.84. AE: no.
P03106,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: fatigue. Adherence ~0.58. AE: no.
P03106,2,neutral,Visit 2: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P03106,3,neutral,Visit 3: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.81. AE: no. CRP 8.8 mg/L; ALT 22 U/L.
P03106,4,neutral,Visit 4: Patient on RX-17A at S017. continues regimen. Notes: abdominal discomfort. Adherence ~0.74. AE: yes. CRP 8.6 mg/L; ALT 26 U/L. Plan: consider dose adjustment; counsel patient.
P03106,5,neutral,Visit 5: Patient on RX-17A at S017. no major change. Notes: joint pain. Adherence ~0.85. AE: no.
P03107,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: nausea. Adherence ~0.92. AE: no. CRP 2.8 mg/L; ALT 24 U/L.
P03107,1,neutral,Visit 1: Patient on RX-17B at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.85. AE: no. CRP 2.7 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P03107,2,neutral,Visit 2: Patient on RX-17B at S012. no major change. Notes: insomnia. Adherence ~0.95. AE: yes. CRP 2.2 mg/L; ALT 23 U/L.
P03107,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: fatigue. Adherence ~0.98. AE: no.
P03107,4,neutral,Visit 4: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~0.80. AE: no.
P03107,5,neutral,Visit 5: Patient on RX-17B at S012. stable symptoms. Notes: brain fog. Adherence ~1.00. AE: yes. CRP 1.6 mg/L; ALT 24 U/L.
P03107,6,positive,Visit 6: Patient on RX-17B at S012. energy increasing. Notes: dizziness. Adherence ~0.92. AE: no.
P03107,7,positive,Visit 7: Patient on RX-17B at S012. tolerating medication well. Notes: headache. Adherence ~0.94. AE: no.
P03108,0,negative,Visit 0: Patient on RX-17B at S001. poor tolerance. Notes: dizziness. Adherence ~0.79. AE: no.
P03108,1,negative,Visit 1: Patient on RX-17B at S001. feels frustrated. Notes: joint pain. Adherence ~0.52. AE: no. CRP 10.4 mg/L; ALT 29 U/L. Plan: consider dose adjustment; counsel patient.
P03108,2,negative,Visit 2: Patient on RX-17B at S001. reports worsening. Notes: insomnia. Adherence ~0.81. AE: no. CRP 9.9 mg/L; ALT 29 U/L.
P03108,3,neutral,Visit 3: Patient on RX-17B at S001. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no.
P03108,4,positive,Visit 4: Patient on RX-17B at S001. feels better overall. Notes: insomnia. Adherence ~0.99. AE: no.
P03109,0,neutral,Visit 0: Patient on RX-17B at S011. stable symptoms. Notes: joint pain. Adherence ~0.73. AE: no. CRP 3.5 mg/L; ALT 25 U/L.
P03109,1,neutral,Visit 1: Patient on RX-17B at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.80. AE: no. CRP 3.5 mg/L; ALT 24 U/L.
P03109,2,negative,Visit 2: Patient on RX-17B at S011. feels frustrated. Notes: nausea. Adherence ~0.79. AE: no.
P03109,3,neutral,Visit 3: Patient on RX-17B at S011. stable symptoms. Notes: joint pain. Adherence ~0.75. AE: no.
P03109,4,neutral,Visit 4: Patient on RX-17B at S011. continues regimen. Notes: headache. Adherence ~0.70. AE: no.
P03109,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P03109,6,positive,Visit 6: Patient on RX-17B at S011. tolerating medication well. Notes: fatigue. Adherence ~0.77. AE: no. CRP 1.8 mg/L; ALT 27 U/L.
P03110,0,negative,Visit 0: Patient on RX-17A at S012. feels frustrated. Notes: nausea. Adherence ~0.99. AE: no. Plan: consider dose adjustment; counsel patient.
P03110,1,neutral,Visit 1: Patient on RX-17A at S012. continues regimen. Notes: joint pain. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03110,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.94. AE: no. CRP 8.3 mg/L; ALT 25 U/L.
P03110,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.96. AE: no.
P03110,4,neutral,Visit 4: Patient on RX-17A at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 7.2 mg/L; ALT 24 U/L.
P03110,5,neutral,Visit 5: Patient on RX-17A at S012. no major change. Notes: fatigue. Adherence ~1.00. AE: no.
P03110,6,neutral,Visit 6: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.85. AE: yes.
P03111,0,negative,Visit 0: Patient on RX-17A at S011. poor tolerance. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P03111,1,neutral,Visit 1: Patient on RX-17A at S011. stable symptoms. Notes: abdominal discomfort. Adherence ~0.59. AE: no. CRP 11.6 mg/L; ALT 28 U/L.
P03111,2,neutral,Visit 2: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.73. AE: no.
P03111,3,neutral,Visit 3: Patient on RX-17A at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P03111,4,neutral,Visit 4: Patient on RX-17A at S011. reviewed dosing instructions. Notes: joint pain. Adherence ~0.50. AE: no. CRP 9.3 mg/L; ALT 31 U/L.
P03111,5,neutral,Visit 5: Patient on RX-17A at S011. stable symptoms. Notes: fatigue. Adherence ~0.54. AE: no. CRP 9.8 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P03111,6,neutral,Visit 6: Patient on RX-17A at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.52. AE: yes. CRP 8.6 mg/L; ALT 34 U/L. Plan: consider dose adjustment; counsel patient.
P03111,7,neutral,Visit 7: Patient on RX-17A at S011. follow-up as scheduled. Notes: brain fog. Adherence ~0.59. AE: no.
P03112,0,neutral,Visit 0: Patient on RX-17A at S018. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P03112,1,neutral,Visit 1: Patient on RX-17A at S018. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 11.4 mg/L; ALT 28 U/L.
P03112,2,neutral,Visit 2: Patient on RX-17A at S018. follow-up as scheduled. Notes: headache. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P03112,3,neutral,Visit 3: Patient on RX-17A at S018. continues regimen. Notes: dizziness. Adherence ~0.70. AE: no.
P03112,4,neutral,Visit 4: Patient on RX-17A at S018. follow-up as scheduled. Notes: joint pain. Adherence ~0.77. AE: no. CRP 8.3 mg/L; ALT 26 U/L.
P03112,5,positive,Visit 5: Patient on RX-17A at S018. feels better overall. Notes: headache. Adherence ~0.76. AE: no.
P03112,6,neutral,Visit 6: Patient on RX-17A at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.64. AE: no.
P03113,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: nausea. Adherence ~0.52. AE: no.
P03113,1,neutral,Visit 1: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.64. AE: no.
P03113,2,negative,Visit 2: Patient on RX-17A at S017. increased discomfort. Notes: dizziness. Adherence ~0.56. AE: no. CRP 2.4 mg/L; ALT 32 U/L.
P03113,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: headache. Adherence ~0.77. AE: no.
P03113,4,neutral,Visit 4: Patient on RX-17A at S017. no major change. Notes: headache. Adherence ~0.69. AE: no. CRP 2.1 mg/L; ALT 30 U/L.
P03113,5,negative,Visit 5: Patient on RX-17A at S017. increased discomfort. Notes: insomnia. Adherence ~0.48. AE: no.
P03113,6,neutral,Visit 6: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P03113,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: nausea. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P03114,0,negative,Visit 0: Patient on RX-17A at S016. poor tolerance. Notes: nausea. Adherence ~0.82. AE: no. CRP 5.2 mg/L; ALT 20 U/L.
P03114,1,neutral,Visit 1: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.76. AE: no.
P03114,2,neutral,Visit 2: Patient on RX-17A at S016. reviewed dosing instructions. Notes: nausea. Adherence ~0.90. AE: no.
P03115,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.75. AE: no.
P03115,1,neutral,Visit 1: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.60. AE: no.
P03115,2,negative,Visit 2: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.55. AE: yes.
P03115,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: brain fog. Adherence ~0.65. AE: no.
P03115,4,neutral,Visit 4: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.45. AE: no. CRP 7.5 mg/L; ALT 22 U/L.
P03115,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: fatigue. Adherence ~0.62. AE: no.
P03115,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: nausea. Adherence ~0.67. AE: no. CRP 6.4 mg/L; ALT 25 U/L.
P03116,0,neutral,Visit 0: Patient on RX-17B at S018. stable symptoms. Notes: joint pain. Adherence ~0.85. AE: no.
P03116,1,negative,Visit 1: Patient on RX-17B at S018. reports worsening. Notes: insomnia. Adherence ~0.78. AE: no.
P03116,2,neutral,Visit 2: Patient on RX-17B at S018. continues regimen. Notes: abdominal discomfort. Adherence ~0.83. AE: no. CRP 8.5 mg/L; ALT 65 U/L. Plan: consider dose adjustment; counsel patient.
P03116,3,neutral,Visit 3: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.99. AE: no. CRP 8.1 mg/L; ALT 59 U/L. Plan: consider dose adjustment; counsel patient.
P03116,4,neutral,Visit 4: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.98. AE: no. CRP 6.8 mg/L; ALT 66 U/L.
P03117,0,neutral,Visit 0: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.75. AE: no. CRP 8.9 mg/L; ALT 23 U/L.
P03117,1,neutral,Visit 1: Patient on RX-17A at S016. reviewed dosing instructions. Notes: fatigue. Adherence ~0.52. AE: yes. Plan: consider dose adjustment; counsel patient.
P03117,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.88. AE: no.
P03118,0,negative,Visit 0: Patient on RX-17B at S005. increased discomfort. Notes: abdominal discomfort. Adherence ~0.85. AE: yes. CRP 2.2 mg/L; ALT 16 U/L.
P03118,1,negative,Visit 1: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~0.62. AE: yes.
P03118,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~0.83. AE: yes.
P03118,3,neutral,Visit 3: Patient on RX-17B at S005. stable symptoms. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P03118,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~0.79. AE: no.
P03118,5,neutral,Visit 5: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~0.69. AE: no. CRP 1.3 mg/L; ALT 17 U/L.
P03118,6,positive,Visit 6: Patient on RX-17B at S005. reports improvement. Notes: insomnia. Adherence ~0.81. AE: no. CRP 1.1 mg/L; ALT 14 U/L.
P03119,0,negative,Visit 0: Patient on RX-17A at S015. poor tolerance. Notes: abdominal discomfort. Adherence ~0.80. AE: yes.
P03119,1,negative,Visit 1: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no. CRP 12.8 mg/L; ALT 31 U/L.
P03119,2,neutral,Visit 2: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P03119,3,neutral,Visit 3: Patient on RX-17A at S015. stable symptoms. Notes: fatigue. Adherence ~0.82. AE: no.
P03119,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: fatigue. Adherence ~0.69. AE: no. CRP 11.3 mg/L; ALT 35 U/L.
P03119,5,neutral,Visit 5: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.71. AE: yes.
P03120,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.30. AE: yes. CRP 16.3 mg/L; ALT 26 U/L.
P03120,1,neutral,Visit 1: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.23. AE: no. CRP 13.0 mg/L; ALT 23 U/L.
P03120,2,negative,Visit 2: Patient on RX-17A at S014. increased discomfort. Notes: brain fog. Adherence ~0.22. AE: no.
P03121,0,negative,Visit 0: Patient on RX-17B at S013. poor tolerance. Notes: nausea. Adherence ~0.53. AE: yes. CRP 6.9 mg/L; ALT 37 U/L.
P03121,1,negative,Visit 1: Patient on RX-17B at S013. reports worsening. Notes: nausea. Adherence ~0.62. AE: no. CRP 7.5 mg/L; ALT 35 U/L. Plan: consider dose adjustment; counsel patient.
P03121,2,neutral,Visit 2: Patient on RX-17B at S013. reviewed dosing instructions. Notes: nausea. Adherence ~0.59. AE: no. CRP 7.1 mg/L; ALT 37 U/L. Plan: consider dose adjustment; counsel patient.
P03121,3,neutral,Visit 3: Patient on RX-17B at S013. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.68. AE: no.
P03121,4,neutral,Visit 4: Patient on RX-17B at S013. no major change. Notes: fatigue. Adherence ~0.61. AE: no. CRP 5.1 mg/L; ALT 37 U/L.
P03121,5,neutral,Visit 5: Patient on RX-17B at S013. no major change. Notes: nausea. Adherence ~0.70. AE: yes. CRP 6.0 mg/L; ALT 38 U/L.
P03121,6,neutral,Visit 6: Patient on RX-17B at S013. reviewed dosing instructions. Notes: dizziness. Adherence ~0.51. AE: no. CRP 3.8 mg/L; ALT 36 U/L.
P03122,0,neutral,Visit 0: Patient on RX-17B at S004. continues regimen. Notes: brain fog. Adherence ~0.99. AE: no.
P03122,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no. CRP 7.7 mg/L; ALT 28 U/L.
P03122,2,negative,Visit 2: Patient on RX-17B at S004. symptoms persist. Notes: insomnia. Adherence ~1.00. AE: no.
P03122,3,positive,Visit 3: Patient on RX-17B at S004. symptoms improving. Notes: insomnia. Adherence ~0.84. AE: no. CRP 6.9 mg/L; ALT 30 U/L.
P03122,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P03123,0,neutral,Visit 0: Patient on RX-17A at S014. follow-up as scheduled. Notes: joint pain. Adherence ~0.84. AE: yes. CRP 10.5 mg/L; ALT 42 U/L.
P03123,1,negative,Visit 1: Patient on RX-17A at S014. reports worsening. Notes: brain fog. Adherence ~0.95. AE: no. CRP 8.6 mg/L; ALT 39 U/L.
P03123,2,neutral,Visit 2: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.82. AE: no.
P03123,3,negative,Visit 3: Patient on RX-17A at S014. symptoms persist. Notes: insomnia. Adherence ~0.77. AE: yes.
P03123,4,neutral,Visit 4: Patient on RX-17A at S014. no major change. Notes: abdominal discomfort. Adherence ~0.71. AE: no.
P03124,0,neutral,Visit 0: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.63. AE: no.
P03124,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: insomnia. Adherence ~0.68. AE: no. CRP 16.0 mg/L; ALT 27 U/L.
P03124,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: joint pain. Adherence ~0.70. AE: no.
P03124,3,neutral,Visit 3: Patient on RX-17A at S004. stable symptoms. Notes: fatigue. Adherence ~0.76. AE: no. CRP 12.6 mg/L; ALT 31 U/L.
P03125,0,neutral,Visit 0: Patient on RX-17A at S005. stable symptoms. Notes: dizziness. Adherence ~0.19. AE: no. CRP 8.1 mg/L; ALT 28 U/L.
P03125,1,neutral,Visit 1: Patient on RX-17A at S005. continues regimen. Notes: dizziness. Adherence ~0.44. AE: no.
P03125,2,neutral,Visit 2: Patient on RX-17A at S005. reviewed dosing instructions. Notes: joint pain. Adherence ~0.30. AE: no.
P03125,3,neutral,Visit 3: Patient on RX-17A at S005. stable symptoms. Notes: insomnia. Adherence ~0.30. AE: no. Plan: consider dose adjustment; counsel patient.
P03125,4,neutral,Visit 4: Patient on RX-17A at S005. reviewed dosing instructions. Notes: nausea. Adherence ~0.28. AE: no.
P03125,5,neutral,Visit 5: Patient on RX-17A at S005. stable symptoms. Notes: nausea. Adherence ~0.36. AE: no.
P03125,6,neutral,Visit 6: Patient on RX-17A at S005. follow-up as scheduled. Notes: joint pain. Adherence ~0.49. AE: no.
P03126,0,negative,Visit 0: Patient on RX-17B at S004. poor tolerance. Notes: abdominal discomfort. Adherence ~1.00. AE: no.
P03126,1,negative,Visit 1: Patient on RX-17B at S004. feels frustrated. Notes: brain fog. Adherence ~0.70. AE: yes.
P03126,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.93. AE: no.
P03126,3,neutral,Visit 3: Patient on RX-17B at S004. no major change. Notes: nausea. Adherence ~0.93. AE: no. CRP 5.3 mg/L; ALT 51 U/L.
P03127,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: insomnia. Adherence ~0.63. AE: no.
P03127,1,negative,Visit 1: Patient on RX-17B at S022. feels frustrated. Notes: headache. Adherence ~0.69. AE: no. CRP 8.3 mg/L; ALT 14 U/L.
P03127,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.71. AE: no. CRP 8.0 mg/L; ALT 15 U/L.
P03127,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.84. AE: no.
P03128,0,neutral,Visit 0: Patient on RX-17B at S011. follow-up as scheduled. Notes: fatigue. Adherence ~0.72. AE: no.
P03128,1,negative,Visit 1: Patient on RX-17B at S011. symptoms persist. Notes: insomnia. Adherence ~0.69. AE: no. Plan: consider dose adjustment; counsel patient.
P03128,2,neutral,Visit 2: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.58. AE: no. CRP 6.0 mg/L; ALT 22 U/L.
P03128,3,neutral,Visit 3: Patient on RX-17B at S011. continues regimen. Notes: abdominal discomfort. Adherence ~0.65. AE: no. Plan: consider dose adjustment; counsel patient.
P03128,4,neutral,Visit 4: Patient on RX-17B at S011. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.73. AE: no. CRP 5.3 mg/L; ALT 21 U/L.
P03128,5,neutral,Visit 5: Patient on RX-17B at S011. reviewed dosing instructions. Notes: headache. Adherence ~0.57. AE: no. Plan: consider dose adjustment; counsel patient.
P03129,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: headache. Adherence ~0.78. AE: no.
P03129,1,neutral,Visit 1: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.86. AE: yes. CRP 6.5 mg/L; ALT 25 U/L.
P03129,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: brain fog. Adherence ~0.87. AE: no.
P03129,3,neutral,Visit 3: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.81. AE: no. CRP 4.8 mg/L; ALT 22 U/L.
P03129,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: joint pain. Adherence ~0.83. AE: no.
P03130,0,negative,Visit 0: Patient on RX-17A at S012. increased discomfort. Notes: headache. Adherence ~0.73. AE: no. CRP 2.2 mg/L; ALT 16 U/L.
P03130,1,negative,Visit 1: Patient on RX-17A at S012. increased discomfort. Notes: brain fog. Adherence ~0.62. AE: yes. CRP 2.6 mg/L; ALT 20 U/L.
P03130,2,neutral,Visit 2: Patient on RX-17A at S012. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: no. CRP 2.8 mg/L; ALT 19 U/L.
P03130,3,neutral,Visit 3: Patient on RX-17A at S012. continues regimen. Notes: nausea. Adherence ~0.62. AE: no. CRP 2.0 mg/L; ALT 18 U/L.
P03130,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P03130,5,negative,Visit 5: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.79. AE: yes.
P03131,0,neutral,Visit 0: Patient on RX-17A at S021. follow-up as scheduled. Notes: fatigue. Adherence ~0.73. AE: no.
P03131,1,negative,Visit 1: Patient on RX-17A at S021. increased discomfort. Notes: insomnia. Adherence ~0.73. AE: no.
P03131,2,neutral,Visit 2: Patient on RX-17A at S021. continues regimen. Notes: fatigue. Adherence ~0.65. AE: no.
P03131,3,neutral,Visit 3: Patient on RX-17A at S021. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no.
P03131,4,neutral,Visit 4: Patient on RX-17A at S021. reviewed dosing instructions. Notes: fatigue. Adherence ~0.68. AE: no.
P03131,5,neutral,Visit 5: Patient on RX-17A at S021. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P03131,6,positive,Visit 6: Patient on RX-17A at S021. reports improvement. Notes: brain fog. Adherence ~0.79. AE: no.
P03131,7,neutral,Visit 7: Patient on RX-17A at S021. no major change. Notes: insomnia. Adherence ~0.56. AE: no. Plan: consider dose adjustment; counsel patient.
P03132,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P03132,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.93. AE: no.
P03132,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.91. AE: no. CRP 9.6 mg/L; ALT 25 U/L.
P03132,3,positive,Visit 3: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.84. AE: no. CRP 11.3 mg/L; ALT 26 U/L.
P03132,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: abdominal discomfort. Adherence ~0.94. AE: no.
P03132,5,positive,Visit 5: Patient on RX-17B at S014. feels better overall. Notes: nausea. Adherence ~0.93. AE: no. CRP 8.0 mg/L; ALT 28 U/L.
P03133,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: nausea. Adherence ~0.83. AE: no.
P03133,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: nausea. Adherence ~0.77. AE: no. Plan: consider dose adjustment; counsel patient.
P03133,2,negative,Visit 2: Patient on RX-17B at S022. increased discomfort. Notes: headache. Adherence ~0.97. AE: no.
P03133,3,neutral,Visit 3: Patient on RX-17B at S022. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P03133,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.58. AE: no.
P03133,5,positive,Visit 5: Patient on RX-17B at S022. feels better overall. Notes: nausea. Adherence ~0.85. AE: no.
P03133,6,neutral,Visit 6: Patient on RX-17B at S022. stable symptoms. Notes: insomnia. Adherence ~0.67. AE: no.
P03134,0,neutral,Visit 0: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.79. AE: no.
P03134,1,neutral,Visit 1: Patient on RX-17A at S012. follow-up as scheduled. Notes: fatigue. Adherence ~0.77. AE: no.
P03134,2,neutral,Visit 2: Patient on RX-17A at S012. continues regimen. Notes: fatigue. Adherence ~0.88. AE: no. CRP 10.6 mg/L; ALT 29 U/L.
P03134,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.72. AE: no.
P03134,4,neutral,Visit 4: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.68. AE: no.
P03135,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: insomnia. Adherence ~0.61. AE: no. CRP 7.2 mg/L; ALT 29 U/L.
P03135,1,neutral,Visit 1: Patient on RX-17A at S004. continues regimen. Notes: joint pain. Adherence ~0.71. AE: no. CRP 6.5 mg/L; ALT 30 U/L.
P03135,2,neutral,Visit 2: Patient on RX-17A at S004. reviewed dosing instructions. Notes: nausea. Adherence ~0.75. AE: no.
P03135,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: fatigue. Adherence ~0.78. AE: no.
P03135,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.63. AE: no. Plan: consider dose adjustment; counsel patient.
P03135,5,neutral,Visit 5: Patient on RX-17A at S004. stable symptoms. Notes: nausea. Adherence ~0.64. AE: no.
P03135,6,neutral,Visit 6: Patient on RX-17A at S004. continues regimen. Notes: abdominal discomfort. Adherence ~0.75. AE: no.
P03136,0,negative,Visit 0: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.61. AE: no. CRP 8.5 mg/L; ALT 27 U/L.
P03136,1,neutral,Visit 1: Patient on RX-17B at S014. reviewed dosing instructions. Notes: nausea. Adherence ~0.69. AE: no.
P03136,2,neutral,Visit 2: Patient on RX-17B at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.60. AE: no. Plan: consider dose adjustment; counsel patient.
P03136,3,neutral,Visit 3: Patient on RX-17B at S014. follow-up as scheduled. Notes: fatigue. Adherence ~0.66. AE: no. CRP 6.1 mg/L; ALT 26 U/L.
P03136,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.66. AE: no. Plan: consider dose adjustment; counsel patient.
P03137,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: abdominal discomfort. Adherence ~0.78. AE: no. Plan: consider dose adjustment; counsel patient.
P03137,1,negative,Visit 1: Patient on RX-17A at S012. poor tolerance. Notes: brain fog. Adherence ~0.81. AE: no.
P03137,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: insomnia. Adherence ~0.81. AE: yes. CRP 12.4 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P03137,3,negative,Visit 3: Patient on RX-17A at S012. increased discomfort. Notes: fatigue. Adherence ~0.79. AE: yes. CRP 9.7 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P03137,4,negative,Visit 4: Patient on RX-17A at S012. increased discomfort. Notes: nausea. Adherence ~0.78. AE: yes. CRP 8.8 mg/L; ALT 25 U/L.
P03137,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.78. AE: no.
P03137,6,neutral,Visit 6: Patient on RX-17A at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.73. AE: no.
P03137,7,positive,Visit 7: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~1.00. AE: no.
P03138,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: nausea. Adherence ~0.57. AE: no.
P03138,1,neutral,Visit 1: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.75. AE: no. CRP 10.2 mg/L; ALT 38 U/L.
P03138,2,neutral,Visit 2: Patient on RX-17B at S018. stable symptoms. Notes: brain fog. Adherence ~0.81. AE: no. CRP 10.1 mg/L; ALT 42 U/L.
P03138,3,neutral,Visit 3: Patient on RX-17B at S018. continues regimen. Notes: headache. Adherence ~0.64. AE: no. CRP 9.6 mg/L; ALT 45 U/L.
P03138,4,neutral,Visit 4: Patient on RX-17B at S018. continues regimen. Notes: joint pain. Adherence ~0.68. AE: yes.
P03138,5,neutral,Visit 5: Patient on RX-17B at S018. stable symptoms. Notes: dizziness. Adherence ~0.75. AE: no. CRP 7.7 mg/L; ALT 45 U/L.
P03139,0,negative,Visit 0: Patient on RX-17B at S020. increased discomfort. Notes: brain fog. Adherence ~0.81. AE: no.
P03139,1,negative,Visit 1: Patient on RX-17B at S020. symptoms persist. Notes: abdominal discomfort. Adherence ~0.80. AE: no. CRP 15.7 mg/L; ALT 51 U/L.
P03139,2,neutral,Visit 2: Patient on RX-17B at S020. continues regimen. Notes: fatigue. Adherence ~0.80. AE: no.
P03139,3,neutral,Visit 3: Patient on RX-17B at S020. reviewed dosing instructions. Notes: headache. Adherence ~0.77. AE: no.
P03139,4,neutral,Visit 4: Patient on RX-17B at S020. follow-up as scheduled. Notes: insomnia. Adherence ~0.98. AE: no. CRP 11.5 mg/L; ALT 48 U/L. Plan: consider dose adjustment; counsel patient.
P03140,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: dizziness. Adherence ~1.00. AE: no.
P03140,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~1.00. AE: no.
P03140,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~1.00. AE: no. CRP 4.0 mg/L; ALT 21 U/L.
P03140,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: insomnia. Adherence ~0.87. AE: no.
P03140,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: dizziness. Adherence ~0.91. AE: no.
P03140,5,positive,Visit 5: Patient on RX-17B at S014. energy increasing. Notes: fatigue. Adherence ~1.00. AE: no. CRP 3.2 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P03140,6,neutral,Visit 6: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.99. AE: no.
P03140,7,neutral,Visit 7: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.96. AE: no. CRP 2.4 mg/L; ALT 20 U/L. Plan: consider dose adjustment; counsel patient.
P03141,0,negative,Visit 0: Patient on RX-17B at S022. increased discomfort. Notes: fatigue. Adherence ~0.99. AE: no.
P03141,1,neutral,Visit 1: Patient on RX-17B at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.88. AE: no.
P03141,2,negative,Visit 2: Patient on RX-17B at S022. feels frustrated. Notes: brain fog. Adherence ~0.98. AE: no.
P03141,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: abdominal discomfort. Adherence ~0.89. AE: no.
P03142,0,negative,Visit 0: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~0.89. AE: yes.
P03142,1,neutral,Visit 1: Patient on RX-17A at S014. reviewed dosing instructions. Notes: headache. Adherence ~0.97. AE: no.
P03142,2,neutral,Visit 2: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.97. AE: no. Plan: consider dose adjustment; counsel patient.
P03142,3,neutral,Visit 3: Patient on RX-17A at S014. continues regimen. Notes: insomnia. Adherence ~0.91. AE: yes.
P03142,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: dizziness. Adherence ~0.77. AE: no. CRP 4.7 mg/L; ALT 22 U/L.
P03142,5,negative,Visit 5: Patient on RX-17A at S014. increased discomfort. Notes: joint pain. Adherence ~1.00. AE: yes.
P03143,0,negative,Visit 0: Patient on RX-17A at S010. increased discomfort. Notes: insomnia. Adherence ~0.78. AE: no.
P03143,1,negative,Visit 1: Patient on RX-17A at S010. symptoms persist. Notes: headache. Adherence ~0.82. AE: yes.
P03143,2,negative,Visit 2: Patient on RX-17A at S010. increased discomfort. Notes: brain fog. Adherence ~0.92. AE: no.
P03143,3,neutral,Visit 3: Patient on RX-17A at S010. no major change. Notes: abdominal discomfort. Adherence ~0.66. AE: no.
P03143,4,neutral,Visit 4: Patient on RX-17A at S010. continues regimen. Notes: insomnia. Adherence ~0.84. AE: no.
P03143,5,neutral,Visit 5: Patient on RX-17A at S010. stable symptoms. Notes: joint pain. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P03144,0,negative,Visit 0: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~1.00. AE: yes. CRP 3.4 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P03144,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: abdominal discomfort. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03144,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: fatigue. Adherence ~0.91. AE: no.
P03144,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no. CRP 3.1 mg/L; ALT 36 U/L.
P03144,4,positive,Visit 4: Patient on RX-17B at S014. feels better overall. Notes: nausea. Adherence ~0.93. AE: no.
P03144,5,neutral,Visit 5: Patient on RX-17B at S014. stable symptoms. Notes: dizziness. Adherence ~0.89. AE: no.
P03145,0,negative,Visit 0: Patient on RX-17A at S002. poor tolerance. Notes: fatigue. Adherence ~0.70. AE: no. CRP 10.2 mg/L; ALT 36 U/L. Plan: consider dose adjustment; counsel patient.
P03145,1,negative,Visit 1: Patient on RX-17A at S002. symptoms persist. Notes: brain fog. Adherence ~0.65. AE: no. CRP 9.2 mg/L; ALT 34 U/L.
P03145,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: brain fog. Adherence ~0.47. AE: no.
P03145,3,neutral,Visit 3: Patient on RX-17A at S002. no major change. Notes: fatigue. Adherence ~0.60. AE: yes. CRP 8.4 mg/L; ALT 40 U/L.
P03145,4,neutral,Visit 4: Patient on RX-17A at S002. continues regimen. Notes: headache. Adherence ~0.64. AE: yes.
P03145,5,neutral,Visit 5: Patient on RX-17A at S002. continues regimen. Notes: joint pain. Adherence ~0.61. AE: no. Plan: consider dose adjustment; counsel patient.
P03145,6,neutral,Visit 6: Patient on RX-17A at S002. continues regimen. Notes: brain fog. Adherence ~0.43. AE: yes.
P03146,0,neutral,Visit 0: Patient on RX-17A at S018. stable symptoms. Notes: headache. Adherence ~1.00. AE: no.
P03146,1,neutral,Visit 1: Patient on RX-17A at S018. follow-up as scheduled. Notes: dizziness. Adherence ~0.89. AE: no.
P03146,2,neutral,Visit 2: Patient on RX-17A at S018. continues regimen. Notes: headache. Adherence ~0.85. AE: no. Plan: consider dose adjustment; counsel patient.
P03146,3,negative,Visit 3: Patient on RX-17A at S018. poor tolerance. Notes: abdominal discomfort. Adherence ~0.84. AE: no. CRP 7.2 mg/L; ALT 28 U/L.
P03147,0,neutral,Visit 0: Patient on RX-17B at S004. follow-up as scheduled. Notes: nausea. Adherence ~0.75. AE: no. CRP 9.1 mg/L; ALT 24 U/L. Plan: consider dose adjustment; counsel patient.
P03147,1,negative,Visit 1: Patient on RX-17B at S004. reports worsening. Notes: nausea. Adherence ~0.94. AE: no.
P03147,2,neutral,Visit 2: Patient on RX-17B at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.74. AE: no.
P03147,3,neutral,Visit 3: Patient on RX-17B at S004. reviewed dosing instructions. Notes: dizziness. Adherence ~0.64. AE: no.
P03147,4,negative,Visit 4: Patient on RX-17B at S004. increased discomfort. Notes: joint pain. Adherence ~0.82. AE: no. CRP 5.5 mg/L; ALT 28 U/L.
P03148,0,negative,Visit 0: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.74. AE: yes.
P03148,1,negative,Visit 1: Patient on RX-17A at S012. reports worsening. Notes: joint pain. Adherence ~0.92. AE: no. CRP 8.9 mg/L; ALT 47 U/L.
P03148,2,neutral,Visit 2: Patient on RX-17A at S012. no major change. Notes: headache. Adherence ~0.81. AE: no.
P03148,3,neutral,Visit 3: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P03148,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.97. AE: no. CRP 6.8 mg/L; ALT 42 U/L.
P03149,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: nausea. Adherence ~0.55. AE: no.
P03149,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: nausea. Adherence ~0.32. AE: yes. CRP 2.9 mg/L; ALT 26 U/L.
P03149,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: abdominal discomfort. Adherence ~0.41. AE: yes.
P03149,3,negative,Visit 3: Patient on RX-17B at S014. increased discomfort. Notes: headache. Adherence ~0.32. AE: yes. Plan: consider dose adjustment; counsel patient.
P03150,0,negative,Visit 0: Patient on RX-17B at S002. increased discomfort. Notes: brain fog. Adherence ~0.87. AE: no.
P03150,1,negative,Visit 1: Patient on RX-17B at S002. symptoms persist. Notes: joint pain. Adherence ~0.90. AE: yes. CRP 5.0 mg/L; ALT 33 U/L.
P03150,2,negative,Visit 2: Patient on RX-17B at S002. feels frustrated. Notes: dizziness. Adherence ~0.84. AE: yes.
P03150,3,neutral,Visit 3: Patient on RX-17B at S002. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P03150,4,neutral,Visit 4: Patient on RX-17B at S002. continues regimen. Notes: nausea. Adherence ~0.93. AE: no. CRP 3.9 mg/L; ALT 32 U/L.
P03151,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: dizziness. Adherence ~0.80. AE: no.
P03151,1,negative,Visit 1: Patient on RX-17A at S004. increased discomfort. Notes: fatigue. Adherence ~0.81. AE: yes. Plan: consider dose adjustment; counsel patient.
P03151,2,negative,Visit 2: Patient on RX-17A at S004. feels frustrated. Notes: insomnia. Adherence ~0.80. AE: no.
P03151,3,neutral,Visit 3: Patient on RX-17A at S004. follow-up as scheduled. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P03151,4,neutral,Visit 4: Patient on RX-17A at S004. reviewed dosing instructions. Notes: fatigue. Adherence ~0.77. AE: no.
P03151,5,positive,Visit 5: Patient on RX-17A at S004. tolerating medication well. Notes: headache. Adherence ~0.88. AE: no. CRP 3.7 mg/L; ALT 53 U/L.
P03151,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.71. AE: no.
P03152,0,negative,Visit 0: Patient on RX-17A at S016. symptoms persist. Notes: brain fog. Adherence ~0.59. AE: no. CRP 7.5 mg/L; ALT 17 U/L.
P03152,1,neutral,Visit 1: Patient on RX-17A at S016. no major change. Notes: brain fog. Adherence ~0.41. AE: no.
P03152,2,negative,Visit 2: Patient on RX-17A at S016. increased discomfort. Notes: joint pain. Adherence ~0.71. AE: no.
P03152,3,neutral,Visit 3: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.60. AE: no. CRP 6.1 mg/L; ALT 20 U/L.
P03152,4,neutral,Visit 4: Patient on RX-17A at S016. continues regimen. Notes: insomnia. Adherence ~0.83. AE: no. CRP 5.3 mg/L; ALT 18 U/L.
P03152,5,neutral,Visit 5: Patient on RX-17A at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.81. AE: no.
P03152,6,neutral,Visit 6: Patient on RX-17A at S016. reviewed dosing instructions. Notes: brain fog. Adherence ~0.73. AE: no.
P03152,7,neutral,Visit 7: Patient on RX-17A at S016. no major change. Notes: abdominal discomfort. Adherence ~0.60. AE: no.
P03153,0,negative,Visit 0: Patient on RX-17A at S004. feels frustrated. Notes: abdominal discomfort. Adherence ~0.98. AE: no. CRP 3.4 mg/L; ALT 27 U/L.
P03153,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: insomnia. Adherence ~1.00. AE: no.
P03153,2,neutral,Visit 2: Patient on RX-17A at S004. no major change. Notes: joint pain. Adherence ~0.83. AE: no.
P03153,3,neutral,Visit 3: Patient on RX-17A at S004. no major change. Notes: nausea. Adherence ~0.83. AE: no.
P03153,4,negative,Visit 4: Patient on RX-17A at S004. increased discomfort. Notes: headache. Adherence ~1.00. AE: yes.
P03153,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.78. AE: yes.
P03153,6,neutral,Visit 6: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~0.95. AE: yes.
P03153,7,positive,Visit 7: Patient on RX-17A at S004. reports improvement. Notes: dizziness. Adherence ~0.95. AE: no.
P03154,0,negative,Visit 0: Patient on RX-17A at S014. poor tolerance. Notes: joint pain. Adherence ~0.88. AE: no. Plan: consider dose adjustment; counsel patient.
P03154,1,neutral,Visit 1: Patient on RX-17A at S014. follow-up as scheduled. Notes: brain fog. Adherence ~0.69. AE: no.
P03154,2,neutral,Visit 2: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.91. AE: no.
P03154,3,neutral,Visit 3: Patient on RX-17A at S014. stable symptoms. Notes: insomnia. Adherence ~0.93. AE: no.
P03154,4,neutral,Visit 4: Patient on RX-17A at S014. reviewed dosing instructions. Notes: fatigue. Adherence ~0.73. AE: no. CRP 3.8 mg/L; ALT 42 U/L.
P03154,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: nausea. Adherence ~0.78. AE: no. CRP 3.0 mg/L; ALT 44 U/L.
P03155,0,negative,Visit 0: Patient on RX-17A at S012. poor tolerance. Notes: nausea. Adherence ~0.53. AE: no. Plan: consider dose adjustment; counsel patient.
P03155,1,negative,Visit 1: Patient on RX-17A at S012. symptoms persist. Notes: nausea. Adherence ~0.51. AE: no. CRP 6.1 mg/L; ALT 35 U/L.
P03155,2,neutral,Visit 2: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.62. AE: no.
P03155,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: fatigue. Adherence ~0.58. AE: no.
P03155,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: brain fog. Adherence ~0.65. AE: no.
P03155,5,neutral,Visit 5: Patient on RX-17A at S012. follow-up as scheduled. Notes: headache. Adherence ~0.48. AE: no. CRP 4.1 mg/L; ALT 34 U/L.
P03155,6,neutral,Visit 6: Patient on RX-17A at S012. no major change. Notes: dizziness. Adherence ~0.67. AE: no. CRP 3.5 mg/L; ALT 37 U/L.
P03156,0,neutral,Visit 0: Patient on RX-17B at S007. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no. CRP 10.9 mg/L; ALT 42 U/L.
P03156,1,negative,Visit 1: Patient on RX-17B at S007. poor tolerance. Notes: joint pain. Adherence ~0.67. AE: no.
P03156,2,neutral,Visit 2: Patient on RX-17B at S007. continues regimen. Notes: headache. Adherence ~0.84. AE: no.
P03156,3,neutral,Visit 3: Patient on RX-17B at S007. reviewed dosing instructions. Notes: insomnia. Adherence ~0.77. AE: no.
P03156,4,neutral,Visit 4: Patient on RX-17B at S007. reviewed dosing instructions. Notes: fatigue. Adherence ~0.71. AE: no. CRP 8.0 mg/L; ALT 47 U/L.
P03156,5,positive,Visit 5: Patient on RX-17B at S007. feels better overall. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P03156,6,positive,Visit 6: Patient on RX-17B at S007. symptoms improving. Notes: nausea. Adherence ~0.79. AE: no. Plan: consider dose adjustment; counsel patient.
P03156,7,positive,Visit 7: Patient on RX-17B at S007. energy increasing. Notes: brain fog. Adherence ~0.77. AE: no. CRP 4.7 mg/L; ALT 49 U/L.
P03157,0,negative,Visit 0: Patient on RX-17B at S005. feels frustrated. Notes: headache. Adherence ~1.00. AE: yes.
P03157,1,neutral,Visit 1: Patient on RX-17B at S005. continues regimen. Notes: insomnia. Adherence ~1.00. AE: no. CRP 8.3 mg/L; ALT 17 U/L.
P03157,2,negative,Visit 2: Patient on RX-17B at S005. feels frustrated. Notes: abdominal discomfort. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P03158,0,negative,Visit 0: Patient on RX-17A at S017. increased discomfort. Notes: abdominal discomfort. Adherence ~1.00. AE: yes.
P03158,1,negative,Visit 1: Patient on RX-17A at S017. reports worsening. Notes: joint pain. Adherence ~0.85. AE: yes.
P03158,2,negative,Visit 2: Patient on RX-17A at S017. poor tolerance. Notes: nausea. Adherence ~0.85. AE: no.
P03158,3,neutral,Visit 3: Patient on RX-17A at S017. no major change. Notes: insomnia. Adherence ~0.83. AE: no. Plan: consider dose adjustment; counsel patient.
P03158,4,negative,Visit 4: Patient on RX-17A at S017. reports worsening. Notes: headache. Adherence ~0.92. AE: no.
P03159,0,negative,Visit 0: Patient on RX-17B at S022. poor tolerance. Notes: headache. Adherence ~0.35. AE: yes. CRP 6.7 mg/L; ALT 28 U/L.
P03159,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: headache. Adherence ~0.18. AE: no.
P03159,2,negative,Visit 2: Patient on RX-17B at S022. poor tolerance. Notes: nausea. Adherence ~0.47. AE: no. CRP 6.0 mg/L; ALT 26 U/L.
P03159,3,neutral,Visit 3: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.48. AE: no. CRP 4.5 mg/L; ALT 26 U/L.
P03159,4,neutral,Visit 4: Patient on RX-17B at S022. no major change. Notes: headache. Adherence ~0.32. AE: no.
P03159,5,neutral,Visit 5: Patient on RX-17B at S022. stable symptoms. Notes: nausea. Adherence ~0.27. AE: no.
P03160,0,negative,Visit 0: Patient on RX-17A at S004. reports worsening. Notes: insomnia. Adherence ~1.00. AE: no. CRP 8.5 mg/L; ALT 67 U/L.
P03160,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.99. AE: no.
P03160,2,neutral,Visit 2: Patient on RX-17A at S004. follow-up as scheduled. Notes: fatigue. Adherence ~1.00. AE: no. CRP 6.3 mg/L; ALT 73 U/L.
P03160,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.98. AE: yes.
P03160,4,neutral,Visit 4: Patient on RX-17A at S004. continues regimen. Notes: insomnia. Adherence ~0.96. AE: no.
P03160,5,neutral,Visit 5: Patient on RX-17A at S004. follow-up as scheduled. Notes: brain fog. Adherence ~1.00. AE: no.
P03160,6,neutral,Visit 6: Patient on RX-17A at S004. reviewed dosing instructions. Notes: headache. Adherence ~1.00. AE: no.
P03160,7,neutral,Visit 7: Patient on RX-17A at S004. reviewed dosing instructions. Notes: joint pain. Adherence ~0.99. AE: no.
P03161,0,negative,Visit 0: Patient on RX-17A at S022. increased discomfort. Notes: insomnia. Adherence ~0.61. AE: yes. CRP 9.3 mg/L; ALT 44 U/L. Plan: consider dose adjustment; counsel patient.
P03161,1,negative,Visit 1: Patient on RX-17A at S022. reports worsening. Notes: fatigue. Adherence ~0.77. AE: no.
P03161,2,neutral,Visit 2: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.84. AE: no.
P03161,3,neutral,Visit 3: Patient on RX-17A at S022. follow-up as scheduled. Notes: insomnia. Adherence ~0.72. AE: no. CRP 8.6 mg/L; ALT 40 U/L.
P03161,4,neutral,Visit 4: Patient on RX-17A at S022. continues regimen. Notes: brain fog. Adherence ~0.73. AE: no.
P03162,0,negative,Visit 0: Patient on RX-17B at S015. feels frustrated. Notes: dizziness. Adherence ~0.68. AE: yes.
P03162,1,neutral,Visit 1: Patient on RX-17B at S015. no major change. Notes: joint pain. Adherence ~0.95. AE: no. CRP 6.0 mg/L; ALT 28 U/L.
P03162,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: brain fog. Adherence ~0.93. AE: no.
P03162,3,neutral,Visit 3: Patient on RX-17B at S015. no major change. Notes: dizziness. Adherence ~1.00. AE: no. Plan: consider dose adjustment; counsel patient.
P03162,4,neutral,Visit 4: Patient on RX-17B at S015. continues regimen. Notes: abdominal discomfort. Adherence ~0.99. AE: no.
P03162,5,positive,Visit 5: Patient on RX-17B at S015. energy increasing. Notes: dizziness. Adherence ~0.93. AE: no. CRP 4.3 mg/L; ALT 33 U/L.
P03162,6,positive,Visit 6: Patient on RX-17B at S015. tolerating medication well. Notes: headache. Adherence ~0.89. AE: no. CRP 3.5 mg/L; ALT 33 U/L.
P03163,0,neutral,Visit 0: Patient on RX-17A at S015. reviewed dosing instructions. Notes: dizziness. Adherence ~0.88. AE: no. CRP 4.8 mg/L; ALT 34 U/L.
P03163,1,negative,Visit 1: Patient on RX-17A at S015. poor tolerance. Notes: brain fog. Adherence ~0.73. AE: no. CRP 3.9 mg/L; ALT 33 U/L.
P03163,2,neutral,Visit 2: Patient on RX-17A at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.85. AE: no.
P03163,3,neutral,Visit 3: Patient on RX-17A at S015. follow-up as scheduled. Notes: fatigue. Adherence ~0.75. AE: no.
P03163,4,neutral,Visit 4: Patient on RX-17A at S015. continues regimen. Notes: joint pain. Adherence ~0.89. AE: no.
P03163,5,neutral,Visit 5: Patient on RX-17A at S015. no major change. Notes: joint pain. Adherence ~0.81. AE: no.
P03163,6,neutral,Visit 6: Patient on RX-17A at S015. stable symptoms. Notes: abdominal discomfort. Adherence ~0.79. AE: no. CRP 3.4 mg/L; ALT 34 U/L.
P03164,0,negative,Visit 0: Patient on RX-17B at S016. symptoms persist. Notes: fatigue. Adherence ~0.80. AE: no. CRP 3.3 mg/L; ALT 30 U/L.
P03164,1,negative,Visit 1: Patient on RX-17B at S016. feels frustrated. Notes: nausea. Adherence ~0.68. AE: yes. CRP 2.8 mg/L; ALT 31 U/L.
P03164,2,neutral,Visit 2: Patient on RX-17B at S016. continues regimen. Notes: fatigue. Adherence ~0.79. AE: no.
P03164,3,neutral,Visit 3: Patient on RX-17B at S016. stable symptoms. Notes: fatigue. Adherence ~0.58. AE: no.
P03164,4,neutral,Visit 4: Patient on RX-17B at S016. follow-up as scheduled. Notes: fatigue. Adherence ~0.79. AE: no.
P03164,5,neutral,Visit 5: Patient on RX-17B at S016. stable symptoms. Notes: nausea. Adherence ~0.61. AE: no. CRP 1.6 mg/L; ALT 33 U/L.
P03164,6,neutral,Visit 6: Patient on RX-17B at S016. continues regimen. Notes: headache. Adherence ~0.66. AE: no.
P03164,7,neutral,Visit 7: Patient on RX-17B at S016. no major change. Notes: abdominal discomfort. Adherence ~0.67. AE: no. CRP 1.6 mg/L; ALT 36 U/L.
P03165,0,negative,Visit 0: Patient on RX-17A at S016. feels frustrated. Notes: insomnia. Adherence ~0.85. AE: no.
P03165,1,negative,Visit 1: Patient on RX-17A at S016. feels frustrated. Notes: joint pain. Adherence ~0.84. AE: no. CRP 5.0 mg/L; ALT 37 U/L.
P03165,2,neutral,Visit 2: Patient on RX-17A at S016. continues regimen. Notes: brain fog. Adherence ~0.71. AE: no. CRP 5.5 mg/L; ALT 40 U/L.
P03165,3,neutral,Visit 3: Patient on RX-17A at S016. continues regimen. Notes: fatigue. Adherence ~0.90. AE: no.
P03165,4,neutral,Visit 4: Patient on RX-17A at S016. no major change. Notes: nausea. Adherence ~0.72. AE: no. CRP 4.5 mg/L; ALT 40 U/L.
P03165,5,neutral,Visit 5: Patient on RX-17A at S016. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.74. AE: no.
P03165,6,neutral,Visit 6: Patient on RX-17A at S016. follow-up as scheduled. Notes: joint pain. Adherence ~0.51. AE: no.
P03165,7,neutral,Visit 7: Patient on RX-17A at S016. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: yes.
P03166,0,negative,Visit 0: Patient on RX-17B at S018. reports worsening. Notes: fatigue. Adherence ~0.81. AE: no. Plan: consider dose adjustment; counsel patient.
P03166,1,negative,Visit 1: Patient on RX-17B at S018. increased discomfort. Notes: joint pain. Adherence ~0.83. AE: no.
P03166,2,neutral,Visit 2: Patient on RX-17B at S018. no major change. Notes: headache. Adherence ~0.81. AE: no.
P03166,3,neutral,Visit 3: Patient on RX-17B at S018. stable symptoms. Notes: nausea. Adherence ~0.86. AE: no.
P03166,4,positive,Visit 4: Patient on RX-17B at S018. reports improvement. Notes: abdominal discomfort. Adherence ~0.89. AE: no. CRP 8.9 mg/L; ALT 25 U/L.
P03166,5,neutral,Visit 5: Patient on RX-17B at S018. continues regimen. Notes: dizziness. Adherence ~0.92. AE: no.
P03166,6,positive,Visit 6: Patient on RX-17B at S018. tolerating medication well. Notes: joint pain. Adherence ~0.94. AE: no. CRP 6.0 mg/L; ALT 24 U/L.
P03166,7,neutral,Visit 7: Patient on RX-17B at S018. reviewed dosing instructions. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 5.0 mg/L; ALT 28 U/L.
P03167,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: abdominal discomfort. Adherence ~0.76. AE: no. CRP 16.2 mg/L; ALT 45 U/L.
P03167,1,negative,Visit 1: Patient on RX-17B at S014. reports worsening. Notes: joint pain. Adherence ~0.72. AE: yes.
P03167,2,neutral,Visit 2: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.73. AE: no.
P03167,3,neutral,Visit 3: Patient on RX-17B at S014. continues regimen. Notes: dizziness. Adherence ~0.60. AE: no.
P03167,4,neutral,Visit 4: Patient on RX-17B at S014. continues regimen. Notes: joint pain. Adherence ~0.54. AE: no. CRP 10.8 mg/L; ALT 54 U/L. Plan: consider dose adjustment; counsel patient.
P03167,5,positive,Visit 5: Patient on RX-17B at S014. tolerating medication well. Notes: abdominal discomfort. Adherence ~0.82. AE: no. CRP 8.2 mg/L; ALT 51 U/L.
P03167,6,neutral,Visit 6: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.66. AE: no.
P03168,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: nausea. Adherence ~0.13. AE: no. Plan: consider dose adjustment; counsel patient.
P03168,1,neutral,Visit 1: Patient on RX-17B at S014. continues regimen. Notes: fatigue. Adherence ~0.49. AE: no. Plan: consider dose adjustment; counsel patient.
P03168,2,neutral,Visit 2: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.19. AE: no. CRP 3.7 mg/L; ALT 18 U/L.
P03168,3,neutral,Visit 3: Patient on RX-17B at S014. stable symptoms. Notes: joint pain. Adherence ~0.30. AE: no.
P03168,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: nausea. Adherence ~0.20. AE: no.
P03169,0,negative,Visit 0: Patient on RX-17B at S012. increased discomfort. Notes: insomnia. Adherence ~0.75. AE: yes.
P03169,1,neutral,Visit 1: Patient on RX-17B at S012. no major change. Notes: brain fog. Adherence ~0.72. AE: no. CRP 2.6 mg/L; ALT 34 U/L.
P03169,2,negative,Visit 2: Patient on RX-17B at S012. feels frustrated. Notes: nausea. Adherence ~0.83. AE: no. CRP 2.2 mg/L; ALT 34 U/L.
P03169,3,neutral,Visit 3: Patient on RX-17B at S012. reviewed dosing instructions. Notes: headache. Adherence ~0.99. AE: no. CRP 2.0 mg/L; ALT 34 U/L.
P03169,4,neutral,Visit 4: Patient on RX-17B at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.87. AE: yes.
P03169,5,neutral,Visit 5: Patient on RX-17B at S012. reviewed dosing instructions. Notes: insomnia. Adherence ~0.63. AE: yes.
P03169,6,neutral,Visit 6: Patient on RX-17B at S012. follow-up as scheduled. Notes: brain fog. Adherence ~0.69. AE: no.
P03169,7,positive,Visit 7: Patient on RX-17B at S012. energy increasing. Notes: fatigue. Adherence ~0.98. AE: no. CRP 1.3 mg/L; ALT 37 U/L.
P03170,0,negative,Visit 0: Patient on RX-17A at S004. increased discomfort. Notes: dizziness. Adherence ~0.86. AE: no. CRP 11.5 mg/L; ALT 22 U/L.
P03170,1,neutral,Visit 1: Patient on RX-17A at S004. stable symptoms. Notes: dizziness. Adherence ~1.00. AE: no.
P03170,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: abdominal discomfort. Adherence ~0.74. AE: no. CRP 12.8 mg/L; ALT 23 U/L.
P03170,3,negative,Visit 3: Patient on RX-17A at S004. increased discomfort. Notes: abdominal discomfort. Adherence ~0.72. AE: no.
P03170,4,neutral,Visit 4: Patient on RX-17A at S004. stable symptoms. Notes: headache. Adherence ~0.92. AE: no.
P03171,0,neutral,Visit 0: Patient on RX-17B at S015. stable symptoms. Notes: dizziness. Adherence ~0.74. AE: no. Plan: consider dose adjustment; counsel patient.
P03171,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: headache. Adherence ~0.89. AE: no. CRP 7.6 mg/L; ALT 31 U/L.
P03171,2,neutral,Visit 2: Patient on RX-17B at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.76. AE: no. CRP 6.5 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P03172,0,neutral,Visit 0: Patient on RX-17A at S002. follow-up as scheduled. Notes: insomnia. Adherence ~0.54. AE: no. CRP 3.3 mg/L; ALT 46 U/L.
P03172,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: fatigue. Adherence ~0.48. AE: yes. CRP 3.0 mg/L; ALT 44 U/L.
P03172,2,neutral,Visit 2: Patient on RX-17A at S002. stable symptoms. Notes: abdominal discomfort. Adherence ~0.63. AE: no. CRP 3.2 mg/L; ALT 45 U/L.
P03172,3,negative,Visit 3: Patient on RX-17A at S002. poor tolerance. Notes: insomnia. Adherence ~0.53. AE: no.
P03173,0,negative,Visit 0: Patient on RX-17A at S011. reports worsening. Notes: abdominal discomfort. Adherence ~0.76. AE: no.
P03173,1,neutral,Visit 1: Patient on RX-17A at S011. reviewed dosing instructions. Notes: fatigue. Adherence ~0.92. AE: no.
P03173,2,neutral,Visit 2: Patient on RX-17A at S011. stable symptoms. Notes: dizziness. Adherence ~0.82. AE: no. CRP 1.1 mg/L; ALT 17 U/L.
P03173,3,negative,Visit 3: Patient on RX-17A at S011. poor tolerance. Notes: headache. Adherence ~0.79. AE: no.
P03173,4,positive,Visit 4: Patient on RX-17A at S011. energy increasing. Notes: dizziness. Adherence ~0.85. AE: no. CRP 1.0 mg/L; ALT 18 U/L.
P03174,0,negative,Visit 0: Patient on RX-17A at S004. symptoms persist. Notes: joint pain. Adherence ~0.93. AE: no.
P03174,1,neutral,Visit 1: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~1.00. AE: no. CRP 4.4 mg/L; ALT 28 U/L.
P03174,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: brain fog. Adherence ~0.90. AE: no.
P03174,3,negative,Visit 3: Patient on RX-17A at S004. poor tolerance. Notes: nausea. Adherence ~0.76. AE: no.
P03174,4,neutral,Visit 4: Patient on RX-17A at S004. no major change. Notes: abdominal discomfort. Adherence ~0.69. AE: no. CRP 3.7 mg/L; ALT 28 U/L.
P03174,5,neutral,Visit 5: Patient on RX-17A at S004. continues regimen. Notes: dizziness. Adherence ~0.83. AE: yes.
P03174,6,neutral,Visit 6: Patient on RX-17A at S004. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.78. AE: no.
P03175,0,neutral,Visit 0: Patient on RX-17B at S005. follow-up as scheduled. Notes: insomnia. Adherence ~0.87. AE: no.
P03175,1,negative,Visit 1: Patient on RX-17B at S005. poor tolerance. Notes: joint pain. Adherence ~0.77. AE: yes.
P03175,2,positive,Visit 2: Patient on RX-17B at S005. reports improvement. Notes: fatigue. Adherence ~1.00. AE: no. CRP 4.7 mg/L; ALT 19 U/L.
P03175,3,neutral,Visit 3: Patient on RX-17B at S005. no major change. Notes: nausea. Adherence ~1.00. AE: no.
P03175,4,neutral,Visit 4: Patient on RX-17B at S005. no major change. Notes: dizziness. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P03176,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~1.00. AE: no.
P03176,1,negative,Visit 1: Patient on RX-17B at S015. reports worsening. Notes: headache. Adherence ~0.87. AE: no.
P03176,2,neutral,Visit 2: Patient on RX-17B at S015. continues regimen. Notes: nausea. Adherence ~0.68. AE: no. CRP 3.1 mg/L; ALT 28 U/L.
P03177,0,negative,Visit 0: Patient on RX-17A at S015. increased discomfort. Notes: headache. Adherence ~0.82. AE: yes. CRP 12.6 mg/L; ALT 22 U/L.
P03177,1,neutral,Visit 1: Patient on RX-17A at S015. reviewed dosing instructions. Notes: nausea. Adherence ~0.95. AE: no.
P03177,2,neutral,Visit 2: Patient on RX-17A at S015. no major change. Notes: headache. Adherence ~1.00. AE: no. CRP 9.6 mg/L; ALT 16 U/L.
P03177,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P03177,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: nausea. Adherence ~0.86. AE: no.
P03178,0,negative,Visit 0: Patient on RX-17B at S013. symptoms persist. Notes: joint pain. Adherence ~0.99. AE: no. CRP 4.4 mg/L; ALT 32 U/L. Plan: consider dose adjustment; counsel patient.
P03178,1,neutral,Visit 1: Patient on RX-17B at S013. no major change. Notes: joint pain. Adherence ~0.82. AE: no. CRP 4.2 mg/L; ALT 33 U/L. Plan: consider dose adjustment; counsel patient.
P03178,2,negative,Visit 2: Patient on RX-17B at S013. reports worsening. Notes: fatigue. Adherence ~0.89. AE: no. CRP 4.0 mg/L; ALT 34 U/L.
P03178,3,neutral,Visit 3: Patient on RX-17B at S013. stable symptoms. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P03178,4,neutral,Visit 4: Patient on RX-17B at S013. follow-up as scheduled. Notes: brain fog. Adherence ~0.92. AE: no.
P03179,0,negative,Visit 0: Patient on RX-17A at S004. poor tolerance. Notes: insomnia. Adherence ~0.54. AE: no. CRP 7.6 mg/L; ALT 23 U/L. Plan: consider dose adjustment; counsel patient.
P03179,1,negative,Visit 1: Patient on RX-17A at S004. poor tolerance. Notes: brain fog. Adherence ~0.54. AE: no.
P03179,2,neutral,Visit 2: Patient on RX-17A at S004. stable symptoms. Notes: joint pain. Adherence ~0.82. AE: no. CRP 6.3 mg/L; ALT 27 U/L. Plan: consider dose adjustment; counsel patient.
P03179,3,negative,Visit 3: Patient on RX-17A at S004. reports worsening. Notes: nausea. Adherence ~0.76. AE: yes. CRP 7.2 mg/L; ALT 28 U/L.
P03180,0,negative,Visit 0: Patient on RX-17B at S013. increased discomfort. Notes: insomnia. Adherence ~0.83. AE: no.
P03180,1,neutral,Visit 1: Patient on RX-17B at S013. follow-up as scheduled. Notes: joint pain. Adherence ~0.95. AE: no. CRP 23.7 mg/L; ALT 40 U/L.
P03180,2,positive,Visit 2: Patient on RX-17B at S013. reports improvement. Notes: joint pain. Adherence ~0.99. AE: no.
P03180,3,neutral,Visit 3: Patient on RX-17B at S013. reviewed dosing instructions. Notes: joint pain. Adherence ~0.96. AE: no. CRP 20.1 mg/L; ALT 40 U/L.
P03180,4,neutral,Visit 4: Patient on RX-17B at S013. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no.
P03181,0,neutral,Visit 0: Patient on RX-17B at S012. stable symptoms. Notes: headache. Adherence ~0.83. AE: no.
P03181,1,negative,Visit 1: Patient on RX-17B at S012. reports worsening. Notes: fatigue. Adherence ~0.90. AE: no. CRP 7.1 mg/L; ALT 47 U/L.
P03181,2,neutral,Visit 2: Patient on RX-17B at S012. continues regimen. Notes: abdominal discomfort. Adherence ~0.95. AE: no.
P03181,3,neutral,Visit 3: Patient on RX-17B at S012. continues regimen. Notes: dizziness. Adherence ~1.00. AE: no.
P03181,4,positive,Visit 4: Patient on RX-17B at S012. energy increasing. Notes: abdominal discomfort. Adherence ~0.87. AE: no.
P03181,5,neutral,Visit 5: Patient on RX-17B at S012. follow-up as scheduled. Notes: insomnia. Adherence ~0.96. AE: no.
P03181,6,positive,Visit 6: Patient on RX-17B at S012. tolerating medication well. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P03181,7,positive,Visit 7: Patient on RX-17B at S012. feels better overall. Notes: fatigue. Adherence ~0.80. AE: no. CRP 3.5 mg/L; ALT 49 U/L.
P03182,0,neutral,Visit 0: Patient on RX-17A at S017. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.86. AE: no.
P03182,1,negative,Visit 1: Patient on RX-17A at S017. symptoms persist. Notes: fatigue. Adherence ~0.66. AE: no.
P03182,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: fatigue. Adherence ~0.96. AE: no.
P03182,3,negative,Visit 3: Patient on RX-17A at S017. symptoms persist. Notes: brain fog. Adherence ~0.70. AE: no. CRP 6.4 mg/L; ALT 36 U/L.
P03182,4,neutral,Visit 4: Patient on RX-17A at S017. follow-up as scheduled. Notes: brain fog. Adherence ~0.78. AE: no.
P03183,0,negative,Visit 0: Patient on RX-17B at S015. reports worsening. Notes: fatigue. Adherence ~0.78. AE: no.
P03183,1,neutral,Visit 1: Patient on RX-17B at S015. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.72. AE: no. CRP 6.0 mg/L; ALT 40 U/L.
P03183,2,negative,Visit 2: Patient on RX-17B at S015. reports worsening. Notes: abdominal discomfort. Adherence ~0.77. AE: no.
P03183,3,neutral,Visit 3: Patient on RX-17B at S015. follow-up as scheduled. Notes: dizziness. Adherence ~0.77. AE: no.
P03183,4,negative,Visit 4: Patient on RX-17B at S015. symptoms persist. Notes: insomnia. Adherence ~0.87. AE: yes.
P03183,5,neutral,Visit 5: Patient on RX-17B at S015. stable symptoms. Notes: headache. Adherence ~0.77. AE: yes.
P03184,0,negative,Visit 0: Patient on RX-17B at S014. reports worsening. Notes: fatigue. Adherence ~0.76. AE: no. CRP 10.4 mg/L; ALT 44 U/L.
P03184,1,negative,Visit 1: Patient on RX-17B at S014. poor tolerance. Notes: joint pain. Adherence ~0.89. AE: no.
P03184,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: headache. Adherence ~1.00. AE: yes. Plan: consider dose adjustment; counsel patient.
P03184,3,positive,Visit 3: Patient on RX-17B at S014. tolerating medication well. Notes: joint pain. Adherence ~0.89. AE: no.
P03184,4,neutral,Visit 4: Patient on RX-17B at S014. no major change. Notes: brain fog. Adherence ~0.93. AE: no.
P03184,5,negative,Visit 5: Patient on RX-17B at S014. reports worsening. Notes: headache. Adherence ~0.93. AE: yes.
P03184,6,positive,Visit 6: Patient on RX-17B at S014. feels better overall. Notes: abdominal discomfort. Adherence ~0.85. AE: no. CRP 5.6 mg/L; ALT 52 U/L.
P03185,0,neutral,Visit 0: Patient on RX-17B at S014. continues regimen. Notes: nausea. Adherence ~0.66. AE: no.
P03185,1,neutral,Visit 1: Patient on RX-17B at S014. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.78. AE: yes. Plan: consider dose adjustment; counsel patient.
P03185,2,negative,Visit 2: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.60. AE: yes. CRP 8.9 mg/L; ALT 24 U/L.
P03185,3,neutral,Visit 3: Patient on RX-17B at S014. reviewed dosing instructions. Notes: insomnia. Adherence ~0.65. AE: no. CRP 8.0 mg/L; ALT 24 U/L.
P03185,4,neutral,Visit 4: Patient on RX-17B at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.59. AE: no.
P03185,5,neutral,Visit 5: Patient on RX-17B at S014. follow-up as scheduled. Notes: nausea. Adherence ~0.46. AE: yes.
P03185,6,positive,Visit 6: Patient on RX-17B at S014. reports improvement. Notes: fatigue. Adherence ~0.84. AE: no.
P03185,7,neutral,Visit 7: Patient on RX-17B at S014. stable symptoms. Notes: headache. Adherence ~0.68. AE: no.
P03186,0,negative,Visit 0: Patient on RX-17B at S022. symptoms persist. Notes: nausea. Adherence ~0.79. AE: yes.
P03186,1,neutral,Visit 1: Patient on RX-17B at S022. continues regimen. Notes: fatigue. Adherence ~0.77. AE: no. CRP 4.3 mg/L; ALT 53 U/L.
P03186,2,neutral,Visit 2: Patient on RX-17B at S022. reviewed dosing instructions. Notes: fatigue. Adherence ~0.59. AE: no.
P03186,3,neutral,Visit 3: Patient on RX-17B at S022. no major change. Notes: insomnia. Adherence ~0.80. AE: no. CRP 3.4 mg/L; ALT 54 U/L.
P03186,4,negative,Visit 4: Patient on RX-17B at S022. feels frustrated. Notes: dizziness. Adherence ~0.71. AE: yes.
P03186,5,negative,Visit 5: Patient on RX-17B at S022. reports worsening. Notes: brain fog. Adherence ~0.79. AE: no.
P03187,0,neutral,Visit 0: Patient on RX-17A at S017. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.86. AE: no. CRP 5.9 mg/L; ALT 30 U/L.
P03187,1,neutral,Visit 1: Patient on RX-17A at S017. reviewed dosing instructions. Notes: insomnia. Adherence ~0.96. AE: no.
P03187,2,neutral,Visit 2: Patient on RX-17A at S017. continues regimen. Notes: nausea. Adherence ~0.85. AE: no. CRP 5.4 mg/L; ALT 29 U/L.
P03187,3,neutral,Visit 3: Patient on RX-17A at S017. stable symptoms. Notes: insomnia. Adherence ~0.89. AE: no.
P03187,4,neutral,Visit 4: Patient on RX-17A at S017. stable symptoms. Notes: fatigue. Adherence ~0.86. AE: no. CRP 4.4 mg/L; ALT 32 U/L.
P03187,5,neutral,Visit 5: Patient on RX-17A at S017. stable symptoms. Notes: joint pain. Adherence ~0.86. AE: no. Plan: consider dose adjustment; counsel patient.
P03187,6,positive,Visit 6: Patient on RX-17A at S017. tolerating medication well. Notes: dizziness. Adherence ~0.83. AE: no. CRP 4.1 mg/L; ALT 28 U/L.
P03187,7,neutral,Visit 7: Patient on RX-17A at S017. follow-up as scheduled. Notes: insomnia. Adherence ~0.69. AE: yes. CRP 2.9 mg/L; ALT 33 U/L.
P03188,0,negative,Visit 0: Patient on RX-17A at S014. symptoms persist. Notes: joint pain. Adherence ~0.73. AE: no.
P03188,1,neutral,Visit 1: Patient on RX-17A at S014. stable symptoms. Notes: fatigue. Adherence ~0.83. AE: no.
P03188,2,negative,Visit 2: Patient on RX-17A at S014. symptoms persist. Notes: fatigue. Adherence ~0.77. AE: no.
P03188,3,neutral,Visit 3: Patient on RX-17A at S014. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.85. AE: no.
P03188,4,negative,Visit 4: Patient on RX-17A at S014. poor tolerance. Notes: abdominal discomfort. Adherence ~0.65. AE: no.
P03188,5,neutral,Visit 5: Patient on RX-17A at S014. no major change. Notes: joint pain. Adherence ~0.73. AE: no.
P03189,0,negative,Visit 0: Patient on RX-17B at S014. feels frustrated. Notes: brain fog. Adherence ~0.76. AE: yes. Plan: consider dose adjustment; counsel patient.
P03189,1,negative,Visit 1: Patient on RX-17B at S014. symptoms persist. Notes: brain fog. Adherence ~0.66. AE: no.
P03189,2,neutral,Visit 2: Patient on RX-17B at S014. continues regimen. Notes: insomnia. Adherence ~0.63. AE: yes. CRP 5.6 mg/L; ALT 38 U/L.
P03189,3,negative,Visit 3: Patient on RX-17B at S014. symptoms persist. Notes: dizziness. Adherence ~0.64. AE: no.
P03189,4,negative,Visit 4: Patient on RX-17B at S014. symptoms persist. Notes: headache. Adherence ~0.43. AE: no.
P03190,0,negative,Visit 0: Patient on RX-17A at S002. feels frustrated. Notes: headache. Adherence ~0.68. AE: no. Plan: consider dose adjustment; counsel patient.
P03190,1,negative,Visit 1: Patient on RX-17A at S002. feels frustrated. Notes: joint pain. Adherence ~0.78. AE: yes.
P03190,2,negative,Visit 2: Patient on RX-17A at S002. increased discomfort. Notes: insomnia. Adherence ~0.69. AE: no. CRP 15.7 mg/L; ALT 28 U/L.
P03191,0,negative,Visit 0: Patient on RX-17A at S022. symptoms persist. Notes: headache. Adherence ~0.54. AE: no.
P03191,1,negative,Visit 1: Patient on RX-17A at S022. increased discomfort. Notes: dizziness. Adherence ~0.50. AE: no. CRP 9.9 mg/L; ALT 18 U/L.
P03191,2,negative,Visit 2: Patient on RX-17A at S022. symptoms persist. Notes: abdominal discomfort. Adherence ~0.41. AE: no.
P03191,3,neutral,Visit 3: Patient on RX-17A at S022. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.47. AE: no.
P03191,4,neutral,Visit 4: Patient on RX-17A at S022. stable symptoms. Notes: headache. Adherence ~0.74. AE: no. CRP 8.3 mg/L; ALT 17 U/L.
P03191,5,neutral,Visit 5: Patient on RX-17A at S022. reviewed dosing instructions. Notes: nausea. Adherence ~0.55. AE: no.
P03191,6,neutral,Visit 6: Patient on RX-17A at S022. stable symptoms. Notes: insomnia. Adherence ~0.62. AE: no.
P03191,7,neutral,Visit 7: Patient on RX-17A at S022. stable symptoms. Notes: fatigue. Adherence ~0.47. AE: yes. CRP 5.9 mg/L; ALT 21 U/L. Plan: consider dose adjustment; counsel patient.
P03192,0,negative,Visit 0: Patient on RX-17A at S012. reports worsening. Notes: fatigue. Adherence ~0.71. AE: no.
P03192,1,negative,Visit 1: Patient on RX-17A at S012. feels frustrated. Notes: brain fog. Adherence ~0.82. AE: no. CRP 6.3 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P03192,2,negative,Visit 2: Patient on RX-17A at S012. poor tolerance. Notes: dizziness. Adherence ~1.00. AE: no.
P03192,3,neutral,Visit 3: Patient on RX-17A at S012. stable symptoms. Notes: insomnia. Adherence ~0.84. AE: no. CRP 5.8 mg/L; ALT 22 U/L. Plan: consider dose adjustment; counsel patient.
P03192,4,neutral,Visit 4: Patient on RX-17A at S012. stable symptoms. Notes: headache. Adherence ~0.73. AE: no.
P03192,5,neutral,Visit 5: Patient on RX-17A at S012. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.75. AE: yes. CRP 4.6 mg/L; ALT 24 U/L.
P03192,6,positive,Visit 6: Patient on RX-17A at S012. feels better overall. Notes: insomnia. Adherence ~0.94. AE: no. Plan: consider dose adjustment; counsel patient.
P03192,7,positive,Visit 7: Patient on RX-17A at S012. energy increasing. Notes: nausea. Adherence ~0.91. AE: no.
P03193,0,negative,Visit 0: Patient on RX-17B at S008. increased discomfort. Notes: joint pain. Adherence ~0.61. AE: no. CRP 15.4 mg/L; ALT 57 U/L.
P03193,1,negative,Visit 1: Patient on RX-17B at S008. increased discomfort. Notes: headache. Adherence ~0.74. AE: yes.
P03193,2,negative,Visit 2: Patient on RX-17B at S008. poor tolerance. Notes: dizziness. Adherence ~0.64. AE: no.
P03193,3,neutral,Visit 3: Patient on RX-17B at S008. follow-up as scheduled. Notes: dizziness. Adherence ~0.54. AE: no. CRP 10.8 mg/L; ALT 54 U/L.
P03193,4,neutral,Visit 4: Patient on RX-17B at S008. stable symptoms. Notes: dizziness. Adherence ~0.45. AE: no. CRP 10.2 mg/L; ALT 61 U/L.
P03193,5,neutral,Visit 5: Patient on RX-17B at S008. reviewed dosing instructions. Notes: abdominal discomfort. Adherence ~0.70. AE: yes. Plan: consider dose adjustment; counsel patient.
P03193,6,neutral,Visit 6: Patient on RX-17B at S008. continues regimen. Notes: fatigue. Adherence ~0.62. AE: no.
P03194,0,neutral,Visit 0: Patient on RX-17B at S022. no major change. Notes: dizziness. Adherence ~0.64. AE: no.
P03194,1,neutral,Visit 1: Patient on RX-17B at S022. no major change. Notes: brain fog. Adherence ~0.66. AE: no. CRP 7.7 mg/L; ALT 33 U/L.
P03194,2,neutral,Visit 2: Patient on RX-17B at S022. stable symptoms. Notes: brain fog. Adherence ~0.57. AE: no.
P03194,3,negative,Visit 3: Patient on RX-17B at S022. symptoms persist. Notes: brain fog. Adherence ~0.68. AE: yes.
P03194,4,neutral,Visit 4: Patient on RX-17B at S022. follow-up as scheduled. Notes: joint pain. Adherence ~0.51. AE: no. CRP 6.0 mg/L; ALT 33 U/L.
P03195,0,negative,Visit 0: Patient on RX-17B at S017. reports worsening. Notes: dizziness. Adherence ~0.97. AE: yes. CRP 3.0 mg/L; ALT 55 U/L.
P03195,1,neutral,Visit 1: Patient on RX-17B at S017. stable symptoms. Notes: nausea. Adherence ~1.00. AE: no. CRP 2.8 mg/L; ALT 51 U/L.
P03195,2,negative,Visit 2: Patient on RX-17B at S017. feels frustrated. Notes: fatigue. Adherence ~0.96. AE: no.
P03195,3,positive,Visit 3: Patient on RX-17B at S017. energy increasing. Notes: joint pain. Adherence ~1.00. AE: no. CRP 2.0 mg/L; ALT 56 U/L.
P03195,4,neutral,Visit 4: Patient on RX-17B at S017. reviewed dosing instructions. Notes: dizziness. Adherence ~1.00. AE: no.
P03196,0,neutral,Visit 0: Patient on RX-17B at S002. no major change. Notes: headache. Adherence ~0.78. AE: no.
P03196,1,neutral,Visit 1: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.91. AE: no.
P03196,2,neutral,Visit 2: Patient on RX-17B at S002. no major change. Notes: insomnia. Adherence ~0.92. AE: no. CRP 13.4 mg/L; ALT 26 U/L.
P03196,3,positive,Visit 3: Patient on RX-17B at S002. energy increasing. Notes: nausea. Adherence ~0.76. AE: no. CRP 12.2 mg/L; ALT 26 U/L.
P03196,4,positive,Visit 4: Patient on RX-17B at S002. energy increasing. Notes: joint pain. Adherence ~0.80. AE: no.
P03197,0,neutral,Visit 0: Patient on RX-17B at S003. stable symptoms. Notes: nausea. Adherence ~0.88. AE: no.
P03197,1,negative,Visit 1: Patient on RX-17B at S003. poor tolerance. Notes: nausea. Adherence ~0.99. AE: no.
P03197,2,neutral,Visit 2: Patient on RX-17B at S003. continues regimen. Notes: fatigue. Adherence ~1.00. AE: yes. CRP 5.9 mg/L; ALT 26 U/L.
P03198,0,negative,Visit 0: Patient on RX-17B at S002. feels frustrated. Notes: fatigue. Adherence ~0.79. AE: no.
P03198,1,neutral,Visit 1: Patient on RX-17B at S002. follow-up as scheduled. Notes: dizziness. Adherence ~0.76. AE: no. CRP 2.3 mg/L; ALT 19 U/L.
P03198,2,neutral,Visit 2: Patient on RX-17B at S002. stable symptoms. Notes: insomnia. Adherence ~0.85. AE: no.
P03198,3,negative,Visit 3: Patient on RX-17B at S002. feels frustrated. Notes: headache. Adherence ~0.85. AE: no. CRP 1.6 mg/L; ALT 17 U/L.
P03198,4,positive,Visit 4: Patient on RX-17B at S002. reports improvement. Notes: fatigue. Adherence ~0.76. AE: no.
P03198,5,neutral,Visit 5: Patient on RX-17B at S002. no major change. Notes: joint pain. Adherence ~0.70. AE: no.
P03198,6,positive,Visit 6: Patient on RX-17B at S002. feels better overall. Notes: nausea. Adherence ~0.97. AE: no. CRP 1.0 mg/L; ALT 20 U/L.
P03199,0,negative,Visit 0: Patient on RX-17A at S015. symptoms persist. Notes: nausea. Adherence ~0.84. AE: no.
P03199,1,negative,Visit 1: Patient on RX-17A at S015. increased discomfort. Notes: joint pain. Adherence ~0.84. AE: yes.
P03199,2,negative,Visit 2: Patient on RX-17A at S015. symptoms persist. Notes: insomnia. Adherence ~0.62. AE: no. CRP 2.6 mg/L; ALT 42 U/L.
P03199,3,neutral,Visit 3: Patient on RX-17A at S015. continues regimen. Notes: nausea. Adherence ~0.83. AE: no. CRP 2.6 mg/L; ALT 42 U/L. Plan: consider dose adjustment; counsel patient.
P03199,4,neutral,Visit 4: Patient on RX-17A at S015. follow-up as scheduled. Notes: headache. Adherence ~0.72. AE: no. Plan: consider dose adjustment; counsel patient.
P03200,0,negative,Visit 0: Patient on RX-17B at S004. reports worsening. Notes: brain fog. Adherence ~0.66. AE: no.
P03200,1,neutral,Visit 1: Patient on RX-17B at S004. no major change. Notes: dizziness. Adherence ~0.80. AE: no. CRP 11.4 mg/L; ALT 35 U/L.
P03200,2,neutral,Visit 2: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.80. AE: yes. CRP 10.0 mg/L; ALT 36 U/L.
P03200,3,neutral,Visit 3: Patient on RX-17B at S004. follow-up as scheduled. Notes: abdominal discomfort. Adherence ~0.52. AE: no. CRP 8.9 mg/L; ALT 35 U/L.
P03200,4,neutral,Visit 4: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.63. AE: no. CRP 8.4 mg/L; ALT 39 U/L. Plan: consider dose adjustment; counsel patient.
P03200,5,positive,Visit 5: Patient on RX-17B at S004. energy increasing. Notes: dizziness. Adherence ~0.79. AE: no.
P03200,6,positive,Visit 6: Patient on RX-17B at S004. energy increasing. Notes: insomnia. Adherence ~0.82. AE: no. Plan: consider dose adjustment; counsel patient.
P03200,7,neutral,Visit 7: Patient on RX-17B at S004. stable symptoms. Notes: dizziness. Adherence ~0.73. AE: no. CRP 5.0 mg/L; ALT 40 U/L.
